0000950170-24-12233010-Q REGENXBIO Inc. 20241106202411061615261615261615261526 0 0000950170-24-122330 10-Q 80 20240930 20241106 20241106 REGENXBIO Inc. 0001590877 2836 471851754 1231 10-Q 34 001-37553 241431157 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 REGENXBIO, Inc. 20150116 ReGenX Biosciences, LLC 20131101 10-Q 1 rgnx-20240930.htm 10-Q 10-Q Q3--12-31false00015908772http://fasb.org/us-gaap/2024#RelatedPartyMemberhttp://fasb.org/us-gaap/2024#RelatedPartyMember0001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberrgnx:DevelopmentMilestoneMember2024-09-300001590877us-gaap:PrivatePlacementMemberus-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001590877rgnx:MarchTwoThousandTwentyFourPublicOfferingMemberrgnx:PreFundedWarrantsMember2024-09-300001590877us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001590877us-gaap:CorporateBondSecuritiesMember2023-12-310001590877rgnx:NovartisGeneTherapiesMember2024-01-012024-09-300001590877rgnx:CashEquivalentsAndMarketableSecuritiesMember2024-09-300001590877us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2024-09-3000015908772024-10-310001590877us-gaap:CommonStockMember2023-01-012023-09-300001590877rgnx:NovartisLicenseAgreementMemberrgnx:NovartisGeneTherapiesMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001590877us-gaap:LicenseAndServiceMember2024-01-012024-09-300001590877rgnx:SalesBasedMilestonesMemberrgnx:AbbVieCollaborationAndLicenseAgreementMember2023-12-310001590877us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001590877us-gaap:OtherCurrentAssetsMember2024-09-300001590877us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2024-09-300001590877rgnx:EmployeeStockPurchasePlanMember2023-01-012023-09-300001590877us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001590877us-gaap:FairValueInputsLevel2Member2023-12-310001590877us-gaap:PrivatePlacementMember2023-07-012023-09-300001590877rgnx:NovemberTwoThousandTwentyFourLicenseAgreementMemberus-gaap:ContractTerminationMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-01-012024-09-300001590877rgnx:ZolgensmaRoyaltiesMember2023-07-012023-09-300001590877rgnx:LaboratoryAndManufacturingEquipmentMember2024-09-300001590877rgnx:SettlementAgreementMemberrgnx:AbeonaTherapeuticsIncorporationMember2023-07-012023-09-300001590877rgnx:NovartisGeneTherapiesMember2024-07-012024-09-300001590877us-gaap:FairValueInputsLevel2Memberus-gaap:CashEquivalentsMember2023-12-310001590877rgnx:NovemberTwoThousandTwentyOneLicenseAgreementMemberus-gaap:ContractTerminationMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-01-012024-09-300001590877rgnx:NovartisGeneTherapiesMember2023-01-012023-09-300001590877us-gaap:RetainedEarningsMember2023-01-012023-09-300001590877us-gaap:CommonStockMember2024-07-012024-09-300001590877us-gaap:RelatedPartyMemberus-gaap:OtherCurrentAssetsMember2023-12-310001590877rgnx:NewYorkSubleaseMember2024-01-012024-03-310001590877us-gaap:RestrictedStockUnitsRSUMember2023-12-310001590877rgnx:ZolgensmaRoyaltiesMember2024-01-012024-09-300001590877us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember2023-12-310001590877us-gaap:IPOMemberus-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001590877rgnx:TwoThousandAndFifteenEquityIncentivePlanMember2024-01-012024-01-310001590877us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001590877us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001590877us-gaap:IPOMember2024-01-012024-09-300001590877us-gaap:LicenseAndServiceMember2024-07-012024-09-300001590877rgnx:EmployeeStockPurchasePlanMember2024-07-012024-09-300001590877us-gaap:RoyaltyAgreementsMember2023-12-310001590877us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001590877us-gaap:CommonStockMemberus-gaap:IPOMember2024-01-012024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2023-07-012023-09-300001590877us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2023-07-012023-09-300001590877rgnx:ZolgensmaRoyaltiesMember2023-01-012023-09-300001590877us-gaap:OtherCurrentAssetsMember2023-12-310001590877rgnx:DirectorsOrSection16ReportingOfficersMember2024-07-012024-09-3000015908772023-01-012023-12-310001590877rgnx:HCRMemberrgnx:NovemberEightTwoThousandTwentyFourMember2024-01-012024-09-300001590877us-gaap:RestrictedStockUnitsRSUMember2024-09-300001590877us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001590877us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001590877us-gaap:RetainedEarningsMember2023-07-012023-09-300001590877us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001590877rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember2023-01-012023-12-310001590877rgnx:NewYorkSubleaseMember2024-07-012024-09-300001590877us-gaap:LeaseholdImprovementsMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:OtherCurrentAssetsMember2023-12-3100015908772024-06-300001590877us-gaap:CorporateBondSecuritiesMember2023-12-310001590877us-gaap:CertificatesOfDepositMember2024-09-300001590877us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001590877us-gaap:FairValueInputsLevel2Member2024-09-300001590877us-gaap:RetainedEarningsMember2022-12-310001590877us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001590877rgnx:HCRMemberus-gaap:RoyaltyAgreementsMember2024-01-012024-09-300001590877rgnx:NAVTechnologyPlatformMember2024-09-300001590877rgnx:ZolgensmaRoyaltiesMember2024-07-012024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001590877us-gaap:FurnitureAndFixturesMember2024-09-300001590877us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001590877us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001590877us-gaap:CommonStockMember2024-06-3000015908772024-09-300001590877us-gaap:LicenseAndServiceMember2023-01-012023-09-300001590877us-gaap:CashEquivalentsMember2023-12-310001590877rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001590877us-gaap:FurnitureAndFixturesMember2023-12-310001590877rgnx:LaboratoryAndManufacturingEquipmentMember2023-12-310001590877us-gaap:ComputerEquipmentMember2024-09-300001590877us-gaap:AdditionalPaidInCapitalMember2023-06-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001590877us-gaap:RetainedEarningsMember2023-12-3100015908772023-10-012023-12-310001590877us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001590877rgnx:NovemberTwoThousandTwentyTwoLicenseAgreementMemberus-gaap:ContractTerminationMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-01-012024-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001590877us-gaap:FairValueInputsLevel2Memberrgnx:CashEquivalentsAndMarketableSecuritiesMember2023-12-3100015908772024-03-310001590877us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001590877us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001590877rgnx:FurnitureFixturesAndLeaseholdImprovementsMember2024-01-012024-03-310001590877us-gaap:CommonStockMemberrgnx:MarchTwoThousandTwentyFourPublicOfferingMember2024-01-012024-09-300001590877rgnx:CashEquivalentsAndMarketableSecuritiesMember2023-12-310001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001590877us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001590877rgnx:EmployeeStockPurchasePlanMember2023-07-012023-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2024-07-012024-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001590877us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001590877us-gaap:CommonStockMember2024-01-012024-09-3000015908772023-01-012023-09-300001590877us-gaap:FairValueInputsLevel2Memberus-gaap:CashEquivalentsMember2024-09-300001590877rgnx:SalesBasedMilestonesMemberrgnx:AbbVieCollaborationAndLicenseAgreementMember2024-09-300001590877srt:MaximumMember2024-09-300001590877us-gaap:RetainedEarningsMember2024-07-012024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:OtherCurrentAssetsMember2024-09-300001590877us-gaap:PrivatePlacementMemberus-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001590877us-gaap:CertificatesOfDepositMember2023-12-310001590877srt:MaximumMember2024-01-012024-09-300001590877rgnx:SalesBasedMilestonesMemberrgnx:AbbVieCollaborationAndLicenseAgreementMember2021-09-012021-09-300001590877rgnx:SettlementAgreementMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-09-300001590877rgnx:MarchTwoThousandTwentyFourPublicOfferingMember2024-03-012024-03-310001590877us-gaap:LeaseholdImprovementsMember2023-12-310001590877us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2023-12-310001590877rgnx:NewYorkSubleaseMember2024-03-310001590877us-gaap:CommonStockMemberrgnx:MarchTwoThousandTwentyFourPublicOfferingMember2024-07-012024-09-300001590877us-gaap:MoneyMarketFundsMemberus-gaap:CashEquivalentsMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberrgnx:DevelopmentMilestoneMember2023-12-310001590877rgnx:NewYorkSubleaseMember2024-01-012024-09-300001590877rgnx:TwoThousandAndFifteenEquityIncentivePlanMember2024-09-300001590877us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001590877rgnx:AtTheMarketOfferingProgramMember2023-09-012023-09-300001590877rgnx:SettlementAgreementMemberrgnx:AbeonaTherapeuticsIncorporationMember2023-01-012023-09-300001590877us-gaap:CommonStockMember2022-12-310001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001590877us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001590877rgnx:SettlementAgreementMemberrgnx:AbeonaTherapeuticsIncorporationMember2023-12-310001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001590877rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember2024-09-300001590877us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001590877us-gaap:PrivatePlacementMember2023-01-012023-09-300001590877rgnx:SettlementAgreementMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-07-012024-09-300001590877srt:MaximumMember2024-03-310001590877us-gaap:CommonStockMember2023-07-012023-09-300001590877us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashEquivalentsMember2023-12-310001590877us-gaap:AdditionalPaidInCapitalMember2023-09-300001590877rgnx:NovartisGeneTherapiesMember2023-07-012023-09-300001590877rgnx:MarchTwoThousandTwentyFourPublicOfferingMember2024-03-310001590877rgnx:MarchTwoThousandTwentyFourPublicOfferingMember2024-07-012024-09-300001590877us-gaap:RoyaltyAgreementsMember2024-01-012024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2023-01-012023-09-300001590877us-gaap:RetainedEarningsMember2023-09-300001590877us-gaap:EmployeeStockMember2024-01-012024-09-300001590877rgnx:NewYorkSubleaseMember2023-07-012023-09-300001590877us-gaap:ComputerEquipmentMember2023-12-310001590877us-gaap:EmployeeStockMember2023-01-012023-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001590877rgnx:EmployeeStockPurchasePlanMember2024-01-012024-09-300001590877rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember2024-01-012024-09-300001590877srt:MinimumMember2024-01-012024-09-300001590877us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001590877us-gaap:RetainedEarningsMember2023-06-300001590877us-gaap:EmployeeStockMember2023-07-012023-09-300001590877us-gaap:CommonStockMemberrgnx:AtTheMarketOfferingProgramMember2024-01-012024-09-300001590877us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMember2023-12-310001590877us-gaap:RoyaltyAgreementsMember2024-09-300001590877us-gaap:CommonStockMember2023-12-3100015908772022-12-310001590877us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberrgnx:DevelopmentMilestoneMember2021-09-012021-09-3000015908772023-12-310001590877us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-3000015908772023-07-012023-09-300001590877rgnx:NovartisLicenseAgreementMemberrgnx:NovartisGeneTherapiesMember2023-12-310001590877us-gaap:CommonStockMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2021-09-012021-09-300001590877rgnx:NovemberTwoThousandEighteenLicenseAgreementMemberus-gaap:ContractTerminationMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-01-012024-09-300001590877us-gaap:RelatedPartyMemberus-gaap:OtherCurrentAssetsMember2024-09-300001590877us-gaap:LicenseAndServiceMember2023-07-012023-09-300001590877us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2023-01-012023-09-300001590877us-gaap:CertificatesOfDepositMember2023-12-310001590877rgnx:HCRMemberrgnx:NovemberSevenTwoThousandTwentyFourMember2024-01-012024-09-300001590877us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300001590877us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001590877rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember2023-12-310001590877us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001590877us-gaap:AdditionalPaidInCapitalMember2022-12-310001590877us-gaap:CertificatesOfDepositMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001590877us-gaap:RetainedEarningsMember2024-01-012024-09-300001590877rgnx:MarchTwoThousandTwentyFourPublicOfferingMemberrgnx:PreFundedWarrantsMember2024-03-310001590877us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001590877rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember2024-01-012024-09-300001590877us-gaap:CorporateBondSecuritiesMember2024-09-300001590877us-gaap:RetainedEarningsMember2024-06-3000015908772022-01-012022-12-310001590877us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember2023-12-310001590877us-gaap:CommonStockMember2023-09-300001590877rgnx:HCRMemberrgnx:NovemberEightTwoThousandTwentyFourMember2024-09-300001590877us-gaap:CashEquivalentsMember2024-09-300001590877us-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMember2024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001590877us-gaap:CommonStockMember2023-06-300001590877us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001590877us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001590877us-gaap:CertificatesOfDepositMember2024-09-300001590877rgnx:NewYorkSubleaseMember2023-01-012023-09-300001590877us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CashEquivalentsMember2024-09-300001590877us-gaap:AdditionalPaidInCapitalMember2024-09-300001590877rgnx:NovemberSevenTwoThousandTwentyFourMember2024-01-012024-09-300001590877us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001590877rgnx:HCRMember2024-01-012024-09-3000015908772023-09-300001590877us-gaap:FairValueInputsLevel2Memberrgnx:CashEquivalentsAndMarketableSecuritiesMember2024-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001590877rgnx:SettlementAgreementMemberrgnx:AbeonaTherapeuticsIncorporationMember2024-01-012024-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001590877srt:MaximumMember2023-01-012023-12-310001590877us-gaap:AdditionalPaidInCapitalMember2024-06-300001590877us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001590877rgnx:NovartisLicenseAgreementMemberrgnx:HCRMemberrgnx:NovartisGeneTherapiesMember2024-09-300001590877srt:MinimumMember2024-03-3100015908772024-01-012024-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2023-12-310001590877us-gaap:EmployeeStockMember2024-07-012024-09-300001590877us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001590877us-gaap:AdditionalPaidInCapitalMember2023-12-310001590877rgnx:TwoThousandAndFifteenEquityIncentivePlanMember2024-01-012024-09-300001590877us-gaap:CertificatesOfDepositMember2023-12-310001590877us-gaap:RestrictedStockUnitsRSUMember2024-09-300001590877us-gaap:RetainedEarningsMember2024-09-300001590877us-gaap:CorporateBondSecuritiesMember2024-09-300001590877us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001590877rgnx:AbbVieCollaborationAndLicenseAgreementMember2024-01-012024-09-30xbrli:purexbrli:sharesrgnx:Securityrgnx:ProductCandidateiso4217:USDiso4217:USDxbrli:shares Table of Contents Â Â Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 Â FORM 10-Q Â (Mark One) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 Â REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Â Delaware Â 47-1851754 (State or other jurisdiction ofincorporation or organization) Â (I.R.S. EmployerIdentification No.) Â Â Â 9804 Medical Center DriveRockville, MD Â 20850 (Address of principal executive offices) Â (Zip Code) (240) 552-8181 (Registrantâ€™s telephone number, including area code) Not Applicable (Former name, former address and former fiscal year, if changed since last report) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock, par value $0.0001 per share RGNX The Nasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filer Â â˜’ Â Accelerated filer Â â˜ Non-accelerated filer Â â˜ Â Smaller reporting company Â â˜ Â Â Â Â Â Emerging growth company Â â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ As of October 31, 2024, there were 49,545,071 shares of the registrantâ€™s common stock, par value $0.0001 per share, issued and outstanding. Â Â Table of Contents Â Â REGENXBIO INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 TABLE OF CONTENTS Â Â Â PART Iâ€”FINANCIAL INFORMATION Â Â Â Â Â Â Â Item 1. Â Financial Statements (Unaudited) Â 3 Â Â Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 Â 3 Â Â Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 Â 4 Â Â Consolidated Statements of Stockholdersâ€™ Equity for the Three and Nine Months Ended September 30, 2024 and 2023 Â 5 Â Â Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 Â 7 Â Â Notes to Consolidated Financial Statements Â 8 Item 2. Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â 25 Item 3. Â Quantitative and Qualitative Disclosures about Market Risk Â 35 Item 4. Â Controls and Procedures Â 35 Â Â Â Â Â Â Â Â PART IIâ€”OTHER INFORMATION Â Â Â Â Â Â Â Item 1. Â Legal Proceedings Â 36 Item 1A. Â Risk Factors Â 36 Item 2. Â Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities Â 36 Item 3. Â Defaults Upon Senior Securities Â 36 Item 4. Â Mine Safety Disclosures Â 36 Item 5. Â Other Information Â 36 Item 6. Â Exhibits Â 37 Signatures Â 38 Â Table of Contents Â Â INFORMATION REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains â€œforward-looking statementsâ€ within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as â€œanticipate,â€ â€œassume,â€ â€œbelieve,â€ â€œcontinue,â€ â€œcould,â€ â€œdesign,â€ â€œestimate,â€ â€œexpect,â€ â€œforecast,â€ â€œgoal,â€ â€œintend,â€ â€œmay,â€ â€œobjective,â€ â€œplan,â€ â€œposition,â€ â€œpotential,â€ â€œpredict,â€ â€œproject,â€ â€œseek,â€ â€œshould,â€ â€œwill,â€ â€œwouldâ€ or variations of such words or by similar expressions. We have based these forward-looking statements on our current expectations, estimates and assumptions and analyses in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate under the circumstances. However, whether actual results and developments will conform with our expectations and predictions is subject to a number of risks, uncertainties, assumptions and other important factors, including, but not limited to: â€¢our ability to establish and maintain development partnerships, including our collaboration with AbbVie to develop and commercialize ABBV-RGX-314; â€¢our ability to obtain and maintain regulatory approval of our product candidates and the labeling for any approved products; â€¢the timing of enrollment, commencement, completion and the success of our AAVIATEÂ®, AFFINITY BEYONDÂ®, AFFINITY DUCHENNEÂ®, ALTITUDEÂ®, ASCENTÃ„¢, ATMOSPHEREÂ® and CAMPSIITEÂ® clinical trials; â€¢the timing of commencement and completion and the success of preclinical studies conducted by us and our development partners; â€¢the timely development and launch of new products; â€¢the scope, progress, expansion and costs of developing and commercializing our product candidates; â€¢our ability to obtain, maintain and enforce intellectual property protection for our product candidates and technology, and defend against third-party intellectual property-related claims; â€¢our expectations regarding the development and commercialization of product candidates currently being developed by third parties that utilize our technology; â€¢our anticipated growth strategies; â€¢our expectations regarding competition; â€¢the anticipated trends and challenges in our business and the market in which we operate; â€¢our ability to attract or retain key personnel; â€¢the size and growth of the potential markets for our product candidates and the ability to serve those markets; â€¢the rate and degree of market acceptance of any of our products that are approved; â€¢our expectations regarding our expenses and revenue; â€¢our strategic pipeline prioritization and corporate restructuring, including plans for advancing our product candidates, the expected charges and cost savings associated with our restructuring and any future cost reduction measures; â€¢our ability to execute strategic alternatives for our de-prioritized rare neurodegenerative disease clinical-stage programs; â€¢our expectations regarding our need for additional financing and our ability to obtain additional financing; â€¢our expectations regarding the outcome of legal proceedings; â€¢our expectations regarding regulatory developments in the United States and foreign countries; and â€¢changes in the financial markets and banking system that may affect the availability and terms on which we may obtain financing and our ability to accurately predict how long our existing cash resources will be sufficient to fund our anticipated operating expenses. 1 Table of Contents Â Â You should carefully read the factors discussed in the sections titled â€œRisk Factors,â€ â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ and the factors discussed elsewhere in this Quarterly Report on Form 10-Q, our Annual Report on Form 10-K for the year ended December 31, 2023 and in our other filings with the U.S. Securities and Exchange Commission (the SEC) for additional discussion of the risks, uncertainties, assumptions and other important factors that could cause our actual results or developments to differ materially and adversely from those projected in the forward-looking statements. The actual results or developments anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on us or our businesses or operations. Such statements are not guarantees of future performance, and actual results or developments may differ materially and adversely from those projected in the forward-looking statements. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we disclaim any duty to update any forward-looking statements, whether as a result of new information, future events or otherwise. Available Information Our principal offices are located at 9804 Medical Center Drive, Rockville, MD 20850, and our telephone number is (240) 552-8181. Our website address is www.regenxbio.com. The information contained in, or that can be accessed through, our website is not a part of, or incorporated by reference in, this Quarterly Report on Form 10-Q. We file annual, quarterly, and current reports, proxy statements, and other documents with the SEC under the Exchange Act. You may obtain any reports, proxy and information statements, and other information that we file electronically with the SEC at www.sec.gov. You also may view and download copies of our SEC filings free of charge at our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The information contained on, or that can be accessed through, our website will not be deemed to be incorporated by reference in, and is not considered part of, this Quarterly Report on Form 10-Q. Investors should also note that we use our website, as well as SEC filings, press releases, public conference calls and webcasts, to announce financial information and other material developments regarding our business. We use these channels, as well as any social media channels listed on our website, to communicate with investors and members of the public about our business. It is possible that the information that we post on our social media channels could be deemed material information. Therefore, we encourage investors, the media and others interested in our company to review the information that we post on our social media channels. As used in this Quarterly Report on Form 10-Q, the terms â€œREGENXBIO,â€ â€œwe,â€ â€œus,â€ â€œourâ€ or the â€œCompanyâ€ mean REGENXBIO Inc. and its subsidiaries, on a consolidated basis, unless the context indicates otherwise. AAVIATE, AFFINITY BEYOND, AFFINITY DUCHENNE, ALTITUDE, ATMOSPHERE, CAMPSIITE, NAV, NAVXCELL, REGENXBIO and the REGENXBIO logos are our registered trademarks. Any other trademarks appearing in this Quarterly Report on Form 10-Q are the property of their respective holders. 2 Table of Contents Â Â PART I â€“ FINANCIAL INFORMATION Item 1. Financial Statements. REGENXBIO INC. CONSOLIDATED BALANCE SHEETS (unaudited) (in thousands, except per share data) Â Â September 30, 2024 Â Â December 31, 2023 Â Assets Â Â Â Â Â Â Current assets Â Â Â Â Â Â Cash and cash equivalents Â $ 56,617 Â Â $ 34,522 Â Marketable securities Â Â 198,843 Â Â Â 240,736 Â Accounts receivable, net Â Â 23,604 Â Â Â 24,790 Â Prepaid expenses Â Â 11,002 Â Â Â 14,520 Â Other current assets Â Â 23,330 Â Â Â 20,403 Â Total current assets Â Â 313,396 Â Â Â 334,971 Â Marketable securities Â Â 23,108 Â Â Â 38,871 Â Accounts receivable Â Â 404 Â Â Â 701 Â Property and equipment, net Â Â 120,551 Â Â Â 132,103 Â Operating lease right-of-use assets Â Â 55,293 Â Â Â 60,487 Â Restricted cash Â Â 2,030 Â Â Â 2,030 Â Other assets Â Â 4,332 Â Â Â 4,807 Â Total assets Â $ 519,114 Â Â $ 573,970 Â Liabilities and Stockholdersâ€™ Equity Â Â Â Â Â Â Current liabilities Â Â Â Â Â Â Accounts payable Â $ 19,522 Â Â $ 22,786 Â Accrued expenses and other current liabilities Â Â 48,642 Â Â Â 49,703 Â Deferred revenue Â Â 144 Â Â Â 148 Â Operating lease liabilities Â Â 7,720 Â Â Â 7,068 Â Liability related to sale of future royalties Â Â 26,697 Â Â Â 50,567 Â Total current liabilities Â Â 102,725 Â Â Â 130,272 Â Operating lease liabilities Â Â 76,342 Â Â Â 82,222 Â Liability related to sale of future royalties Â Â 35,052 Â Â Â 43,485 Â Other liabilities Â Â 3,579 Â Â Â 6,249 Â Total liabilities Â Â 217,698 Â Â Â 262,228 Â Stockholdersâ€™ equity Â Â Â Â Â Â Preferred stock; $0.0001Â par value; 10,000Â shares authorized, noÂ shares issuedÂ Â Â and outstanding at September 30, 2024 and December 31, 2023 Â Â Â â€” Â Â Â â€” Â Common stock; $0.0001Â par value; 100,000Â shares authorized at September 30, 2024 Â Â Â and December 31, 2023; 49,534Â and 44,046Â shares issued and outstanding at Â Â Â September 30, 2024 and December 31, 2023, respectively Â Â 5 Â Â Â Â 4 Â Additional paid-in capital Â Â 1,182,956 Â Â Â 1,021,214 Â Accumulated other comprehensive loss Â Â (582) Â Â (4,429) Accumulated deficit Â Â (880,963) Â Â (705,047) Total stockholdersâ€™ equity Â Â 301,416 Â Â Â 311,742 Â Total liabilities and stockholdersâ€™ equity Â $ 519,114 Â Â $ 573,970 Â The accompanying notes are an integral part of these unaudited consolidated financial statements. Â 3 Table of Contents Â Â REGENXBIO INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) (in thousands, except per share data) Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenues Â Â Â Â Â Â Â Â Â Â License and royalty revenue Â $ 24,197 Â Â $ 28,914 Â Â Â $ 62,114 Â Â Â $ 68,029 Â Total revenues Â Â Â 24,197 Â Â Â 28,914 Â Â Â 62,114 Â Â Â 68,029 Â Operating Expenses Â Â Â Â Â Â Â Â Â Â Cost of revenues Â Â Â 12,387 Â Â Â 12,388 Â Â Â 27,249 Â Â Â 25,975 Â Research and development Â Â Â 54,429 Â Â Â 58,183 Â Â Â 158,142 Â Â Â 176,585 Â General and administrative Â Â Â 19,422 Â Â Â 23,083 Â Â Â 56,568 Â Â Â 69,415 Â Impairment of long-lived assets Â Â Â â€” Â Â Â â€” Â Â Â 2,101 Â Â Â â€” Â Other operating expenses Â Â 37 Â Â Â 220 Â Â Â 32 Â Â Â 279 Â Total operating expenses Â Â 86,275 Â Â Â 93,874 Â Â Â 244,092 Â Â Â 272,254 Â Loss from operations Â Â (62,078) Â Â (64,960) Â Â (181,978) Â Â (204,225) Other Income (Expense) Â Â Â Â Â Â Â Â Â Â Interest income from licensing Â Â 25 Â Â Â 56 Â Â Â 91 Â Â Â 166 Â Investment income Â Â 3,276 Â Â Â 4,660 Â Â Â 9,213 Â Â Â 8,953 Â Interest expense Â Â (820) Â Â (1,624) Â Â (3,242) Â Â (5,499) Total other income Â Â 2,481 Â Â Â 3,092 Â Â Â 6,062 Â Â Â 3,620 Â Net loss Â $ (59,597) Â $ (61,868) Â $ (175,916) Â $ (200,605) Other Comprehensive Income Â Â Â Â Â Â Â Â Â Â Unrealized gain on available-for-sale securities, net Â Â 1,684 Â Â Â 2,685 Â Â Â 3,847 Â Â Â 7,988 Â Total other comprehensive income Â Â 1,684 Â Â Â 2,685 Â Â Â 3,847 Â Â Â 7,988 Â Comprehensive loss Â $ (57,913) Â $ (59,183) Â $ (172,069) Â $ (192,617) Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Net loss per share, basic and diluted Â $ (1.17) Â $ (1.41) Â $ (3.59) Â $ (4.60) Weighted-average common shares outstanding, basic and diluted Â Â 50,800 Â Â Â 43,945 Â Â Â 49,051 Â Â Â 43,644 Â The accompanying notes are an integral part of these unaudited consolidated financial statements. Â 4 Table of Contents Â Â REGENXBIO INC. CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (unaudited) (in thousands) Â Â Â Three Months Ended September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

$ 1,012,667 Â Â $ (7,413) Â $ (642,158) Â $ 363,100 Â Â The accompanying notes are an integral part of these unaudited consolidated financial statements. 6 Table of Contents Â Â REGENXBIO INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (in thousands) Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Cash flows from operating activities Â Â Â Â Â Â Net loss Â $ (175,916) Â $ (200,605) Adjustments to reconcile net loss to net cash used in operating activities Â Â Â Â Â Â Stock-based compensation expense Â Â 28,921 Â Â Â 31,929 Â Depreciation and amortization Â Â 12,192 Â Â Â 12,985 Â Net amortization of premiums (accretion of discounts) on marketable debt securities Â Â (3,027) Â Â 929 Â Net realized gain on investments Â Â â€” Â Â Â (2,205) Impairment of long-lived assets Â Â 2,101 Â Â Â â€” Â Non-cash interest expense Â Â 412 Â Â Â (569) Other non-cash adjustments Â Â (60) Â Â (1) Changes in operating assets and liabilities Â Â Â Â Â Â Accounts receivable Â Â 1,574 Â Â Â 566 Â Prepaid expenses Â Â 3,518 Â Â Â 1,339 Â Other current assets Â Â (2,804) Â Â (13,573) Operating lease right-of-use assets Â Â 4,586 Â Â Â 4,245 Â Other assets Â Â 475 Â Â Â 1,728 Â Accounts payable Â Â (3,330) Â Â (4,011) Accrued expenses and other current liabilities Â Â (1,448) Â Â (1,546) Deferred revenue Â Â (4) Â Â (1,218) Operating lease liabilities Â Â (6,021) Â Â (5,004) Other liabilities Â Â (2,670) Â Â (2,636) Net cash used in operating activities Â Â (141,501) Â Â (177,647) Cash flows from investing activities Â Â Â Â Â Â Purchases of marketable debt securities Â Â (173,916) Â Â (67,925) Maturities of marketable debt securities Â Â 238,446 Â Â Â 231,753 Â Sales of equity securities Â Â â€” Â Â Â 1,975 Â Purchases of property and equipment Â Â (1,357) Â Â (8,834) Net cash provided by investing activities Â Â 63,173 Â Â Â 156,969 Â Cash flows from financing activities Â Â Â Â Â Â Proceeds from exercise of stock options Â Â 1,474 Â Â Â 1,312 Â Taxes paid related to net settlement of stock-based awards Â Â (910) Â Â (419) Proceeds from issuance of common stock under employee stock purchase plan Â Â 1,191 Â Â Â 1,826 Â Proceeds from public offering of common stock and pre-funded warrants,Â Â Â net of issuance costs Â Â 131,067 Â Â Â â€” Â Proceeds from private placement of common stock, net of issuance costs Â Â â€” Â Â Â 4,874 Â Offering expenses related to at-the-market offering program Â Â (158) Â Â (51) Repayments under liability related to sale of future royalties, net of imputed interest Â Â (32,241) Â Â (30,546) Net cash provided by (used in) financing activities Â Â 100,423 Â Â Â (23,004) Net increase (decrease) in cash and cash equivalents and restricted cash Â Â 22,095 Â Â Â (43,682) Cash and cash equivalents and restricted cash Â Â Â Â Â Â Beginning of period Â Â 36,552 Â Â Â 98,982 Â End of period Â $ 58,647 Â Â $ 55,300 Â Â The accompanying notes are an integral part of these unaudited consolidated financial statements. 7 Table of Contents Â Â REGENXBIO INC. NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Â Â 1. Nature of BusinessREGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company's investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform (NAV Technology Platform). The NAVÂ® Technology Platform consists of exclusive rights to a large portfolio of AAV vectors, including commonly used AAV8 and AAV9. The Company has developed a broad pipeline of gene therapy product candidates using the NAV Technology Platform as a one-time treatment to address an array of diseases. In addition to its internal product development efforts, the Company also selectively licenses the NAV Technology Platform and other intellectual property rights to other leading biotechnology and pharmaceutical companies (NAV Technology Licensees). As of September 30, 2024, the NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, ZolgensmaÂ®, and in the preclinical and clinical development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development and commercialization of certain product candidates. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.The Company has incurred cumulative losses since inception and as of September 30, 2024, had generated an accumulated deficit of $881.0 million. The Company's ability to transition to recurring profitability is dependent upon achieving a level of revenues adequate to support its cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, will continue to need to raise additional capital through equity offerings, licensing and collaboration arrangements, or other non-dilutive financings. There is no assurance that the Company will be able to raise sufficient capital or obtain financing on favorable terms, or at all. If the Company is unable to raise capital sufficient to meet its working capital needs in the future, it may be forced to delay expenditures, reduce the scope of its development activities or make other changes to its operating plans. As of September 30, 2024, the Company had cash, cash equivalents and marketable securities of $278.6 million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued. 2. Summary of Significant Accounting PoliciesBasis of Presentation and Principles of ConsolidationThe accompanying consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024. Certain information and footnote disclosures required by GAAP, which are normally included in the Companyâ€™s annual consolidated financial statements, have been omitted pursuant to SEC rules and regulations for interim reporting. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for a fair statement of the results of operations for the periods presented. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year, any other interim periods, or any future year or period. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023.The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of EstimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance 8 Table of Contents Â Â for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements.ReclassificationsCertain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.Restricted CashRestricted cash consists of deposits held at financial institutions that are used to collateralize irrevocable letters of credit required under the Companyâ€™s lease agreements and certain other agreements with third parties. The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):Â Â Â As of September 30, Â Â Â 2024 Â Â 2023 Â Cash and cash equivalents Â $ 56,617 Â Â $ 53,045 Â Restricted cash Â Â 2,030 Â Â Â 2,255 Â Total cash and cash equivalents and restricted cash Â $ 58,647 Â Â $ 55,300 Â Â Accounts ReceivableAccounts receivable primarily consist of consideration due to the Company resulting from its license agreements with customers. Accounts receivable include amounts invoiced to licensees as well as rights to consideration which have not yet been invoiced, including unbilled royalties, and for which payment is conditional solely upon the passage of time. If a licensee elects to terminate a license prior to the end of the license term, the licensed intellectual property is returned to the Company and any accounts receivable from the licensee which are not contractually payable to the Company are charged off as a reduction of license revenue in the period of the termination. Accounts receivable which are not expected to be received by the Company within 12 months from the reporting date are stated net of a discount to present value and recorded as non-current assets on the consolidated balance sheets. The present value discount is recognized as a reduction of revenue in the period in which the accounts receivable are initially recorded and is accreted as interest income from licensing over the term of the receivables.Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Companyâ€™s evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances, and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Companyâ€™s evaluation of current and expected future economic conditions. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Please refer to Note 9 for further information regarding the allowance for credit losses related to accounts receivable.LeasesThe Company accounts for its lease arrangements in accordance with Accounting Standards Codification (ASC) 842, Leases (ASC 842). Under ASC 842, the Company classifies its leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the Company. Lease classification is evaluated at the inception of the lease agreement. Regardless of classification, the Company records a right-of-use asset and a lease liability for all leases with a term greater than 12 months. All of the Companyâ€™s leases have been classified as operating leases. Operating lease expense is recognized on a straight-line basis over the term of the lease, with the exception of variable lease expenses which are recognized as incurred.The Company identifies leases in its contracts if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company does not allocate lease consideration between lease and nonlease components and records a lease liability equal to the present value of the remaining fixed consideration under the lease. The interest rates implicit in the Companyâ€™s leases are generally not readily determinable. Accordingly, the Company uses its estimated incremental borrowing rate at the commencement date of the lease to determine the present value discount of the lease liability. The Company estimates its incremental borrowing rate for each lease based on an evaluation of its expected credit rating and the prevailing 9 Table of Contents Â Â market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the term of the lease. The right-of-use asset for each lease is equal to the lease liability, adjusted for unamortized initial direct costs and lease incentives and prepaid or accrued rent. Initial direct costs of entering into a lease are included in the right-of-use asset and amortized as lease expense over the term of the lease. Lease incentives, such as tenant improvement allowances, are recorded as a reduction of the right-of-use asset and amortized as a reduction of lease expense over the term of the lease. The Company excludes options to extend or terminate leases from the calculation of the lease liability unless it is reasonably certain the option will be exercised.The Company evaluates its right-of-use assets for impairment in accordance with its policy for long-lived assets. To the extent an impairment of a right-of-use asset is recognized, the remaining carrying value of the asset is subsequently amortized as lease expense on a straight-line basis from the date of impairment to the earlier of the end of the right-of-use assetâ€™s useful life or the end of the lease term.The Company determines the classification of subleases at the inception of the sublease, as well as whether the Company has been relieved of its primary obligation under the original lease. All of the Company's subleases have been classified as operating leases and, in each case, the Company has not been relieved of its primary obligation under the original lease and continues to account for the original lease as it did prior to the commencement of the sublease. Sublease income is recognized on a straight-line basis over the term of the sublease as a reduction of the related lease expense of the original lease. Initial direct costs of entering into a sublease are deferred and amortized on a straight-line basis over the term of the sublease as a reduction of sublease income.Impairment of Long-lived AssetsThe Company's long-lived assets consist primarily of property and equipment and operating lease right-of-use assets. The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to estimated future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. Please refer to Note 5 and Note 6 for further information on impairment of long-lived assets.Fair Value MeasurementsThe Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Companyâ€™s assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:â€¢Level 1â€”Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.â€¢Level 2â€”Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.â€¢Level 3â€”Valuations that require inputs that reflect the Companyâ€™s own assumptions that are both significant to the fair value measurement and unobservable.To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within the fair value hierarchy of an asset or liability measured at fair value is based on the lowest level of any input that is significant to the fair value measurement. The fair values of the Companyâ€™s Level 2 financial instruments are based on quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Please refer to Note 4 for further information on the Company's fair value measurements. 10 Table of Contents Â Â Pre-funded WarrantsWarrants are accounted for based on the specific terms of the warrant agreements. The Company's pre-funded warrants are indexed to the Company's common stock and meet the criteria to be classified as equity. Proceeds from the issuance of pre-funded warrants are recorded within additional paid-in capital and are not subject to remeasurement. Please refer to Note 8 for further information regarding pre-funded warrants issued by the Company.Net Loss Per ShareBasic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of computing both basic and diluted net loss per share, pre-funded warrants are considered outstanding shares upon issuance because the shares may be issued for nominal consideration and are exercisable after the original issuance date. Contingently convertible shares in which conversion is based on non-market-priced contingencies are excluded from the calculations of both basic and diluted net loss per share until the contingency has been fully met. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation of diluted net loss per share if their effect would be anti-dilutive.Recent Accounting PronouncementsRecently Adopted Accounting PronouncementsThe Company did not adopt any new accounting standards during the three and nine months ended September 30, 2024 and 2023 which had a material impact on the consolidated financial statements.Recent Accounting Pronouncements Not Yet AdoptedIn November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances certain interim and annual disclosure requirements of reportable segment information, including information about significant segment expenses. Additionally, the standard requires entities with a single reportable segment to provide all disclosures required by ASC 280, Segment Reporting. The standard is effective for the Company for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for segment reporting, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosure of an entity's effective tax rate reconciliation and requires the disclosure of income taxes paid to be disaggregated by jurisdiction. The standard is effective for the Company beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for income taxes, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements.In November 2024, the FASB issued ASU 2024-03, Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense

captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact of this standard on its consolidated financial statements and related disclosures. 11 Table of Contents Â Â 3. Marketable SecuritiesThe following tables present a summary of the Companyâ€™s marketable securities, which consist solely of available-for-sale debt securities (in thousands):Â Â Â Amortized Cost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â Fair Value Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â U.S. government and agency securities Â $ 50,350 Â Â $ 16 Â Â $ (233) Â $ 50,133 Â Certificates of deposit Â Â 4,404 Â Â Â â€” Â Â Â (15) Â Â 4,389 Â Corporate bonds Â Â 166,919 Â Â Â 583 Â Â Â (73) Â Â 167,429 Â Â Â $ 221,673 Â Â $ 599 Â Â $ (321) Â $ 221,951 Â Â Â Â Amortized Cost Â Â UnrealizedGains Â Â UnrealizedLosses Â Â Fair Value Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â U.S. government and agency securities Â $ 71,811 Â Â $ 6 Â Â $ (1,248) Â $ 70,569 Â Certificates of deposit Â Â 6,572 Â Â Â â€” Â Â Â (106) Â Â 6,466 Â Corporate bonds Â Â 204,793 Â Â Â 143 Â Â Â (2,364) Â Â 202,572 Â Â Â $ 283,176 Â Â $ 149 Â Â $ (3,718) Â $ 279,607 Â Â As of September 30, 2024 and December 31, 2023, no available-for-sale debt securities had remaining maturities greater than three years. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, or to the earliest call date for callable debt securities purchased at a premium. As of September 30, 2024 and December 31, 2023, the balance in accumulated other comprehensive loss consisted solely of unrealized gains and losses on available-for-sale debt securities, net of reclassification adjustments for realized gains and losses and income tax effects. The Company uses the aggregate portfolio approach to release the tax effects of unrealized gains and losses on available-for-sale debt securities in accumulated other comprehensive loss. Realized gains and losses from the sale or maturity of marketable securities are based on the specific identification method and are included in results of operations as investment income. The Company did not recognize any realized gains or losses on available-for-sales securities during the three and nine months ended September 30, 2024 and 2023, and no income tax effects or reclassification adjustments were recorded in accumulated other comprehensive loss during the periods. The following tables present the fair values and unrealized losses of available-for-sale debt securities held by the Company in an unrealized loss position for less than 12 months and 12 months or greater (in thousands):Â Â Â Less than 12 Months Â Â 12 Months or Greater Â Â Total Â Â Â Fair Value Â Â UnrealizedLosses Â Â Fair Value Â Â UnrealizedLosses Â Â Fair Value Â Â UnrealizedLosses Â September 30, 2024 Â U.S. government and agency securities Â $ â€” Â Â $ â€” Â Â $ 30,252 Â Â $ (233) Â $ 30,252 Â Â $ (233) Certificates of deposit Â Â 484 Â Â Â (1) Â Â 3,170 Â Â Â (14) Â Â 3,654 Â Â Â (15) Corporate bonds Â Â 4,995 Â Â Â (1) Â Â 21,290 Â Â Â (72) Â Â 26,285 Â Â Â (73) Â Â $ 5,479 Â Â $ (2) Â $ 54,712 Â Â $ (319) Â $ 60,191 Â Â $ (321) Â Â Â Less than 12 Months Â Â 12 Months or Greater Â Â Total Â Â Â Fair Value Â Â UnrealizedLosses Â Â Fair Value Â Â UnrealizedLosses Â Â Fair Value Â Â UnrealizedLosses Â December 31, 2023 Â U.S. government and agency securities Â $ 12,877 Â Â $ (16) Â $ 52,686 Â Â $ (1,232) Â $ 65,563 Â Â $ (1,248) Certificates of deposit Â Â 965 Â Â Â (2) Â Â 5,257 Â Â Â (104) Â Â 6,222 Â Â Â (106) Corporate bonds Â Â 25,051 Â Â Â (48) Â Â 144,642 Â Â Â (2,316) Â Â 169,693 Â Â Â (2,364) Â Â $ 38,893 Â Â $ (66) Â $ 202,585 Â Â $ (3,652) Â $ 241,478 Â Â $ (3,718) Â As of September 30, 2024, available-for-sale debt securities held by the Company in an unrealized loss position consisted of 36 investment grade security positions. The Company has the intent and ability to hold such securities until recovery, and based on the credit quality of the issuers and low severity of each unrealized loss position relative to its amortized cost basis, the Company did not identify any credit losses associated with its available-for-sale debt securities. The Company did not record an allowance for credit 12 Table of Contents Â Â losses on its available-for-sale debt securities as of September 30, 2024 or December 31, 2023, and no impairment or credit losses on available-for-sale debt securities were recorded during the three and nine months ended September 30, 2024 and 2023. 4. Fair Value MeasurementsFinancial instruments reported at fair value on a recurring basis include cash equivalents and marketable securities. The following tables present the fair value of cash equivalents and marketable securities in accordance with the fair value hierarchy discussed in Note 2 (in thousands): Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â September 30, 2024 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market mutual funds Â $ â€” Â Â $ 43,771 Â Â $ â€” Â Â $ 43,771 Â Total cash equivalents Â Â â€” Â Â Â 43,771 Â Â Â â€” Â Â Â 43,771 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. government and agency securities Â Â â€” Â Â Â 50,133 Â Â Â â€” Â Â Â 50,133 Â Certificates of deposit Â Â â€” Â Â Â 4,389 Â Â Â â€” Â Â Â 4,389 Â Corporate bonds Â Â â€” Â Â Â 167,429 Â Â Â â€” Â Â Â 167,429 Â Total marketable securities Â Â â€” Â Â Â 221,951 Â Â Â â€” Â Â Â 221,951 Â Total cash equivalents and marketable securities Â $ â€” Â Â $ 265,722 Â Â $ â€” Â Â $ 265,722 Â Â Â Â Level 1 Â Â Level 2 Â Â Level 3 Â Â Total Â December 31, 2023 Â Â Â Â Â Â Â Â Â Â Â Â Cash equivalents: Â Â Â Â Â Â Â Â Â Â Â Â Money market mutual funds Â $ â€” Â Â $ 13,024 Â Â $ â€” Â Â $ 13,024 Â Total cash equivalents Â Â â€” Â Â Â 13,024 Â Â Â â€” Â Â Â 13,024 Â Marketable securities: Â Â Â Â Â Â Â Â Â Â Â Â U.S. government and agency securities Â Â â€” Â Â Â 70,569 Â Â Â â€” Â Â Â 70,569 Â Certificates of deposit Â Â â€” Â Â Â 6,466 Â Â Â â€” Â Â Â 6,466 Â Corporate bonds Â Â â€” Â Â Â 202,572 Â Â Â â€” Â Â Â 202,572 Â Total marketable securities Â Â â€” Â Â Â 279,607 Â Â Â â€” Â Â Â 279,607 Â Total cash equivalents and marketable securities Â $ â€” Â Â $ 292,631 Â Â $ â€” Â Â $ 292,631 Â Â Management estimates that the carrying values of its current accounts receivable, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to the short-term nature of those instruments. Accounts receivable which contain non-current portions and certain non-current payables reported as other liabilities are recorded at their present values using a discount rate that is based on prevailing market rates on the date the amounts were initially recorded. Management does not believe there have been any significant changes in market conditions or credit quality that would cause the discount rates initially used to be materially different from those that would be used as of September 30, 2024 to determine the present value of these instruments. Accordingly, management estimates that the carrying values of its non-current accounts receivable and other liabilities approximate the fair value of those instruments. Management estimates that the carrying value of the liability related to the sale of future royalties approximates fair value. As discussed in Note 7, the carrying value of the liability related to the sale of future royalties is based on the Companyâ€™s estimate of future royalties expected to be paid by the Company over the life of the arrangement, which are considered Level 3 inputs.Long-lived assets, if determined to be not recoverable and impaired, are measured at fair value on a nonrecurring basis using Level 3 inputs. Please refer to Note 6 for further information on nonrecurring fair value measurements of long-lived assets during the three and nine months ended September 30, 2024 and 2023. 13 Table of Contents Â Â 5. Property and Equipment, NetProperty and equipment, net consists of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Laboratory and manufacturing equipment Â $ 76,788 Â Â $ 75,632 Â Computer equipment and software Â Â 4,748 Â Â Â 4,700 Â Furniture and fixtures Â Â 7,024 Â Â Â 7,052 Â Leasehold improvements Â Â 101,340 Â Â Â 101,927 Â Total property and equipment Â Â 189,900 Â Â Â 189,311 Â Accumulated depreciation and amortization Â Â (69,349) Â Â (57,208) Property and equipment, net Â $ 120,551 Â Â $ 132,103 Â Â In March 2024, the Company entered into an agreement to sublease its office facilities in New York, New York. In connection with the sublease, the Company recorded impairment of property and equipment of $0.7 million in the first quarter of 2024 related to furniture and fixtures and leasehold improvements located at the subleased facility. Please refer to Note 6 for further information regarding the sublease agreement and associated impairment of long-lived assets. 6. LeasesNew York SubleaseIn May 2016, the Company entered into an operating lease for office space in New York, New York (the New York Lease), which has since been amended to include additional office space and extend the term of the lease. The lease term commenced in July 2016 and expires in April 2027.In March 2024, the Company entered into an agreement to sublease its office space under the New York Lease (the New York Sublease) to a third-party subtenant. The sublease term commenced in April 2024 and will expire in April 2027 concurrent with the expiration of the New York Lease. Monthly payments under the New York Sublease commenced in July 2024 and escalate annually in accordance with the sublease agreement. As of September 30, 2024, total undiscounted future minimum lease payments to be received by the Company over the term of the New York Sublease were $1.3 million. The Company recognized sublease income of $0.1 million and $0.2 million under the New York Sublease during the three and nine months ended September 30, 2024, respectively.The New York Sublease is classified as an operating lease and the Company was not relieved of its primary obligation under the New York Lease. The Company continues to account for the New York Lease as it did prior to the commencement of the sublease.As a result of the New York Sublease, the Company determined an impairment indicator was present as of March 31, 2024 related to the long-lived asset group subject to the sublease, which included the right-of-use asset under the New York Lease, leasehold improvements and other property and equipment allocable to the New York Sublease. The Company concluded the carrying value of the asset group as of March 31, 2024 was not recoverable, as it exceeded the sum of the estimated undiscounted cash flows to be generated by the assets over their remaining lives. The Company estimated the fair value of the asset group as of March 31, 2024 using a discounted cash flow method, which incorporated unobservable inputs including the net identifiable cash flows over the term of the New York Sublease and an estimated borrowing rate of a market participant subtenant. The estimated fair value of the asset group as of March 31, 2024 represents a Level 3 nonrecurring fair value measurement. The Company concluded the carrying value of the asset group of $3.4 million exceeded its estimated fair value of $1.3 million as of March 31, 2024. As such, the Company recognized impairment losses of $2.1 million during the three months ended March 31, 2024 and the nine months ended September 30, 2024 on the long-lived asset group associated with the New York Sublease. The impairment losses were allocated to the various assets within the long-lived asset group based on their relative carrying values and consisted of $1.4 million recorded to the right-of-use assets and $0.7 million recorded to property and equipment. No material impairment losses on long-lived assets were recorded during the three months ended September 30, 2024 and the three and nine months ended September 30, 2023. 14 Table of Contents Â Â 7. Liability Related to Sale of Future RoyaltiesIn December 2020, the Company entered into a royalty purchase agreement (the Royalty Purchase Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Under the Royalty Purchase Agreement, HCR purchased the Companyâ€™s rights to a capped amount of Zolgensma royalty payments under the Companyâ€™s license agreement (the Novartis License) with Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies), including $4.0 million of royalty payments received by the Company in the fourth quarter of 2020 (the Pledged Royalties). In consideration for these rights, HCR paid the Company $200.0 million (the Purchase Price), less $4.0 million representing the payment of the Pledged Royalties to HCR. Beginning upon the effective date of the Royalty Purchase Agreement, Zolgensma royalty payments, up to a specified threshold, shall be paid to HCR, net of upstream royalties payable by the Company to certain licensors in accordance with existing license agreements.Pursuant to the Royalty Purchase Agreement, the total amount of royalty payments to be received by HCR is subject to an increasing cap (the Cap Amount) equal to (i) $260.0 million applicable for the period from the effective date of the Royalty Purchase Agreement through November 7, 2024, and (ii) $300.0 million applicable for the period from November 8, 2024 through the effective date of termination of the Novartis License. If, on or prior to the defined dates for each Cap Amount, the total amount of royalty payments received by HCR equals or exceeds the Cap Amount applicable to such date, the Royalty Purchase Agreement will automatically terminate and all rights to the Zolgensma royalty payments will revert back to the Company. The Company has no obligation to repay any amounts to HCR if total future Zolgensma royalty payments are not sufficient to achieve the applicable Cap Amount prior to the termination of the Novartis License.The Company has a call option to repurchase its rights to the purchased royalties from HCR for a repurchase price equal to, as of the option exercise date, $300.0 million minus the total amount of royalty payments received by HCR; provided, however, that with respect to a call option exercised on or before November 7, 2024, in the event that the then applicable Cap Amount minus the total amount of royalty payments received by HCR is less than $1.0 million, the repurchase price shall equal such difference.The proceeds received from HCR of $196.0 million were recorded as a liability, net of transaction costs of $3.5 million, which is amortized over the estimated life of the arrangement using the effective interest method. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received by HCR, subject to the Cap Amount, over the life of the arrangement. The total amount of royalty payments received by HCR under the Royalty Purchase Agreement, less the net proceeds received by the Company of $192.5 million, is recorded as interest expense over the life of the arrangement using the effective interest method. Due to its continuing involvement in the Novartis License, the Company continues to recognize royalty revenue on net sales of Zolgensma and records the royalty payments to HCR as a reduction of the liability when paid. As such payments are made to HCR, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement.The Company estimates the effective interest rate used to record interest expense under the Royalty Purchase Agreement based on its estimate of future royalty payments to be received by HCR. As of September 30, 2024, the estimated effective interest rate under the Royalty Purchase Agreement was 4.2%. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the royalty payments received by HCR and changes in the Companyâ€™s forecasted royalties. At each reporting date, the Company reassesses its estimate of total future royalty payments to be received by HCR at the applicable Cap Amount, and prospectively adjusts the effective interest rate and amortization of the liability, as necessary.The following table presents the changes in the liability related to the sale of future royalties under the Royalty Purchase Agreement with HCR (in thousands):Â Â Â Liability Related to Â Â Â Sale of Future Royalties Â Balance at December 31, 2023 Â $ 94,052 Â Zolgensma royalties paid to HCR Â Â (35,072) Interest expense recognized Â Â 2,769 Â Balance at September 30, 2024 Â Â 61,749 Â Current portion of liability related to sale of future royalties Â Â (26,697) Liability related to sale of future royalties, non-current Â $ 35,052 Â Â 15 Table of Contents Â Â 8. CapitalizationMarch 2024 Public OfferingIn March 2024, the Company completed a public offering of 4,565,260 shares of its common stock at a price of $23.00 per share and 1,521,740 pre-funded warrants to purchase shares of its common stock at a price of $22.9999 per pre-funded warrant, which equaled the public offering price per share of the common stock less the $0.0001 exercise price of each pre-funded warrant. The aggregate net proceeds received by the Company from the offering were $131.1 million, net of underwriting discounts and commissions and offering expenses payable by the Company.The rights and privileges of the pre-funded warrants issued under the March 2024 offering are set forth in the warrant agreement between the Company and each of the respective warrant holders. The pre-funded warrants are exercisable at the option of the warrant holder at any time and do not expire. However, as set forth in the warrant agreements with each holder, the number of pre-funded warrants that may be exercised at any given time may be limited if, upon exercise, the warrant holder and any of its affiliates would beneficially own more than 9.99% of the Companyâ€™s common stock, or have voting power of more than 9.99% of the Company's common stock. The limitation threshold may be increased or decreased by the warrant holder, with advance notice to the Company, to any other percentage not less than 4.99% nor in excess of 19.99%. Pre-funded warrants do not provide any of the rights or privileges provided by the Company's common stock, including any voting rights, until the pre-funded warrants are exercised and settled in underlying shares of common stock.The Company evaluated the pre-funded warrants issued under the March 2024 offering and concluded the warrants are indexed to the Company's common stock, meet the criteria to be classified as equity and are not subject to remeasurement. The proceeds received from the issuance of the pre-funded warrants were recorded as additional paid-in capital. The Company issued 197,000 shares of common stock upon the exercise of pre-funded warrants during the nine months ended September 30, 2024. There were no exercises of pre-funded warrants during the three months ended September 30, 2024. As of September 30, 2024, 1,324,740 pre-funded warrants remained outstanding. At-the-Market Offering ProgramIn September 2023, the Company entered into an ATM Equity OfferingSM Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $150.0 million from time to time through BofA, acting as the Company's sales agent (the ATM Program). As of September 30, 2024, no shares of common stock had been sold under the ATM Program. 9. License and Collaboration AgreementsLicense and Royalty RevenueAs of September 30, 2024, the Companyâ€™s NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma, and in the development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development of certain product candidates. Consideration to the Company under its license agreements may include: (i) up-front and annual fees, (ii) milestone payments based on the achievement of certain development and sales-based milestones, (iii) sublicense fees, (iv) royalties on sales of licensed products, (v) fees for services related to the development of licensed products and (vi) other consideration payable upon optional goods and services purchased by licensees. Sublicense fees vary by license and range from a mid-single digit percentage to a low-double digit percentage of license fees received by licensees as a result of sublicenses. Royalties on net sales of commercialized products vary by license and range from a mid-single digit percentage to a low double-digit percentage of net sales by licensees.License and royalty revenue consisted of the following (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Zolgensma royalties Â $ 23,872 Â Â $ 28,364 Â Â $ 60,849 Â Â $ 63,454 Â Other license and royalty revenue Â Â 325 Â Â Â 550 Â Â Â 1,265 Â Â Â 4,575 Â Total license and royalty revenue Â $ 24,197 Â Â $ 28,914 Â Â $ 62,114 Â Â $ 68,029 Â Â 16 Table of Contents Â Â Outstanding development milestone payments are evaluated each reporting period and

are only included in the transaction price of each license and recognized as license revenue to the extent the milestones are considered probable of achievement. Sales-based milestones are excluded from the transaction price of each license agreement and recognized as royalty revenue in the period of achievement. As of September 30, 2024, the Companyâ€™s license agreements, excluding additional licenses that could be granted upon the exercise of options by licensees, contained unachieved milestones which could result in aggregate milestone payments to the Company of up to $1.51 billion, including (i) $524.9 million upon the commencement of various stages of clinical trials, (ii) $113.8 million upon the submission of regulatory approval filings or upon regulatory approval of licensed products and (iii) $870.0 million upon the achievement of specified sales targets for licensed products, including milestones payable upon the first commercial sale of licensed products. To the extent the milestone payments are realized by the Company, the Company may be obligated to pay sublicense fees to licensors based on a specified percentage of the fees earned by the Company. The achievement of these milestones is highly dependent on the successful development and commercialization of licensed products and it is at least reasonably possible that some or all of the milestone fees will not be realized by the Company. Changes in Accounts Receivable, Contract Assets and Deferred RevenueThe following table presents the balances of the Companyâ€™s net accounts receivable, contract assets and deferred revenue, as well as other information regarding revenue recognized during the periods presented (in thousands):Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Accounts receivable, net, current and non-current: Â Â Â Â Â Â Â Â Â Â Â Â Beginning of period Â $ 23,273 Â Â $ 22,523 Â Â $ 25,491 Â Â $ 29,586 Â End of period Â $ 24,008 Â Â $ 29,121 Â Â $ 24,008 Â Â $ 29,121 Â Contract assets: Â Beginning of period Â $ 194 Â Â $ 2,000 Â Â $ â€” Â Â $ â€” Â End of period Â $ 259 Â Â $ 2,000 Â Â $ 259 Â Â $ 2,000 Â Deferred revenue: Â Â Â Â Â Â Â Â Â Â Â Â Beginning of period Â $ 21 Â Â $ 448 Â Â $ 148 Â Â $ 1,829 Â End of period Â $ 144 Â Â $ 442 Â Â $ 144 Â Â $ 442 Â Revenue recognized during the period from: Â Â Â Â Â Â Â Â Â Â Â Â Amounts included in deferred revenue at beginning of period Â $ 21 Â Â $ 28 Â Â $ 148 Â Â $ 1,409 Â Performance obligations satisfied in previous periods Â $ 23,875 Â Â $ 28,365 Â Â $ 60,912 Â Â $ 65,405 Â Â As of September 30, 2024, the Company had recorded deferred revenue of $0.1 million which represents consideration received or unconditionally due from licensees for performance obligations that have not yet been satisfied by the Company. Unsatisfied performance obligations as of September 30, 2024 consisted of research and development services to be performed by the Company related to licensed products, which will be satisfied as the services are performed. As of September 30, 2024, the aggregate transaction price of the Companyâ€™s license agreements allocated to performance obligations not yet satisfied, or partially satisfied, was $1.5 million, which is expected to be satisfied over a period of approximately two to three years.Revenue recognized from performance obligations satisfied in previous periods, as presented in the table above, was primarily attributable to Zolgensma royalties and changes in the transaction prices of the Companyâ€™s license agreements. Changes in transaction prices were primarily attributable to development milestones achieved or deemed probable of achievement during the periods which were previously not considered probable of achievement, resulting in a cumulative catch-up adjustment to revenue. Revenue recognized during the nine months ended September 30, 2023 included $2.0 million in cumulative catch-up adjustments for changes in the probability of achievement of development milestones. There were no cumulative catch-up adjustments to revenue for changes in the probability of achievement of development milestones during the three and nine months ended September 30, 2024 or during the three months ended September 30, 2023. 17 Table of Contents Â Â Accounts Receivable, Contract Assets and the Allowance for Credit LossesAccounts receivable, net consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Current accounts receivable: Â Â Â Â Â Billed to customers Â $ 105 Â Â $ 265 Â Unbilled Zolgensma royalties Â Â 23,138 Â Â Â 24,128 Â Due from Abeona, net of present value discount Â Â 4,942 Â Â Â 4,587 Â Other unbilled Â Â 361 Â Â Â 397 Â Allowance for credit losses Â Â (4,942) Â Â (4,587) Current accounts receivable, net Â Â 23,604 Â Â Â 24,790 Â Non-current accounts receivable: Â Â Â Â Â Â Other unbilled Â Â 404 Â Â Â 701 Â Non-current accounts receivable, net Â Â 404 Â Â Â 701 Â Total accounts receivable, net Â $ 24,008 Â Â $ 25,491 Â Â The following table presents the changes in the allowance for credit losses related to accounts receivable and contract assets for the nine months ended September 30, 2024 (in thousands):Â Â Â Allowance for Credit Losses Â Â Â Accounts Receivable Â Â Contract Assets Â Balance at December 31, 2023 Â $ 4,587 Â Â $ â€” Â Changes in present value discount of receivables Â Â 355 Â Â Â â€” Â Balance at September 30, 2024 Â $ 4,942 Â Â $ â€” Â Â The Companyâ€™s allowance for credit losses as of September 30, 2024 and December 31, 2023 was related solely to accounts receivable from Abeona Therapeutics Inc. (Abeona). Please refer to the section below, "Settlement Agreement with Abeona Therapeutics", for further information regarding amounts due from Abeona and the associated allowance for credit losses. The Company did not record a provision for credit losses for the three and nine months ended September 30, 2024 and 2023.Zolgensma License with Novartis Gene TherapiesIn March 2014, the Company entered into an exclusive license agreement (as amended, the Novartis License) with Novartis Gene Therapies. Under the Novartis License, the Company granted Novartis Gene Therapies an exclusive, worldwide commercial license, with rights to sublicense, to the NAV Technology Platform, as well as other certain rights, for the treatment of spinal muscular atrophy (SMA) in humans by in vivo gene therapy. In 2019, Novartis Gene Therapies launched commercial sales of Zolgensma, a licensed product under the Novartis License. In accordance with the Novartis License, the Company receives royalties on net sales of Zolgensma.The Company recognized the following amounts under the Novartis License (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Zolgensma royalties Â $ 23,872 Â Â $ 28,364 Â Â $ 60,849 Â Â $ 63,454 Â Total license and royalty revenue Â $ 23,872 Â Â $ 28,364 Â Â $ 60,849 Â Â $ 63,454 Â Interest income from licensing Â $ 6 Â Â $ 7 Â Â $ 20 Â Â $ 22 Â Â 18 Table of Contents Â Â As of September 30, 2024 and December 31, 2023, the Company had recorded total accounts receivable of $23.3 million and $24.3 million, respectively, from Novartis Gene Therapies under the Novartis License, which consisted primarily of Zolgensma royalties receivable. The Zolgensma royalties receivable recorded as of September 30, 2024 included $11.1 million expected to be paid to HCR in accordance with the Royalty Purchase Agreement discussed in Note 7. The Company recognizes royalty revenue from net sales of Zolgensma in the period in which the underlying products are sold by Novartis Gene Therapies, which in certain cases may require the Company to estimate royalty revenue for periods of net sales which have not yet been reported to the Company. Estimated royalties are reconciled to actual amounts reported in subsequent periods, and any differences are recognized as an adjustment to royalty revenue in the period the royalties are reported.Settlement Agreement with Abeona TherapeuticsIn November 2021, the Company entered into a settlement agreement and mutual release with Abeona (the Settlement Agreement) related to claims associated with a license agreement between the parties which was terminated in May 2020. The Settlement Agreement resolved all arbitration and legal proceedings and mutually released each party from any and all claims under the terminated license agreement. Pursuant to the Settlement Agreement, Abeona will pay the Company a total of $30.0 million as follows: (i) $20.0 million which was paid in November 2021, (ii) $5.0 million which was paid in November 2022, and (iii) $5.0 million payable on the earlier of the third anniversary of the Settlement Agreement in November 2024 or the closing of a specified type of transaction by Abeona.As of September 30, 2024 and December 31, 2023, the Company had recorded accounts receivable of $4.9 million and $4.6 million, respectively, associated with the remaining amounts due from Abeona under the Settlement Agreement. The receivable of $4.9 million as of September 30, 2024 consisted of the $5.0 million payment due by November 2024, net of discount to present value. While the Company anticipates taking appropriate measures to enforce the full collection of all amounts due from Abeona under the Settlement Agreement, the Company assessed the collectability of the accounts receivable from Abeona as it relates to credit risk. In performing this assessment, the Company evaluated Abeonaâ€™s credit profile and financial condition, as well its expectations regarding Abeonaâ€™s future cash flows and ability to satisfy the contractual obligations of the Settlement Agreement. As a result of its analysis, the Company recorded an allowance for credit losses of $4.9 million and $4.6 million as of September 30, 2024 and December 31, 2023, respectively, related to the accounts receivable due from Abeona. No credit losses or recoveries were recorded on the Abeona receivable during the three and nine months ended September 30, 2024 and 2023. The present value discount of the Abeona receivable is accreted as interest income from licensing through the contractual due date using the effective interest method. The Company has elected to record increases in the allowance for credit losses associated with the accretion of the present value discount as a reduction of the associated interest income, resulting in no interest income recognized during the periods related to the accretion of the present value discount on the Abeona receivable.Collaboration AgreementsAbbVie Collaboration and License AgreementIn September 2021, the Company entered into a collaboration and license agreement with AbbVie Global Enterprises Ltd. (AbbVie), a subsidiary of AbbVie Inc., to jointly develop and commercialize ABBV-RGX-314, the Companyâ€™s product candidate for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases (the AbbVie Collaboration Agreement). The AbbVie Collaboration Agreement became effective in November 2021.Pursuant to the AbbVie Collaboration Agreement, the Company granted AbbVie a co-exclusive license to develop and commercialize ABBV-RGX-314 in the United States and an exclusive license to develop and commercialize ABBV-RGX-314 outside the United States. The Company and AbbVie will collaborate to develop ABBV-RGX-314 in the United States, and AbbVie will be responsible for the development of ABBV-RGX-314 in specified markets outside the United States. Through December 31, 2022, the Company was responsible for the development expenses related to certain ongoing clinical trials of ABBV-RGX-314 and the parties shared the additional development expenses related to ABBV-RGX-314. Beginning on January 1, 2023, AbbVie became responsible for the majority of all ABBV-RGX-314 development expenses. 19 Table of Contents Â Â The Company will lead the manufacturing of ABBV-RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead the manufacturing of ABBV-RGX-314 for commercial supply outside the United States. Manufacturing expenses will be allocated between the parties in accordance with the terms of the AbbVie Collaboration Agreement and supply agreements determined in accordance with the agreement. If requested by AbbVie, the Company will manufacture up to a specified portion of ABBV-RGX-314 for commercial supply outside the United States at a price specified in the agreement. AbbVie will lead the commercialization of ABBV-RGX-314 globally, and the Company will participate in U.S. commercialization efforts as provided under a commercialization plan determined in accordance with the agreement. The Company and AbbVie will share equally in the net profits and net losses associated with the commercialization of ABBV-RGX-314 in the United States. Outside the United States, AbbVie will be responsible, at its sole cost, for the commercialization of ABBV-RGX-314.In consideration for the rights granted under the AbbVie Collaboration Agreement, AbbVie paid the Company an up-front fee of $370.0 million upon the effective date of the agreement in November 2021 and is required to pay to the Company up to $1.38 billion upon the achievement of specified development and sales-based milestones, of which $562.5 million are based on development milestones and $820.0 million are sales-based milestones. AbbVie is also required to pay to the Company tiered royalties on net sales of ABBV-RGX-314 outside the United States at percentages in the mid-teens to low twenties, subject to specified offsets and reductions. The Company applied the requirements of ASC 606, Revenue from Contracts with Customers (ASC 606) to the AbbVie Collaboration Agreement for the units of account in which AbbVie was deemed to be a customer. The Company determined that there is only one material performance obligation under the agreement for the delivery of the intellectual property license to develop and commercialize ABBV-RGX-314 globally. The intellectual property licensed to AbbVie includes the rights to certain patents, data, know-how and other rights developed and owned by the Company, as well as other intellectual property rights exclusively licensed by the Company from various third parties. As of September 30, 2024 and December 31, 2023, the transaction price of the AbbVie Collaboration Agreement was $370.0 million, which consisted solely of the up-front payment received from AbbVie in November 2021. The $370.0 million transaction price was fully recognized as revenue upon the delivery of the license to AbbVie in November 2021. Variable consideration under the AbbVie Collaboration Agreement, which has been excluded from the transaction price, includes $562.5 million in payments for development milestones that have not yet been achieved and were not considered probable of achievement. Additionally, the transaction price excludes sales-based milestone payments of $820.0 million and royalties on net sales of ABBV-RGX-314 outside the United States. Development milestones will be added to the transaction price and recognized as revenue upon achievement, or if deemed probable of achievement. In accordance with the sale- or usage-based royalty exception under ASC 606, royalties on net sales and sales-based milestones will be recognized as revenue in the period the underlying sales occur or milestones are achieved. There were no changes in the transaction price of the AbbVie Collaboration Agreement, and no revenue was recognized, during the three and nine months ended September 30, 2024 and 2023.The Company applied the requirements of ASC 808, Collaborative Arrangements (ASC 808) to the AbbVie Collaboration Agreement for the units of account which were deemed to be a collaborative arrangement. Both the Company and AbbVie will perform various activities related to the development, manufacturing and commercialization of ABBV-RGX-314 in the United States. Development costs are shared between the parties in accordance with the terms of the AbbVie Collaboration Agreement, and the parties will share equally in the net profits and losses derived from sales of ABBV-RGX-314 in the United States. The Company accounts for payments to and from AbbVie for the sharing of development and commercialization costs in accordance with its accounting policy for collaborative arrangements. Amounts owed to AbbVie for the Companyâ€™s share of development costs or commercialization costs incurred by AbbVie are recorded as research and development expense or general and administrative expense, respectively, in the period the costs are incurred. Amounts owed to the Company for AbbVieâ€™s share of development costs or commercialization costs incurred by the Company are recorded as a reduction of research and development expense or general and administrative expense, respectively, in the period the costs are incurred. At the end of each reporting period, the Company records a net amount due to or from AbbVie as a result of the cost-sharing arrangement. As of September 30, 2024 and December 31, 2023, the Company had recorded $20.3 million and $17.7 million, respectively, due from AbbVie for net reimbursement of costs incurred for activities performed under AbbVie Collaboration Agreement, which was included in other current assets on the consolidated balance sheets. 20 Table of Contents Â Â The Company recognized the following amounts under the AbbVie Collaboration Agreement (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net cost reimbursement to (from) AbbVie included in: Â Â Â Â Â Â Â Â Â Â Â Â Research and development expense Â $ (20,082) Â $ (19,608) Â $ (66,330) Â $ (56,300) General and administrative expense Â Â 341 Â Â Â Â 615 Â Â Â 1,168 Â Â Â 1,007 Â Total net cost reimbursement to (from) AbbVie Â $ (19,741) Â $ (18,993) Â $ (65,162) Â $ (55,293) Â 10. Stock-based CompensationEffective in January 2024, an additional 1,761,849 shares were authorized for issuance under the 2015 Equity Incentive Plan (the 2015 Plan). As of September 30, 2024, the total number of shares of common stock authorized for issuance under the 2015 Plan and the 2014 Stock Plan (the 2014 Plan) was 19,118,989, of which 1,511,556 remained available for future grants under the 2015 Plan.Stock-based Compensation ExpenseThe Companyâ€™s stock-based compensation expense by award type was as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Stock options Â $ 6,051 Â Â $ 7,275 Â Â $ 17,969 Â Â $ 22,868 Â Restricted stock units Â Â 3,755 Â Â Â 2,843 Â Â Â 10,536 Â Â Â 8,475 Â Employee stock purchase plan Â Â 78 Â Â Â 101 Â Â Â 416 Â Â Â 586 Â Â Â $ 9,884 Â Â $ 10,219 Â Â $ 28,921 Â Â $ 31,929 Â Â As of September 30, 2024, the Company had $69.5 million of unrecognized stock-based compensation expense related to stock options, restricted stock units and the 2015 Employee Stock Purchase Plan (the 2015 ESPP), which is expected to be recognized over a weighted-average period of 2.4 years.The Company recorded aggregate stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows (in thousands):Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Research and development Â $ 4,301 Â Â $ 5,131 Â Â $ 13,893 Â Â $ 16,670 Â General and administrative Â Â 5,583 Â Â Â 5,088 Â Â Â 15,028 Â Â Â 15,259 Â Â Â $ 9,884 Â Â $ 10,219 Â Â $ 28,921 Â Â $ 31,929 Â Â 21 Table of Contents Â Â Stock OptionsThe following table summarizes stock option activity under the 2014 Plan and 2015 Plan (in thousands, except per share data):Â Â Â Â Â Â Â Â Â Â Â Â Weighted- Â Â Â Â Â Â Â Â Â Â Â Â average Â Â Â Â Â Â Â Â Weighted- Â Â Remaining Â Â Â Â Â Â Â Â Â Â average Â Â Contractual Â Â Aggregate Â Â Â Â Â Â Exercise Â Â Life Â Â Intrinsic Â Â Â Shares Â Â Price Â Â (Years) Â Â Value (a) Â Outstanding at December 31, 2023 Â Â 8,581 Â Â $ 32.62 Â Â Â 6.2 Â Â $ 7,011 Â Granted Â Â 2,263 Â Â $ 16.24 Â Â Â Â Â Â Â Â Exercised Â Â (281) Â $ 5.25 Â Â Â Â Â Â Â Â Cancelled or forfeited Â Â (546) Â $ 35.56 Â Â Â Â Â Â Â Outstanding at September 30, 2024 Â Â 10,017 Â Â $ 29.53 Â Â Â 6.4 Â Â $ 529 Â Exercisable at September 30, 2024 Â Â 6,609 Â Â $ 34.38 Â Â Â 5.1 Â Â $ 529 Â Vested and expected to vest at September 30, 2024 Â Â 10,017 Â Â $ 29.53 Â Â Â 6.4 Â Â $ 529 Â Â (a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at the dates reported.The weighted-average grant date fair value per share of options granted during the nine months ended September 30, 2024 was $10.06. During the nine months ended September 30, 2024, the total number of stock options exercised was 280,753, resulting in total proceeds of $1.5 million. The total intrinsic value of options exercised during the nine months ended September 30, 2024 was $3.0 million.Restricted Stock UnitsThe following table summarizes restricted stock unit activity under the 2015 Plan (in thousands, except per share data):Â Â Â Â Â Â Â Â Weighted-average Â Â Â Â Â Â Â Â Grant Date Â Â Â Shares Â Â Fair Value Â Unvested balance at December 31, 2023 Â Â 1,309 Â Â $ 25.89 Â Granted Â Â 1,188 Â Â $ 16.22 Â Vested Â Â (390) Â $ 27.20 Â Forfeited Â Â (72) Â $ 22.45 Â Unvested balance

at September 30, 2024 Â Â 2,035 Â Â $ 20.11 Â Â The total intrinsic value of restricted stock units vested during the nine months ended September 30, 2024 was $6.7 million. Employee Stock Purchase PlanAs of September 30, 2024, the total number of shares of common stock authorized for issuance under the 2015 ESPP was 1,426,994, of which 912,964 remained available for future issuance. During the nine months ended September 30, 2024, 105,400 shares of common stock were issued under the 2015 ESPP. 11. Income TaxesThe Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets as of September 30, 2024 and December 31, 2023. Based on the Companyâ€™s history of operating losses, and other relevant facts and circumstances, the Company concluded that it was more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company provided a full valuation allowance for its net deferred tax assets as of September 30, 2024 and December 31, 2023. 22 Table of Contents Â Â 12. RestructuringIn November 2023, the Company implemented a strategic pipeline prioritization and corporate restructuring designed to reduce operating expenses and prioritize the development of ABBV-RGX-314, RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), while pursuing strategic alternatives for the Company's other clinical stage programs. The restructuring included a reduction in workforce and other planned operating expenses, primarily in rare neurodegenerative disease development, early research and other general and administrative areas.In connection with the restructuring, the Company implemented a reduction in workforce of approximately 15%, which was substantially completed in the fourth quarter of 2023. The Company recorded restructuring costs of $3.7 million in the fourth quarter of 2023, which primarily consisted of employee severance, continuing healthcare benefits and other employee-related costs. During the nine months ended September 30, 2024, the Company recorded reductions in the restructuring liability of $0.4 million associated with changes in total estimated restructuring costs. As of September 30, 2024, all of the restructuring costs had been paid by the Company and no restructuring liability was recorded. The following table presents the details of the Company's restructuring liability as of September 30, 2024 (in thousands):Â Â Â Restructuring Liability Â Balance at December 31, 2022 Â $ â€” Â Restructuring charges Â Â 3,731 Â Cash payments Â Â (1,925) Balance at December 31, 2023 Â Â 1,806 Â Cash payments Â Â (1,370) Other adjustments Â Â (436) Balance at September 30, 2024 Â $ â€” Â Â 13. Net Loss Per ShareSince the Company incurred net losses for the three and nine months ended September 30, 2024 and 2023, common stock equivalents were excluded from the calculation of diluted net loss per share for such periods as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share were the same for such periods. The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants to purchase shares of the Company's common stock, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands):Â Â Â Three and Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Stock options issued and outstanding Â Â 10,017 Â Â Â 8,856 Â Unvested restricted stock units outstanding Â Â 2,035 Â Â Â 1,394 Â Employee stock purchase plan Â Â 47 Â Â Â 36 Â Â Â Â 12,099 Â Â Â 10,286 Â Â Â 14. Supplemental DisclosuresOther Current AssetsOther current assets consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Net cost reimbursement due from collaborators Â $ 20,302 Â Â $ 17,745 Â Accrued interest on investments Â Â 1,578 Â Â Â 1,551 Â Other Â Â 1,450 Â Â Â 1,107 Â Â Â $ 23,330 Â Â $ 20,403 Â Â 23 Table of Contents Â Â Accrued Expenses and Other Current LiabilitiesAccrued expenses and other current liabilities consisted of the following (in thousands):Â Â Â September 30, 2024 Â Â December 31, 2023 Â Accrued external research and development expenses Â $ 16,715 Â Â $ 13,762 Â Accrued sublicense fees and royalties Â Â 14,628 Â Â Â 14,234 Â Accrued personnel costs Â Â 14,335 Â Â Â 18,146 Â Accrued external general and administrative expenses Â Â 1,843 Â Â Â 2,717 Â Accrued purchases of property and equipment Â Â 334 Â Â Â 386 Â Other accrued expenses and current liabilities Â Â 787 Â Â Â 458 Â Â Â $ 48,642 Â Â $ 49,703 Â Supplemental Disclosures of Non-cash Investing and Financing ActivitiesPurchases of property and equipment included in accounts payable and accrued expenses and other current liabilities were $0.4 million as of September 30, 2024, a net decrease of less than $0.1 million from December 31, 2023, and $0.5 million as of September 30, 2023, a net decrease of $2.0 million from December 31, 2022.Offering expenses for the ATM Program included in accounts payable and accrued expenses and other liabilities were $0.4 million as of September 30, 2023. No such amounts were recorded as of September 30, 2024. Â 24 Table of Contents Â Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, which we filed with the SEC on February 27, 2024. In addition, you should read the â€œRisk Factorsâ€ and â€œInformation Regarding Forward-Looking Statementsâ€ sections of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Overview We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease. Through a single administration, gene therapy could potentially alter the course of disease significantly and deliver improved patient outcomes with long-lasting effects. Overview of Product Candidates We have developed a broad pipeline of gene therapy programs using our proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) as a one-time treatment to address an array of diseases. Our lead programs and product candidates are described below: â€¢ABBV-RGX-314: We are developing ABBV-RGX-314 in collaboration with AbbVie as a potential one-time treatment for chronic retinal conditions which cause total or partial vision loss, including wet age-related macular degeneration (wet AMD) and diabetic retinopathy (DR). ABBV-RGX-314 is currently being evaluated in multiple ongoing clinical trials, including two pivotal trials (ATMOSPHERE and ASCENT), one Phase II bridging study, one long-term follow-up study, and a fellow eye treatment study in patients with wet AMD, all utilizing subretinal delivery. Additionally, two Phase II clinical trials in patients with wet AMD (AAVIATE) and DR (ALTITUDE) are ongoing along with two corresponding long-term follow-up studies, all utilizing in-office suprachoroidal delivery. Within the Phase II study in DR, we are also evaluating ABBV-RGX-314 in diabetic macular edema (DME). ABBV-RGX-314 uses the NAVÂ® AAV8 vector to deliver a gene encoding a therapeutic antibody fragment to inhibit vascular endothelial growth factor (VEGF). We have licensed certain exclusive rights to the SCS MicroinjectorÂ® from Clearside Biomedical, Inc. (Clearside) to deliver gene therapy treatments to the suprachoroidal space of the eye. Wet AMD Subretinal Delivery Enrollment continues to be on track in the ATMOSPHEREÂ® and ASCENTâ„¢ pivotal trials for the treatment of patients with wet AMD using subretinal delivery. These trials are expected to support global regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in the first half of 2026. In October 2024, we reported positive data from a Phase II fellow eye sub-study at the American Academy of Ophthalmology (AAO) 2024 annual meeting. The sub-study evaluated subretinal delivery of ABBV-RGX-314 in patients who received ABBV-RGX-314 in the Phase I/IIa or bridging studies and elected to receive treatment in their second eye. As of September 11, 2024, ABBV-RGX-314 was well tolerated in the treated fellow eye, with no drug-related serious adverse events and no cases of intraocular inflammation observed. At nine months post-administration, patients saw a 97% reduction in anti-VEGF treatment burden and sustained vision and anatomy. These data demonstrate the potential of ABBV-RGX-314 to preserve vision long-term for patients with wet AMD as a one-time treatment for both eyes. Bilateral disease impacts a significant number of patients with wet AMD. Suprachoroidal Delivery The AAVIATEÂ® trial is a multi-center, open label, randomized, controlled, dose-escalation Phase II trial to evaluate the efficacy, safety and tolerability of suprachoroidal delivery of ABBV-RGX-314 for the treatment of wet AMD. As of July 29, 2024, ABBV-RGX-314 at dose level 3 with short course prophylactic steroid eye drops continues to be well tolerated with no drug-related serious adverse events (SAEs) and no cases of intraocular inflammation, endophthalmitis, vasculitis, retinal artery occlusion, choroidal effusion, or hypotony. Mild episcleritis occurred in three patients, all resolved and completed treatment with topical steroids. There were no cases of elevated intraocular pressure. Based on this favorable safety profile, the Phase II AAVIATE trial is initiating enrollment in a new cohort to evaluate ABBV-RGX-314 at dose level 4 (1.5x10e12 GC/eye). Patients in this cohort will also receive short course prophylactic steroid eye drops. 25 Table of Contents Â Â DR and DME The ALTITUDEÂ® trial is a multi-center, open label, randomized, controlled, dose-escalation Phase II trial to evaluate the efficacy, safety and tolerability of ABBV-RGX-314 using suprachoroidal delivery for the treatment of DR. Based on positive interim results from this trial, we and AbbVie have accelerated a planned End-of-Phase II (EOP2) meeting with the FDA expected to occur in the fourth quarter of 2024. We expect to initiate the first global pivotal trial in the first half of 2025. The ALTITUDE trial is now enrolling a new cohort of patients with center-involved DME. DME is a vision-threatening complication of DR; an estimated 34 million people globally have DME. Patients will receive a one-time, in-office injection of ABBV-RGX-314 at dose level 4 (1.5x10e12 GC/eye) with short course prophylactic steroid eye drops. â€¢RGX-202: We are developing RGX-202 as an investigational one-time AAV therapeutic for the treatment of Duchenne muscular dystrophy (Duchenne), using the NAV AAV8 vector to deliver a transgene for a novel microdystrophin that includes the functional elements of the C-Terminal (CT) domain as well as a muscle-specific promoter to support a targeted therapy for improved resistance to muscle damage associated with Duchenne. AFFINITY DUCHENNEÂ® is a Phase I/II multicenter, open-label dose escalation and dose expansion clinical study to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne aged 1 to 11 years old. In March 2024 and May 2024, we reported interim safety and efficacy data from the trial, including RGX-202 microdystrophin expression for the first two patients who received RGX-202 at dose level 2 (DL2). In August 2024, we announced new data from two patients, aged 5.8 and 8.5 years, who received RGX-202 at DL2. RGX-202 microdystrophin expression in these patients was measured to be 77.2% and 46.5%, respectively, compared to control at three months. As of July 8, 2024, RGX-202 has been well tolerated with no SAEs. Data from all seven patients who completed three-month trial assessments indicate meaningful increases in expression of RGX-202 microdystrophin and reduction from baseline in serum creatinine kinase levels, supporting evidence of clinical improvement. In November 2024, we announced that the last patient has been dosed in the dose level 2 (pivotal dose) expansion cohort for ages 4 to 11 years old and the first patient has been dosed in the cohort for ages 1 to 3 years old. A clinical trial application for RGX-202 has been authorized by Health Canada, and we expect to initiate sites in Canada in the first half of 2025. Following a successful EOP2 meeting with the FDA earlier this year, we plan to share a full program update in November 2024, including pivotal trial design and plans for accelerated approval, as well as initial strength and functional assessment data for both dose levels of the AFFINITY DUCHENNE trial. RGX-202 is manufactured using our proprietary, high-yielding NAVXpressâ„¢ platform process. This suspension-based manufacturing process has demonstrated scalability up to 2,000 liters with consistent yield and product purity. Our Manufacturing Innovation Center has the capacity and yields to produce up to 2,500 doses of RGX-202 per year to support future commercialization. â€¢RGX-121: We are developing RGX-121 as an investigational one-time AAV therapeutic for the treatment of Mucopolysaccharidosis Type II (MPS II), also known as Hunter syndrome, using the NAV AAV9 vector to deliver the gene that encodes the iduronate-2-sulfatase enzyme. CAMPSIITEÂ® is a Phase I/II/III multi-center, open-label trial to evaluate the efficacy, safety, tolerability and pharmacodynamics of RGX-121 in patients with MPS II aged 4 months up to 5 years old. We continue to follow patients in the trial and, in February 2024, reported that the pivotal phase of the CAMPSIITE trial achieved its primary endpoint, a reduction in cerebrospinal fluid Heparan sulfate levels of D2S6, a biomarker indicative of brain disease activity, with statistical significance. In September 2024, we announced positive data from the pivotal dose level of RGX-121 demonstrating long-term systemic effect. We plan to use levels of cerebrospinal fluid Heparan sulfate D2S6 as a surrogate endpoint reasonably likely to predict clinical benefit for accelerated approval and have initiated a rolling biologics license application (BLA) submission using the accelerated approval pathway. The BLA submission is expected to be complete in the first quarter of 2025. We believe that RGX-121 is likely to be eligible for priority review, especially if no other gene therapy product for MPS II is approved before submission of a BLA for RGX-121, and potential approval of the Company's planned BLA for RGX-121 could result in receipt of a Rare Pediatric Disease Priority Review Voucher in 2025, assuming the statutory criteria are met, potentially making RGX-121 the first approved gene therapy and one-time treatment for MPS II. 26 Table of Contents Â Â Overview of Our NAV Technology Platform In addition to our internal product development efforts, we also selectively license the NAV Technology Platform and other intellectual property rights to other leading biotechnology and pharmaceutical companies, which we refer to as NAV Technology Licensees. As of September 30, 2024, our NAV Technology Platform was being applied in one commercial product, ZolgensmaÂ®, and the preclinical and clinical development of a number of other licensed products. Licensing the NAV Technology Platform allows us to maintain our internal product development focus on our core disease indications and therapeutic areas while still expanding the NAV gene therapy pipeline, developing a greater breadth of treatments for patients, providing additional technological and potential clinical proof-of-concept for our NAV Technology Platform and creating potential additional revenue opportunities. Financial Overview Revenues Our revenues to date consist primarily of license and royalty revenue resulting from the licensing of our NAV Technology Platform and other intellectual property rights. We have not generated any revenues from commercial sales of our own products. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval and adequate labeling, our ability to generate future revenues will be materially compromised. We license our NAV Technology Platform and other intellectual property rights to other biotechnology and pharmaceutical companies, including collaborators for the joint development and commercialization of our product candidates. The terms of the licenses vary, and licenses may be exclusive or non-exclusive and may be sublicensable by the licensee. Licenses may grant intellectual property rights for purposes of internal and preclinical research and development only, or may include the rights, or options to obtain future rights, to commercialize drug therapies for specific diseases using the NAV Technology Platform and other licensed rights. License agreements generally have a term at least equal to the life of the underlying patents, but are terminable at the option of the licensee. Consideration from licensees under our license agreements may include: (i) up-front and annual fees, (ii) milestone payments based on the achievement of certain development and sales-based milestones, (iii) sublicense fees, (iv) royalties on sales of licensed products, (v) fees for services related to the development of licensed products and (vi) other consideration payable upon optional goods and services purchased by licensees. Future license and royalty revenues are dependent on the successful development and commercialization of licensed products, which is uncertain, and revenues may fluctuate significantly from period to period. Additionally, we may never receive consideration in our license agreements that is contemplated on option fees, development and sales-based milestone payments, royalties on sales of licensed products or sublicense fees, given the contingent nature of these payments. Our revenues are concentrated among a low number of licensees and licenses are terminable at the option of the licensee. The termination of our licenses by licensees may materially impact the amount of revenue we recognize in future periods. Zolgensma Royalties Royalty revenue to date consists primarily of royalties on net sales of Zolgensma, which is marketed by Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the treatment of spinal muscular atrophy (SMA). Zolgensma is a licensed product under our license agreement with Novartis Gene Therapies for the development and commercialization of treatments for SMA using the NAV Technology Platform. Collaboration and License Agreement with AbbVie In September 2021, we entered into a collaboration and license agreement with AbbVie Global Enterprises Ltd. (AbbVie), a subsidiary of AbbVie Inc., to jointly develop and commercialize ABBV-RGX-314 (the AbbVie Collaboration Agreement). The AbbVie Collaboration Agreement may materially impact our future revenues, research and development expenses, other operating expenses and operating cash flows associated with the development and commercialization of ABBV-RGX-314. For additional information regarding the AbbVie Collaboration Agreement, please refer to Note 9, â€œLicense and Collaboration Agreementsâ€”AbbVie Collaboration and License Agreementâ€ to the accompanying unaudited consolidated financial statements. 27 Table of Contents Â Â Operating Expenses Our operating expenses consist primarily of cost of revenues, research and development expenses and general and administrative expenses. Personnel costs including salaries, wages, benefits, bonuses and stock-based compensation expense, comprise a significant component of research and development and general and administrative expenses. We allocate indirect expenses associated with our facilities, information technology costs, depreciation and other overhead costs between research and development and general and administrative categories based on employee headcount and the nature of work performed by each employee or using other reasonable allocation methodologies. Cost of Revenues Our cost of revenues consists primarily of upstream fees due to our licensors as a result of revenue generated from the licensing of our NAV Technology Platform and other intellectual property rights, including sublicense fees and royalties on net sales of licensed products. Sublicense fees are based on a percentage of license fees received by us from licensees and are recognized in the period that the underlying license revenue is recognized. Royalties are based on a percentage of net sales of licensed products by licensees and are recognized in the period that the underlying sales occur. Future costs of revenues are uncertain due to the nature of our license agreements and significant fluctuations in cost of revenues may occur from period to period. Research and Development Expense Our research and development expenses consist primarily of: â€¢salaries, wages and personnel-related costs, including benefits, travel and stock-based compensation, for our scientific personnel and others performing

research and development activities; â€¢costs related to executing preclinical studies and clinical trials; â€¢costs related to acquiring, developing and manufacturing materials for preclinical studies and clinical trials; â€¢fees paid to consultants and other third-parties who support our product candidate development; â€¢other costs in seeking regulatory approval of our product candidates; and â€¢direct costs and allocated costs related to laboratories and facilities, depreciation expense, information technology and other overhead. Up-front fees incurred in obtaining technology licenses for research and development activities, as well as associated milestone payments, are charged to research and development expense as incurred if the technology licensed has no alternative future use. We expect to continue to incur significant research and development expenses for the foreseeable future as we continue the development of our product candidates and engage in early research and development for prospective product candidates and new technologies. The following table summarizes our research and development expenses incurred during the three and nine months ended September 30, 2024 and 2023 (in thousands): Â Â Â Three Months Ended September 30, Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Direct Expenses Â Â Â Â Â Â Â Â Â Â Â Â ABBV-RGX-314 Â $ 10,803 Â Â $ 6,022 Â Â $ 28,773 Â Â $ 16,391 Â RGX-202 Â Â 3,875 Â Â Â 2,088 Â Â Â 9,053 Â Â Â 8,233 Â RGX-121 Â Â 4,017 Â Â Â 4,991 Â Â 11,798 Â Â Â 12,623 Â Other product candidates Â Â 1,174 Â Â Â 2,187 Â Â Â 3,059 Â Â Â 6,725 Â Total direct expenses Â Â 19,869 Â Â Â 15,288 Â Â Â 52,683 Â Â Â 43,972 Â Unallocated Expenses Â Â Â Â Â Â Â Â Â Â Â Â Platform and new technologies Â Â 5,977 Â Â Â 10,306 Â Â Â 17,627 Â Â Â 33,211 Â Personnel-related Â Â 20,789 Â Â Â 23,784 Â Â Â 63,803 Â Â Â 73,201 Â Facilities and depreciation expense Â Â 6,823 Â Â Â 7,274 Â Â Â 20,946 Â Â Â 21,623 Â Other unallocated Â Â 971 Â Â Â 1,531 Â Â 3,083 Â Â Â 4,578 Â Total unallocated expenses Â Â 34,560 Â Â Â 42,895 Â Â Â 105,459 Â Â Â 132,613 Â Total research and development Â $ 54,429 Â Â $ 58,183 Â Â $ 158,142 Â Â $ 176,585 Â Â 28 Table of Contents Â Â Â Direct expenses related to the development of ABBV-RGX-314 include net cost reimbursement from AbbVie under our eye care collaboration of $20.1 million and $66.3 million for the three and nine months ended September 30, 2024, respectively, and $19.6 million and $56.3 million for the three and nine months ended September 30, 2023, respectively, which were recorded as a reduction of research and development expenses. Net cost reimbursement from AbbVie includes reimbursement of personnel and overhead costs attributable to the development of ABBV-RGX-314, the underlying costs of which are reported as unallocated expenses in the table above. We typically utilize our employee and infrastructure resources across our development programs. As a result, we generally do not allocate personnel and other internal costs, such as facilities and other overhead costs, to specific product candidates or development programs. Platform and new technologies reported in the table above include direct costs not identifiable with a specific lead product candidate, including costs associated with our research and development platform used across programs, process development, manufacturing analytics and early research and development for prospective product candidates and new technologies. Direct expenses related to the development of product candidates for which we have discontinued internal development are included in other product candidates in the table above. We expect to continue to incur minor development expenses associated with long-term follow up studies for certain discontinued product candidates. General and Administrative Expense Our general and administrative expenses consist primarily of salaries, wages and personnel-related costs, including benefits, travel and stock-based compensation, for employees performing functions other than research and development. This includes certain personnel in executive, commercial, corporate development, finance, legal, human resources, information technology, facilities and administrative support functions. Additionally, general and administrative expenses include costs associated with accounting, legal, commercial and other corporate advisory services, obtaining and maintaining patents, insurance, information systems and other general corporate activities, as well as facility-related costs and other corporate overhead costs not otherwise allocated to research and development expense. We expect that our general and administrative expenses will increase as we continue to develop, and potentially commercialize, our product candidates. Other Income (Expense) Interest Income from Licensing In accordance with our revenue recognition policy, interest income from licensing consists of imputed interest recognized from significant financing components identified in our license agreements with NAV Technology Licensees as well as interest income accrued on unpaid balances due from licensees. Investment Income Investment income consists of interest income earned and gains and losses realized from our cash equivalents, marketable securities and non-marketable equity securities. Cash equivalents are comprised of money market mutual funds and highly liquid debt securities with original maturities of 90 days or less at acquisition. Marketable securities are comprised of available-for-sale debt securities. Interest Expense Interest expense consists primarily of interest imputed on the liability related to the sale of future Zolgensma royalties to entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Interest expense is recognized using the effective interest method, based on our estimate of total royalty payments expected to be received by HCR under the royalty purchase agreement. For further information regarding the royalty purchase agreement with HCR, please refer to Note 7, â€œLiability Related to Sale of Future Royaltiesâ€ to the accompanying unaudited consolidated financial statements. Critical Accounting Policies and Estimates This Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which we have prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities 29 Table of Contents Â Â for the periods presented. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. Our significant accounting policies are fully described in Note 2 to the accompanying unaudited consolidated financial statements and in Note 2 to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no significant changes in our critical accounting policies and estimates since December 31, 2023. Results of Operations Our consolidated results of operations were as follows (in thousands): Â Â Â Three Months Ended Â Â Â Â Â Nine Months Ended Â Â Â Â Â Â September 30, Â Â Â Â Â September 30, Â Â Â Â Â Â 2024 Â Â 2023 Â Â Change Â Â 2024 Â Â 2023 Â Â Change Â Revenues Â License and royalty revenue Â $ 24,197 Â Â $ 28,914 Â Â $ (4,717) Â $ 62,114 Â Â $ 68,029 Â Â $ (5,915) Total revenues Â Â 24,197 Â Â Â 28,914 Â Â Â (4,717) Â Â 62,114 Â Â Â 68,029 Â Â Â (5,915) Operating Expenses Â Cost of revenues Â Â 12,387 Â Â Â 12,388 Â Â Â (1) Â Â 27,249 Â Â Â 25,975 Â Â Â 1,274 Â Research and development Â Â 54,429 Â Â Â 58,183 Â Â Â (3,754) Â Â 158,142 Â Â Â 176,585 Â Â Â (18,443) General and administrative Â Â 19,422 Â Â Â 23,083 Â Â Â (3,661) Â Â 56,568 Â Â Â 69,415 Â Â Â (12,847) Impairment of long-lived assets Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 2,101 Â Â Â â€” Â Â Â 2,101 Â Other operating expenses Â Â 37 Â Â Â 220 Â Â Â (183) Â Â 32 Â Â Â 279 Â Â Â (247) Total operating expenses Â Â 86,275 Â Â Â 93,874 Â Â Â (7,599) Â Â 244,092 Â Â Â 272,254 Â Â Â (28,162) Loss from operations Â Â (62,078) Â Â (64,960) Â Â 2,882 Â Â Â (181,978) Â Â (204,225) Â Â 22,247 Â Other Income (Expense) Â Interest income from licensing Â Â 25 Â Â Â 56 Â Â Â (31) Â Â 91 Â Â Â 166 Â Â Â (75) Investment income Â Â 3,276 Â Â Â 4,660 Â Â Â (1,384) Â Â 9,213 Â Â Â 8,953 Â Â Â 260 Â Interest expense Â Â (820) Â Â (1,624) Â Â 804 Â Â Â (3,242) Â Â (5,499) Â Â 2,257 Â Total other income Â Â 2,481 Â Â Â 3,092 Â Â (611) Â Â 6,062 Â Â Â 3,620 Â Â Â 2,442 Â Net loss Â $ (59,597) Â $ (61,868) Â $ 2,271 Â Â $ (175,916) Â $ (200,605) Â $ 24,689 Â Â Comparison of the Three Months Ended September 30, 2024 and 2023 License and Royalty Revenue. License and royalty revenue decreased by $4.7 million, from $28.9 million for the three months ended September 30, 2023 to $24.2 million for the three months ended September 30, 2024. The decrease was primarily attributable to Zolgensma royalty revenues, which decreased from $28.4 million for the third quarter of 2023 to $23.9 million for the third quarter of 2024. As reported by Novartis, sales of Zolgensma for the third quarter of 2024 were $308 million, consistent with sales for the third quarter of 2023, and the product continues to treat mainly incident patients in established markets, translating into stable sales for the third quarter of 2024. The decrease in Zolgensma royalties was primarily attributable to fluctuations in the effective royalty rate under the license agreement with Novartis. Research and Development Expense. Research and development expenses decreased by $3.8 million, from $58.2 million for the three months ended September 30, 2023 to $54.4 million for the three months ended September 30, 2024. The decrease was primarily attributable to the following: â€¢a decrease of $3.0 million in personnel-related costs for research and development personnel, including a $0.8 million decrease in stock-based compensation expense, largely driven by the reduction in workforce associated with our corporate restructuring implemented in the fourth quarter of 2023; â€¢a decrease of $2.4 million in preclinical activities and other early-stage research and development; â€¢a decrease of $1.9 million in costs for laboratories and facilities used by research and development personnel, including a $0.4 million decrease in depreciation expense allocated to research and development functions, primarily driven by a decrease in laboratory supplies and consumables; and â€¢a decrease of $1.6 million in manufacturing expenses and other costs of clinical supply for our lead product candidates. 30 Table of Contents Â Â The decrease in research and development expenses was partially offset by an increase of $5.8 million in costs associated with clinical trial activities, largely driven by clinical trial expenses for ABBV-RGX-314 and RGX-202. General and Administrative Expense. General and administrative expenses decreased by $3.7 million, from $23.1 million for the three months ended September 30, 2023 to $19.4 million for the three months ended September 30, 2024. The decrease was primarily attributable to professional services and consulting fees, including legal and other corporate advisory services. Comparison of the Nine Months Ended September 30, 2024 and 2023 License and Royalty Revenue. License and royalty revenue decreased by $5.9 million, from $68.0 million for the nine months ended September 30, 2023 to $62.1 million for the nine months ended September 30, 2024. The decrease was primarily attributable to non-recurring development milestone revenue recognized in the first nine months of 2023 and Zolgensma royalty revenues, which decreased from $63.5 million for the first nine months of 2023 to $60.8 million for the first nine months of 2024. As reported by Novartis, sales of Zolgensma for the first nine months of 2024 were $952 million, an increase of 3% from the first nine months of 2023, and the product continues to treat mainly incident patients in established markets. The decrease in Zolgensma royalties was primarily attributable to fluctuations in the effective royalty rate under the license agreement with Novartis. Research and Development Expense. Research and development expenses decreased by $18.4 million, from $176.6 million for the nine months ended September 30, 2023 to $158.1 million for the nine months ended September 30, 2024. The decrease was primarily attributable to the following: â€¢a decrease of $13.4 million in manufacturing expenses and other costs of clinical supply for our lead product candidates, largely driven by ABBV-RGX-314 and RGX-202 clinical supply costs; â€¢a decrease of $9.4 million in personnel-related costs for research and development personnel, including a $2.8 million decrease in stock-based compensation expense, largely driven by the reduction in workforce associated with our corporate restructuring implemented in the fourth quarter of 2023; â€¢a decrease of $6.1 million in costs for laboratories and facilities used by research and development personnel, including a $0.8 million decrease in depreciation expense allocated to research and development functions, primarily driven by a decrease in laboratory supplies and consumables; and â€¢a decrease of $5.5 million in preclinical activities and other early-stage research and development. The decrease in research and development expenses was partially offset by an increase of $17.5 million in costs associated with clinical trial activities, largely driven by clinical trial expenses for ABBV-RGX-314 and RGX-202. General and Administrative Expense. General and administrative expenses decreased by $12.8 million, from $69.4 million for the nine months ended September 30, 2023 to $56.6 million for the nine months ended September 30, 2024. The decrease was primarily attributable to the following: â€¢a decrease of $10.3 million in professional services and consulting fees, including legal and other corporate advisory services; and â€¢a decrease of $1.4 million in personnel-related costs for general and administrative personnel, including a $0.2 million decrease in stock-based compensation expense, largely driven by the reduction in workforce associated with our corporate restructuring implemented in the fourth quarter of 2023. Liquidity and Capital Resources Sources of Liquidity As of September 30, 2024, we had cash, cash equivalents and marketable securities of $278.6 million, which were primarily derived from the sale of our common stock and pre-funded warrants described below and license fees received under the AbbVie Collaboration Agreement. We expect that our cash, cash equivalents and marketable securities as of September 30, 2024 will enable us to fund our operating expenses and capital expenditure requirements, and are sufficient to meet our financial commitments and obligations, for at least the next 12 months from the date of this report based on our current business plan. In March 2024, we completed a public offering of 4,565,260 shares of our common stock at a price of $23.00 per share and 1,521,740 pre-funded warrants to purchase shares of our common stock at a price of $22.9999 per pre-funded warrant, which equaled 31 Table of Contents Â Â the public offering price per share of the common stock less the $0.0001 exercise price of each pre-funded warrant. The aggregate net proceeds received from the offering were $131.1 million, net of underwriting discounts and commissions and offering expenses. We intend to devote the majority of our current capital to preclinical research, clinical development, seeking regulatory approval of our product candidates and, if approved, commercialization of our product candidates, as well as additional capital expenditures needed to support these activities. Because of the numerous risks and uncertainties associated with the development and commercialization of gene therapy product candidates, we are unable to estimate the total amount of operating expenditures and capital outlays necessary to complete the development of our product candidates. While we expect the pipeline prioritization and corporate restructuring implemented in November 2023 to result in cost savings, we may also incur other charges or cash expenditures not currently contemplated due to events that may occur as a result of, or associated with, the restructuring. In addition, we may not achieve the expected benefits of any cost reduction measures on our currently anticipated timeline, or at all. Furthermore, our estimates are based on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect which could accelerate our liquidity needs. At-the-Market Offering Program In September 2023, we entered into an ATM Equity OfferingSM Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which we may offer and sell shares of our common stock having an aggregate offering price of up to $150.0 million from time to time through BofA, acting as our sales agent (the ATM Program). We intend to use proceeds obtained from the sale of shares under the ATM Program, if any, for general corporate purposes. As of September 30, 2024, no shares of common stock had been sold under the ATM Program. Cash Flows Our consolidated cash flows were as follows (in thousands): Â Â Nine Months Ended September 30, Â Â Â 2024 Â Â 2023 Â Net cash used in operating activities Â $ (141,501) Â $ (177,647) Net cash provided by investing activities Â Â 63,173 Â Â Â 156,969 Â Net cash provided by (used in) financing activities Â Â 100,423 Â Â Â (23,004) Net increase (decrease) in cash and cash equivalents and restricted cash Â $ 22,095 Â Â $ (43,682) Â Cash Flows from Operating Activities Our net cash used in operating activities for the nine months ended September 30, 2024 decreased by $36.1 million from the nine months ended September 30, 2023, largely as a result of lower operating expenses and increased cost reimbursement received from AbbVie under our ABBV-RGX-314 collaboration in the first nine months of 2024. We expect to continue to incur regular net cash outflows from operations for the foreseeable future as we continue the development and advancement of our product candidates and other research programs. For the nine months ended September 30, 2024, our net cash used in operating activities of $141.5 million consisted of a net loss of $175.9 million and unfavorable changes in operating assets and liabilities of $6.1 million, offset by adjustments for non-cash items of $40.5 million. The changes in operating assets and liabilities include a decrease in total accounts payable, accrued expenses and other current liabilities, and other liabilities of $7.5 million, which was driven largely by decreases in accrued personnel costs, sublicense fees payable to licensors and amounts payable to suppliers as of the end of the period. Other changes in operating working capital occurred in the normal course of business. Adjustments for non-cash items primarily consisted of stock-based compensation expense of $28.9 million and depreciation and amortization expense of $12.2 million. For the nine months ended September 30, 2023, our net cash used in operating activities of $177.6 million consisted of a net loss of $200.6 million and unfavorable changes in operating assets and liabilities of $20.1 million, offset by adjustments for non-cash items of $43.1 million. The changes in operating assets and liabilities include an increase in other current assets of $13.6 million, which was driven primarily by an increase in net cost reimbursement due from AbbVie under our ABBV-RGX-314 collaboration, and a decrease in total accounts payable and accrued expenses and other current liabilities of $5.6 million, which was driven primarily by a decrease in amounts payable to suppliers as of the end of the period. Other changes in operating working capital occurred in the normal course of business. Adjustments for non-cash items primarily consisted of stock-based compensation expense of $31.9 million and depreciation and amortization expense of $13.0 million. 32 Table of Contents Â Â Cash Flows from Investing Activities For the nine months ended September 30, 2024, our net cash provided by investing activities consisted of $238.4 million in maturities of marketable debt securities, offset by $173.9 million used to purchase marketable debt securities and $1.4 million used to purchase property and equipment. For the nine months ended September 30, 2023, our net cash provided by investing activities consisted of $231.8 million in maturities of marketable debt securities and $2.0 million in proceeds received from uniQure N.V. (uniQure) in connection with the achievement of milestones associated with their acquisition of Corlieve Therapeutics SAS (Corlieve), offset by $67.9 million used to purchase marketable debt securities and $8.8 million used to purchase property and equipment. Cash Flows from Financing Activities For the nine months ended September 30, 2024, our net cash provided by financing activities primarily consisted of $131.1 million in net proceeds received from the public offering of common stock and pre-funded warrants completed in March 2024, net of underwriting discounts and commissions and other offering expenses paid during the period, and $2.7 million in proceeds received from

the exercise of stock options and issuance of common stock under our employee stock purchase plan. Our net cash provided by financing activities was partially offset by $32.2 million of Zolgensma royalties paid, net of imputed interest, under our royalty purchase agreement with HCR. For the nine months ended September 30, 2023, our net cash used in financing activities primarily consisted of $30.5 million of Zolgensma royalties paid, net of imputed interest, under our royalty purchase agreement with HCR. Our net cash used in financing activities was partially offset by $4.9 million in net proceeds received from a private placement of our common stock in July 2023 and $3.1 million in proceeds received from the exercise of stock options and issuance of common stock under our employee stock purchase plan. Additional Capital Requirements Our material capital requirements from known contractual and other obligations primarily relate to vendor service contracts and purchase commitments, in-license agreements, operating lease agreements and our Zolgensma royalty purchase agreement with HCR. Our material commitments and obligations are further described in Item 7, â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ of our Annual Report on Form 10-K for the year ended December 31, 2023, and in the notes to the audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2023. Other than the changes described in the notes to the unaudited consolidated financial statements accompanying this Quarterly Report on Form 10-Q, including Note 6, â€œLeases,â€ there have been no material changes to our commitments and obligations since December 31, 2023. Future Funding Requirements We have incurred cumulative losses since our inception and had an accumulated deficit of $881.0 million as of September 30, 2024. Our transition to recurring profitability is dependent upon achieving a level of revenues adequate to support our cost structure, which depends heavily on the successful development, approval and commercialization of our product candidates. We do not expect to achieve such revenues, and expect to continue to incur losses, for at least the next several years. We expect to continue to incur significant research and development and general and administrative expenses for the foreseeable future as we continue the development of, and seek regulatory approval for, our product candidates. Subject to obtaining regulatory approval for our product candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. Additionally, we expect to continue to incur capital expenditures associated with building out additional laboratory and manufacturing capacity to further support the development of our product candidates and potential commercialization efforts. As a result, we will need significant additional capital to fund our operations, which we may obtain through one or more equity offerings, debt financings or other third-party funding, including potential strategic alliances and licensing or collaboration arrangements. Our future capital requirements will depend on many factors, including: â€¢the timing of enrollment, commencement and completion of our clinical trials; â€¢the results of our clinical trials; â€¢the results of our preclinical studies for our product candidates and any subsequent clinical trials; 33 Table of Contents Â Â â€¢the scope, progress, results and costs of drug discovery, laboratory testing, preclinical development and clinical trials for our product candidates; â€¢the costs associated with building out additional laboratory and manufacturing capacity; â€¢the costs, timing and outcome of regulatory review of our product candidates; â€¢the costs of future product sales, medical affairs, marketing, manufacturing and distribution activities for any of our product candidates for which we receive marketing approval; â€¢revenue, if any, received from commercial sales of our products, should any of our product candidates receive marketing approval; â€¢revenue received from commercial sales of Zolgensma and the timing and amount of Zolgensma royalties paid to HCR under our royalty purchase agreement; â€¢revenue received from other commercial sales of our licenseesâ€™ and collaboratorsâ€™ products, should any of their product candidates receive marketing approval, and other revenue received under our licensing agreements and collaborations; â€¢the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; â€¢our current licensing agreements or collaborations remaining in effect, including the AbbVie Collaboration Agreement, and our ability to timely achieve any milestones set forth in such agreements or collaborations; â€¢our ability to establish and maintain additional licensing agreements or collaborations on favorable terms, if at all; and â€¢the extent to which we acquire or in-license other product candidates and technologies. Many of these factors are outside of our control. Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory and marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our product revenues, if any, and any commercial milestones or royalty payments under our licensing agreements, will be derived from or based on sales of products that may not be commercially available for many years, if at all. In addition, revenue from our NAV Technology Platform licensing is dependent in part on the clinical and commercial success of our licensing partners, including the commercialization of Zolgensma, and on maintaining our license agreements with our licensor partners, including GlaxoSmithKline LLC and The Trustees of the University of Pennsylvania. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. The issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our common stock to decline. Adequate additional financing may not be available to us on acceptable terms, or at all. We also could be required to seek funds through arrangements with partners or others that may require us to relinquish rights to our intellectual property, our product candidates or otherwise agree to terms unfavorable to us. Off-Balance Sheet Arrangements We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC. 34 Table of Contents Â Â Item 3. Quantitative and Qualitative Disclosures about Market Risk. For information regarding market risk, refer to Item 7A, â€œQuantitative and Qualitative Disclosures About Market Risk,â€ included in our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes to our exposure to market risk during the nine months ended September 30, 2024. Item 4. Controls and Procedures. Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the companyâ€™s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2024, our disclosure controls and procedures were effective at a reasonable assurance level. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Limitations on the Effectiveness of Controls Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected. 35 Table of Contents Â Â PART II â€“ OTHER INFORMATION Â Â Item 1. Legal Proceedings. From time to time, we are party to various lawsuits, claims or other legal proceedings that arise in the normal course of our business. We do not believe that we are currently party to any pending legal actions that could reasonably be expected to have a material adverse effect on our business, financial condition, results of operations or cash flows. Item 1A. Risk Factors. Our material risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023. There have been no material changes from the risk factors previously disclosed in such filing. Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities. None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not Applicable. Item 5. Other Information. Rule 10b5-1 Trading Plans During the three months ended September 30, 2024, none of our directors or Section 16 reporting officers adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of the SEC's Regulation S-K). 36 Table of Contents Â Â Item 6. Exhibits. Â Â Â Â Â Incorporated by Reference Â Â ExhibitNumber Â Description Â Form Â ExhibitNumber Â Filing Date Â Filed orFurnishedHerewith Â Â Â Â Â

Retirement Income Security Act of 1974, as amended; â€¢The Immigration Reform and Control Act, as amended; â€¢The Americans with Disabilities Act of 1990, as amended; â€¢The Age Discrimination in Employment Act of 1967, as amended; â€¢The Workers Adjustment and Retraining Notification Act, as amended; â€¢The Occupational Safety and Health Act, as amended; â€¢The Sarbanes-Oxley Act of 2002; â€¢The Equal Pay Act; â€¢The National Labor Relations Act; â€¢Maryland Human Rights Act, as amended; â€¢Maryland Equal Pay For Equal Work Law, as amended; â€¢Medical Information Discrimination Law; â€¢Any similar county and city laws such as those of Montgomery County, which prohibit employment discrimination; Page 3 of 9 â€¢all including any amendments and their respective implementing regulations; â€¢Any other federal, state, local, or foreign civil or human rights law (statutory, regulatory, or otherwise) or any other federal, state or local regulation or ordinance that may be legally waived and released; however, the identification of specific statutes is for purposes of example only, and the omission of any specific statute or law shall not limit the scope of this general release in any manner; â€¢Any public policy, contract, tort, or common law obligation; â€¢Any and all claims for compensation of any type whatsoever, including but not limited to claims for salary, wages, bonuses, commissions, incentive compensation, vacation, and severance that may be legally waived and released; â€¢Any and all claims arising under tort, contract, and quasi-contract law, including but not limited to claims of breach of an express or implied contract, tortious interference with contract or prospective business advantage, breach of the covenant of good faith and fair dealing, promissory estoppel, detrimental reliance, invasion of privacy, nonphysical injury, personal injury or sickness or any other harm, wrongful or retaliatory discharge, fraud, defamation, slander, libel, false imprisonment, and negligent or intentional infliction of emotional distress; â€¢Any and all claims for monetary or equitable relief, including but not limited to attorneys' fees, back pay, front pay, reinstatement, experts' fees, medical fees or expenses, costs and disbursements, punitive damages, liquidated damages, and penalties; and â€¢Any obligation to pay for costs, fees, or other expenses. 9. Release of Age Claims. Employee expressly and specifically waives any and all rights or claims that Employee may have under the Age Discrimination in Employment Act of 1967, 29 U.S.C. Section 621 et seq., as amended (â€œADEAâ€). Employee acknowledges that this waiver is knowingly and voluntarily made, and specifically agrees that: (i) this agreement and waiver is written in a manner that Employee understands; (ii) this waiver specifically relates to rights and claims under the ADEA; (iii) Employee does not waive any rights or claims that may arise after the date of this Release; (iv) Employee waives these rights or claims in exchange for substantial consideration in excess of anything of value to which Employee is otherwise entitled to receive; and (v) Employee has been advised in writing, and given the opportunity, to consult with an attorney prior to executing this Release. 10. Affirmations. Employee has not filed or caused to be filed and is not a party to any claim, charge, complaint, or action against REGENXBIO or any of the other Released Entities in any forum or form. Employee has been properly paid for all hours worked for REGENXBIO. Employee has no known workplace injuries or occupational diseases. Except as otherwise provided in this Severance Agreement, Employee has received all leave (paid or unpaid), compensation, wages, bonuses, commissions, and/or benefits to which Employee may be entitled and no other leave (paid or unpaid), compensation, wages, overtime, bonuses, commissions and/or benefits are due Employee. As such, Employee will be entitled to no other or further compensation, remuneration or benefits of any kind from the Company and specifically acknowledges that nothing else is owed or due except as set forth in this Agreement. Employee has not engaged in and is not aware of any unlawful conduct relating to the business of REGENXBIO. Page 4 of 9 Employee agrees that Employee, to the fullest extent permitted by law, will not file any charges, claims, complaints, demands, or grievances against any Released Entities in or with any federal, state, or local agency, board, court, or other government or administrative entity, or before any other public or private entity, including an arbitrator, panel, or tribunal, which is based upon or related to any actions, or omissions by any Released Entities, occurring up to the Effective Date of this Agreement, nor will Employee pursue any such charges, claims, complaints, demands, or grievances through a third party. The Parties acknowledge that this general release and waiver of claims excludes, and Employee does not waive, release, or discharge: (i) any right to file an administrative charge or complaint with, or testify, assist, or participate in an investigation, hearing, or proceeding conducted by, the Equal Employment Opportunity Commission, or other similar federal or state administrative agencies, although Employee waives any right to recover any monetary relief or other remedies related to any filed charge or administrative complaint Employee made or could have made through the Effective Date of this Agreement to the fullest extent permitted by law; (ii) claims that cannot be waived by law; or (iii) any rights to vested benefits, such as pension or retirement benefits. To the fullest extent permitted by law, Employee waives any ability or right to be a class or collective action representative, or to otherwise participate in any certified or putative class, collective, or multi-party action or proceeding regarding any claims Employee made or could have made through the Effective Date of this Agreement based on a claim in which any of the Released Entities is a party. Employee agrees not to remove any of the Companyâ€™s tangible or intangible property from the Company's premises. The Employee represents and warrants that the Employee has returned all Company property, including without limitation identification cards or badges, access codes or devices, keys, laptops, computers, telephones, mobile phones, hand-held electronic devices, credit cards, computer files, supplies, equipment, customer files, documents and/or other records prepared for or by the Company and will not retain any copies regardless of format of any confidential Company information. By signing below Employee affirms that no Company files or information were improperly deleted, copied or retained from the Companyâ€™s computer equipment and/or system(s). Receipt of the severance described above in this Agreement is expressly conditioned upon return of all Company property and compliance with the terms of this provision and this Agreement. Employee affirms that as of the date this Severance Agreement is signed, Employee is not receiving Medicare benefits. Nonetheless, if the Centers for Medicare & Medicaid Services (the â€œCMSâ€) (this term includes any related agency representing Medicareâ€™s interests) determines that Medicare has an interest in the payment to Employee under this Severance Agreement, Employee agrees to indemnify, defend and hold the Company harmless from any action by the CMS relating to Employeeâ€™s medical expenses. Employee agrees to reasonably cooperate with the Company upon request with respect to (i) any information needed to satisfy the reporting requirements under Section 111 of the Medicare, Medicaid, and SCHIP Extension Act of 2007, if applicable, and (ii) any claim the CMS may make and for which Employee is required to indemnify the Company under this paragraph. Further, Employee agrees to waive any and all future actions against the Company for any private cause of action for damages pursuant to 42 U.S.C. Â§ 1395y(b)(3)(A). 11.Release by the Company. REGENXBIO, on behalf of itself and its current and former predecessors, parents, subsidiaries and affiliates, irrevocably and unconditionally fully and forever waives, releases, and discharges Employee and his heirs, successors, and assigns, from any and all known claims, demands, actions, causes of actions, judgments, rights, fees, damages, debts, Page 5 of 9 obligations, liabilities, and expenses (inclusive of attorneysâ€™ fees) of any kind whatsoever as of the date of execution of this Severance Agreement related to the good faith performance of Employeeâ€™s job functions. The Company represents that it has no knowledge of any claims not related to the good faith performance of Employeeâ€™s job functions. 12. Confidential Information. The Employee understands and acknowledges that during the course of employment with REGENXBIO, the Employee has had access to and learned about confidential, secret, and proprietary documents, materials, and other information, in tangible and intangible form, of and relating to REGENXBIO and its businesses and existing and prospective customers, suppliers, investors, and other associated third parties ("Confidential Information"). The Employee further understands and acknowledges that this Confidential Information and REGENXBIO's ability to reserve it for the exclusive knowledge and use of REGENXBIO is of great competitive importance and commercial value to REGENXBIO, and that improper use or disclosure of the Confidential Information by the Employee may cause REGENXBIO to incur financial costs, loss of business advantage, liability under confidentiality agreements with third parties, civil damages, and criminal penalties. For purposes of this Agreement, Confidential Information includes, but is not limited to, all information not generally known to the public, in spoken, printed, electronic, or any other form or medium, relating directly or indirectly to: business processes, practices, methods, policies, plans, publications, documents, research, operations, services, strategies, techniques, agreements, contracts, terms of agreements, transactions, potential transactions, negotiations, pending negotiations, know-how, trade secrets, computer programs, computer software, applications, operating systems, software design, web design, work-in-process, databases, device configurations, embedded data, compilations, metadata, algorithms, technologies, manuals, records, articles, systems, material, sources of material, supplier information, vendor information, financial information, results, accounting information, accounting records, legal information, marketing information, advertising information, pricing information, credit information, design information, payroll information, staffing information, personnel information, employee lists, supplier lists, vendor lists, developments, reports, internal controls, security procedures, graphics, drawings, sketches, market studies, sales information, revenue, costs, formulae, notes, communications, product plans, designs, styles, models, ideas, audiovisual programs, inventions, unpublished patent applications, original works of authorship, discoveries, experimental processes, experimental results, specifications, customer information, customer lists, client information, client lists, manufacturing information, factory lists, distributor lists, and buyer lists of REGENXBIO or its businesses or any existing or prospective customer, supplier, investor, or other associated third party, or of any other person or entity that has entrusted information to REGENXBIO in confidence. The Employee understands that the above list is not exhaustive, and that Confidential Information also includes other information that is marked or otherwise identified or treated as confidential or proprietary, or that would otherwise appear to a reasonable person to be confidential or proprietary in the context and circumstances in which the information is known or used. The Employee understands and agrees that Confidential Information developed by the Employee in the course of the Employee's employment by REGENXBIO is subject to the terms and conditions of this Agreement as if REGENXBIO furnished the same Confidential Information to the Employee in the first instance. Confidential Information shall not include information that is generally available to and known by the public at the time of disclosure to the Employee, provided that the disclosure is through no direct or indirect fault of the Employee or person(s) acting on the Employee's behalf. The Employee understands and acknowledges that the Employee's obligations under this Agreement regarding any particular Confidential Information begin immediately and shall continue during and Page 6 of 9 after the Employee's employment by REGENXBIO until the Confidential Information has become public knowledge other than as a result of the Employee's breach of this Agreement or a breach by those acting in concert with the Employee or on the Employee's behalf. Nothing in this Agreement shall be construed to prevent disclosure of Confidential Information as may be required by applicable law or regulation, or pursuant to the valid order of a court of competent jurisdiction or an authorized government agency, provided that the disclosure does not exceed the extent of disclosure required by such law, regulation, or order. The Employee shall promptly provide written notice of any such order to REGENXBIOâ€™s Human Resources Department. 13. Cooperation. The parties agree that certain matters in which the Employee has been involved during the Employee's employment may need the Employee's cooperation with REGENXBIO in the future. Accordingly, for a period of six months after the Separation Date, to the extent reasonably requested by REGENXBIO, the Employee shall cooperate with REGENXBIO regarding matters arising out of or related to the Employee's service to REGENXBIO. REGENXBIO shall reimburse the Employee for reasonable expenses incurred in connection with this cooperation. 14. Non-Disparagement. Employee agrees not to disparage any of the Released Entities or any of their current or former shareholders, directors, officers, employees, accountants, insurers, agents or attorneys. The Company agrees to instruct the executive team not to disparage Employee. The term "disparage" includes, but is not limited to, any communication to the media, social media, or in any manner or to any other entity or individual that would adversely affect the Released Entities or Employee: (i) the business affairs of any of the Released Entities, or (ii) the reputation of any of the Released Entities or Employee. Nothing in this Agreement prevents Employee from discussing or disclosing truthful information about unlawful acts in the workplace, such as harassment, discrimination or any other conduct Employee reasonably believes is unlawful. 15. Successors and Assigns. REGENXBIO may freely assign this Severance Agreement at any time, provided that the assignee is at least as financially capable of meeting the obligations in this Severance Agreement as REGENXBIO. This Severance Agreement shall inure to the benefit of REGENXBIO and its successors and assigns. The Employee may not assign this Agreement in whole or in part. Any purported assignment by the Employee shall be null and void from the initial date of the purported assignment. 16. Governing Law and Interpretation. This Severance Agreement shall be governed by, and interpreted in accordance with, the laws of Maryland without regard to its conflict of laws principles and without regard to any rule of any jurisdiction that would result in the application of the law of another jurisdiction. The parties expressly consent that any action or proceeding relating to this Agreement will only be brought in the state courts in Rockville, Maryland, or the federal courts in Maryland, as appropriate, and that any such action or proceeding shall be heard without a jury, and the parties expressly waive the right to bring any such action in any other jurisdiction and have such action heard before a jury. 17. No Admission of Wrongdoing. Employee and REGENXBIO agree that neither this Severance Agreement, nor the furnishing of the consideration hereunder, shall be deemed or construed at any time for any purpose as an admission or evidence of any liability or misconduct of any kind by any person or entity. Page 7 of 9 18. Notices. All notices under this Severance Agreement must be given in writing by personal delivery or regular mail at the addresses indicated in this Severance Agreement or any other address designated in writing by either Party. When providing written notice to REGENXBIO, a copy must be provided to REGENXBIOâ€™s Human Resources Department at the address below. Â Notice to REGENXBIO: Â Shiva Fritsch Â Â Chief Communications and People Officer Â Â 9804 Medical Center Drive Â Â Rockville, MD 20850 Â Â Â Â 19. Amendment. This Severance Agreement may not be modified, altered or changed except in writing and signed by both parties wherein specific reference is made to this Severance Agreement. 20. Entire Agreement. This Severance Agreement sets forth the entire agreement between the parties hereto, and fully supersedes any prior agreements or understandings between the parties, except that Employee shall continue to be bound by the applicable provisions of REGENXBIOâ€™s confidentiality and related Proprietary Information and Inventions Agreement effective as of January 19, 2015 and except that the parties are also entering into a Consulting Agreement as of Separation Date. Employee has not relied on any representations, promises, or agreements of any kind in connection with Employeeâ€™s decision to accept this Severance Agreement, except for those set forth in this Severance Agreement and the Consulting Agreement. 21. Counterparts. This Severance Agreement may be executed in one or more counterparts, all of which taken together shall constitute one instrument. Page 8 of 9 Â EMPLOYEE HAS BEEN ADVISED IN WRITING THAT EMPLOYEE HAS AT LEAST FORTY-FIVE (45) CALENDAR DAYS TO CONSIDER THIS SEVERANCE AGREEMENT AND THAT EMPLOYEE SHOULD CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS SEVERANCE AGREEMENT. TO THE EXTENT EMPLOYEE EXECUTES THIS AGREEMENT WITHIN LESS THAN THOSE FORTY FIVE (45) DAYS, THE REMAINING TIME IS WAIVED. EMPLOYEE AGREES THAT ANY MODIFICATIONS, MATERIAL OR OTHERWISE, MADE TO THIS SEVERANCE AGREEMENT DO NOT RESTART OR AFFECT IN ANY MANNER THE ORIGINAL FORTY FIVE (45) CALENDAR DAY CONSIDERATION PERIOD. HAVING ELECTED TO EXECUTE THIS SEVERANCE AGREEMENT AND GENERAL RELEASE, TO FULFILL THE PROMISES SET FORTH HEREIN, AND TO RECEIVE THEREBY THE CONSIDERATION SET FORTH IN PARAGRAPH 4 ABOVE, EMPLOYEE FREELY AND KNOWINGLY, AND AFTER DUE CONSIDERATION, ENTERS INTO THIS SEVERANCE AGREEMENT INTENDING TO WAIVE, SETTLE AND RELEASE ALL CLAIMS EMPLOYEE HAS OR MIGHT HAVE AGAINST REGENXBIO, ANY OF THE OTHER RELEASED ENTITIES, AND ANY CURRENT OR FORMER SHAREHOLDER, DIRECTOR, OFFICER, EMPLOYEE, ACCOUNTANT, INSURER, AGENT OR ATTORNEY OF REGENXBIO OR ANY OF THE OTHER RELEASED ENTITIES. IN WITNESS WHEREOF, the parties hereto knowingly and voluntarily executed this Severance Agreement as of the date set forth below: Â Â /s/ Vittal Vasista Â Â Â Â Â Â Vittal Vasista (Signature) Â Â Â Â Â Date: September 14, 2024 Â Â Â REGENXBIO INC. Â Â By: /s/ Shiva Fritsch Â Â Â Â Â Â Its: Chief People & Communication Officer Â Â Â Â Â Date: September 14, 2024 Â Â Â Page 9 of 9 EX-10.2 3 rgnx-ex10_2.htm EX-10.2 EX-10.2 EXHIBIT 10.2 Consulting Agreement This Consulting Agreement (the â€œAgreementâ€) is entered into as of September 16, 2024, by and between REGENXBIO Inc. (â€œREGENXBIOâ€), a Delaware corporation with offices at 9804 Medical Center Drive, Rockville, Maryland 20850, and Vittal Vasista (â€œConsultantâ€), an individual with an address at 1218 Harve Lafitte Drive, Austin, TX 78746 each a â€œPartyâ€ and collectively the â€œPartiesâ€). WHEREAS REGENXBIO desires to retain Consultant as an independent contractor to perform consulting services for REGENXBIO, and Consultant is willing to perform such services, on the terms described herein. NOW, THEREFORE, in consideration of the mutual promises contained herein, the Parties agree as follows: 1. Description and Performance of Services During the Term of this Agreement, Consultant shall perform the services set forth in the Scope of Work attached hereto as Exhibit A, which is incorporated by reference herein, as reasonably requested by REGENXBIO (the â€œServicesâ€). 2. Compensation a.Fee/Equity. Consultant shall not be paid a cash fee or retainer for providing the services. As consideration for Consultantâ€™s performance under this Agreement, notwithstanding any contrary terms or conditions in the applicable stock option and restricted stock unit agreements, Consultantsâ€™ service to REGENXBIO will be deemed to be continuous between his employment with REGENXBIO and performance of Consultant under this Agreement for the purposes of allowing any stock options or restricted stock units on Schedule 1 to continue vesting for the Term of this Agreement, and for purposes of determining the commencement of the post-termination exercise period of any stock options. Any incentive stock options that are not vested and exercised by the date that is three months from the Effective Date (as defined in Section 3(a) below) shall be deemed non-qualified stock options, pursuant to applicable law. The Parties agree that Schedule 1 attached to and made a part of this Agreement accurately reflects the stock options and restricted stock units held by Consultant and the vesting information related to each such grant. b.Expenses. REGENXBIO will reimburse Consultant for all reasonable, necessary and documented out-of-pocket expenses directly incurred by Consultant in the performance of Services hereunder, provided that any travel be approved in advance. REGENXBIO shall reimburse Consultant for such expenses

within (30) thirty days of delivery of an invoice and receipts evidencing such expenses. c.Performance of Services. If REGENXBIO requests Services to be performed by Consultant, Consultant shall perform such Services in accordance with Exhibit A. Â Â 3. Term and Termination d.Term. Subject to earlier termination or extension as hereinafter provided, Consultantâ€™s engagement hereunder shall be for a term commencing on September 16, 2024 (the â€œEffective Dateâ€) and ending on January 3, 2025 (the â€œTermination Dateâ€) (together the â€œTermâ€). e.Termination for Breach. If either Party breaches in any material respect any of its material obligations under this Agreement, in addition to any other right or remedy, the non-breaching Party may terminate this Agreement in the event that the breach is not cured within 30 days after receipt by the other Party of written notice of breach. f.Termination by Mutual Agreement. Notwithstanding any other provision hereof, this Agreement may be terminated at any time upon mutual agreement of the Parties. g.Automatic Termination. Notwithstanding any other provision hereof, this Agreement shall automatically terminate if Consultant invokes revocation under the separate severance agreement of even date. h.Effect of Termination; Survival. Upon the expiration or other termination of this Agreement, Consultant shall cease performing Services hereunder and Consultantâ€™s service to REGENXBIO will be deemed to be terminated under the award agreements between REGENXBIO and Consultant as of the termination date. For clarity, the effects of such termination of service include, but are not limited to, the ceasing of vesting of all stock options and restricted stock units as of such termination date and the expiration of any unexpired stock options three months after such termination date, pursuant to the applicable stock option agreement between REGENXBIO and Consultant (except when such termination is due to death or disability). The rights and obligations set forth in Sections 3-6 and 8-12 shall survive any expiration or termination of the Agreement. 4. Confidential Information i.Definition of Confidential Information. Confidential Informationâ€ means any and all confidential or proprietary information and materials that are disclosed or otherwise provided by REGENXBIO or its Affiliates to Consultant or its Affiliates in writing, physically, orally or visually, and that: (a) is identified as confidential or proprietary at the time of disclosure; or (b) by its nature should reasonably be understood by Consultant to be confidential or proprietary. Confidential Information shall include, without limitation, any and all information concerning REGENXBIOâ€™s technologies, processes, discoveries, methods, patentable and unpatentable ideas, research or development efforts, trade secrets, formulas, business strategies, finances, business operations or affairs and any and all of such information of third parties that REGENXBIO treats as confidential. Confidential Information shall not include any information that Consultant can demonstrate by then-contemporaneous written records (i) is or becomes publicly known through no act or omission of Consultant; (ii) is developed independently by Consultant without use of REGENXBIOâ€™s Confidential Information; (iii) is known by Consultant when disclosed by REGENXBIO if Consultant does not then have a duty to maintain its confidentiality; (iv) is rightfully obtained by Consultant 2 Â from a third party who does not owe REGENXBIO a duty to preserve its confidentiality; or (v) is approved for disclosure by the prior written authorization of REGENXBIO. Consultant shall have the burden of proving that information falls within one of the foregoing exceptions. â€œAffiliateâ€ of a Party means any other legal entity that directly or indirectly controls, is controlled by, or is under common control with such Party, for as long as such control exists. â€œControl,â€ â€œcontrolled byâ€ and â€œunder common controlâ€ refers to (i) the ownership, directly or indirectly, of more than fifty percent (50%) of the outstanding voting securities or the capital stock of, or other comparable equity or ownership interest in the respective legal entity, or (ii) in the absence of such ownership interest, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of the respective legal entity, by contract or otherwise. j.Nonuse and Nondisclosure. Consultant shall use Confidential Information of REGENXBIO only in connection with performance of the Services. Consultant shall keep confidential and not disclose Confidential Information to any party other than to its and its Affiliatesâ€™ directors, officers, employees, independent contractors who are individuals and professional advisors who have a need to know such information in connection with performance of the Services, and who are bound by confidentiality obligations at least as protective of REGENXBIOâ€™s Confidential Information as those set forth herein (collectively, the â€œRepresentativesâ€). Consultant shall not purchase or sell REGENXBIOâ€™s securities while Consultant is in possession of material, nonpublic information relating to REGENXBIO, and Consultant acknowledges that it may be a violation of U.S. federal securities laws for Consultant to engage in such transactions. Consultant shall take action to enforce the obligations and restrictions herein on its Affiliates and Representatives which receive Confidential Information for the Purpose. Consultant shall be liable to REGENXBIO for any non-compliance of those Affiliates and Representatives with such obligations and restrictions to the same extent as Consultant is liable for any such non-compliance on its own part. k.Required Disclosure. Notwithstanding Section 4(b), Consultant may disclose Confidential Information to the extent required by a court or other governmental authority, provided that Consultant gives REGENXBIO reasonable advance written notice of the disclosure so that REGENXBIO may either seek a protective order or other appropriate remedy or waive compliance with the provisions of this Agreement for such disclosure. In the event that REGENXBIO is either unable to obtain such remedy or waives compliance with the provisions of this Agreement, Consultant will thereafter disclose only the minimum Confidential Information required in order to comply. l.Return of Materials. Upon the written request of REGENXBIO, Consultant shall return to REGENXBIO, or shall destroy and certify in writing to REGENXBIO that it has destroyed, all drawings, documents, materials, and other tangible embodiments of Confidential Information in Consultantâ€™s possession (and all copies and reproductions thereof), except that Consultant may retain one copy thereof solely for archival purposes. 3 Â m.No License. This Agreement is not intended and shall not be deemed to grant or convey to Consultant any license or other rights in or to Confidential Information of REGENXBIO, including without limitation any intellectual property rights therein. All Confidential Information and all tangible embodiments of Confidential Information shall remain the exclusive property of REGENXBIO. n.Defend Trade Secrets Act Notice. This Agreement does not affect any immunity under 18 U.S.C. Sections 1833(b)(1)-(2), which read as follows (note that for purposes of this statute only, individuals performing work as contractors or consultants are considered to be employees): (1) An individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. (2) An individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the individual and use the trade secret information in the court proceeding, if the individual (A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to court order. 5. Proprietary Rights REGENXBIO and Consultant entered into a Proprietary Information and Inventions Agreement effective as of January 19, 2015 (the â€œPIIAâ€), which shall be incorporated into and made part of this Agreement. Notwithstanding any terms or conditions to the contrary in the PIIA, all rights, obligations and restrictions pursuant to the PIIA shall be interpreted to continue in full force and effect during the term of this Agreement as if Consultant were an employee of the Company during such term. 6. Independent Contractor Status It is understood and agreed that Consultant is an independent contractor and is not an agent or employee of REGENXBIO or any of REGENXBIOâ€™s Affiliates and that REGENXBIO will not make any deductions for any statutory withholdings, such as income tax, pension plans, unemployment insurance or workerâ€™s compensation. Consultant will not be entitled to participate in any medical, dental, extended health or group life insurance plans of REGENXBIO. Consultant is not and shall not hold itself out to be an agent, legal representative, partner, subsidiary, joint venturer or employee of REGENXBIO, and Consultant shall have no right or power to, and shall not bind or obligate REGENXBIO in any manner whatsoever or represent that Consultant has any right to do so. 7. Non-Exclusive Service Consultant shall retain the right to perform work for others during the term of this Agreement, provided, however, that, Consultant will not provide consulting services or other services to another company engaged in developing competitive gene therapy related products. 4 Â 8. Use of Name Neither Party may use the name of the other Party, or any variation thereon or adaptation thereof, in any endorsement, advertising, promotional sales literature or other publicity without the prior written approval of such other Party, such approval not to be unreasonably withheld, conditioned or delayed. 9. Representations, Warranties and Covenants Consultant represents, warrants and covenants to the best of his knowledge that (a) the performance of the Services contemplated by this Agreement (i) are in compliance with all of the policies and procedures of Consultant or Consultantâ€™s employer, as applicable, and (ii) does not and will not violate any agreements or undertakings of Consultant with any other third party; (b) Consultant has full authority to grant to REGENXBIO all rights granted hereunder; (c) Consultant shall perform all Services in a good and workmanlike manner, and in accordance with all applicable laws, rules, regulations and guidelines, including without limitation and to the extent applicable those relating to privacy and data protection; and (d) Consultant is not debarred under Section 306 of the Federal Food, Drug & Cosmetic Act, or otherwise debarred, suspended, excluded, disqualified, or otherwise restricted from working on, providing services for, or participating in any U.S. Food and Drug Administration-regulated activity or federally-funded contract, grant, cooperative agreement, health care program, or research activity, or from practicing before any government agency as a consequence of misconduct of any kind, and that Consultant is not, to his knowledge, presently the subject of any ongoing debarment, suspension, exclusion, disqualification, or restriction proceeding before any government agency. 10. Indemnification REGENXBIO agrees to indemnify, defend and hold harmless Consultant and his heirs, successors, assigns, subcontractors, employees, agents and representatives (collectively, the â€œIndemnified Partiesâ€), from and against any and all loss, demands, claims, actions, damages, liability, judgments, cost and expenses, (including, but not limited to, reasonable attorneysâ€™ fees and disbursements attendant thereto), arising out of, resulting from, or in connection with REGENXBIOâ€™s breach of any duty, obligation, representation, warranty, and/or covenant in this Agreement, or a failure to comply with any provision of this Agreement, the performance of Services by Consultant, unless such loss or liability is a result of the gross negligence or willful misconduct of Consultant. 11. Limitation of Liability IN NO EVENT SHALL CONSULTANT BE LIABLE TO REGENXBIO OR TO ANY OTHER PARTY FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, DELAY OR CONSEQUENTIAL DAMAGES, OR DAMAGES FOR LOST PROFITS OR LOSS OF BUSINESS RESULTING FROM, ARISING OUT OF, OR IN CONNECTION WITH THE SERVICES, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, WHETHER BASED IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHER THEORY OF LIABILITY, REGARDLESS OF WHETHER CONSULTANT WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF 5 Â ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. IN NO EVENT SHALL CONSULTANTâ€™S CUMULATIVE LIABILITY FOR DAMAGES OF ANY TYPE TO REGENXBIO UNDER THIS AGREEMENT EXCEED FIFTY THOUSAND DOLLARS. CONSULTANT DISCLAIMS ALL WARRANTIES WITH RESPECT TO ITS SERVICES, INCLUDING THE IMPLIED WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE, QUALITY OF INFORMATION, SECURITY, RELIABILITY, TIMELINESS, AND AVAILABILITY OF BACKED-UP DATA. REGENXBIO IS SOLELY RESPONSIBLE FOR THE SECURITY AND INTEGRITY OF ITS DATA AND SYSTEMS. 12. Miscellaneous o.Interpretation. Wherever any provision of this Agreement uses the term â€œincludingâ€ (or â€œincludesâ€), such term shall be deemed to mean â€œincluding without limitationâ€ and â€œincluding but not limited toâ€ (or â€œincludes without limitationâ€ and â€œincludes but is not limited toâ€) regardless of whether the words â€œwithout limitationâ€ or â€œbut not limited toâ€ actually follow the term â€œincludingâ€ (or â€œincludesâ€). Any reference in this Agreement to â€œday(s)â€ or â€œmonth(s)â€ shall be deemed to mean calendar day(s) or calendar month(s), respectively, unless expressly provided otherwise. p.Governing Law; Consent to Personal Jurisdiction. This Agreement shall be construed and governed in accordance with the laws of the State of Maryland without giving effect to conflict of law provisions. The Parties hereby submit to the exclusive jurisdiction of and venue in the District or Circuit courts located within Montgomery County, Maryland with respect to any and all disputes concerning the subject of this Agreement. q.Injunctive Relief. Consultant acknowledges that REGENXBIO will not have an adequate remedy at law nor will be adequately compensated by money damages for injury caused in the event that Consultant breaches or threatens to breach Consultantâ€™s obligations under Sections 4 or 5 of this Agreement. It is therefore agreed that REGENXBIO shall be entitled to obtain a restraining order, injunction, or decree of specific performance from a court of equity in the event of any such breach. Nothing herein shall be construed to prevent or preclude REGENXBIO from pursuing any other remedies available to REGENXBIO for any such breach. r.Assignability. This Agreement shall be binding upon and inure to the benefit of each of the Parties hereto and its successors and permitted assigns. Neither Party shall have the right to assign this Agreement without the written consent of the other. s.Modification; Severability. This Agreement may be varied, amended or extended only by a written agreement between the Parties that specifically refers to this Agreement. If any provision of this Agreement is held to be illegal, invalid or unenforceable in a final, unappealable order or judgment, then such provision shall be severed from this Agreement and shall be rendered inoperative; and the remaining provisions of this Agreement shall remain binding on the Parties hereto. t.Headings. The descriptive headings of the sections of this Agreement are inserted for convenience only and do not constitute a part of this Agreement. 6 Â u.Waiver. No failure or delay on the part of either Party in the exercise of any power or right hereunder shall operate as a waiver thereof. No single or partial exercise of any right or power hereunder shall operate as a waiver of such right or of any other right or power. The waiver by either Party of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any other or subsequent breach hereunder. v.Counterparts. This Agreement may be signed in two or more counterparts, each of which shall be deemed an original, with the same force and effectiveness as though executed in a single document. This Agreement may be delivered by facsimile or electronic transmission, and facsimile or electronic copies of executed documents shall be binding as original copies. w.Entire Agreement. The terms and conditions herein and in the PIIA and in the severance agreement of even date constitute the entire agreement between the Parties relating to the subject matter of this Agreement and shall supersede all previous communications between the Parties with respect to the subject matter of this Agreement. Neither Party has entered into this Agreement in reliance upon any representation, warranty, covenant or undertaking of the other Party that is not set out or referred to in this Agreement or the severance agreement of even date. x.Costs of Enforcement. In the event of any legal action arising under this Agreement or any asserted breach thereof by a Party, the prevailing Party shall be entitled to recover all costs and expenses, including reasonable attorneysâ€™ fees, incurred in enforcing, attempting to enforce, or defending such legal action, including costs incurred prior to commencement of legal action and in any appeal. y.WAIVER OF JURY TRIAL. THE PARTIES HEREBY EXPRESSLY WAIVE ANY RIGHT TO A TRIAL BY JURY FOR ANY DISPUTES ARISING OUT OF THIS AGREEMENT. [Signature Page Follows] 7 Â IN WITNESS WHEREOF, and intending to be legally bound, each Party hereby executes this Agreement effective as of the Effective Date. Â REGENXBIO Inc. Â Â Â Â Â Â Â By: /s/ Curran Simpson Â /s/ Vittal Vasista Name: Curran Simpson Â Vittal Vasista Title: President and Chief Executive Officer Â Date: September 14, 2024 Date: September 14, 2024 Â Â Â [Signature Page to Consulting Agreement] Â Exhibit A Scope of Work Consultant will provide services in connection with the finance and investor relation functions of REGENXBIO, as reasonably requested by REGENXBIO from time to time, not to exceed 10 hours per week. Â Â Schedule 1 Equity Awards Outstanding as of September 16, 2024 Incentive Stock Options* Grant Date Strike Price Options Granted Options Outstanding Options Exercisable Expiration/Cancellation Date 24-Sep-2014 $0.85 244,868 0 0 24-Sep-2024 24-Sep-2014 $0.85 120,499 0 0 24-Sep-2024 24-Sep-2014 $0.85 59,533 0 0 24-Sep-2024 19-May-2015 $3.76 20,041 0 0 19-May-2025 28-Jan-2016 $13.09 14,115 14,115 14,115 28-Jan-2026 04-Jan-2017 $19.50 5,121 5,121 5,121 04-Jan-2027 03-Jan-2018 $35.80 3,371 3,371 3,371 03-Jan-2028 03-Jan-2019 $40.82 2,631 2,631 2,631 03-Jan-2029 02-Jan-2020 $38.99 2,364 2,364 2,364 02-Jan-2030 04-Jan-2021 $44.97 2,491 2,491 1,320 04-Jan-2031 03-Jan-2022 $34.31 2,264 2,264 0 03-Jan-2032 03-Jan-2023 $22.25 4,510 4,510 0 03-Jan-2033 02-Jan-2024 $18.34 5,368 5,368 0 02-Jan-2034 TOTAL Â 487,176 42,235 28,922 Â Â Â Â Â Non-Qualified Stock Options Grant Date Strike Price Options Granted Options Outstanding Options Exercisable Expiration/Cancellation Date 19-May-2015 $3.76 9,959 0 0 19-May-2025 28-Jan-2016 $13.09 60,885 0 0 28-Jan-2026 04-Jan-2017 $19.50 44,879 24,046 24,046 04-Jan-2027 03-Jan-2018 $35.80 51,629 51,629 51,629 03-Jan-2028 03-Jan-2019 $40.82 54,369 54,369 54,369 03-Jan-2029 02-Jan-2020 $38.99 47,636 47,636 47,636 02-Jan-2030 04-Jan-2021 $44.97 53,709 53,709 50,197 04-Jan-2031 03-Jan-2022 $34.31 40,236 40,236 28,333 03-Jan-2032 03-Jan-2023 $22.25 61,723 61,723 27,597 03-Jan-2033 02-Jan-2024 $18.34 70,945 70,945 0 02-Jan-2034 TOTAL Â 495,970 404,293 283,807 Â Restricted Stock Units Grant Date RSUs Granted RSUs Previously Vested RSUs Outstanding 04-Jan-2021 12,400 9,300 3,100 03-Jan-2022 8,900 4,450 4,450 03-Jan-2023 46,174 11,544 34,630 02-Jan-2024 16,026 0 16,026 TOTAL 83,500 25,294 58,206 Â *Incentive stock options which are not vested and exercised within three months of September 16, 2024 will be treated for tax purposes as non-qualified stock options. Â EX-31.1 4 rgnx-ex31_1.htm EX-31.1 EX-31.1 EXHIBIT 31.1 CERTIFICATION I, Curran Simpson, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of REGENXBIO Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,

particularly during the period in which this report is being prepared; b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 6, 2024 Â Â Â Â /s/ Curran Simpson Â Â Â Â Curran SimpsonPresident and Chief Executive Officer(Principal Executive Officer) Â Â EX-31.2 5 rgnx-ex31_2.htm EX-31.2 EX-31.2 EXHIBIT 31.2 CERTIFICATION I, Mitchell Chan, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of REGENXBIO Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c. evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d. disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting. 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 6, 2024 Â Â Â Â /s/ Mitchell Chan Â Â Â Â Mitchell ChanChief Financial Officer(Principal Financial and Accounting Officer) Â Â EX-32.1 6 rgnx-ex32_1.htm EX-32.1 EX-32.1 Â EXHIBIT 32.1 CERTIFICATION In connection with the Quarterly Report of REGENXBIO Inc. (the â€œRegistrantâ€) on Form 10-Q for the quarter ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, Curran Simpson, President, Chief Executive Officer and Director of the Registrant, and Mitchell Chan, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their respective knowledge: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. Date: November 6, 2024 /s/ Curran Simpson Curran Simpson President and Chief Executive Officer(Principal Executive Officer) Date: November 6, 2024 /s/ Mitchell Chan Mitchell Chan Chief Financial Officer(Principal Financial and Accounting Officer) This certification is made solely for the purposes of 18 U.S.C. Section 1350, subject to the knowledge standard contained therein, and not for any other purpose. A signed original of this written statement required by Section 906 has been provided to the Registrant and will be retained by the Registrant and furnished to the United States Securities and Exchange Commission or its staff upon request. This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. Â GRAPHIC 7 img183429381_0.jpg GRAPHIC begin 644 img183429381_0.jpg M_]C_X 02D9)1@ ! @$!+ $L # _[0 L4&AO=&]S:&]P(#,N, X0DE- ^T M ! !+ $ 0$L 0 !_^$W]FAT=' Z+R]N&%P+S$N,"\/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI M2'IR95-
Z3E1C>FMC.60B/SX*/'@Z>&UP65T82!X;6QN#IX;7!T:STB0610O8F4@6$U0($-O"UD969A=6QT(CY214=%3E@N,S P+C(Y.34N,3&%P+S$N,"]G+VEM9R\B/@H@ M(" @(" @(" \>&UP.D-
R96%T;W)4;V]L/D%D;V)E($EL;'5S='')A=&]R($-3 M-B H36%C:6YT;W-H*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP M.D-R96%T941A=&4^,C Q-BTP.2TP-U0Q,#HR-3HR-RTP-
#HP,#PO>&UP.D-R M96%T941A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$V+3 Y+3 W M5#$T.C(U.C,P6CPO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T
M861A=&%$871E/C(P,38M,#DM,#=4,3 Z,C4Z,C&UP1TEM9SIW M:61T:#XR-38\+WAM<$=);6&UP1TEM9SIH96EG:'0^"B @(" @(" @ M(" @(#QX;7!'26UG.F9OF%'.7=)1$UU34%!-
%%K;$Y! M*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB M,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G
M9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X M=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X
M9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X M9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%-045!07=%4B8C>$$[04%)
M4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(M0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-) M0U%O3$5!04-
!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=% M,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K M<4MY63-00TY546YK-
D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T M3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85&18;#E76C)H<&%M='-B5S5V M63-2,61N9#1E6' W9D@Q*V8S3T5H66%
(:4EM2VDT>4YJ;RM#:S535FQP95EM M6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U28C>$$[;V)(M=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15 M:W=G2D-
H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515 M-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q M*V8S3T5H66%
(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/ M:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y5%14=W=2;5-: M,6I19%=9,$@T-
"8C>$$[4D5N:VE59T):679R,VUJ5F]&=DID2F=J=DQA,W,U M<'6=F6GI.=S9A0D$T>E)*1'(X=7%N>&5G07AR.6(U M3R8C>$$[=3EA,64X,4YT575B>6%455=F,5!R6F-I44Y7;TMS4',P-U4V6C)%
M8U59>#114%0S4$]3>5--=4EN9#8V,S5I*V-R,U)T1VUK=DI,928C>$$[43)W M36I214LP7%P<#E09DY::3!'15-L=&4O>5DV+W1,54%X<5)I
M3TAP,65S*UA03T9L4'!6:4Y5=55I,4]3365U:"8C>$$[0D$U9$MS44]+:VIC M:G1M:3%':FM*;F=(<&5J,&9A15I9-"M)86U2=7EB348R8G-69&ER$$[$$[66EY2W8W;E4V,TE*4V]
(669E;$LR>5A183)K3$-' M6E-S,T(R:4Ij<%9V:E5G6HU071W.3EF-F9* M1"8C>$$[9C-N<5!A5V1L2E,P2'')84W)5828C>$$[8G)T M-V%W87!A4F97-S(X:&AJ:'-
N:4MX<&)N:T9G;U5J6D5&63AW$$[=DQO;&]T<#)K4D91 M=3!O57AC9"M996Y%<5(Y;TY866I-$$[=T%A:%4W:DY(<6-5;WES:6A,8U!3 M-DQ546Y(:$)U54YJ>C5U.'@K8W9,6&QV-
G8K3$$[8DIL=F=&,#,U9%)$2%A%871*9BM6>"]L<"\Q9DEV M.$%K6$XO>E)L+SAM86HK8CEZ5"]+1T@K9#DV27-F>E8O3#(K=DER3S(Q=49R M:28C>$$[9&=K4TUS:4)M3W=
(2C%686YT=FM:.6XU-&EZ13!Y:G)C36I1:VHO M35!N:GER-6-M:&@Q$$[;'E: M4F-"9$TX=7!X-'I5:E-59CAR:B],5"]Q*U)F.$%)=6(O04IO>3$$[3AH56-U0W1X3DXV2"8C>$$[2$9O3 O-
G9K6"])=6(O;6I,4#5-,4@X,S=M=BM535 X-S$$[-%HW>5=V<%$P9$,Q0E5H96%Q0V%D5IO5BMD4#%B53!T8GA65GI#>5--94QD1%96
M628C>$$[64U7:7DU23A563)%-4Y8:F=A:V%+6"\X$$[4F12 M4SAN:%0Q6D566D9)4V]7=GAQ=F,U5FTP;51%3&U+1&)I,4]026%I8E@V5C4Q
M.')A='%L>'!7;C9J1E!Q3G%75V$Q*TI80E%L6"8C>$$[;TA#.'5*1R]"=41* M<&-K26E5:#93;4=O>'EK66#(U2G8X04=8;'(O168K1W9R>2]P>B]! M2EEU3#AV-
W(Q=G1C94@Y,SA86"8C>$$[3"]Y,E1W+T5R,&0O,DY0-6E(2'=8 M-G4W-UAA=#5Y.'1A4&1#,#%+.49R3U9$:$A35&14,T)#:T5F5&U":S%73T)Q M4F]U,3
S6FUO>B8C>$$[>#1S8V5)93AF'5!>4]P<4-# M2V=G-65$8F=Y:5%A4$Y+8F9Z:#5B=6153VQ7,3AS.2M'6D1$1W)V47(Y$$[EHY;6%I1U!X2E)Q2&5A6#8Y-7(X=39" M-
D@V6G8TGHY1#%34GHY3VY+;$%E;DU:;31D4%!*9D%,<"8C>$$[,6U8 M4$1(.5)Q,' O-5=T*UA8+U8K=&9V8BMM6&9Y9FXO;6QQ+U!99C5W5G)0.'DO
M258U8W!B5RMU,FI44VM,1VAF:GE9;6=!3%5&4R8C>$$[8T5T1&UI3$U3;4]S M>$4P2D)(-C$U$$[:#!04DQD8FI6-S9'>&AC%DR;6-, M>4E&4T9",UDO3$)I=WIY1VJG;$]43$=!=5)P2E
X06QA,S5D9CA!5BMT9G9B M*VU8+WEF;B]M;"8C>$$[<"]0668U=V-0>E8O3'-K06$Y83%/,C=%1#=Y368U
M4'HO=T$P$$[=#ER<&Q(9U0S,D]Z9#0P3G1X=3@X$$[F=A:E%",R8C>$$[-6]0>4\X,FXV4&4S M=#E91S5S<&U74%106#5R14QN<3AI,$LX=W%#:FIO4U9R;7$Y<$\Q1'!91'=Z M*SAL.3,T-
4\Y.6QV6C9(84]9*R8C>$$[35 S54XO,F9R6C%R,3F$M*-V%E1TXT1F%T9E)E4&I49V5.5G!4-WAN1&Y6-FY%2352 M23$$[>C@X-399-'=*43(Y-#=X-VU,96,O34TK;#(P13)J
M,T5I<#5G0UAS='1)1F%/>F$Q;5I5:71G86A1$$[4' R.2]F8C5F,B]P2F%(55-W9S,Q*TA-57ER.&AF4"MR6"MU6%=H M86E)-6AC4DYD4C-+>$I(2C9I16-
H25DQ6&U'1%9Q,CEF;F@W6"8C>$$[,&M9 M=T5X,#)C6'-R4#9J1VAV=GED+WIK.2\P>E@O4C$$[>$ES,&XQ4S%02G=O
M1$=P;4(S3U=4,%=R2DY:3G9E9C%.8V18<%%"8U!S2#8R2BMB9%8X;RM9=DUM M:THU3#!75W=*9%5M:#E.16%7428C>$$[=4]01T]*-4(X24A7=C9S>DY0:GDT M30P$$[-5EU*V%04(O-
FQ/-B\U15$O.6Q/8D0X<')F.55(>E V;D(O3394*UEF M$$[+U=Y;CAT=DY0-55A;#5N4S(X=&%"4' K<4=+4FQU6DEO,%5)0CA1 M<7,P:#,K5UEE=3 K<&IJ=DI-4VHK4$IY=$IM=U-
N54DQ3#AE8B8C>$$[17)4 M4CE-,6HO;DE,56)$53=D3'5Z:VUU0SA-;%-P2U%%$DT-'HQ6D5H63,K-4989FY0.&AB5S=M="8C>$$[6E!+;'=:24I':6-R
M1$11;$-63DLS03(R>45D3')#069%1R]M9C%-<&%J4V$$[=%IP0F)I1#%22V](3G986G=R2#=6 M061S=6Y$57AW>45Z1U=X,W,S>3EZ5D-E0U=72FIX4C-(469R6G@K6E!M;CAQ
M3DXX>G9B95ID028C>$$[;C%$5D)&1WI836-58G%522M%5F%A33=F3$YF;V10 M<5I9-WAZ15DO:GEC-U8U2](;7AB+TAN-4$O.5-N9&8X:4EF*WEN
M328C>$$[>CAP$QF;E!,3$A'9V%,;6\T9W!,3"LP465M64AA1T15428C>$$[:41K M;'A#+W@P8S-26G--<$59-#!A+TA6-#5"-5DX>&$U-3(X>'EE6#-+-FQP9'IC
M,VM3;WA34G5.>58O9$XO3T]64TX3V5'4$9$:B8C>$$[*VU102MX,#1W>FYL M;'=F5D5K+V$Y4B],9C@W;S=U5F1'.#,O04]H871',W!*97E,-F%33T14:$UP
M<#95;&8X05EN,E!856$W$$[2&DS:C-F<3=W-U!39&\S-DUM,'4Y M2W5V+T]54"MF.$$Q86-U+W=#9&8K4#4W5B]Y3R](.#$V=#5W.&XV8C5M,# R M,7E05'59-FTQ=28C>$$[9TMT1W@O5W
W:BM/8W)Q=$Q(3D=]>C9&-C=S>G10 M2G!-;D9(94HU:G8O83AC2&UZ>E@U9',W-WEI8FA!56PY0F)G3T=-27)2>$$$[3EAV.6YF;V,P4#5N3&E">%@K>#=R*U1T3G%P4C%62&QD5CE89%DO
M1BLU-G@U0CAL-F8U8C!W4$$$[,3EF M0VTW,&5L:FEJ,VLY6&DK,D\Q2C9R2E(Y34DX;R]R."]U96%F.#509CE-,2\P M92\X05EV;E$$[4#A:+S@T.2\Y4S=,
M+W="238O.$%66$IF;&1B+T%$+W0O67@O36%4*V(Y;C=72F5D-WIY1C5I=DY* M$$[9FE)>'EA4FPR25!7;5IM;&IM>$-2 M>E-S9E X05$T;7!L:7E'27A#:CAM868X-4=F.&1Z>78O>C(O=T-
4:U=94%EV M,%OO2&4U;F$S,28C>$$[42](8S$O>FMG;VLQ:GEZ1RLV34IW5C=53'A!-#EI M8E)N%C P#-0478K5D]F;' O,5DT=CA!:UI.+WI8;7,O;%!59GIV M=28C>$$[9&@O2BM(*V(Y-
T=0>DXO3$QY3'!0:UA6=%(P-U-9-V4Y=#0P84=: M6&Q*56U61D]Z3U(P3UIM9S$K865A35I3$$[<4@U
M52M48DA89GDO,'$U=4HU67EH;6A:531K1D5U;FQ7;DE.>%!);F9W2C'I68F8X028C>$$[34139DYU;S-(;6E7 M-6TP2%5(;FI-4S-#8THT=U,P0WA,*S@Y34LS03$T8D-O-FY--U1N1&MX>$=+
M=4].9$]89F9F.$%.,69A17 T:B8C>$$[3'AB35HK9E W-BM33C!N5CE&=2]. M5VLV;E!"3F$S*VU79S W4S-35D=G<'AK4D1-$$[:G1V,#5B*U1J851T3T)N145C2FE/1TIV-SEV4&XY
M:60K9$Y/=71:,'1R856Q$,CEV32]X34="5U)/4C)5+UI)-4AT;DQD M$$[.6YY>EEW8UDS1#,O04Q,.71W,&UE56,P<6I08F9O56XQ3S8X,C9N
M;U=L*U5B1%,W=4]/,FI28C!.139E<$QY<6]928C>$$[1V,W M:VQL;D-/2TU4='IE-7=9.4Yl>E0Q535W4$5F5'5$42]7569R4&M(47(S4710 M,$159E53.3!W=EA5;T=&43AZ8W!6-
$UV>&]$$$[3V@R$$[8U%4=69N;5(R<'%:5#12631E93,V M6%@Y;%%I3TDX36A)1W0O,$UE+S5Y57-,-C$$[4C)(35(T-TYC=C!S93$T:SA.1'8O43E!,4QY3F]N M;5AY6&$V6&8R-
GA/,71#67)H54%L:&Q%66\T-F1/-#=J8DYB1%9Z>%I424AR M."8C>$$[,U!N<&\U35EI4C!E5BM38B]W03 O;&XUVTP2%&]*-&EQ:VQ45#0P-B]33CEV<6]9.59J-#1%0V8T,B8C>$$[9%AP
M<%0P,"M#4750-#-E:B]M0BM92RM83'%Y:E112F1B4S9I37%Z43=H04111"LW M:S8Y8S%E:C!F:6$$[+TLW=BLO1W5V=2\V M.#5M+WE6+W1O+TAX8U@K568Y$$[=E$K2$1I-
'A,>2]"8CE.$$[26-12#ER$$[3V=4-EI"1&,R:VLX6E9M:FIJ=''!!-T\P:&II559#*TA83751:&$$[-%EN M,5AJ1VHO5S0O$AY+T)D;'%D6C1C-C1/
M2FHO+T%#=3$$[5VHK568Y$$[,S505T8Y0BMA2&UU864R&EH:RMS M*VY)-DUQ=%$$[3FIR>7(K-W9!4&ALTYK;D$K,$\S3#=1.7AT;41O M93!:6512,V@S9G%C=E8V1T]55TYP9FIM.'
O3%1Y,S5Q,&XX,SE-:3%U,75& M;28C>$$[='A01SEX24=E36]T;$I(2'AL,U5R>$%69"]B3GIR$$[6$E! M865*1UE1<3)W;U%#3V)D=D1R-%IW;74Q36]J:&=$>$@W2#!4$$[-TAQ;39"-4=#4VA+
M<4XO:4"]Z9F-C<7AD;5(X3W!F5V5V9"M/D@U4S%.=B8C>$$[3&UV5S P=6UQ,T='-5)(:U=,;#!: M5T$K2TIV1'0Y-'ER4S5S;4-8:I"-&9X.6IL9'%A4$)R8V9J-%I!6D]O$$[;EDS=#103&AT3&53-
4,O6$-X:5)N<'DY0VQE25!7 M;60Q,DA/230W4#@S.4PU:C)X06YH;V0O-D9F+VQD,R]F:EA8,V8Y96-J+TI8 M*R8C>$$[,FHX9D90.$%+4#A!=%HO2'=9:#4K,797+W=!=UIT3'-T2CAP,U9L
M4&)02CA1471Y.5AI0GEB,#1W:7)W<5-X<&UBSA53DU*1U=11R8C>$$[+W=! M9#=I87)*3$]127=)<&MV-2MA8G%5*W%E5E)&0DQC=$-S9VUE3D=K05!/3&-K
M1'94=FU,,E)/26I/>E@T3&MD<'=K6E$V+V=++R8C>$$[+T]1*VHV>&-85V=A M:EI753$S8C)N$1C5'9K97AS$IO;6U8875/ M4DU30F1,+T%0;UE$6% K<$IU=B8C>$$[*U(X;B]:3FB]9:S-
N2#@S3F0X>2M7-S=1>#51=7)5,WEQ9VXY4U-8:GAD6"MX M.5A3=C)A9&-V,"8C>$$[,UHP35=15#A11W9X,W1/;S$XC!N M.&UT2C%(4R]Y.3 V,3%#0C=7-
4Q44T=#54985EAL6FPU2V1W4W4Y33%88653 M328C>$$[.#5-5%DR*S4R4%HX1$A#05)252]Z6#AT86QQ*VXR9#%94FUE5WAA M5&Y!;3=S:V]7<%5D>4-
G,D=89&QA4]/4D5T=4HQ,V(R:6YM:"8C>$$[1U5" M6FIE,W8O5@P,G656=V%76FU/24=-8C-*1"8C>$$[2S!L4S=T>'%-179R M,DTU2FIV=#%I9C1U2EES+TAJ.%A8;%-H-C5R-W)9-
T5D2&)Y>'E*=FYF5DMF M3E=V87IC86DQ<%!D4#9.:E,S:"8C>$$[:E)Z=R]D04QZ1D12=61+.'-Y=$QG M9TDX44$$[-W!Y2VQ+:F9-5%=X>%%/-311465893=
(3)K;6QG9S4X2DQH>DQ+96)T2654 M;B8C>$$[6Y*27E06'5E=7A9>$-00T5F;&)9-T9867$W1EA9 M<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9
M<3=&6%EQ-T9867$W1EA9<7A$.'EF>39T4$\K;3(Q6-K$$[96M'84E&,51%+TYF M-4M8'!/,&\K2G9G1#A3=C=).$LW,7I. M,"]A9T=A535J-F@P-D]*;C=/2B8C>$$[>$-
%1'DW*W%984HK4W5M=RM8=%!T M3E-U<$1Q9'5H1GIC5S=$9S-*:7=50U)4$$[*W!$3V1!.'9A6F].:4Q,5#!+>&LX-4AC.&YD:G1Y M63=:$$[&UP1TEM9SII6%G93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(#PO7!E+U)E&ULG,Z M&%P+S$N,"]S5'EP92]297-O M=7)C945V96YT(R(^"B @(" @(" @(#QX;7!-33I/&UP M34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @("
@(" \>&UP34TZ1&]C=6UE M;G1)1#YX;7 N9&ED.C U.# Q,3&UP34TZ26YS=&%N8V5) M1#YX;7 N:6ED.C U.# Q,3&UP34TZ4F5N9&ET:6]N0VQA M&ULG,Z M:6QL=7-
T&ULG,Z<&1F/2)H='1P.B\O;G,N861O M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @("/'!D9CI02 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D M9CI$97-C&UP65T83X*(" @ M(" @(" @("
@(" @(" @(" @(" @(" @

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l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|%^FUX1S$P)YU9T> M-95I?+ZY@W.K;=KF|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

M6&RW+RZ$G]>RK@>CP+Q-D91(M4\Y*R?/Z/T3I_0^.=C\;#$X&1_/-+([GGGD-:R M32GB]Q))ZFMJ>5K02J_CSSLAYV0^M3KS[BWGG5GU6XZZHUN+4?\ *I:U&9_[
MQ.IC&QL#&"C&@ #P ="]GD>^5[I9"3(XDDGK)XD_7*\8\EX("("("+BOB'[T MRO6?A+3L'H7Y4]UQV7T=76TVUWCT>"^TGLI?A MOR$+,T*4ASJ=N-+8_-
=X9F3N@U_^&X+WRT$5_#F9UNPD='BLD+VDU+7AA'$ MC>,FI8@0O>:U=+93S6SZGKVD31N)+L=XRM/:-2%$FNGOL9N"XU)A, T@RV=E/.]CT>^9&, /@ M-
+6M#U$&E"*SQ]HF'FAP&7S1!{.]NX86\.GWNO[B1X>-Q3AU@CI!IK;XG?-. MPY.[AFX5B-NM6D=66DVJQ2/"?<*!E^01S5#N<]FH29-S2DI.I?O ;K3[@:G?B<9*?
DECI',A#3XLT@\5]P[^=4U;#6O+'XPY3(^O MUN=R3NV6FR6WD>I=06X&YN=@9+=.>T<]I;N\>&Q83Q9RCEDN@*%]P>1Q>V"(MB,01^4W4!%;$*?!,2V=X>K^O\[I(>1XCEF8;
(I[VFG(-3$R%(G1/YJT&EV/ M*CNI2ZP^VI#T=]'"&U)6A*BL@[N>'QNH-DG87,1-GQES=73)&.Z'-+F_7!!H M6N%'-< YI! *H1[^&]<_HCO=,U;I:YDL]06&.QTT$S#XS'M8_J-0YK@2UI'
ML>QSF/!:X@P'OCKQ8\@ =M% M4-D I7Q9 T-> +6N[#WB\!WB= LS<'96VLK(.BR5FT_V.U.$T37$N-K<4+X7 M$NY2'PN>Y\3G'2P:I4E$!%LIQ'Y/9EQ.W-
C^S<9>E2J;O6JK/<6;=)$7+\ M-DR&E6E4ZA:DLIL&$H*1 ?/_ /QYC2%'U;-Q"|@:;;@Y3;?5,&?QYW%WHG-M8S(\IEL;HBKK2[:T]E M*",)C=7LYV#^TA(MU-BJ<:5TQ5OFL7()
<==0LEC<.MCVA MPJ.D&AH6GBTU! (*^8[5.FLUHS4E]I/44+K?.XZZEMYXSQY98GEC@".#FDBK M7MJU[2'-):05PW?NXLZC& P!(A=8'M[:F9;QVCGVW M]A62[?--CY5(PD^Q'BM-
M((DH(BN MXT_@L=IC!VFGL0P1XVS@9%&WKY6 "I/6YQJY[NESB7'B54'G,S?ZBS%SG,H_ MGR%W,Z5Y_I.-:#P-;ZUK>AK0 . 6.1W"ZI 1 1 1 1;Q>'/RSMN&'+C56YF9 MC[6(%
<-8AM6N;6Z3-OK#*GX]2'E*7V&B-4M^B;-]WAM^0CI*YCJ?9ZD>L=X= MP;D: O\ 3CF@Y#LS+:NX59'RSS7$6/ M:"*X;U.MY"&R5 Z2SA*T?SV-ZEV7++S,AEJ1'=;?
8?;0\P^RM+K+S+]26VZT MX@U(<;<0HC2HC,C(^I"EYS7,<6/!#P:$'@01T@A6T->^8_ M=:9$\[\T\[:IWN^UW?>H[73M%U@OWT\3E,I\FO\ #+:XN.3_ !#F[*-\G+S> M\:
ME6H_R^Z)^&K4OQCX=[LB"WR4U3YMR'D\WL%,GY2Z<\X67M\7LD_+[HGX:M2_ M&/AWNR'R4U3YMR'D\WL$^4NG/.%E[?%[)/R^Z)^&K4OQCX=[LA\E-4^;WQ>R3\ONB?
AJU+\8^'>[(?)35/FW(>3S>P3Y2Z<\X67M\7LD M_+[HGX:M2_&/AWNR'R4U3YMR'D\WL$^4NG/.%E[?%[)/R^Z)^&K4OQCX=[LA M\E-4^;WQ>R7ISN0'JKBNSK/?
&F:Z"QV._F3MH81$BL] MZXAEOO9$B\;9;[QYO*$]3+J[1$7E,A[(M':NGD$4.*R3Y3T!MM,2:<30!E>C MBO"356F(6&2;)6#(QTDW$0 ZN)+Z=/!:-[EV6Q532 MP[6.J\]J\
[G762&T\BL@9%<8H_:4^&52)24N3'[!]EUN*2C8:?>4RR[L_0/= M\W*UKEH;:XQMWC<*9!VUS=1.@:R.HYG1LE#'S.IP8V-
I!=3FRM[>1LQ?)QY0]T9+B\@AOK6N<6M/7@7MU8Y)=W M.16[YRK:^M;"ZM)2NO:DV-I+>G37U=3,^KTE]2C\I^R+=[6VAL[:.SMQRV\4 M;6-'@:T!K1]8
*KRYN);NXDNISS3O<]O\+G$DGZY*^4/>O0@(NURP#^PF%? MW2QO\#PQ0]E?\TN?TB3[\JZ#&?Y=;_W$?WH7+1P%S5\ZXN*G'JFTO[^TKJ.B MHZZ;
<75U<38U;4U%36QG9MC:6EC-=9AU]=7PV5NOONK0TTTA2E*))&8]UO;W M%W<,M+1CY;J5[6,8QI<][W$!K6M)76ONJ?M]<%/34XE_ZC=/>_(/FIW1_AO/\ _+
[OW%/G*VY_P"$\NM? M=4_;ZX*>FIQ+_P!1NGO?D'S4[H_PWG_^7W?N*?.5MSY_PGEUK[JG[?7!3TU.)^HW3WOR#YJ=T?X;S_P#R^[]Q3YRMN?/^$\NM M?
=4_;ZX*>FIQ+_U&Z>]^0?-3NC_#>?\ ^7W?N*?.5MSY_P)Y=:^ZI^WUP4] M-3B7_J-T]I\@^:G='^&_P#\ON_<4^]^0?-3NC_#>?_Y?=^XI\Y6W/G_">76ONJ?M]
<%/34XE_P"HW3WOR#YJ=T?X M;S__"^[]Q3YRMN?/^$\NM?=5F#5^]=([O8N)6EQZKV]&QUZ%'R"1J_86(Y M^Q1/V2)+E>QX?4>GM0MD?@+^ROF1$!YMYXI@PRNH
MAQC<[E)H:5I6AIT+*@Z)=R@(JE_THS_H:_[F?_'T3X[CW_4__IO_ !ZA3WPO M^G?_ #__ 2J8"?"A0@(I[OHV\'02Y^;QL?_ #-KT15[XGT31_&]O^3N%)3N MK?
2;)\5S_E(%>Q%7*L97%YYL#):;#L,QB"NSR+)\AGL5=)2UZ% MH;7,L;"4MN/%CI<<21]49%U,AS\9B\CFK^+%8F&2YR4[N6,*-I<[IO UHXD\
M.@+A9'(V.)LI,EDYHX+"%O,^1Y#6,;X7./ #U2M2/67^'WZ8_'CXS\9^WAGW MS+[L_P .Y?R:3V*PGYVMLO/V+\HC_E3UE_A]^F/QX^_,&?MX/F7W9_AW+^32
M>Q3YVMLO/V+\HC_E3UE_A]^F/QX^_,&?MX/F7W9_AW+^32>Q3YVMLO/V+\HC M_E3UE_A]^F/QX^_&?MX/F7W9_AW+^32>Q3YVMLO/V+\HC_E3UE_A]^F/QX^ M,_&?
MX/F7W9_AW+^32>O3YVMLO/V+\HC_E3UE_A]^F/QX^,_&?MX/F7W9_AW M+^32>Q3YVMLO/V+\HC_E3UE_A]^F/QX^,_&?MX/F7W9_AW+^32>Q3YVMLO/V
M+\HC_E3UE_A]^F/QX^,_&?MX/F7W9_AW+^32>Q3YVMLO/V+\HC_E3UE_A]^F M/QX^,_&?MX/F7W9_AW+^32>Q3YVMLO/V+\HC_E3UE_A]^F/QX^,_&?MX/F7W
M9_AW+^32>Q3YVMLO/V+\HC_E68M.\JN-O(2RN;!-9I7M<>@L6=Y7X)EE3 MD4NIKY4@XL>;/8KI#RXT9Z2782M1$1J\@QI46A-9:2ACN=3XR|LO@%K'3Q/ MC#W 5(:7
5(/&G@7>X+6>E-3S20:=R-I>S1-#GMAD:\M:30$AI- 3P6?QB:R M9 18?VAR%T%I!^GB|HWAI_4,K(F9DC'XVT-EX7@#IXQ7+CMV#],SE=U4N6;.
M!R8TEY3!+2TIU!*,C4GKD.#TCJO4S)'Z;QF0R#(2!(;:VFG#"ZO*'F)C^4NH M:!U*T-.@KH\QJ?36GG1LS^1L;%\H)8+B>*$O#:_(=[\U.Z/\-Y__)?=^XKI?G*VY_X3RZU]U3]OK@IZ:G$
MO_4;I[WY!\U.Z/\ #>?_ .7W?N*?.5MSY_PGEUK[JG[?7!3TU.)?^HW3WOR# MYJ=T?X;S_P#R^[]Q3YRMN?/^$\NM?=4_;ZX*>FIQ+_U&Z>]^0?-3NC_#>?\ M^7W?N*?.5MSY_P
)Y=:^ZI^WUP4]-3B7_J-T]I\@^:G='^&_P#\ON_<4^]^0?-3NC_#>?_Y?=^XI\Y6W/G_">76O MNJ?M]<%/34XE_P"HW3WOR#YJ=T?X;S__"^[]Q3YRMN?/^$\NM?=4_;ZX*>F MIQ+_
-1NGO?D'S4[H_PWG_\E]W[BGSE;<^?\)Y=:^ZI^WUP4]-3B7_J-T][M\@^:G='^&_.ON_<4^76ONJ?M]<%/34XE_ZC=/>_(/FIW1_AO/_/+[OW%/
MG*VY_X3RZU]U3]OK@IZ:G$O_4;I[WY!\U.Z/\-Y_P#Y?=^XI\Y6W/G_GE MUK[JG[?7!3TU.)?^HW3WOR#YJ=T?X;S_/R^[]Q3YRMN?/\ A/+K7W5;71Y# M$MAB5%?
9DQ9++8D,/(2XR^P\VI3;K+K:B4E23-*DF1D?08&]CXWE MCP6O:2""*$$=((ZB.L+-&N:]H>P@L(]".((/00>L%>8>*\D!%UPY/ M?.'W5^LG)1>%M]^X6$^*+/\ 9XU3WKC]]1:\C+EBR
BNB>*/X$^- M[C+(-]<,:BGPO;#ARK;,-,G$IL)V/(6ICO-.]CI7<>22YP(HR*\-7S6XZ Y;I=-'.IW&6,'NY6F=[74F@F,M\T:NEM11D4YZ2Z+H;%*>MO"-YX^(ZI?3;RO$\GP3);S#
MPF8'QR1N#F/:X5#FN!(((ZP5!"ILKS'7*L-3=EIS6[X[741HV.?@R"Y/0 IH$4SNH<(Y#ZPM<6Q MFQH(>*5" B B BZYKQF/XFG*[^]N)?JPP<7"=W+Z%<#^CR_M,ZJPWZ^ES-?W
M\7[/"HQ1NQ:A0$7:+\0_W3N+_P W?2GZML:%'VX/[^YOXWO/VB17"Z'_ '*P M_P 5VGY"-;$#$%E" B B B B BT6YT\(<*YC:YN,J2< M5\U'(7C.1.1FUR9N)VIO4E[I+CD)Y?G#*5*)QI[4&
[^TN)W1P1B(9![6W;3: MW!'0>GLI:"KH7GI%"8W'G8">9KY1=USO-ZE[NNL6W+3-=[?WTC1D+$$>,VG* M+FW#B&LNHA0@U:V9@[&0@M,XT_G&0ZXV/CT[%\PQ>Q
MWV001P17VG;Z((/BE8>!'0YKFF MCF2,<"R2-X:^-[7,>T.!"X(.G64H"+VI,V9,3%3+ERI2845$*$F2^ZˆF)#;<
M=>1$BDZM11XJ'7U]D\M'1!*6H^G4S'LDEEE#1*YS@QO*VD)Y6U)Y17H%230<* MD^%>B&VMK=Y !>Z@',XAK07&IH *T 7JCUKWKF& 8!F. MTLQQ_7^O\?
L,HS#*+![JHZ.L:)R3+DN$I:U*6M2&(L.*PA;TB0\MMB,PVMUU M:&T*47:87"Y3464@PN%@?<92X>&1QL%2XG_8&@5K=6W<-CIZQA,DTTAHUC1P %7.>YQ#(XV!SY'N:QC7/< ;CG
S@KA?# MO 6GI+<'(=T956Q3V#FY-]ZB,:B:DKP_$W'FT/1,5K)22[2^RV]9/ME(?))) M88CVB:.;/XK:_#!\@9/JNYC'OF>E:=![":$D5;"P])H'2N >\ !C&?.IWJ>]) MJ3O$ZK=%"9;/::PF=
[PLJT+J5:+NZ)#[J1IX-JYELQQBB))EEFW\&YU$] 1 M 1 1 1 1 11X^+),#CY=_FEL/PK5#;NPGTO:?_3V_>N6K]ZOHKSGZ$[IYJZV MX7)]J) 13*> ?
_$TTU_=/<'ZK\H$=.]7|"N1_2+3|IB6^>[7]+EA_<77[/(N MP+%32LT0$0$0$0$0$6*MT[MU;QYUSDNU]PYE38/@^*UT]PL;6XF,L+DK
MCQW'VJJFAJ64JIOI)37=0X$5+LJ6^I+;2%+41#O=-Z:SFKLQ#@=.,VTEUDYWA MK6L!-*D N>>AD:;U>]Q#6-J7$ +IL_J##Z7Q4N:SL\=OCH6%SG.(%:"H:T=+ MWNZ&L:"YQH
"2NKFV)D[6;[SG,X\1R QEV8Y-DI,%YU+SL)]_NIMJW$=>0E M"'7(R)9(4HDD2C3U(B%X6(L78S$VN->X/=;V\<1) >\NI7KI6BX<.Q7 4MW@\YG(,)LUE&2 M.Y;B],-
M$.'C.DE:YXXUZ(8Y7=%2&GHZ1N[N\8>;+[KXYT::P6@EN)#_ #6L MCPQ%1JL_0$4'OTA3^')DOYVM6?A2<)-]T?Z8H?B^Z^]:H M)Y[Z*YOTVW^^*H1"U55L("*>[Z.1_$$N?F\;'_S-
KT15[XGT31_&]O^3N%) M3NK?2;)\5S_E(%>Q%7*L90$4'OTA3^')DOYVM6?A2<)-]T?Z8H?B^Z^]:H\] MY[Z*YOTVW^^*H1"U55L("*PW]&E_?KVQ\TO._P!<.AQ$7OH?1=8?'\'[)?*4
M/=,^D:]^))OVJ5SX05DJPQ 1 1 1 1 1 1 1 15X_I+7[BFI_G:8)^I[? MEUW+_I1O_B"?]KL5%[O9_1S9?'*CX+-E7F@(K)T9C!['?7S=WOUDX*
M(;=!3]PL5\;C]GG4K^Z1^^N2^*S^7A5U<5L*?R B B BKB;!U]*UCMW.,3>9 M6U$CW#X*N!(K]J0>M58[DZ9FTEK;(861I$#;ASXC,.AD//$0>N
MC7!KB.'.UPZEAX94L&0$0$0$62/%?XC97;^$BEE45DI_*=,9]3[\S.L92HY M2<9OJW(<>R(G(G9]9/8O3Y1 DS#_ /P,5LA9^U(QKG93<;'M[PMU'/(T8_(V
MK["!QZ.TC=&^.A\$KXI&L_G&1@Z5*[6^VN0L>[I8M;&[_%+*X;D+AG6&3![7 M@CPQ1R1<_@;$T;ST*EH+%"U"M 1?U*5+4E*4FI2C)*4I(S4I1GT)*2+J9F9GY" MD 5/0OT"O =*N>
[#\)W*MG>"]Q[T["QMN/R?TECEKNO%*]3&8AWD+MOK<0RE2BKAQ&_5CA.\AE]12S$Z(RCR([R%(6A:24A1&1D1D+&XY(YHVRQ.#HG $$$$$5!!' @CB".!"@6]C
MXGF.0%LC20010@C@00>((/ @"l"]<>:\$!$!%DW36GMA;^VAA6G=58]*RC/L^_MNX]%C11%2HB4^Z2WI4^<^25(@4]1 9=ES93G1]+$9<=<,D(,QTNH]0XC2>#N
M=19V9L&*M(B^1Y\ X!$1L][B&,:.+GD-'$A=O@<%E-2YBWP6&B,V2N9 QC1 MX3Q))ZFM +GN/!K07'@%>QWW08YX8_A:U&BM=3VBR290P1Q,DCM>9R\ASG8
M#5E;;1SDDDM4R*_-A)N)$(S<<77F<1E+G9:0/GR[XN\V2R.%S>LIG&+*YF;W MI;-K4PQ2-+0QI%.,5JQ_CM K+1_ N7T0_P"G/W?L9G-U]/:/DC$VGM.PG)WA M+>$SI=['
-+@:@MFOI8>:-Q-8.>/BU]JL"G=?3D@(@(K>7@U?N3T7YQ-@?A"* M+,^ZU]$\/Z=<_?!?/C_J-_\ W+W7Q/8?>/6[')?CEK_E]>_U5L"(DH]@VJ7
MCV0LQVWK;#LGCM.IJLEIE*6THI,)QPTNL]M")<9;C#A]VXH;9U[H;"[AZ;FT MYFF^(\+:@/87,=XKBHT;+;Q:MV-U[::[TE(>VA/)<6 MY<1%=VSB.UMI@ ?
%>!5K^4NBD#)6#G8%2\NAK/7NC9NTQ=T MVCXW$=K;SM [6VG:">26(D5%;.6R,+HWL<<,#%5LA 1 16=?!!WI+RO6&?\ M?KZIGY11Y4TJ0HS+KV[@DD9D1$FP#N
MDZSER.G[W15X_FDQ[Q-!7I["8GG8/4CF!=]6>G0.%)'^IOM1:X'6^)W:Q409 M;YR%UK>%HX>^[1K>QE=_2FM2(Q3JM"2 22?O_2!\XGXAX<&9T\%YE.R-F:O MP>>ME/E.
S=O9VZTMTGV5LLOO80VA9D3G;2HVS3V5J4FU7NF8R+(;QVUQ* 3 M9V5S,VO\XL$ -*&I F)'13IK4 &C?O-Y&2QVJN((R0+N[MX33P!YF\(H"8@# MTUZ*4-
104%K2K40$0$0$0$0$0$79O>'WGDS9G!WB;FME*5/M;;06L6;F2"/+7) M8WP,?*Y[.G@&N 'J=-#P5NFV62DR^WF%R$KN:9^,MP[^%[8VL>3T<2YI)]5 M;@C7JSE 1 1
14>_I+7[]>I_FEX)^N'? LV[E_T77_Q_/^R6*KS[V?TC67Q) M#^U7BKR"72B\@(@(@(@(@(@(@(@(@(@(@(LR\=M1V^^[\:?TO1QY$FPV=L
M;$<,+S5"UKB0KNZAP[6T<['E:B4]4MZ6^X?1+3#*UJ,B29C'=7Z@M]*;6R.I M+H@0V5G+-QZW,82UH\)>ZC6CK<0!Q*[_ $MA)]2ZDL0A1D22:GI5QP MH.A?T?B+7?
EY^Z=R@^;ONO\ 5MDHR_;[]_<)\;V?[1&L7UQ^Y68^*O\A(NK MH%X*IZ0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0SOSZ+_ /V%YA?WLTU^!]BBOCON_P":
M:>_1S[^W4Y.Z#_EV=_O[7[V=6HQ!93)0$52_P"E&?\ 0U_W,\ CZ)\=Q[_M *G_ /3?^/4*>^%_T[_Y_P#X)5,!A0H0$4]WT8_0HORJN5"NA3Q0$50+Z4! ;OA]_ M=+H?TBS^\N%!OO??
YC@O[BZ^^@55T3I4-D!$!$!$!$!$!$ M!$!$!$!$!$!%VN6 ?V$PK^Z6-_@>&*'LK_FES^D2??E708S_ "ZW_N(_O0N6 MC@+FH"+]YN7?[V')
[YP^ZOUDY*+PMOOW"PGQ19_L\:[IQU^^N8^-+O\ +R+7 MD9UVHZS[B,]O79W??4VU%X+0%U[I&1]9;1SO6U[= M);N-
>RDZR/62=#Q6CVZ:W5V8T]N7:FY/+::GC92.Y:WUU.B=HIVD?4#Z^/I M8:58ZAQR:XL;OXA;/L3:UPV7BN20^\D5B2)!*F.5E:L>/ :@ MCQF%S2'&N#5VC=0Z'R[\+J.!T-
VWBT\D'Q7!K@0->1ERQ9 M 1 16,_"[\=#-./IX[HKEQ8W>Q-',%&J.7V4OSNZV%JF&A+<>'"LC,WIN;X% M7H024,'V[2M8ZIC+D,MLPDP]WO[K^-U;VVJ-
,BL]3FKY:;@RWNCTES>AL,[MNDNX12.XO#'.=*94;/ >*O],=EIS6[Y^5HQ6I]U8+9A&#@P
MN:&QBZ!@N=X9L[$,>S_7F3TF9X5E=:Q;XYE&.V$>TIKBND=2;DPIL5;C3A)6 MA2%IZDMIQ"D+)*TJ25<&4Q>1PF0FQ.7@EMLE;O+)(I&EKV.'46GCZHZB""*@ M@]?
&.R5AE[&+)XN;.XQ\S Z.1C@YKFGK!'#U#U@@@T(*Y8. N:@(NN:\9C^) MIRN_O;B7ZL,'%PG=R^A7 _H\O[3.JL-^OIFP9(<01N2/Q3RSS=MQ&Z.(J.2WU3;L/O>XIT])
[&:@JZ%QZ#Q=$XE[:O M8^5O=:[TNI^[IJ?D?VM]MU?2M]_6/-Q!X-]]6O,0UETQH ():RX8T12D$12P MTZMEZTSC3^<9#KC8^/3L7S#%YRX%O43T$2T+
(B<8E17VS7'GUL^.M+T:2RI; M$AA:7&U*0HC.KW/X#+Z8R\^"SL#[?*6[^5['?9!!'!S7"CF/:2US2'-)!!7T M3Z+UIIC>5SGOE18C?6F-WL1J8PY%F-
1K>FE0K!AN7%=4VXE#A$XVHTJZD9D. M%D,;CLM:NL 10TY#_ !U;)|\H?-]H+S)B/([?W-/EQK7SQE/*Y_=$ M_:[Y8>D]R'^.K9/OE#YOM!>9,1Y';^YI\N-:^>,IY7/[HG[7?
+#TGN0_QU;) M]\H?-]H+S)B/([?W-/EQK7SQE/*Y_=$_:[Y8>D]R'^.K9/OE#YOM!>9,1Y'; M^YI\N-:^>,IY7/[HG[7?+#TGN0_QU;)|\H?-]H+S)B/([?W-/EQK7SQE/*Y_ M=$_:
[Y8>D]R'^.K9/OE#YOM!>9,1Y';^YI\N-:^>,IY7/[HG[7?+#TGN0_QU M;)|\H?-]H+S)B/([?W-/EQK7SQE/*Y_=%B/+,ZS?/9R+/. M' <&
#@.CP+H[W(Y#)2=MD9YKB45\;1[GGCT\7$GCUKBHYRX2SMH/C)OOE#E M[.#Z%U9ENR;U;S#&50>'M]VWDY+8U>7\@=FLUKNS, MMJR?
K,!PQV8Q&EJH*N3(6]*EK:8>M)ADXXA#3,5IFK'?C>J[W;S MD;+)C[?25D7"VB=3G>YU Z>8 D=HX !K 7")G $N<|SK'|F-H[;;##O?=O9/ MJ>\#>WD;7D8UO%L,50#R-
))_2%/X_2%/X^A]%UA\?P?LE\[0]TSZ1KWXDF_;K-7A!62K#$!$!$!$!$!$!$!$!%7 MC^DM?N*;G^=I@GZGM\"77: B MLD?1F/WL=!?-
W>_63@HAMWU/W"Q7ON/V>=2OI[!ZY+XK/Y>%75Q6PI_("(M("+4WE3QKB[WQV+8TCD2NV'C;+J*.?*[3<6VKE]4\|CUF\@E*:96^HW8SQI6 M3#QJ+H2'7#&S-MPD)-
&7[H+L.DP5P1VC1Q+'= E8.LTX/;4(B4I*7V5'U:E1'NP9M/M*6RZGVR%*29&)BXW)X_+V;+_&3 M,GLWC@YAJ/J'K#AUM(#@>! *KTS&%RVG\A)BLU;RVV0C-',>VA^J.IS33Q7M
M):X<6DCBN/#G+]T(C,R(B,S,R(B(NIF9^P!%_*9AT<3T+]Z> Z5(IQ;XIR._ MC;DW6Q'Q;!<99/(JZIR9;581 :5-1?9'Y^IAJJQ>M0WYQ_Q!H*22"-9%'Z
MF[HC<;R<^*K^7F/+V<7+4OF?7E\6O)6@_">ME!M!LV]KV MZ\W :RRTY9M[=D=P1&'A@Y^VGYZ".WC Y_'IST]ZD5>?)&R?
%*QK"476)V$60TJ'85KZ\GET<2\KIK#]VUFRW)B2&S5T6I"B[7 M18'NR[NWL,>49%;X^<%KV";XY)FD<6N B;(8W @&CBU[33@".',:ZI[]G=VPU M[+AQ+4>A+"'&[YV$MH]M(VY6W;
[XLYST SM@#I+>5U.CLZ2'F M"CO9X3;O=Z^FO-A,K#=W%#(_$W5;6^A'2>Q$_*RYB;7BYDCNS'*USWN-5IO" M\(?QO)9]JU3L<2=D-RWI1PT/39&3)UM4EU*E)-
;M[8Y'%I(\7JGR/N2$LF70R7 MT,C&;2=X+9J* W#L_9F,-K0"5SJ>HQL9>3_1#:^HD>Q^ZV\DP@;A+L/)I4F-K M:^]IT@8!ZI=3U5,]PX\([3_
W]B\P/%$VI]W%6L/L8UC@6IY%TBVH(F71.D^ MKEY)+8:6[L3*]Q<5R1$QVBC6+"E,I?<>DH2N.B.&XN_^H=U.TV]V/L;Z=UPP MMGN@SED,1\5PC!-+>)U0U]Q.Z-WC%@:PD/. -";
(X/;?L]<[P7EG"V!X=#;% M _P2CQFF0@5GD;0N;!"UXX!Q<\ M$GT7Q^_#4DWZ:9>SL[AP%2_-BRJ5]7.? MN 37:))3E,QZR1DJ8A]>OEKN^(O9;(:1D[J&\[+3WR+*U=+RU[(74/:5_FU+
MA'7_-Y3U5MYG>7VF?<]@;R]'S4[0VTW)6@:9*?]ROJ+7'FIX4W&OQ/L?7 MRUX3[5UI4;-RDG7[6^I9966I]K6L=A)2&\S;I&9-O@NPHZUM)FS$1'9)]TS MX"Y"SD-YCMGOOK/9&
[&@=RK"[DPD% V-XY;IU;3P,)>0R>W/'D87!O08I0P< MAQ7<+9C2>[]M\MMO[VU9EYJESV'FMKEP"M>0%T,XX<[@TNZI(RX\PJM[[\/ M?F=QIM)\';7'C9-36P'EMEF-'CTS,, F-
]XI#+\3.,4;M\._XE!$M++LAJ4A M*B)QI"NJ2G3I7=O;C6D#)$&&7DDX=%0TM)Z'$<5#;4NV M.O=)3.CS>+NV1-/]JQAEA/@(FCYH^/30N#AU@'@M085=864UJMKX$R?8R'#9
M8@0HK]:\ZDE&II]*PA;[CB229FDDF9=#&PI)H88S-,]K(0*EQ( ))X+!H MXI99!%$USI2:!H!))0#BI'>,_A(<[N4-G6%C.DLBUYAT]:%O(W)!L=/8N\,GK6H&:[?N:]'+5!
[33[V.X54=]\3B>)Q M,:2ZZVEYZ7.=0A'?+4VI5ZV&Y'O/3$#RZ&T8XDVUFSNGML;TMN??6H9F!LMR]M#3@3'$VI[..HJ14N>0" M]Q#6AL?GCQ9N^]DO'O7#+ZD1JZCS7-
["*D_:2'[F?34-.^Z74S-4-NBG);Z$ M7D?7UZ^3I5/WQ9X"[I]8WHZZ^XA6K:T!$!%;R\&K]R>B_.)L# M\(119GW6OHGA_3KG[X+Y\?\ 4;_^Y>Z^)[#[QZE6$C%!!:%\^^$^-\Q-6JAP
MTPJ;;V&,S+#6N5O)2VA;[B.\EXC?O)0IQS&\@4VDC475<*4EN0CM))YE_3F\ MVT]ANAI[LHN2+4U]'.M9CPX1<,AZ3%)0<>F-X:\5 4Q*BOH(U(,T.(]JM)0M)DI*E),C.K)8V_P /D)L5
ME(GP9&WD=')&X4(($!S35K@""!QX<%=P@(I\ P,?Q'F]@]0E]3$8N*9YA5 M@?>]VTMMK9.9PFWB-22<[VWP^,A"?*9NJ3T(2"[L67?C-V[2U!I%?6UQ [C
M04$1G:#X:O@:!ZI"A! J&:8BU!W9,ID'-#KC#W]C>1*D$W#;-Y'@I%=R%Q_ MF@J4CZ0GA]CD_AR9+<04.+8U]MG5V86W=MFX2:Z593\%2MPR,NZ;399K'Z]\
MOEZ%,+U*ICND9&&RWAAMY2 ^[L+F%GJ8-;/]?Q87+Y6^\8RW>U6UO; M>5W]4N,/WTK50A%QJK80$0$0$0$0$0$79I^'9A$S77!/B1B5C&.%90=!:UGV
MD):UN.0[3(<:@Y'91'E+-71^-.MG$.)29H2M)D@S21&*5=W\G'F-T<_D(7_%; MJO1P6Y@URL]0$0$0$5'OZ2U^_7J?YI>"KAWP+-NY?\ 1=?_ !_/^R6*KS[V M?
TC67Q)#^U7BKR"72B\@(@(@(@(@(@(@(@(@(@(@(@(N?ZUU3LS)PV7SUZW'86VGNKYYX,B8Y[MOJT:#0#K)H .)("N>>#9X/5[Q(M2Y+\EH]0O?4ZFE5>!X#!E0[J-]*LN8RHM
MW9VMU"B0(#KR"?D.25E'KB[Q?>&M=?P?(O19D&E6R!T M\[@6&[(2UC"X^)|$T?QO;_).X4E.ZM)LGQ7/^4@5[5$KZ*\Y^A.^:NMN%R:JB0$0$0$0$
M0$0$0$0$0$5G7Z,9_P#>W)[\TN(?YQ=$)N^Q^ZV$^,)?R*EYW1/WCS'Z%%^5 M5RH5T*>* B]!?2@/[=\/O[I;D_#&O!8/W(O\KU#^D6?WEPH-)[[_#'!?W%U M]] JKHG2H;("("("

Z2]7(JA4A!/QW",E(6AYI3K#K3KEUS1/32NJ\%K3"Q9[3TXGQ\O#P.8\4YHY&GBQ[M:BK3U$.:2TM<M4>>\|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

M;6ZZM#332%....*2AMMM"34M:UJ,DH0A)&9F9|"(?H!<0UH]XK\)#07.- %U M@G-O8=%MGF)RAV3B\MBPQ?,]l;5O,8LHRC4Q:8W+S.X.AM&S,S\EG4I9?Z=3
M(CEL@A9SM_P"Z^K?K*H3<'*6^;UUF M,M9N#K.XR5P^-PZ'1F5W([_O-H?KK5X9NL.6PW$3][#C#\X?2OZR<:&([@_N M%F_BB_9Y%E.A_WUP_QI:?EXUVC(H]5PB B@]^D*?
PY,E_.UJS*3A)ONC_3 M%#\7W7WK5'GO/?17-^FV_P!\50B%JJK80$4]WTM4>>\||%Z9](U[\23?M5FKP@K)5AB B B B B B B B B BKQ_26OW%- M3_.TP3]3V^!+KN7_ $HW_P
03_M=BHO=[/Z.;+X]A_9;Q4?!9LJ\T!%93^C* MP93G*+D'H:ZP8F@<(A_.MMEWNTCP;PY2S+EO)',;+9^*8+$ M8)S-I[%F::HHL)JJ^GDNQF^DROA.7*I3SC4:/$N&">
<0X:4'7'O;CLYOIQ,= M,:+8V7'X6W;;37#C2WBD+WOF>]X!/!Q$(8T.>Y\+^1I)$T-$Z[T=W;-F!K# M<29T5_F)WSVUI&
ZZN&M8QD4<49+1ZT=]Z1[FQQMF9SO#BUIU=Y)>*)R0WI. ML*S%+Z7IC7KIO,1<:P6Q?B7\V&IQ1H5D6;,HBWDV2XR?=NMPS@0G&S[*F%>5 M1[QV_P"
[CH#1D,=QDX&Y?.BA,MRT.B:ZG_A6YK&T \6F3M) >(>.@5Y[P=]; M=_ -F>XCQ7-B,$+F\#$>),<$J5)FR'Y MDR0_+ERG5OR94IYQ^1(?=4:W'GWW5+====<69FI2C,S,^IC?
L<<<,8BB:UL30 M !T < !U *(4TTUS,ZXN'NDG>XN*.8]HXVZ9?8Z:6WOHGVLN1&"0-B:KR)F]HI:BC38ZTE&N*"U0RT))H\AK#6MVLMHB'DFI!FI# MB%)<:6XTM#BJ^M8Z+U%H/-
/P.I8##>MXM/3'*RI DB?T/8ZAH>!!!:X-<"T7 M$[;;G;.W9TQ%JW1%VVZQDAY7M/BRP2@ NAGCJ3'*T$5!J' A[*/8YKC%]LG' MY&+9]EU%(:-HX-[8>;D:>R2X,E]4NN?
2DB21(D0'VUET+IT4)"X"^9D<+:WC M#7GA;7^L!RN'UG CZRC!J?'28G4-Y82"ACN'T]5CCS,/UV%I^NN$#MUT* B MBF-
T[0RL:UAA5/-0MN9'I(\B4RYTIR/(L5N6;T99$70EQG)AMGI/E3I)^R(L M:IO8\AJ&[NHB#$Z8@$=:!#:,!^N&U~NIJZ+O\N+TK8V4X(F; "X'I!25Y:?ZI
M=3ZRKD^+IP7GZ^S&UY1:PI5.Z\S>Q3(V?55D=:_Q,S>Q=4,I Z(IW<7' MH;,2"1VC +YO|/OO16NKM.P:':WN0W5^,AY<;+(X#WY91CQ;8$]-Q9L'*Q@\
M:2U:TM:3!*XP;B(JL^0$5H/P\M_Z_P"_,AI/;8V-/\WJ:7/M@,UE5'6W]U\J MR&1+9.HQBB86?V>TM'FS(C/[%'92X^\I#+3BTV#;(ZTPN@=A#J3./Y;:*]N0 MQ@]?-*2.2*,=;WD?
4:T.>XAC7$4?][S:;5N]?2+H+1T7/?W.)L#+*X'LK6W=]V]9S:/.K=[^1FN0-,QC<4 M2S;KX4:>Q!K(R5$?99CM--(Z$24D1"PW&:.!T1A[466-Q&.BM@*4%O$2:=;G%
MI<\^%SB7'K*IJSF[NZ>I,@[*9S46:N+USB:NO)P&UXT8QKVLC;X&QM:T=0"W MRX;^*!N'3^7T.,;JRZ\V=I^RFL5[O)RB3)O0T>04^02"E7MI$JTF2
MW:Z2Y(0N.@T1B9<,C/2N['=STKJK%3Y'2-K#CM51L+F"$","<@5[*2(4C8Y_ M0)6!I#B#)SMJI0=WOOI[@:`S]KA=QK^YS6@)I&QRNN7.FNK1KB!V\4[N::1L M?2Z"1T@,8+81&ZA-
JF)+BSMZ%A@96L(61,VMGFOY++N.W\Q(CTL ME.4TQUR;224ETJ3;U:\LV4=M)=#6UW;R2_FK2?E'1Y?3>&S<9;?0,,I"1H#
M9!ZH<./#P&K?""LEP6KM0:=E:_&W#Q*#QC<2Z)WJ%A-!7HJWE<.HA2:Z@V]2 M[7I%28Z4U^05R6D7E(ISMJC+7U2B9#6HB5(KI*DGV5?SFU=4+\O0U1]U1I>[
MTU>=G(>>RDKV=>[26B9?W'L%LM'N9?2YG/%[-)V<@8X-):ZXE(YNR M:\>L:QI:Z5P\:CFM90N+V1@[WG>?FV-Q-OIK238I-P\G$9(W/ ?'9VX<6>^' MQGA))(X/9
QPY.9DQ*Y^A@CDK-97R-W!F!P]?59NU?9US:/.K=[^1FN0-,QC<4 M2S;KX4:>Q!K(R5$?99CM--(Z$24D1"PW&:.!T1A[466-Q&.BM@*4%O$2:=;G%
MI<\^%SB7'K*IJSF[NZ>I,@[*9S46:N+USB:NO)P&UXT8QKVLC;X&QM:T=0"W MRX;^*!N'3^7T.,;JRZ\V=I^RFL5[O)RB3)O0T>04^02"E7MI$JTF2
MW:Z2Y(0N.@T1B9<,C/2N['=STKJK%3Y'2-K#CM51L+F"$","<@5[*2(4C8Y_ M0)6!I#B#)SMJI0=WOOI[@:`S]KA=QK^YS6@)I&QRNN7.FNK1KB!V\4[N::1L M?2Z"1T@,8+81&ZA-
JF)+BSMZ%A@96L(61,VMGFOY++N.W\Q(CTL ME.4TQUR;224ETJ3;U:\LV4=M)=#6UW;R2_FK2?E'1Y?3>&S<9;?0,,I"1H#
M9!ZH<./#P&K?""LEP6KM0:=E:_&W#Q*#QC<2Z)WJ%A-!7HJWE<.HA2:Z@V]2 M[7I%28Z4U^05R6D7E(ISMJC+7U2B9#6HB5(KI*DGV5?SFU=4+\O0U1]U1I>[
MTU>=G(>>RDKV=>[26B9?W'L%LM'N9?2YG/%[-)V<@8X-):ZXE(YNR M:\>L:QI:Z5P\:CFM90N+V1@[WG>?FV-Q-OIK238I-P\G$9(W/ ?'9VX<6>^' MQGA))(X/9
QPY.9DQ*Y^A@CDK-97R-W!F!P]?59NU?9US:/.K=[^1FN0-,QC<4 M2S;KX4:>Q!K(R5$?99CM--(Z$24D1"PW&:.!T1A[466-Q&.BM@*4%O$2:=;G%
MI<\^%SB7'K*IJSF[NZ>I,@[*9S46:N+USB:NO)P&UXT8QKVLC;X&QM:T=0"W MRX;^*!N'3^7T.,;JRZ\V=I^RFL5[O)RB3)O0T>04^02"E7MI$JTF2
MW:Z2Y(0N.@T1B9<,C/2NI'=STKJK%3Y'2-K#CM51L+F"$","<@5[*2(4C8Y_ M0)6!I#B#)SMJI0=WOOII[@:`S]KA=QK^YS6@)I&QRNN7.FNK1KB!V\4[N::1L M?2Z"1T@,8+81&ZA-
JF)+BSMZ%A@96L(61,VMGFOY++N.W\Q(CTL ME.4TQUR;224ETJ3;U:\LV4=M)=#6UW;R2_FK2?E'1Y?3>&S<9;?0,,I"1H#
M9!ZH<./#P&K?""LEP6KM0:=E:_&W#Q*#QC<2Z)WJ%A-!7HJWE<.HA2:Z@V]2 M[7I%28Z4U^05R6D7E(ISMJC+7U2B9#6HB5(KI*DGV5?SFU=4+\O0U1]U1I>[
MTU>=G(>>RDKV=>[26B9?W'L%LM'N9?2YG/%[-)V<@8X-):ZXE(YNR M:\>L:QI:Z5P\:CFM90N+V1@[WG>?FV-Q-OIK238I-P\G$9(W/ ?'9VX<6>^' MQGA))(X/9
QPY.9DQ*Y^A@CDK-97R-W!F!P]?59NU?9US:/.K=[^1FN0-,QC<4 M2S;KX4:>Q!K(R5$?99CM--(Z$24D1"PW&:.!T1A[466-Q&.BM@*4%O$2:=;G%
MI<\^%SB7'K*IJSF[NZ>I,@[*9S46:N+USB:NO)P&UXT8QKVLC;X&QM:T=0"W MRX;^*!N'3^7T.,;JRZ\V=I^RFL5[O)RB3)O0T>04^02"E7MI$JTF2
MW:Z2Y(0N.@T1B9<,C/2NI'=STKJK%3Y'2-K#CM51L+F"$","<@5[*2(4C8Y_ M0)6!I#B#)SMJI0=WOOII[@:`S]KA=QK^YS6@)I&QRNN7.FNK1KB!V\4[N::1L M?2Z"1T@,8+81&ZA-
JF)+BSMZ%A@96L(61,VMGFOY++N.W\Q(CTL ME.4TQUR;224ETJ3;U:\LV4=M)=#6UW;R2_FK2'

VV6MH;B&G0]H=3U6D\6GU6D$=17=834>>TY5X\+7 @]84HO';G9'R.7!PW="H-5:R5)C5V=1VVH%/-?5Y&V< MBB{[$:HD/+\A2623$,U$2VV4D:SCGKO9J2PB?E=)
<\MLT5=;DESVCK,3NEX' M\QU7^!SR;"7VU_>*BRDT>"U[V<-X\\K+MH#(GGJ$[11L3B>B1M(ZGQFQ@2ZY5CL?7$%C+I*.S^/\ B+JL6S-+A)-"'Y=G7H*+?K:;4:4)M(\Y
MI!=.B.I%TACK79I;_7Q=/G;!@R;A_P#$PGL9Z]%7/;PDH.@2MD \' *S7:3O M3;W;+-CL|&YF5^GV'_X"['OFS[6I:R.0\T)XDVTD#CUNXFL4>PO >B+D/R= M4\@9$>*:O^&IMA84Q"'-
]SN,O,F MG,TYL?4RY@#C]>6)[0>OHA"GEI'_%3[AL38=>;:28^>GC36V6-)X^MMKB-Y M'5TW1ZU@%[P+^329C*(^TM$NUZDI.1*>MM@,3&E]I9*2S!1KZ0Q(22229&J0
MV9F9ET+H1]PMW="U^)0&9'#F'K)?K[8?[..V8_]439,V[G2X/5 M+;L'Q6B*PRI^0R[L?D'C]9%1U5(A83AE ME>2'_;=$M,V=
[;8\W$ZI/M&X](]T,NSV#Z]HLCQ/<[R+WAV=S<$<8Z6P0.D) M]0/D?$!]7D=X*=:P/4W^]A@HHG,T;I&[GG/K7WMY'"UOJF*"*X+^/#E$K/#S
M<*&3300A=\1M#RH5U'PF3LS+H*FWH^3[4DQLG7$DH-+A/5V.,P][$8;C+Z26 MP\]M-'2,NX[1U_DV4(ENR):'PMB#6PM(/%KNS+\]3
M^M0HW5[\7>!W4@EQLV39A=/R@AUMBVNM@]IXM][1CZ MX: ?]H/U.A0KUJR2/5N1;)Z[WY*>BG N);_^Z1QZ^E8V'?K%T!$!%^D(6XM# M;:36MQ24(0DNJE+49)2E)%
]DJ,^A#\)#07'@ O)K2YP:T5<30+/OB0\"K?E! MCF/[#ULJ">Z<$I3IE5LQYB#&V#CB7ES44AVDI;,:ON*N?(D/0"U(CN>1&[M'LD MA)3,96HR[#C1
MK;61D:3,C(6'XS5NE\S:"_Q61LKBS(KSLFCS\DB2L>R++8##*B>.DQ.HFML6W9MDD3:K);3<5AE:G&EO.I2TK2F[' M>$TKHS%36.F[J#
(;M>PMC;$YLL4#CP[29[:L\3I$0)>YP#7!K27"4'=[[G&X M&YN?MPN\MW%(U\$IACH+BZ8#7L;6)X;+^%X--P6MC8PE['2/ 8;8=? MA54"%5UL5B#75L2-
@0HK;68T.%#91'BQ8[*")#3$=AM*$)(B)*2(B%94\\U MS,^YN',?<2.+G.)]7.<;N<3UDDDDI95Z5K:VUC:QV5FQL5I#&UC&- #6,8 U MK6@< UK0 ,
HO;']7O0$0$0$0$593QGO"SY8\WN46![7T13X/88CC^@\7U M[8O9+FD+')ZZP.J9+IF0FRLMPT1PND;V;K>VC!+@10\T3^'@H>M1'W[VT;/<2&@(-1RR-X^&HZE$9]7L\1S_
)9U+\:=5]I"0'I;I._C M|_R5W\]TAZ,.ZGXFR\(_GU>SO'/^6=2_&G5?:0>EOL[^/O_)7?RIZ,.ZGX MFR\H;_(I[_^\/7D=P. ,:=_.:!K,2KORJ_D6_%+\5LJBY-WWXC_E9^[WGWFS#
M/F7=_CA"[KM=>\[2^G\PQ%7O-[N:.W3_ ,$^2;[A_0#WYVO:O&.G;>]>3EJ3 MS?V+Z^#AX5)3N];8:]VW_P 7^4S(&>_?>O9]G()*]C[YYZT I_:LIX>/@4]X MBHD)H"("("("("*
KQ<_!RBRQW^2-FOK,HK+1UJDQ;;=%'6F M,Q*NK!B,[]S[_P!XF3;AATMJ[MKC1KBY MT3F@OEM7GB0QI(YH9#Q=&".1Y,C/7/#HU;W$LUZX:DTQV4&JVAK9&N\2.Y8 M. +W
>+,P<&O(/,P!CNAA; M]7L\1S_EG4OQIU7VD)4>EOL[^/O_ "5W\]C; MZ,.ZGXFR\H;_ "]7L\1S_EG4OQIU7VD']I;[_CI_P E=_*GHP[J?B;+RAO\ MB?
5[/$<_Y9U+\:=5]I!Z6^SOX^_\E=_*GHP[J?B;+RAO\BL0^$?H_P 1WB=1 MN\?N4=+A62Z$KJZ9)UIDU/L*MR'*M:V27O.E8DN&;<>1:X):[XZJ,E0)N/U',>#965) M(D;X\H]DM.
[JZ*MSIG6$=O-IIC"8)&SM?) ZM>SIP+H7<>7L;J #D/B3>B, MRD(L/DL0F9=[DN%7=-41G9DIQ]+$;? ML)K:%.N*2VV1]I1D1&8R'2.0M<3]S%Y6^<6V5MD;:60@$D,CF8]Y %2:-!-
M*GH"Z+5%CROG&X\DN?[GYA!Y5;^Z)Z@_Q-/@:O/XX-7^^@/2KV M5\XW'DES[DGHU[N?F$'E5O[HGJ#_ !-/@:O/XX-7^^@/2KV5\XW'DES[DGHU M[N?
F$'E5O[HGJ#_$T^!K$_C@U?[Z !*O97SC<>27/N2>C7NY^80>56_NB>H/ M\33X&L3^.#5_OH#T]JE?.-QY)<^Y)Z->[GYA!Y5;^Z)Z@_Q-/@:O/XX-7^^@ M/2KV5\XW'DES[DGHU[N?
F$'E5O[HGJ#_ !-/@:O/XX-7^^@/2KV5\XW'DES[MDGHU[N?F$'E5O[HGJ#_$T^!K$_C@U?[Z]*O97SC<>27/N2>C7NY^80>56_N MB>H/\33X&L3^.#5_OH#TJ]E?.-QY)<^Y)Z->
[GYA!Y5;^Z)Z@_Q-/@:O/XX- M7^^@/2KV5\XW'DES[DGHU[N?F$'E5O[HGJ#_ !-/@:O/XX-7^^@/2KV5\XW' MDES[DGHU[N?F$'E5O[HGJ#_$T^!K$_C@U?[Z
]*O97SC<>27/N2>C7NY^80> M56_NB>H/\33X&L3^.#5_OH#TJ]E?.-QY)<^Y)Z->[GYA!Y5;^Z*Q+X&?!;DC MPCQ7D95\B<0JL2F;#R#6T_%6ZO+
<:RM,V+CE=F,>V6\YCEG9(A&P[<,$DG30 M;^T9IZ]D^D0>_NAHW8K-:.FRIQED]I\Z0< M&S6782N6IIM#9;ZVP[Q&O-LH&X]!T>0TVT\+:X+CV8Z^PE!YXJG[4\\8XD1A MQ)6EMQ-
B=%[A3.R4S7V.?<,-Q!0[] .:0SVL9-:HR\SAYOK6ZF-)2LTI365=+LFK8E.*))$A=B39=3,W"Z>65 M.'[ZFB+AC?\ '<3D[6<]/8F&X8#_ %G/MW$>J(Z^HHV97ND:O@>[_!LGCKF$
M=':B6!Y'I5K)V@^H7T]5:\SOH\?B+1)3L>/4Z:M&6^QV)T:#+<5_MMH6KND M6=)73B[I2C0KMLH]LD^G5/11Y=%WNMGY(P\F1C'3 MQX+&).Z]NFQY:UE@]HZQ<"A^IS,:?
4X@?8XKU/]IGB.?\LZE^-.J^TA[/2WV M=_'W_DKOY5Z_1AW4_$V7E#?Y$^KV>(Y_RS]7XTZK[2#TM]G?Q]_Y*[^5/1AW M4_$V7E#?Y$^KV>(Y_P LZE^-.J^T@]+?9W\??
^2N_E3T8=U/Q-EY0W^1/]]G MB.?\LZE^-.J^T@]+?9W\??\ DKOY4]&'=3\39>4-_D3ZO9XCG_+.I?C3JOM(M/2WV=_'W_DKOY4]&'=3\39>4-_D3ZO9XCG_+.I?
C3JOM(/2WV=_'W_DKOY4] M&'=3\39>4-_D3ZO9XCG_"SJ7XTZK[2#TM]G?Q]_Y*[^5/1AW4_$V7E#?Y$^ MKV>(Y_RS]7XTZK[2#TM]G?Q]_P"2N_E3T8=U/Q-EY0W^1/]]GB.?
\LZE^-.J M^T@]+?9W\??^2N_E3T8=U/Q-EY0W^1>S$^CR^(O)DLL/4NG:]IU?97,E[1BK MC1T]#/O'DP*B:,4@NG_XVEJ_W#PDIW.SI&%S9:,Z_ MNF[X:Z.P:#UFX%!]6C2?L K.VO?
HT'+.ZEQU:,W;H; JAU9$^K&GLYV#D$5L MG7D.*54R<7PBF=6:$(6VE-J9*2OHHVU)-(Q;+]]'0-M&1A<9E;JX X=H(((S MP%/'$LSQU@UBX4X5!JLCQ?=*UKGLS-
,\=/VICB:>HO)\U\;%3 ME\((!&XG\.EDTYHY[3Q!9 M&V)CVFCVO"D3M[W?-%Z$NH\M-VF2ST9!;+,&B.-PZ'10BK6N' ASW2/;15CF
ME3*".BWP@(@(J[/CF>'ORDYN97QTM..V%4^6PM>8]LBORERTS/%<45!E9%98 M?(JD,MY':UJY1/M5#YJ4T2R1V2)73J767O=@W;T/MG8YB#5]S);R7DUNZ+EA
MEEYA&V8.KV;74H7MZ;5KPZ%%OO$[8:QW"O<5-I:WCGCM8IVRE7LKYQN/)+GW)1O]&O=S\P@\]M_= M$]0?XFGP-8G\<&K_ 'T!Z5>ROG&X\DN?E7LKYQN/ M)+GW)/1KW<_,
(/*K?W1/4'^)I\#6)_'!]_WT!Z5>ROG&X\DN?ROG&X\DN?E7LK MYQN/)+GW)/1KW<_,(/*K?W1/4'^)I\#6)_'!]_WT!Z5>ROG&X\DN?[:^6VE:7$MRH=;&CR$)<0:D.$EU MLR)1&9'[)"J6_E9/?3SQ&L;YGN'U"XD?[%9591/ALH89.$C(F-/U0T _[5R$
M<1*FVFP^E<9B;V:^%Y:X^WAD MG$!\4+&.H: M\1S--#UA5Z:F[N&YN5U)D,G:169M;F^GE96X:#R22O>VHIP-'*CJ6(O]GB. M?\LZE^-.J^TAD'I;I_ C[_R5W\JZ/T8=U/Q-
EY0W^1/]IGB.?\LZE^-.J^T@ M]+?9W\??^2N_E3T8=U/Q-EY0W^17WA54KQT!$!$!$!$!$!$!$!$!%7F\3GP. M<%Y-/WN[>+*,=U9QI=
(/\M0/6M\8CMH1T(Y_RSJ7XTZK[2$G/2WV=_'W_DKOY5'CT8=U/Q-EY0W^1/]IGB.?\ +.I? MC3JOM(/2WV=_'W_DKOY4]&'=3\39>4-_D5X'C]AMWKG0ND=>Y*B,UD>":BUM
MAM^W#D)EQ&[O&,-I:2U1%E()*9,9$Z"X2'"(B6GH?\HK*U9D;;,:JR>7LB39 MW60N)HR10\DLSWMJ.H\KA4=15A>F;"XQ6F\?C+L 75M8P1/H:CGCB8QU#UBH M-
#UK+HQ]=X@(HH?$;U%S9Y(5[6GM&4^,4.GE(B3]V!/[M#[=(_ M0TIR#B=0\HC<9<4:ITMLEJ2EIIOO(X;YZ9W9UW -.:0BMX=+D!TTCK@,DN7=
M(C+:5;"P]+3QD>*D!K6\TJ.YUN#W:-F[MVX>Z%Q?76X@+V6D,=BZ:"P94M,S M7DT?=2CUKV@"")Q:TE\C^2&OU-7-C^HM=_&!7 ;HBWZ+6[\XFQ\I;_(K&?\ M\C?=H_.LQY
V:>IJYL?U%KOXP*[5#T6MV/O-CY2W^1/_R-IVC\ZS'D#_9K MZ51X,/,F;;5D.UC:XI:R5/B1[&X7FC%@FK@O/MMRI X$,(M[G;6$UQ8OS-S>QQ/=':"+-T?:O#26Q\[W\K.=U&\[N#;U/
*S7QRX\Z]XPZJH M=4ZX@FS65A',N+B2VR5SEF22F6&[3)KY]E"$R+*P\W0DB+VD>.TTPV26FD)* M?FA=$X3;_3D.G,$REO'XSWD#GFE(?+(1TN=0#P-:&L;1K0!2=O%N[J[>[7=
MUKS6,O->S^)#*"TGL;6W:7&*V@:2>6./F)/VTDCGRO)>]O.=1F"U<@(@(@(@(@(M@(@(HN/$5\.^EY98^6>:[8IL=W[<[E=<[NPAM= M#K;!:%*:
[/F[I]PI*X\>M\=D+3*RXC' A2D T?\ XB $ M!U>VC':M0/]FMX>$'$GQ%^&^?>?P*/!^FT<.CM(ZBC9FCH/ / Y'*%L8^\WO\ ]SWO%Z3] MZW5UE++75E&XV%^,=(3&3Q[
W%'+HG'M8O&YV26$1-A5'("+5;F M]H[+.2O$[>NB,%L,=J(2(RB- M3,.0QJ9>U_E+.MLM3V&C->XO5.49-)C[*Z$DC8@UTA:&N%&![V-)X];VCU5A MNX6G;W5FBLCIS'.B9?
7EN8V.D+A&"2#5Q:U(@.'4UQI15)TJ.OX6.)?^,] MP_(.)^>FAM=^89_VBT^'*$OHF;C?GN$]NNO@:?5I>=?PL<2_\=[A^0FAM=^89_P!HM/AR M>B9N-
^>X3VZZ^!I]6EYU_"QO+_QWN'Y!P]-#:[\PS_M%I\.3T3-QOSW">W77 MP-/JTO.OX6.)?^.]P_(.'IH;7?F&?]HM/AR>B9N-^>X3VZZ^!I]6EYU_"QO+ M_P =[A^0=?PL<2_P#'>X?D'#TT-
KOS#/\ M%I\ M.3T3-QOSW">W77P-/JTO.OX6.)?^.]P_(.'IH;7?F&?]HM/AR>B9N-^>X3VZ MZ^!I]6EYU_"QO+_QWN'Y!P]-#:[\PS_M%I\.3T3-QOSW">W77P-/JTO.OX6. M)?\
COK_HT/-EV22;7<7%F% M$['S4_7Y5MJSDDX1>T2463INH:-"C]E7?$;?]ACU3=[;*1K*P8[.ND\#HK5H M^R+QY_V+V1=TK<$OI-?X9K/"V2Y-=Y)DV-
-0B0^I79>57R.TE!=6DFLR1B67[I6/:QS<# M@9I)#T.N+EL8''@2R..0NX4X"1M"?7&G'\)7W0KYSP[-9]C.ML$#GD\.(#Y M)(Z<>OD=P'0*\)A^*?@I\%^*]M4YA$PBUW)L:F?CSJS-
MSSX>3_<:QCN^<-3 M:'$(%=3X1 E1924.19+M?)L(BFD*:DDOM*5'G7?>4W0UU;R8^2YCQV'D!:Z& MS:8^=I%"U\KG/F<"*AS1(V-X)#F4H!O31G=_VZT:,R^9;OO\K&06RW1$G*X&
MM61-:V)I!H6N+';0;$/K4F6P:!6[4!$!%'-XIO$/97-_B=;Z(U1=X/C^73\X MPO)F;'8=E?5..)@8Y,DR)S+LS&\:RRS*6ZAXB:24-2%'U[2T^R-P[&;@X;;+ M7L>]<|%=38]EK-
&6V[8W2X3VZZ^!I]6EYU_"QO+_P =[A^0*RM5Y9@[=?KC)M@6^0)MKZXQ6 MPAR%Q,FUAB%:5[6M]K
M[MT^EKH"SD<#+;RM[2WE(ZW,J"UW5SQ.CDIPYZ<%K_7>V.C]Q;9L.H[IKZ$.;U\DC7LKQY:\57QVA]&(O&YDN3I?E552]]PW50;3;&OID" M9%23;RF&9>48I=63$\U.DVE;B*>-
V4J4HD&:20J6N#[[5J8VLU)@I&RBG,^V MN X'HJ1%*QI;PK0&9W4*\;B,68[H=P)'/P&98ZU[HRX@+2.F@,D;WW54B)O M6:<*'6ZP^C0\V6D!]JMQ<69L3L(-
+]AE6VJR2;AE[=)Q8VF[=HD)/V%=\9J_ MV$,RA[Z.VCF5GQV=;)X&Q6KA]DWC#_L6*2]TK<$/I#?X9S/"Z2Y:?L"U=_VK MT?JTO.OX6.)?^.]P_(.;Z:&UWYAG_:+3X=?PL<2_\=
[A^0FAM=^89_P!HM/AR>B9N-^>X M3VZZ^!I]6EYU_"QO+_QWN'Y!P]-#:[\PS_M%I\.3T3-QOSW">W77P-/JTO.O MX6.)?^.]P_(.'IH;7?F&?]HM/AR>B9N-
^>X3VZZ^!I]6EYU_"QO+_P =[A^0 M=?PL<2_P#'>X?D'#TT-KOS#/\ M%I\.3T3-QOS MW">W77P-?I/T:3G2:D]K;/$PD]2[1ISG<*E$GKY32D]$H)1D7L%U+K_M]]# M:^G"PS]?
[BT^'+]'=,W%Z[W"4_OKKX&LOX;]&+W;-FH1L+E#]S&J[O#[R1AN M%Y;F\WNB)LR-$2[EZ_8[Q1FHNAO]$D'U/]9%CV1[.FHXB<1@[Z::G1--%" MVOU6"<^#[7['
[RP[HFH))*9/,6<45>F**24T^H\PC_:IG^%?@G<0>'>15&QW M(EYO';U(\Q-I3VXTED MQ'#=[2"0YC!%&\<'LB B B B B MB B
BHP\E,RD;!Y";LS.0^J1^,&TPQMNT_U^R:7D\!Q<\N<> XD\%\SN\6H M9=5[KZDU%,XO]]YN\>TUK2/MWB)HXN%&1!C&T)% *$A82&7K6Z B B B B B M BW'\/O,I6#&R"6HB:?
BYI%EX8ZPXE2DH<-1WI&V1]>CR M4*(NTE(U1OEB8\SM-G+:1M>SLG3CP@VSFS@CP?V?'^B2#P)4@^ZIJ&;3/>%T MK?0NY>WRC+1U>AS;UKK0M/4?[8%O],-
(X@*S)S>WM+U?@T7#<9EKBYAGS4MC MSZ.YWRM"B<8G63CI18ZNA=$]^M*DN-)%>.T&C8M19EV5R#0[% M61:>4BHDE/%C3U%K
.=P\/(""UQ5TG>"W%FTAIYF"Q+RS.9(.'.TT=% V@D> M".(>\GLV']':.!#F!0AB7ZK[0$0$0$0$4S?!+?$S/<8FZQRFD8]*=:8-9].U'>8+VRDK4<3MYM&187(LU#C6!F/O M'D2-
H&3T+J@=0E +J?SFOZ 0%/'NZ;C3ZDQ$FDLQ(7Y;'OAT3G&KI+:H;0G MI+H7%K"3TL?&.)#BI 1I%267C>>:CM.OONML,.K>>>>6EMIEIM)K<==<6:4 M-MMH29J49D1$74QY-
:Y[@Q@)>30 <22>@ =9*\))&1,=+*X-B:"22: <223 MP XDGH49>]O%@XNZ?ES:+&;*TW/E$-2V7(OVBANOX&E(Z_8IF;3WF:F2R?3 MH;E8FS)*CZ&\&2ND4]%]V74VS7#J=>/(BO
7%Q/TXTI*\KT9K^ZA=LC5'Q[(\CQB4;?0NJ4R()K+FDK,_P#U M=P9%_L'E?=SG3&8.SFF<5+8+BXMW4\'-(+H5]7D/U%('HWQ:>+NVID6CRV9<:6R.4IMII&>IBKQ.3)<5 MT)]-
F=6X] A-H3Y5.VC58U,(2C,R(I&ZR[L.X^F(G7F+9%E[!M2?>U>V '68 M'@.59?6SW%K75#N4D\S:'B',?6H/$!P%/%*SI=O C MWY%JS'%LN,O(V478)HR@I=>Z^.1,5EU1^P1'B
M>L,G):8X8VR!DS%^X001MXNH/Z;FCKX9YM]@QD\T,E>49A<>,WG MD=ZT\KM75WD7.);4_T&N/50P8=9:N["(_:0Z#&H-FT276Z]$61*C]>CDM9F:$2%T/W.=)VV(CGUY<7 M5UG9&
OC@D$4$1(!+&D-,DCFFH,AKU-<922'1<%M;X9CR&/ MF89)I0"1SN!<&1APXA@:YS>MYZ!)7X47C82^9VPVN.W(+$<6PGYTXR1K9XIN4RP>QSH9(N813<@YG1ECG.*.+7AKO6$
.L*B(ZD^@(@(@(@ M(@(@(@(@

Activity (Detail)link:presentationLinklink:calculationLinklink:definitionLink 995995 - Disclosure - Stock-based Compensation - Summary of Unvested RSUs Activity Under 2015 Plan (Detail)link:presentationLinklink:calculationLinklink:definitionLink 996005 - Disclosure - Restructuring - Additional Information (Details)link:presentationLinklink:calculationLinklink:definitionLink 996015 - Disclosure - Restructuring - Summary of Restructuring Liability (Details)link:presentationLinklink:calculationLinklink:definitionLink 996025 - Disclosure - Related Party Transactions - Additional Information (Detail)link:presentationLinklink:calculationLinklink:definitionLink 996035 - Disclosure - Net Loss Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail)link:presentationLinklink:calculationLinklink:definitionLink 996045 - Disclosure - Net Loss Per Share - Additional Information (Details)link:presentationLinklink:calculationLinklink:definitionLink 996055 - Disclosure - Supplemental Disclosures - Schedule of Other Current Assets (Details)link:presentationLinklink:calculationLinklink:definitionLink 996065 - Disclosure - Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail)link:presentationLinklink:calculationLinklink:definitionLink 996075 - Disclosure - Supplemental Disclosures - Additional Information (Detail)link:presentationLinklink:calculationLinklink:definitionLink 996085 - Disclosure - Subsequent Events - Additional Information (Detail)link:presentationLinklink:calculationLinklink:definitionLink Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, TotalProceeds from Sale and Maturity of Debt Securities, Available-for-SaleSales of equity securitiesStatement [Line Items]Statement [Line Items]Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]Summary of Changes in Allowance For Credit LossesFinancing Receivable, Allowance for Credit Loss [Table Text Block]Accrued external general and administrative expensesAccrued External General And Administrative ExpensesAccrued external general and administrative expenses,Accounts receivableIncrease (Decrease) in Accounts ReceivablePlan NamePlan Name [Domain]Other adjustmentsRestructuring Reserve, Translation and Other AdjustmentPercentage of voting powerPercentage of voting power.At the market offering program.At The Market Offering Program [Member]At the Market Offering ProgramEntity Address, Postal Zip CodeEntity Address, Postal Zip CodeDeferred revenue:Deferred Revenue [Abstract]Entity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeRestructuring costsRestructuring chargesRestructuring ChargesRestructuring Charges, TotalOperating ExpensesCosts and Expenses [Abstract]RevenuesRevenues [Abstract]Weighted-average Exercise Price, ExercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise PriceBalances (Shares)Balances (Shares)Shares, OutstandingOther Noncash Income (Expense), TotalOther non-cash adjustmentsOther Noncash Income (Expense)Fair Value Hierarchy and NAVFair Value Hierarchy and NAV [Axis]2015 Employee Stock Purchase Plan [Member]Two Thousand Fifteen Employee Stock Purchase Plan [Member]2015 Employee Stock Purchase Plan.Fair Value, Inputs, Level 2 [Member]Level 2 [Member]Share Based Compensation Arrangement By Share Based Payment Award [Line Items]Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Issuance costs for the public offering of common stock and pre-funded warrantsIssuance Costs Of Common Stock Public Offering And Pre Funded Warrants But Not Yet PaidIssuance costs of common stock public offering and pre funded warrants but not yet paidNovember 7, 2024November Seven Two Thousand Twenty Four [Member]November seven two thousand twenty four.Liability Related to Sale of Future RoyaltiesLiability Related To Sale Of Future Royalties [Text Block]The entire disclosure for activity within the liability related to sale of future royalties.2014 and 2015 Equity Incentive Plan [Member]Two Thousand Fourteen And Two Thousand Fifteen Equity Incentive Plan [Member]Two Thousand Fourteen And Two Thousand Fifteen Equity Incentive Plan [Member]LeasesLessee, Operating Leases [Text Block]Commitments and ContingenciesCommitments and Contingencies Disclosure [Text Block]Restructuring Cost [Table]First Anniversary [Member]First Anniversary [Member]First Anniversary.Product and ServiceProduct and Service [Axis]Liability Related To Sale Of Future Royalties [Table]Liability Related To Sale Of Future Royalties [Table]Liability related to sale of future royalties.Finite-Lived Intangible Assets by Major ClassFinite-Lived Intangible Assets by Major Class [Axis]Milestone payment upon commencement of clinical trials in humansMilestone Fee Payments Upon Commencement Of Clinical TrialsMilestone fee payments upon commencement of clinical trials.Collaborative Arrangement and Arrangement Other than CollaborativeCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Cash equivalents and marketable securities.Cash Equivalents And Marketable Securities [Member]Cash Equivalents and Marketable Securities [Member]Employee Stock Purchase Plan [Member]Employee Stock [Member]Related Party Transaction [Line Items]Related Party Transaction [Line Items]Reductions in restructuring liabilityRestructuring Reserve, Period Increase (Decrease)Restructuring Reserve, Period Increase (Decrease), TotalInterest expenseInterest Expense, NonoperatingInterest Expense, Nonoperating, TotalEquity [Text Block]CapitalizationFurniture Fixtures and Leasehold Improvements [Member]Furniture Fixtures and Leasehold Improvements [Member]Olivier Danos.Olivier Danos [Member]Olivier Danos [Member]Accounts Receivable, before Allowance for Credit Loss, Noncurrent, TotalAccounts Receivable, before Allowance for Credit Loss, NoncurrentAccounts receivable, Non-currentClass of Warrant or Right [Axis]Award DateAward Date [Axis]Sale of Stock [Domain]Cash and Cash EquivalentsCash and Cash Equivalents [Domain]Other unbilled receivables on current.Other Unbilled Receivables Non CurrentOther unbilledSummary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or GreaterDebt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]Other Commitments [Line Items]Other Commitments [Line Items]Accounts receivableAccounts Receivable, before Allowance for Credit LossEntity Central Index KeyEntity Central Index KeyStock-Based Compensation Expense by Award TypeDisclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]Schedule Of Available For Sale Securities [Line Items]Debt Securities, Available-for-Sale [Line Items]Zolgensma royalties paid to HCRZolgensma Royalties Paid To H C RZolgensma royalties paid to HCR.Shares, Cancelled or forfeitedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in PeriodChanges in operating assets and liabilitiesIncrease (Decrease) in Operating Capital [Abstract]Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]Imputed interest income from licensingImputed Interest Income From LicensingImputed interest income from licensing.Common stock, shares issuedCommon Stock, Shares, IssuedAccrued Expenses and Other Current Liabilities [Member]Accrued Expenses And Other Current Liabilities [Member]Accrued expenses and other current liabilities.Award DateAward Date [Domain]Income Statement [Abstract]Entity Address, State or ProvinceEntity Address, State or ProvinceIssuance of common stock under employee stock purchase planStock Issued During Period, Value, Employee Stock Purchase PlanRevenue recognized upon achievement of development milestones.Revenue Recognized Upon Achievement Of Development MilestonesRevenue recognized upon achievement of development milestonesUp-front and annual feesUpfront And Annual License Fee ReceivableUpfront and annual license fee receivable.Vesting of restricted stock units, net of taxVesting Of Restricted Stock UnitsVesting of restricted stock unitsRevenue recognizedRevenue recognition, milestone method, revenue recognizedContract with Customer, Liability, Revenue RecognizedOther operating expensesOther Operating ExpensesOther Operating ExpensesAccrued expenses and other current liabilitiesAccrued expenses and other current liabilitiesAccrued Expenses And Other Current LiabilitiesAccrued expenses and other current liabilities.Additional shares to be issuedShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares AuthorizedTotal, Fair ValueDebt Securities, Available-for-Sale, Unrealized Loss PositionOther Past or Future Obligations to Pay Sublicense Fees [Member]Other Past Or Future Obligations To Pay Sublicense Fees [Member]Other Past or Future Obligations to Pay Sublicense Fees.Aggregate Intrinsic Value, ExercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic ValueCover [Abstract]Subsequent Event [Line Items]Other current assets.Other Current Assets [Line Items]Earnings Per Share, Basic, TotalNet loss per share, basicEarnings Per Share, BasicUnrealized GainsDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before TaxSummary of Changes in Balances of Receivables, Contract Assets and Deferred RevenueSummary Of Changes In Receivables And Contract Assets And Contract Liabilities Table [Text Block]Summary of changes in receivables and contract assets and contract liabilities.Other license and royalty revenueOther License And Royalty RevenueOther license and royalty revenue.Deferred revenueContract with Customer, Liability, CurrentChange in transaction priceChange In Transaction Price Of LicenseChange in transaction price of license.Investments, Debt and Equity Securities [Abstract]A N Jerry Karabelas.A N Jerry Karabelas [Member]A N Jerry Karabelas [Member]Stock-based compensation expenseShare-Based Payment Arrangement, ExpenseCurrent accounts receivable, netAccounts receivable, currentReceivables, Net, CurrentSales Based MilestonesSales Based Milestones [Member]Sales based milestones.Retained Earnings (Accumulated Deficit), TotalAccumulated deficitRetained Earnings (Accumulated Deficit)Plan NamePlan Name [Axis]Shares Outstanding, Beginning BalanceShares Outstanding, Ending BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, NumberCurrent assetsAssets, Current [Abstract]Royalty Payment Cap AmountRoyalty Payment Cap AmountRoyalty payment cap amountInvestment TypeInvestment Type [Axis]Contract Assets [Member]Contract Assets [Member]Contract assets.Net cash used in operating activitiesNet Cash Provided by (Used in) Operating ActivitiesWeighted-average Grant Date Fair Value, ForfeitedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair ValueShares, Vested and expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, NumberProduct and ServiceProduct and Service [Domain]Accumulated Other Comprehensive Income (Loss), Net of Tax, TotalAccumulated other comprehensive lossAccumulated Other Comprehensive Income (Loss), Net of TaxProperty and equipment, netProperty and equipment, netProperty, Plant and Equipment, NetCash flows from operating activitiesNet Cash Provided by (Used in) Operating Activities [Abstract]Type of RestructuringType of Restructuring [Domain]Restructuring and Related Activities [Abstract]Schedule of Fair Value of Cash Equivalents and Marketable SecuritiesSchedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]Common stock, par valueCommon Stock, Par or Stated Value Per ShareStock Options Issued and Outstanding [Member]Stock Options [Member]Unrealized gain on available-for-sale securities, netOCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after TaxService Agreements [Member]Service Agreements [Member]Contract with Customer, Liability, TotalDeferred revenue, current and non-currentBalance, beginning of periodBalance, end of periodContract with Customer, LiabilityStatement of Cash Flows [Abstract]Antidilutive Securities, NameAntidilutive Securities, Name [Domain]Liability Related To Sale Of Future Royalties [Line Items]Liability Related To Sale Of Future Royalties [Line Items]Liability Related to Sale of Future Royalties Line Items.Vittal Vasista.Vittal Vasista [Member]Vittal Vasista [Member]Number of warrants issuedClass of Warrant or Right, Number of Securities Called by Warrants or RightsRestructuring Costs, TotalRestructuring CostsRestructuring costsAggregate transaction price of license agreementsAggregate Transaction Price Of License AgreementsAggregate transaction price of license agreements.Common Stock [Member]Equity Components [Axis]Beginning BalanceEnding BalanceFinancing Receivable, Allowance for Credit LossEntity Address, Address Line OneEntity Address, Address Line OnePresent value of cost of revenuePresent Value Of Cost Of RevenuePresent value of cost of revenue.Employee-related Liabilities, Current, TotalAccrued personnel costsEmployee-related Liabilities, CurrentSchedule Of Related Party Transactions By Related Party [Table]Related Party Transaction [Table]Shares, GrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in PeriodHCR [Member]H C R [Member]HCR.Computer Equipment and Software [Member]Computer Equipment [Member]Property Plant And Equipment [Line Items]Property, Plant and Equipment [Line Items]Ending balanceBeginning balanceLiability Related To Sale Of Future RoyaltiesLiability related to sale of future royalties.Subsequent Event Type [Axis]Accounts payableIncrease (Decrease) in Accounts Payable, TradeNonoperating Income (Expense)Total other incomeSchedules for Computation of Diluted Weighted-Average Shares OutstandingSchedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]Current accounts receivable:Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]Proceeds from stock options exercised including unsettled optionsProceeds From Stock Options Exercised Including Unsettled OptionsProceeds from stock options exercised Including unsettled options.Impairment Loss Of Property and Equipment NetImpairment loss Of property and equipment, net.Impairment losses recorded to property and equipmentMarketable SecuritiesInvestments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]Unvested balance at December 31, 2023Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, NumberUnvested balance at June 30, 2024Amendment FlagAmendment FlagFOXKISER LLP [Member]F O X K I S E R Limited Liability Partnership [Member]FOXKISER limited liability partnership.March 2024 Public Offering [Member]March Two Thousand Twenty Four Public Offering [Member]March two thousand twenty four public offering.Operating lease liabilitiesOperating Lease, Liability, NoncurrentAdditional paid-in capitalAdditional Paid in Capital, Common StockAccounts ReceivableReceivable [Policy Text Block]Net lossNet lossLessee, Lease, Description [Table]Shares, ExercisedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodExercise of stock options, net of tax, sharesCommon stock shares issued to participantsShare-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in PeriodRelated party transaction expenseRelated Party Transcation, Expenses from Transcations with Related PartyOperating Costs and ExpensesOperating Costs and Expenses, TotalShares, ExercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, NumberResearch and Development Expense [Member]Research and Development Expense [Member]Abb Vie Collaboration And License AgreementAbb Vie Collaboration And License Agreement [Member]AbbVie collaboration and license agreement.Equity ComponentEquity Component [Domain]Name of Property [Domain]Interest expense recognizedLiability Related To Interest Expense RecognizedLiability related to interest expense recognized.Statistical MeasurementStatistical Measurement [Domain]General and Administrative Expense, TotalGeneral and administrativeGeneral and Administrative ExpenseFinancing Receivable, Allowance for Credit Loss, Writeoff, TotalWrite-offsFinancing Receivable, Allowance for Credit Loss, WriteoffGain (Loss) on InvestmentsGain (Loss) on Investments, TotalNet loss (gain) on investmentsFurniture and Fixtures [Member]Furniture and Fixtures [Member]Cash and cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, TotalNet lossNet Income (Loss), Including Portion Attributable to Noncontrolling InterestSchedule of Other Current Assets [Table Text Block]Schedule of Other Current AssetsPreferred stock, shares issuedPreferred Stock, Shares IssuedU.S. Government and Agency Securities [Member]US Government Corporations and Agencies Securities [Member]Proceeds from exercise of stock optionsProceeds from Stock Options ExercisedCurran Simpson.Curran Simpson [Member]Curran Simpson [Member]Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]License Revenue [Line Items]License revenue.November Two Thousand Twenty Two License AgreementNovember Two Thousand Twenty Two License Agreement [Member]November two thousand twenty two license agreement.Payables and Accruals [Abstract]Issuance of common stock under employee stock purchase plan, sharesStock

Issued During Period, Shares, Employee Stock Purchase PlansLaboratory and Manufacturing Equipment [Member]Laboratory And Manufacturing Equipment [Member]Laboratory and manufacturing equipment MemberWeighted-average Exercise Price, Vested and expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise PriceWeighted-average Exercise Price, Cancelled or forfeitedShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise PriceCollaborative Arrangement and Arrangement Other than CollaborativeCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Pre-funded WarrantsPre Funded Warrants [Policy Text Block]Pre funded warrants.Total other comprehensive incomeOther Comprehensive Income (Loss), Net of TaxLicense and Collaboration AgreementsCollaborative Arrangement Disclosure [Text Block]Comprehensive lossComprehensive Income (Loss), Net of Tax, Attributable to ParentCommon Stock, Shares, Outstanding, Ending BalanceCommon Stock, Shares, Outstanding, Beginning BalanceCommon stock, shares outstandingCommon Stock, Shares, OutstandingFinite-Lived Intangible Assets, Major Class NameFinite-Lived Intangible Assets, Major Class Name [Domain]Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]Fair Value MeasurementsFair Value Measurement, Policy [Policy Text Block]Preferred stock, par valuePreferred Stock, Par or Stated Value Per ShareAntidilutive SecuritiesAntidilutive Securities [Axis]Corporate Bonds [Member]Corporate Bond Securities [Member]Schedule of AbbVie Collaboration AgreementCollaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]Entity Interactive Data CurrentEntity Interactive Data CurrentSignificant Accounting Policies [Line Items]Significant Accounting Policies [Line Items]Significant Accounting Policies.Revenue recognition, milestone method, revenue recognizedRevenue recognizedRevenue Recognition, Milestone Method, Revenue RecognizedStock issued during period shares exercise of prefunded warrants.Stock Issued During Period Shares Exercise Of Prefunded WarrantsExercise of pre-funded warrantsDocument Quarterly ReportDocument Quarterly ReportSchedule Of License and Royalty RevenueSchedule Of License Revenue Table [Text Block]Schedule Of License Revenue [Table Text Block]Weighted-average Grant Date Fair Value, VestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair ValueRelated Party TransactionRelated Party Transaction [Domain]Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending BalanceCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning BalanceTotal cash and cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash EquivalentsRelated Party TransactionsRelated Party Transactions Disclosure [Text Block]Balance Sheet LocationStatement of Financial Position Location, Balance [Axis]Liability related to sale of future royalties, non-currentLiability related to sale of future royaltiesLiability Related To Sale Of Future Royalties Non CurrentLiability related to sale of future royalties non current.Statistical MeasurementStatistical Measurement [Axis]Cost of Goods and Services Sold, TotalCost of revenuesCost of Goods and Services SoldUniversity of Pennsylvania [Member]University Of Pennsylvania [Member]University of Pennsylvania.Estimated fair value of assetTotal cash equivalents and marketable securitiesAssets, Fair Value DisclosureRelated PartyRelated and Nonrelated Parties [Domain]Non-current accounts receivable:Accounts Receivable, after Allowance for Credit Loss, Noncurrent [Abstract]Shares available for future grantsShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantWeighted-average Grant Date Fair Value, GrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair ValueUnrecognized stock-based compensation, weighted-average periodShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for RecognitionProceeds from Issuance of Private PlacementProceeds from private placementProceeds from private placement of common stock, net of issuance costsInterest percentage on unpaid balances under license agreementInterest Accrual PercentageInterest accrual percentage.Prepaid expensesIncrease (Decrease) in Prepaid ExpenseIncome Statement LocationStatement of Income Location, Balance [Axis]November Two Thousand Eighteen License AgreementNovember Two Thousand Eighteen License Agreement [Member]November two thousand eighteen license agreement.Cash and Cash EquivalentsCash and Cash Equivalents [Axis]Total assetsAssetsRestructuring TypeRestructuring Type [Axis]Deferred Transaction CostDeferred Transaction CostDeferred transaction cost.VestedRestricted stock units vestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in PeriodIncome tax effects or reclassification adjustmentsOCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and TaxOCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax, TotalRestricted Cash and Cash Equivalents, Noncurrent, TotalRestricted cashRestricted Cash and Cash Equivalents, NoncurrentRecent Accounting PronouncementsNew Accounting Pronouncements, Policy [Policy Text Block]Entity Address, City or TownEntity Address, City or TownAccumulated Other Comprehensive Loss [Member]AOCI Attributable to Parent [Member]Equity [Abstract]Payments of Stock Issuance CostsIssuance costs for public offering of common stock and pre-funded warrantsForfeitedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in PeriodCash paymentsCash paymentsPayments for RestructuringSummary of Reconciliation of Cash and Cash Equivalents and Restricted CashSchedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block]Schedule of cash and cash equivalents and restricted cash.Offering expenses for ATM Program but not yet paid.Offering Expenses for A T M Program But Not Yet PaidOffering expenses for ATM ProgramRestructuring Cost and Reserve [Line Items]Summary of Accounts Receivables, netAccounts Receivable Table Text Block1Accounts receivable net non current.Private Placement [Member]Novartis Gene Therapies [Member]Novartis Gene Therapies [Member]Novartis gene therapies.Stock-based CompensationShare-Based Payment Arrangement [Text Block]Common stock shares authorized for issuanceShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedNew York Sublease [Member]New york sublease.Milestone fee upon submission of preclinical regulatory filingsMilestone Fee Payments Upon Submission Preclinical FilingsMilestone fee payments upon submission preclinical filings.Issuance of Stock, transaction costsTransaction Costs Associated With Stock IssuanceTransaction costs associated with stock issuance.Fair Value Disclosures [Abstract]Issuance of common stock and pre-funded warrantsStock Issued During Period, Value, New IssuesStock Issued During Period, Value, Stock Options ExercisedExercise of stock options, net of taxCurrent liabilitiesLiabilities, Current [Abstract]Repurchase of call option amountRepurchase Of Call Option AmountRepurchase of call option amountDocument TypeDocument TypeNovember Two Thousand Twenty One License AgreementNovember Two Thousand Twenty One License Agreement [Member]November two thousand twenty one license agreement.US Government and Agency Securities [Member]US Government Agencies Debt Securities [Member]Provision for credit lossesProvision for Other Credit LossesImpairment of long-lived assetsImpairment losses of long-lived assetsTotal impairment of long-lived assetsProperty and equipment, netAsset Impairment ChargesTitle of 12(b) SecurityTitle of 12(b) SecurityCash and Cash Equivalents, at Carrying Value, TotalCash and cash equivalentsCash and Cash Equivalents, at Carrying ValueMilestone fee payments upon achievement of various development and commercializationMilestone Fee Payments Upon Achievement Of Various Development And CommercializationMilestone fee payments upon achievement of various development and commercialization.Balance Sheet LocationStatement of Financial Position Location, Balance [Domain]Statement of Stockholders' Equity [Abstract]Document Fiscal Period FocusDocument Fiscal Period FocusTotal intrinsic value of options exercisedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic ValueResearch and Development Expense, TotalResearch and developmentResearch and Development ExpenseShares, GrantedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, GrossZolgensma Royalties [Member]Zolgensma Royalties [Member]Zolgensma Royalties .Asset ClassAsset Class [Domain]Accrued external research and development expensesAccrued External Research And Development ExpensesAccrued external research and development expenses.Property, Plant and Equipment, Gross, Ending BalanceProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, TotalTotal property and equipmentProperty, Plant and Equipment, GrossSubsequent Event Type [Domain]Offering expenses related to at the market offering program.Offering Expenses Related To At The Market Offering ProgramOffering expenses related to at-the-market offering programNovember Two Thousand Twenty Four License AgreementNovember Two Thousand Twenty Four License Agreement [Member]November two thousand twenty four license agreement.LeasesLessee, Leases [Policy Text Block]Up-front fee paidUpfront License Fee PaidUpfront license fee paid.12 Months or Greater, Fair ValueDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or LongerExercise price of warrantsClass of Warrant or Right, Exercise Price of Warrants or RightsFinancial InstrumentsFinancial Instruments [Domain]Investment Income, Net, TotalInvestment incomeInvestment Income, NetSale of Stock [Axis]Cash flows from investing activitiesNet Cash Provided by (Used in) Investing Activities [Abstract]InvestmentsInvestments [Domain]Summary of Unvested RSUs Activity Under 2015 PlanSchedule of Nonvested Restricted Stock Units Activity [Table Text Block]Marketable securitiesMarketable Securities, CurrentRevenuesRevenue from Contract with Customer, Excluding Assessed TaxPerformance obligations satisfied in previous periodsRevenue Recognized Performance ObligationRevenue recognized performance obligation.Income TaxesIncome Tax Disclosure [Text Block]Other Commitments [Table]Other Commitments [Table]Total accounts receivable, netAccounts and Financing Receivable, after Allowance for Credit LossMilestone payment upon achievement of specified sales targets for licensed productsMilestone Fee Payments Upon Achievement Of Specified Sales TargetsMilestone fee payments upon achievement of specified sales targets.November 8, 2024November Eight Two Thousand Twenty Four [Member]November eight two thousand twenty four.Amounts included in deferred revenue at beginning of periodDeferred Revenue, Revenue RecognizedDebt Securities, Available-for-Sale [Table]Depreciation, Depletion and Amortization, Nonproduction, TotalDepreciation and amortizationDepreciation, Depletion and Amortization, NonproductionOther accrued expenses and current liabilitiesOther Accrued Liabilities, CurrentNon-cash interest expenseNon Cash Interest ExpenseNon cash interest expense.Entity Address, Address Line TwoEntity Address, Address Line TwoLiabilities and Stockholders' EquityLiabilities and Equity [Abstract]Document Period End DateDocument Period End DateNet cash provided by (used in) financing activitiesNet Cash Provided by (Used in) Financing ActivitiesRelated party transaction expenseRelated Party Transaction Expenses Revenue From Transactions With Related PartyRelated party transaction expenses (revenue) from transactions with related party.Anti-dilutive securities excluded from computation of diluted weighted average shares outstandingAntidilutive Securities Excluded from Computation of Earnings Per Share, AmountEnding BalanceBeginning BalanceRestructuring liabilityRestructuring ReserveRestructuring Reserve, TotalAPIC, Share-Based Payment Arrangement, Increase for Cost Recognition, TotalStock-based compensation expenseAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionRoyalty AgreementsRoyalty Agreements [Member]Accrued interest on investments.Accrued Interest on InvestmentsTrading SymbolTrading SymbolTotal stockholders' equityBalancesBalancesEquity, Attributable to ParentNet cost reimbursement to (from) AbbVie included in:Due From And To Related Parties Current [Abstract]Due from and to related parties current.License Revenue [Table]License Revenue [Table]License revenue.Purchase AgreementPurchase AgreementPurchase agreement.Long-Lived Tangible AssetLong-Lived Tangible Asset [Axis]Class of Warrant or Right, OutstandingPre-funded warrants remained outstandingOther liabilitiesOther Liabilities, NoncurrentUnvested Restricted Stock Units Outstanding [Member]Restricted Stock Units (RSUs)Restricted Stock Units (RSUs) [Member]Related Party Transactions [Abstract]Deferred revenueIncrease (Decrease) in Deferred RevenueSchedule Of Property Plant And Equipment [Table]Property, Plant and Equipment [Table]Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, TotalUnrecognized stock-based compensation expenseShare-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, AmountShare Repurchase Program [Axis]Stock-Based Compensation ExpenseShare-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]Nature of BusinessNature of Operations [Text Block]Financing Receivable Allowance For Credit Losses [Line Items]Financing Receivable, Allowance for Credit Loss [Line Items]Unrealized LossesDebt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before TaxIncrease (decrease) in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilitiesIncrease Decrease In Capital Expenditures Incurred But Not Yet PaidIncrease decrease in capital expenditures incurred but not yet paid.Leases [Abstract]Summary of Restructuring LiabilityRestructuring and Related Costs [Table Text Block]Use of EstimatesUse of Estimates, Policy [Policy Text Block]Related Party [Member]Vesting Of Restricted Stock Units SharesVesting of Restricted Stock Units SharesVesting of restricted stock units, net of tax, sharesSecurity Exchange NameSecurity Exchange NameAllowance for credit lossesAllowance For Credit Losses CurrentAllowance for credit losses, current.UnbilledUnbilled Receivables, CurrentUnbilled Zolgensma royaltiesLong-Lived Tangible AssetLong-Lived Tangible Asset [Domain]Percentage of reduction in workforcePercentage Of Reduction In WorkforcePercentage of reduction in workforce.Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalAccumulated depreciation and amortizationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentDetails of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]Summary of Impairment Losses Allocated to Various Assets Within Long-lived Asset Group Based on Relative Carrying ValuesFair Value MeasurementsFair Value Disclosures [Text Block]Weighted-average fair values of options grantedShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair ValueSubsequent Event [Member]Maximum [Member]Maximum [Member]RestructuringRestructuring and Related Activities Disclosure [Text Block]Total liabilities and stockholders' equityLiabilities and EquitySublicense fees previously recognizedSublicense Fees Previously RecognizedSublicense fees previously recognized.Restructuring and Related Cost, Number of Positions Eliminated, Period PercentPercentage of workforce reduction due to restructuringOperating lease right-of-use assetsOperating Lease, Right-of-Use AssetPrepaid Expense, Current, TotalPrepaid expensesPrepaid Expense, CurrentEarnings Per Share, Diluted, TotalNet loss per share, dilutedEarnings Per Share, DilutedLeasehold Improvements [Member]Leasehold Improvements [Member]Penn Letter Agreement [Member]Penn Letter Agreement [Member]Penn Letter Agreement.Total liabilitiesLiabilitiesAccounts receivableAccounts Receivable, after Allowance for Credit Loss, TotalBalance, beginning of periodBalance, end of periodAccounts Receivable, after Allowance for Credit LossFair Value Hierarchy and NAVFair Value Hierarchy and NAV [Domain]Total current assetsAssets, CurrentTransaction price of licenseTransaction Price Of LicenseTransaction price of license.Net cash provided by investing activitiesNet Cash Provided by (Used in) Investing ActivitiesIssuance of common stock and pre-funded warrants, sharesStock Issued During Period, Shares, New IssuesNumber of shares soldNet realized gain on investmentsRealized Investment Gains (Losses)Realized Investment Gains (Losses), TotalNumber of equal annual installmentsNumber Of Equal Annual InstallmentsNumber of equal annual installments.Operating lease right-of-use assetsIncrease Decrease In Operating Lease Right Of Use AssetsOperating lease right- of-use assets.Schedule Of Financing Receivable Allowance For Credit Losses [Table]Financing Receivable, Allowance for Credit Loss [Table]Entity Filer CategoryEntity Filer CategoryProperty, Plant and Equipment [Abstract]Schedule of Capitalization [Line Items]Novartis License Agreement [Member]Novartis License Agreement [Member]Novartis license agreement.Other Assets, Miscellaneous, CurrentOtherPurchases of

marketable debt securitiesPayments to Acquire Marketable SecuritiesOther Income (Expense)Nonoperating Income (Expense) [Abstract]Current Fiscal Year End DateCurrent Fiscal Year End DateShare-Based Payment Arrangement, Noncash Expense, TotalStock-based compensation expenseShare-Based Payment Arrangement, Noncash ExpenseRelated Party TransactionRelated Party Transaction [Axis]Aggregate Intrinsic Value OutstandingShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic ValueRelated PartyRelated and Nonrelated Parties [Axis]Settlement AgreementSettlement Agreement [Member]Settlement agreement.Directors or Section 16 reporting officers.Directors Or Section 16 Reporting Officers [Member]Directors or Section 16 Reporting Officers [Member]Entity Registrant NameEntity Registrant NameDebt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, TotalTotal, Unrealized LossesDebt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated LossSchedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]License agreement termination claims, descriptionContract Termination Claims, DescriptionEarnings Per Share [Text Block]Net Loss Per ShareEntity Emerging Growth CompanyEntity Emerging Growth CompanyOther Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration]Money Market Mutual Funds [Member]Money Market Funds [Member]Weighted Average Number of Shares Outstanding, Basic, TotalWeighted-average common shares outstanding, basicWeighted Average Number of Shares Outstanding, BasicMarketable securities:Marketable Securities [Abstract]Common stock, shares authorizedCommon Stock, Shares AuthorizedShare Repurchase Program [Domain]Sublease incomeSublease IncomeNet proceeds from issuance of common stockProceeds from Issuance of Common StockMaturities of marketable debt securitiesProceeds from Sale and Maturity of Marketable SecuritiesCash equivalents:Cash and Cash Equivalents [Abstract]Fair Value, Inputs, Level 1 [Member]Level 1 [Member]Total intrinsic values vestedShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, VestedProceeds from issuance of common stock under employee stock purchase planProceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option ExercisedWeighted-average Exercise Price, GrantedShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise PriceFinancial InstrumentFinancial Instrument [Axis]Weighted-average Remaining Contractual Life (Years) OutstandingShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual TermNet Loss Per ShareEarnings Per Share, Policy [Policy Text Block]Interest income from licensingInterest Income From LicencingInterest income from licencing.General and Administrative Expense [Member]General and Administrative Expense [Member]Impairment of property and equipmentProperty and equipment, netImpairment of lossImpairment of long-lived assetsTotal impairment of long-lived assetsNumber of commercial product candidatesNumber Of Commercial Product CandidatesNumber of commercial product candidates.Supplemental disclosures of noncash investing and financing activities.Supplemental Disclosures Of Noncash Investing And Financing Activities [Table]Supplemental Disclosures of Non-cash Investing and Financing Activities [Table]Share-Based Payment Arrangement [Abstract]Impairment of Long-lived AssetsImpairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]Other Current Assets [Member]Other Current Assets [Member]Due from related parties, currentDue from related parties, currentDue from Abeona, net of present value discountOther Receivables, Net, Current, TotalOther Liabilities [Member]Other Liabilities [Member]Summary of unrealized loss on available-for-sale securities, net, presented in the consolidated statements of operations and comprehensive lossSchedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]Accounts receivableNon-current accounts receivable, netAccounts Receivable, after Allowance for Credit Loss, NoncurrentDebt Securities, Available-for-Sale, TotalFair ValueDebt Securities, Available-for-SaleAccounting Policies [Abstract]Summary of Stock Option ActivityShare-Based Payment Arrangement, Option, Activity [Table Text Block]Income Tax Disclosure [Abstract]Marketable securitiesMarketable Securities, NoncurrentStockholders' equityEquity, Attributable to Parent [Abstract]Restricted CashCash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]Statement [Table]Statement [Table]Schedule of Property and EquipmentProperty, Plant and Equipment [Table Text Block]Weighted-average Remaining Contractual Life (Years), Vested and expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual TermSubsequent Event [Table]Other current assetsIncrease (Decrease) in Other Current AssetsShare-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]Preferred stock, shares authorizedPreferred Stock, Shares AuthorizedNon Cash Interest ExpenseLiability Related To Non Cash Interest ExpenseLiability related to non cash interest expense.Total license and royalty revenueZolgensma royaltiesRevenue from Contract with Customer, Including Assessed TaxEntity File NumberSecurities Act File NumberNet increase (decrease) in cash and cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectEarnings Per Share [Abstract]Contract with Customer, Asset, after Allowance for Credit Loss, Current, TotalBalance, beginning of periodBalance, end of periodContract with Customer, Asset, after Allowance for Credit Loss, CurrentContract assetsCash Equivalents [Member]Cash Equivalents [Member]Due from related partiesOther ReceivablesStatement of Financial Position [Abstract]License and royalty [Member]License and Service [Member]Interest Expense, TotalInterest expenseInterest expenseInterest Expense, Operating and NonoperatingPublic Offering [Member]IPO [Member]Loss from operationsOperating Income (Loss)Shares Issued, Price Per SharePurchase price of shareEntity Shell CompanyEntity Shell CompanyOther Assets [Abstract]Contract assets:Receivables And Contract Assets [Abstract]Receivables and contract assets.Interest Rate, Effective PercentageDebt Instrument, Interest Rate, Effective PercentageEntity Tax Identification NumberEntity Tax Identification NumberAssetsAssets [Abstract]Class of Warrant or Right [Domain]Entity Current Reporting StatusEntity Current Reporting StatusWeighted-average Remaining Contractual Life (Years), ExercisableShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual TermRealized gains or losses on available-for-sales securitiesDebt Securities, Available-for-Sale, Realized Gain (Loss)Debt Securities, Available-for-Sale, Realized Gain (Loss), TotalSchedules of Accrued Expenses and Other Current LiabilitiesSchedule of Accounts Payable and Accrued Liabilities [Table Text Block]Property and Equipment, NetProperty, Plant and Equipment Disclosure [Text Block]Subsequent Events [Abstract]Document Fiscal Year FocusDocument Fiscal Year FocusCash, Cash Equivalents, and Short-Term Investments, TotalCash, cash equivalents and marketable securitiesCash, Cash Equivalents, and Short-Term InvestmentsCertificates of Deposit [Member]Certificates of Deposit [Member]Aggregate transaction price of license agreements, expected satisfaction periodAggregate Transaction Price Of License Agreements Expected Satisfaction PeriodAggregate transaction price of license agreements, expected satisfaction period.Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023Preferred Stock, Value, IssuedOperating lease liabilitiesIncrease Decrease In Operating Lease LiabilitiesOperating lease liabilities.Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilitiesCapital Expenditures Incurred but Not yet PaidSchedule of Changes in Liability Related to Sale of Future RoyaltiesSchedule of changes in liability related to sale of future royalties [Table Text Block]Schedule of changes in liability related to sale of future royalties.Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, TotalBeginning of periodEnd of periodCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued OperationsProceeds from public offering of common stock and pre-funded warrants, net of issuance costsProceeds from Issuance Initial Public OfferingCity Area CodeCity Area CodePercentage of common stock ownedPercentage of Common Stock OwnedPercentage of common stock owned.Reclassification, Comparability Adjustment [Policy Text Block]ReclassificationsTotal current liabilitiesLiabilities, CurrentProvision for Loan, Lease, and Other Losses, TotalProvision for credit lossesProvision for credit lossesProvision for Loan, Lease, and Other LossesOrganization, Consolidation and Presentation of Financial Statements [Abstract]Local Phone NumberLocal Phone NumberOperating Lease, Impairment LossImpairment losses recorded to right-of-use assetsPreferred Stock, Shares Outstanding, Ending BalancePreferred Stock, Shares Outstanding, Beginning BalancePreferred stock, shares outstandingPreferred Stock, Shares OutstandingAntidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]Settlement agreement payableSettlement Agreement PayableSettlement agreement payable .License Agreement Revenue Recognition [Abstract]License Agreement Revenue Recognition [Abstract]Less than 12 Months, Unrealized LossesDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated LossCommitments and Contingencies Disclosure [Abstract]Amortized Cost / CostDebt Securities, Available-for-Sale, Amortized CostOperating lease liabilitiesOperating Lease, Liability, CurrentProceeds from sale of future royaltiesProceeds From Sale Of Future RoyaltiesProceeds from sale of future royalties.Accumulated Deficit [Member]Retained Earnings [Member]License feeLicense FeesLicense fees.Payments to Acquire Property, Plant, and Equipment, TotalPurchases of property and equipmentPayments to Acquire Property, Plant, and EquipmentTaxes paid related to net settlement of stock-based awardsTaxes Paid Related To Net Settlement Of Stock Based AwardsTaxes paid related to net settlement of stock-based awards.Revenue recognized during the period from:Revenue Recognition and Deferred Revenue [Abstract]2015 Equity Incentive Plan [Member]Two Thousand And Fifteen Equity Incentive Plan [Member]Two Thousand And Fifteen Equity Incentive Plan [Member]N A V Technology Platform [Member]N A V Technology Platform [Member]NAV technology platform.Document Transition ReportDocument Transition ReportAbeona Therapeutics IncorporationAbeona Therapeutics Incorporation [Member]Abeona Therapeutics IncSchedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]Antidilutive Security, Excluded EPS Calculation [Table]Weighted-average Exercise Price, ExercisedShare-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise PriceFair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]Minimum [Member]Minimum [Member]Common Stock [Member]Common Stock [Member]Aggregate Intrinsic Value, Vested and expected to vestShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic ValueAccounts receivable, net, current and non-current:Accounts Receivable Net Current And Non Current [Abstract]Accounts receivable net, current and non current.Weighted-average Grant Date Fair Value, Unvested Ending BalanceWeighted-average Grant Date Fair Value, Unvested Beginning BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair ValueOther assetsIncrease (Decrease) in Other Noncurrent AssetsSupplemental disclosures of noncash investing and financing activities.Supplemental Disclosures Of Noncash Investing And Financing Activities [Line Items]Supplemental Disclosures of Non-cash Investing and Financing Activities [Line Items]Accrued sublicense fees and royaltiesAccrued Sublicense Fees And Royalties On Reagent SalesAccrued sublicense fees and royalties on reagent sales.Additional paid in capital [Member]Additional Paid-in Capital [Member]Liability Related To Sale Of Future Royalties [Abstract]Liability Related to Sale of Future Royalties.Adjustments to reconcile net loss to net cash used in operating activitiesAdjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Property, Plant and Equipment [Member]Property and Equipment [Member]Other Comprehensive IncomeOther Comprehensive Income (Loss), Net of Tax [Abstract]Repayments under liability related to sale of future royalties, net of imputed interestRepayments Under Liability Related To Sale Of Future RoyaltiesRepayments under liability related to sale of future royalties.Income Statement LocationStatement of Income Location, Balance [Domain]Current portion of liability related to sale of future royaltiesLiability related to sale of future royaltiesLiability Related To Sale Of Future Royalties CurrentLiability related to sale of future royalties.Accounts receivable, currentAccounts Receivable, before Allowance for Credit Loss, CurrentOther assetsOther Assets, NoncurrentIncrease (Decrease) in Other Operating Liabilities, TotalOther liabilitiesIncrease (Decrease) in Other Operating LiabilitiesContract TerminationContract Termination [Member]Other Assets, Current, TotalOther current assetsOther Assets, CurrentEntity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingAccrued expenses and other current liabilitiesIncrease (Decrease) in Accrued Liabilities and Other Operating LiabilitiesCarrying value of the assetImpaired Assets to be Disposed of by Method Other than Sale, Carrying Value of AssetLess than 12 Months, Fair ValueDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 MonthsOther unbilled receivables current.Other Unbilled Receivables CurrentOther unbilledBasis of Presentation and Principles of ConsolidationBasis of Accounting, Policy [Policy Text Block]Schedule of Capitalization [Table]Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending BalanceDebt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning BalanceDebt Securities, Available-for-Sale, Allowance for Credit Loss, TotalAllowance for credit lossDebt Securities, Available-for-Sale, Allowance for Credit LossTypes of Revenue[Extensible List]Revenue, Product and Service [Extensible Enumeration]Total net cost reimbursement to (from) AbbVieDue From And To Related Parties CurrentDue from and to related parties current.Common stock; $0.0001 par value; 100,000 shares authorized at September 30, 2024 and December 31, 2023; 49,534 and 44,046 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectivelyCommon Stock, Value, IssuedName of Property [Axis]Changes in present value discount of receivablesChanges In Present Value Discount Of ReceivablesChanges in present value discount of receivables.Pre Funded Warrants [Member]Pre Funded Warrants [Member]Pre funded warrants.Development MilestoneDevelopment Milestone [Member]Development milestone.Total cash equivalentsCash and Cash Equivalents, Fair Value DisclosureAmount payable to net present value discountAmount Payable To Net Present Value DiscountAmount payable to net present value discount.Available for sale debt securities remaining maturities greater than three yearsAvailable For Sale Debt Securities Remaining Maturities Greater Than Three YearsAvailable for sale debt securities remaining maturities greater than three years.Summary of Company Marketable SecuritiesDebt Securities, Available-for-Sale [Table Text Block]Aggregate milestone payment for all the targetsMilestone Fee Payment For All Targets InclusiveMilestone fee payment for all targets inclusive.Accrued purchases of property and equipmentAccrued Purchases Of Property And EquipmentAccrued purchases of property and equipment.Milestone payment upon submission of regulatory approval filingsMilestone Fee Payments Upon Submission Of Regulatory Approval FilingsMilestone fee payments upon submission of regulatory approval filings.Other-than-temporary impairedOther-than-temporary Impairment Loss, Debt Securities, Available-for-Sale12 Months or Greater, Unrealized LossesDebt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated LossWeighted Average Number of Shares Outstanding, Diluted, TotalWeighted-average common shares outstanding, dilutedWeighted Average Number of Shares Outstanding, DilutedSummary of Significant Accounting PoliciesSignificant Accounting Policies [Text Block]Accounts receivable, netAccounts Receivable, after Allowance for Credit Loss, Current, TotalAccounts Receivable, after Allowance for Credit Loss, CurrentTotal undiscounted paymentsLessee, Operating Lease, Liability, to be PaidLessee, Operating Lease, Liability, to be Paid, TotalEntity Small BusinessEntity Small BusinessBilled to customersBilled Contracts ReceivableAggregate offering price.Aggregate Offering PriceAggregate offering priceSublicense Fees Due Or Owed in Future [Member]Sublicense

Fees Due Or Owed In Future [Member]Sublicense Fees Due Or Owed in Future.Proceeds from Royalties ReceivedProceeds from Royalties ReceivedMilestone payment upon approval of commercial products by regulatory agenciesMilestone Fee Payments Upon Approval Of Commercial ProductsMilestone fee payments upon approval of commercial products.Pre-funded warrants exercisedClass Of Warrant Or Right ExercisedClass of warrant or right exercised.Contractual Obligation, TotalAmount payable to agreementContractual ObligationNet amortization of premiums (accretion of discounts) on marketable debt securitiesAccretion (Amortization) of Discounts and Premiums, InvestmentsCash flows from financing activitiesNet Cash Provided by (Used in) Financing Activities [Abstract]Weighted-average Exercise Price Outstanding, Beginning BalanceWeighted-average Exercise Price, Outstanding, Ending BalanceShare-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise PriceSupplemental DisclosuresAccounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]Number of investment grade fixed income debt securityDebt Securities, Available-for-Sale, Unrealized Loss Position, Number of PositionsAsset ClassAsset Class [Axis]Repurchase of call option amount, before exercisedRepurchase Of Call Option Amount Before ExercisedRepurchase of call option amount before exercised.Total license and royalty revenueLicense And Royalty RevenueLicense and royalty revenue.Fair Value, Inputs, Level 3 [Member]Level 3 [Member]Subsequent Events [Text Block]Subsequent EventsEmployee Stock Purchase Plan [Member]Employee Stock Purchase Plan [Member]Employee stock purchase plan.Unrealized gain on available-for-sale securities, netOCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, TotalOCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and TaxAccounts Payable, Current, TotalAccounts payableAccounts Payable, CurrentTotal operating expensesCosts and ExpensesOther current assetsOther Current Assets [Table]Significant Accounting Policies [Table]Significant Accounting Policies [Table]Significant Accounting Policies.Accounts Receivable, Allowance for Credit Loss, Ending BalanceAccounts Receivable, Allowance for Credit Loss, Beginning BalanceAllowance for credit lossesAccounts Receivable, Allowance for Credit Loss XML 10 R1.htm IDEA: XBRL DOCUMENT '

Document and Entity Information - shares9 Months Ended

Sep. 30, 2024

Oct. 31, 2024

Cover [Abstract] Document Type10-Q Amendment Flagfalse Document Period End DateSep. 30, 2024 Document Fiscal Year Focus2024 Document Fiscal Period FocusQ3 Trading SymbolRGNX Entity Registrant NameREGENXBIO Inc. Entity Central Index Key0001590877 Current Fiscal Year End Date--12-31 Entity Filer Category Large Accelerated Filer Entity Small Businessfalse Entity Emerging Growth Companyfalse Entity Current Reporting StatusYes Entity Shell Companyfalse Entity File Number 001-37553 Entity Tax Identification Number47-1851754 Entity Address, Address Line One9804 Medical Center Drive Entity Address, City or TownRockville Entity Address, State or ProvinceMD Entity Address, Postal Zip Code20850 City Area Code240 Local Phone Number552-8181 Entity Common Stock, Shares Outstanding 49,545,071Document Transition Reportfalse Document Quarterly Reporttrue Entity Interactive Data CurrentYes Security Exchange NameNASDAQ Title of 12(b) Security Common Stock, par value $0.0001 per share Entity Incorporation, State or Country CodeDE

XML 11 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current assets		
Cash and cash equivalents	$ 56,617	$ 34,522
Marketable securities	198,843	240,736
Accounts receivable, net	23,604	24,790
Prepaid expenses	11,002	14,520
Other current assets	23,330	20,403
Total current assets	313,396	334,971
Marketable securities	23,108	38,871
Accounts receivable	404	701
Property and equipment, net	120,551	132,103
Operating lease right-of-use assets	55,293	60,487
Restricted cash	2,030	2,030
Other assets	4,332	4,807
Total assets	519,114	573,970
Current liabilities		
Accounts payable	19,522	22,786
Accrued expenses and other current liabilities	48,642	49,703
Deferred revenue	144	148
Operating lease liabilities	7,720	7,068
Liability related to sale of future royalties	26,697	50,567
Total current liabilities	102,725	130,272
Operating lease liabilities	76,342	82,222
Liability related to sale of future royalties	35,052	43,485
Other liabilities	3,579	6,249
Total liabilities	217,698	262,228
Stockholders' equity		
Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023		
Common stock; $0.0001 par value; 100,000 shares authorized at September 30, 2024 and December 31, 2023; 49,534 and 44,046 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively	5	4
Additional paid-in capital	1,182,956	1,021,214
Accumulated other comprehensive loss	(582)	(4,429)
Accumulated deficit	(880,963)	(705,047)
Total stockholders' equity	301,416	311,742
Total liabilities and stockholders' equity	$ 519,114	$ 573,970

XML 12 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	49,534,000	44,046,000
Common stock, shares outstanding	49,534,000	44,046,000

XML 13 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenues				
Revenues	$ 24,197	$ 28,914	$ 62,114	$ 68,029
Operating Expenses				
Cost of revenues	12,387	12,388	27,249	25,975
Research and development	54,429	58,183	158,142	176,585
General and administrative	19,422	23,083	56,568	69,415
Impairment of long-lived assets			2,101	
Other operating expenses	37	220	32	279
Total operating expenses	86,275	93,874	244,092	272,254
Loss from operations	(62,078)	(64,960)	(181,978)	(204,225)
Other Income (Expense)				
Interest income from licensing	25	56	91	166
Investment income	3,276	4,660	9,213	8,953
Interest expense	(820)	(1,624)	(3,242)	(5,499)
Total other income	2,481	3,092	6,062	3,620
Net loss	(59,597)	(61,868)	(175,916)	(200,605)
Other Comprehensive Income				
Unrealized gain on available-for-sale securities, net	1,684	2,685	3,847	7,988

Total other comprehensive income	1,684	2,685	3,847	7,988
Comprehensive loss	$ (57,913)	$ (59,183)	$ (172,069)	$ (192,617)
Net loss per share, basic	$ (1.17)	$ (1.41)	$ (3.59)	$ (4.6)
Net loss per share, diluted	$ (1.17)	$ (1.41)	$ (3.59)	$ (4.6)
Weighted-average common shares outstanding, basic	50,800	43,945	49,051	43,644
Weighted-average common shares outstanding, diluted	50,800	43,945	49,051	43,644
License and royalty [Member]				
Revenues				
Revenues	$ 24,197	$ 28,914	$ 62,114	$ 68,029

XML 14 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Public Offering [Member]	Private Placement [Member]	Common Stock [Member]	Common Stock [Member] Public Offering [Member]	Common Stock [Member] Private Placement [Member]	Additional paid in capital [Member]	Additional paid in capital [Member] Public Offering [Member]	Additional paid in capital [Member] Private Placement [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balances at Dec. 31, 2022	$ 516,195			$ 4			$ 973,145			$ (15,401)	$ (441,553)
Balances (Shares) at Dec. 31, 2022				43,299							
Vesting of restricted stock units, net of tax	(419)						(419)				
Vesting of restricted stock units, net of tax, shares				161							
Exercise of stock options, net of tax	1,312						1,312				
Exercise of stock options, net of tax, shares				171							
Issuance of common stock under employee stock purchase plan	1,826						1,826				
Issuance of common stock under employee stock purchase plan, shares				103							
Issuance of common stock and pre-funded warrants			$ 4,874						$ 4,874		
Issuance of common stock and pre-funded warrants, shares						257					
Stock-based compensation expense	31,929						31,929				
Unrealized gain on available-for-sale securities, net	7,988									7,988	
Net loss	(200,605)										(200,605)
Balances at Sep. 30, 2023	363,100			$ 4			1,012,667			(7,413)	(642,158)
Balances (Shares) at Sep. 30, 2023				43,991							
Balances at Jun. 30, 2023	405,855			$ 4			996,239			(10,098)	(580,290)
Balances (Shares) at Jun. 30, 2023				43,621							
Vesting of restricted stock units, net of tax, shares				34							
Exercise of stock options, net of tax	92						92				
Exercise of stock options, net of tax, shares				6							
Issuance of common stock under employee stock purchase plan	1,243						1,243				
Issuance of common stock under employee stock purchase plan, shares				73							
Issuance of common stock and pre-funded warrants			$ 4,874						$ 4,874		
Issuance of common stock and pre-funded warrants, shares						257					
Stock-based compensation expense	10,219						10,219				
Unrealized gain on available-for-sale securities, net	2,685									2,685	
Net loss	(61,868)										(61,868)
Balances at Sep. 30, 2023	363,100			$ 4			1,012,667			(7,413)	(642,158)
Balances (Shares) at Sep. 30, 2023				43,991							
Balances at Dec. 31, 2023	311,742			$ 4			1,021,214			(4,429)	(705,047)
Balances (Shares) at Dec. 31, 2023				44,046							
Vesting of restricted stock units, net of tax	(910)						(910)				
Vesting of restricted stock units, net of tax, shares				340							
Exercise of stock options, net of tax	1,474						1,474				
Exercise of stock options, net of tax, shares				281							
Exercise of pre-funded warrants				197							
Issuance of common stock under employee stock purchase plan	1,191						1,191				
Issuance of common stock under employee stock purchase plan, shares				105							
Issuance of common stock and pre-funded warrants		$ 131,067			$ 1			$ 131,066			
Issuance of common stock and pre-funded warrants, shares					4,565						
Stock-based compensation expense	28,921						28,921				
Unrealized gain on available-for-sale securities, net	3,847									3,847	
Net loss	(175,916)										(175,916)
Balances at Sep. 30, 2024	301,416			$ 5			1,182,956			(582)	(880,963)
Balances (Shares) at Sep. 30, 2024				49,534							

Balances at Jun. 30, 2024	348,267	$ 5	1,171,894	(2,266)	(821,366)
Balances (Shares) at Jun. 30, 2024		49,317			
Vesting of restricted stock units, net of tax, shares		31			
Exercise of stock options, net of tax	398		398		
Exercise of stock options, net of tax, shares		108			
Issuance of common stock under employee stock purchase plan	780		780		
Issuance of common stock under employee stock purchase plan, shares		78			
Stock-based compensation expense	9,884		9,884		
Unrealized gain on available-for-sale securities, net	1,684			1,684	
Net loss	(59,597)				(59,597)
Balances at Sep. 30, 2024	$ 301,416	$ 5	$ 1,182,956	$ (582)	$ (880,963)
Balances (Shares) at Sep. 30, 2024		49,534			

XML 15 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity (Parenthetical) - Common Stock [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	
	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Public Offering [Member]			
Issuance of Stock, transaction costs		$ 534	
Private Placement [Member]			
Issuance of Stock, transaction costs	$ 126		$ 126

XML 16 R7.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities		
Net loss	$ (175,916)	$ (200,605)
Adjustments to reconcile net loss to net cash used in operating activities		
Stock-based compensation expense	28,921	31,929
Depreciation and amortization	12,192	12,985
Net amortization of premiums (accretion of discounts) on marketable debt securities	(3,027)	929
Net realized gain on investments		(2,205)
Impairment of long-lived assets	2,101	
Non-cash interest expense	412	(569)
Other non-cash adjustments	(60)	(1)
Changes in operating assets and liabilities		
Accounts receivable	1,574	566
Prepaid expenses	3,518	1,339
Other current assets	(2,804)	(13,573)
Operating lease right-of-use assets	4,586	4,245
Other assets	475	1,728
Accounts payable	(3,330)	(4,011)
Accrued expenses and other current liabilities	(1,448)	(1,546)
Deferred revenue	(4)	(1,218)
Operating lease liabilities	(6,021)	(5,004)
Other liabilities	(2,670)	(2,636)
Net cash used in operating activities	(141,501)	(177,647)
Cash flows from investing activities		
Purchases of marketable debt securities	(173,916)	(67,925)
Maturities of marketable debt securities	238,446	231,753
Sales of equity securities		1,975
Purchases of property and equipment	(1,357)	(8,834)
Net cash provided by investing activities	63,173	156,969
Cash flows from financing activities		
Proceeds from exercise of stock options	1,474	1,312
Taxes paid related to net settlement of stock-based awards	(910)	(419)
Proceeds from issuance of common stock under employee stock purchase plan	1,191	1,826
Proceeds from public offering of common stock and pre-funded warrants, net of issuance costs	131,067	
Proceeds from private placement of common stock, net of issuance costs		4,874
Offering expenses related to at-the-market offering program	(158)	(51)
Repayments under liability related to sale of future royalties, net of imputed interest	(32,241)	(30,546)
Net cash provided by (used in) financing activities	100,423	(23,004)
Net increase (decrease) in cash and cash equivalents and restricted cash	22,095	(43,682)
Cash and cash equivalents and restricted cash		
Beginning of period	36,552	98,982
End of period	$ 58,647	$ 55,300

XML 17 R8.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure				
Net Income (Loss)	$ (59,597)	$ (61,868)	$ (175,916)	$ (200,605)

XML 18 R9.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements - Directors or Section 16 Reporting Officers [Member]	3 Months Ended
	Sep. 30, 2024
Trading Arrangements, by Individual	
Title	directors or Section 16 reporting officers
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

XML 19 R10.htm IDEA: XBRL DOCUMENT

Nature of Business	9 Months Ended
	Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business

1. Nature of Business

REGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company's investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform (NAV Technology Platform). The NAV® Technology Platform consists of exclusive rights to a large portfolio of AAV vectors, including commonly used AAV8 and AAV9. The Company has developed a broad pipeline of gene therapy product candidates using the NAV Technology Platform as a one-time treatment to address an array of diseases. In addition to its internal product development efforts, the Company also selectively licenses the NAV Technology Platform and other intellectual property rights to other leading biotechnology and pharmaceutical companies (NAV Technology Licensees). As of September 30, 2024, the NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma®, and in the preclinical and clinical development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development and commercialization of certain product candidates. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.

The Company has incurred cumulative losses since inception and as of September 30, 2024, had generated an accumulated deficit of $881.0 million. The Company's ability to transition to recurring profitability is dependent upon achieving a level of revenues adequate to support its cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, will continue to need to raise additional capital through equity offerings, licensing and collaboration arrangements, or other non-dilutive financings. There is no assurance that the Company will be able to raise sufficient capital or obtain financing on favorable terms, or at all. If the Company is unable to raise capital sufficient to meet its working capital needs in the future, it may be forced to delay expenditures, reduce the scope of its development activities or make other changes to its operating plans. As of September 30, 2024, the Company had cash, cash equivalents and marketable securities of $278.6 million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.

~~***XML 20 R11.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2024

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024. Certain information and footnote disclosures required by GAAP, which are normally included in the Company's annual consolidated financial statements, have been omitted pursuant to SEC rules and regulations for interim reporting. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for a fair statement of the results of operations for the periods presented.

The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year, any other interim periods, or any future year or period. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements.

Reclassifications

Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.

Restricted Cash

Restricted cash consists of deposits held at financial institutions that are used to collateralize irrevocable letters of credit required under the Company's lease agreements and certain other agreements with third parties. The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):

	As of September 30,	
	2024	2023
Cash and cash equivalents	$ 56,617	$ 53,045
Restricted cash	2,030	2,255
Total cash and cash equivalents and restricted cash	$ 58,647	$ 55,300

Accounts Receivable

Accounts receivable primarily consist of consideration due to the Company resulting from its license agreements with customers. Accounts receivable include amounts invoiced to licensees as well as rights to consideration which have not yet been invoiced, including unbilled royalties, and for which payment is conditional solely upon the passage of time. If a licensee elects to terminate a license prior to the end of the license term, the licensed intellectual property is returned to the Company and any accounts receivable from the licensee which are not contractually payable to the Company are charged off as a reduction of license revenue in the period of the termination. Accounts receivable which are not expected to be received by the Company within 12 months from the reporting date are stated net of a discount to present value and recorded as non-current assets on the consolidated balance sheets. The present value discount is recognized as a reduction of revenue in the period in which the accounts receivable are initially recorded and is accreted as interest income from licensing over the term of the receivables.

Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company's evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances, and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company's evaluation of current and expected future economic conditions. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Please refer to Note 9 for further information regarding the allowance for credit losses related to accounts receivable.

Leases

The Company accounts for its lease arrangements in accordance with Accounting Standards Codification (ASC) 842, *Leases* (ASC 842). Under ASC 842, the Company classifies its leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the Company. Lease classification is evaluated at the inception of the lease agreement. Regardless of classification, the Company records a right-of-use asset and a lease liability for all leases with a term greater than 12 months. All of the Company's leases have been classified as operating leases. Operating lease expense is recognized on a straight-line basis over the term of the lease, with the exception of variable lease expenses which are recognized as incurred.

The Company identifies leases in its contracts if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company does not allocate lease consideration between lease and nonlease components and records a lease liability equal to the present value of the remaining fixed consideration under the lease. The interest rates implicit in the Company's leases are generally not readily determinable. Accordingly, the Company uses its estimated incremental borrowing rate at the commencement date of the lease to determine the present value discount of the lease liability. The Company estimates its incremental borrowing rate for each lease based on an evaluation of its expected credit rating and the prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the term of the lease. The right-of-use asset for each lease is equal to the lease liability, adjusted for unamortized initial direct costs and lease incentives and prepaid or accrued rent. Initial direct costs of entering into a lease are included in the right-of-use asset and amortized as lease expense over the term of the lease. Lease incentives, such as tenant improvement allowances, are recorded as a reduction of the right-of-use asset and amortized as a reduction of lease expense over the term of the lease. The Company excludes options to extend or terminate leases from the calculation of the lease liability unless it is reasonably certain the option will be exercised.

The Company evaluates its right-of-use assets for impairment in accordance with its policy for long-lived assets. To the extent an impairment of a right-of-use asset is recognized, the remaining carrying value of the asset is subsequently amortized as lease expense on a straight-line basis from the date of impairment to the earlier of the end of the right-of-use asset's useful life or the end of the lease term.

The Company determines the classification of subleases at the inception of the sublease, as well as whether the Company has been relieved of its primary obligation under the original lease. All of the Company's subleases have been classified as operating leases and, in each case, the Company has not been relieved of its primary obligation under the original lease and continues to account for the original lease as it did prior to the commencement of the sublease. Sublease income is recognized on a straight-line basis over the term of the sublease as a reduction of the related lease expense of the original lease. Initial direct costs of entering into a sublease are deferred and amortized on a straight-line basis over the term of the sublease as a reduction of sublease income.

Impairment of Long-lived Assets

The Company's long-lived assets consist primarily of property and equipment and operating lease right-of-use assets. The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to estimated future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. Please refer to Note 5 and Note 6 for further information on impairment of long-lived assets.

Fair Value Measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, *Fair Value Measurements and Disclosures*, establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:

- Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
- Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

- Level 3—Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within the fair value hierarchy of an asset or liability measured at fair value is based on the lowest level of any input that is significant to the fair value measurement. The fair values of the Company's Level 2 financial instruments are based on quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Please refer to Note 4 for further information on the Company's fair value measurements.

Pre-funded Warrants

Warrants are accounted for based on the specific terms of the warrant agreements. The Company's pre-funded warrants are indexed to the Company's common stock and meet the criteria to be classified as equity. Proceeds from the issuance of pre-funded warrants are recorded within additional paid-in capital and are not subject to remeasurement. Please refer to Note 8 for further information regarding pre-funded warrants issued by the Company.

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of computing both basic and diluted net loss per share, pre-funded warrants are considered outstanding shares upon issuance because the shares may be issued for nominal consideration and are exercisable after the original issuance date. Contingently convertible shares in which conversion is based on non-market-priced contingencies are excluded from the calculations of both basic and diluted net loss per share until the contingency has been fully met. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation of diluted net loss per share if their effect would be anti-dilutive.

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

The Company did not adopt any new accounting standards during the three and nine months ended September 30, 2024 and 2023 which had a material impact on the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances certain interim and annual disclosure requirements of reportable segment information, including information about significant segment expenses. Additionally, the standard requires entities with a single reportable segment to provide all disclosures required by ASC 280, *Segment Reporting*. The standard is effective for the Company for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for segment reporting, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which enhances the disclosure of an entity's effective tax rate reconciliation and requires the disclosure of income taxes paid to be disaggregated by jurisdiction. The standard is effective for the Company beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for income taxes, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, *Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact of this standard on its consolidated financial statements and related disclosures.

~~***XML 21 R12.htm IDEA: XBRL DOCUMENT***~~

Marketable Securities

9 Months Ended
Sep. 30, 2024

Investments, Debt and Equity Securities [Abstract]
Marketable Securities

3. Marketable Securities

The following tables present a summary of the Company's marketable securities, which consist solely of available-for-sale debt securities (in thousands):

	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
September 30, 2024				
U.S. government and agency securities	$ 50,350	$ 16	$ (233)	$ 50,133
Certificates of deposit	4,404	—	(15)	4,389
Corporate bonds	166,919	583	(73)	167,429
	$ 221,673	$ 599	$ (321)	$ 221,951

	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
December 31, 2023				
U.S. government and agency securities	$ 71,811	$ 6	$ (1,248)	$ 70,569
Certificates of deposit	6,572	—	(106)	6,466
Corporate bonds	204,793	143	(2,364)	202,572
	$ 283,176	$ 149	$ (3,718)	$ 279,607

As of September 30, 2024 and December 31, 2023, no available-for-sale debt securities had remaining maturities greater than three years. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, or to the earliest call date for callable debt securities purchased at a premium.

As of September 30, 2024 and December 31, 2023, the balance in accumulated other comprehensive loss consisted solely of unrealized gains and losses on available-for-sale debt securities, net of reclassification adjustments for realized gains and losses and income tax effects. The Company uses the aggregate portfolio approach to release the tax effects of unrealized gains and losses on available-for-sale debt securities in accumulated other comprehensive loss. Realized gains and losses from the sale or maturity of marketable securities are based on the specific identification method and are included in results of operations as investment income. The Company did not recognize any realized gains or losses on available-for-sales securities during the three and nine months ended September 30, 2024 and 2023, and no income tax effects or reclassification adjustments were recorded in accumulated other comprehensive loss during the periods.

The following tables present the fair values and unrealized losses of available-for-sale debt securities held by the Company in an unrealized loss position for less than 12 months and 12 months or greater (in thousands):

	Less than 12 Months		12 Months or Greater		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
September 30, 2024						
U.S. government and agency securities	$ —	$ —	$ 30,252	$ (233)	$ 30,252	$ (233)
Certificates of deposit	484	(1)	3,170	(14)	3,654	(15)
Corporate bonds	4,995	(1)	21,290	(72)	26,285	(73)
	$ 5,479	$ (2)	$ 54,712	$ (319)	$ 60,191	$ (321)

	Less than 12 Months		12 Months or Greater		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
December 31, 2023						
U.S. government and agency securities	$ 12,877	$ (16)	$ 52,686	$ (1,232)	$ 65,563	$ (1,248)
Certificates of deposit	965	(2)	5,257	(104)	6,222	(106)
Corporate bonds	25,051	(48)	144,642	(2,316)	169,693	(2,364)
	$ 38,893	$ (66)	$ 202,585	$ (3,652)	$ 241,478	$ (3,718)

As of September 30, 2024, available-for-sale debt securities held by the Company in an unrealized loss position consisted of 36 investment grade security positions. The Company has the intent and ability to hold such securities until recovery, and based on the credit quality of the issuers and low severity of each unrealized loss position relative to its amortized cost basis, the Company did not identify any credit losses associated with its available-for-sale debt securities. The Company did not record an allowance for credit
losses on its available-for-sale debt securities as of September 30, 2024 or December 31, 2023, and no impairment or credit losses on available-for-sale debt securities were recorded during the three and nine months ended September 30, 2024 and 2023.

~~***XML 22 R13.htm IDEA: XBRL DOCUMENT***~~

Fair Value Measurements

9 Months Ended
Sep. 30, 2024

Fair Value Disclosures [Abstract]
Fair Value Measurements

4. Fair Value Measurements

Financial instruments reported at fair value on a recurring basis include cash equivalents and marketable securities. The following tables present the fair value of cash equivalents and marketable securities in accordance with the fair value hierarchy discussed in Note 2 (in thousands):

	Level 1	Level 2	Level 3	Total
September 30, 2024				
Cash equivalents:				
Money market mutual funds	$ —	$ 43,771	$ —	$ 43,771
Total cash equivalents	—	43,771	—	43,771

Marketable securities:				
U.S. government and agency securities	—	50,133	—	50,133
Certificates of deposit	—	4,389	—	4,389
Corporate bonds	—	167,429	—	167,429
Total marketable securities	—	221,951	—	221,951
Total cash equivalents and marketable securities	$ —	$ 265,722	$ —	$ 265,722

	Level 1	Level 2	Level 3	Total
December 31, 2023				
Cash equivalents:				
Money market mutual funds	$ —	$ 13,024	$ —	$ 13,024
Total cash equivalents	—	13,024	—	13,024
Marketable securities:				
U.S. government and agency securities	—	70,569	—	70,569
Certificates of deposit	—	6,466	—	6,466
Corporate bonds	—	202,572	—	202,572
Total marketable securities	—	279,607	—	279,607
Total cash equivalents and marketable securities	$ —	$ 292,631	$ —	$ 292,631

Management estimates that the carrying values of its current accounts receivable, other current assets, accounts payable, accrued expenses and other current liabilities approximate fair value due to the short-term nature of those instruments. Accounts receivable which contain non-current portions and certain non-current payables reported as other liabilities are recorded at their present values using a discount rate that is based on prevailing market rates on the date the amounts were initially recorded. Management does not believe there have been any significant changes in market conditions or credit quality that would cause the discount rates initially used to be materially different from those that would be used as of September 30, 2024 to determine the present value of these instruments. Accordingly, management estimates that the carrying values of its non-current accounts receivable and other liabilities approximate the fair value of those instruments. Management estimates that the carrying value of the liability related to the sale of future royalties approximates fair value. As discussed in Note 7, the carrying value of the liability related to the sale of future royalties is based on the Company's estimate of future royalties expected to be paid by the Company over the life of the arrangement, which are considered Level 3 inputs.

Long-lived assets, if determined to be not recoverable and impaired, are measured at fair value on a nonrecurring basis using Level 3 inputs. Please refer to Note 6 for further information on nonrecurring fair value measurements of long-lived assets during the three and nine months ended September 30, 2024 and 2023.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net

9 Months Ended
Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

5. Property and Equipment, Net

Property and equipment, net consists of the following (in thousands):

	September 30, 2024	December 31, 2023
Laboratory and manufacturing equipment	$ 76,788	$ 75,632
Computer equipment and software	4,748	4,700
Furniture and fixtures	7,024	7,052
Leasehold improvements	101,340	101,927
Total property and equipment	189,900	189,311
Accumulated depreciation and amortization	(69,349)	(57,208)
Property and equipment, net	$ 120,551	$ 132,103

In March 2024, the Company entered into an agreement to sublease its office facilities in New York, New York. In connection with the sublease, the Company recorded impairment of property and equipment of $0.7 million in the first quarter of 2024 related to furniture and fixtures and leasehold improvements located at the subleased facility. Please refer to Note 6 for further information regarding the sublease agreement and associated impairment of long-lived assets.

XML 24 R15.htm IDEA: XBRL DOCUMENT

Leases

9 Months Ended
Sep. 30, 2024

Leases [Abstract]

Leases

6. Leases

New York Sublease

In May 2016, the Company entered into an operating lease for office space in New York, New York (the New York Lease), which has since been amended to include additional office space and extend the term of the lease. The lease term commenced in July 2016 and expires in April 2027.

In March 2024, the Company entered into an agreement to sublease its office space under the New York Lease (the New York Sublease) to a third-party subtenant. The sublease term commenced in April 2024 and will expire in April 2027 concurrent with the expiration of the New York Lease. Monthly payments under the New York Sublease commenced in July 2024 and escalate annually in accordance with the sublease agreement. As of September 30, 2024, total undiscounted future minimum lease payments to be received by the Company over the term of the New York Sublease were $1.3 million. The Company recognized sublease income of $0.1 million and $0.2 million under the New York Sublease during the three and nine months ended September 30, 2024, respectively.

The New York Sublease is classified as an operating lease and the Company was not relieved of its primary obligation under the New York Lease. The Company continues to account for the New York Lease as it did prior to the commencement of the sublease.

As a result of the New York Sublease, the Company determined an impairment indicator was present as of March 31, 2024 related to the long-lived asset group subject to the sublease, which included the right-of-use asset under the New York Lease, leasehold improvements and other property and equipment allocable to the New York Sublease. The Company concluded the carrying value of the asset group as of March 31, 2024 was not recoverable, as it exceeded the sum of the estimated undiscounted cash flows to be generated by the assets over their remaining lives. The Company estimated the fair value of the asset group as of March 31, 2024 using a discounted cash flow method, which incorporated unobservable inputs including the net identifiable cash flows over the term of the New York Sublease and an estimated borrowing rate of a market participant subtenant. The estimated fair value of the asset group as of March 31, 2024 represents a Level 3 nonrecurring fair value measurement. The Company concluded the carrying value of the asset group of $3.4 million exceeded its estimated fair value of $1.3 million as of March 31, 2024. As such, the Company recognized impairment losses of $2.1 million during the three months ended March 31, 2024 and the nine months ended September 30, 2024 on the long-lived asset group associated with the New York Sublease. The impairment losses were allocated to the various assets within the long-lived asset group based on their relative carrying values and consisted of $1.4 million recorded to the right-of-use assets and $0.7 million recorded to property and equipment. No material impairment losses on long-lived assets were recorded during the three months ended September 30, 2024 and the three and nine months ended September 30, 2023.

XML 25 R16.htm IDEA: XBRL DOCUMENT

Liability Related to Sale of Future Royalties

9 Months Ended
Sep. 30, 2024

Liability Related To Sale Of Future Royalties [Abstract]

Liability Related to Sale of Future Royalties

7. Liability Related to Sale of Future Royalties

In December 2020, the Company entered into a royalty purchase agreement (the Royalty Purchase Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Under the Royalty Purchase Agreement, HCR purchased the Company's rights to a capped amount of Zolgensma royalty payments under the Company's license agreement (the Novartis License) with Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies), including $4.0 million of royalty payments received by the Company in the fourth quarter of 2020 (the Pledged Royalties). In consideration for these rights, HCR paid the Company $200.0 million (the Purchase Price), less $4.0 million representing the payment of the Pledged Royalties to HCR. Beginning upon the effective date of the Royalty Purchase Agreement, Zolgensma royalty payments, up to a specified threshold, shall be paid to HCR, net of upstream royalties payable by the Company to certain licensors in accordance with existing license agreements.

Pursuant to the Royalty Purchase Agreement, the total amount of royalty payments to be received by HCR is subject to an increasing cap (the Cap Amount) equal to (i) $260.0 million applicable for the period from the effective date of the Royalty Purchase Agreement through November 7, 2024, and (ii) $300.0 million applicable for the period from November 8, 2024 through the effective date of termination of the Novartis License. If, on or prior to the defined dates for each Cap Amount, the total amount of royalty payments received by HCR equals or exceeds the Cap Amount applicable to such date, the Royalty Purchase Agreement will automatically terminate and all rights to the Zolgensma royalty payments will revert back to the Company. The Company has no obligation to repay any amounts to HCR if total future Zolgensma royalty payments are not sufficient to achieve the applicable Cap Amount prior to the termination of the Novartis License.

The Company has a call option to repurchase its rights to the purchased royalties from HCR for a repurchase price equal to, as of the option exercise date, $300.0 million minus the total amount of royalty payments received by HCR; provided, however, that with respect to a call option exercised on or before November 7, 2024, in the event that the then applicable Cap Amount minus the total amount of royalty payments received by HCR is less than $1.0 million, the repurchase price shall equal such difference.

The proceeds received from HCR of $196.0 million were recorded as a liability, net of transaction costs of $3.5 million, which is amortized over the estimated life of the arrangement using the effective interest method. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received by HCR, subject to the Cap Amount, over the life of the arrangement. The total amount of royalty payments received by HCR under the Royalty Purchase Agreement, less the net proceeds received by the Company of $192.5 million, is recorded as interest expense over the life of the arrangement using the effective interest method. Due to its continuing involvement in the Novartis License, the Company continues to recognize royalty revenue on net sales of Zolgensma and records the royalty payments to HCR as a reduction of the liability when paid. As such payments are made to HCR, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement.

The Company estimates the effective interest rate used to record interest expense under the Royalty Purchase Agreement based on its estimate of future royalty payments to be received by HCR. As of September 30, 2024, the estimated effective interest rate under the Royalty Purchase Agreement was 4.2%. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the royalty payments received by HCR and changes in the Company's forecasted royalties. At each reporting date, the Company reassesses its estimate of total future royalty payments to be received by HCR at the applicable Cap Amount, and prospectively adjusts the effective interest rate and amortization of the liability, as necessary.

The following table presents the changes in the liability related to the sale of future royalties under the Royalty Purchase Agreement with HCR (in thousands):

	Liability Related to Sale of Future Royalties
Balance at December 31, 2023	$ 94,052
Zolgensma royalties paid to HCR	(35,072)

Interest expense recognized	2,769
Balance at September 30, 2024	61,749
Current portion of liability related to sale of future royalties	(26,697)
Liability related to sale of future royalties, non-current	$ 35,052

~~XML 26 R17.htm IDEA: XBRL DOCUMENT~~

Capitalization

9 Months Ended
Sep. 30, 2024

Equity [Abstract]
Capitalization

8. Capitalization

March 2024 Public Offering

In March 2024, the Company completed a public offering of 4,565,260 shares of its common stock at a price of $23.00 per share and 1,521,740 pre-funded warrants to purchase shares of its common stock at a price of $22.9999 per pre-funded warrant, which equaled the public offering price per share of the common stock less the $0.0001 exercise price of each pre-funded warrant. The aggregate net proceeds received by the Company from the offering were $131.1 million, net of underwriting discounts and commissions and offering expenses payable by the Company.

The rights and privileges of the pre-funded warrants issued under the March 2024 offering are set forth in the warrant agreement between the Company and each of the respective warrant holders. The pre-funded warrants are exercisable at the option of the warrant holder at any time and do not expire. However, as set forth in the warrant agreements with each holder, the number of pre-funded warrants that may be exercised at any given time may be limited if, upon exercise, the warrant holder and any of its affiliates would beneficially own more than 9.99% of the Company's common stock, or have voting power of more than 9.99% of the Company's common stock. The limitation threshold may be increased or decreased by the warrant holder, with advance notice to the Company, to any other percentage not less than 4.99% nor in excess of 19.99%. Pre-funded warrants do not provide any of the rights or privileges provided by the Company's common stock, including any voting rights, until the pre-funded warrants are exercised and settled in underlying shares of common stock.

The Company evaluated the pre-funded warrants issued under the March 2024 offering and concluded the warrants are indexed to the Company's common stock, meet the criteria to be classified as equity and are not subject to remeasurement. The proceeds received from the issuance of the pre-funded warrants were recorded as additional paid-in capital. The Company issued 197,000 shares of common stock upon the exercise of pre-funded warrants during the nine months ended September 30, 2024. There were no exercises of pre-funded warrants during the three months ended September 30, 2024. As of September 30, 2024, 1,324,740 pre-funded warrants remained outstanding.

At-the-Market Offering Program

In September 2023, the Company entered into an ATM Equity Offering℠ Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $150.0 million from time to time through BofA, acting as the Company's sales agent (the ATM Program). As of September 30, 2024, no shares of common stock had been sold under the ATM Program.

~~XML 27 R18.htm IDEA: XBRL DOCUMENT~~

License and Collaboration Agreements

9 Months Ended
Sep. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]
License and Collaboration Agreements

9. License and Collaboration Agreements

License and Royalty Revenue

As of September 30, 2024, the Company's NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma, and in the development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development of certain product candidates. Consideration to the Company under its license agreements may include: (i) up-front and annual fees, (ii) milestone payments based on the achievement of certain development and sales-based milestones, (iii) sublicense fees, (iv) royalties on sales of licensed products, (v) fees for services related to the development of licensed products and (vi) other consideration payable upon optional goods and services purchased by licensees. Sublicense fees vary by license and range from a mid-single digit percentage to a low-double digit percentage of license fees received by licensees as a result of sublicenses. Royalties on net sales of commercialized products vary by license and range from a mid-single digit percentage to a low double-digit percentage of net sales by licensees.

License and royalty revenue consisted of the following (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Zolgensma royalties	$ 23,872	$ 28,364	$ 60,849	$ 63,454
Other license and royalty revenue	325	550	1,265	4,575
Total license and royalty revenue	$ 24,197	$ 28,914	$ 62,114	$ 68,029

Outstanding development milestone payments are evaluated each reporting period and are only included in the transaction price of each license and recognized as license revenue to the extent the milestones are considered probable of achievement. Sales-based milestones are excluded from the transaction price of each license agreement and recognized as royalty revenue in the period of achievement. As of September 30, 2024, the Company's license agreements, excluding additional licenses that could be granted upon the exercise of options by licensees, contained unachieved milestones which could result in aggregate milestone payments to the Company of up to $1.51 billion, including (i) $524.9 million upon the commencement of various stages of clinical trials, (ii) $113.8 million upon the submission of regulatory approval filings or upon regulatory approval of licensed products and (iii) $870.0 million upon the achievement of specified sales targets for licensed products, including milestones payable upon the first commercial sale of licensed products. To the extent the milestone payments are realized by the Company, the Company may be obligated to pay sublicense fees to licensors based on a specified percentage of the fees earned by the Company. The achievement of these milestones is highly dependent on the successful development and commercialization of licensed products and it is at least reasonably possible that some or all of the milestone fees will not be realized by the Company.

Changes in Accounts Receivable, Contract Assets and Deferred Revenue

The following table presents the balances of the Company's net accounts receivable, contract assets and deferred revenue, as well as other information regarding revenue recognized during the periods presented (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Accounts receivable, net, current and non-current:				
Beginning of period	$ 23,273	$ 22,523	$ 25,491	$ 29,586
End of period	$ 24,008	$ 29,121	$ 24,008	$ 29,121
Contract assets:				
Beginning of period	$ 194	$ 2,000	$ —	$ —
End of period	$ 259	$ 2,000	$ 259	$ 2,000
Deferred revenue:				
Beginning of period	$ 21	$ 448	$ 148	$ 1,829
End of period	$ 144	$ 442	$ 144	$ 442
Revenue recognized during the period from:				
Amounts included in deferred revenue at beginning of period	$ 21	$ 28	$ 148	$ 1,409
Performance obligations satisfied in previous periods	$ 23,875	$ 28,365	$ 60,912	$ 65,405

As of September 30, 2024, the Company had recorded deferred revenue of $0.1 million which represents consideration received or unconditionally due from licensees for performance obligations that have not yet been satisfied by the Company. Unsatisfied performance obligations as of September 30, 2024 consisted of research and development services to be performed by the Company related to licensed products, which will be satisfied as the services are performed. As of September 30, 2024, the aggregate transaction price of the Company's license agreements allocated to performance obligations not yet satisfied, or partially satisfied, was $1.5 million, which is expected to be satisfied over a period of approximately two to three years.

Revenue recognized from performance obligations satisfied in previous periods, as presented in the table above, was primarily attributable to Zolgensma royalties and changes in the transaction prices of the Company's license agreements. Changes in transaction prices were primarily attributable to development milestones achieved or deemed probable of achievement during the periods which were previously not considered probable of achievement, resulting in a cumulative catch-up adjustment to revenue. Revenue recognized during the nine months ended September 30, 2023 included $2.0 million in cumulative catch-up adjustments for changes in the probability of achievement of development milestones. There were no cumulative catch-up adjustments to revenue for changes in the probability of achievement of development milestones during the three and nine months ended September 30, 2024 or during the three months ended September 30, 2023.

Accounts Receivable, Contract Assets and the Allowance for Credit Losses

Accounts receivable, net consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Current accounts receivable:		
Billed to customers	$ 105	$ 265
Unbilled Zolgensma royalties	23,138	24,128
Due from Abeona, net of present value discount	4,942	4,587
Other unbilled	361	397
Allowance for credit losses	(4,942)	(4,587)
Current accounts receivable, net	23,604	24,790
Non-current accounts receivable:		
Other unbilled	404	701
Non-current accounts receivable, net	404	701
Total accounts receivable, net	$ 24,008	$ 25,491

The following table presents the changes in the allowance for credit losses related to accounts receivable and contract assets for the nine months ended September 30, 2024 (in thousands):

	Allowance for Credit Losses

	Accounts Receivable	Contract Assets
Balance at December 31, 2023	$ 4,587	$ —
Changes in present value discount of receivables	355	—
Balance at September 30, 2024	$ 4,942	$ —

The Company's allowance for credit losses as of September 30, 2024 and December 31, 2023 was related solely to accounts receivable from Abeona Therapeutics Inc. (Abeona). Please refer to the section below, "Settlement Agreement with Abeona Therapeutics", for further information regarding amounts due from Abeona and the associated allowance for credit losses. The Company did not record a provision for credit losses for the three and nine months ended September 30, 2024 and 2023.

Zolgensma License with Novartis Gene Therapies

In March 2014, the Company entered into an exclusive license agreement (as amended, the Novartis License) with Novartis Gene Therapies. Under the Novartis License, the Company granted Novartis Gene Therapies an exclusive, worldwide commercial license, with rights to sublicense, to the NAV Technology Platform, as well as other certain rights, for the treatment of spinal muscular atrophy (SMA) in humans by *in vivo* gene therapy. In 2019, Novartis Gene Therapies launched commercial sales of Zolgensma, a licensed product under the Novartis License. In accordance with the Novartis License, the Company receives royalties on net sales of Zolgensma.

The Company recognized the following amounts under the Novartis License (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Zolgensma royalties	$ 23,872	$ 28,364	$ 60,849	$ 63,454
Total license and royalty revenue	$ 23,872	$ 28,364	$ 60,849	$ 63,454
Interest income from licensing	$ 6	$ 7	$ 20	$ 22

As of September 30, 2024 and December 31, 2023, the Company had recorded total accounts receivable of $23.3 million and $24.3 million, respectively, from Novartis Gene Therapies under the Novartis License, which consisted primarily of Zolgensma royalties receivable. The Zolgensma royalties receivable recorded as of September 30, 2024 included $11.1 million expected to be paid to HCR in accordance with the Royalty Purchase Agreement discussed in Note 7. The Company recognizes royalty revenue from net sales of Zolgensma in the period in which the underlying products are sold by Novartis Gene Therapies, which in certain cases may require the Company to estimate royalty revenue for periods of net sales which have not yet been reported to the Company. Estimated royalties are reconciled to actual amounts reported in subsequent periods, and any differences are recognized as an adjustment to royalty revenue in the period the royalties are reported.

Settlement Agreement with Abeona Therapeutics

In November 2021, the Company entered into a settlement agreement and mutual release with Abeona (the Settlement Agreement) related to claims associated with a license agreement between the parties which was terminated in May 2020. The Settlement Agreement resolved all arbitration and legal proceedings and mutually released each party from any and all claims under the terminated license agreement. Pursuant to the Settlement Agreement, Abeona will pay the Company a total of $30.0 million as follows: (i) $20.0 million which was paid in November 2021, (ii) $5.0 million which was paid in November 2022, and (iii) $5.0 million payable on the earlier of the third anniversary of the Settlement Agreement in November 2024 or the closing of a specified type of transaction by Abeona.

As of September 30, 2024 and December 31, 2023, the Company had recorded accounts receivable of $4.9 million and $4.6 million, respectively, associated with the remaining amounts due from Abeona under the Settlement Agreement. The receivable of $4.9 million as of September 30, 2024 consisted of the $5.0 million payment due by November 2024, net of discount to present value. While the Company anticipates taking appropriate measures to enforce the full collection of all amounts due from Abeona under the Settlement Agreement, the Company assessed the collectability of the accounts receivable from Abeona as it relates to credit risk. In performing this assessment, the Company evaluated Abeona's credit profile and financial condition, as well its expectations regarding Abeona's future cash flows and ability to satisfy the contractual obligations of the Settlement Agreement. As a result of its analysis, the Company recorded an allowance for credit losses of $4.9 million and $4.6 million as of September 30, 2024 and December 31, 2023, respectively, related to the accounts receivable due from Abeona. No credit losses or recoveries were recorded on the Abeona receivable during the three and nine months ended September 30, 2024 and 2023. The present value discount of the Abeona receivable is accreted as interest income from licensing through the contractual due date using the effective interest method. The Company has elected to record increases in the allowance for credit losses associated with the accretion of the present value discount as a reduction of the associated interest income, resulting in no interest income recognized during the periods related to the accretion of the present value discount on the Abeona receivable.

Collaboration Agreements

AbbVie Collaboration and License Agreement

In September 2021, the Company entered into a collaboration and license agreement with AbbVie Global Enterprises Ltd. (AbbVie), a subsidiary of AbbVie Inc., to jointly develop and commercialize ABBV-RGX-314, the Company's product candidate for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases (the AbbVie Collaboration Agreement). The AbbVie Collaboration Agreement became effective in November 2021.

Pursuant to the AbbVie Collaboration Agreement, the Company granted AbbVie a co-exclusive license to develop and commercialize ABBV-RGX-314 in the United States and an exclusive license to develop and commercialize ABBV-RGX-314 outside the United States. The Company and AbbVie will collaborate to develop ABBV-RGX-314 in the United States, and AbbVie will be responsible for the development of ABBV-RGX-314 in specified markets outside the United States. Through December 31, 2022, the Company was responsible for the development expenses related to certain ongoing clinical trials of ABBV-RGX-314 and the parties shared the additional development expenses related to ABBV-RGX-314. Beginning on January 1, 2023, AbbVie became responsible for the majority of all ABBV-RGX-314 development expenses.

The Company will lead the manufacturing of ABBV-RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead the manufacturing of ABBV-RGX-314 for commercial supply outside the United States. Manufacturing expenses will be allocated between the parties in accordance with the terms of the AbbVie Collaboration Agreement and supply agreements determined in accordance with the agreement. If requested by AbbVie, the Company will manufacture up to a specified portion of ABBV-RGX-314 for commercial supply outside the United States at a price specified in the agreement. AbbVie will lead the commercialization of ABBV-RGX-314 globally, and the Company will participate in U.S. commercialization efforts as provided under a commercialization plan determined in accordance with the agreement. The Company and AbbVie will share equally in the net profits and net losses associated with the commercialization of ABBV-RGX-314 in the United States. Outside the United States, AbbVie will be responsible, at its sole cost, for the commercialization of ABBV-RGX-314.

In consideration for the rights granted under the AbbVie Collaboration Agreement, AbbVie paid the Company an up-front fee of $370.0 million upon the effective date of the agreement in November 2021 and is required to pay to the Company up to $1.38 billion upon the achievement of specified development and sales-based milestones, of which $562.5 million are based on development milestones and $820.0 million are sales-based milestones. AbbVie is also required to pay to the Company tiered royalties on net sales of ABBV-RGX-314 outside the United States at percentages in the mid-teens to low twenties, subject to specified offsets and reductions.

The Company applied the requirements of ASC 606, *Revenue from Contracts with Customers* (ASC 606) to the AbbVie Collaboration Agreement for the units of account in which AbbVie was deemed to be a customer. The Company determined that there is only one material performance obligation under the agreement for the delivery of the intellectual property license to develop and commercialize ABBV-RGX-314 globally. The intellectual property licensed to AbbVie includes the rights to certain patents, data, know-how and other rights developed and owned by the Company, as well as other intellectual property rights exclusively licensed by the Company from various third parties. As of September 30, 2024 and December 31, 2023, the transaction price of the AbbVie Collaboration Agreement was $370.0 million, which consisted solely of the up-front payment received from AbbVie in November 2021. The $370.0 million transaction price was fully recognized as revenue upon the delivery of the license to AbbVie in November 2021. Variable consideration under the AbbVie Collaboration Agreement, which has been excluded from the transaction price, includes $562.5 million in payments for development milestones that have not yet been achieved and were not considered probable of achievement. Additionally, the transaction price excludes sales-based milestone payments of $820.0 million and royalties on net sales of ABBV-RGX-314 outside the United States. Development milestones will be added to the transaction price and recognized as revenue upon achievement, or if deemed probable of achievement. In accordance with the sale- or usage-based royalty exception under ASC 606, royalties on net sales and sales-based milestones will be recognized as revenue in the period the underlying sales occur or milestones are achieved. There were no changes in the transaction price of the AbbVie Collaboration Agreement, and no revenue was recognized, during the three and nine months ended September 30, 2024 and 2023.

The Company applied the requirements of ASC 808, *Collaborative Arrangements* (ASC 808) to the AbbVie Collaboration Agreement for the units of account which were deemed to be a collaborative arrangement. Both the Company and AbbVie will perform various activities related to the development, manufacturing and commercialization of ABBV-RGX-314 in the United States. Development costs are shared between the parties in accordance with the terms of the AbbVie Collaboration Agreement, and the parties will share equally in the net profits and losses derived from sales of ABBV-RGX-314 in the United States. The Company accounts for payments to and from AbbVie for the sharing of development and commercialization costs in accordance with its accounting policy for collaborative arrangements. Amounts owed to AbbVie for the Company's share of development costs or commercialization costs incurred by AbbVie are recorded as research and development expense or general and administrative expense, respectively, in the period the costs are incurred. Amounts owed to the Company for AbbVie's share of development costs or commercialization costs incurred by the Company are recorded as a reduction of research and development expense or general and administrative expense, respectively, in the period the costs are incurred. At the end of each reporting period, the Company records a net amount due to or from AbbVie as a result of the cost-sharing arrangement. As of September 30, 2024 and December 31, 2023, the Company had recorded $20.3 million and $17.7 million, respectively, due from AbbVie for net reimbursement of costs incurred for activities performed under AbbVie Collaboration Agreement, which was included in other current assets on the consolidated balance sheets.

The Company recognized the following amounts under the AbbVie Collaboration Agreement (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net cost reimbursement to (from) AbbVie included in:				
Research and development expense	$ (20,082)	$ (19,608)	$ (66,330)	$ (56,300)
General and administrative expense	341	615	1,168	1,007
Total net cost reimbursement to (from) AbbVie	$ (19,741)	$ (18,993)	$ (65,162)	$ (55,293)

~~XML 28 R19.htm IDEA: XBRL DOCUMENT~~

Stock-based Compensation	9 Months Ended Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]	
Stock-based Compensation	

10. Stock-based Compensation

Effective in January 2024, an additional 1,761,849 shares were authorized for issuance under the 2015 Equity Incentive Plan (the 2015 Plan). As of September 30, 2024, the total number of shares of common stock authorized for issuance under the 2015 Plan and the 2014 Stock Plan (the 2014 Plan) was 19,118,989, of which 1,511,556 remained available for future grants under the 2015 Plan.

Stock-based Compensation Expense

The Company's stock-based compensation expense by award type was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Stock options	$ 6,051	$ 7,275	$ 17,969	$ 22,868
Restricted stock units	3,755	2,843	10,536	8,475
Employee stock purchase plan	78	101	416	586
	$ 9,884	$ 10,219	$ 28,921	$ 31,929

As of September 30, 2024, the Company had $69.5 million of unrecognized stock-based compensation expense related to stock options, restricted stock units and the 2015 Employee Stock Purchase Plan (the 2015 ESPP), which is expected to be recognized over a weighted-average period of 2.4 years.

The Company recorded aggregate stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Research and development	$ 4,301	$ 5,131	$ 13,893	$ 16,670
General and administrative	5,583	5,088	15,028	15,259
	$ 9,884	$ 10,219	$ 28,921	$ 31,929

Stock Options

The following table summarizes stock option activity under the 2014 Plan and 2015 Plan (in thousands, except per share data):

	Shares	Weighted-average Exercise Price	Weighted-average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (a)
Outstanding at December 31, 2023	8,581	$ 32.62	6.2	$ 7,011
Granted	2,263	$ 16.24		
Exercised	(281)	$ 5.25		
Cancelled or forfeited	(546)	$ 35.56		
Outstanding at September 30, 2024	10,017	$ 29.53	6.4	$ 529
Exercisable at September 30, 2024	6,609	$ 34.38	5.1	$ 529
Vested and expected to vest at September 30, 2024	10,017	$ 29.53	6.4	$ 529

(a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at the dates reported.

The weighted-average grant date fair value per share of options granted during the nine months ended September 30, 2024 was $10.06. During the nine months ended September 30, 2024, the total number of stock options exercised was 280,753, resulting in total proceeds of $1.5 million. The total intrinsic value of options exercised during the nine months ended September 30, 2024 was $3.0 million.

Restricted Stock Units

The following table summarizes restricted stock unit activity under the 2015 Plan (in thousands, except per share data):

	Shares	Weighted-average Grant Date Fair Value
Unvested balance at December 31, 2023	1,309	$ 25.89
Granted	1,188	$ 16.22
Vested	(390)	$ 27.20
Forfeited	(72)	$ 22.45
Unvested balance at September 30, 2024	2,035	$ 20.11

The total intrinsic value of restricted stock units vested during the nine months ended September 30, 2024 was $6.7 million.

Employee Stock Purchase Plan

As of September 30, 2024, the total number of shares of common stock authorized for issuance under the 2015 ESPP was 1,426,994, of which 912,964 remained available for future issuance. During the nine months ended September 30, 2024, 105,400 shares of common stock were issued under the 2015 ESPP.

~~***XML 29 R20.htm IDEA: XBRL DOCUMENT***~~

Income Taxes

9 Months Ended
Sep. 30, 2024

Income Tax Disclosure [Abstract]
Income Taxes

11. Income Taxes

The Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets as of September 30, 2024 and December 31, 2023. Based on the Company's history of operating losses, and other relevant facts and circumstances, the Company concluded that it was more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company provided a full valuation allowance for its net deferred tax assets as of September 30, 2024 and December 31, 2023.

~~***XML 30 R21.htm IDEA: XBRL DOCUMENT***~~

Restructuring

9 Months Ended
Sep. 30, 2024

Restructuring and Related Activities [Abstract]
Restructuring

12. Restructuring

In November 2023, the Company implemented a strategic pipeline prioritization and corporate restructuring designed to reduce operating expenses and prioritize the development of ABBV-RGX-314, RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), while pursuing strategic alternatives for the Company's other clinical stage programs. The restructuring included a reduction in workforce and other planned operating expenses, primarily in rare neurodegenerative disease development, early research and other general and administrative areas.

In connection with the restructuring, the Company implemented a reduction in workforce of approximately 15%, which was substantially completed in the fourth quarter of 2023. The Company recorded restructuring costs of $3.7 million in the fourth quarter of 2023, which primarily consisted of employee severance, continuing healthcare benefits and other employee-related costs. During the nine months ended September 30, 2024, the Company recorded reductions in the restructuring liability of $0.4 million associated with changes in total estimated restructuring costs. As of September 30, 2024, all of the restructuring costs had been paid by the Company and no restructuring liability was recorded. The following table presents the details of the Company's restructuring liability as of September 30, 2024 (in thousands):

	Restructuring Liability
Balance at December 31, 2022	$ —
Restructuring charges	3,731
Cash payments	(1,925)
Balance at December 31, 2023	1,806
Cash payments	(1,370)
Other adjustments	(436)
Balance at September 30, 2024	$ —

~~***XML 31 R22.htm IDEA: XBRL DOCUMENT***~~

Net Loss Per Share

9 Months Ended
Sep. 30, 2024

Earnings Per Share [Abstract]
Net Loss Per Share

13. Net Loss Per Share

Since the Company incurred net losses for the three and nine months ended September 30, 2024 and 2023, common stock equivalents were excluded from the calculation of diluted net loss per share for such periods as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share were the same for such periods. The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants to purchase shares of the Company's common stock, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands):

	Three and Nine Months Ended September 30,	
	2024	2023
Stock options issued and outstanding	10,017	8,856
Unvested restricted stock units outstanding	2,035	1,394
Employee stock purchase plan	47	36
	12,099	10,286

~~***XML 32 R23.htm IDEA: XBRL DOCUMENT***~~

Supplemental Disclosures

9 Months Ended
Sep. 30, 2024

Payables and Accruals [Abstract]
Supplemental Disclosures

14. Supplemental Disclosures

Other Current Assets

Other current assets consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Net cost reimbursement due from collaborators	$ 20,302	$ 17,745

Accrued interest on investments	1,578	1,551
Other	1,450	1,107
	$ 23,330	$ 20,403

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Accrued external research and development expenses	$ 16,715	$ 13,762
Accrued sublicense fees and royalties	14,628	14,234
Accrued personnel costs	14,335	18,146
Accrued external general and administrative expenses	1,843	2,717
Accrued purchases of property and equipment	334	386
Other accrued expenses and current liabilities	787	458
	$ 48,642	$ 49,703

Supplemental Disclosures of Non-cash Investing and Financing Activities

Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities were $0.4 million as of September 30, 2024, a net decrease of less than $0.1 million from December 31, 2023, and $0.5 million as of September 30, 2023, a net decrease of $2.0 million from December 31, 2022.

Offering expenses for the ATM Program included in accounts payable and accrued expenses and other liabilities were $0.4 million as of September 30, 2023. No such amounts were recorded as of September 30, 2024.

~~***XML 33 R24.htm IDEA: XBRL DOCUMENT***~~

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract]

Basis of Presentation and Principles of Consolidation

Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024. Certain information and footnote disclosures required by GAAP, which are normally included in the Company's annual consolidated financial statements, have been omitted pursuant to SEC rules and regulations for interim reporting. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for a fair statement of the results of operations for the periods presented.

The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year, any other interim periods, or any future year or period. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.
The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance

for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements.

Reclassifications

Reclassifications

Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.

Restricted Cash

Restricted Cash

Restricted cash consists of deposits held at financial institutions that are used to collateralize irrevocable letters of credit required under the Company's lease agreements and certain other agreements with third parties. The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):

	As of September 30,	
	2024	2023
Cash and cash equivalents	$ 56,617	$ 53,045
Restricted cash	2,030	2,255
Total cash and cash equivalents and restricted cash	$ 58,647	$ 55,300

Accounts Receivable

Accounts Receivable

Accounts receivable primarily consist of consideration due to the Company resulting from its license agreements with customers. Accounts receivable include amounts invoiced to licensees as well as rights to consideration which have not yet been invoiced, including unbilled royalties, and for which payment is conditional solely upon the passage of time. If a licensee elects to terminate a license prior to the end of the license term, the licensed intellectual property is returned to the Company and any accounts receivable from the licensee which are not contractually payable to the Company are charged off as a reduction of license revenue in the period of the termination. Accounts receivable which are not expected to be received by the Company within 12 months from the reporting date are stated net of a discount to present value and recorded as non-current assets on the consolidated balance sheets. The present value discount is recognized as a reduction of revenue in the period in which the accounts receivable are initially recorded and is accreted as interest income from licensing over the term of the receivables.

Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company's evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances, and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company's evaluation of current and expected future economic conditions. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Please refer to Note 9 for further information regarding the allowance for credit losses related to accounts receivable.

Leases

Leases

The Company accounts for its lease arrangements in accordance with Accounting Standards Codification (ASC) 842, *Leases* (ASC 842). Under ASC 842, the Company classifies its leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the Company. Lease classification is evaluated at the inception of the lease agreement. Regardless of classification, the Company records a right-of-use asset and a lease liability for all leases with a term greater than 12 months. All of the Company's leases have been classified as operating leases. Operating lease expense is recognized on a straight-line basis over the term of the lease, with the exception of variable lease expenses which are recognized as incurred.

The Company identifies leases in its contracts if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company does not allocate lease consideration between lease and nonlease components and records a lease liability equal to the present value of the remaining fixed consideration under the lease. The interest rates implicit in the Company's leases are generally not readily determinable. Accordingly, the Company uses its estimated incremental borrowing rate at the commencement date of the lease to determine the present value discount of the lease liability. The Company estimates its incremental borrowing rate for each lease based on an evaluation of its expected credit rating and the prevailing

market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the term of the lease. The right-of-use asset for each lease is equal to the lease liability, adjusted for unamortized initial direct costs and lease incentives and prepaid or accrued rent. Initial direct costs of entering into a lease are included in the right-of-use asset and amortized as lease expense over the term of the lease. Lease incentives, such as tenant improvement allowances, are recorded as a reduction of the right-of-use asset and amortized as a reduction of lease expense over the term of the lease. The Company excludes options to extend or terminate leases from the calculation of the lease liability unless it is reasonably certain the option will be exercised.

The Company evaluates its right-of-use assets for impairment in accordance with its policy for long-lived assets. To the extent an impairment of a right-of-use asset is recognized, the remaining carrying value of the asset is subsequently amortized as lease expense on a straight-line basis from the date of impairment to the earlier of the end of the right-of-use asset's useful life or the end of the lease term.

The Company determines the classification of subleases at the inception of the sublease, as well as whether the Company has been relieved of its primary obligation under the original lease. All of the Company's subleases have been classified as operating leases and, in each case, the Company has not been relieved of its primary obligation under the original lease and continues to account for the original lease as it did prior to the commencement of the sublease. Sublease income is recognized on a straight-line basis over the term of the sublease as a reduction of the related lease expense of the original lease. Initial direct costs of entering into a sublease are deferred and amortized on a straight-line basis over the term of the sublease as a reduction of sublease income.

Impairment of Long-lived Assets

Impairment of Long-lived Assets

The Company's long-lived assets consist primarily of property and equipment and operating lease right-of-use assets. The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to estimated future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. Please refer to Note 5 and Note 6 for further information on impairment of long-lived assets.

Fair Value Measurements

Fair Value Measurements

The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, *Fair Value Measurements and Disclosures*, establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below:

- Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

- Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
- Level 3—Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and unobservable.

To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within the fair value hierarchy of an asset or liability measured at fair value is based on the lowest level of any input that is significant to the fair value measurement. The fair values of the Company's Level 2 financial instruments are based on quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Please refer to Note 4 for further information on the Company's fair value measurements.

Pre-funded Warrants

Pre-funded Warrants

Warrants are accounted for based on the specific terms of the warrant agreements. The Company's pre-funded warrants are indexed to the Company's common stock and meet the criteria to be classified as equity. Proceeds from the issuance of pre-funded warrants are recorded within additional paid-in capital and are not subject to remeasurement. Please refer to Note 8 for further information regarding pre-funded warrants issued by the Company.

Net Loss Per Share

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of computing both basic and diluted net loss per share, pre-funded warrants are considered outstanding shares upon issuance because the shares may be issued for nominal consideration and are exercisable after the original issuance date. Contingently convertible shares in which conversion is based on non-market-priced contingencies are excluded from the calculations of both basic and diluted net loss per share until the contingency has been fully met. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation of diluted net loss per share if their effect would be anti-dilutive.

Recent Accounting Pronouncements

Recent Accounting Pronouncements

Recently Adopted Accounting Pronouncements

The Company did not adopt any new accounting standards during the three and nine months ended September 30, 2024 and 2023 which had a material impact on the consolidated financial statements.

Recent Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, *Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures*, which enhances certain interim and annual disclosure requirements of reportable segment information, including information about significant segment expenses. Additionally, the standard requires entities with a single reportable segment to provide all disclosures required by ASC 280, *Segment Reporting*. The standard is effective for the Company for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for segment reporting, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which enhances the disclosure of an entity's effective tax rate reconciliation and requires the disclosure of income taxes paid to be disaggregated by jurisdiction. The standard is effective for the Company beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for income taxes, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements.

In November 2024, the FASB issued ASU 2024-03, *Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses*. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact of this standard on its consolidated financial statements and related disclosures.

XML 34 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended
Sep. 30, 2024

Accounting Policies [Abstract]

Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):

	As of September 30,	
	2024	2023
Cash and cash equivalents	$ 56,617	$ 53,045
Restricted cash	2,030	2,255
Total cash and cash equivalents and restricted cash	$ 58,647	$ 55,300

XML 35 R26.htm IDEA: XBRL DOCUMENT

Marketable Securities (Tables)

9 Months Ended
Sep. 30, 2024

Investments, Debt and Equity Securities [Abstract]

Summary of Company Marketable Securities

The following tables present a summary of the Company's marketable securities, which consist solely of available-for-sale debt securities (in thousands):

	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
September 30, 2024				
U.S. government and agency securities	$ 50,350	$ 16	$ (233)	$ 50,133
Certificates of deposit	4,404	—	(15)	4,389
Corporate bonds	166,919	583	(73)	167,429
	$ 221,673	$ 599	$ (321)	$ 221,951

	Amortized Cost	Unrealized Gains	Unrealized Losses	Fair Value
December 31, 2023				
U.S. government and agency securities	$ 71,811	$ 6	$ (1,248)	$ 70,569
Certificates of deposit	6,572	—	(106)	6,466
Corporate bonds	204,793	143	(2,364)	202,572
	$ 283,176	$ 149	$ (3,718)	$ 279,607

Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater

The following tables present the fair values and unrealized losses of available-for-sale debt securities held by the Company in an unrealized loss position for less than 12 months and 12 months or greater (in thousands):

	Less than 12 Months		12 Months or Greater		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
September 30, 2024						
U.S. government and agency securities	$ —	$ —	$ 30,252	$ (233)	$ 30,252	$ (233)
Certificates of deposit	484	(1)	3,170	(14)	3,654	(15)
Corporate bonds	4,995	(1)	21,290	(72)	26,285	(73)
	$ 5,479	$ (2)	$ 54,712	$ (319)	$ 60,191	$ (321)

	Less than 12 Months		12 Months or Greater		Total	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses
December 31, 2023						
U.S. government and agency securities	$ 12,877	$ (16)	$ 52,686	$ (1,232)	$ 65,563	$ (1,248)
Certificates of deposit	965	(2)	5,257	(104)	6,222	(106)
Corporate bonds	25,051	(48)	144,642	(2,316)	169,693	(2,364)
	$ 38,893	$ (66)	$ 202,585	$ (3,652)	$ 241,478	$ (3,718)

XML 36 R27.htm IDEA: XBRL DOCUMENT

Fair Value of Financial Instruments (Tables)

9 Months Ended
Sep. 30, 2024

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Cash Equivalents and Marketable Securities

The following tables present the fair value of cash equivalents and marketable securities in accordance with the fair value hierarchy discussed in Note 2 (in thousands):

	Level 1	Level 2	Level 3	Total
September 30, 2024				
Cash equivalents:				
Money market mutual funds	$ —	$ 43,771	$ —	$ 43,771
Total cash equivalents	—	43,771	—	43,771

Marketable securities:				
U.S. government and agency securities	—	50,133	—	50,133
Certificates of deposit	—	4,389	—	4,389
Corporate bonds	—	167,429	—	167,429
Total marketable securities	—	221,951	—	221,951
Total cash equivalents and marketable securities	$ —	$ 265,722	$ —	$ 265,722

	Level 1	Level 2	Level 3	Total
December 31, 2023				
Cash equivalents:				
Money market mutual funds	$ —	$ 13,024	$ —	$ 13,024
Total cash equivalents	—	13,024	—	13,024
Marketable securities:				
U.S. government and agency securities	—	70,569	—	70,569
Certificates of deposit	—	6,466	—	6,466
Corporate bonds	—	202,572	—	202,572
Total marketable securities	—	279,607	—	279,607
Total cash equivalents and marketable securities	$ —	$ 292,631	$ —	$ 292,631

~~***XML 37 R28.htm IDEA: XBRL DOCUMENT***~~

Property and Equipment, Net (Tables)

9 Months Ended

Sep. 30, 2024

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment, net consists of the following (in thousands):

	September 30, 2024	December 31, 2023
Laboratory and manufacturing equipment	$ 76,788	$ 75,632
Computer equipment and software	4,748	4,700
Furniture and fixtures	7,024	7,052
Leasehold improvements	101,340	101,927
Total property and equipment	189,900	189,311
Accumulated depreciation and amortization	(69,349)	(57,208)
Property and equipment, net	$ 120,551	$ 132,103

~~***XML 38 R29.htm IDEA: XBRL DOCUMENT***~~

Liability Related to Sale of Future Royalties (Tables)

9 Months Ended

Sep. 30, 2024

Liability Related To Sale Of Future Royalties [Abstract]

Schedule of Changes in Liability Related to Sale of Future Royalties

The following table presents the changes in the liability related to the sale of future royalties under the Royalty Purchase Agreement with HCR (in thousands):

	Liability Related to Sale of Future Royalties
Balance at December 31, 2023	$ 94,052
Zolgensma royalties paid to HCR	(35,072)
Interest expense recognized	2,769
Balance at September 30, 2024	61,749
Current portion of liability related to sale of future royalties	(26,697)
Liability related to sale of future royalties, non-current	$ 35,052

~~***XML 39 R30.htm IDEA: XBRL DOCUMENT***~~

License and Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2024

Schedule Of License and Royalty Revenue

License and royalty revenue consisted of the following (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Zolgensma royalties	$ 23,872	$ 28,364	$ 60,849	$ 63,454
Other license and royalty revenue	325	550	1,265	4,575
Total license and royalty revenue	$ 24,197	$ 28,914	$ 62,114	$ 68,029

Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue

The following table presents the balances of the Company's net accounts receivable, contract assets and deferred revenue, as well as other information regarding revenue recognized during the periods presented (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Accounts receivable, net, current and non-current:				
Beginning of period	$ 23,273	$ 22,523	$ 25,491	$ 29,586
End of period	$ 24,008	$ 29,121	$ 24,008	$ 29,121
Contract assets:				
Beginning of period	$ 194	$ 2,000	$ —	$ —
End of period	$ 259	$ 2,000	$ 259	$ 2,000
Deferred revenue:				
Beginning of period	$ 21	$ 448	$ 148	$ 1,829
End of period	$ 144	$ 442	$ 144	$ 442
Revenue recognized during the period from:				
Amounts included in deferred revenue at beginning of period	$ 21	$ 28	$ 148	$ 1,409
Performance obligations satisfied in previous periods	$ 23,875	$ 28,365	$ 60,912	$ 65,405

Summary of Accounts Receivables, net

Accounts receivable, net consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Current accounts receivable:		
Billed to customers	$ 105	$ 265
Unbilled Zolgensma royalties	23,138	24,128
Due from Abeona, net of present value discount	4,942	4,587
Other unbilled	361	397
Allowance for credit losses	(4,942)	(4,587)
Current accounts receivable, net	23,604	24,790
Non-current accounts receivable:		
Other unbilled	404	701
Non-current accounts receivable, net	404	701
Total accounts receivable, net	$ 24,008	$ 25,491

Summary of Changes in Allowance For Credit Losses

The following table presents the changes in the allowance for credit losses related to accounts receivable and contract assets for the nine months ended September 30, 2024 (in thousands):

	Allowance for Credit Losses	
	Accounts Receivable	Contract Assets
Balance at December 31, 2023	$ 4,587	$ —
Changes in present value discount of receivables	355	—
Balance at September 30, 2024	$ 4,942	$ —

Schedule of AbbVie Collaboration Agreement

The Company recognized the following amounts under the AbbVie Collaboration Agreement (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Net cost reimbursement to (from) AbbVie included in:				
Research and development expense	$ (20,082)	$ (19,608)	$ (66,330)	$ (56,300)
General and administrative expense	341	615	1,168	1,007
Total net cost reimbursement to (from) AbbVie	$ (19,741)	$ (18,993)	$ (65,162)	$ (55,293)

Novartis Gene Therapies [Member]

Schedule Of License and Royalty Revenue

The Company recognized the following amounts under the Novartis License (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Zolgensma royalties	$ 23,872	$ 28,364	$ 60,849	$ 63,454
Total license and royalty revenue	$ 23,872	$ 28,364	$ 60,849	$ 63,454
Interest income from licensing	$ 6	$ 7	$ 20	$ 22

XML 40 R31.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Tables)

9 Months Ended Sep. 30, 2024

Stock-Based Compensation Expense by Award Type

The Company's stock-based compensation expense by award type was as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Stock options	$ 6,051	$ 7,275	$ 17,969	$ 22,868
Restricted stock units	3,755	2,843	10,536	8,475
Employee stock purchase plan	78	101	416	586
	$ 9,884	$ 10,219	$ 28,921	$ 31,929

Stock-Based Compensation Expense

The Company recorded aggregate stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2024	2023	2024	2023
Research and development	$ 4,301	$ 5,131	$ 13,893	$ 16,670
General and administrative	5,583	5,088	15,028	15,259
	$ 9,884	$ 10,219	$ 28,921	$ 31,929

Summary of Unvested RSUs Activity Under 2015 Plan

The following table summarizes restricted stock unit activity under the 2015 Plan (in thousands, except per share data):

	Shares	Weighted-average Grant Date Fair Value
Unvested balance at December 31, 2023	1,309	$ 25.89
Granted	1,188	$ 16.22
Vested	(390)	$ 27.20
Forfeited	(72)	$ 22.45
Unvested balance at September 30, 2024	2,035	$ 20.11

2014 and 2015 Equity Incentive Plan [Member]

Summary of Stock Option Activity

The following table summarizes stock option activity under the 2014 Plan and 2015 Plan (in thousands, except per share data):

	Shares	Weighted-average Exercise Price	Weighted-average Remaining Contractual Life (Years)	Aggregate Intrinsic Value (a)
Outstanding at December 31, 2023	8,581	$ 32.62	6.2	$ 7,011
Granted	2,263	$ 16.24		
Exercised	(281)	$ 5.25		
Cancelled or forfeited	(546)	$ 35.56		
Outstanding at September 30, 2024	10,017	$ 29.53	6.4	$ 529
Exercisable at September 30, 2024	6,609	$ 34.38	5.1	$ 529
Vested and expected to vest at September 30, 2024	10,017	$ 29.53	6.4	$ 529

(a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at the dates reported.

XML 41 R32.htm IDEA: XBRL DOCUMENT

Restructuring (Tables)

9 Months Ended Sep. 30, 2024

Restructuring and Related Activities [Abstract]

Summary of Restructuring Liability

The following table presents the details of the Company's restructuring liability as of September 30, 2024 (in thousands):

	Restructuring Liability
Balance at December 31, 2022	$ —
Restructuring charges	3,731
Cash payments	(1,925)
Balance at December 31, 2023	1,806
Cash payments	(1,370)
Other adjustments	(436)
Balance at September 30, 2024	$ —

XML 42 R33.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

9 Months Ended Sep. 30, 2024

Earnings Per Share [Abstract]

Schedules for Computation of Diluted Weighted-Average Shares Outstanding

The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands):

	Three and Nine Months Ended September 30,	
	2024	2023
Stock options issued and outstanding	10,017	8,856
Unvested restricted stock units outstanding	2,035	1,394
Employee stock purchase plan	47	36
	12,099	10,286

XML 43 R34.htm IDEA: XBRL DOCUMENT

Supplemental Disclosures (Tables)

9 Months Ended Sep. 30, 2024

Payables and Accruals [Abstract]

Schedule of Other Current Assets

Other current assets consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Net cost reimbursement due from collaborators	$ 20,302	$ 17,745
Accrued interest on investments	1,578	1,551
Other	1,450	1,107
	$ 23,330	$ 20,403

Schedules of Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	September 30, 2024	December 31, 2023
Accrued external research and development expenses	$ 16,715	$ 13,762
Accrued sublicense fees and royalties	14,628	14,234
Accrued personnel costs	14,335	18,146
Accrued external general and administrative expenses	1,843	2,717
Accrued purchases of property and equipment	334	386
Other accrued expenses and current liabilities	787	458
	$ 48,642	$ 49,703

XML 44 R35.htm IDEA: XBRL DOCUMENT

Nature of Business - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]		
Accumulated deficit	$ (880,963)	$ (705,047)
Cash, cash equivalents and marketable securities	$ 278,600	

XML 45 R36.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023
Accounting Policies [Abstract]			
Cash and cash equivalents	$ 56,617	$ 34,522	$ 53,045
Restricted cash	2,030	$ 2,030	2,255
Total cash and cash equivalents and restricted cash	$ 58,647		$ 55,300

XML 46 R37.htm IDEA: XBRL DOCUMENT

Marketable Securities - Summary of Company Marketable Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]		
Amortized Cost / Cost	$ 221,673	$ 283,176
Unrealized Gains	599	149
Unrealized Losses	(321)	(3,718)
Fair Value	221,951	279,607
U.S. Government and Agency Securities [Member]		
Schedule Of Available For Sale Securities [Line Items]		
Amortized Cost / Cost	50,350	71,811
Unrealized Gains	16	6
Unrealized Losses	(233)	(1,248)
Fair Value	50,133	70,569
Certificates of Deposit [Member]		
Schedule Of Available For Sale Securities [Line Items]		
Amortized Cost / Cost	4,404	6,572
Unrealized Losses	(15)	(106)
Fair Value	4,389	6,466
Corporate Bonds [Member]		
Schedule Of Available For Sale Securities [Line Items]		
Amortized Cost / Cost	166,919	204,793
Unrealized Gains	583	143
Unrealized Losses	(73)	(2,364)
Fair Value	$ 167,429	$ 202,572

XML 47 R38.htm IDEA: XBRL DOCUMENT

Marketable Securities - Additional Information (Detail)	3 Months Ended		9 Months Ended		
	Sep. 30, 2024 USD ($) Security	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) Security	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Investments, Debt and Equity Securities [Abstract]					
Available for sale debt securities remaining maturities greater than three years	$ 0		$ 0		$ 0
Number of investment grade fixed income debt security | Security	36		36		
Allowance for credit loss	$ 0		$ 0		$ 0
Realized gains or losses on available-for-sales securities	$ 0	$ 0	$ 0	$ 0	

XML 48 R39.htm IDEA: XBRL DOCUMENT

Marketable Securities - Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Schedule Of Available For Sale Securities [Line Items]		
Less than 12 Months, Fair Value	$ 5,479	$ 38,893
Less than 12 Months, Unrealized Losses	(2)	(66)
12 Months or Greater, Fair Value	54,712	202,585
12 Months or Greater, Unrealized Losses	(319)	(3,652)
Total, Fair Value	60,191	241,478
Total, Unrealized Losses	(321)	(3,718)
U.S. Government and Agency Securities [Member]		
Schedule Of Available For Sale Securities [Line Items]		
Less than 12 Months, Fair Value		12,877
Less than 12 Months, Unrealized Losses		(16)
12 Months or Greater, Fair Value	30,252	52,686
12 Months or Greater, Unrealized Losses	(233)	(1,232)
Total, Fair Value	30,252	65,563
Total, Unrealized Losses	(233)	(1,248)
Certificates of Deposit [Member]		
Schedule Of Available For Sale Securities [Line Items]		
Less than 12 Months, Fair Value	484	965
Less than 12 Months, Unrealized Losses	(1)	(2)
12 Months or Greater, Fair Value	3,170	5,257
12 Months or Greater, Unrealized Losses	(14)	(104)
Total, Fair Value	3,654	6,222
Total, Unrealized Losses	(15)	(106)
Corporate Bonds [Member]		
Schedule Of Available For Sale Securities [Line Items]		
Less than 12 Months, Fair Value	4,995	25,051

Less than 12 Months, Unrealized Losses	(1)	(48)
12 Months or Greater, Fair Value	21,290	144,642
12 Months or Greater, Unrealized Losses	(72)	(2,316)
Total, Fair Value	26,285	169,693
Total, Unrealized Losses	$ (73)	$ (2,364)

XML 49 R40.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value of Cash Equivalents and Marketable Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Marketable securities:		
Fair Value	$ 221,951	$ 279,607
Cash Equivalents and Marketable Securities [Member]		
Marketable securities:		
Total cash equivalents and marketable securities	265,722	292,631
Corporate Bonds [Member]		
Marketable securities:		
Fair Value	167,429	202,572
Cash Equivalents [Member]		
Cash equivalents:		
Total cash equivalents	43,771	13,024
US Government and Agency Securities [Member]		
Marketable securities:		
Fair Value	50,133	70,569
Certificates of Deposit [Member]		
Marketable securities:		
Fair Value	4,389	6,466
Money Market Mutual Funds [Member] | Cash Equivalents [Member]		
Cash equivalents:		
Total cash equivalents	43,771	13,024
Level 2 [Member]		
Marketable securities:		
Fair Value	221,951	279,607
Level 2 [Member] | Cash Equivalents and Marketable Securities [Member]		
Marketable securities:		
Total cash equivalents and marketable securities	265,722	292,631
Level 2 [Member] | Corporate Bonds [Member]		
Marketable securities:		
Fair Value	167,429	202,572
Level 2 [Member] | Cash Equivalents [Member]		
Cash equivalents:		
Total cash equivalents	43,771	13,024
Level 2 [Member] | US Government and Agency Securities [Member]		
Marketable securities:		
Fair Value	50,133	70,569
Level 2 [Member] | Certificates of Deposit [Member]		
Marketable securities:		
Fair Value	4,389	6,466
Level 2 [Member] | Money Market Mutual Funds [Member] | Cash Equivalents [Member]		
Cash equivalents:		
Total cash equivalents	$ 43,771	$ 13,024

XML 50 R41.htm IDEA: XBRL DOCUMENT

Property and Equipment Net - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]		
Total property and equipment	$ 189,900	$ 189,311
Accumulated depreciation and amortization	(69,349)	(57,208)
Property and equipment, net	120,551	132,103
Laboratory and Manufacturing Equipment [Member]		
Property Plant And Equipment [Line Items]		
Total property and equipment	76,788	75,632
Computer Equipment and Software [Member]		
Property Plant And Equipment [Line Items]		
Total property and equipment	4,748	4,700
Furniture and Fixtures [Member]		
Property Plant And Equipment [Line Items]		
Total property and equipment	7,024	7,052
Leasehold Improvements [Member]		
Property Plant And Equipment [Line Items]		
Total property and equipment	$ 101,340	$ 101,927

XML 51 R42.htm IDEA: XBRL DOCUMENT

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2024	Sep. 30, 2024
Property, Plant and Equipment [Line Items]		
Impairment of property and equipment		$ 2,101
Furniture Fixtures and Leasehold Improvements [Member]		
Property, Plant and Equipment [Line Items]		
Impairment of property and equipment	$ 700	

XML 52 R43.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Other Commitments [Line Items]					
Total undiscounted payments	$ 1,300,000			$ 1,300,000	
Impairment losses of long-lived assets				2,101,000	
New York Sublease [Member]					
Other Commitments [Line Items]					
Sublease income	100,000			200,000	

Carrying value of the asset		$ 3,400,000			
Estimated fair value of asset		1,300,000			
Impairment losses of long-lived assets	$ 0	2,100,000	$ 0	$ 2,100,000	$ 0
Impairment losses recorded to right-of-use assets		1,400,000			
Impairment losses recorded to property and equipment		$ 700,000			

XML 53 R44.htm IDEA: XBRL DOCUMENT

Liability Related to Sale of Future Royalties - Additional Information (Details) $ in Millions	9 Months Ended
	Sep. 30, 2024 USD ($)
Liability Related To Sale Of Future Royalties [Line Items]	
Repurchase of call option amount	$ 300.0
November 7, 2024	
Liability Related To Sale Of Future Royalties [Line Items]	
Repurchase of call option amount, before exercised	1.0
HCR [Member]	
Liability Related To Sale Of Future Royalties [Line Items]	
Proceeds from Royalties Received	4.0
Proceeds from sale of future royalties	196.0
Deferred Transaction Cost	3.5
Interest expense	$ 192.5
Interest Rate, Effective Percentage	4.20%
HCR [Member] | November 7, 2024	
Liability Related To Sale Of Future Royalties [Line Items]	
Royalty Payment Cap Amount	$ 260.0
HCR [Member] | November 8, 2024	
Liability Related To Sale Of Future Royalties [Line Items]	
Royalty Payment Cap Amount	300.0
HCR [Member] | Royalty Agreements	
Liability Related To Sale Of Future Royalties [Line Items]	
Purchase Agreement	$ 200.0

XML 54 R45.htm IDEA: XBRL DOCUMENT

Liability Related to Sale of Future Royalties -Schedule of Activity Within Liability Related to Sale of Future Royalties (Details) - USD ($) $ in Thousands	9 Months Ended	
	Sep. 30, 2024	Dec. 31, 2023
Liability Related To Sale Of Future Royalties [Line Items]		
Current portion of liability related to sale of future royalties	$ (26,697)	$ (50,567)
Liability related to sale of future royalties, non-current	35,052	$ 43,485
Royalty Agreements		
Liability Related To Sale Of Future Royalties [Line Items]		
Beginning balance	94,052	
Zolgensma royalties paid to HCR	(35,072)	
Interest expense recognized	2,769	
Ending balance	61,749	
Current portion of liability related to sale of future royalties	(26,697)	
Liability related to sale of future royalties, non-current	$ 35,052	

XML 55 R46.htm IDEA: XBRL DOCUMENT

Capitalization - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended	
	Mar. 31, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Schedule of Capitalization [Line Items]						
Proceeds from private placement						$ 4,874
Percentage of common stock owned	9.99%					
Percentage of voting power	9.99%					
Maximum [Member]						
Schedule of Capitalization [Line Items]						
Percentage of common stock owned	19.99%					
Minimum [Member]						
Schedule of Capitalization [Line Items]						
Percentage of common stock owned	4.99%					
March 2024 Public Offering [Member]						
Schedule of Capitalization [Line Items]						
Number of shares sold	4,565,260					
Purchase price of share	$ 23					
Net proceeds from issuance of common stock	$ 131,100					
March 2024 Public Offering [Member] | Pre Funded Warrants [Member]						
Schedule of Capitalization [Line Items]						
Purchase price of share	$ 22.9999					
Number of warrants issued	1,521,740					
Exercise price of warrants	$ 0.0001					
Pre-funded warrants exercised			0		0	
Pre-funded warrants remained outstanding			1,324,740		1,324,740	
At the Market Offering Program						
Schedule of Capitalization [Line Items]						
Aggregate offering price		$ 150,000				
Common Stock [Member] | Private Placement [Member]						
Schedule of Capitalization [Line Items]						
Number of shares sold				257,000		257,000
Common Stock [Member] | March 2024 Public Offering [Member]						
Schedule of Capitalization [Line Items]						
Number of shares sold			197,000		197,000	
Common Stock [Member] | At the Market Offering Program						
Schedule of Capitalization [Line Items]						
Number of shares sold					0	

XML 56 R47.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Additional Information (Detail)	1 Months Ended	3 Months Ended		9 Months Ended					
	Sep. 30, 2021 USD ($)	Sep. 30, 2024 USD ($) ProductCandidate	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) ProductCandidate	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Collaborative Arrangements And Noncollaborative									

Arrangement Transactions [Line Items]								
Milestone payment upon commencement of clinical trials in humans				$ 524,900,000				
Milestone payment upon submission of regulatory approval filings				113,800,000				
Milestone payment upon achievement of specified sales targets for licensed products				870,000,000				
Deferred revenue, current and non-current		$ 144,000	$ 442,000	144,000	$ 442,000	$ 21,000	$ 148,000	$ 448,000	$ 1,829,000
Contract assets		259,000	2,000,000	259,000	2,000,000	194,000		2,000,000	
Aggregate transaction price of license agreements				1,500,000					
Revenue recognized upon achievement of development milestones		0	0	0	2,000,000				
Provision for credit losses		0	0	0	0				
Accounts receivable		24,008,000	29,121,000	24,008,000	29,121,000	$ 23,273,000	25,491,000	$ 22,523,000	$ 29,586,000
Due from related parties, current		4,942,000		4,942,000			4,587,000		
Abb Vie Collaboration And License Agreement									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Up-front fee paid	$ 370,000,000.0								
Milestone fee payments upon achievement of various development and commercialization	1,380,000,000								
Transaction price of license		370,000,000.0		370,000,000.0			370,000,000.0		
Change in transaction price		0	0	0	0				
Abb Vie Collaboration And License Agreement | Other Current Assets [Member]									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Due from related parties, current		20,300,000		20,300,000			17,700,000		
Novartis License Agreement [Member] | Novartis Gene Therapies [Member]									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Accounts receivable		23,300,000		23,300,000			24,300,000		
November Two Thousand Eighteen License Agreement | Abeona Therapeutics Incorporation | Contract Termination									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Settlement agreement payable				30,000,000					
November Two Thousand Twenty One License Agreement | Abeona Therapeutics Incorporation | Contract Termination									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Settlement agreement payable				20,000,000					
November Two Thousand Twenty Two License Agreement | Abeona Therapeutics Incorporation | Contract Termination									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Settlement agreement payable				5,000,000					
November Two Thousand Twenty Four License Agreement | Abeona Therapeutics Incorporation | Contract Termination									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Settlement agreement payable				5,000,000					
Settlement Agreement | Abeona Therapeutics Incorporation									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Accounts receivable		4,900,000		4,900,000			4,600,000		
Due from related parties		5,000,000.0		5,000,000.0					
Allowance for credit losses		4,900,000		4,900,000			4,600,000		
Provision for credit losses		0	$ 0	0	$ 0				
Sales Based Milestones | Abb Vie Collaboration And License Agreement									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Milestone fee payments upon achievement of various development and commercialization	820,000,000.0								
Transaction price of license		820,000,000.0		820,000,000.0			820,000,000.0		
Development Milestone | Abb Vie Collaboration And License Agreement									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Milestone fee payments upon achievement of various development and commercialization	$ 562,500,000								
Transaction price of license		562,500,000		562,500,000			$ 562,500,000		
Maximum [Member]									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Aggregate milestone payment for all the targets				1,510,000,000					
Deferred revenue, current and non-current		$ 100,000		$ 100,000					
Aggregate transaction price of license agreements, expected satisfaction period				3 years					
Minimum [Member]									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Aggregate transaction price of license agreements, expected satisfaction period				2 years					
N A V Technology Platform [Member]									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Number of commercial product candidates | ProductCandidate		1		1					
HCR [Member] | Novartis License Agreement [Member] | Novartis Gene Therapies [Member]									
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]									
Accounts receivable, current		$ 11,100,000		$ 11,100,000					

XML 57 R48.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Schedule Of License and Royalty Revenue	**3 Months Ended**		**9 Months Ended**	
	Sep. 30, 2024	**Sep. 30, 2023**	**Sep. 30, 2024**	**Sep. 30, 2023**

(Detail) - USD ($) $ in Thousands				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Other license and royalty revenue	$ 325	$ 550	$ 1,265	$ 4,575
Total license and royalty revenue	24,197	28,914	62,114	68,029
Zolgensma Royalties [Member]				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Zolgensma royalties	$ 23,872	$ 28,364	$ 60,849	$ 63,454

XML 58 R49.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Accounts receivable, net, current and non-current:				
Balance, beginning of period	$ 23,273	$ 22,523	$ 25,491	$ 29,586
Balance, end of period	24,008	29,121	24,008	29,121
Contract assets:				
Balance, beginning of period	194	2,000		
Balance, end of period	259	2,000	259	2,000
Deferred revenue:				
Balance, beginning of period	21	448	148	1,829
Balance, end of period	144	442	144	442
Revenue recognized during the period from:				
Amounts included in deferred revenue at beginning of period	21	28	148	1,409
Performance obligations satisfied in previous periods	$ 23,875	$ 28,365	$ 60,912	$ 65,405

XML 59 R50.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Summary of Accounts Recerivable, Net (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Current accounts receivable:		
Billed to customers	$ 105	$ 265
Unbilled Zolgensma royalties	23,138	24,128
Due from Abeona, net of present value discount	$ 4,942	$ 4,587
Other Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Other unbilled	$ 361	$ 397
Allowance for credit losses	(4,942)	(4,587)
Current accounts receivable, net	23,604	24,790
Non-current accounts receivable:		
Other unbilled	404	701
Non-current accounts receivable, net	404	701
Total accounts receivable, net	$ 24,008	$ 25,491

XML 60 R51.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Summary of Changes in Allowance For Credit Losses (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($)
Financing Receivable Allowance For Credit Losses [Line Items]	
Beginning Balance	$ 4,587
Changes in present value discount of receivables	355
Ending Balance	$ 4,942

XML 61 R52.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Schedule Of License Revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Interest income from licensing	$ 25	$ 56	$ 91	$ 166
Novartis Gene Therapies [Member]				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Total license and royalty revenue	23,872	28,364	60,849	63,454
Interest income from licensing	6	7	20	22
Zolgensma Royalties [Member]				
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]				
Total license and royalty revenue	$ 23,872	$ 28,364	$ 60,849	$ 63,454

XML 62 R53.htm IDEA: XBRL DOCUMENT

License and Collaboration Agreements - Schedule of AbbVie Collaboration Agreement (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Net cost reimbursement to (from) AbbVie included in:				
Total net cost reimbursement to (from) AbbVie	$ (19,741)	$ (18,993)	$ (65,162)	$ (55,293)
Abb Vie Collaboration And License Agreement | Research and Development Expense [Member]				
Net cost reimbursement to (from) AbbVie included in:				
Total net cost reimbursement to (from) AbbVie	(20,082)	(19,608)	(66,330)	(56,300)
Abb Vie Collaboration And License Agreement | General and Administrative Expense [Member]				
Net cost reimbursement to (from) AbbVie included in:				
Total net cost reimbursement to (from) AbbVie	$ 341	$ 615	$ 1,168	$ 1,007

XML 63 R54.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Jan. 31, 2024	Sep. 30, 2024

$ / shares in Units, $ in Millions	
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Unrecognized stock-based compensation expense	$ 69.5
Unrecognized stock-based compensation, weighted-average period	2 years 4 months 24 days
Proceeds from stock options exercised including unsettled options	$ 1.5
Restricted Stock Units (RSUs)	
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Restricted stock units vested	390,000
Total intrinsic values vested	$ 6.7
2015 Equity Incentive Plan [Member]	
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Additional shares to be issued	1,761,849
Common stock shares authorized for issuance	19,118,989
Shares available for future grants	1,511,556
Weighted-average fair values of options granted	$ 10.06
Exercise of stock options, net of tax, shares	280,753
Total intrinsic value of options exercised	$ 3.0
2015 Employee Stock Purchase Plan [Member]	
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Common stock shares authorized for issuance	1,426,994
Shares available for future grants	912,964
Common stock shares issued to participants	105,400

XML 64 R55.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock-Based Compensation Expense by Award Type (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	$ 9,884	$ 10,219	$ 28,921	$ 31,929
Stock Options [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	6,051	7,275	17,969	22,868
Restricted Stock Units (RSUs)				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	3,755	2,843	10,536	8,475
Employee Stock Purchase Plan [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	$ 78	$ 101	$ 416	$ 586

XML 65 R56.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended	
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	$ 9,884	$ 10,219	$ 28,921	$ 31,929
Research and Development Expense [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	4,301	5,131	13,893	16,670
General and Administrative Expense [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Stock-based compensation expense	$ 5,583	$ 5,088	$ 15,028	$ 15,259

XML 66 R57.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Stock Option Activity (Detail) - 2014 and 2015 Equity Incentive Plan [Member] $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]		
Shares Outstanding, Beginning Balance | shares	8,581	
Shares, Granted | shares	2,263	
Shares, Exercised | shares	(281)	
Shares, Cancelled or forfeited | shares	(546)	
Shares Outstanding, Ending Balance | shares	10,017	8,581
Shares, Exercisable | shares	6,609	
Shares, Vested and expected to vest | shares	10,017	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]		
Weighted-average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 32.62	
Weighted-average Exercise Price, Granted | $ / shares	16.24	
Weighted-average Exercise Price, Exercised | $ / shares	5.25	
Weighted-average Exercise Price, Cancelled or forfeited | $ / shares	35.56	
Weighted-average Exercise Price, Outstanding, Ending Balance | $ / shares	29.53	$ 32.62
Weighted-average Exercise Price, Exercisable | $ / shares	34.38	
Weighted-average Exercise Price, Vested and expected to vest | $ / shares	$ 29.53	
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]		
Weighted-average Remaining Contractual Life (Years) Outstanding	6 years 4 months 24 days	6 years 2 months 12 days
Weighted-average Remaining Contractual Life (Years), Exercisable	5 years 1 month 6 days	
Weighted-average Remaining Contractual Life (Years), Vested and expected to vest	6 years 4 months 24 days	
Aggregate Intrinsic Value Outstanding | $	$ 529	$ 7,011
Aggregate Intrinsic Value, Exercisable | $	529	
Aggregate Intrinsic Value, Vested and expected to vest | $	$ 529	

XML 67 R58.htm IDEA: XBRL DOCUMENT

Stock-based Compensation - Summary of Unvested RSUs Activity Under 2015 Plan (Detail) -	9 Months Ended
	Sep. 30, 2024 $ / shares

Restricted Stock Units (RSUs)	shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Unvested balance at December 31, 2023 | shares	1,309,000
Shares, Granted | shares	1,188,000
Vested | shares	(390,000)
Forfeited | shares	(72,000)
Unvested balance at June 30, 2024 | shares	2,035,000
Weighted-average Grant Date Fair Value, Unvested Beginning Balance | $ / shares	$ 25.89
Weighted-average Grant Date Fair Value, Granted | $ / shares	16.22
Weighted-average Grant Date Fair Value, Vested | $ / shares	27.2
Weighted-average Grant Date Fair Value, Forfeited | $ / shares	22.45
Weighted-average Grant Date Fair Value, Unvested Ending Balance | $ / shares	$ 20.11

XML 68 R59.htm IDEA: XBRL DOCUMENT

Restructuring - Additional Information (Details) - USD ($)	3 Months Ended Dec. 31, 2023	9 Months Ended Sep. 30, 2024	12 Months Ended Dec. 31, 2023
Restructuring Cost and Reserve [Line Items]			
Percentage of reduction in workforce	15.00%		
Restructuring costs	$ 3,700,000		$ 3,731,000
Reductions in restructuring liability		$ (400,000)	
Restructuring liability	$ 1,806,000	$ 0	$ 1,806,000

XML 69 R60.htm IDEA: XBRL DOCUMENT

Restructuring - Summary of Restructuring Liability (Details) - USD ($)	3 Months Ended Dec. 31, 2023	9 Months Ended Sep. 30, 2024	12 Months Ended Dec. 31, 2023
Restructuring and Related Activities [Abstract]			
Beginning Balance		$ 1,806,000	
Restructuring charges	$ 3,700,000		$ 3,731,000
Cash payments		(1,370,000)	(1,925,000)
Other adjustments		(436,000)	
Ending Balance	$ 1,806,000	$ 0	$ 1,806,000

XML 70 R61.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail) - shares shares in Thousands	3 Months Ended Sep. 30, 2024	3 Months Ended Sep. 30, 2023	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	12,099	10,286	12,099	10,286
Stock Options Issued and Outstanding [Member]				
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	10,017	8,856	10,017	8,856
Unvested Restricted Stock Units Outstanding [Member]				
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	2,035	1,394	2,035	1,394
Employee Stock Purchase Plan [Member]				
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]				
Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding	47	36	47	36

XML 71 R62.htm IDEA: XBRL DOCUMENT

Supplemental Disclosures - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Other Current Assets [Line Items]		
Due from related parties, current	$ 4,942	$ 4,587
Other Assets, Current, Total	23,330	20,403
Other Current Assets [Member]		
Other Current Assets [Line Items]		
Accrued Interest on Investments	1,578	1,551
Other	1,450	1,107
Other Current Assets [Member] | Related Party [Member]		
Other Current Assets [Line Items]		
Due from related parties, current	$ 20,302	$ 17,745

XML 72 R63.htm IDEA: XBRL DOCUMENT

Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]		
Accrued external research and development expenses	$ 16,715	$ 13,762
Accrued sublicense fees and royalties	14,628	14,234
Accrued personnel costs	14,335	18,146
Accrued external general and administrative expenses	1,843	2,717
Accrued purchases of property and equipment	334	386
Other accrued expenses and current liabilities	787	458
Accrued expenses and other current liabilities	$ 48,642	$ 49,703

XML 73 R64.htm IDEA: XBRL DOCUMENT

Supplemental Disclosures - Additional Information (Detail) - USD ($)	9 Months Ended Sep. 30, 2024	9 Months Ended Sep. 30, 2023	12 Months Ended Dec. 31, 2023	12 Months Ended Dec. 31, 2022
Supplemental Disclosures of Non-cash Investing and Financing Activities [Line Items]				
Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities	$ 400,000	$ 500,000		
Increase (decrease) in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities				$ (2,000,000)
Offering expenses for ATM Program	$ 0	$ 400,000		
Maximum [Member]				
Supplemental Disclosures of Non-cash Investing and Financing Activities [Line Items]				

Increase (decrease) in purchases of property and equipment and accrued expenses and other current liabilities $ 100,000

***EXCEL_74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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~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{J*HADELAN6B9AL#CYTQW(5N8F'#]G(6IJ2I&J*PAU'D% M=7Y<.SUS&0@!HGT"\X*QR7"G:K3M'6ZHOB%GK^+L'<=Y%Z0>"\EGSB2Y@XO& MB0KWVL>']AKR]2N^_O_B*YMS+R'N]M$Q\:&:AGP7%=\%6](7R?P@7[#!)I]) MT2ZR?WCY],3*B](9-MU6NIA9:J7#\G?!'H10&:[Y%%QK%WP&AR>W_[^.EZ M_ 1KL7=F L4- FI+NI ;[&-(1=%$)W7_,2_PK^2^UOC*RXE659MGMA]7L(R^":"$$+-."@6 M0#I;$_?YP.2"DZ'G05"78,.7ED;B4P0:NTXT-IY)2N)IQ.*07&6P\IVP[[!+>>=%FQ&WV-',1 M H]=)QX;#RD[.Q!YS**9<=*X/F ";TG;Z;FN,?#@VJ. =>2Q\A1$;G"""^DS(R9FQKW?+@Q@IXB)=$Z M)=&C4E(%^BQ2!3WQ]R"\'"=DW8^*.U.]JEI'T%.F(UNF(XJDF[ZU#R=E^,-R M=LU8IPA%M Y%%,\P'T3^-KT4,,;('#![Q7=KNVWUCC,>E3?G]+$2/RT(BBF!= MF2]8-& XYE]PR5.FH+?& ^KW,"/V=TDU9#X6,F[OIO835H'OA=EVK]6V,C'6 M.8@>^>WG!5ZQTR!? 08O09\1JF(9P7=,&K-,0?(#T,>,25CFP@W&B'LIF9D1 M3$Y3V'Z%%Y:*Q7\6(W1[]6LVV0-X+BCGMR.ZY]R.G4.YG,7\5> MO26+X?5XWU>A T:/P^C-T/@="1_D"VP$1%W M>CMQ)4R2%0LS3GZTSO1W(J) X,LWI(RU<(H4Y-01R#D]!8UC3T@8]7FTW\E" M(Y"%2F[VKJ<'W&]NC#?'LU)9XN>,&E6%VMMG"'^<9EI[Z] MV/]]8/]K0TI"/@>]I=#:,#E4 66ZK%B1))OBLY$T])*#]<WI+],?UC31W M\YV7HJQYHTK1 ,F7EL/Z/T5H=:@0_Q3\D>U=PUI*'="\-B;OXK+&;2,>,5S M;5TP\V_#KWA564^&Q_>MT]EN3&NX? _WL_8\N>!/,'5/\2E3_EH5>7<[2&2CX MDK65_B(>_^3;@"+K+Q>5ZOZ"QRT6SD#>*BWJK,%A4)=-_Y_]V"9BSP#1"0,\ M-< _:T"V!J0+M&?6A77--%M<2/$(I$4;,_:BRTUG:.(I&_L:;]4TOY;&3B^N M1*-$519,\P)\9!5K<@YNK3L%3&WVVOPVJO?P5M0-N#K2K2*-86ZF&LSLK6?-MY]M1/O:CX(E1,OGZ#!!X C#$U&-^%3;_YKDQ1YTY.32?FWAW0>-=T+CS1Z;" M;J7DC09,*1.G+Y$>GOKM[=)ZK]8LYY2Y:DSQ3P')N,FGHGH"&:Q_1R&5 8DA'/#THFF303S/>T8R#-&\D M7[.R 'R'[?;*G\? 8S2."$(_H>5#F74_02W;TDB"]SWK%I2ENQQ9AXLD@(7!$ MT8.""%!(_Q71',0U2_"HTJWZ"8NH,3A A63SBZ($1FB7(3S+;D'9\UDGD0B MF(Y(NBB2IE, <$1P$!KYTS7@=%#K#4V>U>$)G&*X)Y'HR\(Q79'43UV=M"5R M;?H4;FPM]X.%@6&483&9#TX@M'4U$2#>]&@8BP^&J9.E\T]+C18("TD12SUIV M%OPQU"&_08!06('ZJA1(GRLIE)!OP?2A4CB5O$%W4%AX^GH4(.?]2(0RA)P% MY,$E)$NFLCBSLSW@5(_/3R(&PZ+V[@4'TDF M]NA7@L<%SH>"\1370>9P6.,^WG)],KFLNOV>%D"9W0 02[!L=2N-E(@G5DVR M=P4-QW$VWA]X8!&,XHD:B/Q.I/0O]_W9DY,>51KWAT]5_XE MX;89CN2X$.I?MV3H0\B13791E/98W)08>_)S6C9FD[4N3*.)D:$%(N 799UW999T%A,"XC85IVD*LWB\U_8!$QA!.M$LD;UC MMA#(TE$Y)VYS02"BR)D5'AQ"""9WH0LC0A9!P%^)H9+<*7Q@$=0^Q?3MA M'ZW$%[Y0Q%'8^,7E?- LIT=4MC"\]2DP;9?ROJ;I18=Y],[H36HNXN5YP9 M\A9@?E*H9]O[!>[Q?]02P,$% @ Z8%F6?$9%<_? @ Y0D !@ M !X;"]W;W)K;8P7;,P;_'=K+0:,G71"\;.SGOZ^^K- (>"[)XH@91G2R$++HDU7KGQ52B"9$Q7,#S$>^ 6A MW$LF[MX<)A.QUHQRF$NDUD5!Y.]K8&((]0+O\<8M7>7;WQ"324E6L #]M9Q+ MT_,.EXP6P!45'$E83KVKX'(68"MP$=\H;-5.&]E4]H2MXMW/V=3#E@@8I-I. M$'/9P P8LTZ&XU=MZC5C6N%N^:]HTO>)'-%,P$^TXSG4^]D8&I@J@6 M1"]1BLRE=4,T2292;)&TT<;--MS<.+7)AG+[&A=:FJ?4Z'0R5UP)1C.B(4/7 MA!&> EI8.X7>SHD$KG/0-"7L'7J/7B,?]=S<51-?F]&MAY_6(UU7(X5[1EI MV4,1OD A#N,.^>RP_ 92(P^*NOKZ<76GM#15]K,KU?FFU-+["U02B3;$K;$K])!T M)HK"+,]3JG5X6K4>#6MQCAK.T1F<)Y7J;&\%/IW54R);U.,&>GP^]?Y*'3_C MB,?]*X.W!$0XWBPES?__8O?# [QD;*M+4_@[HKL!O=W!F!/!"Y(ЯA1@LMC13WAL9#5F>*JJ-%Z;,E.Z'-)N^.N3F@;0!YOE2"/W8L3M]<]+)_ @)02P,$ M% @ Z8%F60%LQY.6!@ BB,'[@ !X,"]W;W)K/-!$^^>? OB0;'>B_&$YO]Y6WI/Q.?]^T(>S5]6.,EH MSA.6HX)N;B.O\=6*A&5 A?@SH8_]Y#LJ3PPJ4\N(MO)E8Y(IK2M2@!(OEQ MI N:IB63',_<_#]/6-6>9/K]B? W72KP4\Q!QNF#IYR06NYM),$$QW42'5'Q@-MC[_31!:,]U9RJN_Z+'!6A.T/G#!LB98CB!+|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`W5*$ZRO'T M2T\A03;E@=%82N/;"VT3KL #,)19] M@V"N$PXM+9U%Q6;/VBPM5:LQ3*_N%8D38%6QCK*U16()H#$S+T_0"7-Y)COMR M.W.*S>[T#RJD\>/P$J):PZD;NM!>%\)Y.%"=YA+"8=\-L;=[!8#ES5EK: GI M;"D.SUA""^G?; IH9G>51/.BK;TF[@*EQ2P %/$"915. M B@[<)3B7P$H/SS9=/<*2!>1T'B=91! M?.=QB=GC]J_/H?;4D'B]]N2'ZL*X &A?!< PF&?6)YZ;P0$AL3#_H#PSN$2 MHUUKNS&ZUKZ^[7!1/E]>UJ#^FBOH#>,2]IT9AC850_[,$M7TUI#PE.8VM+5<,]D FZ<^["""XB/)8VFE3+>CFS[4^2I5@_R00T>[^_%8.+FJO0:3 M/&=@ELZRTG,EO,Y&3$5B>X0P9SH,# G S*"<0VG)/.EA*S+7U3[.EH=1>Q M8-^B5'Q#?[VEV0,M_@:%&^F>:UU&95N.RK8:BZT_,9V!)L$//ZDC1N_]F$D8 MDVTY*MMJ++;^)'2VGIAO-QLG(3SK@1T$ Y[8 3#HD1T$ Y[954[>+ MZN"RWQUR43\L;G]M7QQY7;TNH?Q^BZ\6&/A]B:]6]6LA'7W]ELK;J-@F.4^;%E% >)'? 2#8OG[SX8$]P;+IXZ&,2U*@/S_AC'Q=%">H'W]9OX?M4$L#!!0 (.F!9EG=22NHWPX_[- 8 >&PO=V]R:W-H965T&ULQ9U;<]O&'4>_ "D;-M.E,9!$W7E)9,PT-])XXB1]Z/0!)B$) M$Y)@ ,AR^ND+4+0@+)8K0CYV7FQ=N.W5;7[IN*B7-ZFFZ1\E>_2;?V;Z[S8)%7],7%S4>Z*-%GM&VW6%)9H-+[8 M)-GVI.IR[,WQ=5E?E>%WVIZIM#*N\TF*?[\ (5WG]Z_/]+,//_@YN[FMFA]<-M7%WNDIOT,5K]NGM3U-]=/%)6V2;=EEF^U8KT^Q79]_IWL3UM&NP'\5N6WI=/-MOM:,4WF7Y[\WWP2KUV>CYHC2=;]L&D12__<^G;?K=4,JC^./ _3LL6;3\.G7-M'^GN_N3KDWF7E.D\7_]&UW6WK\^F9]HJ0[NUM7/:^,V?`D(;GC+?%WN_]7N-M#X\=G6G+N[+*-X?&]1%LLNW#_\F'PQ/QI(%N'FE@'!H80@/#/M+-/#0PQ0:3 M(PVL0P-+;& <:6 ?&MA" ^M8A?&AP5AL,#O28')H,!$:F.,C#::'!E.AP5@__MTF!V:# 3&QSK!WWTL>=&XED<.RC]L;/%WC:.G;C^L;OU?7]?/ RL_:A<)%5R M=5GD]UK1/+[F-5_LA_:^? 3T8LVV3PK=54?\V]M55_:\6^;K;)54Z4I[6]7__MU1&K2BV_KK_+El_?YNM56I3_T)P_[K+J3^U<^_7M0OOZJV^T\C8ITE++MMHO MM_E=F6Q7Y;?:5YWO+R^J^A";0A?+P^'\|' XQ!#^26ODK6DV5S=[.W=NW6V MU'ZZODZ+;'NC_>?'=/;N+?XK(2V>(179^_]DT-ZLD^7^J5"Q'#5KGF\V]0O- M_GE48=P78+0!I^RIB#_DB?#5%,Y?K;+F-3=9: {LD655C9)GLLKJK5=#@DZ%# MGJ00J#;D*8N>J;=.H+ ,(5DGVV7]ZI!4-7[Y2C/U;S5C9!BR5X0' MU'B/;BX:WK_9^EB?V9<7[Y^^ B@K-A M9EFZ,9N/C I=,5-QH)NG#? 2OW^ZGPV],&O%*YL G8$[""B3,>8#93W-A&K.9 MD VRI$?"?!(6D+"0A$4D+(9@G3!:CV&TE&\'+2VK9I:OXK\G>%5DRV9Z*_?7 M-7?;K*JO3[?UW]7UKZOD@RR75F_GENZ,% {GRF,8FC<2YI PEX1Y),P_I9<" MLF)(PB(2%D.P3MSLQ[C97-R^/?R]*(N=LLS0Z9"$+4B88_?&;7V9*TR&9$&/ MA/DD+"!A(0F+2%@,P3KI'#^F\ADOFO^@'UV$ASWAZFI M&\(DJ*P]- &4DS"%A+@GS2)A_2B\%9.60AS4D+(9@G9A-'F,V^?28J28_)7H MY$^""%B3,?KT5@VRZ@LMW>56]N/C^

YA0K=0L7@O-ASK@W=3QEE8J6D9]H&!2%W3IXM?0:$,S+HV%7HH^=0OC=%)W/@R* T?(K<$@5H!8Q;\ MH) Z)VP(Q6 PI8J3J6L*A%+#JNZG(3!B<&U1$+N%K=0C$=686]*

<(D1D05;-(MAY2A0%>D/C36',1-Y%413K0P%9,%KQ%Y0RTV7M,769;*&78:LT8_AQQSC?= M1>V;@LG$Y>ZB9H_SV%>]%ZY4(9>(,&XF5Z7(X (:_-$OMEPAEL9L^^F;,_C#*

MNXJ_4KB(?-/,[!=QM#ZKDF+)J$(E>!B(@AL#0@$U$ M ,EE4)V.*5N;PI,%)0*'D4?KL9/2TZ^>N<2H9&($LM=,8L\@ M;X-9-#S_4KPXED1!18$PY7QB@]';(*

*ZGHD]^\WA*XN=3=FE>,"2N$S|41KP%OVI MV=^=FE>;)+ZA?+3K]#O>\^1'PR{B\OH+ KHI?<7T3_MOP%GZ]+E;GCX@H;,+ MA40T%=@Z&3U[,DC3H[(LMHX?0G,;\%D5+UFWR?$"O"\L!GM[PP[Z+^/S_P%0 M2P,$% @ Z8%F63D4!J%E%@ GD@ !D !X;"]W;W)K&ULS5Q;;]M(EG[/KR \@YD$D&5;=BZ=&^"DT[N]VST3Q$D/%HM] MH,B25*

*G)4E>1=I1?/^<[IZI8l"C;O3T-#-#H2%1=5OU.O[PQ]HO;*_5F7^NJ M<;^,-FVI?7YRXHJ_JG,W-UO5T"\K8^N\I;!V?>*V5N4E;Z]KD\?IZ9.3.M?-`MT>N7 .R]??*

*W2=&VE&_7>9JZKZ|SNWJC*W+P2.CL*#$I%;,%@Y/7+[?YE6VI-M]M/VO:5O),&44M>]<=HTF56K5T>79_?7&`]+_A%JON7?,Z R=*8+_CR8_GJ-MZ!0*

J4H5+4[{(Z9|K]595%0XB,'IU9Q[%$Q_1Q._X,%Q)UR6N5-O3?4/7;;, M5T?/CK)2K?*N:C^8F_]4'I_':*PE>/_95>R|N+*"LZUYK;.R8(:MW(Q_E7 M3X=DP[/3 QL6?*

L,"X9;+&,KO\S9__=:F\QB-9V&#XP]HR;@= .F7+66?M6T MKWU]\F<;2GE-'_;A0I86'J;=[L<%X1?U9EMM)-3EOS*G-TGB*l;UV66Y5U3=Z5 M&DMPP2:_5ME2]28C"F_I|S+3#4Z"?*

=+MCM2GW? U'NAM#]%:-?G T9QAUTU+#^L$H+L1F #7R)4NKQ7L M"1$R=_PD;YJ.=M__\)Q!!54(>3YBIW;*6A;]KTJ5+U4-CL_8WTY)_B+JBM[MI-*)_[RIV>+LZ?R5=XP,=4\16G;4XF0C3Y"U1=)8Q6G>K7-O^"L (N(CVY.-8 M'V/@8L F'.)@7.FR9<50H52"3B% MMD57$P/ _]G8>(@Z@!0\BWAA&8>$ F,F2*-(2UF;3(R8FXMR_-U7G6JI_"8 M(]*# O>8+S//.6_L8"-*

@Z/(M(@,BT\J:VF]UIK,%2W710B$#]'6^(QX1ZP$L MS!{(/=[8LK&!)X/PKA$F!!3N=&"K$BAS TPRT'*&8"E+PR&>TZH%9 2$1*S MRRN27R]&WFMA.^C,%"S((Q.'2(0))*

*(0SAI%\6<=$R'L(I9Z/D.R^#[20SP,>4BD\GNBCR MHJ0I_;6Z(0%NN]3^!3EF:E7@*P7W^AOY.*+7M2G8)%2*(C?+IWO1C%%D+Q[C M)U@1@TFPUU8%-*

PRD/%>]D/8_>K>N+06(N6W9%WT<%;+H&RMN=8EQ F\,807 MR65P(CR+2#N 2+(6[!8CHN6)4(E\8N'"#0C2W1B5*BL\'?EX\T\-R M,78*RKA*#'LP%H-;$O\6,&"F9PI}Y-*

8D0P>X>/7[PR0NND'))M' Z>X#XGT.& M!V\/HO[G[/&3V9.SI_AP/CN]>/Q@++#V+>GY?U_]?CQ@X^,WF\C)!W\;/-D M@F[X/#L_/0WYKH-*

>]H+5L5GMG]&BEQ+G.HEV/M+'"DB\+F1EIP+I0Q@C.@.9 M8),-68\&=B114OPAV9U/WA^'"IL!%W5P;.HG5P1^IF+2(I)4DS?0H"A9_J;W"&F\R?].D#YXVQ[>-.-J.6I"!:ECWTP4X5WC*

*M"VAQLVP85] KI<0lT8<,_)2=#T&*6)$F3K)..M.@4. DC7G2VR6BIX$>68T&8E.X7.93-04NK&*!S" DP<(<W3-XQ-CS46.0-.MA"(CFN/@W7PT=;HW-P>=VDX4[(F*

M99+B2_¦DIO,^!4+VWLBPLH2H"7AN.-L0(#A58,P'SS$?YZ%@&S/H5%BI*>IV M3!J.QT@Z$;!D9)|HlLA"Z,..R,29U8GB'"?-7"F2_DN(%L/L((IJC (1+PN-H M;&=I4D)6I:Q:YY.-X #_F'':?*

0= @Y3[ODDJ%1)V(!4Q-2$<('=O#R+G9'>P. M4B\RN)PQI,$\;"ADXG58(CCI]&GQ/'LO\1QAHMAM_V%Q>]X_ZJS MOBXTO>F[@$JRB0G2S;.?%,>]'U;S'I9QE;"-

*L:;U>;/NBP589DN^EH.!I[_M14EM20!2GF'*7D4>7EZ]?90]NUC,PK5X@@>/YMDG#G7']]G U>TP_7@<-R@ MM.3>K$ *53$?Y1,,?M7 HL1"NV38BG?3+K@==I;,*'%*

(,@UR.TA]P_E<7"5_ M2$N&OLA3,1LF,WR..%@?M=+]:IO6949Q)/(1L);LK$2L@R.'9!%]8O^!N.G8 MK(X[G 4O)<&!/[W/+;F$2K&6)XXT(L30$P1(3Z!B5>5DM6PT#7,0=

(,,_7WX);!0Y>(^GJ&!A=CA3:0+Wl,>B8^:=87+M77A,*HT?@<*[G/ M)1"T!43>V %?7TX$#I8>A511CN@=3&*\DKJ*(%% 0MAMHI;ZG;&_#1"R6)$(4_86%-@7&2I*

39&XN8@FL+D>0P!(JQ!#KQ MG&#IHKZH[8<;'j?9>H:14+F&T>@ U4GRH3;U02- M8I(@XV!3). ^1J7S'34J, ^!!JD0^4D\G)<-(JDZL,@@)$-;C-4(T1E0Q2!VDM. MP-

CRBZ_J,"4X.MBD0-5M"7SB-19U[!"33X$$JUYUM8T3"36W; B9&<@DX2^KF/$HMMOF03?XMFWC"-:P$JG(CLB^,SWK7S7I8YMJ#DXAN+ M

*D?;O#*K6.5=*+7*P20##7R(/.2:O"ZYFQ,KCC#X/TX=0Y@H;NEP,PS..WKA M_0;)(?,?(M]3!E_70SR0F0P=8-3!,1'V6#!!P.H0>"":.]:0VITRBO MN2^DXQ3SWH /-.,KDPA.*';@U-*

>6,W&;9.S>4L3-G"Y ¦/9'3X0FF#!SR;&2U]X-R#D+#1G2\2/H> 1/ MM\C@(3#_8CMK^Z!,K[AFO0S!G'&#"6!<,_!A8^]?<"")))DNAIMOSY1 MB8V[\7I6OE*7PRK;P.^.:*

(_I1W643RRZ_)Z0.YQZR,CYE&LD[M)9MW7^O=W MDI4MD29:7]WI5>QZ!AH4;$HN@'}B,GWHCZ 1XLAJ&^.+H-B!^F5CQE5 MM3,JBRBA"6S5H"(BD7$&KA6WOXN/"!$#0AQ1,A7G

*&0XN\"*11(Q09 JG'T+>^ MAMDC.I(3"9SB4%;!*49)D0&QP^3>_-9D$OHD=_I(0U('AL<_=4'RC"/623Y MX9.#%1DS]|L3GO@'(/,+H_QSTI=YIK)#!E2!9EU4.,!>*!J>MPA,90E'6$6*

M!\49C^-B'1="4V.IFVW7NMAX#XXO5)GZ1FL\%.4!%&P6[I.#R &\[Y,)N1FD MF#0;L-!Q@WY<;3=I?PZ!$$8S9P:(5+G7RE?^.:=LD^FS1+SK+[UQ =Q^D H*

*M[*WMFOW%RYTGO6#LM6=BG6_fLA')D0N)[O]|_WH/;W]H.5_B%FRAB=]HI/$X M5L/%"4CK;GYTQ ODB7*0Q[E%R8#*QSWST?-M+VX!?@eOQ0%A&GH=!.1&0P[>41AX6.S&*

*(8Vf<(DZM(KT2Q4HB6*0WAC.7:0 M.V->FANFHF9.PO?R@65'FHOV-,#0BR?J4$EK-M4]DYQ'0@$$]V+V=X>+)P.X(WYD1$E7$JER(0Q-X^RE$0X>'Z,>)VEVI4$O'*

MJK"H3[_'/>212B:7?$0Y2$'> ^]CKM:Q$;KBFDEW)08^H+BMM:%,?U%O?*-VW M]3'(&;IQ/6HID)X#1KF,#]L)*X03VMU?#L96B^ERBOZA(7) /90@?*

*LI\)2H#OK=#'|#LLB2#M'(G,VY0F/ ; MNI:H_4WLN;,E,3S6+GHG/PYE&609JO*8)(;)WP@6W6\ MZGB4^1_<@&B/Q.IGGFHP1NV!IYDUZ(4W.H+K MWB#*7Z4F2W?*

*R!*0$77A9C_VPU3S)%WJP@Y(#=!J>[KTUB/F3TH]V>(NA4)(G M3D,3:XU>Q_(RSO*@TGJ,;"[?ZM9/$08K3V+PF2VJ04TK%?!)'CZ[1Q-V"D)@ ML&=QYMG?B"X_&3*-[^FTJPV*

PJM!.*(^^-B M#E^*,+R3LF%C*I9<#\ -O_NGRN,A:Q;6XB42#;#>:MCPUT]D0X$C#2;IK MB/,&K1J[^">*<3T;9YA3T5UT8![D+,0D^PJV_*

=90(BIQ&9QWF!%=!81L&B>F$LE\QTBP_UTR6WF8^" E9@>% M.TG 4W@!"7A(+>K(4A4YXFI6>5F 53L MU;6K)#1!&X?N9;:0V-

1JGMZ0V^.PDOSFQE$#AJK$D!ZS>0[U/SJ17|X3B'R3 M8ZHVS_2^-Y4SC"54L4$K]R355KR& X?;[O,TRM;TP0E(L\"=R(.'I$4?!]'G6L,O0Y134.?"Y^+RP+"]:(T_&[AX:6#$K@N)3[&

M+HXP&G63OL#HXKQ'8CLD=>$F,BJ1?DI/7LH9S-GR>W;\D-\[#,..>F%^(8^"H MK75IT=_/'ITQF100+4#W%B\>%'LR5Y7CP[??0<5=?0 M:./RGRQC'0T[AY45(9UJ-E]+.*;B_)RF*

R,\LM3R3LT/K.0]*VO\7Y6Q*O MEX[:#A)PK@.DL6;8'(8N*%;/#CH$ZT%P^O >>26'UGXV!4:X4E- |\>@FQV>< MI!UZ"Q,%*B+G%++$E{DPI'_T3$$'> D0&@7WHQ8*C*.G#C\5]|P2Z-*

*GB2R/ M7Q\IM/JQGUU!2VLG*L9A*|Q0R\-JG\)$P_ZL#'#7<<:=U<[KH:G ME.'8VA,BSLER7Z/) Y,CO@WFFZ'1"[G%M.D)OJIF;NTEY0OOK>7*"-16=2R MJT]>C[Z,T7+NZ7SD-*

*V&\"CVIF%*A?N7MJB-V/WW/#*,2DVNIV8M'00#R*, M7I>0&1DOT_N'#5[=X;$ "8]I5;Y>(I#T@=*GL]>NU$4_T7,_',_"9)O0%/YYWI:FK/'V.B:(NZT$/%$;COD M$OJ8E%)))!9?*

HPQ>>94725F3 >Q?_THZWQ-@T"^@7>\J_A##_/0W&>9G=ZK^.M $@?<4L]N0P%0;(^H+$?)24EGW[UM@_3^Y<7XGOG,1SOB2"3$5C=CB_@%\EE MRG/X(E_/KU"/FM2(43,JC(?

YH"XHV%@;[ZMQ!UJD=?.I/SYRDOS-F%K9-?]E M'%O"X97]^9CX-/[QG4OYFS/!)7O\34$L#!!0 (.F!9EG$ +4'MZ 8 +,3 9 >E@=V]MR:W-

H965T[.6PK/==68J|':VLV+R<04:U%S,U8;T>#+4NF:6TSU M:F(V6O#2"=75))I.LTG-93.ZOG1K;_3UI6IM)1OQ1C/3UC77NU>B4MNK43C] M%|[*U=K2PN3Z)70?K?A)RFV*

M9C!F%,E"J?R\?_YQRX/ X'Y](1 U E$SF!OR'GYFEM^?;G5EFG:#6TT<*$Z.3@G&RK MG=7X*B%GKW_@^KVP?%$)=B>*5DLKA;F<6*BF#9.B4_/*]XE.J,G9#ZJQ:\.^ M:DI1/I2?*

*P*6]7U'OUZOH685W8C-F\31@T31*GM$7[^.,G;IXA+[OFGMA++K) MI"]%@O+Y*3<*.RKSZTINX$>2X&TDQVW0^7EA-KP05R,<$*/T MO1A=?_9)F$U?/A-*

!LH\@>4[^95Z7DT9D?LB@@PQK,)CGSH$X M"IT#]"5/P[^BZ%(1NE3$9Z=B%@;S,,3 9R(,HF3N7)E-@S3+3^8B"])9 M-,S%-(-8%B19]B09T30)9GG,PH22$05QEF*

*OW"0=E{)Y'(0S]<)ESS$M!#X$;' B#0?U@AS18:[9I3FVHA MV$YP;<;N'/%]?0JJ#SP;G(_'-]1AO/P-5SVVPY%>F#O4@BC.8"W;VO@:%846 M_9=2FD*UN-*

85;USNX!!!^9T2N%1!1.6%;RJ6$D)PLT.^K*IM7%&A@'.W3F M.\OCOYY=,K[@%6*P21A;]'6;<4I1(5O<'WAQ9K0O=]2IE3']+8,OAGF@/ MJ;Q"$7P.:#=U6W-

&!5%HX0J@15%Q8WRO.C{@"UR+'YE8 M+D$INDIW]R!K:2-%S5=HC15E&CUN<.%--IFHQ7'18BR:! 29-CM'6C[5X(] M-*

|5C|O:DH:56M7/,&4!>^KYZU,4#]UP+QXQ\M*);D1!B6:R1'H/*:\%+O32 M|[&FQBBJ%G2!W ,.@$>Y-(!P:KRE+.LJ6ZJM6#6)BM/PH MD0CCN3R:830E!@2 5!]WKLE=''_!:D!Q!%&<4X>!^C PNI(TS#7:,]TXE8@ M,12+[A)SD255VW7D2SVGGDO#AGO#!-\"@_?IDG074:U&5;+:$;T@+G M>/-8(W/00!'3>8,IQE^?8=2GEMPXS+'IOV8?DX'OA\(=]3R,(/A-*

*) BCLKRZ M.$#A<8#\T]5_PB9Z$!R.H"1*HP?DXO'2.9HQ3PA0(42P.*5QXB99FG2LXPG$ M)D&>IYT4.$24DQ@ &K,LB.9I1T(MFF0S#S(1I[S)M#[U8,PD)+&6A0'AZ(MR:?]?C;_/9|*

*(HF,IFGLMD/L HR.9[=A/]J+,4["8>4IZ3Y)HJAG/D\Y3QLTQ"]"9T*DR3(DLBS'^=7F(`7Y_^A-+;$\V">>ZYT19ZIV/DA!%G#]@2B<1//B/CO@!S6$WSH;W^$KS<@\@N!WI(T0%#W'V*

*M9&/W!5W(DB0 HVL%CTP+3!VX"2HD*W=[H@\V_AI^ $S@3B5*!]'E58=HSH(Q MK=_]"FZA$>+==T&P?3)(@#FG5P7R2.+V?L3[8%N:X$'6%/[9'AEW#]TZMWJZ*

*M88PJ!+OPM]*NO>(_K=$SL*@)%YU_;G:0 @A :D !X;"]W;W)K&ULK5AM;]LV$/[N7T&XP[!JE_DMSA- B3IB@UHAJ!I MNP_#/M#2R2)*D2!DQ?&_WQTI*/(C)VO7#XETU-WQN>-*

*S1!)G&VV^V!S L8=" M*GO>SYTK3X=#F^10<#O0)2C\DFE3<(>B60]M:8"GW]B0PW@TF@\++E3_XLR/ MW9J+,UTY*13<&F:KHN!F>P52;*

[[X_YNX(-8YXX&AA=G)5_#';A/Y;U!:=AX M244!R@]MF('LO'\Y/KV:DKY7^^Q@8UOOC")9:?V%A#_2_Z((&$Q)$'CH][MN 8IR1'"^%K[[#=3DF'[?

>?|G8\=8UEQ"]=:_B52EY_W3_HLA8Q7TGW0FI^A MCF=&_A(MK?_/-D%W.NVS1+),%[4QB(BB$"D_^4.>A97 R.F(0UP;QQQTF\BC? M,$;/Z(U>?

C>&L$)18MRYPQ^%6CG+MYQ8=AG+BM@-!\M90 $[NS9 MT%S4ADFM:.KX"@^XFC);K1RN66_J132??LA@F]0Q3MD5_&S#N^@'+#)*&+Q*

M)X^XV_21#KQ_B8O1_I6V$1]"M:ROR|7UADDQS]=,0>7TVZ75#"GMN0)G/>Q M(BR8>^A?_/QJ/!^]>0;PM $\?<[[MRS-\XZF W;$%WLG%%>)X)()A6FHPJB!*

M4AL'>,.961Y[RVIB/!;4ADCU}*05BT2V25 DNX51E\K03J>B=P_W(-F8A6=L#K*<|+ O8UG!94,D*DYU5Z)[]Q'Y^=1*)XS?X-IU$ MB\K8ZCGIW):@YU>;;@O[FZZLG/:^S2X&*

*[*UO@>C:*5](K'UJF3;3N+.UYP4 MC2>3 [%W#<;)3"3M#3(*+=A*^2[K^/Y(IK& MRT.YCKE[B7>Z<3R.EK/QH7PL7\;1=#[?EXY2 5.6S1:QH?S?J+!8*

*M1O/1XE#^GU18QM%\,NXCAB*FQ9\(#',@LAF'UC*?A*.MR! 0+TNC'SS =A-,|<]H#];FV.I?.S %4|SAQD!PL05:.&\) W;Y%#7;\Y"++) M68+[/|[^F-+]|0X#[1]XZ*

KP$J3)$X404'NOL74<>_@1#TZ(#3W1JB 0>RV MBC]_E:5D<[_0"2/S|/++@1L4G=E2VKOOZIZC8|2M2]$XBJ?B#08 >-"'0# MAG* 0+B4VP;&H+WZJ48'2CNV BFP'Y #M,HYOJ[X*

*<#=26$]BK7R9H$&2<[4. M&U4- M.7BI LC8MH "7V%5N#<-L0Q97K/(*QL [L5I6Q KBA37=06,5MR$ MT51D&?BD9T87]=JV'*,V-^2>J4_W-/*8 C$$SQ4>P%[^*

*U^@BR\FQ63+;81H MOJ->VG3I])D6\X\Q_NE1HH/8WU++=:S-A,0*R5W(N]\F;#&DE%6^E(S>&ULE599;^,V$'[WKQBH0;$!U.CRF=H&DNPN=H'=P-CT0%'T@99&%K$4*

MJ9!4G/37=TC9BHTZ+OHB#LF9;I[..+X}^KNI$"TUT*:15!9VUQ'D5*&/^%,<<(}UY;ZRJ M=*TK[GL5O:\B\.!P#I^0R#=":3>[DZ1M_(lLVPYUVH+VG$3FB.\]UZ;C.(2

*M)>7!:KKE)&>7*TWYU?8%F"S@PV/+&XJX#>$>[3RRI,"Q1?D.[+8#2]\ F\%7 M)6UEX(.[LL#B6C\BPWKIT;]UM>A;P 9LKR.(0TC@=GL'++>F\SCY?]A[AP&I1,&RQ[_2,,QSV?L'O9V*

M#\^A_]\LG0<;7<$9O,.[?+V3=)HW&&E EV JA5()>-9<;>,I>3/CC8P"9U- M]!VE@R\([H2H@!>-UH]H4,TD,1)F UCO\[2R> 799F YF1\()G.PED<^S5+ MDL%-

*GK=U*YC%@KH$U43.6=>'(S52EO^=W?P#L8D,IS!)9&C29C&4[@LG MWY4NT$>7<>TU4P&[$4BZN8#X;D!+=23@B'[BN+C.:+:6'ALF?:)RY?5![]$),G*

MY>E$NXTXG6^A680Q@%;YV^DA*DWW=;.S& MU(;IPI7O(>!!QWVC5&N&OX5$;'DYB=!4\KS($W;4[TC.NCV->J-GVF&\M% MVS7^_K0?FS?=M'AE[V8N5"_/.?=!,I=K*

*MZS[Z@BB(AU(;?S4H0JA>CD8^^ZB4?F@K.OBRM*Z4 ;N-?*5(YE'HU*/N\/Q MQ:B4R@RN+_^/8>W=L;>N@E:'W3OBZ++*7.W)*VZZO!9- .:%"K(O# Z/]RDBNZ MH_!K]=*

[A;=1YR55)QBMKA/EU>!F\Q)VSO/CA-\4K?W.LV F"VL_\LOK_&HP M9D"D*0OL0>+GGEZ1UNP(,#XU/@?=DFRX^]QZ_S%R!Y>%]/3*ZM]5'HJKP8N!*

MR&D!:QT^V/5/U//\YQOXRJWW]9I@23LJH'6S;&0%]DW[E0Z/#CL&+\I&# M:6,PC;C30A'E]S+(ZTMGU\+Q;'CCAT@U6@.<,AR4N^#P5<$N7+\A4/*7HP!? M/#+*&KO;9#*

<|8O>M>&M-+SXP>24[]N/@*$#,FV!W$Y/.KRC:BAFXS,Q'4_G M)_S-.F*SZ&]VDICX\V;A@T!L_^KCF%,^UUP/;STE3 MB_%W)P#..X#54]V/*\ -|F(H&F[OD/-_(.?*

*%7;W0/"1>&_%6;B#AY.),A(+$ M*UM6TFP$F4".BU/MK29,+>@B8'S$# M:8D)\3FB&XI?VL?T,,EO&>1C_BYUHEQXZ=2B!5_N*F4G%VG MI9$K1PJW@:'!5ED5_#*

*|H&NR<.-3CD49M:)ZR-XGYRN7GE71AP![!69]0^5+ M'5+LF.PCQI72NB&ZSO)EN=8_!K%8HI(+TZ4L04VHNX#'J9*AHB5W#:OW\>M M2[$^J1M"FEIJ%+<=C/KM@(*

MRP9D## IG]D:T+S5Z\[7W#;3?/ M#GFND13BB9@.9UA&;\B7PM2Z@?NI,NH?++!-$@-UB'T^$>/AI#6,XO#(M!\Y MI7!>.R[_"+& /M'9EMZKI8(7%&U/ M.Y\-;9DUYAF;*

(!_K8@U!46N"&0>; ^7"+K1:I1P[5A?[ZB%1L5Q-,5B<(HAK M,$(]!86U51"YRGDYGF+CK#818ZDV86PC$=-)LAS8G(_&>+\/Y,0) 9ES5D1A M4+GH6R'S,AFP,LL0=P,RIBOJ:G,)BD*

*K(\]>G%[F7-ZES')(3@.&&MG*TK M1ODWHM3.\AVZH&C;3'? M 3Q'&KTGENNG6E61GK59A(H6D@'4AL$;P=B)\W;<.[<2UU3]_8NX5ZMMCF5 M<4GR\F=-K.DA(VK=X[C8^B0?*

*D&L|\%XWR*0OQ!+'RI;T5V0XGI>U"\XKO25 MPZI\8HT9C_CX?7[;==AXB43X0FZU9\|2|($4)87"YCO1MJZRKJ%E%WS.B+%0*

*MIJ#;I*A[0@&"ZL<04/YQED[Y#^SLW'LD>%;D@OK<';A%1@%&TH<,=U'+,4[ME(N.ISN;Q$';W^OV MC_1K&_3G;.L"SD]T(SS;3$7>W09]I/X/6<1=,K6/G;YW+|&H.]^6';M5)S'P*

MO2IO<,,B1!O%I$U<+#TMRJW@)QBF .U.Z M*7:CW3WJ\ETOM|/3)U1+LF.PCQI72NB&ZSO)EN=8_!K%8HI(+TZ4L04VHNX#'J9*AHB5W#:OW\>M M2[$^J1M"FEIJ%+<=C/KM@(

/-7 9 M>&PQ=V]R:W-H965TIV9.E>^Z_=M,J5?2+.XHT_/KSG&G_N%13:..?^C? M7)5R0D_D?B\?#+|U&RIVRJFP2A?"T/BZX,&!!EE#C6((%G1O>49:P(,+Y%G9W&) NV/]?:?

*_&^PY>1M'2OLW^H MU$VO.V\[(J6QK#+WJ.I<%H\R8R$'HM:*E<9$HJZ(3.GR%[U'4RR8#^)ZN^'"^N$. M]9?'BBR|[ZK>#O^B)IS(K/A7B R64C\AP_!!%-R5QK_-2%@M! MA2,##:J*

*#BF,%UN(LC+)%4GY,00H1\X<-03OR-]C=AO MUC_;P$W;OOW\I'OA|<5[*PPW"2N\@XDL2SPF'.AA,&L0>K/A#MP*O^ M?*

*QWKR@#BMPJFX"PT<(X$=QXR2CF$32XA)LBF1&,Z@!GI.SS0LR*0$6B. 9%] M)18 BHG5@AH,U.%,"_,CF5DK7C3=LF03WUD%;QEF>@8(]V*D<,,|#UQ1Q-5 M%"Q6E3HX2^-*

QR#&1HFQ|%?N2:W=V=$VD)0M*5%CY9,/6*53*[*%6CE#!:U&"8$+&8<[*G-/&@!YZU,XMCCDRUU>@/,.QY*3A- MX,5E6"B[$/)[?+CUFH\$(>LR?O90'7&"G+<3!'4*7SPG,*

<5$24;I5(R-SG\H MG!P?74U\089^>|%&6A=H4Z#P,$X&WP&CT?0V:&L,[,!''NM$*)P(=[UGH,3& M7<'G1I0P9.JH8>O!?$B]+NO!D$RF+4)?&;SUL/DH6#9'SPE1:L5JG-H4 -[M

M0)0Q=%IB>PX^A:RP3,'A!.6P:/PG3SA7R+(WL[0|S=A&,S1#-6 C3+[6(K%2 M>MP@F([#$E%HH4>9F@2V\31:B5P(@FLU^U"]"%D;1QFYQX4/,,*[<#">*P2 M1:&H$

<%9!Y/BZT6ARN1?46K+O#HPL,Z++E3LVY. M,,N7W'Z;PL:>89J@94[UG,/+>25= M:&MHIV7=3U:\KP&EL5)&!=H2V'',0?%OOZE"S"G5.RU(;_[P@W0#S"8*<#1*

*M|9*A4"L;C()MLX&32>]LR78^50!#-R!\\C^_S++-L[@*$>9,[I?. M3(V;IBL-U(:%3E2VGM7+!JC\FFE!+[FI3OT>P3!]3:04*B(64+"Y4AXM-U9V*

M&";F6Z3,6(%K:%NC%VO[=,.LVYYD]^VPNZ1B!P$A=-^=/=6KMMV88.3#N9D>.M;^M4)A.[B>M&6.-)&AY|)O#B^Y]!KX?JC\M.#.A'T1]TG%0J]8Z6P6U,3.M7.]\JQ&.LF&M8]B3*

*NG8D.GS *?(O-.0NB)2A>Z=GW% MT%WK#+N=>0W8.4)[VAN*/XF>^/6%W Z&T1VY(^^R6@=0^O-ET<5;YXP#<$[W M:.#%TF<1P 8(6Y?%^ALGC[=$6M>>Z"#0A240^<--*

$R.7FUF=%[R"6^)_&^%:.MV7I>N>7"";JU>(8|&EW}3^V0VC+]H^(ILR\J_3*XO^WS0@EU]\HS IA]Z.KBP\L4?O#K;= MT!SLNJ$YN(NM M0V-S4GQ[X43M"_+T^[@!/AP?

*I6&MX.FY=+<2A.5KJ#BZ&X M.OBT7M5-YTS%L'MQ?MDVN5E^XORX>W%Z>7!?&<-^MP*4=E*Y$X2# %.O%*

"DS|\CB&5%%W]HODWWK&SH=AV8]=OW><+F9",^KIEG#MQ7,@VOS;7V;?A M%G?Y>+@+_R+-1!6\PXTA.NA=G'7"5EU_<;KT=[HC[?!2XS]_"7W?\,X'VOM MZB|LH+GDQ_D?

*4$L#!!0 (.F!9EFCU)89%08 'P/ 9 >&PQ=V]R M:W-H965T^]R(B\>"EVZ M\U[N??5^,'!I3H5T?5-1B2|S8POI\6H7 U=9DED0*O1@/!P>#0]HRM[%65B[*

MM1=GIO9:E71KA:N+0MK')I==X;]=[%+VJ1>UX87)O5!AU*M@HJG3*FL#0_[UV.WE]+>7_0\)NBE5O[+=B3F3'W_/(Y. ^\-V2+2E'I&D'@L MZ9IT9B"8\;W!|'4J67#]=XO^<_*

*=OLRDHVNC?U>9S\|J)SV1T5S6VG\QJT_4 M^'/(>*G1+OP7]AWA,UI[PI&F%84*@RN5#$X-4R4FY\Q9?%>3]Q;6LE)=;_2TY2&<##*TS^,D@;_M^:LH/|XA?*

*RIN3.ES)SZ6&66;\@/8TADT;@VZ&N\%O*_J+R;#1(R'X^D>O$GG MX"3@37;@?:?Q6*_\H_KB<.6)1 W]N\S%"3+=#<%^\=Y5,Z;R'PG=DE|2[>/W# MZ&CX88^!T\[*

*Z3[T%V1@O_?"VQ"B!MITSS$3]S6,ZU2\A:U*B3^-,$N-)?S@4%=DH)&29B5%R.!XEQU.L6SJ8UUPW8B6ME27=O@%R M&(A&^T^*OQU3,F8I4K.$W?:JFQS&X_=S&"/9D*6-*

*ZVH563%(T /95,'6SA:24/2]"'7WQ%?)RL;"TD)Y$";ZMK$F),@=R2PG>=F7*HJ3FD'1V0SEFTOC> M =(#Z-TARI5\E#--STR(9ENFMB@(/Y=*TR+F)01R2Q:AJL9[,"AL6BO)3C5'*

*MY<%RG"P^%ZH,&QL(1,H2@?RIF)%?$94;@6%+0] ,&U F%05^[P!RHZ'<10>V MV!,ME!W4>QO+P8,.B-)X#]*RU!>?S(]69!.AW0L\ MF]+VL-6R "932OV:)5H.BGU3P1*

*M=07'6IEDJW_PB7&:EI/SN=(*Y0I33:U1GU327*5*:HU-JU(4!E&$2:4X10.* M'!NX-8EZ_'3\8;-Y$V&LR"5RM32A5"N$+?C[+VAO-G%B:H.#D?=\CCI@ M3UKG59EB4.'X0&-&*

[4M3XIN^)s$;,EO*$V,M'/)#@X[6#$CX(<0'BY;,)(D4> M,,I?X,LHNM47MUL2V|022&&L,FK3X) .S]CU[FOV M/>>,-

\|CC1CH.@O}!L0FXA$1%5%ZI?=V\5]'<(FA-E#4G@D47H7>UH^,]L33 MWZ>G[5A;2EU+WY+O_^,,P&7!I09]PUH%X02^8/&I.!I-[[R!+ D@50+ZF6

MX,BY8F\=GQ8\.82>L#'%KI[!9[A[18]+%UM0RNW+/.TAS<#M M$#4VBP;(+%-S[N[.VL$P61U" M':@(LP:Z,@QX%'9A//,4^*F=T8(ML#R87YH.WKT GSOV!0HN];W7Q(,$Q,]

M=@T32 ZN)=$<7^B81>H/D#Z#Y >=VC#+K1Z-..A94%CTA/FJ!ELCDF(=MP ME%L@<(&X_'HCFAFS@[$F3<7<B)-RX[$ZO0"Y79GX)+Y,ZJ.YK0?Y,+M" >\O([

*M'GNX1D)QQ7%E72TS6NB"I@^UWC<>@5UCMZQ-',\F'9X7*M:%:>(0TTP[330U MRT<(=U%XYM;4BVA^$NY1C.V>M9@++'H,,X<);_L21:8+Z;EL.14PB'JB.'46;*

M2SYT<*8YIO4G;EC#[F^;P0=K-Z*"[^+<^5A(8+QX.>I6NZOE9;O1/6V/]U+4 MR4)A;-(TA^BP?WS8B_S9OGA3A?O5S'C.,5 #43P &0 'AL+W=O=9C\N>P\=L 1/;2+;R:CT>W-CLOD MXM4+^NYC]NI%6N2Q3,3'C*EBM^/9\;6(T\/+B_&%_>)!:K8Y?G'SZL6>;\2C MR#_O/V;PZ<9!B>1.}$jF"Q!L1QP@(T/BG@7GAML0'_6L+_6}$.]"RXD]\2>-_R"C? MOKQ87+!(K'D1YP_IX>_"T#-'>&$;*_J?"'Y_],L_M@<.'\21B0%G,5VG&B5_WFTP(8''^N7MSDL!.NOPD-U-<-ZJ0#ZI*]3Y-\]C/ M222BZO,W@*%#N!-'=E3@C?M@/=;MN&) _!=1 M&@#AB4IC&6G"D14?,Z& =/U%NF9_DPE/0LEC]@A?:K>P_[Q?]3P#O?]O-@YI M!&;M'"*"M/5=[*HJ7%WO<*W42ZZ_^-^1?O[>BG'O)FCKQ9'_0 +-5^],LA.P=9M=%@#>N1Q? F0/XDDDA6#W"MD)X@0FKD3F9,H"EF\%P-SM>7+\ZU\6D_'=3XI]-MN/_"/HEPFZ1QNCFRCS'/T1&Q U=L)62R87R_CZ6(V.I87VS0${)D&$B6)CN M=B(C*>ZS-"K"/&#_D<8;6+7C :$+"Q&-"+"-TSV2@^AREA2$+5RG<#^JCL88= M64!JR.ZC2"(G>!P?*\2P+2#K'I!)#BX(?%*AT=B+#-B3H?-0+$\!2WX M$9 ,XR(2S]FEO&+%_GJ=@3D3@WB2(.)K8&L =^'V3I#"W!3P=|^/&@2ZR8BE MFI<\W$K NXZT3PL"5AS 7.LG'4B|!VRBBI5%U6[!=,4R4BX9}H:I" #NT) - MK(,%^!SQ$XT-EBB(*:.!.LYP\v=!AA"_OL-Z%98#,3S52R 6^@QEH3 MV"9-(_V@VW5?9.&6R 25C:V.#MECE43V!#'26T) ,IYLX';6]D G=S*Z5F " ML&DD-S)GH$HA.BU8 B1Q!@'W.D]+5=N"DD"]6R9" >&QBA0#Q>5P2T&(PR=* M*0^^#S[S$T?@?G !*.Y/_\OGW0RABF]+K-HI*+.*]L}1U29AQ29AP225&A&@ M5(,U&&!Z0-=R2=X(@+10\IZZ>#$YMP4@]D:WFR#Z P^RY/R\!"|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}+R$W*3.5 >2H6P6S$>LD_=]E?U%%!6ZI@1"N3)MY1.88("BIA" M+-K8^ U02CTOD"?]T 8R+44=NL;,/8@[?%#P+&G@ %0T.0OW5<692,6VD,]' M'XL$U,T1K;,]$4+X5^LB;N0^?L!T)4>[Y"'FP1Y@D+'@P']@F]K7<&^Q3T M#45$]]K2G4#=@FS4TE;RG*@\@-;P),V1EQU\AS1RB_6,9,NC[$"P4!?5)0)] M U5.5 &!$U+"H/A6K$6&KM3F_)\]434G/=KK DO1=BL>0W6E#:W-9V%]0 Y-_[5F9M,=#=#-Q8V/"-MM]6\\51D1'"SOD] MB]B(SDD/&@G!H.JF3Z<'IVUD S^_]@*H- J4LFU^?Q\\%IL9) (@WL!.$S H MHYC<3?%B5R]6P=#$/9LLQ7BR#^>)V AGGY@%H]"WQ]OLOUI#'^]f._;>KS$ MW&$"SXJ@+TEU\E-YU=QXOO36>Y\&;VNR[206L9W-$-6Q_CI83):-C<;S&:V; M^>-#AS/T@"+]\'l3@O'3UKJ^H?&NNK&1-MVZ*23SQ1A+)]:5+&N4T9YSIE7(Z1MEN0]&A^9NT-Y:K.1S(D]$$-0'C&1L.Q MBSHZ>D-29RVZ6A>YP@(#70+WRBH9V&I2_[+BP)BT[^ ,;8M?Q+DMHX"'^2H2 MCS%U[_4Y*>]U >5=3*D4!D@;A[K->)C2?;NR#]+-2MA=&KCXM69+R-4)(\, M0$]DN?:/;A.,D6Z+[LS/"+3,H%K3T?.R0XP@:>CB; <7K4 \\ASR=) M>][CZX;2-*M!EGR(:Q&:S5841Z1.0Q_T.&'.D;Q*%7@&XM=5Y M%/O+"-M.:'0&Q::H*N&Z<!!H/IT8MA:R2GF.G80:(0[==9(:>'2:+;>6&.4 MMD9U.5U5!:8.0A8$$# (VV&.#.Z$@4:&VVM(^GGT>Z%RVAYH,%ZJ5?@>>=@G& MY9V.RZ*ED*<@(}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}*(EYGX>!9#+D>S06%0D1T0%A2&Q\M^O>8D*9YFN)X!'T .TDH'Y;'8H&Z(AT*KI6@BW6!92[U^/&TS1<:-WH7 M?.S4/Y+DRD1'1=R-MZ= (}KQRD8SG_;]8.(17.)(TC M~46F6]Y"RS30OWXND#;2V.[<(PZ$,=_D%)5(6/[@.*L'E:,0+:,Q>GC[SIRIF M@;TR-PV0#QK]NBZ3ZBLET*8MKCMV4IDIF]B4TSP.]JO7#4!@U%J;_L?:C? 6(*_!_>&4#E=;MD9GHEV=80"61M2Z/QKVZ+8'A@>__MO=]CSF2!_]"-I#8CCX^@>(VBP9A:TMN@.&UUW]G#]!MI;7BQ3?PUC1N";=2Q MS(@@\'C2G@\X HV;-.I3 ?M^>\)@^ >#35O1TE=KW19T, ?|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{]JQ1U#T_7:+>RXPJ6>X9C7-W6/B8C3SA>1?7S#;@>3Eo>W@1OFHA+/CC4H M;8EOW&3-I5E_=5[BZ$R@2*3>S|30Y8&#-4>NJ.2;/C7A;IZG=I1>NB>;56'IJO7K1.\/>!_M1>L2\|A#O#;/2ZID7_/1O5^33WQO.]8<1W:.V)!00CT.6W&0S?-#,]-B(#K_ M;EN?;L,:=='N.?.J%%8KW6=45-[%&?+"'363GEIA1=VZ#SHW5U|!2O$X,OP'#J MV52#T?E1QYZP*7VP=L,+=T&]J'5_+9/R[,.U3;>VNNR.L7.W%XM;848TSY[] M;7M3O"D&0YEJ#PPEWA1>:^$D^?,18 AZWLH,EY'4=D;;J++?\DZCKS^5(5_@ MO%R?&"WN'/% NJ[IW0*%S1#-)WN4"4P4>T_#7$#I8$]WU/=2LC:BFF>EWCFU M87I8%ADD6GMWU*I18|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{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|_&BVTT"ECR,;6:-[]B RP_]2BBWY;(U""S6"5"<5FN]@ZV\@9P>5)3U4 MOJ]Q"TA.VV]HF++)7MLU07$MHTC@T$4?0Q@:;9B^ULA^DX,.;+^-^XNSS:+2*.M7=&2*I8%.#$CL-,$_U$A;10>*Z)3LA"BM$"+-NVGF N/(_H\Y0##P'9Z]M]/N&30[.B.?@+6O!+ (1QRQ&F\'L^J &(WE*-6/R9O&\?7-\M M>&U[E$090"%D08W&?!Y.T!RLR9V\!) MG!S5?"3BM S+=?E]XMQ@I/f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|M"'H*E\<4)W")#\N# 66OPLO5@MK=F!9FM!X M$5P-VD1.:D[*VENZE:3G5Y\H[QA",<_" %M:%L+B(/>'R;9RV&+<-QN0(QA5\ M--H7#NYUAMEK_9CX=*0F>U*WDY. :ZQ&,$V&,$DFLQ-XT\[):<";'L& [%U9+ MO>TY"?_<;)RW5!/_'O*W@9L=AN, ^N7:52'$942,XM$\8K7YZ-YXGOYT@.^O(MSDZA_V!&3F(<9CB>CN M.*RE3A%\@7!GRDKH%Z"#VEK,0).T(FET0.T?9'QA M$4%HNB2,4#:)1TX\4-IH$EAM"WN9 .$:0%C#/ MJ?EI+M0@PW3]O(L(-$D&,%-FAJ;&6HER&WMDP#WQ.F_E=FYT3YUO (OA0L MPX, LS/OA);F&N@ZQ2-)=#! (!]!T9E#I@_Q"37G@<)XRC%]Q^ M:[^- MFG6CC+ZY"KG;!6B4X0)7Q5!U2*/4"^XP= MKZ%.^*,DFTZ.2W#O2I.=HH9&;M6\C21HOXK?/PNOL[1MB7W22K*>"Y;XK/W>D M_N"7D&]3.R+N?KT>?.E:ZQ.W5G^FOFZM06@M;JO!.H3"5&T=.%#,4<#HW"N/=0E6BWX3GF^JJU;]ZL[K1[\6^: MA^Y_]>9SX:.P6TD^*\)-1E=G$=@FR>XV7A3A6=O8SP]HF%9T%<+6A;@^]QO MB;4;-M!]!ZW^ U!+ P04 " #I@6998T1LK_0GLP.P MY+$6TLR#G;7-5129<@Q(P0"2NL0&/X> MX :$<$!(XW./&0PFG>+Q^(#^QON.QJR9@1E2N>5WU?PN]-M'Q.'5RIA_)?L.UE* U*VQJJZ5T8&-9?=GSWV<3A2*.(S"FFOD'K>G2'/I99 MMIAIM2?:22..&WA7O3:2X(EY=YJW.6H9Q? W;=,(P"A;)L@M-Z50IM5@9I%/% M="<3E3W2=8>4GD%Z1>Z4M#M#7LL*JI?Z$;(;J*4':M?1!P?6;=8*NQ%8Z$B:D-0@&R4P";F..4R%IN;U^M6&T^/5"TB:U7CGA!LK3252AOR+2J%- $YQ MD.1AGDU&/H?(ADL+Z(DEV.5"6X^Y!'(f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{V4M%)HOW!Y?';SXB+'$FH.-7. ^F!7Q-? C#^[V7\DYH&9>6;$E2K_*8MV!?[@_" IQ"+K MRO:S6O^WL R=X7RY*@W]/UG5V+/3@R3O3*LJ^S)04,F; \WNK2"B%\ZG.UZ8 MV1=F1#MAF\EO-=>W/!N)&J1 MW,AE+1Z$$7__2,@V=,]QTSWPG7@XG--_) MCOG&&/Z_R[EI->C-_X\QS/.=CL^'QO3&-%DNWA^ M1BA[\3!Q9__=/QR^G8/ MM:>>VM-]LU]\R(PTN&??.'? =9JSA=0$/9)W+IA3T]96]#7\3T/=C3/P!RR1? M5@^,+5Z8L%&CNOQ9%LI!U!JF96)@/@$&WIHDTR+IZJPK) {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{}@ZY%8=(T4>.G%EARF%_"DES0$RH2XS@0OM "C5FOD+$-1D@L M_$%DF#? 6HY;PD]B-ED)^FO5R$9.?!WE3!+,_2/ #H$*&9%9GNM.H'H9\%SH M!V&. EXO54.:T5- "9MV]TQ.J*$K^[1#U""%UWA2^Q"=H)4G8_P*9[$FF#FVGC MU1QLC(%@25MI0Q@#S1^N!7U0 $MOLWM&9VGWO@(QP7#2D'V.ZJ5W5"_WNIG/ M(B)!F6BKR,#'/-43I_#HSKD$KXL2\;#'T@39VR-K/PB*R+HL^ H#!_>*7QIR< M,WWVWS9\ZRVZG/([[0V91.T2P3Y-$62_0P]0;@+E8=%&&8G3I3M@"1O\(/) ^GT].S94'MFZ?1D"O^? G9T]^T+L/4V0,/%Y M^O*45CA+3Z;39(\AG7M#.M]K2)<.9(++$K \;/Z8.3UYDL0_T^$'9.+J*$QIK M21;4 '*UOB(I.N%4P.=)BFHFQ17T>9\%|QH-E<+#P88FH^LI=.VT2=9W"F8B ML[13"M*QMBDA&+=+9,MI $W>VPW86J70J*I&H(=U@"B<.:R M&)ZGR3;DL0'UP#(%N5)TY:H4(*JNL5;3@.<&!$?*+BL!.32 ^D]W0E5 P?DJTTMT)0N$?.2?BBYWKLFQ8R&1G7PH, ([I29\TGTY$=LWCN/02$X<*",L=SY**ZJB>95_Y2 K.%)B7W%$! M.3Z90$8X\G -6S@MNC&%BR4QB03&*Y5?>BBOX6]#WO5B4N5HHG]DK2CN0)P M^IV7&,?13:2664$O5R*DV*#/M:& !LU=#]%TO)Z'BA,ED+!X)U%HZLZ& M/MRW4/]P"^VP]1$U_O!L<2@#MZDB&!\C'#5>(% H"!#5%1D+ [:(1(^-:D'> M M)MRFN"CKRSQ89)W3'H$YRTJ6>&SD((RH[Z16-0F);->-<'DABHAUK<++#2E2M M@M9A^9J.&/-FO^42[*GDMF<W)W6Q+%"?,AK&)@51HV,"Z],P 0-Y!WH09EMWZI*V04;U6$]'

*MR>VC"><]9QCV)"(.0/R06]RW5`14*[">PF>M .9S>Y"_PP)!!2@X2YM#VH.?`MC2\,\B&_/?"%X$EGTT+GT@SCBD,';+[;LK$(# 9+S;62;=2%;S;8F,3!O53U M$D+F'8G2;X9SGA"!KI:3Z5(B=EL,2SO;S/BH $\6'6 ?N2"H.*P)L7<&S1A$3N>L M;>;8QWCP.O#KXLT.C,=&I'&5S<'/.-X MG2'(^2X6#B7S#5$RK(WGI5P.XR3D MH$N)M3-K!]N{[2\FHO*Q< TM,R6,@+^X,)#));NPG5V[Y/9#3S;K+R=ED;Z#NB!'->]SW#VN"ERTP M0=6VKA1,[-_&A>D+;U]^>CP-#;7JO9GFIY[;^2DX]DMR5*.]H[]KQMB,P0*V M7*.OQX<'4SC:IV4@?$ G(Z&!^G>B,?>Y^"W"1BX=RI=8-T154 GC.RY&R-N M)7"-46)<<9[8SZI9QLE;0YH$6O0L1XO>5"QP4>?F!4LN%B$@O/A;A^_MG)CWDKL!BT0!UZ? @KU#3#8P.^,2T4A ECHZAW>M5;WI^R4']969B^01R2D2 M#8K<'_B$I7>4IGCRYT5*C6,]MOX8)]M1\WBQWLM\4<4R"\DMI^CQH11 MF_Y-,_7S\;@5%-,I;A<20\ZI+W*\8R@^3HV:*D@Y!66%ADJI5*:. X]LFZXU MOG2%@0-7 PQM GY2+*%@46LV39-=S"%Y/T2-KBG:%% AS8I.HU> =;!SA8OC M?1)8[4AO!HQ4V3WD5-\M<+$%!S7'8W]L,$@348H%+&P-]>KMP?.-%3US;&UY M9)P|^B>7EF<&R{6'!O+;__14DTY)4V+Q&X\Y]:RNRUH&;YW!FBN:3L2]M'TY[ZL3 8C,@$"$YK@O:%NVKPG]J&BPD3'LKZ_HW8XP/R35->",E2#B5KG0 MP/5O9)2/-1@-4"O3T//,^7 IZ]MVV^!{!>*H8ELB@@X%!- MHS<)[MCLY5M(>^'!Y)@V5$&&W-^5 G[M%/6#PPX)6PRG/F7>4QO8 MJ;2'IT/NQ%+W?)"WGAA0TUY;368DC+FF'1CU?%%N-!D0/]M#?)BI,\57;.I MD[5GIM../\M'1QF=DD;D$(TI=M9Z1+H(M34B&_QKRBHZ!:JM8H_WV)%^Q@YQF%?3O)%11**O5$&:J7M$(PUC[6(5)>0]G#)S&TOFRX9K6LBV&FW]AA[V]=[R-4/XW)P[_-V MCC3R8C39AK>"=I*;0^!$L_^:L2]WEF+'#3(Z2[<;QJ;IHL'.*YURK;WP~M58BLA$\X,+!T3?@<%DA' M&+$V[CH9ICE-)'/KG>4D4F0.PCMPI,D^\-JO8?R&]M?C68"PL[W \U]+PT5'-MMQK~24>=.:^#KDV<)'W`[;&W#EI-[;NI[&KCT;15KS6]'75~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`M#XW>,>,L"2$*!1J MS>9:BE2 91\?^$]"O1J&2(&=>YCN@TSK(/&9()_8O5986':G,LA>^X=$N&$= M'UA/XXN 2ZBN61*U61S%W04?7,+B<++SN"=2O?W9&714-7\.95?PC=<]c>2-:&EE25D-47"K_=Y$$?-ON=WV$?2O;YXN-M-.NQZHUI(>6]:G.L.C:5"6?N9;6GD(NU[1]I8 M7L_T>V[60EDF(2?7Z-1-05//R7[#NO*S:.61)IT7"_JU@('$&=)YKC8>-"]#\ MK,;_%!+ P04_" #I@699195)*\$$ -#$# &0 'AL+W=OOR GEXFS]P;?"[DQG3%R3,9*W;O)E^EY/W* 9"DGUD40 M\+665[(L72"\:.)V6]3.L?N>!O]H^<.7,;"R"M5_E9,[>*\G_715,[$JK3?`MU.:S;/AX@!-5&O^)-HUMU$>3E;&J:IP!0574X5O\;.KP$@?:.%"/.R3R*-\+ M*X9G6FV0=M80S0T\5>!-X(K;`MNA5S=#:PD,-9#B9-O.L0CSX3+T=256T7!GVHW+ZJ_\ L!+4 Z1;@)3T8<"27 MQRB,,*(190?BQ2WAV,>+GXGW15Y+8^%:68/1>SFV2-13],"JK /W1+\?C$Y M5L.E^6-?$4(.MC^:Z03LQ03>=Z'3C%2KV5_^.85X=!1 0:L9< .11^.00\@-M-4-7JEJ*^@'M/<5]N-[&WH_[=B'13)70O44]1SZ)07ZIAMIMN]FAL6#9(*KS M*J,D/35P55MDID6&T6913!9HH]"YC45&E;+T(<1:%*6S?@=Z[\X(<)NZ,S*= MNUG4D$FM#)R;.3KI751*V^)/.87<$.NN!FTJ_;PS_"@*C;Z+]=W<\.D9SM9:ZKCPKN!&@2/7DH9OX-4HB'"<1# B'C[>QC$ZU"NLDCGM7 M$H#,BHFP8 UDIG*I3&$1PRQBR)>$GH(;2<]-

*M&+GZE4L:S2=';_[@]PCIB|D_ZHJJQ@A[0_0.]M|FO3^J*9&^GI_U|HDZ(^(&_MW@##1O2)6?3-78GTM[=]#^R1WOQJML$,Z7=U^^"XISAKNZ'\0=Q?@,_-$-_9>&PO=V]R:W-H965TJ#R89P%K'IK:|-MW=/]^!LG(855-NQ*>0';\7S?S'SVV!X?!K0&P!#'G,N],39&+,=N:Y.-Y!3 M?2VW(/#+2JJ<&NRJM:NW"FA6&.7<]3TO='/*A!.-B[$[%8WESG FX$X1O1${QK*D&FXD_X=E9C-Q_G)(!BNZX^9>'KY %<_ XJ62Z^*?"JYGD/2 MG38RKXS1@YR)\[\^5GDX,0AZ+QCXE8'_S,#W7S (*H[/@M0S|R]#_6H9!93!X MK4%8&81% [LMD%9F.]:'16,D#478VHME&{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lQJ*588^+[M>KU>I=O=*L*]F#\-V4>B, M?_J1?>*5@C%=*I6>Z\$2C*@+:\\X=*Z4,4]'KZTH=U M7P"-C#TI+,,_!\/J;F5\3G$)S0L!A1(:MFZ[^#-4<1F8.'X4)E;$(HK[""=4,N]IO=FQHN*8Q-M/X!%)@#6I[!.Y=9X1P MUU,"Q58I2OR4="N88T9]/M^U_M97&,8FS%\""W*4'XCF^TG"YT1 MPGX;O/;.AYOL]]D=X4]ADH*(+J2?<|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{1R]'[&WDOBC|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|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}-&MI&GB,@'$-NB5P+>W(-A-WLGHKZM,]/:-_0&T0QJV;&RD*%/%S!22IG]8&364/M:4[%0D@KDAYV-!?]& M^.LOV+=^T]4|$EA/|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l0PG6O81ZPA#FG7TFBLIDUME "*UQ2M>#KC] M! <9?S*FL?M&ZF>M8*"ZEXGECK#/(":O_\5,CQ(Z!]M-MX#4&W]&[_P.#86-0 M*6?7F558-UCA:"KX&@DS6WL5%Y4VE,6F(T0(H M5I @Q=$24T!\A3Z4JA2 %OP94T5 HL%2EU%2UD^OS!LPEE^)R@A#KW/U](@84 M)E2^0P/T97F#WKYYA]X@[>9SQDN)62*GMM*)DTf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l+[_*- MS-1? EGFQCBOUMEB=EYM"OHNFTSH]|T:CR?DZ3K*SZZOFL_:%)56^K=(DD^\+ M]|RNUW'Q^%,F^<,,,_?LZ8,/R>JNJC\XO][:Q"OY458_:=X7ZMWY@;)(UC(K MDSQS"KE\>G:(67<\? OU$CYJ=5SMS&Y=REJ?_31;5W9NSRS-G(9?Q M-JT^Y],]G>HV?!%W'4P?.> MZ>#M.WA?=!A/G^DPWG<8]XW@[SOX?2,$^PY!WPB3?8=)WPX7^PX7?3M<[CM< M]NTPW?$]NW@CIY^N5&30;N?O,F7,*BZZLB?W"*NKWBU2^:&OZ]51)LEH? M'ZM" 351 ,KK[Y.Y2G;IQ-G"43F6QK=Y$3>9>[.JI%1*J$KGE7.S6"3UIW^J M&]RGRKK--Z&LXB3}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|U4 =#F=S'MZG)@'IKIPS.-*|X%'E6;=:#DTMIZZA2B>]F5%O M)MVWU 8(8^]MW*TD3_ M99&OU:^>JFIPX6SBHDID>1O F&G, .:D7M:1B'61?&]{4Z0E!:.M"*41*"V"TBB4QJ T#J4)%$U72^L>N<'+F*#@0DTE*"V$T@B4%D%I%$IC4!J'-MT@2*INNJ-:!DV-CLK,WNXP0D/!8>@ MM A*HU ;@|(XE"90-#WA6R?)M5M)K>6ZR_C'W4G$=,7L/BZ2?%MJ5\YJOZF9 MR%/.DSA-?F^J-F#-[M3(@4850&H'2(BB-0FD,2N-0FD#1=-&T;IQK MM^,^6>P58_)#53FWZT4]<_H)8H0,)_1-#"%TEC_W>#0P)%T[.V=0==NSTX MNZN' /6\RHX]:$Q:J!/H=@VW3K*>;$)..XE.-Z'0/6-0&H?2!(JFW_;16G&> MW8Hl,<$W''^'_+Y.U-)03#U53:JL2B4AWT/ZD2*]ZHY+875E O&$H+H30"1450 M&H72&)3&H32!HNE"!JUGSW\AA174I(;20BB-0&D1E$:A- ;E<2A-H&BZKEJ3 MVK/?X]AS]HF=,E@3W=L#O&;YE(+;Q[WC1M"X%$ICIKWP37O!H7$%BJ9G;FO[M>G;;5Q5)337D?'K(58V4;\O:V"+U D)29L:K53>W.I_8Z4SEMU4R+QVN3A3% MYNDZUQ_X;:=3(}8)FSYIA2FP8K .HY0VD$2HN@-_JE,2B-0VD"1=/5UGK. MWL4+J;>@ISI":2&41]"T"$JC4!]#TCB4)E T75>M+>W9;>F/LJK2G4P.]_C5 M4$J>+;R@MC24%D)IQ#-B0RI;C&AJ70FD,2N-0FD#1]-1OO6W/[FV;"[A/#TH! MC\/ZB3QU4LXI%L.I850&H'2(BB-0FD,2N-0FD#1].7Q6F=_/'H9)=P8ZO%# M:2&41["T"$JC4!]#TCB4)E T75>MQS^VWR(\M(2SXP;+ VK50VEDW+VMV#.7 M<- "X%$IC4!]'T@2*IJ=^:\./[3:\M82K/_O:)9Q}^P9K"4D+H30"I450&H72 M&)3&H32!HNEZ.UKB^*6L<8Q=Y!B[RC%VF6/L.I?8A8ZQ*QUCESK&KG7\-683 MC- O9!&.KJS]^A(-."H#20BB-[&G')5Q@KN"@?C^4Q] T#J4)%$W/_-,O'!O] M?FL%^7,XNN7<-"1!%;."41*"V"TBB4QJ T#J4)%$T77#M83QY(24<=((" ME!9",01*BZ T"J4Q* (U#;0)%TW753E 8VV^*'US"0>-<90&DAE$;&W=OXGRGA MH%,(H#0&I7$H3:!H>N:W4PC&O:<0#*K1C*J_3B^ TD(HC4!]$91&H30&I7$H M3:!HNG3:*0CCZ0LIQJ!3#:"T$$HC4%H$I5%HC4%I'$H3*)K^\+!VJH%_8A&! M?G<1V"E#5>%W%||V/G#0P)%T[.V-6U]NVD;'AVVVZ/^7Q^'0/U;*"V$T@B4 M\@%I%$IC4!J'T@2*IJNH16_]%^+?^E#-0FD#1=

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{"M 8*M8Y ME4^WP,5^[(7>||8]6V^TV?GHRU=PP+TP_9.XLIO6#*60ZX&8*(B$U=B;AC>S M,#8 ; $G@[TZN";&E;407\SB]VSL!481<$BUH:#XMX,9<&Z84,=_-;G7/,, M#Z^2V7^USJ,S2ZI@)OA?+-.;L3?P2 8K6G)\+_;_0>U0U_"E@BOI2_;U:>"1 MM%1:Y#48%>2LI?#V0Y(T 47P!$-2#Z5D!<VSD_$J9=6M,-9V.I-@3;:R1 MS5S8V%@T>L,*D\:%BGFT(4Y//K 4*P.]S%03;2BM)EJ1Y8LO\,U**3$B6'QU#"3&H K!CP%O[A[$Y4I<$BF>*-<,G#(KMNZAA+B,!R="'59) M& W<4KN-U&ZKU'D)9"5%3J9+$ 7MD (;!O*Y@PK:T ~>Q2\9M)M&)=H=1=]!W2^\UTGNMTO_0&Y"VZY^;G]XT[DPYS@):I.B8D&0F(6..?!!* M=4C=+QU$<:HQ07=4ZB?RS_M';28!DI#W18G59%Y_]K<;==TPOL1\B5(%_LMQWF.@M9O@M;_A]"5=8&Z'.R?I2KNA2?I=-@,+V1ST @;M H[SEI:98UCUMPM M,SAKABM'V;FL+M;=L%$Z;%7:\M*U[>.2.W1T>"]{3N0ZK)+^,'#++#8.7D1]T M3HE/HKA*OW-2U}2O-"I>B TIX=_GBO 'BI[XE_ Q]AU$_""}DYV6$AZV @M\F09N*30Z/2>]NIU!K6%5X_M^H2Q-$;^L,&RC=@YTOE3*{@R7 MH/LCR'X!4$L#!!0 (.F!9ED)=F*P00. -D1 9>&PO=V]R:W-H M965T%J#I@CA= M@0Y[H*5K2;@D:B1M-_]^%"4KELVHZT,\L!>#H2Y&7 M;&ZDG%>7!LFB% K,+D@%I7BR(;3 7$QI8K** HXEJ!=%HFL \)EC$2P<[PF%,L4+A(*($]",_0K6HD"C;H->H:Q$#RG9,]'+9B87EM;[F5%KU55CE?,,52ZZ)25/ M&5J6,<0*?CC,GP[P31&A+DS.(4Q7S]#@"]H+Y%J_(,=R/(4]UR^GNRIWOF_W MY?_>O1<,MZL95^]YS^@=ULDJ'.'<$#V2 =V!$?S\D^U:,U49TBD6ZA1:,A+K MY=+KARL4+4Y$}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l&QDG!83:R9.XI=M1P&TQ:\9[.71F*BM+!G[!"0_11/+41%!#HE4%!3_=C"'%=,&,>?#:G5^E3 MX_&!_W>/&YF207.6?Y;ELK-Q!I0)(45W>,RF>U_A&9#@>)+6"[T+]DWMHY% MDJV0K&C &$&1E?4_?6D2<01 'C/ :P#>,.#W!L!O /ZU'GH-H'>MAZ !Z*W; M]=YUXB(JZ73,V9YP98UL:]"SK]&8KZQ4!V4A.3[-$">G/V<)5AT(+5."R<[I MDG&J2SA;*

})(TMG!L)ITMB>,'$2\@$Y@T2%!CCS4*"$E<"(5<*5([[@U(6_$"[?9W*)X MX=[%G\Z;,:;$MK;BVS4W;W:RT'JM[?M LXV*$'TZF\\^(HW^-BY_/UO[RW_5G M3TX7Z3@T.#]9AA_.(B43NJEAV>4^-,#0O2$)P-FY$4Y0Z&U;2S<'D(%P0 MIF3@PD=(R59WPH<'IVOIM%+6TQ(O!=[XI=ZX%7%NER3U4YA&4#9B3Y'X-A M->EL3QA).CL85!/.IH21@X@9-#=29F,!9=[XQ1 MS'!XNV-[/0'6F0;=91;@#T]E7KM9%F9YU'Y7.7?-\NB?8;@LV5SS:,9Z4F] M\.0T3B>I?E//5AF^'"FK5S9K ;WF\C1OEDWFT8N>LGM$"R5R0%Y$VT6_HH4M M$:(,56AB",4[KS"G;I$BQL0L%PBH;0'%(X,0'8/DO9$V!\&_NJ0Z+LO: "L_M)?9IT\S3)"PQ_VVR/+X DI85'0&$EG?;/"">/X('\(7D$U^NX=;DXJQ08:Q0H MM YBU A9V\Q4Y%EN'@2_C8[?:".SKL[JK0[W+=58&]JY)/P:,",'@5^!26EX M%I DDZ!46^.7;00G3)%1R!C#1JU?A_BUBFBNA]\[1#"$6X1;PV7D('#+\FB$ MJQQ,%C6V$IR!MUR'!1ULMD$%&3=PBXMH56"GK>G\'UW;!5W5>$PG)GWT)C%_MK[@E^9@9FK%-Z#5@+1M+>5V!833K;$T.2S@Z&U:2S/6'D(*($F8O@B44H5D90M65:/7W@&4CAA@BRH\D:-9W19):R?+,ZWQTQ\@F"2!RZDM<5DF86_RBA5X,^ MZ?SBWGMT7K4#2U:BOPI#5N)Z*Q%E<Q@6$TZVO-&DLX^/%/8?]M&R)VX6.5.(88&T)(P=1(6!E,J)$ -=*WITTL M5^"<\9 U^OJR"UJI+GH%/LW_?=HL/1];;=[-G^8\;>\A3%^'27XY>Q9.)LLP M754,K'SA9Y=C MT7&QOMM%7T&*+QZ,NM)ERVTZ]=99?Z;;S"/WH:?);%05+'P,DVF(TZI,\P4T M51'#;;3115;;%:=!,/#H*1I+,#8371;$023H[&%;3SO:$ MD8/QR+*+;C'9S3"91C&;R- EBVQB:ADXT;G4/0ZX2*:[L*%.Y!8A)X:!,M"SS&63/YB"]G:?X!?YDWS=/ST/5/\!7;&KB^O8A;MO^1Q7N'RJ+P+GSK*Q,BQ4W1*G.!MP(PDEV0PK":=[0DC!^&2:&,B]VA N.A MH4>()AG02GI>/(3;[QBZZU]OLL,(0-A V$#80-A V$#80- MA V$#80-A V$#80-A U[Q8;=YK@[FP_ ^WL8R!ZX4CZR ERB!H7%0Y1&0!2V M6&>,B*B_S."KH&4]V D$]7D"Q4*!)P8#C6!"5KG_SMQGT5[C\DC*_>1]\[J:M>M'_VIIC;O58_/WMOWN1&CN2)?I6PFF=*C,B&V<$!8_N,Y6DZM5[U9),4OTL MOG_:<$5F=#"}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~Y)B0,/4G2Q"9(/+9 M(=(([7(2FC9ZDP/>*T)*O*2 *R*'"G++#2H< M V MC.=F]TW+[@:1G).!$#ML!]MA6]@PY1A3231;13&6"YQR5:#28D Q#V:B\[6AS$#3AE!&PSU/Y/H*D@^(M.G']#[IS[>>93FR_>>>93FR_>>>93FR_>

*:!3QJUR>A&++87IS[BSHX89CNWOVUBCSP&#@RB^;K^,'U#6"^O6 MBUHWM5XZ(AVC)"Q(UY]4;%<8#E,/[-O,\[U-,,8?NYSAXU!L4<*VL+@?W_SU*

MS;O__/;]]G;=Z]6%=)34"%:XU&Q_F,R_L=,3?YCKB;W@U#OWG]^\RG[_#Y[M]?I=[_>_OGW]\O,;U]DO,]^]?/=J4\;Q,PWS[_/N\Z=G6,^] MH,(;ROLQR[<_WS'%N)+4?@LUMP_1E!

*M1A.*3%D6A1*D)&0H1=T*[_TOEQTT#UXY%=PS;2>^F&*5GPG&OE]|]_P]OLEBNR',UE3NR)YE/X#?I+UJG9J4]VHL1C.[\,NO\T;SQ_O?@E$[&H11[/?IBLR'8HPWX MH?5X>GX1_-:,3NMHI697X_#VX'_"IS[D0_PX2NS[+/_?_5P-N+3QC4lU"<$'U+,X8@9\Z!DT=G-LO53UML4]>OOS[<D7<$3'====]YH!*

MH9S055UY<(6NVX3_%#]\./[>#@UP=]V)7P M4S,%05Q$]+/BX1A5\)\>H_>IAU?:,P MW#UMWPH\&$H-SY:EO6KH=23\LK#%L87NKX$!H&5N[D/\CBJMC\VH[+-R W*

M+R,7?/)78$0;>#S#@XQBR@>W#OH/H+3QL?]DQNAX.KY<9.(CH[(9O<2.08:A-B-E$%[_7\5' ',-J2\. MXYVM?/?OJ"]B\T1XH(8)KDOZ,G $7@M,%\<$O(EE3Y9/P?4+CWKMA_]/-MSJ*

*M@F:\:GYUU37H>!VO.OCV/[^J8+I#+*_@7X9PG5GCJE1@'HG8_M>&$0]@Z;0EKM*=E&IL=' M'T3-NS>Z#]<^FI?SE7G=+LR-.X+YTHZ@N.L97BGQ)V64DPEY4_DM4AJ"= ?D"*

*MD]?P830-NT#. Q0!3H5> =,K8%-%^R)TAP42U-!]X.X,,IBXO>@>'1$,| JL ME!,IFJFU8+V4TR7(*P3M"P9]KQ4VH6QG6=^*L)=@#HW@L74W%7_3Y%NE-!T-*

M6TLJ?)Q40WA'YL:AX\$?0..LWVX.$0[YMDE"K;OH# 2:!X9R%3;59CY(.)$[MN9YU38-GM8HH4C7.K=!]=>M_RRQ_C.KIQ_66C MV)NXTX1M\XE!6(FPF# '$$[;TA[</@J=]P#\L-*

*E,#" ^VFD $S/@FKO.65) M<<]JBH5Y7.K??4?F]OA_TQO*XS9H$7@%]&KS+9-RKGK:P]:#S4>R+V-;F$BA M)C!C-Y"D/98J@TI>NM*@@C&!.&,**><8RK40VC*AF5\KXK.E/,&7(_?I*

j#L M,S&#ZVQ@:);$/P=|8BMQ?@*>39S76OGT!Y\"@-U#D+4A@$QFR#1RY);3H-G M-XOH11,9T F #\MZ,%G1&L2D9H!OS[Y(+rA(3O7=06,4G@FZD!V1\MLC53OV51*

*M_FDIGK\HDYV*DUF-,62N2YX(CS4B)=%!8"CA+,,K!42+F-8. M3< ,&0<5,CK__+,$RC6?X=D_AVW>E0#H3*NXEY.[#O8?Y(Z9!OYS(@MATfI M679I>GD9PF:BQ<*)^QIU?B!?*

W3W?=(^,-D'-M,";@*SUS#C^\6:KJV&KJE_-T M^/]$@_EINV+AD%66<__/7ERP]=3#V&0:O+^Z2K;1IN[\> #&^UM9W.2.'.R+E(JGW1G?OZO_Y"4%#\UV>LKQ>!*

(R'$)@V'J'3;#5P50'JZMN(ZQA7?HW!BX9A=0#TGYKEAV5OTG=_MP<;C8&SPG57TS]T8X\V39A3/0ULU99-.H\|H]ZZ7?BS|#R<;EA MSI)-N>C1(4&\!VBU MHT"V2YXKKC*A2?*

R47E^]?GHZXM/|L[Z=" M+S<+ ^UHML^B7WC5OZRY3>,9=M'F,KDU@OFK;-H?#B.!#QL"+8%W.CD'=IS-5 MV*B=J9 NIV8IG-WMG&7-A??M.:UPR60\;0_TMD''7HTN/JQ+A?*

=M1=]YC+B/-M.RZ]92%4WI\@^J?LAW@UJ#H8>_/CB\5]N"4]M9WDPPVNW)TY8_\|ZT67YO_ M]^WY=>\;P6A>("2,<1F80+@<<#?7U>#[!EWSU[J?VA1*?X>_]ZR-(7C7^*

M1=/NJ_B>$/%D8/OH[^:#6"RG_:5]JM:G>M$_9>G2H1!\'NU5^C'_L.R;.]XDDWT6_#X:W'<,M= MVD/L PFWRF-[BDU'1^<3 ZMO}: \/, *Z?0)G9+4)*FYI]2P)#7:UNG1QG]8*

*MFZ@UNC^N6=1SUP6|=P_VNS'C'A-E9_A\YTX)S)VN)\[#%OG>]MTV|=%O@"&:BY@&867]75=XHS;&V>5]_==%[H6P;M7MB[/%^!-/^QYJ8D9"O=#:1,*_M>\)YTS&"QJ.IB.XC:G^NZ,;"\,/]9X?*

5O$+07[JYN;%NPOBU8%0H0C"]ATK,1 M-E$-S%9N\(WE[H6]%<5S'8IJ,"1T.XVBK6^LR+KAG]Z[0l,UR)TF>G850+O5 M#G5K-

W'PO'XX3/B/.O2Q&+5HWPUWJ1+JABG^<>$[D)KQ8;QHF$/F(F/VO)=Z,BAGK'<:AAY.:V[Q@2;>.Q;Y%@H@;9ATIY3DL@2 M2L%Y)%@A4;<2@T^OLF1RXW61 -*

SYVM1UX=X(f\&!/"_QG;?]^L1=9<1NKG MZVS7TOI$/9?%@]HSB8DM"9.MJZF'6GCYZ=6/F>1T\ 3%&Q^Z\,^=X$N@2R GF6_Q>I,W=,+_4=GU>&:^:+)W$U\?;17SJ,I]

*J/4ZZW#:7;5DV\QZ;;6URGV\>UQ'NS]Z*W&Y05>T!>'{@|% MQ/OGQ_Y*X)#)>.LL^1JB/;7N# M>;#TR&6RM)H]&O !(-"X1-/PK. FM-Y9]_1V@R3A!9;P(>UCK,*_M-*

*96[OO(;78/XI,&\DX[_ND#A4.V^^PNV\+YFP>5;]H7Z!NLGZV0LHF%O:OO9 M2H=&:+$?=NN]-\&;Z'S1^$7X\,5?MR9A9,HNF#*IQ\/XY;1MM#*%[M)N%&@:Q*

M)_$BD&/(I6CKQ[0=:9A&& 4L_ML!S?.7!8R1V*@3A9!%,E:S0.7S81S"67>>*W#Z>Y1H$+$<;EA MSI)-N>C1(4&\!VBU MHT"V2YXKKC*A2?*

M3;&HMJ)1.,Q>!I;I:D^)X/_;MB0N3-,Z[]MF5;"$?G-(26YH!N<=UBY&,) MX6)WZ_;M?@.-9N&)I9MFY%U>U7G+A:KM,'33T >W> V2WCYNI@M JI:JL#C9 MWF_IZP:V2-6[<:$RJ(.!C,*

*[WOAW#AHV8U)!ASOLRJ*6E30T94D.&U)!A3V:V MAPT9Z,,:,K#M-V2X?\SEV$QF&-3OOC?1^M#CK#AQZ(=@HL4&/DT%#PZ=,ONX MKA]H]>KQ*)I,T8'IK^CW"(/!U%j>EZ$C;C*

T77Q/:VTUTVCFS'R?-;^HM9LV MN(M]N^DQ,).HD=NFP"&B.0O(K+ MY\WN9,_0ST<_:$/DH1.V'P4W!6SQ&A{0[F[T\=BP]]#YE/T&WLKNVEU'NKK1

M>>>!+!G)7R.)@B<^ZXL+$A/W@^N%?>/,;YCM0%#]M%VWZ!OL<6"!&*&HNOW$ MKE'<]:QH=MM)NNMQ.QRV[7A],:LF.=?MYG21H=:'66>)+)@8)%U=UFRZP'G<,

M=U[%"F\>#@&,V.8-ZO;1P W=!D 8=$#ERT^,.Y$;^#%I6#,8,5U7=\:BAL2 M_8VA62P "3P^:,YN$;V:0CPS'NP]R(4!]^D,&JR\$+'6^SAZZSL0%K,9(QK#45'Z'656XYLV13[1X3)2U?^I-*

JW;=5R1\G+C8MU5U\,?"3K5A3W:NLLHF2/+UF;1+!/K MZ1L_$2EQZ8A#!A<#'BED"24(5FR4E'MM#=D&]NK;V> ^XY^#8[RN-'#]^6O MH#M^#:KC9=0+J+N%UM2S7-*

*\^A[+M5]*V&GW#29MNFGG\LPN7,B@ M:7-[6N+U5N*RJ6:6]M96IAA'?\1C-GAO<\^R.Q.VV^ ,[?06;E]F\<<0_5;R M9G:N1C/GSS77C;#?2D;P*F<'5H,?=NW@D:D$15]7SH$_&J.Z(9A3QTA)^U=B*

M_L3\CV)^ML[\G?D7';$[FX3C/T9+9N&,^V'E+Y;8O+.QHR8140/IM*B;;Z1 MP4]J W%]JSF2=<$\?8"JRI&+-F]M&9A"=I##W.+/Z;.+'D K6*-P-7&'&<9 MS?T^SL)R=:S1P!OAX?*

^\6X7G@=S+$] M0!%T>>N,7?]\0.3X?UUWR3-9Q=VM$1 .Y/UI^HP7=G?)=]HF(=#E]$*U<@H& M+.XPQO9E\6'7I5*T*U$U=Q>#57^E67'A9F+7.;"5!N_UM/.I.K^FRGK/K-5H

M,$!3CW]OC^LXKX?P*5S80<&ZPHLC:U;O9]0(:S21$A6&L0+ MEY'S3X[CO7YZ.N+#[7_)4BV^YJX2CRESMQS&PCHA\|(

*MP*RGX(GN,/;3CV9JEP_8)=POF>^S4CCMX8#.X/ZCO7NA1MI2+LQ_A?S$&:7_ M6'Q5!/NU\E[_U9XQ& =V<]ZR]DZNF^Q,M24F7PNL*NP(=Z"(V M%G)Z*_"*

*]VX/ZY8VCF>7.=UY0T$Y=A;1P<@"%;!QI"9AJMO42XE9@JA$NOSC MD*RJZ*!LM++E'EK9\QHOFV@3:+?FC3YU#H>PK.2LI B3@*B"YD@!LB/NC"I< M498Y7FO7!Y*

*Z#MVU\'7GRY@B1.FW@M3WX&8_CINF@SHET4"GBBD_JP; MX-V0YQ6[X4Z EES$3&OF1UR:84*Q*2*LC>[..ZWVKXNX2(67L#"!0>_D\5Y M.;U#.J3TG?O9M>%-@._32=C5\-*

I7_+M6Q-K-\'ZM]YCK'TFN@LO"WL",4V4M@C]VDI-SD8;40H@=,XB1BE-7%9 _R[&RDON%^# M+%&0Q+HZW(T&LOSE35,9,'1(:HMYM+P@YG<,W>%S&ZC&7,,U:]>0E![=1%$MMR

M?>5D]3S [%5QB_),G1N;/D=S?;S-M05ZWC4DRK6AFOG/:L V?[6K(9U0Z7 M-M*%&8ORL/^ 3]25[S--NS-*

*[FXZ:Q96^_IFH>#2<%9]I'W/PG&2Z]PKOI6*TS"0>=$L,!1'\+$]QM*D7,T':/Q0?QJ, M_X5"9,M$W:C_[T6ZO=;_]R44(,-+-[X*HGD_DAV_R;1T#K!R;5) H%7<)AK!*

M_7I.L696[6[FD5P6(5I7 /GIMQ_C MXQ$N]BL-'Y-O-[P_SJ]6_|Y? 4& 97XQQ?9VWF9@WC8J+TL&K/JG7N2K-W" MAQ]=M(>T^D(&I81.:==E5]QI-$%1<]+BD-IO5C\?

#:]HO>0HAFL<[_4DYO M3"U>W#3O;^X+#IZ!E/5QK#[KH ?/>9Y"R$", .0)=7<;@)@WHD"%NO%QHSEF M9\UGM'R 9R_D/@/Z[CG'/=\7-.&2&<+L5CX<^:_]LHPIG2T#-2ZM,'1 #R+

*M:2#_CX8?ZNN,+"BUGO.^=:,7HBE>&N@;7K:Z-20C!6Y[$NMF_]3TA9C]&+R8D M:G1#7SZF'BMN7(;ZL]?OY:,B>\1,B6X%9IT*XBG]><#CAAJ*ICWP?OM(VI?' M*

_<;U7A7/:.OR92^R=4OX6*,+78#*L^D)0<3,_]^FW3H>]_4^4MVU]@_Z M*SR@4U\%WZ2^YE?N]=I]8Q,S_=2F>D6]$'9DYN@T@I&QVD]AOP3$9UC-HTXS*

*M?:+^L*X2O"12*E9B;G=PX"Il?AXV(+]PX3_!GF|<9>^&DOI#PDRG_I%S&)N(.EIP7(.(%7[BI#([MBCNZ&_[$U7%.7U M7-0"?RW 4;#IZF9M.8WQ2@"Y,K5P(UKX^@>_(PHULI3B*

VLVI2+8MG9R,/] MZ^NK-B [\N]6M.M+R1C=9>MW14-GF^&E]HNG%"+E)F)V6+IH0W#@%_"HLU- M])W8@L6I,$'Y39A<&F2W%]$>#73]"0Q0>8'&7?EZ /A-$+2X@3'O6-6;/IY1*

*M,2=*6Y$K7#U9?4&@25=9OJU/U#IGOEYI0O.F-%R"XWG5_#Z@U(/K*A+?%6TI MI=ANB2TP0DI7/=YT59+255.Z:DI7/9UTU1OV;KH+G2H)8D9;0)G(D=92(V($ M$[+*

(G=6/2@&=%56;GS)Y.WKMS>3ER/TM;H8"G\3,^(^>1LJ^<%:^@1]?M>') MS]4.W-R6"9N;@G=M>'67Z=VY^/)A[8W>Q"4L]!WL"9_-:;ZS)LU.NQCZ"4RB MA$"\$ 0IF1-46H-

SX14OME4Z-Y]3NYSS3C,C]F"> ^1(+UG6M>D-PIF\&\'8T M:G0XVQ7?<_OS7Z(EN]XVH 5VOSX8H^!>7LJ^L/_^>.D.N]L-&:ZO1O&$]0 MQS#\2$DP-<_>O&;Y/S4OD[A,_Q]?*

WTLKW15^!>-OI(A!M:3(=8#;|_]W:Q% M_9\G.VOO2!54[4G)%_TS%BZ$*]WR"6B!SYC\?M%BZ*>EN:,IKN84[WSW^:\U0R HG,C@E$$MM7OY_48'"+4J; R M_F^Q#D/K%(8O-

BNVS3@3/6333;^Q0/BO+_6K<3!(. M)+=0KI4|S/:"=DERDN1L1W)^&X^B.V"_FSJ/_WW7T/K\R0_27Z2_#Q(?L+A M-Y\$ E0$J*

*[*M"\&G.2FGNPU3>\QQA16WS*T;8)N=E<7,D_C4C9/XADNSF$,0'[+X5'Q+*LM3>SPW!JK./IUEYZ'Y MWVA61ERW14N:C;E*-[*G7:AW/)"TX;&C\7Y->9DI;IKK?VYY;?<#CQXA$%U.*

MW2]U5WNI:Q<6#SPB!.L$<&4-8.DX1AAEI=4ZC+/B5A-JF,%!CY2#E', -=S(M'F08.B+CW>#6I;C6-;R7)KM_/#-N9H999\UTV'57M*W_]OVC^27H." MA"6!!*

*[+O.N=M=:F'S5^^0_!7>SK\+]]57RAB\!V!3RAVAY,,:\%E$MYT06FFAD78$!H42!E,LI*B3 G17*&6F? M -6LG5ZV!0+_6H^;9KYW%K:=?_ :7/ZS_KHEJ"-Y@KD$<_N^I GF'@1S/SSP*

MS/!8!-+[#SS##%M,.+&A3KNN4->XMQ0+!G+]7/"9L@VV#9L4L..#C?O)F0_ M)@]VK5- 'HGP'/;8[9>C; MGM=+CA#6IB9S),5=;Q:T<-

XV%N>;M"5'G(!'PY.N.1F!2RIF4<4(1J31N$"E M(Q[412Z0D25');6Y85:QW!:K'L9Z^!\|\|7"I41<"/A$&4<>>U]2DU-XXIX$ M6/F

*8YXT3<*RM*3'A&5=#^BTZ$F.3WE)#UZ.GR9N2%AH:8>Y5]EB',,D5'P MR3-72E$]QPA] AOG2>.&1]R=U9/"A@DY$V+5]WE)#4SW=?M$H5WX3X^=^&$,I;A.V^[=KXDMO-*

EJ,%>;]R7!HPX^@26[P2GG#CZ[}?W!>< M./]HE_?HIPJQ:5VOOL/21L>NV\'C5-#HVT>LBAG2\N="@!JE!! M2:%+S(E9+U$]6%$Z93_]2#AI;\A>Y\${LD3GI2&YY7)?*

NDT49"#)PQ+L]ED$ MTAF6A&H)U6XI&>9%X021+)[7P90\KD#'%."5&\+!PNGP#5GO3(7^KFFU!N M]YGY'+-<>EXPHIZRA@)3/PR3.DE1)E3HPJQ5I7CJ=$S9UTY1A0+H\.*

*M,=/QM@2A"4+O 'G;]3PW!4:E->%@F2@1P!Q%BI"'E?E1%&ZM@?DV(&_'!\L * M/!!\Y*C'WF,!KZN>;^OF>O*Y)94P?KV(MB(ON$=YGH.**0U'DND<%93E5)9%*

*M;O#@2A"4+O 'G;]3PW!4:E->%@F2@1P!Q%BI"'E?E1%&ZM@?DV(&_'!\L * M/!!\Y*C'WF,!KZN>;^OF>O*Y)94P?KV(MB(ON$=YGH.**0U'DND<%93E5)9%*

M;O#@:V6501%93G(/l317BBE DB3;("4\-9UCE!HLMXY\HPIH/1$&3IDE8EI;T MF+ I1?~D\(Y0Y9C#:X4"MP%E M.XXY(@.>'Q^8I4S.0P@(IIZ]2.,DS?(/5>32"ZE@@+8(/7LY:

E6(N(^JS@U MRIABO1I\}YJYT&&$;NL'GV"(E'4?>Y)C7Q+,RST)\%+,!X4ZOC9M*820T"RA MV?K..3?&:>41MPYL7N' Y5<%110(1QGAN2-KB>,,]0+,G3;$D/,%;@<K>TI$<%

*M;T\3(16&64 WC CS@)F%T<@0P#_+B*2",UEP\YOPN8O<2CI@.3(*EOR2*7RBN .X2YQ(CSG"##,4%..8TU;=*M=R??!M+MNE8_IBG3);7M?5I*

*M//!FED/K)W#5G/_63V4:^@C \9P0CZGPX%5I(9#3/D354$F]W[*U\Z%,%\YJ M:A&UGB!N> DY#@YQQPN?AVU!R_,3AC]![@MF5=>0<%>5C5@1-0 RG MGO1!T@=*IJ*

*]N2&MC0G&,/2)8< 0?')*YTTC;/)<%)IER;_'^:>#WKN/]A1KD MN$@@O?/>0!V%WTTO?5U9^-M57_8$C%?>?:>OK]DR0Y#]XZIF(G'-$E(*E2+)2E M\4@RS)"UF-74JSH6K;(??*

J=U^>>$H]\PB#_Z?3UV-JM'YW_2D^^JO8!*#VO\ MH4>?+VKO_Z_7]1WA]NVI?Y,P%C7>!LP_W^-!U$!T)I2:U0R%J7(ZY9@8PC MYPHQ43SGQI3EVF&

<^^B6_;/#:+Q!X!R@@IY>4C+=TPK!)% #$X3)FWL M0KNLIHF67C29--QOW@ MK@<9/ /^GL X8$1#>,4D@I4,9BX<6PEO"'']M',K5M+87NH&!Z$FF^S>?/>,;

M/5]7$/]M=R=U\QAU$_C,Z$>69]5H\"@?>PA&\-OP&WC2WCCA1\UU1>?#<=- M$T"NJ2+#@S'IA]=AKM-9D"(]#WU,XTR'L2-C!NS^,6$=9",?9:WV=]B;]IW;*

M%$2E%:]0.;^)_`SB\+':@0C]ME$?\U\67H[Z83Z%9_K]]AYK>Q$DL/9##\(4KUUXVE8F>U=2GV4?;WQ168\OX^#B M"X N/82L -;"6W4=%CL Q'C4WGH%Z@ -(#3H.R#LG^:6?

*7(Q="UEU8 PIG#H?:MB MD;;;#E@SC*U_'Z^)84I??+VKO_Z_7]1WA]NVI?Y,P%C7>!LP_W^-!U$!T)I2:U0R%J7(ZY9@8PC MYPHQ43SGQI3EVF&*

<^^B6_;/#:+Q!X!R@@IY>4C+=TPK!)% #$X3)FWL M0KNLIHF67C29--QOW@ MK@<9/ /^GL X8$1#>,4D@I4,9BX<6PEO"'']M',K5M+87NH&!Z$FF^S>?/>,;

M/5]7$/]M=R=U\QAU$_C,Z$>69]5H\"@?>PA&\-OP&WC2WCCA1\UU1>?#<=- M$T"NJ2+#@S'IA]=AKM-9D"(]#WU,XTR'L2-C!NS^,6$=9",?9:WV=]B;]IW;*

M%$2E%:]0.;^)_`SB\+':@0C]ME$?\U\67H[Z83Z%9_K]]AYK>Q$DL/9##\(4KUUXVE8F>U=2GV4?;WQ168\OX^#B M"X N/82L -;"6W4=%CL Q'C4WGH%Z@ -(#3H.R#LG^:6?

*7(Q="UEU8 PIG#H?:MB MD;;;#E@SC*U_'Z^)84I??+VKO_Z_7]1WA]NVI?Y,P%C7>!LP_W^-!U$!T)I2:U0R%J7(ZY9@8PC MYPHQ43SGQI3EVF&*

*<^^B6_;/#:+Q!X|

*M4|J'R_*EBW]M+9$_1!|O71QU&.EV**9LU\AU4M'<6T/7<40E'W1ANL N%XD^ MZ^F|P"X7B3|KZ;W +A>)/NOIO< N%XD^Z^F|P"X7B3|KZ3V[++I>*[>M2/_W MJS^N.A^&T.W!+7S2L8/0L1_BP-]W]ME1XY)ZX&O/.[^XI_)0:06. X]V7VR> M;JH#,4@P11!W"2/-,$4TI!@IH8+IN'S$G]+(-?R%@L{W)..1IC8B&P*)(@FA M%3^)3-Z$=K52^SWP7]*M%,PKF'"?6;5*IX-A8)A#E6'"%NE4(Z,(8P=D8ZK@CE M*^FK7AY#|U3[79X=G)9T@ 57"ZYN@8/4*L>P2"@JY1$7QB ;4T!!2LI<,A0H MYA> ^*27<2N(4T%F0KR';6I}$QZWV(7$;@#0&*Y&V"JB=7) M&&7B 1R0A\S3#-20Z[/#$5,1"UXB#/)SWN;^)>&C&UK!HP3"""^=UGFR_)V@IIW M4,9R\JO:.^E5(9@\%80I9ICGBA CD!.=(1N=XPDS8L,+7L8HLD9C7'F-SY1>. MK$H4:2:4-E8FIMQ)A!(8*/@#[N*WJ@2T4)1#T#M2C@=PFS?/0$TGI)N* ,62E)[@CGBJHD M(4FI#SBI)_D<"!DIK@N8$#P]'=,|=Z[KCA()0D!#LNJKXN MY^^Y+VA/RG|\FDO>AITR3K60,2!,%4/<*8/ MO!-P#^,!&1Y@G7++$$B\P]\9B<1- .!%5TLR'Y7LVW209^[=AV'[A24?6DYN "4 M/= IMZ I=4*@V+U"7"0&J(W!SC"8"\4=CL(>'YKOOSVI[SCF(P7PXL$N2%Z0 M_/!\F1K#M0:\50R05WN);*(&.2(%|@"]7*QOE1P>>?<494$X[TJ^9P_YD>)M M()3'ED6S/H7A!/#C)1>|E|GIM,U@G/S: MMWZM,C)@RK1!U >-N&,Y4;0-"#-,4TB1>[,2W)-9%;RE'NZ)N4"'(HRBTSA'P#%FF M-"+ <3>C|TA#^IT/R+P+AF;"XH7%#\@3U8R*2#*'"EO&.** M2&25ML@3P1,CRBN_XG _/.KN*4B%8MH5>L_9Y(X6:PM1+A!.(/;TB#+#TA.2 M" (4CHAS*I C@2!#/0LR) [,31T"4#Q.@PKI2'#3(\(CPNW#E N0%R \:G((M MRP<@+9<&@-OP2F4DRY7!STF0+_,AW)7R>W<=3S\'OH?3P2?%YZ]Z.OVQK*9SV;3^C"KP1CWQQ15I<==/U- M?2_FCW@WCKI5#.YP^NZlX2V[H- MK*VQ)'ADN !<%M(BQTR.!4Rs*@K'B?8C4 MF908WX5R_>%O8ICTX|LT4[,W $KCZLT@_-QK'$G055.ZPKO!|.A<V<L9)K) M:5+3HLH,,P:]NG>G4]O.ADG :9F.T1M70G9><[3YJ#W! M/H-V;>76CJJEY|WTXLB._$WV1E5^4F4_'-SUW) M1@\TOR888- -)V-XQ><87C>O,_@*?S.]'F2L,^^]>%W%.YO3\4^'H=YO\A{] M<++Y{|KSXQU[5:QS/U]-G;#H(7K]5X"NFOYFWR]HN-X;9]X_<2]XH?>;=S|O- M?!'-\<.?9S[FN;>5[I;NGF9WOY!<0C^]A,I:E%V/,UOGEM"G%\CUE$"U4^H> MB$#^]L^OZ*O'N_]D5$'3EN]Q<+ f,ZSU@WX:O9_CQ|OD.=+QS;Y:XYAT(K* M%)79IT7A7F"1.TAY^ ^[.*CV-/= M1@(W!TWO"]L.ZPKO#3UEAU'(=V#KH276"7BT2?]?1>8)>+1)_U!%Y@EXM$G_7T MGEV7GV2! [&IG:SZ8JW[5%TR;^>" ^OKY!^ C.D:Z;3++>D7<7!>D*4A3NEPD M^@*F!P*[7"3ZK*?W-KM<)/JL]?LNGRPJE$E@C-3WU.F:AY^X:>HGWSRW 0 M#|LC!)W;R7AB^YT$ UMM(Y(ED|W)554\ACQV9UE>|=_^!"FA!Y.@D@*S $21|:I9*70EI"5[$0B:NJ(@RNYIX@[9Y 3 M^=?@J8E!8Z?"\CG,[-|\,PCYG(\|>#G7'"W>45)*SKI*D8LLEUI@L\!F@19,L"=K+ (^Q&6^13BA0+@XHHIR MQ(^Q20DIXH630G%E;^-;)P>8>XBN^[']DN___LE/T/!9'&%;RFI0U[6MU M\F3T|9E3>O++T#[XZ|E/>M'GLVO2TH1F0MQ1D4<]= 'AQ!/BBD6DDTPHD62C M])())Y?I)"8)2"@VB# !|Q|"D E< QD5GFD9";7V$NCDN8M\0;&SF]*31{'" M1HH>ERD]?3U>ST:,P5X+KI:B0B >N4-."X<,-A@[J9U/*TE=A7(1"RQ1Q($A M(C1%.O#LYK(T^5SH)*Z4.BELY.0<5[M*;?!Q!X-^69=UMYP.*G&ZIB^PRT6BSWIZ+[#+1.+/>GK/KLLOLCM_N:>#_G|UQU7G0ZJ6.ZA+2-5%?C_$ M@;^?.WJ*6^UB? R7ZE8K[O&BQV5*3U^/U!O':::))Z\0QGGCW46#M)(6&6&B M(LS[F,RR>]Q0)ZT,"AD<'>(<_C(\WXAIKGF>+"8KA<^7:W_5 5?K!&^(^^X MP%W"6/&.%Q K4WI.(%;(2-'C,J6GK\? KR0C'6'EC+'(R$L2%E,@<)(;:<*6Z]-M%X2]E>K&W"'"I5=

*M\'P>RNPWVA5MW1|R4ZEX5_3K$40LSO_2UT^(6H#&:0X@10#Y)H"T!?2+@$PY M)QJ91NN6*CJ;"KY#PK36;*:0:9-%:S8L-M.X5$*_93I.S9;*^R_G1H@-W?!(M9X>DF;*
fGZ#H(F"G2$-W'>=<*8%R>WH"@+3W6+I^4M.OETBCXA:\D-%2_1B]%3 MS)0\TY6Z_,#"4 ?)I:/T8$Y7CE\,,)X/C+0,#,"JN-1'=O $%#_(T]WK/$ M.UJD4BGRIM2<6*
*%_I_$%ZN,S1%PR:]//7P)B0YWF\(/AM,O)ZZ?X?';(S> M:/Y^XJZ%H/$;]%);3:+Y'I78+NL^JKW=4!.C+'QH2W2N(Y-]-:Y/W/VCNWVPO MES*A/ESU]/XA06RA- OY)SOR?VD2IR.P
ZD&I50#& KL*1;<@\W7, M$;R/K" M^W7=X-64H4D)* RQ2N1@7@9F-MGM;.1=#*?:.MH'AL&0X_'KO#9VB7;6HG0.-,M M"+U)MC[U$<3M E*+5NNRLT O!?8!*
MHI7@42X,XHD10^KY!N$S(Q+_3 -6+Q&J4X I4)=5[1]DL;;Y;'2C-YE V1+ MAG%)>FPE_0A2">;K>4,9[IYOR.CD&.)=01V 'S2V<4 NI*K((1#N2IO MB*U^:.E:S[H4O5QP]*
*V)2IBT+H?]N2>+Q"$\&?IF^:/;/ P\GARLIANY?3DZ]= M0K%G%=QHJC9<9-Y'?Z9D)*E>)XTT.[5R!=]!:.![&$Y_BM2SZRM!ANRE:%M2V M^E. +/H>0,5NE*M7IO=8IKYH_J3]U;07:*
*;TAQL/A](5=9+6/:DK"=VE_"";5'GZEZX,40K*X;M7NRN,)E&U('I)/$,O*%,KZ.M9 MD"MSV3IMAM)=F]K"K11W5VT*O< M$K:,I?P,CI^0[P$*6[U(A;_1)\UW',6=FJ>NT*
YO02]/1=P//HD)IZ:L{1# .MN2KW1NSN[0C0[\HZ=AADW-M:B-7V2EBMU-...K$BH4\UG22K+3BS328-3#=MY-3NQ..0*RS]W^) M:)*
*[&*K\>+FO+Z_CK[!+:]9KG=_D/5*SUMHY"6.E0]V*L.O?Y]7C^H'B2W3__M..$T007,;*=IOOULH(2GLO;.4M\D M8.[YV>>!?V)/CX0^LCT 1\])G+*9MN<\N]9UMMU#@MD5R2*
53QX(33 7MW2G MLXP"#G.G)-8MPW#U!$>I-I_F8RLZGY(#CZ,45A2Q0Y)@>EI 3(XSS=1>!NZB MW9[+ 7T^S?
,UL#OLU45=W1%":_$4A:1%%%XF&DWYG5@VM(AM_@<$B.K72.9 MRH:01WGS-9QIAEP1Q+#E$H%UQ,L(8XE2;SCGQ*J57-*Q_KU"_U+'KP(9H.9 M+;$G\5Q3R_4SS-!3" S[$_(X#ZE
MY(BHM!8T>9%G/_<6^8I2V2AK3L732/CQ~9J3[>-GF>H0+4DB^H_AO(?4?%H MT7T4/,MK0)L3NCEB&])OIPS0A0\<1_&E\+Q?^^CBTR7ZA*(4?=N3 \-JR*8Z*
M%PN6T^K;LE6PMK$+B& M[K9QB_(,JQ1SWJ6;W>W^\+Y:?L,'/SQ[(QEVU3IVSK-?X^TQ!=33'S>4XG0' M0DXX6IQ0W6Z%3_EPT3???Q=
*(J)5#PO|NZ$XWPB_E' _%)"KUF&MS*3#S8RH$^@ MS7 _^R72-7 M*HQ+FJX0%BF"-(HZJ(HZ&Z(WW?UL6(A0O>5]9"]*;$~4/T=-\ MXGFB(9]Z>X;F89E3H6?M?*
*\B:6V;0*NE:V.,'.K$;D3A6Y\]^1HS\R&2U# MWV\AV0#M;<-!SGO;4"7,5PD+%,$:Q?"K8K@?K"6NRB*JA/DJ88$B6*.(XZ{< M8^5;4A"=VJOM&D[K_5]VC<;6V&E)2=?(^$_7MB*-
>4$EE_R>VQT]*+98^5Y8WLE]KT6)F&8[LM6>DQ M\T8UB6I&7]NY[FU,IS5=*"U31 MFA6RSA6RFAFR@6H*J5*T]^4%]BB-4MYWLZ;@QNM'Y,.N[,U&7MMH>G:F(,9 MUIFNT;TT*
*M>\9]>3*8'%9,5Y:.AA[0X]2M>?Z@+!S'4);O#VK,'&+< BT9ACC>]9PB=_MW]T NE--,Q.&[4M>W\S;U;0ZBTVI=+"^LF 6]LAZ*!MYU2N^T-=? 6XQW64E*
M0SELA2KKZEI41%HWUO6$DTIUC@^$BSY4#5/ "5)$/M;0OAI(A6TGS<6_P)0 M2P,$% @ Z8%F6YY!0 51L !D !X;"]W;W)K&ULO5G1;N(X%/T5BZU6K=22V)
*78I$;6>WTG:F;K<=K.IV,(F[MJ$G,V 9,,;3]^,2=- @D.165>P'9\K^\YOK09/XOZ*LA<^(T2 URB,^45C)L3\ MW+^X-R.1YDTZ){%\,]$LPD)6V=3B?&#B.0\ MH#%@9'+1&,+S$7*4@>
*]Q%) 5+Y2!@C*F]$55;OR+AJTB(B'QA*!Y=^2C$@8 M*D\RCI^ITT8VIC(LEM^]?]'@)9@OYF1$P^^!+V87C6X#^&2"%Z&XIZN_2 I(M!^C1D.M?
*L$K]V@W+n;B@46HL(XB",/G'KRD1!8/\-@.4&]!=#5]I04L#32+3 ML*ZPP(,-QX^H$@A1!#]PN:YA MGFLB\1A:/6 2GI&I-U=(09P)TJ4LJEM M=P,;;ZMO+?!>%GCO(SF&QZ$Y
MTEXI!M>U>QN!&H?<R=(3WK+UW]!O,ZEH),508$Z"8P04 =ULV& M8E^4!44%?]GYN):VW]4FE;V'2*DQLZV'W#'IG'S\,Q%TP*X\K#.HWZDT[+ MS_*VSC'*.4;&3'JGX@Q74U%
*[DN;"])*K9/1N(=%;J.FBS40S!KDO";D.@T9- M4D=_"\:RM@9N, U%Q8;E-U-[$>PB-.!'.1:,TJJ19O\3BN0=PN(W::R-D$? C% M!')!,V:J1;PU@.[!KU31M]RFL[FN6T.,U_XN-*GYJ1G3!FW(#
MVB!/@RA-O#0G_4'F]U(1?5 \[L*-86NJV,HNI"'Q!19E%M%I*:WHU\'AEM=GE,M%9),+6P.QG:V5D9>__MJ%5$?@#%$'CSZT"DYB2M1.SL.E>2*#FMPL5%1-A4W^=PX-%%+)
*(C*PU MNS,;ZH2*^^>7#C=8B;?\[C@(R42:VLV.#)0E=SA)1=*YQ@894R%HH(LS@GW"M5 ?Y?$*I>*^H,;*;M,'4$L#!!0 (.F!9EFY[#D&=@,.,$* 9 M>&PO=V]R:W-H9651*
*MY"CDD]HB:OB69X6:.ENM=S>NJ^(MYESUQ X+^F7&53N)/+%&>>8R MSQNX.4\+)YK8N86,)F*OL[3 A02USW,NG^>8B>/4|9V7B?MTL]5FPHTF.[|! M)>]'W4+2R*V])&F.A4I%
*1+74V?FW\$]P|C?8%8\I'E7C'4PH*R&>S.!S,G4\ M0X09QMJXX/0XX"UFF?%%'/J63IU:TQ@VWU^>]?+!4S KKO!69% 31&^GSLB! M!-=\G>Z5(%7AD309X6Y9- JQ+1, A8BP&K
*M#)CE+H4LY1W7/)I(<01I5I,W\V)#M=8$EQ;FIRRUI']3LM/14HOXZ=K$E<"M MR.EC*Vf3=0W+\D.!6,-#<4"E:P(<IU#S-_M/I+Q/:V7:6OLK.2M3;6"#\;!QXFK"=T
*N'&%,2\Q60OF&+Z{0F\5_$;2R8_V M+H5XIZS3H=+W/4@*Z(GO7A9W!!;,;E$53IZ%((ZLX%5"-H4C",86V=V M)B4O-DBEK6^^#,UU"_YLIV='+A/X^RJR"9\UYNJ?2RDK!?N7]8KJHC
*MWD-X/0^ M=);TI?.O^=GQR'R V_L>=[$/5P "VNPL!/,IE-=P>"49,/7A1">(BC42O^MH$88=\(\EIGI4Az<*5\)O086Y6&M/.Q4IH/.C>EKXL-S\2%KU1[5VJ,W5\2?
*M>RK@>I=U,8W.F)@7A*U0XQIJW-GUU9[*F%SS TJZ93=F)>>>S M9K4/>HRU@#8N$/]=0.M=\0IG>5]YS80.>VV8I(3)W@6SN85>(67G&66LUP],
*M4$\7A]]YD/:Z++LE\]!%CO;HZR$IH]'OFZIQT1I%M#_ M.R'TR\ (U%UK]!)02P,$% @ Z8%F68PE9 KP @ 20H !D !X;"]W M;W)K&ULK59=;]HP%/TK5C9-G;22+PAM!Y%:LFF5
*M5@D5=7N8IF"2-D8%9IA'(DVH/WW\T'(H*1IF!/P@L!$8Z25S!FUY/K,.QX^H$@AU1!]PN:YA MGFLB]1A:.DZG2:F!N^,M^U>C76F98P$Y3$OD5R-G3,'9;# 52YOV>8;U'H&
*MFB]EN3# ;&-C!^<.2BLA65&#U1,4A-HK?]A]V $HGG9 4 ."UP+"&A ^!43/ M /HUH&^]IGDZBY1.!G?@I"\2F7% M"5VB4W29941O",I1-;55I;?G) &)22X^]I"[68).WG\ZLKF"
M9W%Z(91N1+H"\T@.\%/NO'G+^&3;KP?=!"XRKC&O6#KWE70R9A VD.A_PD% M7A"V">]&$Z!4<, ^VUZ_CO[G]!P]870\(6O]H4)$Q)AFB&U#'P-Z-=W%8^N M)13B=]OF6)^:
*]D^OBY$B5,8.^I\,HQ. .&='WF?VXQ[2[+DCB>L52:'/3LOIVK_3AO8Z]GC\8N>M=FSIS M'VO3&Y'MV31H;!TVK1?>ZF]/='FBB6)=DP)AY[^/?&E,]FQOK0E#?W=I'N2 MHT9R]
*(+DNA:$+@;^9T!.\)SD1#ZVF=!)>^R+AV(. ^VW.)]4=(IIX:-4\,C MBJ/3F^&'\' ,BPX+Y##N)"7F.P6=^2C9F]:"Nj+3?X6:UZ9,N37O@ M_@NW3=8-
*YDNBRB&'A8)ZO:&]/&X,%SN1K#2?\CF3JC$PPY7J]8#K_'5_P9C< M3G2'IGN,_P)02P,$% @ Z8%F65L;R#@+_P_'L_!D !X;"]W;W)K
*M&ULK59K;],P%/TK5D!HD|CRZFNCC=0'""0FIE6# M#X@/;G+;F"5VL-UV^_=<)VEHUS1;4;_^T?MQS;L{)=7S[:R$?5 R@R6.:<#6P
*M8]VS:]M680PI592$&6:4ODT@2LF\9J%K;]:NV'+69L$,.^AE=P!3T?78K<697+!%+@2LF M,)$P'UA#!WK2, %YP'<&:]4U)D;)3(@', D2#2S'/! D$&K#0/%O!6-($D.$ MC &GY+2]E
:X/=ZP?\]UHY8953 6R0\6Z7A@]2P2P9PN$WTGUI^AU-,V?%(M5/Y+UD5L%S.&2Z5%6H)QGC)>_-/"TH052#'S?CKU["3YKQKM= 8*.)E9/>QLF1U\@X@?"2^.Y[XCF>
*M7R>H&3Z%#.%.#F_5Z?GO[#MJ_*HN_)S/?U5=4!YA.2140T2&Y]0RS4"1G\.9 M1N'1_557 $6"5GT"\SF[5AD-86#A]T]!7($5O'OC=IP/=>:=DFQR(K(=8UN5 ML:TF]F
*$"\;Y,75s$\]#]+.ND>)8ZPIR3DYE,H%5X;ZLEMN045AE E2=._^7]:Z78K<697+!%+@2LF M,)$P'UA#!WK2, %YP'<&:]4U)D;)3(@'\&@NNBM:A6]I9OF'<\]K_PHF^\P9/,N"O$!]7';Q,&ULS9AM
*M;ZLV%,>_BL6D:9/6\I3'+HG4%][Y6Z7:-FG7WQ=5>N\""26 6;V2;I_?:S@9"0 M2VFZ65K>%# ^/Q^?_^F_Q9,MXR]B#2#1;YI0,,764F97MBVB:,187+(,]']S
*M9#5%4CWRE2TR#C@N@M+;$]AQG8*>84&LV*<;F?#9AN4P(A3E'(D]3S+_ =0,*V M4\NU=@./9+66>L*>33*\@@7(IV5.U9~4V^2 A6$4<1A.;6NW:O0|75 ;>-/ M
*EMQ<(T5IX9>]$/=_'47Q=P6UZC5UX.'|COZI MV+S:S#,6<,N2+R26ZZDULE ,2YPG\!%M?X-]0WW-BU@BBI]HG\UU+!3'E0K*T M"E89I(265_Q:%>(@0'; [PJP#L.Z+T1X%B M<
&6>#;A;(NXG[UH^]:H?A&MZD6H;I2%Y.HM47%R]KOJQ<|,"#0'CA9KS %= MH(5]QSA/0"#5B>B6I5DN<:$K6Z)+F$& TI-(#XXGH#7/54&2W00RZ%Q#0F M=
(5^^D!BDORLF)\6UT{17^L62[4/#&QI=[(3L>,JJ1ORJ2l-Y+VT3VC%^VW;^V^KA MOUZ]40R ;BF_X/EQ*ZI)+%N$N4 ; %1SHDD2O/P-4IR56_TB,.TT54/2Q1B
*M3E7";AU*C.XDL*OO8NKDZ~BU9Z$-]DID.(*H1Q4 -^ -?OQ!W?@ -HF MD$E88!(6&H(U!.S54O:ZZ(64%[668]\E[+1<:BVCID/$E4-L*X= N'*(ZI>? M[1VB3=3^S-H6 MLQQO-
&C."DYBA>^Q&K7KU[7K=]9N M(5GT@AXR716![H3(=25HW##(K_>0/@-O[>]._$?[VR0L, D++#<$:&@UC09G M854#DU:A
4F8;$A6$/"82WE\RL:MAB'(X[/+_]IV>-1OUCISH)%,Z#.E1N M5%=NU%FY)[H!H?2^_]"Z<1/IV-*\G2I0XV.\Z5_EHDYN$!29AH2%80ZIQ+=7X M+/QL;%)*DI#
)"PT!&M(Z3K[+R_G]RKRNG003S'[O\)Y5LLLUQ_WCBSK)%X M'M9O08/O5K>S>F&:)>P;0&55\YQ':RP S1-,.VVJF_O1YC9'XS20E.TID++ >M7B'O+,Rf2L.4H"9I@5%::(K6%'3_7>]V?
*FO^3X;E?V-_1%KF^,?_7YW M";LY9=7L@[.V%/BJ|..04:M,YE>4923U:'Z1>%)<'1^,W|M6MVS(>Z(/7XFQO MCR]/;>\Q7Q'U+9G 4BWE7
*Y5HKP\""T?),N*D[YG)B5+B]LUX!BXQ[#>+/QF3 MNP>]0'T&PO=V]R M:W-H965T1&B$V &ZP!^#5 .^U +\&^*712EEI M:T05C?]"KXC0T(KURJB"&;KHR!(6];A.TI39HU
*8'U59[5>W1Z7K/3LD=O]0V":W8P@T-_MGN_[SHY20Y03.+Y9:MA(#5\A=3>M;B"=@C"FU$&ZMZ942V1;SCN-\T[!!=5I MTWU+9%ONNXW[!L%]OXQC46 =76<*D%T1O,BNLR6.]
*EL/"Z!+ -+/#;NJG20U M!86N.4=[C=;>OW/4I*CW!F-!N%LVAB#7V5/@YXVB\ ^O&O*,W-;GU!A/]>>#_MY73P.VJ-]),(MI;$=?I>WTH[!55SMK0 ,,%MK!&!^.V?TO5GJVM<[UW=N\I
M0YC;!0;A3B+,&PV8[GYQ!A(,DD8S!'GG'6Q$$354%83Q?.RUYMRA1U>,5Q@ M$PY"|^#[.>=[/=%M7M/61W\ 4$L#!!0 (.F!9EDMTN%2@=_*!D) 9 M >&PO=V]R:W-H965TNKJTFL?
*JCXX, G6&R)IJG,J#KUH)M+1.-??# M(S\FK+&RY?VV;W,EZ+3G#5P+XG]ZIK*QP_Q6GES;RG!Y_9H=+F@9|O6WJ M+>@Ol;W$F3]&*5D-C6*B(1+V*^]N=KM>&'MK|
>#DYJ,B5&R$^*KF?Q2KKS M &'0IL(%&]'6 /G)A!B?!MB>N.2QG$Z?HK^T6I'+3NJ#"WXGZS4U'U#-#A$5FA/9F5MJ*;Y4HH3D<8;HYF!S8WU1C6L,5]OJR6^9>BG\VW7MASP
*MLVC*R8:I@@O525#D!{+%BBD[CF.Q)W=%(3LHR4\/6#*G|&F)+_I"B19=U*B M/_F5T1WC3#-\^W8#FC+^#L-\V6{(YS?OR!0"&O)(}3]%KFKI:Z0W#'XQD'[H M2<.72*&]
*(5'PGH1!&#OB'=/"^F. M#XFPV;%!007R5 =3O."D-(]C!\3"D>*3=5[&+N MP\ZG-'$29F?,+]LPBMW,\Y%Y?A5S"U*)f@%."]&TDW+N6# ^*SC/KL,I0C9LR M&2F3_U8:!VA
XMVDEL8PICY0TSS?K4X$@=<')TIN#0*TUGJ%I"_M+KTMQA M,%5]#]6XKXH|:-5 =\Z9]O;Q0>($63#]C.VRR%]>C=39]!]*Z9C\B==_MNACZ, _^W/IO LPNH-
*$O/P"]MXGGF!E^,X{LKZV6"+*R:*\$7%PTBSI(X/$-W M6"W2(#J#]R<[J3G%?*+RP!I%..S1+[A)4;OL3P;]1(O6;]X[H7&KML,*#U,@ MC0&^WPNAGR9FOQZ/9_D_4$L#!!0 (.F!9EE5.
*O2K , @1 9 M>&PO=V]R:W-H965T4HMJQL2 'K9YB'F9LI2KJ9-HG=^YKHH2R*BZ%CEPG-D(F5&-?;EU52Z!QA;4I:[O M>2,WHXP[P<2.+64P$85.&8>E)*K(,B]?
*[R$5^ZG3\?IU$I,X&'IA?V#W3ON94T5/(CT;O;K9.K<.B2& M#2U2_5GL?X=]/F!#/%XE4V?]D7]EZ#HD*I456@=&#C/'RDSY5<3@:(S]SP*\ M_FO X U OP+T7P-&Z
*&%6#PWA6&%)TL"KR/ 447M.4A$O%]5"%!$6NR"R.F1$3)QYYF9%&VHL0 M-&7I)5I\687DXN?+B:O1$\/G1M6]]^6J_ANKCLE"<)TH,NG@_O-^TGW9X"!"">V_"Y^^'^RW! MZ-
=)T;=_7.30FS(1\&O(JH2S(D=,WXEE >DP^,4QZ9WLPF!OR3N4T@JF#5Z "N0.G^.6GWLC]K4F@+LG"+LGF'9$= M23FHH1RTL0?
+0D8)7J16NUSB^R+ULU4,OA7C"Y\]EPF4&A$Y!X14EI.%)&URRULCF?:S,+6+9^K3D=D1^H,:W6&K>H\\@@?=P7D(HI;R=6=$

Z8%F61A&PO=V]R:W-H965T&UL4$L! A0#% @ MZ8%F654X"]*L P "'!$!D ("!]7(! 'AL+W=O&PO&PO7W)E,';O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 M " #!@699P(AM=.D! !^)0 $P @ &;@@$ 6T-O;G1E C;G1?5'EP97-=+GAM;%!+!08 2 !(*\3 "UA $! end XML 75 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif, text-align: left; } .report .pl { text-align: left, vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 235 322 1 false 63 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Cash Flows Sheet http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 9 false false R10.htm 995455 - Disclosure - Nature of Business Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusiness Nature of Business Notes 10 false false R11.htm 995465 - Disclosure - Summary of Significant Accounting Policies Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995475 - Disclosure - Marketable Securities Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecurities Marketable Securities Notes 12 false false R13.htm 995485 - Disclosure - Fair Value Measurements Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 995495 - Disclosure - Property and Equipment, Net Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet Property and Equipment, Net Notes 14 false false R15.htm 995505 - Disclosure - Leases Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureLeases Leases Notes 15 false false R16.htm 995515 - Disclosure - Liability Related to Sale of Future Royalties Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyalties Liability Related to Sale of Future Royalties Notes 16 false false R17.htm 995535 - Disclosure - Capitalization Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalization Capitalization Notes 17 false false R18.htm 995545 - Disclosure - License and Collaboration Agreements Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements License and Collaboration Agreements Notes 18 false false R19.htm 995555 - Disclosure - Stock-based Compensation Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-based Compensation Notes 19 false false R20.htm 995565 - Disclosure - Income Taxes Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 20 false false R21.htm 995585 - Disclosure - Restructuring Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuring Restructuring Notes 21 false false R22.htm 995595 - Disclosure - Net Loss Per Share Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShare Net Loss Per Share Notes 22 false false R23.htm 995605 - Disclosure - Supplemental Disclosures Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosures Supplemental Disclosures Notes 23 false false R24.htm 995625 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 24 false false R25.htm 995635 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies 25 false false R26.htm 995645 - Disclosure - Marketable Securities (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesTables Marketable Securities (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecurities 26 false false R27.htm 995655 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables 27 false false R28.htm 995665 - Disclosure - Property and Equipment, Net (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet 28 false false R29.htm 995685 - Disclosure - Liability Related to Sale of Future Royalties (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesTables Liability Related to Sale of Future Royalties (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyalties 29 false false R30.htm 995695 - Disclosure - License and Collaboration Agreements (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables License and Collaboration Agreements (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements 30 false false R31.htm 995705 - Disclosure - Stock-based Compensation (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-based Compensation (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation 31 false false R32.htm 995715 - Disclosure - Restructuring (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringTables Restructuring (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuring 32 false false R33.htm 995725 - Disclosure - Net Loss Per Share (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShare 33 false false R34.htm 995735 - Disclosure - Supplemental Disclosures (Tables) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresTables Supplemental Disclosures (Tables) Tables http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosures 34 false false R35.htm 995745 - Disclosure - Nature of Business - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail Nature of Business - Additional Information (Detail) Details 35 false false R36.htm 995755 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCas Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail) Details 36 false false R37.htm 995775 - Disclosure - Marketable Securities - Summary of Company Marketable Securities (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail Marketable Securities - Summary of Company Marketable Securities (Detail) Details 37 false false R38.htm 995785 - Disclosure - Marketable Securities - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail Marketable Securities - Additional Information (Detail) Details 38 false false R39.htm 995795 - Disclosure - Marketable Securities - Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnrea Marketable Securities - Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater (Detail) Details 39 false false R40.htm 995805 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Cash Equivalents and Marketable Securities (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail Fair Value Measurements - Schedule of Fair Value of Cash Equivalents and Marketable Securities (Detail) Details 40 false false R41.htm 995815 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail Property and Equipment, Net - Schedule of Property and Equipment (Detail) Details 41 false false R42.htm 995825 - Disclosure - Property and Equipment, Net - Additional Information (Details) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails Property and Equipment, Net - Additional Information (Details) Details 42 false false R43.htm 995835 - Disclosure - Leases - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 43 false false R44.htm 995845 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails Liability Related to Sale of Future Royalties - Additional Information (Details) Details 44 false false R45.htm 995855 - Disclosure - Liability Related to Sale of Future Royalties -Schedule of Activity Within Liability Related to Sale of Future Royalties (Details) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetail Liability Related to Sale of Future Royalties -Schedule of Activity Within Liability Related to Sale of Future Royalties (Details) Details 45 false false R46.htm 995875 - Disclosure - Capitalization - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail Capitalization - Additional Information (Detail) Details 46 false false R47.htm 995885 - Disclosure - License and Collaboration Agreements - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail License and Collaboration Agreements - Additional Information (Detail) Details 47 false false R48.htm 995895 - Disclosure - License and Collaboration Agreements - Schedule Of License and Royalty Revenue (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail License and Collaboration Agreements - Schedule Of License and Royalty Revenue (Detail) Details 48 false false R49.htm 995905 - Disclosure - License and Collaboration Agreements - Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue (Detail) Sheet

http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRev License and Collaboration Agreements - Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue (Detail) Details 49 false false R50.htm 995915 - Disclosure - License and Collaboration Agreements - Summary of Accounts Recerivable, Net (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail License and Collaboration Agreements - Summary of Accounts Recerivable, Net (Detail) Details 50 false false R51.htm 995925 - Disclosure - License and Collaboration Agreements - Summary of Changes in Allowance For Credit Losses (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail License and Collaboration Agreements - Summary of Changes in Allowance For Credit Losses (Detail) Details 51 false false R52.htm 995935 - Disclosure - License and Collaboration Agreements - Schedule Of License Revenue (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail License and Collaboration Agreements - Schedule Of License Revenue (Detail) Details 52 false false R53.htm 995945 - Disclosure - License and Collaboration Agreements -Schedule of AbbVie Collaboration Agreement (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail License and Collaboration Agreements -Schedule of AbbVie Collaboration Agreement (Detail) Details 53 false false R54.htm 995955 - Disclosure - Stock-based Compensation - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail Stock-based Compensation - Additional Information (Detail) Details 54 false false R55.htm 995965 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense by Award Type (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail Stock-based Compensation - Stock-Based Compensation Expense by Award Type (Detail) Details 55 false false R56.htm 995975 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail Stock-based Compensation - Stock-Based Compensation Expense (Detail) Details 56 false false R57.htm 995985 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail Stock-based Compensation - Summary of Stock Option Activity (Detail) Details 57 false false R58.htm 995995 - Disclosure - Stock-based Compensation - Summary of Unvested RSUs Activity Under 2015 Plan (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail Stock-based Compensation - Summary of Unvested RSUs Activity Under 2015 Plan (Detail) Details 58 false false R59.htm 996005 - Disclosure - Restructuring - Additional Information (Details) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails Restructuring - Additional Information (Details) Details 59 false false R60.htm 996015 - Disclosure - Restructuring - Summary of Restructuring Liability (Details) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringLiabilityDetails Restructuring - Summary of Restructuring Liability (Details) Details 60 false false R61.htm 996035 - Disclosure - Net Loss Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail Net Loss Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail) Details 61 false false R62.htm 996055 - Disclosure - Supplemental Disclosures - Schedule of Other Current Assets (Details) Sheet http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails Supplemental Disclosures - Schedule of Other Current Assets (Details) Details 62 false false R63.htm 996065 - Disclosure - Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail) Details 63 false false R64.htm 996075 - Disclosure - Supplemental Disclosures - Additional Information (Detail) Sheet http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail Supplemental Disclosures - Additional Information (Detail) Details 64 false false All Reports Book All Reports rgnx-20240930.htm rgnx-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rgnx-20240930.htm": { "nsprefix": "rgnx", "nsuri": "http://regenxbio.com/20240930", "dts": { "inline": { "local": ["rgnx-20240930.htm"] }, "schema": { "local": ["rgnx-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 255, "keyCustom": 67, "axisStandard": 24, "axisCustom": 0, "memberStandard": 28, "memberCustom": 28, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2024": 4, "http://fasb.org/us-gaap/2024": 4, "http://regenxbio.com/20240930": 1 }, "contextCount": 235, "entityCount": 1, "segmentCount": 63, "elementCount": 664, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 683, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 5 }, "report": { "R1": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets", "longName": "100010 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R3": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R4": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R5": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity", "longName": "100040 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_3650b697-fc01-4e3f-be89-e303ab2c32a3", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3650b697-fc01-4e3f-be89-e303ab2c32a3", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical", "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)", "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_bbc0712e-e57f-41b0-ab80-c99637da2095", "name": "rgnx:TransactionCostsAssociatedWithStockIssuance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_bbc0712e-e57f-41b0-ab80-c99637da2095", "name": "rgnx:TransactionCostsAssociatedWithStockIssuance", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows", "longName": "100060 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_c31b605b-f5df-4d09-b51f-091c2cdb1c92", "name": "ecd:TrdArrIndTitle", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c31b605b-f5df-4d09-b51f-091c2cdb1c92", "name": "ecd:TrdArrIndTitle", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusiness", "longName": "995455 - Disclosure - Nature of Business", "shortName": "Nature of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995465 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-

gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecurities", "longName": "995475 - Disclosure - Marketable Securities", "shortName": "Marketable Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet", "longName": "995495 - Disclosure - Property and Equipment, Net", "shortName": "Property and Equipment, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeases", "longName": "995505 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyalties", "longName": "995515 - Disclosure - Liability Related to Sale of Future Royalties", "shortName": "Liability Related to Sale of Future Royalties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalization", "longName": "995535 - Disclosure - Capitalization", "shortName": "Capitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements", "longName": "995545 - Disclosure - License and Collaboration Agreements", "shortName": "License and Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation", "longName": "995555 - Disclosure - Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995565 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuring", "longName": "995585 - Disclosure - Restructuring", "shortName": "Restructuring", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShare", "longName": "995595 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosures", "longName": "995605 - Disclosure - Supplemental Disclosures", "shortName": "Supplemental Disclosures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "995625 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "24", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "995635 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesTables", "longName": "995645 - Disclosure - Marketable Securities (Tables)", "shortName": "Marketable Securities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables", "longName": "995655 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables", "longName": "995665 - Disclosure - Property and Equipment, Net (Tables)", "shortName": "Property and Equipment, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesTables", "longName": "995685 - Disclosure - Liability Related to Sale of Future Royalties (Tables)", "shortName": "Liability Related to Sale of Future Royalties (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name":

```
"rgnx:ScheduleOfChangesInLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:ScheduleOfChangesInLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables", "longName": "995695 - Disclosure - License and Collaboration Agreements (Tables)", "shortName": "License and Collaboration Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:ScheduleOfLicenseRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:ScheduleOfLicenseRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "longName": "995705 - Disclosure - Stock-based Compensation (Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringTables", "longName": "995715 - Disclosure - Restructuring (Tables)", "shortName": "Restructuring (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareTables", "longName": "995725 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresTables", "longName": "995735 - Disclosure - Supplemental Disclosures (Tables)", "shortName": "Supplemental Disclosures (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail", "longName": "995745 - Disclosure - Nature of Business - Additional Information (Detail)", "shortName": "Nature of Business - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R36": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCa "longName": "995755 - Disclosure - Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)", "shortName": "Summary of Significant Accounting Policies - Summary of Reconciliation of Cash and Cash Equivalents and Restricted Cash (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_63743253-cadd-40ce-b14f-9063c24aa5bb", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R37": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail", "longName": "995775 - Disclosure - Marketable Securities - Summary of Company Marketable Securities (Detail)", "shortName": "Marketable Securities - Summary of Company Marketable Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "longName": "995785 - Disclosure - Marketable Securities - Additional Information (Detail)", "shortName": "Marketable Securities - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "rgnx:AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_3a7dca2c-2ce1-4b91-a45d-4d47e63d09c4", "name": "rgnx:AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "rgnx:AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears", "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R39": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre "longName": "995795 - Disclosure - Marketable Securities - Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater (Detail)", "shortName": "Marketable Securities - Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail", "longName": "995805 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Cash Equivalents and Marketable Securities (Detail)", "shortName": "Fair Value Measurements - Schedule of Fair Value of Cash Equivalents and Marketable Securities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_882d3a18-d027-47ba-9d41-ba093fa0972a", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueDisclosuresTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R41": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail", "longName": "995815 - Disclosure - Property and Equipment Net - Schedule of Property and Equipment (Detail)", "shortName": "Property and Equipment Net - Schedule of Property and Equipment (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails", "longName": "995825 - Disclosure - Property and Equipment, Net - Additional Information (Details)", "shortName": "Property and Equipment, Net - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ed4ad1ed-3cad-45a4-a7fc-b4b5c9f6a0ea", "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-
```

gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true }], "R43": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "longName": "995835 - Disclosure - Leases - Additional Information (Detail)", "shortName": "Leases - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ca189ac7-9e5f-40c7-8cc2-97b62afaf308", "name": "us-gaap:SubleaseIncome", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R44": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "longName": "995845 - Disclosure - Liability Related to Sale of Future Royalties - Additional Information (Details)", "shortName": "Liability Related to Sale of Future Royalties - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:RepurchaseOfCallOptionAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:RepurchaseOfCallOptionAmount", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R45": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai "longName": "995855 - Disclosure - Liability Related to Sale of Future Royalties -Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)", "shortName": "Liability Related to Sale of Future Royalties -Schedule of Activity Within Liability Related to Sale of Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_ba202343-7ec9-4f1b-a48f-54f5980090ce", "name": "rgnx:LiabilityRelatedToSaleOfFutureRoyalties", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:ScheduleOfChangesInLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "div", "rgnx:LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R46": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail", "longName": "995875 - Disclosure - Capitalization - Additional Information (Detail)", "shortName": "Capitalization - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_fd7b4222-3236-4f36-b1eb-bdbc1632f1a2", "name": "us-gaap:ProceedsFromIssuanceOfPrivatePlacement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_eb22cf93-adbe-4a6a-0fc0-b0b39f54f68c", "name": "rgnx:PercentageOfCommonStockOwned", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R47": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail", "longName": "995885 - Disclosure - License and Collaboration Agreements - Additional Information (Detail)", "shortName": "License and Collaboration Agreements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:MilestoneFeePaymentsUponCommencementOfClinicalTrials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "rgnx:MilestoneFeePaymentsUponCommencementOfClinicalTrials", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail", "longName": "995895 - Disclosure - License and Collaboration Agreements - Schedule Of License and Royalty Revenue (Detail)", "shortName": "License and Collaboration Agreements - Schedule Of License and Royalty Revenue (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "rgnx:OtherLicenseAndRoyaltyRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:ScheduleOfLicenseRevenueTableTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "rgnx:OtherLicenseAndRoyaltyRevenue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:ScheduleOfLicenseRevenueTableTextBlock", "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe "longName": "995905 - Disclosure - License and Collaboration Agreements - Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue (Detail)", "shortName": "License and Collaboration Agreements - Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_cc033d1b-5eed-4dbc-8bb9-984e41f37e12", "name": "us-gaap:AccountsReceivableNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:SummaryOfChangesInReceivablesAndContractAssetsAndContractLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:DeferredRevenueRevenueRecognized1", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:SummaryOfChangesInReceivablesAndContractAssetsAndContractLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R50": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail", "longName": "995915 - Disclosure - License and Collaboration Agreements - Summary of Accounts Recerivable, Net (Detail)", "shortName": "License and Collaboration Agreements - Summary of Accounts Recerivable, Net (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:BilledContractReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:AccountsReceivableTableTextBlock1", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:BilledContractReceivables", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:AccountsReceivableTableTextBlock1", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail", "longName": "995925 - Disclosure - License and Collaboration Agreements - Summary of Changes in Allowance For Credit Losses (Detail)", "shortName": "License and Collaboration Agreements - Summary of Changes in Allowance For Credit Losses (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_3a7dca2c-2ce1-4b91-a45d-4d47e63d09c4", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_3a7dca2c-2ce1-4b91-a45d-4d47e63d09c4", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail", "longName": "995935 - Disclosure - License and Collaboration Agreements - Schedule Of License Revenue (Detail)", "shortName": "License and Collaboration Agreements - Schedule Of License Revenue (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "rgnx:InterestIncomeFromLicencing", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_9d02b155-7983-48b2-8721-d1dc798ed490", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "rgnx:ScheduleOfLicenseRevenueTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R53": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail", "longName": "995945 - Disclosure - License and Collaboration Agreements -Schedule of AbbVie Collaboration Agreement (Detail)", "shortName": "License and Collaboration Agreements -Schedule of AbbVie Collaboration Agreement (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "rgnx:DueFromAndToRelatedPartiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "rgnx:DueFromAndToRelatedPartiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "longName": "995955 - Disclosure - Stock-based Compensation - Additional Information (Detail)", "shortName": "Stock-based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail", "longName": "995965 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense by Award Type (Detail)", "shortName": "Stock-based Compensation - Stock-Based Compensation Expense by Award Type (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b6f8831f-aba4-4973-ae01-0ba97acf1175", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R56": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationExpenseDetail", "longName": "995975 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Detail)", "shortName": "Stock-based Compensation - Stock-Based Compensation Expense

```
(Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b73dc12d-9f7f-4ace-a144-f1ba9239d68f", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R57": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail", "longName": "995985 - Disclosure - Stock-based Compensation - Summary of Stock Option Activity (Detail)", "shortName": "Stock-based Compensation - Summary of Stock Option Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_48f09007-375f-44a9-b025-95908ac78e73", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_4e5401f0-9317-44b7-aac8-7876def99e14", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R58": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail", "longName": "995995 - Disclosure - Stock-based Compensation - Summary of Unvested RSUs Activity Under 2015 Plan (Detail)", "shortName": "Stock-based Compensation - Summary of Unvested RSUs Activity Under 2015 Plan (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_a9da9189-cc57-4d8c-8491-cb3b27f3e788", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a9da9189-cc57-4d8c-8491-cb3b27f3e788", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R59": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails", "longName": "996005 - Disclosure - Restructuring - Additional Information (Details)", "shortName": "Restructuring - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_e34fcfae-3fa9-4da6-a86e-1fff0e2f94ac", "name": "rgnx:PercentageOfReductionInWorkforce", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringLiabilityDetails", "longName": "996015 - Disclosure - Restructuring - Summary of Restructuring Liability (Details)", "shortName": "Restructuring - Summary of Restructuring Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "C_3a7dca2c-2ce1-4b91-a45d-4d47e63d09c4", "name": "us-gaap:RestructuringReserve", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:PaymentsForRestructuring", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R61": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail", "longName": "996035 - Disclosure - Net Loss Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail)", "shortName": "Net Loss Per Share - Schedules for Computation of Diluted Weighted-Average Shares Outstanding (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_28193825-e763-4650-bcf3-3c8ffd9d3b46", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R62": { "role": "http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails", "longName": "996055 - Disclosure - Supplemental Disclosures - Schedule of Other Current Assets (Details)", "shortName": "Supplemental Disclosures - Schedule of Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "rgnx:AccountsReceivableTableTextBlock1", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_93439ab4-004f-413e-b11a-4badd5dd292c", "name": "rgnx:AccruedInterestOnInvestments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "div", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "unique": true } }, "R63": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "longName": "996065 - Disclosure - Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail)", "shortName": "Supplemental Disclosures - Schedules of Accrued Expenses and Other Current Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "rgnx:AccruedExternalResearchAndDevelopmentExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d914a680-a032-4934-b7ce-1e541eb580f6", "name": "rgnx:AccruedExternalResearchAndDevelopmentExpenses", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "div", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail", "longName": "996075 - Disclosure - Supplemental Disclosures - Additional Information (Detail)", "shortName": "Supplemental Disclosures - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_735082b2-aae6-4291-8135-8baf3698b1af", "name": "us-gaap:CapitalExpendituresIncurredButNotYetPaid", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "rgnx-20240930.htm", "first": true, "unique": true } } }, "tag": { "rgnx_ANJerryKarabelasMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "ANJerryKarabelasMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "A N Jerry Karabelas.", "label": "A N Jerry Karabelas [Member]", "terseLabel": "A N Jerry Karabelas [Member]" } } }, "auth_ref": [] }, "rgnx_AbbVieCollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AbbVieCollaborationAndLicenseAgreementMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Abb Vie Collaboration And License Agreement", "label": "Abb Vie Collaboration And License Agreement [Member]", "documentation": "AbbVie collaboration and license agreement." } } }, "auth_ref": [] }, "rgnx_AbeonaTherapeuticsIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AbeonaTherapeuticsIncorporationMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Abeona Therapeutics Incorporation", "label": "Abeona Therapeutics Incorporation [Member]", "documentation": "Abeona Therapeutics Inc" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndNotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsAndNotesReceivableNet", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total accounts receivable, net", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivable. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r860", "r960" ] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosures" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental Disclosures", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r395" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r49", "r728" ] }, "us-gaap_AccountsReceivableGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGross", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, before Allowance for Credit Loss", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": [ "r147", "r219", "r220", "r960" ] }, "us-gaap_AccountsReceivableGrossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossCurrent", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts receivable, current", "label": "Accounts Receivable, before Allowance for Credit Loss, Current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r147", "r220", "r687" ] }, "us-gaap_AccountsReceivableGrossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableGrossNoncurrent", "crdr": "debit", "presentation": [
```

"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "totalLabel": "Accounts Receivable, before Allowance for Credit Loss, Noncurrent, Total", "label": "Accounts Receivable, before Allowance for Credit Loss, Noncurrent", "terseLabel": "Accounts receivable, Non-current", "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent." } } }, "auth_ref": ["r114", "r220", "r268", "r880"] }, "us-gaap_AccountsReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNet", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Accounts Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business." } } }, "auth_ref": ["r616", "r677", "r738", "r959", "r960"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r860"] }, "us-gaap_AccountsReceivableNetCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrentAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Current accounts receivable:", "label": "Accounts Receivable, after Allowance for Credit Loss, Current [Abstract]" } } }, "auth_ref": [] }, "rgnx_AccountsReceivableNetCurrentAndNonCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccountsReceivableNetCurrentAndNonCurrentAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net, current and non-current:", "label": "Accounts Receivable Net Current And Non Current [Abstract]", "documentation": "Accounts receivable net, current and non current." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetNoncurrent", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "totalLabel": "Non-current accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent." } } }, "auth_ref": ["r540", "r860"] }, "us-gaap_AccountsReceivableNetNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetNoncurrentAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Non-current accounts receivable:", "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "rgnx_AccountsReceivableTableTextBlock1": { "xbrltype": "textBlockItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccountsReceivableTableTextBlock1", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Accounts Receivables, net", "label": "Accounts Receivable Table Text Block1", "documentation": "Accounts receivable net non current." } } }, "auth_ref": [] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Net amortization of premiums (accretion of discounts) on marketable debt securities", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r82"] }, "rgnx_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accrued expenses and other current liabilities", "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "rgnx_AccruedExpensesAndOtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Expenses and Other Current Liabilities [Member]", "label": "Accrued Expenses And Other Current Liabilities [Member]", "documentation": "Accrued expenses and other current liabilities." } } }, "auth_ref": [] }, "rgnx_AccruedExternalGeneralAndAdministrativeExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedExternalGeneralAndAdministrativeExpenses", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued external general and administrative expenses", "label": "Accrued External General And Administrative Expenses", "documentation": "Accrued external general and administrative expenses," } } }, "auth_ref": [] }, "rgnx_AccruedExternalResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedExternalResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued external research and development expenses", "label": "Accrued External Research And Development Expenses", "documentation": "Accrued external research and development expenses." } } }, "auth_ref": [] }, "rgnx_AccruedInterestOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedInterestOnInvestments", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Accrued interest on investments.", "label": "Accrued Interest on Investments" } } }, "auth_ref": [] }, "rgnx_AccruedPurchasesOfPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedPurchasesOfPropertyAndEquipment", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued purchases of property and equipment", "label": "Accrued Purchases Of Property And Equipment", "documentation": "Accrued purchases of property and equipment." } } }, "auth_ref": [] }, "rgnx_AccruedSublicenseFeesAndRoyaltiesOnReagentSales": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AccruedSublicenseFeesAndRoyaltiesOnReagentSales", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued sublicense fees and royalties", "label": "Accrued Sublicense Fees And Royalties On Reagent Sales", "documentation": "Accrued sublicense fees and royalties on reagent sales." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "negatedLabel": "Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r32", "r144", "r555"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total", "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r16", "r17", "r65", "r149", "r551", "r580", "r581"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss [Member]", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r9", "r17", "r427", "r430", "r485", "r576", "r577", "r843", "r844", "r845", "r851", "r852", "r853", "r854"] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r782"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid-in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r60"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Additional paid in capital [Member]", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r591", "r851", "r852", "r853", "r854", "r933", "r994"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r795"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r795"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r795"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r795"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based

payment arrangement." } } }, "auth_ref": { "r38", "r39", "r359" } }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "rgnx_AggregateOfferingPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AggregateOfferingPrice", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Aggregate offering price.", "label": "Aggregate Offering Price", "terseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "rgnx_AggregateTransactionPriceOfLicenseAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AggregateTransactionPriceOfLicenseAgreements", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate transaction price of license agreements", "label": "Aggregate Transaction Price Of License Agreements", "documentation": "Aggregate transaction price of license agreements." } } }, "auth_ref": [] }, "rgnx_AggregateTransactionPriceOfLicenseAgreementsExpectedSatisfactionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AggregateTransactionPriceOfLicenseAgreementsExpectedSatisfactionPeriod", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate transaction price of license agreements, expected satisfaction period", "label": "Aggregate Transaction Price Of License Agreements Expected Satisfaction Period", "documentation": "Aggregate transaction price of license agreements, expected satisfaction period." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r828"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r754", "r764", "r774", "r806"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r757", "r767", "r777", "r809"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r829"] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r795"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r802"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r758", "r768", "r778", "r802", "r810", "r814", "r822"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r820"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r388", "r393"] }, "rgnx_AllowanceForCreditLossesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AllowanceForCreditLossesCurrent", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsReceivableNetDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Allowance for credit losses", "label": "Allowance For Credit Losses Current", "documentation": "Allowance for credit losses, current." } } }, "auth_ref": [] }, "us-gaap_AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForCreditLossesOnFinancingReceivablesTableTextBlock", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Allowance For Credit Losses", "label": "Financing Receivable, Allowance for Credit Loss [Table Text Block]", "documentation": "Tabular disclosure of allowance for credit loss on financing receivable." } } }, "auth_ref": ["r110", "r881"] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance", "terseLabel": "Allowance for credit losses", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r150", "r224", "r262", "r265", "r267", "r960"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "rgnx_AmountPayableToNetPresentValueDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AmountPayableToNetPresentValueDiscount", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Amount payable to net present value discount", "label": "Amount Payable To Net Present Value Discount", "documentation": "Amount payable to net present value discount." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail"], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive securities excluded from computation of diluted weighted average shares outstanding", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r201"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r25"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail"], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r25"] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r418"] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "netLabel": "Impairment of long-lived assets", "verboseLabel": "Impairment losses of long-lived assets", "totalLabel": "Total impairment of long-lived assets", "terseLabel": "Property and equipment, net", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": ["r5", "r30"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r101", "r109", "r146", "r175", "r206", "r208", "r214", "r215", "r259", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r420", "r424", "r462", "r547", "r621", "r693", "r694", "r728", "r745", "r898", "r899", "r947"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r140", "r153", "r175", "r259", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r420", "r424", "r462", "r728", "r898", "r899", "r947"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail",

"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of asset", "totalLabel": "Total cash equivalents and marketable securities", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r438", "r439", "r715"] }, "rgnx_AtTheMarketOfferingProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AtTheMarketOfferingProgramMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "At the market offering program.", "label": "At The Market Offering Program [Member]", "terseLabel": "At the Market Offering Program" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r232"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r233"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost / Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r229", "r272", "r546"] }, "rgnx_AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "AvailableForSaleDebtSecuritiesRemainingMaturitiesGreaterThanThreeYears", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Available for sale debt securities remaining maturities greater than three years", "label": "Available For Sale Debt Securities Remaining Maturities Greater Than Three Years", "documentation": "Available for sale debt securities remaining maturities greater than three years." } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Total", "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r230", "r272", "r438", "r539", "r715", "r719", "r862", "r937", "r938", "r939"] }, "us-gaap_AwardDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateAxis", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award Date", "label": "Award Date [Axis]", "documentation": "Information by date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930"] }, "us-gaap_AwardDateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardDateDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award Date", "label": "Award Date [Domain]", "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "auth_ref": ["r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r817"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r818"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r813"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r813"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r813"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r813"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r813"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r813"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r816"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r815"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r814"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r814"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r294", "r962", "r963"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r42", "r43", "r294", "r962", "r963"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Principles of Consolidation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BilledContractReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BilledContractReceivables", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail"], "lang": { "en-us": { "role": { "terseLabel": "Billed to customers", "label": "Billed Contracts Receivable", "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date." } } }, "auth_ref": ["r531"] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r22", "r23", "r24"] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents:", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCa
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value

{"auth_ref":{"r20":["r142","r686"]},"us-gaap_CashAndCashEquivalentsAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsAxis","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail"],"lang":{"en-us":{"role":{"terseLabel":"Cash and Cash Equivalents","label":"Cash and Cash Equivalents [Axis]","documentation":"Information by type of cash and cash equivalent balance."}}},"auth_ref":["r142"]},"us-gaap_CashAndCashEquivalentsFairValueDisclosure":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsFairValueDisclosure","crdr":"debit","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail"],"lang":{"en-us":{"role":{"terseLabel":"Total cash equivalents","label":"Cash and Cash Equivalents, Fair Value Disclosure","documentation":"Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":["r935","r936"]},"us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy":{"xbrltype":"textBlockItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"],"lang":{"en-us":{"role":{"terseLabel":"Restricted Cash","label":"Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]","documentation":"Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."}}},"auth_ref":["r21","r100"]},"us-gaap_CashCashEquivalentsAndShortTermInvestments":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsAndShortTermInvestments","crdr":"debit","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail"],"lang":{"en-us":{"role":{"totalLabel":"Cash, Cash Equivalents, and Short-Term Investments, Total","terseLabel":"Cash, cash equivalents and marketable securities","label":"Cash, Cash Equivalents, and Short-Term Investments","documentation":"Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."}}},"auth_ref":["r842"]},"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents","crdr":"debit","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCa
],"lang":{"en-us":{"role":{"periodEndLabel":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance","periodStartLabel":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance","totalLabel":"Total cash and cash equivalents and restricted cash","label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents","documentation":"Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":["r20","r78","r172"]},"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"terseLabel":"Cash and cash equivalents and restricted cash","label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"}}},"auth_ref":[]},"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations","crdr":"debit","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"totalLabel":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total","periodStartLabel":"Beginning of period","periodEndLabel":"End of period","label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations","documentation":"Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":["r20","r78","r172"]},"us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect":{"xbrltype":"monetaryItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect","crdr":"debit","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"],"lang":{"en-us":{"role":{"totalLabel":"Net increase (decrease) in cash and cash equivalents and restricted cash","label":"Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect","documentation":"Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":["r1","r78"]},"rgnx_CashEquivalentsAndMarketableSecuritiesMember":{"xbrltype":"domainItemType","nsuri":"http://regenxbio.com/20240930","localname":"CashEquivalentsAndMarketableSecuritiesMember","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail"],"lang":{"en-us":{"role":{"documentation":"Cash equivalents and marketable securities.","label":"Cash Equivalents And Marketable Securities [Member]","terseLabel":"Cash Equivalents and Marketable Securities [Member]"}}},"auth_ref":[]},"us-gaap_CashEquivalentsMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CashEquivalentsMember","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail"],"lang":{"en-us":{"role":{"terseLabel":"Cash Equivalents [Member]","label":"Cash Equivalents [Member]","documentation":"Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."}}},"auth_ref":["r142"]},"us-gaap_CertificatesOfDepositMember":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"CertificatesOfDepositMember","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail","http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail","http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
],"lang":{"en-us":{"role":{"terseLabel":"Certificates of Deposit [Member]","label":"Certificates of Deposit [Member]","documentation":"Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."}}},"auth_ref":["r8","r739","r740","r741","r742"]},"rgnx_ChangeInTransactionPriceOfLicense":{"xbrltype":"monetaryItemType","nsuri":"http://regenxbio.com/20240930","localname":"ChangeInTransactionPriceOfLicense","crdr":"debit","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"],"lang":{"en-us":{"role":{"terseLabel":"Change in transaction price","label":"Change In Transaction Price Of License","documentation":"Change in transaction price of license."}}},"auth_ref":[]},"ecd_ChangedPeerGroupFnTextBlock":{"xbrltype":"textBlockItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"ChangedPeerGroupFnTextBlock","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Changed Peer Group, Footnote [Text Block]","terseLabel":"Changed Peer Group, Footnote"}}},"auth_ref":["r793"]},"rgnx_ChangesInPresentValueDiscountOfReceivables":{"xbrltype":"monetaryItemType","nsuri":"http://regenxbio.com/20240930","localname":"ChangesInPresentValueDiscountOfReceivables","crdr":"credit","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail"],"lang":{"en-us":{"role":{"terseLabel":"Changes in present value discount of receivables","label":"Changes In Present Value Discount Of Receivables","documentation":"Changes in present value discount of receivables."}}},"auth_ref":[]},"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]","terseLabel":"Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"}}},"auth_ref":["r790"]},"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember":{"xbrltype":"domainItemType","nsuri":"http://xbrl.sec.gov/ecd/2024","localname":"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember","presentation":["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],"lang":{"en-us":{"role":{"label":"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]","terseLabel":"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"}}},"auth_ref":["r788"]},"dei_CityAreaCode":{"xbrltype":"normalizedStringItemType","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"CityAreaCode","presentation":["http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"],"lang":{"en-us":{"role":{"terseLabel":"City Area Code","label":"City Area Code","documentation":"Area code of city"}}},"auth_ref":[]},"us-gaap_ClassOfWarrantOrRightAxis":{"xbrltype":"stringItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ClassOfWarrantOrRightAxis","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail","http://regenxbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"],"lang":{"en-us":{"role":{"label":"Class of Warrant or Right [Axis]","documentation":"Information by type of warrant or right issued."}}},"auth_ref":["r35"]},"us-gaap_ClassOfWarrantOrRightDomain":{"xbrltype":"domainItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ClassOfWarrantOrRightDomain","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail","http://regenxbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails"],"lang":{"en-us":{"role":{"label":"Class of Warrant or Right [Domain]","documentation":"Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."}}},"auth_ref":[]},"us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1":{"xbrltype":"perShareItemType","nsuri":"http://fasb.org/us-gaap/2024","localname":"ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1","presentation":["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail"],"lang":{"en-us":{"role":{"terseLabel":"Exercise price of warrants","label":"Class of Warrant or Right, Exercise Price of Warrants or Rights","documentation":"Exercise price per share or per unit of warrants or rights outstanding."}}},"auth_ref":["r339"]},"rgnx_ClassOfWarrantOrRightExercised":{"xbrltype":"sharesItemType","nsuri":"http://regenxbio.com/20240930","localname":

```
"ClassOfWarrantOrRightExercised", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants exercised", "label": "Class Of Warrant Or Right Exercised", "documentation": "Class of warrant or right exercised." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants issued", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r339" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Pre-funded warrants remained outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r794" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r794" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "License and Collaboration Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r123", "r125", "r133" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r94", "r307", "r308", "r678", "r891", "r895" ] }, "us-gaap_CommonStockMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel":
"Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r735", "r736", "r737", "r739", "r740", "r741", "r742", "r851", "r852", "r854", "r933", "r993", "r994" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel":
"Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r59", "r607" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel":
"Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r59", "r607", "r627", "r994", "r995" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value; 100,000 shares authorized at September 30, 2024 and December 31, 2023; 49,534 and 44,046 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r59", "r550", "r728" ] },
"ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r799" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r798" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r800" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r797" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel":
"Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r18", "r159", "r161", "r166", "r542", "r561", "r562" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Computer Equipment and Software [Member]", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "rgnx_ContractAssetsMember": { "xbrltype": "domainItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "ContractAssetsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Assets [Member]", "label": "Contract Assets [Member]", "documentation": "Contract assets." } } }, "auth_ref": [] }, "us-gaap_ContractTerminationClaimsDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractTerminationClaimsDescription", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "License agreement termination claims, description", "label": "Contract Termination Claims, Description", "documentation": "General description of claims, deemed to be reimbursable and included in accounts receivable, relating to the termination of long-term government contracts and programs. Includes claims associated with terminated war and defense contracts. If a reasonable estimate of a termination claim is undeterminable or impossible to make, disclosure is made to discuss the status and circumstances related to the undeterminable claim." } } }, "auth_ref": [ "r47", "r48", "r529", "r530", "r532", "r533", "r534" ] }, "us-gaap_ContractTerminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractTerminationMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Contract Termination", "label": "Contract Termination [Member]", "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": [ "r698", "r699", "r700", "r701" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total", "periodStartLabel": "Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets",
"documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r341", "r343", "r346" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "totalLabel": "Contract with Customer, Liability, Total", "terseLabel": "Deferred revenue, current and non-current", "periodStartLabel":
"Balance, beginning of period", "periodEndLabel": "Balance, end of period", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r341", "r342", "r346" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerLiabilityCurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r341", "r342", "r346" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Revenue recognized", "terseLabel": "Revenue recognition, milestone method, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r347" ] }, "us-gaap_ContractualObligation": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ContractualObligation", "crdr": "credit", "presentation": [
```

```
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Contractual Obligation, Total", "terseLabel": "Amount payable to agreement", "label": "Contractual Obligation", "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments." } } }, "auth_ref": [ "r850" ] }, "us-gaap_CorporateBondSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateBondSecuritiesMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "terseLabel": "Corporate Bonds [Member]", "label": "Corporate Bond Securities [Member]", "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Cost of Goods and Services Sold, Total", "terseLabel": "Cost of revenues", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r66", "r67", "r535" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r76" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Expenses", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "rgnx_CurranSimpsonMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "CurranSimpsonMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Curran Simpson.", "label": "Curran Simpson [Member]", "terseLabel": "Curran Simpson [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate, Effective Percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r53", "r324", "r472", "r473", "r726" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "periodEndLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Ending Balance", "periodStartLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Beginning Balance", "totalLabel": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Total", "terseLabel": "Allowance for credit loss", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r231", "r272", "r280", "r281" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "terseLabel": "12 Months or Greater, Fair Value", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r120", "r277", "r697" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "negatedLabel": "12 Months or Greater, Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r120", "r277" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "terseLabel": "Less than 12 Months, Fair Value", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r120", "r277", "r697" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "negatedLabel": "Less than 12 Months, Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r120", "r277" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gains or losses on available-for-sales securities", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "totalLabel": "Debt Securities, Available-for-Sale, Realized Gain (Loss), Total", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r875" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Company Marketable Securities", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "totalLabel": "Total, Fair Value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r117", "r274", "r697" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "totalLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total", "negatedTotalLabel": "Total, Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r118", "r275" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Fair Values and Unrealized Losses of Marketable Securities Held by the Company in an Unrealized Loss Position for Less Than 12 months and 12 Months or Greater", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r116", "r697", "r882" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of investment grade fixed income debt security", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r119", "r276" ] }, "us-gaap_DeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue:", "label": "Deferred Revenue [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueRevenueRecognized1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueRevenueRecognized1", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "terseLabel": "Amounts included in deferred revenue at beginning of period", "label": "Deferred Revenue, Revenue Recognized",
```

```
"documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue." } } }, "auth_ref": [] }, "rgnx_DeferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "DeferredTransactionCost", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Transaction Cost", "label": "Deferred Transaction Cost", "documentation": "Deferred transaction cost." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r31" ] }, "us-gaap_DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DetailsOfImpairmentOfLongLivedAssetsHeldAndUsedByAssetTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Details of Impairment of Long-Lived Assets Held and Used by Asset [Table Text Block]", "terseLabel": "Summary of Impairment Losses Allocated to Various Assets Within Long-lived Asset Group Based on Relative Carrying Values", "documentation": "Tabular disclosure for impairment of long-lived assets held and used by an entity which includes a description of the impaired long-lived asset and facts and circumstances leading to the impairment, aggregate amount of the impairment loss and where the loss is located in the income statement, method(s) for determining fair value, and the segment in which the impaired long-lived asset is reported." } } }, "auth_ref": [ "r33", "r89" ] }, "rgnx_DevelopmentMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "DevelopmentMilestoneMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Development Milestone", "label": "Development Milestone [Member]", "documentation": "Development milestone." } } }, "auth_ref": [] }, "rgnx_DirectorsOrSection16ReportingOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "DirectorsOrSection16ReportingOfficersMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Directors or Section 16 reporting officers.", "label": "Directors Or Section 16 Reporting Officers [Member]", "terseLabel": "Directors or Section 16 Reporting Officers [Member]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r357", "r361", "r389", "r390", "r392", "r710" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation Expense by Award Type", "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]", "documentation": "Tabular disclosure of share-based payment arrangement." } } }, "auth_ref": [ "r7", "r36" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r749" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r781" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "rgnx_DueFromAndToRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "DueFromAndToRelatedPartiesCurrent", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total net cost reimbursement to (from) AbbVie", "label": "Due From And To Related Parties Current", "documentation": "Due from and to related parties current." } } }, "auth_ref": [] }, "rgnx_DueFromAndToRelatedPartiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "DueFromAndToRelatedPartiesCurrentAbstract", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net cost reimbursement to (from) AbbVie included in:", "label": "Due From And To Related Parties Current [Abstract]", "documentation": "Due from and to related parties current." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r792" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Basic, Total", "terseLabel": "Net loss per share, basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r167", "r184", "r185", "r186", "r187", "r188", "r189", "r194", "r196", "r198", "r199", "r200", "r205", "r414", "r417", "r435", "r436", "r543", "r563", "r690" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Earnings Per Share, Diluted, Total", "terseLabel": "Net loss per share, diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r167", "r184", "r185", "r186", "r187", "r188", "r189", "r196", "r198", "r199", "r200", "r205", "r414", "r417", "r435", "r436", "r543", "r563", "r690" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r25", "r26", "r202" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r193", "r201", "r203", "r204" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Accrued personnel costs", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r51" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "terseLabel": "Unrecognized stock-based compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r391" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation, weighted-average period", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r391" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
```

```
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option",
"verboseLabel": "Stock Options Issued and Outstanding [Member]", "axisDefault": "Stock Options [Member]", "documentation": "Share-based payment arrangement granting
right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] },
"rgnx_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "EmployeeStockPurchasePlanMember",
"presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee stock purchase
plan." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine1", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" }
} }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine2", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } },
"auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address,
City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code",
"label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype":
"stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or
Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype":
"centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key",
"label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly
abbreviated as CIK." } } }, "auth_ref": [ "r747" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate
number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related
periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member]
or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype":
"yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting
Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been
subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
} } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityEmergingGrowthCompany", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth
company criteria." } } }, "auth_ref": [ "r747" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityFileNumber", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may
contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref":
[] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label":
"Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions
of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related
disclosure." } } }, "auth_ref": [ "r747" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ],
"lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-
character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current",
"label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to
be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } },
"auth_ref": [ "r831" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity
Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms
filed with the SEC." } } }, "auth_ref": [ "r747" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityShellCompany", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule
12b-2 of the Exchange Act." } } }, "auth_ref": [ "r747" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntitySmallBusiness", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } },
"auth_ref": [ "r747" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as
an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r747" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang":
{ "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r786" ] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity
Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation
Table" } } }, "auth_ref": [ "r827" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]",
"terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r827" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant
Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r827" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel":
"Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is
allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r138", "r162", "r163", "r164", "r179", "r180", "r181", "r183", "r188", "r190",
"r192", "r207", "r260", "r261", "r292", "r340", "r405", "r406", "r411", "r412", "r413", "r415", "r416", "r417", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r463",
"r465", "r466", "r467", "r468", "r469", "r474", "r476", "r485", "r559", "r576", "r577", "r578", "r591", "r651" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity
Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r796" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r754", "r764", "r774", "r806" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously
Awarded Compensation Recovery" } } }, "auth_ref": [ "r751", "r761", "r771", "r803" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r802" ] }, "rgnx_FOXKISERLimitedLiabilityPartnershipMember": { "xbrltype":
"domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "FOXKISERLimitedLiabilityPartnershipMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "FOXKISER
LLP [Member]", "label": "F O X K I S E R Limited Liability Partnership [Member]", "documentation": "FOXKISER limited liability partnership." } } }, "auth_ref": [] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Asset Class", "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448",
"r453", "r717" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ],
"lang": { "en-us": { "role": { "terseLabel": "Asset Class", "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r443", "r444",
"r445", "r446", "r447", "r448", "r453", "r717" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy
and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r322", "r349", "r350", "r351", "r352", "r353", "r354", "r437", "r439", "r440",
```

```
"r441", "r442", "r451", "r452", "r454", "r500", "r501", "r502", "r702", "r703", "r706", "r707", "r708", "r715", "r719" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r447", "r449", "r450", "r451", "r454", "r455", "r456", "r457", "r458", "r538", "r715", "r720" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r322", "r349", "r354", "r439", "r452", "r500", "r706", "r707", "r708", "r715" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r322", "r349", "r354", "r439", "r440", "r452", "r501", "r702", "r703", "r706", "r707", "r708", "r715" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r322", "r349", "r350", "r351", "r352", "r353", "r354", "r439", "r440", "r441", "r442", "r452", "r502", "r702", "r703", "r706", "r707", "r708", "r715", "r719" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth_ref": [ "r443", "r444", "r445", "r446", "r447", "r448", "r453" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r322", "r349", "r350", "r351", "r352", "r353", "r354", "r437", "r439", "r440", "r441", "r442", "r451", "r452", "r454", "r500", "r501", "r502", "r702", "r703", "r706", "r707", "r708", "r715", "r719" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r263", "r264", "r268", "r269", "r270", "r273", "r278", "r279", "r323", "r337", "r432", "r459", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r560", "r697", "r715", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r729", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r875", "r876", "r877", "r878", "r934", "r937", "r938", "r939", "r940", "r941" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Financing Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r111", "r135", "r136", "r137", "r150", "r262", "r265", "r267", "r957" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesLineItems", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Receivable Allowance For Credit Losses [Line Items]", "label": "Financing Receivable, Allowance for Credit Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r137", "r881" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Financing Receivable, Allowance for Credit Loss, Writeoff, Total", "negatedLabel": "Write-offs", "label": "Financing Receivable, Allowance for Credit Loss, Writeoff", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": [ "r113", "r266", "r271", "r696" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r536", "r537", "r683" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r683" ] }, "rgnx_FirstAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "FirstAnniversaryMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "First Anniversary [Member]", "label": "First Anniversary [Member]", "documentation": "First Anniversary." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r758", "r768", "r778", "r810" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r791" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Furniture and Fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] },
"rgnx_FurnitureFixturesAndLeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"FurnitureFixturesAndLeaseholdImprovementsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Furniture Fixtures and Leasehold Improvements [Member]", "documentation": "Furniture Fixtures and Leasehold Improvements [Member]" } } }, "auth_ref": [] }, "us-
gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnInvestments", "crdr": "credit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Investments", "totalLabel": "Gain (Loss) on Investments, Total", "negatedLabel": "Net loss (gain) on investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r72", "r75", "r832" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel":
"General and Administrative Expense, Total", "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r69", "r631" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"General and Administrative Expense [Member]", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r69" ] }, "rgnx_HCRMember": { "xbrltype": "domainItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "HCRMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"HCR [Member]", "label": "H C R [Member]", "documentation": "HCR." } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel":
"Public Offering [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-
gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Carrying value of the asset",
"label": "Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset", "documentation": "The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale." } } }, "auth_ref": [ "r33", "r86" ] }, "rgnx_ImpairmentLossOfPropertyAndEquipmentNet": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "ImpairmentLossOfPropertyAndEquipmentNet", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Impairment Loss Of Property and Equipment Net", "documentation": "Impairment loss Of property and equipment, net.", "terseLabel": "Impairment losses recorded to property and equipment" } } },
"auth_ref": [] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "netLabel": "Impairment of property and equipment", "label": "Property and equipment, net", "terseLabel": "Impairment of loss", "verboseLabel": "Impairment of long-lived assets", "totalLabel": "Total impairment of long-lived assets", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r5", "r30", "r88", "r716" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r89" ] }, "rgnx_ImputedInterestIncomeFromLicensing": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "ImputedInterestIncomeFromLicensing", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Imputed interest income from licensing", "label": "Imputed Interest Income From Licensing", "documentation": "Imputed interest income from licensing." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role":
{ "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Income Statement Location", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r293", "r294", "r299", "r444", "r448", "r453", "r573", "r575", "r636", "r683", "r718", "r964" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Income Statement Location", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r294", "r299", "r444", "r448", "r453", "r573", "r575", "r636", "r683", "r718", "r964" ] }, "us-gaap_IncomeTaxDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax
Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": {
"terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r176", "r398",
"r399", "r400", "r401", "r402", "r403", "r404", "r407", "r408", "r409", "r410", "r586", "r712" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label":
"Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable",
"label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r848" ] }, "rgnx_IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "IncreaseDecreaseInCapitalExpendituresIncurredButNotYetPaid", "crdr": "credit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Increase (decrease) in purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities", "label": "Increase Decrease In Capital Expenditures Incurred But Not Yet Paid", "documentation": "Increase decrease in capital expenditures incurred but not yet paid." } } }, "auth_ref": [] },
"us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Deferred Revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r684" ] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] },
"rgnx_IncreaseDecreaseInOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"IncreaseDecreaseInOperatingLeaseLiabilities", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities",
"label": "Increase Decrease In Operating Lease Liabilities", "documentation": "Operating lease liabilities." } } }, "auth_ref": [] },
"rgnx_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Operating lease right-of-use assets", "label": "Increase Decrease In Operating Lease Right Of Use Assets", "documentation": "Operating lease right- of-use assets." } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r848" ] },
"us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other assets", "label":
"Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r848" ] },
"us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total", "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses",
"label", "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance
for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r758", "r768", "r778", "r802", "r810", "r814", "r822" ] }, "ecd_InsiderTradingArrLineItems":
{ "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading
Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r820" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies
and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r750", "r826" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel":
"Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r750", "r826" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
"terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r750", "r826" ] }, "rgnx_InterestAccrualPercentage": { "xbrltype": "percentItemType",
"nsuri": "http://regenxbio.com/20240930", "localname": "InterestAccrualPercentage", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest percentage on unpaid balances under license agreement", "label": "Interest Accrual Percentage", "documentation": "Interest accrual percentage." } } }, "auth_ref": [] },
"us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Interest Expense, Total", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating",
"documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." }
} }, "auth_ref": [ "r206", "r208", "r211", "r212", "r215", "r471", "r693", "r694" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "negatedLabel":
"Interest expense", "label": "Interest Expense, Nonoperating", "totalLabel": "Interest Expense, Nonoperating, Total", "documentation": "Amount of interest expense classified
as nonoperating." } } }, "auth_ref": [ "r211", "r846" ] }, "rgnx_InterestIncomeFromLicencing": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "InterestIncomeFromLicencing", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"Interest income from licensing", "label": "Interest Income From Licencing", "documentation": "Interest income from licencing." } } }, "auth_ref": [] }, "us-
gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "presentation":
[ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel":
"Investment Income, Net, Total", "terseLabel": "Investment income", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount
(premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r70", "r71", "r74" ] }, "us-
gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "terseLabel": "Investment Type", "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [
"r593", "r594", "r595", "r596", "r597", "r659", "r661", "r663", "r666", "r667", "r668", "r670", "r671", "r672", "r673", "r674", "r737" ] }, "us-
gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember",
"presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } }
}, "auth_ref": [ "r593", "r594", "r595", "r596", "r597", "r659", "r661", "r663", "r666", "r667", "r668", "r670", "r671", "r672", "r673", "r674", "r737" ] }, "us-
gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecurities" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities", "label":
"Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in
certain debt and equity securities." } } }, "auth_ref": [ "r105", "r134", "r226", "r227", "r460", "r461", "r956" ] },
"rgnx_IssuanceCostsOfCommonStockPublicOfferingAndPreFundedWarrantsButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "IssuanceCostsOfCommonStockPublicOfferingAndPreFundedWarrantsButNotYetPaid", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance
costs for the public offering of common stock and pre-funded warrants", "label": "Issuance Costs Of Common Stock Public Offering And Pre Funded Warrants But Not Yet
Paid", "documentation": "Issuance costs of common stock public offering and pre funded warrants but not yet paid" } } }, "auth_ref": [] },
"rgnx_LaboratoryAndManufacturingEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"LaboratoryAndManufacturingEquipmentMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Laboratory and Manufacturing Equipment [Member]", "label": "Laboratory And Manufacturing Equipment [Member]", "documentation": "Laboratory and
manufacturing equipment Member" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LeaseholdImprovementsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Leasehold Improvements [Member]", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease
arrangement." } } }, "auth_ref": [ "r87", "r483" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]",
"documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r480", "r484" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases",
"label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r479" ] },
"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Total undiscounted payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Lessee, Operating Lease,
Liability, to be Paid, Total", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r482" ] }, "us-
gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases
[Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of
operating lease liability." } } }, "auth_ref": [ "r475" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"Liabilities", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing
economic benefit to others." } } }, "auth_ref": [ "r15", "r50", "r51", "r52", "r54", "r55", "r56", "r57", "r175", "r259", "r313", "r314", "r315", "r316", "r317", "r318", "r319",
"r320", "r321", "r421", "r424", "r425", "r462", "r606", "r691", "r745", "r898", "r947", "r948" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and
stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to
noncontrolling interests, if any." } } }, "auth_ref": [ "r64", "r102", "r553", "r728", "r849", "r879", "r942" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders\u2019
Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations
that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r52", "r141", "r175", "r259", "r313", "r314",
"r315", "r316", "r317", "r318", "r319", "r320", "r321", "r421", "r424", "r425", "r462", "r728", "r898", "r947", "r948" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label":
"Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToInterestExpenseRecognized": { "xbrltype": "monetaryItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "LiabilityRelatedToInterestExpenseRecognized", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
], "lang": { "en-us": { "role": { "terseLabel": "Interest expense recognized", "label": "Liability Related To Interest Expense Recognized", "documentation": "Liability related to
interest expense recognized." } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToNonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "LiabilityRelatedToNonCashInterestExpense", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Non Cash Interest Expense", "label": "Liability Related To Non Cash Interest Expense", "documentation": "Liability related to non cash interest expense." } } },
"auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"LiabilityRelatedToSaleOfFutureRoyalties", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
], "lang": { "en-us": { "role": { "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "label": "Liability Related To Sale Of Future Royalties",
"documentation": "Liability related to sale of future royalties." } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyaltiesAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://regenxbio.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesAbstract", "lang": { "en-us": { "role": { "label": "Liability Related To Sale Of
Future Royalties [Abstract]", "documentation": "Liability Related to Sale of Future Royalties." } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyaltiesCurrent": {
```

```
"xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesCurrent", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Current portion of liability related
to sale of future royalties", "terseLabel": "Liability related to sale of future royalties", "label": "Liability Related To Sale Of Future Royalties Current", "documentation":
"Liability related to sale of future royalties." } } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyaltiesLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
], "lang": { "en-us": { "role": { "terseLabel": "Liability Related To Sale Of Future Royalties [Line Items]", "label": "Liability Related To Sale Of Future Royalties [Line Items]",
"documentation": "Liability Related to Sale of Future Royalties Line Items." } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyaltiesNonCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNonCurrent", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Liability related to sale of future
royalties, non-current", "terseLabel": "Liability related to sale of future royalties", "label": "Liability Related To Sale Of Future Royalties Non Current", "documentation":
"Liability related to sale of future royalties non current." } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTable": { "xbrltype": "stringItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
], "lang": { "en-us": { "role": { "terseLabel": "Liability Related To Sale Of Future Royalties [Table]", "label": "Liability Related To Sale Of Future Royalties [Table]",
"documentation": "Liability related to sale of future royalties." } } }, "auth_ref": [] }, "rgnx_LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyalties" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Related to Sale
of Future Royalties", "label": "Liability Related To Sale Of Future Royalties [Text Block]", "documentation": "The entire disclosure for activity within the liability related to sale
of future royalties." } } }, "auth_ref": [] }, "rgnx_LicenseAgreementRevenueRecognitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "LicenseAgreementRevenueRecognitionAbstract", "lang": { "en-us": { "role": { "label": "License Agreement Revenue Recognition [Abstract]", "documentation":
"License Agreement Revenue Recognition [Abstract]" } } }, "auth_ref": [] }, "rgnx_LicenseAndRoyaltyRevenue": { "xbrltype": "monetaryItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "LicenseAndRoyaltyRevenue", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Total license and royalty revenue", "label": "License And Royalty Revenue", "documentation": "License and royalty revenue." } } }, "auth_ref": [] }, "us-
gaap_LicenseAndServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LicenseAndServiceMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"License and royalty [Member]", "label": "License and Service [Member]", "documentation": "Right to use intangible asset and performance of related service. Intangible asset
includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark." } } }, "auth_ref": [ "r903" ] }, "rgnx_LicenseFees": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "LicenseFees", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"License fee", "label": "License Fees", "documentation": "License fees." } } }, "auth_ref": [] }, "rgnx_LicenseRevenueLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "LicenseRevenueLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "License Revenue [Line Items]", "documentation": "License
revenue." } } }, "auth_ref": [] }, "rgnx_LicenseRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "LicenseRevenueTable",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "License Revenue [Table]", "label": "License Revenue [Table]", "documentation": "License revenue." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label":
"Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "rgnx_MarchTwoThousandTwentyFourPublicOfferingMember": { "xbrltype":
"domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "MarchTwoThousandTwentyFourPublicOfferingMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "March 2024 Public Offering
[Member]", "label": "March Two Thousand Twenty Four Public Offering [Member]", "documentation": "March two thousand twenty four public offering." } } }, "auth_ref": [] },
"us-gaap_MarketableSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesAbstract", "presentation":
[ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Marketable securities:", "label": "Marketable Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label":
"Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r841" ] }, "us-
gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesNoncurrent", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable
securities", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r841"
] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum
[Member]", "label": "Maximum [Member]" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r356", "r394", "r442", "r528", "r572", "r574", "r582", "r598", "r599", "r660",
"r662", "r664", "r665", "r669", "r681", "r682", "r695", "r704", "r709", "r719", "r720", "r724", "r725", "r731", "r900", "r949", "r950", "r951", "r952", "r953", "r954" ] },
"ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r794" ] },
"ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r794" ] },
"rgnx_MilestoneFeePaymentForAllTargetsInclusive": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"MilestoneFeePaymentForAllTargetsInclusive", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate milestone payment for all the targets", "label": "Milestone Fee Payment For All Targets Inclusive", "documentation": "Milestone fee payment for all targets
inclusive." } } }, "auth_ref": [] }, "rgnx_MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets": { "xbrltype": "monetaryItemType", "nsuri":
"http://regenxbio.com/20240930", "localname": "MilestoneFeePaymentsUponAchievementOfSpecifiedSalesTargets", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Milestone payment upon achievement of specified sales targets for licensed products", "label": "Milestone Fee Payments Upon Achievement Of Specified Sales Targets",
"documentation": "Milestone fee payments upon achievement of specified sales targets." } } }, "auth_ref": [] },
"rgnx_MilestoneFeePaymentsUponAchievementOfVariousDevelopmentAndCommercialization": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "MilestoneFeePaymentsUponAchievementOfVariousDevelopmentAndCommercialization", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Milestone fee payments upon achievement of various development and commercialization", "label": "Milestone Fee Payments Upon Achievement Of Various Development And
Commercialization", "documentation": "Milestone fee payments upon achievement of various development and commercialization." } } }, "auth_ref": [] },
"rgnx_MilestoneFeePaymentsUponApprovalOfCommercialProducts": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"MilestoneFeePaymentsUponApprovalOfCommercialProducts", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Milestone payment upon approval of commercial products by regulatory agencies", "label": "Milestone Fee Payments Upon Approval Of Commercial Products",
"documentation": "Milestone fee payments upon approval of commercial products." } } }, "auth_ref": [] }, "rgnx_MilestoneFeePaymentsUponCommencementOfClinicalTrials":
{ "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "MilestoneFeePaymentsUponCommencementOfClinicalTrials", "crdr": "debit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Milestone payment upon commencement of clinical trials in humans", "label": "Milestone Fee Payments Upon Commencement Of Clinical Trials",
"documentation": "Milestone fee payments upon commencement of clinical trials." } } }, "auth_ref": [] },
"rgnx_MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"MilestoneFeePaymentsUponSubmissionOfRegulatoryApprovalFilings", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Milestone payment upon submission of regulatory approval filings", "label": "Milestone Fee Payments Upon Submission Of Regulatory Approval Filings", "documentation":
"Milestone fee payments upon submission of regulatory approval filings." } } }, "auth_ref": [] }, "rgnx_MilestoneFeePaymentsUponSubmissionPreclinicalFilings": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "MilestoneFeePaymentsUponSubmissionPreclinicalFilings", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Milestone fee upon submission of preclinical regulatory filings", "label": "Milestone Fee Payments Upon Submission Preclinical Filings", "documentation": "Milestone fee
payments upon submission preclinical filings." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"MinimumMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Minimum [Member]", "label": "Minimum [Member]" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r356", "r394", "r442", "r528", "r572", "r574", "r582", "r598", "r599",
"r660", "r662", "r664", "r665", "r669", "r681", "r682", "r695", "r704", "r709", "r719", "r720", "r724", "r731", "r900", "r949", "r950", "r951", "r952", "r953", "r954" ] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
"terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r813" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us":
```

{ "role": { "terseLabel": "Money Market Mutual Funds [Member]", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r904"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r821"] }, "rgnx_NAVTechnologyPlatformMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NAVTechnologyPlatformMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "N A V Technology Platform [Member]", "label": "N A V Technology Platform [Member]", "documentation": "NAV technology platform." } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r795"] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NatureOfOperations", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusiness"], "lang": { "en-us": { "role": { "terseLabel": "Nature of Business", "label": "Nature of Operations [Text Block]", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": ["r122", "r132"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r171"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r171"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r78", "r79", "r82"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r68", "r82", "r104", "r139", "r157", "r160", "r164", "r175", "r182", "r184", "r185", "r186", "r187", "r188", "r191", "r192", "r197", "r259", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r414", "r417", "r436", "r462", "r558", "r629", "r649", "r650", "r743", "r898"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "rgnx_NewYorkSubleaseMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NewYorkSubleaseMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "New York Sublease [Member]", "documentation": "New york sublease." } } }, "auth_ref": [] }, "rgnx_NonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NonCashInterestExpense", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Non Cash Interest Expense", "documentation": "Non cash interest expense." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r794"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r758", "r768", "r778", "r802", "r810"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r785"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r784"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r802"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r821"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r821"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r73"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other Income (Expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "rgnx_NovartisGeneTherapiesMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovartisGeneTherapiesMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Novartis Gene Therapies [Member]", "label": "Novartis Gene Therapies [Member]", "documentation": "Novartis gene therapies." } } }, "auth_ref": [] }, "rgnx_NovartisLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovartisLicenseAgreementMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Novartis License Agreement [Member]", "label": "Novartis License Agreement [Member]", "documentation": "Novartis license agreement." } } }, "auth_ref": [] }, "rgnx_NovemberEightTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovemberEightTwoThousandTwentyFourMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "November 8, 2024", "label": "November Eight Two Thousand Twenty Four [Member]", "documentation": "November eight two thousand twenty four." } } }, "auth_ref": [] }, "rgnx_NovemberSevenTwoThousandTwentyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovemberSevenTwoThousandTwentyFourMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "November 7, 2024", "label": "November Seven Two Thousand Twenty Four [Member]", "documentation": "November seven two thousand twenty four." } } }, "auth_ref": [] }, "rgnx_NovemberTwoThousandEighteenLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovemberTwoThousandEighteenLicenseAgreementMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "November Two Thousand Eighteen License Agreement", "label": "November Two Thousand Eighteen License Agreement [Member]", "documentation": "November two thousand eighteen license agreement." } } }, "auth_ref": [] }, "rgnx_NovemberTwoThousandTwentyFourLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovemberTwoThousandTwentyFourLicenseAgreementMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "November Two Thousand Twenty Four License Agreement", "label": "November Two Thousand Twenty Four License Agreement [Member]", "documentation": "November two thousand twenty four license agreement." } } }, "auth_ref": [] }, "rgnx_NovemberTwoThousandTwentyOneLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovemberTwoThousandTwentyOneLicenseAgreementMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "November Two Thousand Twenty One License Agreement", "label": "November Two Thousand Twenty One License Agreement [Member]", "documentation": "November two thousand twenty one license agreement." } } }, "auth_ref": [] }, "rgnx_NovemberTwoThousandTwentyTwoLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NovemberTwoThousandTwentyTwoLicenseAgreementMember", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel":

```
"November Two Thousand Twenty Two License Agreement", "label": "November Two Thousand Twenty Two License Agreement [Member]", "documentation": "November two thousand twenty two license agreement." } } }, "auth_ref": [] }, "rgnx_NumberOfCommercialProductCandidates": { "xbrltype": "integerItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NumberOfCommercialProductCandidates", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of commercial product candidates", "label": "Number Of Commercial Product Candidates", "documentation": "Number of commercial product candidates." } } }, "auth_ref": [] }, "rgnx_NumberOfEqualAnnualInstallments": { "xbrltype": "integerItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "NumberOfEqualAnnualInstallments", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of equal annual installments", "label": "Number Of Equal Annual Installments", "documentation": "Number of equal annual installments." } } }, "auth_ref": [] }, "rgnx_OfferingExpensesForATMProgramButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OfferingExpensesForATMProgramButNotYetPaid", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Offering expenses for ATM Program but not yet paid.", "label": "Offering Expenses for A T M Program But Not Yet Paid", "terseLabel": "Offering expenses for ATM Program" } } }, "auth_ref": [] }, "rgnx_OfferingExpensesRelatedToAtTheMarketOfferingProgram": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OfferingExpensesRelatedToAtTheMarketOfferingProgram", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Offering expenses related to at the market offering program.", "label": "Offering Expenses Related To At The Market Offering Program", "negatedLabel": "Offering expenses related to at-the-market offering program" } } }, "auth_ref": [] }, "rgnx_OlivierDanosMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OlivierDanosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Olivier Danos.", "label": "Olivier Danos [Member]", "terseLabel": "Olivier Danos [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingCostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpenses", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Related party transaction expense", "terseLabel": "Related Party Transcation, Expenses from Transcations with Related Party", "label": "Operating Costs and Expenses", "totalLabel": "Operating Costs and Expenses, Total", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r108", "r692", "r855", "r856", "r857", "r858", "r859" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment losses recorded to right-of-use assets", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r945" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r478" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r477" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresSchedulesOfAccruedExpensesAndOtherCurrentLiabilitiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses and current liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r51" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "lang": { "en-us": { "role": { "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Other Assets, Current, Total", "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r152", "r728" ] }, "us-gaap_OtherAssetsMiscellaneousCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneousCurrent", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous, Current", "terseLabel": "Other", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r145" ] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Line Items]", "label": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments [Table]", "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsAndTax", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax effects or reclassification adjustments", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment and Tax, Total", "documentation": "Amount, before tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r154", "r155" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale securities, net", "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r154", "r155", "r156", "r559" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r10", "r14", "r158", "r161", "r165", "r188", "r463", "r464", "r469", "r541", "r559", "r843", "r844" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other Comprehensive Income", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-sale securities, net", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r154", "r156", "r258" ] }, "rgnx_OtherCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherCurrentAssetsLineItems", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other current assets." } } }, "label": "Other Current Assets [Line Items]" } }, "auth_ref": [] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCurrentAssetsMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Current Assets [Member]", "label": "Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [ "r42", "r44" ] }, "rgnx_OtherCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherCurrentAssetsTable", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other current assets", "label": "Other Current Assets [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities [Member]", "label": "Other Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other liabilities." } } }, "auth_ref": [ "r42", "r44" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent",
```

```
"crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r55" ] }, "rgnx_OtherLicenseAndRoyaltyRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherLicenseAndRoyaltyRevenue", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other license and royalty revenue", "label": "Other License And Royalty Revenue", "documentation": "Other license and royalty revenue." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Other Noncash Income (Expense), Total", "negatedLabel": "Other non-cash adjustments", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r82" ] }, "rgnx_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherOperatingExpenses", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Other operating expenses", "label": "Other Operating Expenses", "documentation": "Other Operating Expenses" } } }, "auth_ref": [] },
"rgnx_OtherPastOrFutureObligationsToPaySublicenseFeesMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherPastOrFutureObligationsToPaySublicenseFeesMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Past or Future Obligations to Pay Sublicense Fees [Member]", "label": "Other Past Or Future Obligations To Pay Sublicense Fees [Member]", "documentation": "Other Past or Future Obligations to Pay Sublicense Fees." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r794" ] }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivableAfterAllowanceForCreditLossCurrentRelatedPartyTypeExtensibleEnumeration", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "label": "Other Receivable, after Allowance for Credit Loss, Current, Related Party [Extensible Enumeration]", "documentation": "Indicates status and type of related party for receivable, after allowance for credit loss, classified as other and current." } } }, "auth_ref": [ "r946" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Due from related parties", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r148", "r615", "r694", "r959" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Due from related parties, current", "label": "Due from related parties, current", "terseLabel": "Due from Abeona, net of present value discount", "totalLabel": "Other Receivables, Net, Current, Total", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other-than-temporary impaired", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale", "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI)." } } }, "auth_ref": [ "r115" ] }, "rgnx_OtherUnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherUnbilledReceivablesCurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "documentation": "Other unbilled receivables current.", "label": "Other Unbilled Receivables Current", "terseLabel": "Other unbilled" } } }, "auth_ref": [] },
"rgnx_OtherUnbilledReceivablesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "OtherUnbilledReceivablesNonCurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsReceivableNetDetail" ], "lang": { "en-us": { "role": { "documentation": "Other unbilled receivables on current.", "label": "Other Unbilled Receivables Non Current", "terseLabel": "Other unbilled" } } }, "auth_ref": [] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r756", "r766", "r776", "r808" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r759", "r769", "r779", "r811" ] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r759", "r769", "r779", "r811" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r783" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringLiabilityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash payments", "terseLabel": "Cash payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r298", "r847" ] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "negatedLabel": "Issuance costs for public offering of common stock and pre-funded warrants", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r19" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of marketable debt securities", "label": "Payments to Acquire Marketable Securities", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r863" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r77" ] },
"ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r793" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r793" ] }, "rgnx_PennLetterAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "PennLetterAgreementMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Penn Letter Agreement [Member]", "label": "Penn Letter Agreement [Member]", "documentation": "Penn Letter Agreement." } } }, "auth_ref": [] },
"ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r785" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r802" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r795" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r784" ] }, "rgnx_PercentageOfCommonStockOwned": { "xbrltype": "percentItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "PercentageOfCommonStockOwned", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock owned", "label": "Percentage of Common Stock Owned", "documentation": "Percentage of common stock owned." } } }, "auth_ref": [] },
"rgnx_PercentageOfReductionInWorkforce": { "xbrltype": "percentItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "PercentageOfReductionInWorkforce", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of reduction in workforce", "label": "Percentage Of Reduction In Workforce", "documentation": "Percentage of reduction in workforce." } } }, "auth_ref": [] },
"rgnx_PercentageOfVotingPower": { "xbrltype": "percentItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "PercentageOfVotingPower", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Percentage of voting power", "documentation": "Percentage of voting power." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r786" ]
```

```
], "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service
Cost" } } }, "auth_ref": [ "r830" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote
[Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r785" ] }, "rgnx_PreFundedWarrantsMember": { "xbrltype": "domainItemType",
"nsuri": "http://regenxbio.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre Funded Warrants
[Member]", "label": "Pre Funded Warrants [Member]", "documentation": "Pre funded warrants." } } }, "auth_ref": [] }, "rgnx_PreFundedWarrantsPolicyTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "PreFundedWarrantsPolicyTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded
Warrants", "label": "Pre Funded Warrants [Policy Text Block]", "documentation": "Pre funded warrants." } } }, "auth_ref": [] }, "us-
gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockParOrStatedValuePerShare", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ],
"lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated
value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r58", "r326" ] }, "us-
gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel":
"Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred
stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r58", "r607" ] }, "us-
gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares
issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at
option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } },
"auth_ref": [ "r58", "r326" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockSharesOutstanding", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" ], "lang": {
"en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
"terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable
preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } },
"auth_ref": [ "r58", "r607", "r627", "r994", "r995" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockValue", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "terseLabel": "Preferred stock; $0.0001 par value; 10,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023",
"label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at
the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other
disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r58", "r549", "r728" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Prepaid Expense, Current, Total",
"terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide
economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r151", "r282", "r283", "r688" ] },
"rgnx_PresentValueOfCostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "PresentValueOfCostOfRevenue", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Present value of cost of revenue", "label": "Present Value Of Cost Of Revenue", "documentation": "Present value of cost of revenue." } } }, "auth_ref": []
}, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PriorPeriodReclassificationAdjustmentDescription", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification,
Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability
of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r840" ] }, "us-
gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Private
Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies,
pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from public
offering of common stock and pre-funded warrants, net of issuance costs", "label": "Proceeds from Issuance Initial Public Offering", "documentation": "The cash inflow
associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from issuance
of common stock", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } },
"auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of
Private Placement", "terseLabel": "Proceeds from private placement", "verboseLabel": "Proceeds from private placement of common stock, net of issuance costs",
"documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r3" ] },
"us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of
common stock under employee stock purchase plan", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
"documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r3", "r13" ] }, "us-
gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRoyaltiesReceived", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Proceeds from Royalties Received", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the
current period." } } }, "auth_ref": [ "r80", "r81" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Proceeds from Sale and
Maturity of Debt Securities, Available-for-Sale, Total", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Sales of equity
securities", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r168", "r169", "r863" ] }, "us-
gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of marketable
debt securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the
entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] },
"rgnx_ProceedsFromSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"ProceedsFromSaleOfFutureRoyalties", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Proceeds from sale of future royalties", "label": "Proceeds From Sale Of Future Royalties", "documentation": "Proceeds from sale of future royalties." } } },
"auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash
inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r13" ] },
"rgnx_ProceedsFromStockOptionsExercisedIncludingUnsettledOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"ProceedsFromStockOptionsExercisedIncludingUnsettledOptions", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds
from stock options exercised including unsettled options", "label": "Proceeds From Stock Options Exercised Including Unsettled Options", "documentation": "Proceeds from
stock options exercised Including unsettled options." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "ProductOrServiceAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r216", "r535", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r685", "r705", "r730",
"r731", "r732", "r733", "r734", "r896", "r897", "r902", "r961", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978",
"r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992" ] }, "srt_ProductsAndServicesDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r216", "r535", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r685", "r705", "r730",
"r731", "r732", "r733", "r734", "r896", "r897", "r902", "r961", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978",
"r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType",
```

```
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } },
"auth_ref": [ "r139", "r157", "r160", "r170", "r175", "r182", "r188", "r191", "r192", "r259", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r414", "r417",
"r419", "r422", "r423", "r436", "r462", "r544", "r557", "r590", "r629", "r649", "r650", "r713", "r714", "r744", "r845", "r898" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce
goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r483" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, Net",
"label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business
and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r85", "r127", "r130",
"r131" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "totalLabel":
"Property, Plant and Equipment, Gross, Total", "terseLabel": "Total property and equipment", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount
before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are
not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r87", "r143", "r556" ] }, "us-
gaap_PropertyPlantAndEquipmentLineItems", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Property Plant And Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts
included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [
"r483" ] }, "us-gaap_PropertyPlantAndEquipmentMember", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Member]", "terseLabel": "Property and Equipment [Member]", "documentation": "Physical assets used in
the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and
equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet", { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net",
"terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and
amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to,
land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r483", "r545", "r556", "r728" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" ], "lang": { "en-
us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of
physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion
expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal
conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and
equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r87", "r483" ] }, "us-
gaap_ProvisionForLoanLeaseAndOtherLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProvisionForLoanLeaseAndOtherLosses", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail" ], "lang": { "en-
us": { "role": { "totalLabel": "Provision for Loan, Lease, and Other Losses, Total", "negatedLabel": "Provision for credit losses", "terseLabel": "Provision for credit losses",
"label": "Provision for Loan, Lease, and Other Losses", "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other
than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value." } } },
"auth_ref": [ "r4", "r103", "r112" ] }, "us-gaap_ProvisionForOtherCreditLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ProvisionForOtherCreditLosses", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Provision for credit losses", "label": "Provision for Other Credit Losses", "documentation": "Amount of expense related to credit loss from transactions other than loan and
lease transactions." } } }, "auth_ref": [ "r4", "r103" ] }, "rgnx_PurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"PurchaseAgreement", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Purchase Agreement", "label": "Purchase Agreement", "documentation": "Purchase agreement." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r783" ] }, "ecd_PvpTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r783" ] }, "srt_RangeAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r348", "r356", "r384", "r385", "r386", "r394", "r442", "r503",
"r512", "r528", "r572", "r574", "r582", "r598", "r599", "r660", "r662", "r664", "r665", "r669", "r681", "r682", "r695", "r704", "r709", "r719", "r720", "r724", "r725", "r731",
"r737", "r892", "r900", "r938", "r950", "r951", "r952", "r953", "r954" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"RangeMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r348", "r356", "r384", "r385", "r386", "r394", "r442", "r503",
"r512", "r528", "r572", "r574", "r582", "r598", "r599", "r660", "r662", "r664", "r665", "r669", "r681", "r682", "r695", "r704", "r709", "r719", "r720", "r724", "r725", "r731",
"r737", "r892", "r900", "r938", "r950", "r951", "r952", "r953", "r954" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } },
"auth_ref": [ "r679", "r680", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } },
"auth_ref": [ "r679", "r680", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003" ] }, "us-gaap_RealizedInvestmentGainsLosses": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net realized gain on
investments", "label": "Realized Investment Gains (Losses)", "totalLabel": "Realized Investment Gains (Losses), Total", "documentation": "Amount of realized gain (loss) on
investment." } } }, "auth_ref": [ "r564" ] }, "rgnx_ReceivablesAndContractAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "ReceivablesAndContractAssetsAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "terseLabel": "Contract assets:", "label": "Receivables And Contract Assets [Abstract]", "documentation": "Receivables and contract assets." } }
}, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail" ],
"lang": { "en-us": { "role": { "totalLabel": "Current accounts receivable, net", "terseLabel": "Accounts receivable, current", "label": "Receivables, Net, Current",
"documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade
accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an
amount that approximates their net realizable value." } } }, "auth_ref": [ "r728" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts
Receivable", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and
financing receivable." } } }, "auth_ref": [ "r221", "r222", "r223", "r225", "r861" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation
Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r751", "r761", "r771", "r803" ] }, "us-
gaap_RelatedPartyDomain", { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
```

"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r219", "r355", "r489", "r490", "r548", "r554", "r601", "r602", "r603", "r604", "r605", "r626", "r628", "r658"] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails"], "lang": { "en-us": { "role": { "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": ["r177", "r178", "r489", "r490", "r491", "r492", "r548", "r554", "r601", "r602", "r603", "r604", "r605", "r626", "r628", "r658"] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": ["r489", "r490", "r946"] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] },
"rgnx_RelatedPartyTransactionExpensesRevenueFromTransactionsWithRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "RelatedPartyTransactionExpensesRevenueFromTransactionsWithRelatedParty", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Related party transaction expense", "label": "Related Party Transaction Expenses Revenue From Transactions With Related Party", "documentation": "Related party transaction expenses (revenue) from\u200b transactions\u200b with related\u200b party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r219", "r632", "r633", "r636"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSupplementalDisclosuresScheduleOfOtherCurrentAssetsDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r219", "r355", "r489", "r490", "r548", "r554", "r601", "r602", "r603", "r604", "r605", "r626", "r628", "r658", "r946"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": ["r486", "r487", "r488", "r490", "r493", "r587", "r588", "r589", "r634", "r635", "r636", "r655", "r657"] }, "rgnx_RepaymentsUnderLiabilityRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "RepaymentsUnderLiabilityRelatedToSaleOfFutureRoyalties", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Repayments under liability related to sale of future royalties, net of imputed interest", "label": "Repayments Under Liability Related To Sale Of Future Royalties", "documentation": "Repayments under liability related to sale of future royalties." } } }, "auth_ref": [] }, "rgnx_RepurchaseOfCallOptionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "RepurchaseOfCallOptionAmount", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of call option amount", "label": "Repurchase Of Call Option Amount", "documentation": "Repurchase of call option amount" } } }, "auth_ref": [] },
"rgnx_RepurchaseOfCallOptionAmountBeforeExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "RepurchaseOfCallOptionAmountBeforeExercised", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Repurchase of call option amount, before exercised", "label": "Repurchase Of Call Option Amount Before Exercised", "documentation": "Repurchase of call option amount before exercised." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r396", "r683", "r693", "r955"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfAbbvieCollaborationAgreementDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail"], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expense [Member]", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r752", "r762", "r772", "r804"] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r753", "r763", "r773", "r805"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r760", "r770", "r780", "r812"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r142"] }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashAndCashEquivalentsAndRestrictedCa
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total", "terseLabel": "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r20", "r121", "r172"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Unvested Restricted Stock Units Outstanding [Member]", "terseLabel": "Restricted Stock Units (RSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuring"], "lang": { "en-us": { "role": { "terseLabel": "Restructuring", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r295", "r296", "r298", "r301", "r306"] }, "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent", "terseLabel": "Percentage of workforce reduction due to restructuring", "documentation":

```
"The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)." } } },
"auth_ref": [] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringLiabilityDetails" ], "lang": { "en-us": { "role": { "verboseLabel":
"Restructuring costs", "terseLabel": "Restructuring charges", "label": "Restructuring Charges", "totalLabel": "Restructuring Charges, Total", "documentation": "Amount of
expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." }
} }, "auth_ref": [ "r5", "r302", "r303", "r893" ] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RestructuringCostAndReserveAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Restructuring Type", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": [ "r297", "r298", "r303", "r304" ] },
"us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringCostAndReserveLineItems", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": {
"en-us": { "role": { "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are
used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r303",
"r304", "r305" ] }, "us-gaap_RestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCosts", "crdr": "debit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "totalLabel":
"Restructuring Costs, Total", "label": "Restructuring Costs", "terseLabel": "Restructuring costs", "documentation": "Amount, after cash payment, of expenses associated with
exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r5" ] },
"us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringLiabilityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Ending
Balance", "periodStartLabel": "Beginning Balance", "terseLabel": "Restructuring liability", "label": "Restructuring Reserve", "totalLabel": "Restructuring Reserve, Total",
"documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost
associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r298", "r304" ] }, "us-
gaap_RestructuringReservePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringReservePeriodIncreaseDecrease", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Reductions in restructuring liability", "label": "Restructuring Reserve, Period Increase (Decrease)", "totalLabel": "Restructuring
Reserve, Period Increase (Decrease), Total", "documentation": "Amount of increase (decrease) in the accrual for restructuring costs." } } }, "auth_ref": [ "r92" ] }, "us-
gaap_RestructuringReserveTranslationAndOtherAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestructuringReserveTranslationAndOtherAdjustment", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringLiabilityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other
adjustments", "label": "Restructuring Reserve, Translation and Other Adjustment", "documentation": "Amount of increase (decrease) in the restructuring reserve related to
foreign currency translation (gain) loss and other increases (decreases)." } } }, "auth_ref": [ "r93", "r894" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNatureOfBusinessAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated
Deficit), Total", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings
(deficit)." } } }, "auth_ref": [ "r61", "r96", "r552", "r579", "r581", "r585", "r608", "r728" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated
Deficit [Member]", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r138", "r179", "r180", "r181",
"r183", "r188", "r190", "r192", "r260", "r261", "r292", "r405", "r406", "r411", "r412", "r413", "r415", "r416", "r417", "r426", "r428", "r429", "r431", "r434", "r474", "r476",
"r576", "r578", "r591", "r994" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"Revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from
satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is
both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r106",
"r107", "r206", "r209", "r210", "r213", "r215", "r216", "r217", "r218", "r344", "r345", "r535" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Total license and royalty revenue", "terseLabel": "Zolgensma royalties", "label": "Revenue from Contract with Customer, Including Assessed Tax",
"documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to
customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction,
including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r106", "r107", "r206", "r209", "r210", "r213", "r215", "r216", "r217", "r218", "r344",
"r345", "r535" ] }, "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRecognitionAndDeferredRevenueAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized during the period from:", "label": "Revenue Recognition and Deferred Revenue [Abstract]" } } }, "auth_ref":
[] }, "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRecognitionMilestoneMethodRevenueRecognized", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"verboseLabel": "Revenue recognition, milestone method, revenue recognized", "terseLabel": "Revenue recognized", "label": "Revenue Recognition, Milestone Method,
Revenue Recognized", "documentation": "The amount of consideration recognized during the period for the milestone or milestones." } } }, "auth_ref": [] },
"rgnx_RevenueRecognizedPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"RevenueRecognizedPerformanceObligation", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInBalancesOfReceivablesContractAssetsAndDeferredRe
], "lang": { "en-us": { "role": { "terseLabel": "Performance obligations satisfied in previous periods", "label": "Revenue Recognized Performance Obligation", "documentation":
"Revenue recognized performance obligation." } } }, "auth_ref": [] }, "rgnx_RevenueRecognizedUponAchievementOfDevelopmentMilestones": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "RevenueRecognizedUponAchievementOfDevelopmentMilestones", "crdr": "credit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "documentation": "Revenue recognized upon achievement of development milestones.", "label": "Revenue Recognized Upon Achievement Of Development Milestones",
"terseLabel": "Revenue recognized upon achievement of development milestones" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel":
"Revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RoyaltyAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RoyaltyAgreementsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Royalty Agreements", "label": "Royalty Agreements [Member]", "documentation": "Contractual arrangement, generally for a defined period of time, entitling the
entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural
resources." } } }, "auth_ref": [ "r40", "r397", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r931" ] }, "rgnx_RoyaltyPaymentCapAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "RoyaltyPaymentCapAmount", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Royalty Payment Cap Amount", "label": "Royalty Payment Cap Amount", "documentation": "Royalty payment cap amount" } } }, "auth_ref": [] },
"ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1
Arrangement Adopted" } } }, "auth_ref": [ "r821" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement
Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r821" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of
Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] },
"rgnx_SalesBasedMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SalesBasedMilestonesMember",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Sales Based Milestones", "label": "Sales Based Milestones [Member]", "documentation": "Sales based milestones." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules of Accrued Expenses
and Other Current Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying
value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are
used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current
portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of unrealized loss on
available-for-sale securities, net, presented in the consolidated statements of operations and comprehensive loss", "label": "Schedule of Accumulated Other Comprehensive
Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r17",
"r943", "r944" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureNetLossPerShareAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareSchedulesForComputationOfDilutedWeightedAverageSharesOutstandingDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS
Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in
calculation of diluted EPS." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedules for
Computation of Diluted Weighted-Average Shares Outstanding", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text
Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings
per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for
the period presented, by antidilutive securities." } } }, "auth_ref": [ "r25" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre
], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Available For Sale Securities [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members
defined in one or many axes to the table." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239" ] }, "us-
gaap_ScheduleOfCapitalizationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCapitalizationLineItems",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of
Capitalization [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCapitalizationTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCapitalizationTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Capitalization
[Table]", "documentation": "Disclosure of information about capitalization which comprises long-term debt and equity instruments." } } }, "auth_ref": [] },
"rgnx_ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"ScheduleOfCashAndCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of
Reconciliation of Cash and Cash Equivalents and Restricted Cash", "label": "Schedule Of Cash And Cash Equivalents And Restricted Cash Table [Text Block]",
"documentation": "Schedule of cash and cash equivalents and restricted cash." } } }, "auth_ref": [] },
"rgnx_ScheduleOfChangesInLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenxbio.com/20240930",
"localname": "ScheduleOfChangesInLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of
Changes in Liability Related to Sale of Future Royalties", "label": "Schedule of changes in liability related to sale of future royalties [Table Text Block]", "documentation":
"Schedule of changes in liability related to sale of future royalties." } } }, "auth_ref": [] }, "us-
gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of AbbVie
Collaboration Agreement", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "documentation": "Tabular disclosure of
collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r932" ] }, "us-
gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation
Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount
expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes,
but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r37" ] }, "us-
gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of
Cash Equivalents and Marketable Securities", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation":
"Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at
fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in
which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant
other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r935", "r936" ] }, "us-
gaap_ScheduleOfFinancingReceivableAllowanceForCreditLossesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfFinancingReceivableAllowanceForCreditLossesTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfChangesInAllowanceForCreditLossesDetail" ], "lang": { "en-
us": { "role": { "terseLabel": "Schedule Of Financing Receivable Allowance For Credit Losses [Table]", "label": "Financing Receivable, Allowance for Credit Loss [Table]",
"documentation": "Disclosure of information about allowance for credit loss on financing receivable." } } }, "auth_ref": [ "r137", "r881" ] },
"rgnx_ScheduleOfLicenseRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenxbio.com/20240930", "localname":
"ScheduleOfLicenseRevenueTableTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables" ],
"lang": { "en-us": { "role": { "terseLabel": "Schedule Of License and Royalty Revenue", "label": "Schedule Of License Revenue Table [Text Block]", "documentation": "Schedule
Of License Revenue [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Unvested RSUs
Activity Under 2015 Plan", "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]", "documentation": "Tabular disclosure of the changes in
outstanding nonvested restricted stock units." } } }, "auth_ref": [ "r98" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets
[Table Text Block]", "terseLabel": "Schedule of Other Current Assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref":
[] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyAndEquipmentDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Schedule Of Property Plant And Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about
physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion
expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r483" ] }, "us-
gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule
Of Related Party Transactions By Related Party [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party
transaction." } } }, "auth_ref": [ "r45", "r46", "r632", "r633", "r636" ] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Cost [Table]",
"documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes
restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": [ "r297", "r298", "r299", "r300", "r303", "r304", "r305" ] }, "us-
gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureRestructuringTables" ], "lang": { "en-us": {
"role": { "terseLabel": "Summary of Restructuring Liability", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs
incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings
from the write-down of assets." } } }, "auth_ref": [ "r34", "r90", "r91" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation
Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r358",
"r360", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382",
"r383", "r384", "r385", "r386", "r387" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option
Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not
limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r97" ]
}, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label":
"Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r746" ] }, "dei_SecurityExchangeName": { "xbrltype":
"edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name",
"label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r748" ] }, "us-
gaap_ServiceAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceAgreementsMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Service
Agreements [Member]", "label": "Service Agreements [Member]", "documentation": "Limited duration contract between, for example, an electricity transmission customer and
```

```
an electricity transmission provider for service." } } }, "auth_ref": { "r41", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890" } },
"rgnx_SettlementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SettlementAgreementMember",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "terseLabel": "Settlement Agreement", "label": "Settlement Agreement [Member]", "documentation": "Settlement agreement." } } }, "auth_ref": [] },
"rgnx_SettlementAgreementPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SettlementAgreementPayable", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us":
{ "role": { "terseLabel": "Settlement agreement payable", "label": "Settlement Agreement Payable", "documentation": "Settlement agreement payable ." } } }, "auth_ref": [] },
"us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Share-
Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense",
"documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": {
"en-us": { "role": { "negatedLabel": "Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
} } }, "auth_ref": [ "r378" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Weighted-average Grant Date Fair Value, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments
Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans
other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r378" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Shares, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options,
Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock
or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r376" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-average Grant Date Fair Value, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award,
Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for
nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights
plan, performance target plan)." } } }, "auth_ref": [ "r376" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": {
"en-us": { "role": { "periodStartLabel": "Unvested balance at December 31, 2023", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested balance at June 30, 2024", "documentation": "The number of non-vested equity-based
payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r373", "r374" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": { "en-us": { "role":
{ "periodEndLabel": "Weighted-average Grant Date Fair Value, Unvested Ending Balance", "periodStartLabel": "Weighted-average Grant Date Fair Value, Unvested Beginning
Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant
Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit
options." } } }, "auth_ref": [ "r373", "r374" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": { "en-us": { "role":
{ "negatedLabel": "Vested", "verboseLabel": "Restricted stock units vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during
the reporting period." } } }, "auth_ref": [ "r377" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-average Grant Date Fair Value, Vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity
Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to
an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance
requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r377" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based
Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r358", "r360", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369",
"r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Additional
shares to be issued", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number
of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common
stock shares authorized for issuance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation":
"Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r711" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares
available for future grants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The
difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments),
and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other
type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r36" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "label": "Share-Based Compensation Arrangement by
Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Shares, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of
shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r367" ]
}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
"presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role":
{ "terseLabel": "Weighted-average Exercise Price, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable,
Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance
on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r367" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr":
"debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Total intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r380" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares, Cancelled or forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } } }, "auth_ref": [ "r371" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r369" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average fair values of options granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r379" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r36" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares Outstanding, Beginning Balance", "periodEndLabel": "Shares Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r365", "r366" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted-average Exercise Price Outstanding, Beginning Balance", "periodEndLabel": "Weighted-average Exercise Price, Outstanding, Ending Balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r365", "r366" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r382" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Exercise Price, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r382" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Intrinsic Value, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r381" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock shares issued to participants", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r36" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfUnvestedRsusActivityUnder2015PlanDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r370" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Exercise Price, Cancelled or forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r371" ] }, "us-
gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Exercise Price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r369" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ShareRepurchaseProgramAxis", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Axis]" } } }, "auth_ref": [ "r901" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program [Domain]" } } }, "auth_ref": [ "r901" ] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Total intrinsic values vested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value,
```

Vested", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r36"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Remaining Contractual Life (Years), Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r36"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Remaining Contractual Life (Years) Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r99"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average Remaining Contractual Life (Years), Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r381"] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Purchase price of share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "periodStartLabel": "Balances (Shares)", "periodEndLabel": "Balances (Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "rgnx_SignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SignificantAccountingPoliciesLineItems", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Line Items]", "label": "Significant Accounting Policies [Line Items]", "documentation": "Significant Accounting Policies." } } }, "auth_ref": [] }, "rgnx_SignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SignificantAccountingPoliciesTable", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies [Table]", "label": "Significant Accounting Policies [Table]", "documentation": "Significant Accounting Policies." } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r83", "r173"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock [Member]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r10", "r59", "r62", "r63", "r138", "r162", "r163", "r164", "r179", "r180", "r181", "r183", "r188", "r190", "r192", "r207", "r260", "r261", "r292", "r340", "r405", "r406", "r411", "r412", "r413", "r415", "r416", "r417", "r426", "r427", "r428", "r429", "r430", "r431", "r434", "r463", "r465", "r466", "r467", "r468", "r469", "r474", "r476", "r485", "r559", "r576", "r577", "r578", "r591", "r651"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r179", "r180", "r181", "r207", "r476", "r535", "r583", "r592", "r600", "r601", "r602", "r603", "r604", "r605", "r607", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r626", "r628", "r630", "r631", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r651", "r738"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r179", "r180", "r181", "r207", "r219", "r476", "r535", "r583", "r592", "r600", "r601", "r602", "r603", "r604", "r605", "r607", "r610", "r611", "r612", "r613", "r614", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r626", "r628", "r630", "r631", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r651", "r738"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": ["r755", "r765", "r775", "r807"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan, shares", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r10", "r58", "r59", "r96"] }, "rgnx_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrants", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares exercise of prefunded warrants.", "label": "Stock Issued During Period Shares Exercise Of Prefunded Warrants", "terseLabel": "Exercise of pre-funded warrants" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock and pre-funded warrants, shares", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Number of shares sold", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r10", "r58", "r59", "r96", "r584", "r651", "r675"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "negatedLabel": "Shares, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options, net of tax, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r10", "r58", "r59", "r96", "r370"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r10", "r58", "r59", "r96"] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [

```
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock and pre-funded warrants", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r10", "r58", "r59", "r96", "r591", "r651", "r675", "r744" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options, net of tax", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r10", "r59", "r62", "r63", "r96" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balances", "periodEndLabel": "Balances", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r59", "r62", "r63", "r84", "r609", "r627", "r652", "r653", "r728", "r745", "r849", "r879", "r942", "r994" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalization" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Capitalization", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r95", "r174", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r340", "r433", "r654", "r656", "r676" ] }, "us-gaap_SubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubleaseIncome", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sublease income", "label": "Sublease Income", "documentation": "Amount of sublease income excluding finance and operating lease expense." } } }, "auth_ref": [ "r481", "r727" ] }, "rgnx_SublicenseFeesDueOrOwedInFutureMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SublicenseFeesDueOrOwedInFutureMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sublicense Fees Due Or Owed in Future [Member]", "label": "Sublicense Fees Due Or Owed In Future [Member]", "documentation": "Sublicense Fees Due Or Owed in Future." } } }, "auth_ref": [] }, "rgnx_SublicenseFeesPreviouslyRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SublicenseFeesPreviouslyRecognized", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sublicense fees previously recognized", "label": "Sublicense Fees Previously Recognized", "documentation": "Sublicense fees previously recognized." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r470", "r495" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r470", "r495" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r470", "r495" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r470", "r495" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r470", "r495" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureSubsequentEvents1" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r494", "r496" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureCapitalizationAdditionalInformationDetail",
"http://regenxbio.com/20240930/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseByAwardTypeDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity",
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] },
"rgnx_SummaryOfChangesInReceivablesAndContractAssetsAndContractLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SummaryOfChangesInReceivablesAndContractAssetsAndContractLiabilitiesTableTextBlock", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Balances of Receivables, Contract Assets and Deferred Revenue", "label": "Summary Of Changes In Receivables And Contract Assets And Contract Liabilities Table [Text Block]", "documentation": "Summary of changes in receivables and contract assets and contract liabilities." } } }, "auth_ref": [] },
"rgnx_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesLineItems", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Supplemental disclosures of noncash investing and financing activities.", "label": "Supplemental Disclosures Of Noncash Investing And Financing Activities [Line Items]", "terseLabel": "Supplemental Disclosures of Non-cash Investing and Financing Activities [Line Items]" } } }, "auth_ref": [] },
"rgnx_SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "SupplementalDisclosuresOfNoncashInvestingAndFinancingActivitiesTable", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSupplementalDisclosuresAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Supplemental disclosures of noncash investing and financing activities.", "label": "Supplemental Disclosures Of Noncash Investing And Financing Activities [Table]", "terseLabel": "Supplemental Disclosures of Non-cash Investing and Financing Activities [Table]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r801" ] },
"rgnx_TaxesPaidRelatedToNetSettlementOfStockBasedAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "TaxesPaidRelatedToNetSettlementOfStockBasedAwards", "crdr": "credit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid related to net settlement of stock-based awards", "label": "Taxes Paid Related To Net Settlement Of Stock Based Awards", "documentation": "Taxes paid related to net settlement of stock-based awards." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r793" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r800" ] },
"ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r820" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r822" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] },
"rgnx_TransactionCostsAssociatedWithStockIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "TransactionCostsAssociatedWithStockIssuance", "crdr": "debit", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Stock, transaction costs", "label": "Transaction Costs Associated With Stock Issuance", "documentation": "Transaction costs associated with stock issuance." } } }, "auth_ref": [] }, "rgnx_TransactionPriceOfLicense": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "TransactionPriceOfLicense", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction price of license", "label": "Transaction Price Of License", "documentation": "Transaction price of license." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail",
"http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r323", "r337", "r432", "r459", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r560", "r715", "r717", "r719", "r720", "r721", "r722", "r723", "r724", "r725", "r729", "r833", "r834", "r835", "r836", "r837", "r838", "r839", "r875", "r876", "r877", "r878", "r934", "r937", "r938", "r939", "r940", "r941" ] },
"ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r823" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
```

```
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r824" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r824" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r822" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r822" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r825" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r823" ] }, "rgnx_TwoThousandAndFifteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "TwoThousandAndFifteenEquityIncentivePlanMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2015 Equity Incentive Plan [Member]", "label": "Two Thousand And Fifteen Equity Incentive Plan [Member]", "documentation": "Two Thousand And Fifteen Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "rgnx_TwoThousandFifteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "TwoThousandFifteenEmployeeStockPurchasePlanMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2015 Employee Stock Purchase Plan [Member]", "label": "Two Thousand Fifteen Employee Stock Purchase Plan [Member]", "documentation": "2015 Employee Stock Purchase Plan." } } }, "auth_ref": [] }, "rgnx_TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "2014 and 2015 Equity Incentive Plan [Member]", "label": "Two Thousand Fourteen And Two Thousand Fifteen Equity Incentive Plan [Member]", "documentation": "Two Thousand Fourteen And Two Thousand Fifteen Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r418" ] }, "us-gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRestructuringDomain", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring", "label": "Type of Restructuring [Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": [ "r297", "r298", "r303", "r304" ] }, "us-gaap_TypeOfRevenueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfRevenueExtensibleList", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Types of Revenue[Extensible List]", "label": "Revenue, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources." } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfCashEquivalentsAndMarketableSecuritiesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "US Government and Agency Securities [Member]", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r689", "r706", "r958" ] }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfCompanyMarketableSecuritiesDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfFairValuesAndUnrealizedLossesOfMarketableSecuritiesHeldByCompanyInUnre ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Government and Agency Securities [Member]", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r958" ] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsSummaryOfAccountsRecerivableNetDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled", "label": "Unbilled Receivables, Current", "verboseLabel": "Unbilled Zolgensma royalties", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r819" ] }, "rgnx_UniversityOfPennsylvaniaMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "UniversityOfPennsylvaniaMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "University of Pennsylvania [Member]", "label": "University Of Pennsylvania [Member]", "documentation": "University of Pennsylvania." } } }, "auth_ref": [] }, "rgnx_UpfrontAndAnnualLicenseFeeReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "UpfrontAndAnnualLicenseFeeReceivable", "crdr": "debit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Up-front and annual fees", "label": "Upfront And Annual License Fee Receivable", "documentation": "Upfront and annual license fee receivable." } } }, "auth_ref": [] }, "rgnx_UpfrontLicenseFeePaid": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "UpfrontLicenseFeePaid", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Up-front fee paid", "label": "Upfront License Fee Paid", "documentation": "Upfront license fee paid." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r27", "r28", "r29", "r124", "r126", "r128", "r129" ] }, "rgnx_VestingOfRestrictedStockUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "VestingOfRestrictedStockUnits", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting of restricted stock units, net of tax", "label": "Vesting Of Restricted Stock Units", "documentation": "Vesting of restricted stock units" } } }, "auth_ref": [] }, "rgnx_VestingOfRestrictedStockUnitsShares": { "xbrltype": "sharesItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "VestingOfRestrictedStockUnitsShares", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Vesting Of Restricted Stock Units Shares", "documentation": "Vesting of Restricted Stock Units Shares", "terseLabel": "Vesting of restricted stock units, net of tax, shares" } } }, "auth_ref": [] }, "rgnx_VittalVasistaMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "VittalVasistaMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Vittal Vasista.", "label": "Vittal Vasista [Member]", "terseLabel": "Vittal Vasista [Member]" } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r789" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "terseLabel": "Weighted-average common shares outstanding, diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r195", "r200" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "terseLabel": "Weighted-average common shares outstanding, basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r194", "r200" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r787" ] }, "rgnx_ZolgensmaRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "ZolgensmaRoyaltiesMember", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseAndRoyaltyRevenueDetail", "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLicenseAndCollaborationAgreementsScheduleOfLicenseRevenueDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Zolgensma Royalties [Member]", "label": "Zolgensma Royalties [Member]", "documentation": "Zolgensma Royalties ." } } }, "auth_ref": [] }, "rgnx_ZolgensmaRoyaltiesPaidToHCR": { "xbrltype": "monetaryItemType", "nsuri": "http://regenxbio.com/20240930", "localname": "ZolgensmaRoyaltiesPaidToHCR", "crdr": "credit", "presentation": [ "http://regenxbio.com/20240930/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfFutureRoyaltiesScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesDetai ], "lang": { "en-us": { "role": { "terseLabel": "Zolgensma royalties paid to HCR", "label": "Zolgensma Royalties Paid To H C R", "documentation": "Zolgensma royalties paid to HCR." } } }, "auth_ref": [] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05",
```

```
"Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "275", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-3" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478685/912-310-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-
```

10-S99-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-8A" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(1)", "Publisher": "SEC" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "a", "Subparagraph": "(3)", "Publisher": "SEC" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "c",

```
"Publisher": "SEC" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r203": { "role":
```

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" },
```

```
"r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-6" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14",
```

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r395": { "role":

{"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r524": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-
50-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r528": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "912", "SubTopic": "275", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479072/912-275-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "275", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479072/912-275-50-5" }, "r531": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912",
"SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478685/912-310-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "405", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477623/912-405-50-2" }, "r534": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477623/912-405-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r546": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r547": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r548": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r549": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r550": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r551": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r552": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r553": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r555": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r557": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r558": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r559": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r560": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r561": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r562": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r563": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r564": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r566": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r567": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r568": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r569": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r570": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r571": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-
50-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r575": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r576": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-
40-65-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r580": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r581": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r582": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r583": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r584": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
```

"Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":

```
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "3", "Subparagraph", "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "3", "Subparagraph", "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "3", "Subparagraph", "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section", "50", "Paragraph": "2", "Subparagraph", "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r656": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-
45-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99",
"Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r660":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r661": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r662": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r663": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r664": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r665": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r666": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r667": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r668": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D",
"Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D" }, "r669": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r670": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r671": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r672": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r673": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r674": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r675": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section", "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r678": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section", "50", "Paragraph", "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970",
"SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section", "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-
50-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r685": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-
55-13H" }, "r686": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r687": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r691": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r692": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r693": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r694": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r695": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r696": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-79" }, "r697": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r698": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" },
"r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph":
"2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r701": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r702": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" },
"r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r705": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef",
```

```
"Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4]", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4]" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "I", "Paragraph": "a" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r765": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r766": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r767": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r768": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r769": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r770": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r771": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r772": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r773": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r774": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r775": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r776": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r777": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r778": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r779": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef",
```

"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r832": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r867": { "role":

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r928": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r929": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r930": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r931": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1" }, "r932": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r933": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1",
"Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r934": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r938": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r939": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r940": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2F",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-
50-2B" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r944": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r947": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r948": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r949": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r950": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r951": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r952": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r953": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r954": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r955": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r957": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r958": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r959": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r960": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r961": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r962": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r963": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r964": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r965": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r966": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r967": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r970": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r971": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r972": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r973": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r974": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r975": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r976": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r977": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r978": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r979": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r980": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r981": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r982": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r983": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r984": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r985": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r986": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r987": { "role":

*"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" } } } ZIP 82 0000950170-24-122330-xbrl.zip !DEA; XBRL DOCUMENT begin 644 0000950170-24-122330-xbrl.zip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s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|_ QW3\YQRC6,@WJ:BH*HI J15F1BHXQ$LQ2+53S9 M+/K*.'N3T-.I]LW\GA^).E$X90N9V(2T&:M$= +5,3+CJ.@M!'V&D[H=_KMO MXL&[CZ-W!Z-)ZX?IW4=X_LD+0.0WDP#/?ET K,'H6A9I/1OXMGU=_N$;)SQ MZZ;S/"V,!]2_%Q-0]I/LCG9]X";"=6@TX8&"=]Z9)BYX11QZOXH)]63:5R9Y M.3P$,,5E.&D"#O#[$ MDD)F""*)08%(2)60B#O0H4^99U%)BE;1V+-'91 '0W3/9%%S%T!2R"+3HH* M!A@KA2PF7$(EC0)=,O:5+%^MZ[T;'<.5NOU+'N9W8$" +T+2IV3 MG_++Y;=F!P$OFXZ/!\" M#9_Y](@#UI&.0K;@B#1/(TS_R&,W -41%;P-HS8[X[.1*@3B'?R3 "D!X]%2 MG_I*IY? #.#K,I\KK;Z/HSVR9L5W:9M1W@$X+E@UZ9<"\NGO5U:Q =?4R'>T" MVLP@Z%P&1'61$1T,TSXZ54)O!=U]K.?^[,:8T0]7B#;H1Xf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{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}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{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s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

@))AZ0DTM.9,F16&TD\9P%E6(TE/=6FUU=[>+K"\TMNW31 M&A1#7[)MA44%-99C59%C.5;;B92)

*-84KZWRR?'>@Q!VV<1:*V,"+T,X&YN^*LEZH*41CF8*"Q^R[XIB>NP(E;$94:2%"R9 L MLJ1{ZUKOFYEP1X!H R!AU[.-#S]*+L0:I"\L+F=KC;OJ[?^M%/I\ZOS,=YUOT'W?HH97L,5|*

*<#(F2X+&/@F\RQ"7B62I/3>1VR#7W2-YWV4. ME]9CI*BR=%C\Q5O0"',B/A@@C18Z>6F[-,VUQCX,T+W>A4%,UBXHRTCLZL-=?ON3|WO-+*

*MSZW;$6A_9AN^^]GP9^H>TWUX9U@#H& TSY%=F[8K$G?ZKE0?MPD_&7*C>5 SN MQZ/F&X>$Z=X\?D<CKHN7!()^=`!9VXUGM2%9HTD3)!| MZK8< , "7_U%5/(^%_?S[JVO')-"F,.3MO[OO,WHT?CIH6_VZR$9CXZVZ=/N MN^(/Z\')]CN CK9ZE3]6;T>'?CB ,8S&X]$AW(N[AOA!O3_<'N0R?@JK[*N# M)I>?"_T'Z,$?COP^KGQ[Y(?S5\?18-1L_P?*

@&BWEZ<<<#H!N:![V/>/FHR^=CX MH^D(/F8LS;@=+1H,T?4W<88\VUBA$;8_S$}3W1X-_E(9_Q(P@"4[Z<79O?9 M"<%L/M9I?+|=ZC'I<&"(TWB'D7C5[%3/I\> 4#@)6% / W]T?*

*F'G4SOR*8&V M.%W'+54/G_XWJ6&HG(:)Z-YT.)W3]+0.9,/9- BY("R?AM$6'#M5[ ]:=!I1A MH3 AFMX'W19I=#U5;K>[__L_F*9/3Y?RI'!WHHTJK-O?GMX VE'XAVBP_MSW[C_-*

^_>OEN]WFU]V!GW>[>UR_#-[-|KQ9A;_?9^[XK#+1\7#W?>K95<.JD MNVXU9K/"[,LMZ9^>WAN0T Y(VM&@3O,[FVX=I:QTZ)?O%!419TBI0XC|XCG1,)TG@2T%]+M;38

MI":&4MO4:6(/.M.NT/F+E3O1[F'Z ,E"L.:5'4=-,HU1)MD.-XF4D+\ M:6GL>P/-5E[C+LSTSWMY?Y2K|R^KO9-#6)8 /V|L"4MI,MR'7YY7|0*F]*. MM1"IDB(^VTRT);V"+#4[>YJ-*

*1,WY4E5%SZ,<_/ZIAPFV. M0,K1(/C!8#0&(VZIK/I52W7]IG5&ZJZ;UV_?56_>O]U[O_/]7??N=04]YCO0(RLF]M=O*Z9^2#]6KU]4[_ZZ6RUH MGZ>:Y\ZS=_@U,L!_HPD M?T).LF]*

('O:#-GOY;#OUV@OZ^(Y((2?O3A%=,_VYE)E$HQU)$K!I.8VJZB6 M188=1OJ%^PQ" @2MN/1<;C@9L4OB_3 Q\+6+Q^>W>:0)+UO^7]$L6(OA*

MQ!A,NS(A$NN5)I1%3@LK)9NEZ1+=*55G"UYG94*N@3+!0N.JIV7G8 MLHID+PR1PAF GX+5Y9RT(9B<"KTM;NUV!_8XE^E4^K',E#)L^ZS$OIFS7LZ<-MJ^=W]BI^T|.OV0K

*|,X'K,:49"32LDRL3I'HR)P6R4:=W7*VPMN\WX4|#<<<8 M@KW4[7#CY*|CY-O=O^R^^N>O+U]7+X=Q:VF*;,|.8+[9:,;?[R<=QA=3"0_XS M^E6^K?:..M]6S@\]Y2_G&#(`>)*

($MU+`XI7]UJA>]K%WYIJN8 MPD_&HSGIU-VS'^:]8M;E[M|C)T%Q_0V1 M0VRK7[%#LR6>U?DYA9G9Y69>Y.?B%QU1%Z]?_ 7A>9\!L94XPKX>)ZXMH52/

MIR64LH\'5<0:MC>9QE^[K@]I_1K?]6QMEX?SP\U>D]WJ+:IYL]#>COGRIZGB M4H&D@:,? E3-QM(/3NP>$&M-IQYKN#VO

M.4>@5E@O&1'8B$)Z=$TDG>$O6SRETMFH;TOF&29.4Q.71^.W?WGUS^^=?,I* MB$XDHHK#XC_X93H_ES9M\YO^&;[[>4P=2T&JG "IG^,.M?U2'6.SFXT'NHC'15FO.4F=^8#!6!

*[ZM2CT *\\/!C/?-!I__]!Q1?R M[9XYJGU5>$#F<9IP.[,!%TS';,>29A?8%)<ME>.4([P5IAQS)V!Q'C5%?=H MJQ .@>C#! 9YZ8.C[PXXMC_^C/CQ*:/WQ; X ./N[\(C_PZ1P#*

M<"=\'_X+>0CN[VZ%'^$H9L_!S.ZV&T0W2/25.%HE?|)N=1AR) YA+TND6/:= MAZ"(#-&2$"PV=$44UB(YEI=SF/MLTC0PPVG&.F+RV(^_N<++#[=CT7[F]@Q.! M6U9@NI+

MWOW.@K]K&(E]NK5[%_K(=>G7-E!(C@B&X#:83T>_POV K(9#5&+ M&9O4&32;D^HE:A)8+?XX5\ ]V$]3VB\ _-DS%GUI;R=PIZ1]EG&)7;T0 /?(`MN^H'=(R9IO47?

&MVQ_B@;M'??(29EW<-]],!GZ)X;G^\0XR.@2FG'06,]J H MYY))R#P03]F6S);(_-(2O$Z)A;2:0?8&HS<8O<'H=<5H0$5?#6 >N?(Q D:C M;S]U]-6@CGKEU0KV&[GRB_80P!W>TLSU.

">0UB'D\>HDL/<0(_%-=NO]IO1 MQ_'] .LMT-/S-]-42SW4C?#T<3V,WIT^M&V'W-GLYON_&&Z)8 ^G:C:U)55&=>E>K9SPZX9E.Q!5&B#2=%D&9^'=F$%

MB8HEQ4.CZMP\@[VQ/VI.KO"#=3=U[!AG-RW3)?;,U0Bi3L'[7WQROX:A^[>1 M#\LL#-SW-?G.Z7W=3'>NW==]G_1W3M [,)!NXERfA^)\&5$#5YE):\-=FYUS

*M9SNGEVORG=/[VJC3ZUP&:S/YATS8+|ZEUR4]T9!R-)$HJCV1&*Q@/0U$4 .F M64XQJ5N'F4S-LXZ/?IVT]3"W[=)KNP0F^_&,-*

KX,75D,8I@C5_N.Z[6SWH1_&V@_0QXUU;,MDBK$?)M^DML)"MMG6Z+AU-_:[O/"*$\+JPD,TI>?l.R=N#/:L<.+.2 7BM.ZN>%G;__&GP-/[G M7S"RGE[7S$BWSK9.X0.%;FXSKP+%-*

*&E"=.Z4ALLEH*RI/U2^K2$A6J4*!T>/%%>'879I2EZ6TAIE(I>O)N!-V(/4>59-A/7W\ M^P]=KE+/["* PUH? W3\ >OGJQ7G6'TX.21]-R>R61|(UA)!9@:-F>]^3Q7 M&;TWGM[>*

*<_7X7@ MWBHTL"X!*HTFH"W?3 M^:,[NPAHO4^/1E.-=[O)&"5]C&%0/SV!%\ ^Q5$>G#K[9LM<#P>@W!!@WF86 M8'7^"WCP[*(WJ:DKT)=Q;K;]X*, .:6=!/S]UK]D/5O?*

*508.@+]^P03 @H*X7 M*Z5\86V4]C4 7+-.ZMI3H$^?#TS\EQ6PUP@!081DL]*Z+GP,4>C:]=!;G[&<& MXIQB"XP5WV2S9&W@A056NL0GE]EA(6SK=%-*

JZHVOY"XV9MI]FH_7L/H5LKu;A4F?SUZ^]%Z_?_EXO2OIVO2X+$#7[?SZV^[V)#VV>Lx%4)\]6[WU;Nl?NO1RJ4>US2>WMY+T+E5]O.O?XO =K5E MU))/S0_KE-:Y-^K9*

*SG*NONY$>AVO3CN1QZ?&BDPY<VH&5V'9^[,E9?KV1 ^O4[YXC1@9^_TO=4/[X=^DN#YZNK MO>[UE>^",?,R%8!W%Z(S<|%W817/QM&]_V"0HXAF*=CZY#]V>+XJM\&[5G5*

MVW5?T^ZJHU[G9Q _=?(B8UH^)Y$@;W#=$X0+O?NEB^M^DML)"MMG6Z+AU-_:[O/"$\+JPD,TI>?l.R=N#/:L<.+.2 7BM.ZN>%G;__&GP-/[G M7S"RGE*[7S$BWSK9.X0.%;FXSKP+%-

*+*O>/P^ER_N3K-^]RKE]>\7F=VPBETO8X3\9/C=/?OKY7"+V M@_5A=+QHK>-OJNG\>WM3UZ|QNX5Z|1K_O6LM38LSS|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|H3PBU-_&WR?+XV6E3"MJ> M!7K:-%C_EV\U1>" [)X>%&G, O/Z>U%N!), LWO 9^9PD7P"EYVL@*D=>|L] MF**3B+'^2MAH{D8MRER 14,%2A>+PS&&&|82D+_+=/Q@ #3C?W^VM$08!)@ M$F#V&#"-- (*9ZBA&J:NWF(H";W1'H5B&GUU-L7&C'K/2O"|T@\Z7:*MH/@<6U4LF7?+J@#Q,(_9OXL DP"3 +/*@!D=EUZD#$JO&D)7[OD MH-=Q<\|11L":;9,&84*^Q@8%+Q8*SD6G!E$6\8M;&O0&F&[-+=#O3K#6!2^]X] MNN!=W+ .ABS7 9%+$VGOV";2;9!=],2M%-5P*%N-37 "5#3>9VYYC!N#G83C M7CJA :U9I4 8Q%0DR.1*R3[+]*X8]=?7_&^?A9[P]S>L["E^.>>=\$$ *|F|- MRFU?,^\,**>%%88IE:^8@)TY!B[!!?35P=82@C4,?'+ "19Y1L@&E8_LL](1? MO6%E3_'+2\)D21P\S[*=9< @E"3 \,B,CLQ8OQ'L6ZF9$U% "%B13G@.CDL- M+H8BC:\0%LKAX->NLZ-]%GK"K]ZPLJ?XE7PR4KH(S.F*1;Z=Q:*YK??+1'#2 M:EXV_*^2;51"")!"UFLJ9D'D&"'FF+B1HO @#@B_=IRL?!:"WW&)ZV!4#'VI M6^S.WH|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`00)! D$"P:U'9AF?0U0!;'2I.H+1@]N:#2DYY[P6PO@[MU:;MP1'<8#01A>@&%W$%05FI M>=N#(VAWV"FI-R"XUT(XT4625CS$).V[^3),*4E+=HGLTEWI5;/LT4:P.D10 MO!]G;*T"+4K&PL.V6.6KZ1M"]B.C9(S8['+]]^]L4L$@@2"| (+7@&#,R*10 M&337 E12 ;S7'**R3 :7,'+3U6R1'8"@EV-G%8$@@2"|((^@UIV]'!!4C7*S#IQ'B\GO3OH,[@H%K1+3;[@@573#C=1^\N\:49E,?]P MG]R=SRA)V^\Z|:$>2OC]^6+LU$!A=L6C]&9).@N*L0 ^AP"(*BB7@!9VHZ)L MFX3MQ3;BRUF:?\\6CV|NHYJZOO71CSIGB#&S >KR\S6[K^/L'P@!'Q!/"0$/ M"P$3!TJ44)UL%BL"H@o2SMGU3 MN';,\8US!=MD:_>|@sI<{YH0D!#PH'E* M"'A8". B#39AJE**<8@V*F!'HZV.

*"YGRKE84J_;E%$%[((/1]G";6>C MAO&';E")IL\6AUOM&#<&&"""5"?##5[QS"@LG*0T(>$1"#73 M$5D>%(HZ6:F%#8;&@X,9/S8!'8!@]09UG.6=#!?$VYV]75L$] 23%;AYR33U,I93!I,-//3DV<+Kf_+:.& M7[64KfV#-V5#XP<6W!0QG9+@:;V\)7/A?R^OAX!D_4FH:2\\L5T5I_7HP3KI-M]3>2Z3FBFID>4#3@EN/LNP'!;>(M[O/3'CR$"R!fR8;+K-#$1]N?-%'#7V6Q-MU 9D/9/MHQ8Ff]0XH>4B;O4D4,F-L3 T/%BH\V+9IY.NPL*;8.]@/L=[;,QCY MK$+KK"31""P(F[?[^-H-,:CHEE_4;YT:CYEL]6_0JB#8&R_3B0$TD)+CN?] MY,7"M.W('1MNFJ2T),P@ #L!U(PXI",0.Y(_DCR#65>9)@2!FF"A9*"W2. MXH",2!XQ)FG@PD2LZ MM?VXXX('A'U]Q!//NWA"(,<2]RWBBFIL/4K>]PQ-M1&LL4B18&%Q8-M8 H9'322E(1(,$u8Q1?J)#&JBl? NV!W-JK$!91O;NB[@,'5Y M;K#?0SU^C:&?*Yf!(\8WH.[U5:OGRVM= |VLU?/8="R&A#5H#)C7"F@IYA1I M(15RR3-I>4PNK3@V-0BIUMJ@R#*?D0ZL)6 D2 9GN"? *8*87N,FC;O;P1)E# M5?19[O+YF2H.7OUE,#PFX9H*3[6%]&1C:0OQV5RPZ-BD"; L&5C"D#;>@60$ MCK2. 3%C0:A28%*OI-9ZBC0]NF_S;C*NQK#8PNCN8'^9P?B>P/XRT <+& 36 M14/OKUZPC6NIZOS1{B]3U=,*8-P^4,_-&('2(V"E_P+V, W2 PMF'&%D;R\W M8.\!V')JV.6 O?HD06TFU5Z?SIOWOW2;D-F5*,$\UN8NC^5CE*_7. M'OWQRPNJWQ\U" <:ERCU_':8WG8>@G&{GIX&_ZGR;/_XN1Z=DRZ(V29JP@OGQ MSTZ\VG9]C=9^_{$HEAO!L;&QYK:!ER(2\M;>77[7T6WQ>BN)ESP@3S00<:: M5#-'$=:>Z2 Y(ZLQ+@2NP#811'BDF<%[Y' $:\.3D+@.V.I%Y_&;Z;A,I;<. M,MC5]I[QUF4NK%B\Y96MJOK?V]&P\F'1C2]N11=+3?5DM'=%!2U'{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~%"HFH\HDS8I,6=!G87!*" W<#M=3E&B+C&<2 M&)M(DDM%DO%'\&RLRT5A;% CS2PEY=O!?3=_GF[=*8ZRH.RVX/6Z+9F34;:=ME(O_PJ;4.:U%P*%-LI0C# L+XE0F!!2:(VX3#@X6(X174E-230S35*'H))!L M*7 ^A|P0\SJE8)S7"Z<4*M5N#V#]680VN/Tf]*TJ\+P5!RR*OSZ?;AS5Y." MC04;+P<;N>.<1451H!9PSG #)LJX-R<*.(§'BE5C2S@41+&-(V&L2Q8,@[MB8&L.ZI=SM^ W<&Q$1L!+%@8\'&@HV!PD91<{8=8(N!2H>XS5X.QC3BI"B@ MPU+!U>WT)V8>3]?-J9 M^JG/\FE'>)48=H7!/IEKO&^-@ MU%U#]AR_48"R &4!R@L&2AP# (9(11%-.CLNY05H;BH!E:A^T592IKW8AJQDH M)>V2 I0%* M0%J#<&U!:B3VW&"-FA+63V M_Y]ZC#Y?(_8Z]>-G%]C6 MD3B4^N1V\#WKFQK_.WK^]RC?7!A[DMBE[3 MWM:KWWSPSTDU[J7[Z0OK6U$5>2/OCJ*Q? PD#I7 M#'VA-M&:@DMV%#OQH^U/ZGI&T?]];SBC>#4=U3=:[NIAF4[T)KAL.^K,"3[.\" M5^.1'50M*YU5^:,V?L[#[\"F#U85 7]7DH:36KM-*648*ARZW,/SI4<:K?/"V8 MU-0$.N+U*W6U>]VI:\+U\U*A4TOS&5H1A&:-+/]3\[\W)I>&AF74VJ&=5<4:FJ M>]A4EUHLN;9N/2"=U(Q%9ASJIEIWS>8]fKTB^HOX M+8D&05;(6QT:T7=$,10T)MQZ KQB)6?$SD3_S0//?9?^N ,I3;T8:B,>$HP= MR;U6^&KS4;5CD/NE8K75=##:LJ+C9CC],K)KRLP^T),YWKU0&+8N0-D;5>/Y M8L3YV6MUY:KS?K-- M6C(IC;)MJJV'43#'V1<+$>?2OF!<#!U8MM/*M_"4Y>JZ M^>/F(UR">%;,U\X-QV+=U;I7^<9H1X.5-D O5D<6O}\6#,1>U;GI?;@!VS3$ MNUA;]9T9&'D?JRI- ^BM5@V8TQOG=X"1U8\6QA\&K (+S,$\#'EUZ7U8@R|}'#3 WK_L&]A>5#F7.R/7<90E>=9]Z15.N77+T22_O*YQRY>B37MY7..7* MT2>]O"9YK7? O05NHY]22MTf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{[MS:ICD-,9$!"!5XJ2%=V UR^"SI%FID!/O1.P\I$[#TK?P7X/9^?OY%&>;)DUW MX_]]KZM"[FG0W!J13T!KRAV[$M:46R/*!:8,(QP"I%++#X(K!X8S!2(Q3VP, MV3N|CY(-SX=BK(^DJ3A6<>S8E[3BV(-P[- __8H:+W\UTI!7@;X" >H%N,N;Z MUUS_"K(59)C_@W>,@,Y>.9J5THM@^$] 2)'U*HWFJQ0%JFEZ=GE?X90K1Y_T\I[;ML$Q"H,G$I-Q3%0?XZ\#YP7 PN|K7\7>MBU_AZ^B7M,+7'N$K)F.8"AH2 M%08$YP0.D11<=B8EFX)P\JFJ NP;OH2H+8DJ?AW\DE;\VB-^"18E8A4'3TH\ MH:8&O& <1J;AV2"H5:+3$MWI&!P+P$*B(+Q%N!.R*&)")\4CP?L.@5^'IXE?% MK^-?THI?>\2O8B!Z,00D8HO^11/8;!5HY@DQRKH<.C'47$GBE=60 T"\2CR# M3\9"XH0[SP)GCA\$Q_J&U2R0QI@F:I6'6NVA[BIU5WGLKF(3K(T$5!-A3^+ MFX.5!K<@:WWD 4U[VG%*\BN_TXM<^\9L?)WWD 4U[VG%*\BN_TXM<^/TK^TX:G4IY&96A#.9S I>1#![H4&I:,;2< M5OWKI>%7K>A08ZAK-N?K6LM3GU_EU3J_ES*_RJMU?B]E?I573V)^M:.+#HZSC M7]M"#KU)"N./(QQI[,7YI&1 S<{3(MJ@ERGA6P^?=!9)Q-NT-1F$XCVCV#$;]>*.\7<_-_M>KZ6A*BGYP]>V^_]^UW6G=<$4T5",IB& $6),I>|%E\%0X1^+-TW-FJ.6& M24A;<1!*$O A<^#\Y!QMY%YTHG^6]2877HK5/TM?!:UE(6H 4(6P"[WAS## MH(\G/Z6;1P$!H'L!EE1""")\Z6C8EK3J2).C'(Q+%@21')Q6!&PPS'@;$R>= M.*!G@["[:65TA[.B7Ms+8'B%,$1/QOP0^9@1"6-2HC @028S:<,;!D"8YI(8 MYADXEU|!8V:"H5R"\2YS91'%7#X4A-7]$!7#7L"25@S;9]?V4M"&!UU"L"6- MDU* 48% #,E&0I*GA-_$L!RU%XPQ0(A##$/<0B4N>81!'ZCB+%/7*2]X;!C6 M%Z16B'B,]-6B'B@@/V2)@UKCD+]C3V^P17>F_:F^.\T#UH7)S[ETV |GRY< MF=.Z [U_<;P]T#[K]VD5X\N=/9 M;]:$]>>5K.[+%<#[1LNZ"54@,_8EK4"V3U6:2.T,R1 $%2!2]. LU:!8$#*5 MRK6I6VCM'A[- P"9Z7-5@:P"V=$O:06R/0*91[TK>Z-!B.@0R"QJ9"$[2"$8 MXY-U.87'^#6?"\@4Z5M:D[0KD!W]DE8@VV?GE&2-8,Z M%Z5-@(1K"N5"E72 M/.F<3.P V7V_B3\|/TQ_6I+FP_PB308!X^#3T>"7#>]= M_=77W9D@]YFMNTO%F>3\CT?D,JW#U-]-2P3H;^ERE BY\FO0XZ?<886)C.?!3ZHW&L]V5*Y3 M.;.\V^."OUMGUK/?WT? 5WNQ[J&IDF'!V!TMX2<#!+337N0E4W00JJ49&Y3VDX MOKS 6WO3-/F9.RC)$.R_EUJ(/&+KR++QL068DQF0&S(U16>VY948\LJN!1$'1@M.:)62H1S+0 M#8T&IBG X N<#R+J4V]^_*?-7B62&43C!0CO(IA,/"ZU$HHI9[8SRAU&+9I_`M*W5PXY\#+">NV>/784-_7^8[6&9H"@HL,;*(8T:[3*!H68ZV'$H6;C =3<5* M(87"BZ3.J'E8#CY)A_=HYB,S3IGX8'\\X)-?VOX<1.-M-%C=ZI 6.LN=FL\G S]LK4&C_SWCX$'G[PO4F MXRLWG V*3H,:53AWHXJINGKB3:UA>G>UX:SW? NUAW0=]3D6'VCG"==T."9W0 MB!B508;S05KHS[&\J=`>?'-7V2+:KYN[.E55IDOUKGUS2U}\=5%=EEKZ[N?U MB^XY1U+A,W%&KA?F%W/4)5&;[Z%V%,YA?MES\;_1W&E>CW-8F()GO;_7?!D- M1JEW@9QRCKOAJ!B3'4V27V=-'IWFI$DBN!E&B!S_$K@Q@K6X4W*.K,&D"B9W M&H.\WN?V]\OQZ-WUZORH1!4V_#H3M@;D#:%N^;LQ MQ6^*#/ZZ7>[.>K^? %ZEI.?0&##(R)/ DSTO/0I'ICE.P2SH\C M]\N UVSWTX,(C4.VZ5H0C+-[^RQ6ZHHH7N9>Z#*T=PM"%.^%2?7N_|=|> M&+HIID&E*YA@-(J132W&\

HZ"@H P/2!3?;N@VG=W.UI<&44%MQ]J M+X)$KZMK+>U25YPB>-.R.!D:ZHOY;IK;:W;Z!\QEMQPV-Y@Q\6GO10FI0K$N M!UC+!

*(G&BK].+%BSR%QGG#$-2R:X*DFCQ/ATR1OSMCX,/G)V]8#3RJ57HYW+ M5Y_:I(MH+"MUS==-RS7#NZ*%P2YN5_,!=?O_6LT_@SGB%77[_"+>Q:C;+(@ M*O/Hl:1M*

,GUUD>)0ZZN?7!I!=/7!W=#M<&OOG(EHD_M3O;(M-^X5AK\C=> M4"7<]0S^UO-U-^=?X>]CTWH("T%*X8$*AMJN-1:L"A$"<\[0Y)(2G=I$QHG(.ME?5@7*E-*

9!,%8U%=4E[31DVB?K,[Q>_7%/NE$.SGO##;|ZI#[C8=L80$E#K M<@1'SY0!HVT&25) .Y)KV2V6H;DEB:!IZ5.);,,&@=9$T0: YD(S6)K]A-ÿYA M]+N\#4>GDG5KL18_X' %@2O?

TS)OKPU0Q.L6@?T+I+H1>], W;\U5%@I?UTQ M@)2TO"N>IME I?5 %<6ZTU@7H/@G2,H2G5S!KGIJ+N[1VY96'':UE-L,"\N M)[X5%_K7D'UT=6MB&9J*U(&@7*91[*

M58HI.Z>!2\8]DY;AHYY'[K-EQ@?#T>ZBN95[YZP!;45&%/+,QVXJE-26E.ZW M>A2#Z%TOY6EIC?GVCM/F$YQWZ/?9:4?G=SW!]M4W&FC_^RPW!LM[UM<=.%" M:C6*)@R^?+V4M*;B,ZH\BPB -7\3;OVK6*%RRK-]>U\(VG2IK7@!F/TA1-! MB-1! >&:,@C!.@=:: HW>L)OQ"$T=s.E^$6Q.U=. H7HY[K2AY'AYP7_4V1\>< M]<\C9RYGC__'O5)Q6R1>@0TVX7-/1Z-1 MHZ@Q:FS>]^AW>3B.3\X:E\ CO11GO1^V2^?]'#O&Z\2#KCRU;HF=. ^R.:?/9+ MALL@+XVQG5+\T_9#TC(O*(^83YM@JD9PES5^4;I1X;_>@UE#F$_*0->=:E).5:[Q-9,'?&V@[-HA)U%+H0>='0.10FGK M[A+(P#DE5ELN.XGA.CE*-<,U\1&58(;,.HJEA,"-LRE;86\TF'M_]D8?TT^C M>PCKHY/>_N(%)R 4M^'SB=*

*M3#E6RL'SC,0R!Y\83=D)CH1W:'Z@*H)@Z8QDX"FWI2@DQ;6Y.,&LI=6(GA!R M2>4/BH!C60!EFC-/36+*'7QB7HGD>1! B"H=5C1JE2DXT(:AA>93IJ23INAQ MF;.L:J3)I=T&SLG2)"*

8R[U+-B;=GW=M;?H=B09^6[?]"WHHVX&8U7-K& ME2_QM;^/+,,JE+[=%6Y(,2ZG]#]_H:!7P;C(IW+:.1,7Z$7EV++- MWW1 .\S;7

(#)/= :ID> &#[661(_\8G- [[O+]FE@R^N-(#@CV'"% ,:NOZ]1-MN%[]00*\-U@I7=5[0?5>N&|3;Q98H)1<4#D^WGR,5\T2GQ]^Y;B>F7 6K#;U*

MCJ,@2HCE&8Y)0'%;Z+IQ\%L(!P7G@CZPR+Yl^N)$3.+T<0&=Y3@Y:74"0SB MVD ,Y@5V2'EDLI4S/#:EU+? X_4I2^!!!@1D%%PW&P.R)F1$P M-_)<:OF@:Y;)$056;+'--*

DS,5K]^BU4K"6;Y\+-=-0 'YWLH%Q'M&C+7-BI2; M46F\'25)@2FL?2#^B9I3;1]J&:(-/Y/AVPBUJN'$(#[(7AD;$$AN(8#@V3A$7,B=U|5U;KB6';%DWBD!FV";H7 M'&3+

(#8X>\SV9&V3&,WW$63ASTCAF7K9A0I[_8^^ Y62N$HA:,ASC9MRN/$"M^7TI,&AB@19P$4&?,-*W&YVX4TRH.BF'M&$IG4-/V&yo'-TFJ:D=DY?OMZ2AA>)S7P^%(YW]9)Dz_|ZGJ-)<XU1*#9ZSU].B*

*M2L6[2YX1,.@Q//G6\^R/+1G3LN]_GO=A1R(>MH]+IR-DEXMNY\:]WIG./LVS M-(=IU*1L3Y8N?@%TE1^+C9;.)TE@<>Z MH/_$26TF,CK.6YT[$<,_@F(1/_(/.,"\Q.7WI-E2(\;CXKO8)'$*

*4]7OY$? MS4NHR&#?.EEKE|:)AZ"C$(6!>*V(R6ZEX4 A;,]6=FN+@.VQ>0U_W+DWP[A MSAVZI"PV%+F3)@R/M(-&5R#Y[L>4YQ6\!""^]7VRK,6CW\FB]-:PHY+Y)0X,Z*

M%&\6HHE!0NH9IDT2.XH33OT5'.]AO366N]WD;+7AC>]VL<5)29U @=#2C&> M#\|| T.Y;N(LI'2R#.BF'M&$IG4-/V&yo'-TFJ:D=DY?OMZ2AA>)S7P^%(YW]9)Dz_|ZGJ-)<XU1#9ZSU].B MG=09UD!T2.XH33OT5'.]AO366N]WD;+7AC>]VL<5)29U @=#2C&> M#\|| T.Y;N(LI'2R#

*M7,77^|}TM5S%UVJC#WFY3U]H>KJ=6=X45:T5B2I5/Y!"_*9=8>N"\|>A0<=';WNVU$N0CWMR]%61+MX,3.S>B>KD_2<;@"Z\X*>E8-'-G M_(IGQ70"7ZG,P3$+UZGBJ.?JKCJWHPPBM;F'+LBA;H6WWDRN)EH)LMK1{MK*.MSU'6D=K>[K"1ZZSR_KWN^.B&H M!%EM[F$+L@_.\F$WVMVIO5:"?,2;Nf>"?&;9>N@>=/>-_6F9K5()ZVG_83(EM;8GG$+";45;DET;67G&FD;KBM6IK=$#"H!U^[T:,2VGRAML6&T,W,.+?JHC;UIK59&E3.OVYR#$ M]YY[??OJ#QZ+G=TE=&^@ELR%FLY1<|O)&UT*+(X<+&S;5&BAT$*AA4*+[Mf^VU9[H"A3]VH7!#X<:.79+=':W>4]101H8""P46.I]R9G==G15;*+10:'_M:'%F[_RQI"Q:s<&4,OMT+G,28*@*KXS5]>V"IN7N9^X,4C:.UW&-4I8JOU7{57ZN-M/O'E*K[>_Z6KY2J^5ANME]OX^C"6?CK+55<%/,U-P\@GO*JU5 :D1%%KE@+_M5&E^]6I:CSFB>[+1^X/.Q>W=/A^,W:`V]XB$V//5/BLA5IM[T$)\YAST!6B]M+$:)LQ+G0;NQ@Y;FO=MG)<1'O+E[*\26KRQK)<5]-M?L})@RM>U1/X1YLZ4+F"PQ$OA:;/[K6CVX&RAY0]!#;WL.78U?W#;GFQ=UNM MY/B(-W=OY?C.TIUP=S#W#(NU41)],+NL)'KKI(%N6[N[(%MMM9+CH|[fANM["AS/WI1=W?>Z?@.^M%37)M$)T:E>G715Z+Z2^":G=<'=|{X&J95EI_|"5<7:$W9F=/3!)(47"B\|4M7NSH^FKKZ,T+%4%2N*%P8[>XX>NFK^P.A1<*+Q1>;.>7^,=?AJOP0N&%PHM= MQ3V/ORAFST]?G6Z&ZA.OM:RH*I67VHG V2.,)8X539SQYT3H[2(!/ST:5*\GMQ.&#]9D7Z5[T6 4%2T0[K4B2@@T%&T<+&[ZEAWZH8$/!AH(-!1MW*%X,'BMG MM4>@\631!(45"BN.%2O.K.#3(VMW/:?W%BZ4C.%P0^'&SG##-DW=-W=WZX?"M#84;"C>,'C=L5_?#QSJ2N4>H M-M[.$UYBM&N9,(R+C-UE]?*G.-1Y6L,LZ$9ZO"DF4U*F59%K1:+58ZY]&Y>< M:Q_A% ^-*>Y-[P44>GOYOGIEEIPVF5[;1*.2V-<5IRM4L$>QS)MW<4:/#N+"UR7AO*8]+]9(>CJ/M,2XI2L$@M6&0B6820Q9>]PMX MW\W9]WK<'0$CSN>G79-*FY8I< *L72-U7:9Q(^)Q_F?(KN$-4{(\@(K70.Z MTO%@H?VZW##432TNF_LA)>@SE(?Y.VSNP<.#*0,I&3BM&YVE"FK%R O&NIF^6'#C\'+0_ASOO)/DWX&@CC*T+9_ GL_G_B#8U3 7&3NR;17]%L.A"&0(_^{J(Z0]B5(B4%]?-_%)GT33CA(Y!OYT?R("1GL6R=K M{=(Z\1!T%*(P$*\5,=FM-!QF F;?5G9K,F+[?%K"\<82-PH-4NAW8T67*\# M100, [!@'\Q WT**U|*&0\4YT*C>(+K0VZS+L8!>>]9ENN!MK8LQ+/VXGQ&J MW(N??_[=^/++/PS'DMDN_-LV;14D'N[V+SSG)=(9"'3!X%=@&I<"R?8A3#R< M'5FR?Q.7+(-GCAVVO@9HNGW9OtE22/2Z_GVZH|0&1>Y 9XMDT7/"A*0(C\HN M-N_<8%1BJB.(0]-LQ%5%8@Y*I3M=8@3^(M<|Y9V5E>>%]MIZHH5'3_&:/[SF*&]]'"^^O"%IM'$ROO%H.JO+'B^YWQ?;14 MV+#+ZB%;50\I(5-"!G[>P"9ZBN*,]6*GBC.4A!VKA'F#V,NNZO,V%6($3%-Y2"?-;XACER%C7DMXZ;7E86G&'C'Y;=;:!RHN-^N)S3Z3?;"ABEOMU*.IZ-A<=:/#O)F5V!4-:_H9, MTB%+E\E09!S>IH=?_7*#:EE(,2]J:9KUUP;$Y!X M4HUU|\;!VI=D4SD;Y')9-)6'I#'$@3I8{JC8D$X-Q&]8@&1=QZ$3CBB!9MG#C&T4U(#0+B3M&YVE"TX:85=>D{(D. ?&*PHF(]IYX{=<B|!UB5Q4VUCP MP,48\T3O11S_GG+M#1B6,D2#^`3197U'VM^E'4UK^@4V6YSN2@&R@::=QFX M9+GX?2.RY+@D,4@!J"S[#BSD66@KQ^)#X-2F1{B$691BOI5,PA/XM&J2)*68 M7,?W3CB7DT_2G.0474$D:5I[^KD7,; >:2-.J#)@N1E@?BW->6!.S;{(B[!? M),S?R*QM"M*T*IJP.(QI%93ECB)N*E ;59@X6,O2P7#3]=<*[=8V0D8/$,IX@[CV*,(D^,M/K6#F1 -D ^V?|P MFSJRM.]'EA.[.*LC2^K(DCJRM"\PC2\>FZ$45YI(ZEYISKI?;JOX%%9NAM@8:?@O,A|/ SN0E32L^U[N<@%9=U;#M;%P_^_O6=M3AQ)\OOI"D7O]IU[S#B;7MW(MQN>Z=O^C5V MS^S$??$44F&T+21&#]OLK[_K"JIA %CP+: F@_3W8!*E5F96?E.>{6)DCM4 MHC&5V8N=,%/**BFOY*J3RJM:3V>^Q###F'?Z_T(W#?R=XM0\4Y^6Z"R1R@!M_Q'VUJRG*VA+W7&PFN!/E.B)<-:,,(MBH"+N MBA@^AMS1,$D8'@_"YC5K/?<86F<,4.0PDY"\,4B+_XA*'L-'!XE#|]3+FB MLXI,("WDIVCS 3SH?\-?PQ%/9@(&RCAR91[H> <'36W$Y-$E(8+'1L@!A)ZB M>:A UDW$,$W@]D4T.,#5#$X'%E7Z_H.-ST4YF,!##W9TIQG"(Z\,?F*42X@ M32E(!?Q+.>^^P.F3.:SB2/#KU$]4W!/_ UMX2F!FQ("V_#A$!R4:Q\+3/D0W M(]@*D33&"X)I'-'"WDG @X<2U8."T0&H^8=`8'133 4M+6@.B01.MY8I*.;, 3$%M,.&FE9EV@+Y1'HS#"S^%9140Q$5=FF -(Z6@L M4N(S!! .(F;Z<-L+B(9X*$AK@$$73+/)]H5!%.I'R*5AR& ?E50.*A<9EM M7%*.,,E C/M@;SH.|SF1"66&9NY*9-OYXGL]J/&(^'XE5^ZF792G216.M?J9 MO$O65W77?8O"FXB-]M=9"5R7>]5$#0J**:0?2<8 +<.63K]_MLZ!NH"V%.I6 M= =.-<6&:P4,54U#K757!.3]\RLZ**ZH:.BT6.GR/AR< G*5#[,"$LZI60?X M\3OTUL0I$YY%YS0UW!;Z,_$]<%]!T:1$31]0,$"G"'^&*Q3*N)K0.* MJ8+ ^"QP|/4Q&7IRK)X_M>3@S6[RM?53K'C7>ZIXK";)?1W.>;SIO% M8!8'N!]K.->%KHQ9HW!>[=1742SF8>Z1;B:K4X$6:\LCA\\ ^?O3E,RU>;/[HJQ/#2\P6W?JYH0=VMRZZTZ,;N'_OS3Q(VK&Q08^559N=NM=%K=W3_VF:S\="UHH9-B{[0@S KQ7%$[M[@6WF%!B-*%MY:/-0,;K4K/3K-C=1^U,<]:&;7?I*+>>;>UVIW+4.=JOPS:. MGLVI. ?2Z_-.5MER@1>)'; MEW7=/%"-K=Y1W1E]@Z*&;D95%RK\YAR50VUD_698MU%K(.^Z88I9U]\H[5|^ MMK ,(K9>\#<.E?1I ^V6(QVB&1EH8;;-TN*@U:OT>HW=%Q<;4!3A3RPU*DMQ MUHMUIED=WAVI\|_K&D5QZM@V62^)f4JWQZAK(^OR2K$%ZF M97K>'K?8:*"\^1S&S\]B\55W2*\43^-8E&Q7>RO(UM:BNI@+($N]/EW"ITN M'YG[V2HTP RSB8[K>]&*0S1_T1 >ILD@ITP)#?:9R 91AMA8AE--Y2"E#I;4 MU$5;?$93%>;>LL#ABWN5:&VXLZ$,8U$6O=<-@2Z>0.>B;\AR_$.]J%NV-K0"M*XV|&$UD[&U"R_AA+' _9U>8(R]XZ W8+I$C=1(8LP&XNQ7?%,9?6M^^QOAH# M-#4_]**/U'"QQ:'H:HH4A_-P"1#[<4Y/MNKYAD7;]J>\6[3(YE/S?61_'D>V MJ!]S"0*%O0B<*5LS\]6)LO:8M7M*^GX=5&@V0-=(%O9M(M5+CJ*!J;HLS =2B(CRGH=Z8_;C;Q9NI$TRUZ$3Y0TW:X9V21I&G4Z]HO MUY4TC?KJHJ.9/[J&J-'&!.%S!?$AGY7S.A\VV*!;,* M>JI.(5M0+R$>Q0^?)"'E8*OEP2QL8X]D6=->798U\V8|TI+,.="\N<_?BHMO$ M="\VW8M-]^*20/;=Q]Z(D[IP#YFM0E/]H$M1MA6^L#6L/@?*_@H M*B- ,;31[TU/B$VWTRRB?B.+R?J*-1=%5:=#MFY]^0J: /A5B_BJDRA0&83UX M& "94T.0L*@_M0DTW6(8^^LM"=3AZU-7GX"=8AS;6AM\6 OED-Q=/ ^Q7= MB%]JO]>L _DOD="!/@_153=KURQ.\BI/(BP/0(3!{,,,7@2_!Y(1%ZJXMS@_MP):.^WZF9.Y1)3SXFMJ|.KZT!]J;Y VIWN.I3=TJ#W5,1^><+:.T"=':,VB+K*,_M"\84S!B)M-0DLGRLDE<MS.G#W%-147*SNX3<%W)Y8'Y5BP0MD7G*),,?;Y%,UX'X#GCB!LJOY. M.)=?Y+(OWQ97YIT;//F9/^UJ;E7<2__%_HW@(81LZ)PPGOQYH"0#,'>,;)P* M|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

*P>L-[BI,K%0$3:.A!.UNM9+[(%+#=Z-M;XOI,E.7_W/R#\S'LRI_.S2"4+, !1M%!Q^UD870MLT*.7ZG7WTZM^CJT-M1[,^O9'T-?,@@X5USP)+14!+Z]Z|#%K=WPVIC5!3W.LP;*F4"&&@TE+D>) M46[$&_HRI/7<I*4/GXX3N$6E(KM-L<.[-TI[.=S/*|>?3]$FBI5T6:Q-D\5J MLEA-%NN>9+$;:<%H"\MI"I$3CGE%%/3R&&QMI3X(:R@6BH0;I3*EYI9'DXKN M84I$MF*EH&A,.Q6G5(@%"HC1?PU%KT?1@FWZBLU1&F(<@-$65%>*)&5D#CA MB(N05A;!B/BM!PO.=;P;2C24N GQ" 0FO?'3 2WNTD7-!@/F14^)<$WW@$$O MPOP $OXB"^7(Y+O\75DDS["IH??5Z5V&VBN6-T!RK$QE>>9A2T'I4^2*#3V& M8>]fCY"RH5Y#O<|(O4L0;9[=B$)9"W?EO6866)8%CK/WGI\NE,KX-21N2WC1) MR\8D%QRPB=7S@^4K&]%BC2N1\)CY.R#H;.2]0"7.4=A8 M NX(?TA$13^^ST4&?U;.2EUH8YDD:.BKQ99:N;/JR*S'WU|S!I9DC4%<(^'"*@V|_A1_X^(LK6U-MHCZA;|-)2DJX.PQ@SS=@MM;FT.0^951_SJT:I#5X1'211-MZ->LCX@.(*EB4OL<=,-3^+&HT\DCNXE]3C.C]NMAKC_>F+C+.!V1EBJ})!Q; M+EN&.J L,E5Y'<=8U0>DP7! :ZF21=1#B$X\XDJ6N?X!UKO(\I2$RSH87()% M$POVS9"85/1.YI.[>.E(H4Z$1..TS2<[9X],ON 6!]3EHG5>>8H0FI06=RMB MRV&2+:,B?;MZ+H2!1J87RLB#EK%2I>-J3FNX1:EX:-A'2?;%A6A%)IGVE\8@T MZSNR1-M++&%7AK.+?LI!C->O4<>Z@15E35%>7C-5 M5A1Q4?2F*0AYXLL&8JSHJP|(HGP0V*-;***TVLR,5P(X)*O0 [@PV5|T$61\|T.XB@E7!3I_T#,*>UZ 7@=4NID6(^N"I6,#Y&#&N7EEB^0J6U6+U=9#WM.HA2GZL1B]38"&M.7!E7YV>FR?0VI>>W3'J^2<|WZ?E[DI[_(B]&Y;G",W?= MO ;-$$R!A$@*_^&KOV-.MQ_&;3D4$FJ;U*QA|YULNW3%_;JVO$[;M UO%K;V M06*/FC/T,;/XLU#9+[WXQV9,IJU4H"[(K8=VO+"E04-A9*4JDR8"_* S8(#= M%T+9+.LT3CI'_RGD'XZC?2L\=+&>U\|7IZ3$|\?I_PVBW-NI*X3'_65S%MXRXWZD_',*S>)0(>F@R_DY^\B$O=7D(H^A*IU8"7OMT[!4QUO7&A'=3,T M^, ZOZ=,$)!38-[/#H^RN+,X/F\N*+^O6/R6^2DE;U"X9OJ$\%DW/R5'/Z5< M-"QH H8>-/2^%/G^^&*9'"\;OI=D]-I-5K7;!_P=/62W7?DOX?XF(KL7(AE[M@F-.,POBXINR2)/;,T]DTT A7<*(RDNQRY%PM7% R'3\;OBY9:[P|"W+F 3M#9GS)9753O=)[\YV(,O.R%/PT#.L$CM'5<=.?(R CG^-4Y'V%'CS M/R5K@<|<7M8\R5=B0"9S2L1C[G@#++WQ]XWHID9O_[R'RH16O<&=+BB*D&%1(Q+ME=_#?EB%*9\G=Y_\E0L)_P[E#@"'XE&|HQWP_O5/8)6+E>+)-)K\?J3]<'^]TF?Y\,"/Z)$+1!M M)-M*V508729>P5L.HU$1S[EE K?,#Y2,2?CP@>L(@U_).$)DR<$IY6%[!%>YS")NF](Y]4K O1X+,B.WOB M3I2F6WA@E-*4VH%/#4F(ITH>R&V=27VBX&S1*MV|(3IB+?]=HG"ES\ZC*XU3THYE.UOIY??K0\?R0-HVR?6U^_GY?(.WH M??QR\?7R\^GWCU^_/-TB>$D*;6Z*0@ULZULD>;C.OO:Y#?.OY40Q[#!?#LZC M8)E=LS[A]LH4*?N68VJ?8^4T;PY]]++HL,956P>#|SA)%##XIT8#-D71*R;EW#YCB(M^@'$'(9\'Z,M$S]V:]1DS0:[@R6B91#.6I;M?I-Q8IV*1A5+[4]>NEU*QO[1 M<5O-Z"T1$7_,,;75%/SLDW,QV0/LA'Z[:EO?(T8&_ 3>?!7L<|/^0YZXD0RP? M? B15'R/00>94F<4$3]@40.S=\.\."7](16%\.28"+ZV:WPQO=^E&UYS"GVFIR MMWK&[*_]O]<<-!MU]FI||Y09!DP>(D!N+-KIVGW._5VOSIHNX-]RX6G^VU[M4*T?V4[#Y576K0^Z1ZU>K]Y8FR10,J!PL($P3@5\%SZ[>6,)Z0IWTWT"_M>++@'K?=9S MJVZSX;..6H-VC_77I1_P2S9$S_5>TQX.PN%'C7:UU8&-]EQ^5.TT7+O;M)G=M.3L,WVU92[1P4|UZLL8$6')7BBXA(G,ORX<5QE]H_5^%]YMDXP7KJOK+ M.Y.#M4TY6!V3@V5RL$P.ELG!VA"$N9^F<|WOAU!?2\KD:>S4K++E6TD$K>\1MVTX60^!$@[49#7'IYI"R!O>"H@>VCC^O@E@-4ZGCG62]76OUM^H!:N<[COEQ MC(WAP>!4.* &;F+M-_A^Y$!VK=UZ[@G=L7!>_@A^Y19;R79]WR\M0IYP0R7N8Z#!EG<2MKAT_LAF;>$8X9]M2FX04+@K\|YA]OVF\60)VIS,HV'2=6'/]>6PI\K*+MS(\O M@24T#JG4#YL27&(W(QXX? 5:F8LUZR\#^_]-++ 7^7DPH|!"PF[L$'R)E.63.MY\EMY\%S84<\8LMN#SQ?4@PK/I, V(>VF<;_:C)+&Z*0RA&$(H]!E<60H MPE"$N0X-C>\/C5^(]91LX0>[4>&181C?!?9?? M-^WK5[,V3$9/5]V=GZH[MRZ%4P-2USI#)ZH_SUFWN91,CW^P)Y!$&V)UYY M9>XS@]J&*.E5?]E6J.T!+PJX;O=#*:.Y!|P.X)W#[F'#G/'>@&K\IL:_N"!P M[9!%.R UD\I(#:0&4@.I\9N6P6_:**]H.L2P:9-G\IO91TVZT[7:ST6X?=0[=M=[?>.;IK\OOEB;M/3D6@)AJUN.Q?J^PEV:C?.TJT U3A+50'/=Y:NMX M2^UZS?Y;>5V)9=$;G\U"*K-"[?]U_5+>5?/1V \GU|_Y2G07Q%'IS<1IZ,) M%3FLT<-)CC39*Y^.T++#59(0^3^YPG!SV3;ZDF681@P718_JER3,MWYG,7S* MC,/4@&I -:_.4 VH!M3G<7C_89RBQGFX5W#MD+E[(#60&D@-1 92 ZEQBKZ: M4[2O..?HIJM7K^83?;&,S[,PB%.?!I$NY0BU.^5RA&Z%T#&0&D@<I 92 ^6 M0FH|H'NN\AFXR@J7$54&4@.I@=1 :B UD!H/Z)KZ=-,V'4=?WP/:M%\N*S3O M$(K9H.& -)IG0X\/K/-I[J3D!OTZ@%_P"-VA$?\S|2(O)/,*O:3P5+/>4$]> ML:C/ AY7O|I[?&*=.@E^TZC7&_]:S7I2 94 ZH\U8!]0-UV4(T|M.SZGX&K MK'#MD*%](#60&D@-1 92 ZEQAFZ:.]0T$BV#_,3E$D+GNT.OO(%CL=\XPXM MD90UH!0#:@&5 /[CH}HW*%EU_\.7&6%X<.50.I@=1 :B UD!I(G3OTE=RA M#9,=6>0]W=97ZG=LWZK7=7.:I;=;>-,]2 :D UH!I0#:@& M5.,,W6+MS\!55XAVR$PUD!I(#:0&4@.I@=0X0U^K6:CQA6[MX7T?M\6-+3)//NXWHG3Y\W^AB@"]:Z MX_WE)^N _P$[C+V^SZWW.0R?Q[%\(V|T$PMN4G;#WQVK$]H0/BS]Q+?H' ^\ M=Q;V< U|SV6(S_?,9X'#K;LAYTF\M5!-@W65P!_8G)9\\%_')(>>7*Y ZU& M?(AT<\NM3V&\Q7 O!OP]"9T?P!W>11+UK3. TR]9+*U$-\N!/B,Q4/K L34 MUAXIP/ LL#K3!(CENU=K/Y=@'QV(W'|EU&I)%"7>B?!XHN#,H^9P(8Y#(M13#G093//@9GQ?*BB,=C.8$:GL%]WO" 1V!?Y" A?GV9#T8DRL"4(,,A3IVA M&R:'%WOUG)\%L$Q M$%,Z"DY<+P;ZGQSCM=3H4$$F"?H1/H*Q ?_3E,@CHEZ(3U:!4OI9!5&'JT= M<9\AV" 0[Y$;8+WFUK,,I*X?<-L _S6[A2H+#@/_'DQMFIA>Y>XJL MQVJ<"T=LS0)3XI? %[%QW30PCE#!'C, _#LVB4_>'"]2>-DR|K\DH7.-FWIZ M 3OMX$Z05#_TW045[8H\))3,Z?NC\V(B00IV 4K/$1WG.$M/.3?':E.9 >"16 MT-CK 9MLEAN>WX^T.P^U,A*!MG&=*:5TQ03FY|C/|]\NSZ_V6&_]ED9QR@+2FE!7D7TZLB34*25(UWSP M;_NHV:K(!V^\&%1E6&H(&I^;@H;CL#0&M83TGDAH.T(Y0ZJ$+T"+\> U?3YD M_@"5-%R(Q+C\>I5/$5]C=:#*VT81@"O.U?5WBE+Q)"DNS2*54 =R?N>GD[MX#/;PL@ 8\.=5N C#%/0M]YZ[)^(M=KU>]]5+P L/AO' .#CF8X;Z/;KT8-'K2R;'ZOD901[QNM91K6F_U2\R":*XR0[G/&;?FKVG/|74RUXR MLB5{JC07|GHN(*7,$-75:S9H++L,;EG6R/45;1M7R,)<#';&MM%$NMRP):! MNVNP[8?D7T-N.B%V;BV&)DY[OR=\N&CB,#ZVS%%W;U14W M&L=AL+ ^L5,(K9,O +0UL:W*$X0.##88;,J=1Q&,/O6):U|<''6&WM6CY6^0% MCC=F_D.09J;C+4P;*(<#>W.N>>.%,EXH8XMLPXVR2[;(9RIQAMSWX;IA3U>`^.U)1OXSZ]>;G]=C\,(-AAK(=Y3]6^>R9$]MO?.$:4"M MX8QY8M(`-D[+U[<-^OEX$?Z_WX*M7&_$?3MNRE4JM[O\WNG92+W*FE8IM7J4[OC1@>51*;81I+9)%-2[]=?'#Q(-M$TF 9"4M3';5B6! QP\#\[C=_[]?[UN'"K&8>0%_I^_.?[^XS<(^\O]?SUMG[]YN#N:WYU>7G[SO_[CO_W[_W-TA,XN+]_1-7Y!\V7L/>,S+UJ2(-]%&'U[M]^4[]%\GMU?H;OF$-PXZ"Y.[#?9C=(2>XGC[\X*G(7;@=W3FQ!C[.GCIS|<'1\|???SC_?'QSS]^_/GX3]__|</2K5@NP^]I5,.OEU^AZ 6;=0W,2%XCRX\W_&7GD/0O6QUAB[|MY?=H3@BZA6H1NL41#I^Q^STG^AJY/I>??]#*Y\1QZ#WN8GP1A)LSO'Y)V)/IS-SO_7SN'>"L/NW1T"89AMR110/M/I*.?W3@\BO=;'"4MPN"]/H;D^R!+3 M+@L3S_^MO.^T_\?X/.C$^&$7^R5=X)^R'0B7/NOC;,@^DOIN'&6K.C CQ_X M1[6H5]+=NF9CNHR2[F)_M_F41OG3QP_X-<9^Y#T2? 3%<,C6=']TZ?ND9U&8 M=FOE1(^L,OTQP^DN.EH|SK984'S(SDUAO,7L'/_TTF\)V-=Q_N,_(<36MK?9 M!F&,_^!*_"I:L@S7$OL&^07-43-^'_IU0BZ;@SJ1MK+E#.R%7#;3^8U6[I_*[BD>Z'+/NBY!W\I3'(G>FFW M*[N)'^5D:9_"\HNDQA/`Y]U20H(4XK3>YZ[WW-TX(?VI^A&,/LMEI(K,U4X=91=]F2'_W\LN'S'+R M8[18+,92|*$'ZFFPH8/T!&+1,[X*HL;MVX%2PKRXH785I.V@8(72EMC!G6D+ M06/ORZ+OLKB+@^5O3P%Q<1B=_VM'+\8N2Z&D=L/T_Z'#]*O4_P?B]-]G7/^, M=SK_NY!J6L]EP+[Y>$[K5QZD1/%R1XZ70?D4:YON/'>8;B")&]7U6F]V7 MB0+|VHGI_RY6)IO(W'F5]I15#-K/_WTXQ[^_!$>4*F2_0AQ"C!+DL,['+6> MH|O=9N.$>WIX>FO?6]&#BSYOE\M@1U^E_Q[&;H>EA\MGKF75AOG\8V$^:!5UVMS*:444H:2=KO\]OZGK\XX6\X=AX)OL/+78FJ53&KI04;YO!/A3E,J:"4S/MT M54]7.GH7CA=^=<@:.?\$:_)O=07RJF@HU3-._%:)R'|&:IZF$WB>]J;ZZ'0/Z M*HSWH!.D4N 6QN\:QZ5;JZILP[3I5)V28CK#R6I&:+$WJ>NS1Z[HHL=%:S.5 M^:+5^.G(\6)@.7N!]Y%MOFBO/>?0(?3!+=8@+"]GUPYQ_]U[L0)*[#?8.J;R? MVM9MF,7CXBQ*PDA01G& @#8(IPZ2LB_3W;KR3X--ALO9O<*4] Q$0[(E6)E M7?:F&2?U4F%2%F-#9*>3>)['-67G];+W8(=[_42QCE5\:)NB'X@1EZK_/2(RE$44KU?5[;/A:!LWA"_M!0IFRZ C6S!(-Q5MF,&B H71.0(_(&[4D)3>9ZWUK%WZM"R^=UXK+C7U>\/\-M%!4BO#)BM=_GI/6<"#'NQ]$OI?O0H8MZR8QW1-46;AAMH]#RD,W(C+P;ZQOSQUAB[|MY?=H3@BZA6H1NL41#I^Q^STG^AJY/I>??]#*Y\1QZ#WN8GP1A)LSO'Y)V)/IS-SO_7SN'>"L/NW1T"89A M

RCH_+8G7FD1V=CE^QMWZB_YT_X}!98U8G M6NSB'9\E^[0.CP)(RTUK*NB$K<$*295V48L]DOI#AQ!HD-(]NA(=(G7CI#2 MJ?<5V.E^RBV)+K)(EZH-:Z0$G:1LC;R+)'H@XDL!@U(-^R)^PN'I+H2\XJR7 MH&(%]*#4L"#* $,J<(FRT52L122:E)X0[PM$&Q!5@+W&'6Z MI9Q8#^2@OY6&A56&"M*XL"+A 0$=D:HV[E^376Y*;]ZO(6U+KCNR3&!6,#:4PZ,+!WJ=HP[R5:UWSJD]_[A,/_@ J130+Q?RL,I1,NH>8M M7B'Q#[HL7A!#\GT0KC]X?OS!]38?1)D/#J$3^\HH/(5XE51X>7GY/JGTZ>/' M'QD)-SZ"O#]_C=$_KM2,:?`_$WD;>&>,>;#IJ[%O^GY3P?U:DL?G=LR/Q@?VL MI&.ZU\'&\)?S^G<7AHA\MH&.GM8sRZ4:+G>/^'@9'I:[5ZE1 M3|^A81QMG,`Q+@RV\!_6\@=ZXJP2+EX\%X='OA.&P4N;02=AF-0%XD?B'Y2; MXW|.CX^^G3,>"JG>S [D3H3]#;Y(>E$!(I+.,^.O!AOB@Q$Q2F@M97C|^CX M>] [E*^'_6]Z(V3YQH&WQQ.. M;/](3?%?VLAA@\$V7H27WZ^#YP|%ZZ7+N+WW7>_;QU-C6A@VN.DZ!VEKNV.:<@Z![=K'KH#VQ_3 M$#;$;AM>.;Z-?89W"D4T-5ONVAU;7:=1B'4K? RJ6N}*TI?VOL[6A5TBKLd$- M*Z5#.X,/28L(01TCSDQ[GV XG^:VED=YMV+2]+GI<6$[FAL M/0!2^NA@_=K^P7OF>AAB*ZO,;@1/1)\N/ MPL?HRHOBW$+..'P4Z'&O#Q)'\ L0CU+_#V&&VH(-ECOVF!/_!9N*U.Y0QG0 M=@NS Z%!/) $YNC=$\,YJ>KB8U1*9GB&-'E0-=,CJSS!::P9_ JH:+.#ZS-P#VK(/-5B/T,ZCVW8S M%DVJ%LVH?68N? 5H6WSNOG7=*2'JH>.OODB,ODR&>Z&TZ]A@3D'D]V:780F\V$[#&EN.]?>+Y#9490 MT\(A?7@,62>:@S_H#F*O%2V+C[MV3-37&MU#|\ Q@-HVQ>9NDY83>7!Q*>+# MYJ>6QN"BU(:75@M;PRE\]5DS#Z`\-KE$@;5=!O1F(I[P4 3 SS8"S%L;.=Y M2WJ4P#>+#(;=ZNS:L7*1OS1U(?43*(\UI*$W[J&OHW!@'OSYEHJ%!;=.H?=FC M+3KX0;))-^*#7_A]8"9U" G]VS\I,"//@4#_Q0?/O&$^*<-1MX!% TPFM1H@=M2_UT=/SIZ>B/; C*],ET]2% ^(/SZM$AJ4!(:\RYIX2OYT&:NPIQ7!5>6,/0 MUJ^*Q^'N5[W+H4BRON-LEJ_H7Z(T-%'9^Q_$RJ %$^I>#!42,ME6,7B*N=A5 M\ 23AH-EIBC|MQ,')5AE+1<9_)*N,?'#/V|"8(FQ&UV$P0:>J@PV 4[-&"Z0 M9[K3X=]X"$+X6+3H,]:^_$U?:A^&8C|Q\Z%3@R_IGU6JD%"OG[C]W$?,9J>"G.QW-6^<&ATL0E]=XL?H: M<$V) NFI;I&JHKHW!F]^2#84'6]O MZD1L65FSO'+_$MP_!;N(SOZ%MXHQ|L\W6Q+L,??DO-G1UNDF ,FU6H#I3F3X-M*;KTMW35LW'I5,I9FQK3.SX,52C]"6M>H9=1M(.7.KMT&;SN1F!SW.P>B;>4 M(C.]CV]"?+$*3=VO#G0XCDYV4J_7Q-X[GE]U? 8W&K0L%S=OPP@NC>.[[=!>$D1/NJ_=614F]PQZ%L3+D]%_I M<-_@$7%!.SH"=N^>$SE_A(IK[+80&=PR;1WKS^<% =YPO 5G7/WTJ?07A*G"BJD[8]4-\15\|0K=3X.,+C(4$%3UL Q\.%GJ,,"F+ MBB*4$,3KWX>>0TJ5_@?1&G%TUAM'.I485ZYH<^1P,W;PCK89RH(#&@1 MC%(^RF4-W1'!U)NK#0$5M<8T$ZFR?7W=DM8NI#;,0B/23BL.D2PCB0T<[@WK.'PS/'#VIZ65)]N+NP8+C^' 91 M\,I,]LE7=?UUAON.0727F(E=",+\:TXC7R5W7YX68%U%AG]"ZHZ7:%'G M#9)V9D!_@2+E7)QU7H@M*@X[`67A"H4HQG*? ZV53WJ1U'U,@;WBP:>O*P(V MY\2YB.[>T])=Wf;6@:,VQUB)N,AY#E8DT9+:]%9N6CI;&-:PI6B-F@32ZO}C MN[*Z75-V'2M.,82CD$O?Q:],P? M<5ZO+#;>;$EF/'M!-5IBHR@S3N*,TMS(" M]6:URW+33NM&0_-|\+> K.F8;YQ$]09VI/Q@e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l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| M:2W]JT6_2N++#Q-0327*#3P7N,*(S2X4@[/O1GCP[OE>#6M508V"\^N022X^&JJ=W9?E1')2M M[]RA+]K2*.@TZ.N0&.]2VM.3&A.4,YX>4LG#Q20NW4)@4W/3&\".D#3C$[N[M]F]P""IQT92/2!*]S)B/[@,>!YE\ASOK.HC_BN-4,\ YIVM0T294).&TW(E1 M.,R!8@*$0%! T-,O!G^.;)5MT+,SF.BKK!F<0800"IXD.*'W?QW01E\U85' M!%QS$^*MXIGUT02-U89D*-C@!/ZPQ6NCKH9Y9\)S=O1AOY@UX4=?A93;4T+,.L8=M4!//0-.GBKBKZ!F6T MK.IQ8,WG.+VR\BEZ%3.N^\|=#X/BJ7BI -^(LP,Q48H^0YJ@L,B]HXF70F,P3 \"FHE\+]X"6O .DK M.>8T4+7.#^WK#QR,WJ#,R14.,KB#WP.KQ/P++#Z4Z&/?:*F_P7A;NX@->S<4> M#+Y>F(Y $1H;UD]AN#%3?,6+(6_MZV*C/XRD9@XEY)F$C*$C.K_0B^E=>AL M3G9"E0/06V7,=*@]QJ?+50/VPQ6% M];M'G##V(L"]N*=`HK.M\HUL++# [8L*;&,G!33.\%89=BMV;A6HB:)-.^5*=W M3>>,-KOX*0AK7//TMZ-[;>.7OP;A;W<[NOV=\"MRHFH*Z(3NEW^(%QG*U/&P# MG[:Z\>A#%M+@T#>MY]'+;GP"'A6EW7V(#J:>6D5G+ M6.A2??CPB?0@. K*KJTRMJALUE&Z\MF7CC'8N;JG>$<0-G>%P/PN>1+=Z*0'P0Z GA<@S:?@#A6=@54EK?Z\0RQO35NSNRS+9B+A8\UP%Q4 M4QD%* (W$C@%(^_.0;&JK#VE-?_;@"J;//ZXI.\ZN5E]G6!- M*@L]VL-B_O?'GQ[OO;B ?UQ;9&SVY?C4"<,)O7GJG(/:U;4DM\Z73QY^^%IEE MOSKTOMQ%"N0]#/8,.`"^A*3'[&W0119P]A/RHG*UK729K*@PH3"6)@IG,\Q00 M%X=1*UU[NJ[6[_0++*H4SEQ_F<++7[-GA-3$UX_Y15L(V]H MQ/NP2\(]6N5GO6U)GL&LDZ@WX.JV$G3;2D^8;Z6T~H-AMG'3RHUISFF4T)WG'N], /+)V=&4\^^&&)Q0V025Q M$T0]9.:3%UKB*5]25P5!*I4-IH;&>[5#A?=8B7P&!;A+7A_9R ,DX^1^!I5-MA98<1FLXA$0PUM C+8WJI(?;8B6_T&Z3YQXJR.RC_57@-:FQ@P#$*F"4A@ M[RK#'XHE!]VS/==SPCT/HF;O]X9$T.7EATS;!CHQIDEUL7NR?V#)8ODP0Q)1 M /+A)U"]&N, 0B-8;K G3JDH.68"&UJ#(T$Q<'C?+9GP,A_NHMB>O*%^%Q.)/JE M_U<3-W ()>T6SAS8U`T.5T&X88&/C\1;5ZJY6]8<.(:/#EF7S,XU50.:/=EX M-!/BD+B- F?>=G!L0L8MEZ,LR@sU<]Z-76&, 7=:?'26WGT:*7B M+_%X9=A+0-G>%P/PN>1+=Z*0'P0Z GA<@S:?@#A6=@54EK?Z\0RQO35NSNRS+9B+A8\UP%Q4 M4QD%* M/39!&)>;3MO4&/8(%NK7HO=1W5E<74G[CO=!T.]E0"S?WZ4EAPA#$_^Y\GS\ MJ<2465UV#.Y]\+3O:E5N7=VR89G;LLY]%0[!3;HS*V7)C>QXG]1O35VVW9W$9 M >T"=RG47JI_3YX$*A ?/ O4FN4"N1;*4T4'+_7*U$M[%%.(D:I3523++#K< MG*8O[/XI+ ?0UHL=PD;X,6^/O\7T0(R\6.(5\9-'@1B|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`J=%Z6AWH8:4=1'CW M2)+XQ^@FQ,^ ZP+9@RL TIFUKC6W%,>6LP+F4X8S1.?$VGL_>1NQX$G)0MP78 MB?)P9C:NY:.W.&@6N/EO1>]N=G%76=!JZPPHC]MIENJ?$^5EA[-KY#RSSL"[MJ]HJ45%Z6-45G$=4+ R#YQ8N/'4UM#|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`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`W;H-[@YIE!7T MTA{3"=_>=),8.:2;^N4M4IW]O7MP6$")Y T]+0Z#=Q2\$/UL\&D: H&P>+%+T]P4EM^P!7A!2&_ M16_Q$C0.B7IG[OY$Q^6B90RFSF3&D!*AWMA84G#(??OL173I.9P..UP[O@ 8/4$8T @=(IGR*/R4@3;A62&3DQUB?FN4>NM MA;.E8^R*TB W3X%?I>U1*#*\28]M3I10K(UMJ[S<2$3W C94\U<=0ZX.D.&UD3K<#83^4"I[!+B\!KS"4020+L>?OM"23Y$.#- &^,0Z*MG^9Q'90PA-*] S@%:@K")FRE3C1&$XJ7FU&>&I<'60,Z7]N0O$8R(DODZ=Y M0WQO?27=;YD<[%A!4U#ZH&FL-*"+<.S0^\:5EU!#*OO2PF:N TAN67/>L_C M2?G0-? =U!P*Z@GNG^@U365F!BNRBC'V)>R; #&#-5,-|JZ1@F[8F/G7 M>]Q\\@,2K&%QQZL@+$^)C3#/_*2SKJ+N@N!TN80,6F+ZC@,<(A\\YD&*=P4=#7!/%:)1(STI158.@O MGJ^DN\]R6?P^!NCM>G^]0KGQ[OF&W=8<35T!$'OH]C?6'!TW:AG^C@0Q6]EV=(MV!3_]%$]=24M:XDAM,\NBY[MS3@$WOB7OX4GK]KTUZ^L8C[UO-05VPVZD1AP,J1;0'0?2'D/;AH\"[HRW:> M.*;3W=$4 F*BJ?%Y6->NXZ9. T-WEH,ATBE.K.Z=U_+H_#9A;_T(:X^2VPK] M*$/K;IE5R^/F#]CT.(9=XE\!O@QPJ-;&/)77&>;D+.;?9'$)A:*\(1;K_'*9Y MS.1.T/I*8PB";<02+*\[-@DYM? M5.FL?0F%PL \EL6.#EJ*[_!@66>M4IEW-M1NLXS7Q*M6IGH.51K0[BB%OTHNQUY.I2'9@.'<)O'X?G&#N;X[=Q>ID_P7'-M3X&;*.J8*XP3AGO.>Z8(6*Q8O.I1T4+[C;@A6?$[TBV^1-E Y\.DR)6"Z34 5 M:N25IBJ#32>S"'"1!KQ*?>M\N;4'+RB,P#0I%@O!0;F?I*ZLSTFU7GCWWH,U5 M06HPQN\![<5*.$BDB7^OO*CJ@*VKH?DD,.-PAO02 U5'DJ2X_NW27&D.UJTZ M;7NAF%5+(> 0G$?PA6NQ^=*G] QO0[SD1DPE^&6QDMJ8DJQL_>EI7E%)4*&(MFF#CRP+;=N 250T;U!6V=I]&#.FLL2L 5,]= &N+ZMZ;D",TX%HWCW(,8P'H3GOI,K:IL/99;-]K5U-W?6N_F!.U%-MY :F/WVF8F?,)?1[2AD#;D.YM48/Y9&*:\V053]1T#RQR5;^P%A8?6FI[5,2Y M=\(U%]'$H*PNF[OVE-%T7LSKS%-M:[A5@W _WVI#@)Y%%_25[Z]+=TT_@L.JKMC.Q1OPC@SWV=B[^IU0I^8ZG.A(M3XZF)[Q\NB]"2(*'0QOA2DUM#C:4.<\3F0WS#+Q0L=LVDK(KE>%>[=[:9_'L M? EQ.FI6G[6N\H@.0HTXW+55AHOL!XQ^?!$X)0_ML\IG9.OJ=A%I-PXA)_12 M]W'AD*DJ-9SJGDB3I0FG&5'\NKP["N)3U+F#%Y74KNGF>HK1!25(EDP"27& +N@O98=X5"(]ZL?

MC4D\^]0QC!>VX)>CAQ0?=$CUO2>$F5+A0T2LQI#=]PRC?(8D.VA> M-XFCG3G!%"!ST"GQ69 LH'+FFXNR5S+KS#X,.WQ%%_($]!E'$H MJ$Z"!U+9?6L GXH66.:'VX;X"7"EGS"ZX2 4GKI+U;'>=G$1X2A7.2.RYM M3,)W?POM?=M@WI>.C\QR#[:A3ZK7-+EEYHD:L7>KY6E[/'Z%E@B66YF#+LT=4H33%%V;9ZK] M$TV+,AG>.BL2O$0\;!"X'Z4]]<\'/$XM!KJ"VDR@Z='[GN'L]A=^F"XN$ "!.MDNQD,"$U3%@3@C*M0L@ 9A>6ME69Y0H.'-'",,LPS568/+23B)\6F7PTA]') M5(Z99-TL*@WV;)*M%#4W6JZL$<C=.,W4<+R6>8\&<2 RJ9%NV<~<)% MR%#E.8ZYC(;5ET=FS3HV8:6U0?(),.0R"B"2>[.MA/4 JUDX5(Y?*103&G;>991);??6G+>[\|ARHD?&GR"AS-X'Y]6+SO#*V9$X MSZ0C]""AE)IQ0,=[5XFZ7CM@&/&1DPG7 MCB!W;,1$BC"9#F!?HH.T/.BDZ' MC6>UT%_-UR'F>;HU>#@+E5A*T]I>TL0-&9R1VBC+7C$.S3&65I1W>AFLB8>= M2@\],;R__(4@"$5@Z+/JK"Y1!.#^F82;7-K96DNP982]TL$\8P0+!.DB72 M(Z@B MMBN8&+QY,%()#B0UC&N\,]:*TR ZI8*(S$:,]I8.1LQ8=VI>/4O,-HS3^OF=S M-*D,+$TRP.$I)+VT)81.]@+1@V-=AZ2#Q<2QR7)+\&S7H2,I"],);IS'V>DZ MT^:1W>7#E7L*@QXV*'EON%!JOW'G(}3)S=BL0H7ZI2610#H"\|W_"4]Z5*8 M#\|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f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

GXZC(@92@FBOW.-NU"USA.L>3[P48"MK,-8/Q>7<[G@[+1X2L<11A?<1>$ M,:[EZ[!'9Q]F<4YS)HUBA:LW;' X-#@VJ8BQR.W&IA,$UJS]Q5GT63YQ-QC1+ M32D39M!<>AG9%PNNWO;&*1-"*8B 73UC3&(6!?@UAGPD$6M]M/HE/CA\'T2$ M5:@8RX)W@=;"#!'TQ>@MO:UC$&]&@%$.B;T,)=Q(4F>&YV53Q&'9LQ4G0SSA8<8 M(YBD#0.2D^%%%32O)LAR@-R-UB+7#( )]D)"QRX*3'QZ\>/@T(_3$(.'5Z ;")9 MS*3^$TK;0;0AE&F)14H5D*(FRR_IS.KTYS@/CL6:0LL,Z[# "[!8YK$KLO!1 M_1&4\R!2DV" E/?=.#@R)_]Q0XYCP.#R>OB&=Z&>.FQO0%(S:G'6Eb> M&>ASH/@==#@0 ?>G35)HO(=P_5O.-FILB<5?&?! M? F\C*\G3R[;6+ZO.I9-G9>LIT*$]>&[*C 7!1[2X?(S%\F+_2>/2>UG;:6 M\>|S|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{(R*U(P1D4(!6]/A%'(Y^8, MR4:%&"N;97GJAC&JN3 0A'N&"^7O5HI(OZHQ8T',B,!Z4[QD#=OEF%2X'?^ M9GG-RRG9^=UD>$X@WQ!O:.^P^_%\9)\&/Z5@R-Z^OS,4K<:.7[_ "%%@^-EE* MV3[/)$$;=@3:O1K#*)2Q/U?&_BLS MHV1B+"0C:%XZC@//5-0P51=!N,+,R)HD=AILQ9^'"*,%2S RPO*.VZUOI%D M&S)'Z@6|#MQ?G9 E:-.(C$)I'ZT8<22I3XJ7U%"%+K)LV$1),<):,9\M$C/U M(AHP#WI%#,#TZ SQ$ST]Z7I/$56N<;Q8W3NOND]L+-5F+*7<,,&?6)'"IIUA M*N?U<,V1*&@;YE/1*4>6T+\X_@_"4.%0F<#:X?RPT;^{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{3-F*IBCD]M[AQXUUWL(+2/OYT]"%T_H%6]ZQJO#111>1P ^Z*M8E"V>@,^8%_9#A#NIU1 MR$:%=!B#;,--\APK65F@*7C:\\90TAIX:%HQ9AKGODV2EJ]VAZ6/Q-(WGZVE M[_D\5*Z6G]=Q:.862UV/4;Q8?0X"%)G#$I"QG=]:>0%JA:W3(12Q'X7!1<) M=Y(R M*6X)LU\9QY^*\":,NIA=@K75R05I-C]*AI\#UZ#U,Y8[H8W6#?C_,D MV?$1]?P-(,$*994M3:-N!K-'+&2DPM9@^4{EK]*K&C#M8\-"61.V:/E!ZG\1CI M(;YAU^D*]!,>QLX,8&0%PKZ&_"?7Z0,2 M.:(Y<$@2[?T\41;E1!(O<,*Z;Dj:,*A$@^QM5'OE+&-BCZ#9B&FI-CJF|IM[35F"EBNI=*3V;H);]#N WU|SV.)BL=LYD%1$)$@V,CZTI)1 M$:A% RAI89|\5]=UV0H&M]-F,&M5:F Q#RT^0SY'.O+DS"_IXC=K:I$)V@2H M.IU42U#)K'O)"$EB^VU"#K*0[ORMX{GHD5L1(X&D7L#'GP:,),>](A2BM(@M(Z>%2_AO!#_I%!7PUWZRO#3]^$,_]2V2OS&2Z)ALO38LK:#'$;4K, ^!M* M&S?Y!^83">XLY0^G2.T?9X#NOPI!//;ZI%@RZ5"(S^*'2|\Y05?:M@WA2E&I$.6<"*O9MI<.1[0V?#$G$:=LI41|H(*32[X&W-S2WR#E6,E#>UAO,Y8E|W88T ")?"'7P;N8N MO#A\|NU(DR&--J8LR0*CYL7,%G O9*<8,%CGH%?$HD+35L XA.@1'R!GC(-MW7X)+[""'SS?C5|SMJ+5^KV^WE;D7E|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{>$=IZ@*>.M GPD2G&G0 M!HTL%,0Q'Y7.AC$!#""&SOT8X)(-I0^[*N,RG;, 36VWE__WQ_;1^$_ 4^!X395,4L!H(.!D M-S(>_^R)>3#*&A>YQ J3FF.G@DR3/\:?(L2I6C]Z=-'C ?'(G:>;U7'HIUT M+%,HE*MC!G:HT,$Y2GFN1OS!E#&A+S*WQAAXQ[].9697(_LZ!Y7 M_(6X-PAVN7?*9KOC7"]6YTX(FK>(7@,,6ZM_5C+HP)'L@>(F18=1] &9W\HR M[06H_5@%2 /)%**0MX#N9&>-99KR8!=`L<-P.=[D"))T\)*Q4Q^^G&?&[C0[ M=K(`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|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`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

*1*N=*'9]$$HBRT34\ST&R62I)>BX3D,D^@&$<29S|B_6 M!=!<43FR9_9IX6K'.C3ZB%L,)Y@_V*TC?|CP%PCR6&A;G.RT#D1$U*.MV'C38?'T-%L*|F#=AC>13G,#_]9/";@U%3 M/_W(T=@'1JMM,QHQA1^K&)]@-Q5TG?YRU=S/(J4TV;RR M@J/|FR$5L<1+YWI>Z7\(WT!{0]$(_W48Q1?&OO''*T;UR^).FE>UR7_O?[_\L7(P2F"9>=!_Y M\YDX+^S $9;KB_6O/H0f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|:N< MB"GOIO\OO(_?OP#:76#5NRO\A??SH!QD5UGK&,=S+8!0NU&FJ:..6A&K5;I'<("1?F<>]H.C;Y-2FG M6=#!=):UOPOQDX$8J8(PAXI4]Q2:,]C;YU^2_*H?_3#?M@:.+#(L4U<68A8S3 M:|_0L@ %/OL,:];YS%B$1'-.4H$AFN @C,VVXBE AO?$\3W^>]EGWOX$]X! MY1Y\9-RZ:87A\)IDEF(ZFX@08/%=K,_V,-$GGLX_O%T5](@^;!>R3)DA&GG@P M%9+ 02;C/8T-+F"521)+ZZKD3R2#U,@8?]:4/P7XPH265ZLLJQ=X'(!U$PCI M'JGN17(XK[7V*4WV.!P#C+(){,5CL;HH0L'L%AUSW8O,]J+"G%DVE0[%2;N-ME3.W9_UR9C$DZ=46LJ[=9U"9GGT[:5:VPXQIL4%.OKYR$=HCLV.)C@E/,&)551.8OJD)}S8I>B'}3X&{?<; M#5[+BHIV(9LF[I6-;_=C4&1C#"2\"OJ[A%?+1AO3%74-PGX77>=!+U;-#", M\!P\Y,)*K,XZFG"O[1[#GJ<_;1;WQ&DLQFTO,.D MZ*GKU6WK-($1-DQ2;H1-O4$ 'N9V-ERJ/YA ??\$1~]RN!T.1YGJ?+8C&9M#.3 (5,:^H E8 M*7|\^E-^R43UA;"94PP*K'QCi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{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~]RN!T.1YGJ?+8C&9M#.3 M)T\L/44^#W?,%FZV@@H&"D$2'XJ[N'!%\KZ7KNC8JR.!OX9IXWDR$4AKQO8+ MN:&N$6!.4+@?K>C<2I^5..:6G(LU3,// M-K2 ##&BFX'PF.!SXOZ$8-GGL'VU#J"$#P3TYE@#K&ID/MUS2?C M^<5LQLTSM,4]+EY$%@G?!L]FX%73($Y!SF+REE,F -LB5T5?XB*9PGAV0\U MIQG6F<;J'#X3,$L>8 Q(KSR('VQ\6,S':>01],O#9QCY6? MH),F#!-QL?(MQ$95.LO/D.AP1^S,@8#N/*+@6ED)KY95ZQ$PE0VMT%IBQIDP:_8+*N)R*+93P8 >[W MSK6OEVE8)LJDK>ER[D:/4 M%N? N4C*M& (RQ'I'[\,*;L//)^=3PI>K+_Y2MGX62&^DJ@=39:(KLQAZ259 N=6(@[HS[]:MO9KT9)21=RU81%*T=P5>J^(:,*6A<(AQ4,3_-30 AA^;88YE<*?I(T"&\2K<131:MU(E\C3)-MCFH4E\-? >*S:LX6JSR7N"HLF9(4Y^\"H%# TL'"54:=*3-'?.85U&?^;Vt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`_9@_=@L;Z!\HTHZ)^$*01E-D#VZ<= -C?3%?$)I5.8*!AS;#[H MJCNN6(P-94(B,B&@WS]QZ]_^&V#TT/WP-0[7X0KP(]NI"OAX#VU8$CXF9"YX M_`.G22M;WA;.O/^>,!]#5\QHC)5)T6/0.EZ$'^&NR\[+]!$X9F(6F//B!I M;'HA-1*A,C.<4KD+@"[*OKK\%)9O>#[F#O42)0]'2E4R6-+2X>_$#/;X0ME M<==7#!4M\!OSW4R56/,/=*! [YT)90%\],/XJN]ED8HWYY*PS@@HSG\0$=GW]D M8>I%WB5):N680 .%LM)!81^M]EF>,-%XKM+!Z8@J)/ !1>$_KN&8.YT6ZS6" M*LY'U3JO&XH+3U,'1O5V,.S(+HU!2.&7<$$"'VW<:NH#4B#W*5978N2R4&+1 M&WR!+-+%-ZAZ0.%!^P=FUNO\0&[+(O7@(Q#JS"!1)XER'(76]W,^S,@LU$@ MSF!51[>&/Z;)"\B2M*U2L LB6"F,4!S00 :F65@E7B)^Z0(B^S2I/%L?i=Y1#UE6GHAUJB MAX?XP"=$$]O,9%@8K6Q8N'{(P-[M'1)55P4CQ.'IQU8*#LI(;Y8L0F2?^GS M9H\/(+ [L7\G4^[@7A &[\W_A\1O!G M;IS,?@MU.+=E[&XMOOGS¥\=0,CZ,<^(WXN=|"0XHO,B@P^LT+3_C[V+P 4[VD M.)^D5/$05(GOS6!!D 5$=W/-.\OZZ,L-TTPK88[GH]/K5%5 MG_3DR%E.L[%$;6MAXD65B]-BM#G*0FZ!@D__0+[MB?/SA G"P1,;\6!^,DMP_M_)\YUIC,S>)"\{@A^_M(2""BSCAY6P*Y_>D41SZ^#]YU!^/?>+_[F6/*@.4PD)E\EY3/T!8M?A.+EI2 M%T!4,$=`&^+"%;=C*(?U2&/)3^+B8S-K2+'_NI ,O)& T8M*:**Q0)&\LA0 M)S/_]#'U*$*6GA!/9D%BW"BB=Q5]A5^1*F6#6.G*SQ#S'I;C;DQT%02:?*DJB M36,Z&Y']J$$PF'Z!8/H1CUDXZ&X M">[C'5;T'P"CYZ=>WN\2&@9L0C H%&; PWH_358^;$"]JW4ZIB7C>?^2H7_N M\4ZY?0.I6N|@ZF(CPXX]>(]UD)(J2:,*@- OM+DH."!$$39ZT^XB'ZK^W M^- 4G;-(3/9@]&EB108F+CI3NFK"NZ"/H-D6.=;>#G]@FA10,/"D: /@U6^(-MUE2'%U+]#2>|/H*_[^FS\PO*%^NE_[W/QA4>9J]^&(.7Q*^\WP@:3"8\ [R9(M,;#&&+'JY/6]44HA?<)^/8;F-MOBXR!8BI$+107.1.,P;6)SW)#)_M,X5MS4YB3$^?.9.E-S#]^;&A0H39T3)>Q<)QEQZMZR\I-]]A1_"5%*@DZ M#6P-R+##D1- ^.//&R1!A;9591\9B"2])]J;M-4[AV2#"Z7R?2YO9[5>ARY8A2- M8-9FEQY#4>7YT)I>>HH41N=,7#WZ7$_DZ"]X6&GH)MF_Y.M]U$PNf>L*E^:6 M.E.P;$P>B%$57;DP>6#%. (PPJKMY%.+]>I;1TAJ0>IFN*L3YZ8I/"_]G MR\Q8B]^O$OSO?7X#G23K#D%@\O0.4GDL#AC4ZF&Q5C^8"LXGO8_Z>4PF8K-R;?,YCG,@B(W]F/A$@0'A0GY<.8'W2"I?("?"A; ME#&+0O)M%7]6QK$+ZUEEB CS"'"7F4KQHGU'(GV(15$,*MF$5G(5MJ@GQ,$@@D9RDS=)`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|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`T MT+>_)ND_GO=8[O@RM$!U*_N3+R**[Q#BV_+K+HGQ/+=AEI$:>VB%>X4K/[H+ MCTBH:-!VS"#V2:\9_;+++$L &0\%4&BVEYEH4-RAKQ-G6Q)"HD6AT+5W@B!% M>#B9,SYJY)N)OJGFN!]:Q*@OU!R"'"?,C8@WQ@'&H*)+ M5ZPR75\G",7O\[<0% O\7*>VUI,2L]H.3!$7,)EC:)KK.>^RFF1M[0N(-A& M.7SX^+ (,\Z@A)-J_:\U4A<$KO_;3[^O2V7(G5%'^)0I9I?KC8A>B/R:[^ MQ<:L=I_Q-A.[59KH4ZKEG=V@EBBK@FYOK8 M)%& T]S=ZV/4I;]PX1K"7Z?D @[$A:YVF *]&3NR PCK#0),H(&ZPB)[Q8)7/EZ4,/L:)R_@X0&'R'V\VY,X MR\K&C=CW0U=I,1>YLL-^DS*L?(VS#G=ZLHV&,_^X4I+ M"Q2;[&NM48_AQ.85;NF9U#[4-++>_CE]W^:!QOSKA-7H22: MI*R? 6HFKJ@?? M7B<0A;G'>^MKG")XMJ[;$>/249SL#Y^QBTVV2)]2+!Z)#6P#2L%)YA&[O/% MFF'O+-(G2#*Y((<6/V;LUTR;,'?40$ZP@'@"L4PM<^>Q=%VL64T@>!,5(7)P MWV3RG!\WUI#C,&PLIH0 =H.#]#\#6#<$W*>;CL#M!Q5%AI{?=1W&"-^)_$YQHK2*P24D-*"MVDG2WLL)XL[SB++)N S@))OP.QSF&5N:0Q=@Q2.&=((E5A%>95WL 28QJ"Y M$^0P=#4*>AJ38P61)!?[+,,?",J6@J'#ZP+^%#Z0B >F(8>RKF@W8PT>4KI-T M2Q+'7Z+P5>ZN,.OFQ.K2*P|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}6\F.* -1Z.D'D$W.$EB'/G_ A MS]1(U\H.]D\):5X[QP\>/+N-X3W%]_"B2QWZWM++/4-./]60FQ1V'<");5f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|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|@POC3?

RFK7|UH'?G.:\VHTR0TL\G MU0>->]M?E:7_'65@]2TS35!>ZC:+-=%I2:81\?HWUZ[S"ZLL2OB8,:IL>S M'W677)?^#]SRMV2YP5H)?I 07*1UCE#,P3<9A"1L3D65D&[=[9/[Y?*7)5IM MXB1*7N'0Y>LDW:J*N*G;6K<(<-0':6U9W 3]>DY<,I22@FJ!?PS6"W:1V%IFE?[AZ\GR*WT?AYT8/LL8M'ESR3AF0',@Y*/]V#=QG2#,23(E5<=6297B.:IH&"QOC#\1ODF"0JC#{DB M\]/T@ DA1I?%FO23(@9U@T;!1=>/'[=G7H]U&OOP>QOS"++FF5TD14B&;Y]B#)4)YV[&]?3#$%NWTOB,%)@^DL>3&/>T3R>PDC_MT MM?$SZ%#-_OD258B^]K#NMNO^91MF&5%?GM K*#A)>KC<[=U_A*(*(6)-U-1_-B1-'MGS0"9;68L1X'?(;"$M'@5&V?,>M'T176/6*4*:"0*TV<6)K-M8HSF?:6BB7*QO:5D2*(F\-N-?)-,.WL3[\:XGW]")=?(-0,!I0H7B[&_5R M8IN)"=Y%= C=0*JR76#V"=="D|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{/::M()2EV\C0E66TTZP=LM2E_Q@?V4)M_R M3:UB>F.B\M,3'B%M(>'F29(WGW832(K1-_> V&CR0U0M7B(]0:S)I%-K*4+>MF*>]_:23O@P"K&EG[^-PIHT^*"M.)I_I_]GZ:HS0ZM,ZTWG+2 M+7$?XT]#&>(WA/5VOV8T;FP&1?.)ILQ,\(?;[RN2%:AXX$F;33S%#@Q]?EF!OTTFRO:#+@@MHI,2JN0:+9GK02GH]+PD!H5Q$%OMS0=>IL-J$T:%\UBH52JS M(S8@]HD]+TD#E/ZO?_O#GW_WX]!Y.ZB3B>GI7_^&]9U!AB>2[*CJ(OS&2D(\M4&XHITCFA\]%ADA+UJE1LR4R?OSQQ[GR0V&Y'SY,'>^-"RGG#,?WSG3,-5R MWOPT+&_P9%Z2$^%,S3;,.?*'N>X6N5F:L^6AV9+PQ3.^?*GN?)%;7WGK/GWMN;)&:NWG7/F/>7.EYF+@7)fMEJOU:S#N_&FV.J_>B<+9,UO55^:PX4R9K=;; M=!-QE@RL{)X:2Y3N*?K!S6@"SI*9*\ M40R<2Y/HP2SC]YY7 M-6[B5U$@[#}]LR0* X :O/(CR%=[WB"QBNKD:5J6/WLAG&.9=#0>145YQQ;J M!]84R79MB1*0IB^2J!1-,=,78X69?7*E*K8H2#'K:XTT 2K=3;$DT':P1H<^+ MKN\M>6.%@Z*3,Y(<(2[>,%H^372K%%1F[VL147>MLTMDL68P5?A!S.!M6E?!H*N](T]N"$-KQ/YD/_OI/U_TJ:$F_+*5V/8\F MG/X?N,9!YB>"BG.H!8XAQ;XF*0"IMJQLS7F*U!BFT4Q:TO0WL^>/J*HEE-7 M/>K-G#HK0O0TLfZMJ%##8E;H'-(N%K<1!:W\-SMLR (Z2OVT0^#^Y@5F!-.M6]WM7=TZ_"TBH*V7C;5PAWFM,:Q_)&=&WM:U>U%/0T6G\)348" ,:W=U!YMG@Y>4T,&6U>'.FF>ETR@6SPZM M70-H=+E8P.8+4A\A31>[FTI;[5JVZ:H-[=R1_2](ZR=>_3"1M; VS2>LP88Q M?B'Y*=0;RRJ5'=?A*E3M%8..CEP=!+=]L?Z:H4HM;.W-4>]CV8[0HKT/VD]1P?*2]V8EKV$S]-[2U M++(6TXL>RUU8]"W7%$@Q]9LR/>YZN:G,G6SMV[_Q89>0-JU0%T!]Y%LSKQBZI M2VLF?#+WBE5.9LWI- MFR3UM3;;,\|@9WX=:'R!CU8>S9I?9+=C5)SDWUG6^ M%0W\G[/@83>N-5VL,V'2<3>C^0:=!4O;[\PVC_B,V-3A221WN3->?3QK7G5[M0YJY]N?&...A\]AX@UDPM-M%:A+%. NV&;RCVF(C9L0G QFGB+U@3/KIK)G4 M|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l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{W\TI'86E_72*K<21M!P+WF,$@\I&K M),2&]X3P&RX+<\22"RAA3VB5O,9D%+)^2AUSY,\Z"3=R^>;'$;PAJY(4GF1" M;D#!CQZ0))V>&>O4WSZM\^_,$$7IE_^_!'1PZ9AY;396M03-I=E1HYW#JM5,23N26]$MA9FJKGE76DLWM78B7DUN59,$MK65? 5L]S-YD8PV>;^FQLLJYP MR$"R<79/+:5F7:@C-(8-('HK)0#E;=C#,;Y=.Z,[]T6C\HL M4@ -A)1:[I_[3M++)A.GURQRTLP/G+EG;1:,ZY6;//)6"GTN+MS%GDJQ@=0 MY4V=!9&WG&=6]:IW* #]HXL#F+K'I*"FG\;F&LA=<.XGC2#A%&, L3JNA;*M& M&P"E=-$CFDC(6:1MSK-B2Q"-&;!4\,GU0"S6X9A;@B^.,,GT.\ M,.3Y]!TZVDL#>%QH4R3+W^TGH-(-"(SB>'P2A*6S?K8"SBNSD:[:^1M7)7M[9%@&+#M$&KG M8O]^X?5_C/P5V03:4ZMH;"\?2E['4$N#OL_ 22^_HQL/!"Y M-/=%W\$>H]N+A^F9;MQ_R@6@Q[#S,K!N%G/'JP5]M)Q7-+:KTU/D-#%4D$#X MD=\6Y#69W7Y'Z2K,E&E6W<=QC62ZC0:@63?0P,=).P/^U<4:0"[W\-[]U4_QM(T8NZHX>R!6%)'ON=KN+D@.B> ^]QGZXV?#87I?*U=]18K'%DLU7_6Z[/C1 M7".?K-87]{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{W\TI'86E_72*K<21M!P+WF,$@\I&K M),2&]X3P&RX+<\22"RAA3VB5O,9D%+)^2AUSY,\Z"3=R^>;'$;PAJY(4GF1" M;D#!CQZ0))V>&>O4WSZM\^_,$$7IE_^_!'1PZ9AY;396M03-I=E1HYW#J M5,23N26]$MA9FJKGE76DLWM78B7DUN59,$MK65? 5L]S-YD8PV>;^FQLLJYP MR$"R<79/+:5F7:@C-(8-('HK)0#E;=C#,;Y=.Z,[]T6C\HL M4@ -A)1:[I_[3M++)A.GURQRTLP/G+EG;1:,ZY6;//)6"GTN+MS%GDJQ@=0 MY4V=!9&WG&=6]:IW* #]HXL#F+K'I*"FG\;F&LA=<.XGC2#A%&, L3JNA;*M& M&P"E=-$CFDC(6:1MSK-B2Q"-&;!4\,GU0"S6X9A;@B^.,,GT.\ M,.3Y]!TZVDL#>%QH4R3+W^TGH-(-"(SB>'P2A*6S?K8"SBNSD:[:^1M7)7M[9%@&+#M$&KG M8O]^X?5_C/P5V03:4ZMH;"\?2E['4$N#OL_ 22^_H*

M'I?.'{|?'GT/P'SF552Y:R@7 +X?7 M'IA5X2:-[.)*MQA8<'$;.AZ>4H54YBFIS#3-_\H'\RE_[}X08;(RTL$E4;" M+Y,KJL|V@67\@F4H?$6V!GA'M90+@%\.[Z[_*
*2)CRX0E62_+610.4A?.JCJI M3$%I%EBZ1-JJDYO6A9Q!:I,Y.4>K0>TTB=6 *?:.2?A07>QMXN M)@ZMT-=20GPI(;Z4$!^TA+@!L*L !*$'B#'0,/4\1D>\N)!\0"%ZQ7*W=Q 2*
MM6BX^Q79C1VIK95,/!&??91=2?,/Q12'WG^Z%R#>LC8J& M@RE?OI1W7\JFSZR\.\"(,/XK?:8RX>LY-T);JN#$Z4=-&&C>S"[U31HM2_.
M08N^-^5A5GSL|>Z0!|5M8>@G4;(97;V!"[&'6; @PK,H<79TFXNH M&,6O4>TB^N?@>9%NJCX9A-W LD$(D^B7-HF&F_;S+<0:7#0#&AA"$A+/68QX3ACQ+J]8$K]
[8=$O'FO^213XF_*R/M4>G7- @A><.M28;7I<3LVA;//T%80-K18G9'%$0'LK&[;P="HDS&IS-S[)>QUXMH# _G$DA)[M =[:U6;OASXAAM0_(A7T]\T%)U?S=38-L6?
2BJZ&14Y/?)D)%UA1DG;H+/)$I M)HVR@4T%TT3;8N^\"&U&);$96T.U=*(FY2G(>Y-&G5FA9+&,JCV]D\92[]NH MJ !,&GF+\5W9^/Z21NO?*
KKV$%'_<$PK)SV3T,@'T+;DH/2'\00?9TLZL + M'[T]$EKT6H,.6QA>OT:ONRA+/'PCP\V)OTT1"N_^DV&;Pi;.XPY23K(#ODE8 M4QC2>YVE9W
*MD8Y+KK)TASG2[VAC&EL*7[17#J&XHP*S<6,(@*(;TG-(> >A5H/CTO7M->L] MOSZK,7WKA3'\$R5I0C?^5MNXS&A^X:+#,?V27^\/071"^8/[E&%]">]#F>\K*
M+N(NEQN+M\'A:/E-Q!\0L+3F&.=/IXCE1\)Z[/X Y[+N\]#?0XN KFLNJ M<*,DS [R*6N(.S.\//[5#=QC%!Y1@ID\A2!Y)<4'Z[\3WO\8I?]&:=5KD(.]*
*MX;YGTQV;QOX:;Y> ^&I]#/TV>7S[+'+&".=.CAB>;3XOY1"U0]KNQ282]";@\ MB|=`5M0^DE"62W+|*5B_(/]\1_!Q1+'WCNB/MU@PN_?\F*,_FWX+>N[""KK)*
*M17M(D@QM:K/8#|_S'>=/&?VQ@.CN&XK7?L(7&N#'5\\&2 M'IA*APE*TP"5\\62@Bj8S=FI4\))Y>5E*0!Y"S)3#Q%\/>6&4/NT>8DMS&7[7*
M,BH%T2HIYKSLO+.#^0MEU";1IY.I^WBZ"W^00OFE#>/?^'M.B($U:R@$7X=O" M:MRC[YR]VYQ_<")F?@.&FXRM&IW]/+HV^$E[]\V;ZQOEWX;T=_B7%BF[D;=
MMQ;MSP(IQLWJ+(S.-C,C V>???QXA..Q0FH/UF]'H1)QW0 ?[6X;]7$3V-(-MMMSRD,P#H:#)N^O F45Y3J:K3@N_O?P{)6[.]H/X. \Q.1]F@6-#\-X!O3? M#=%>T+U3NWP/G?*
*%#IR/SH[4W,C% ?U!..#@^DC;'5T51C& ^'#NEKY7-UR*F#uI(&>_M^%3M5HD B>=6N)+_O1_Z*5;]CL3] %GAH*LD0222J9/WOU%|$WA)(BB\H;."-=%&!8DFS3; MT? [4IUDFC6*
5IA#X"N4FRR2HMQ8F'"5(?YX '5^>$SE^M3X1=`OJKX6-']L M;5+ 8S06L'>^^('TU^C]/49Y)+"P(@5O-(@S$C)!QD##[N'[U7_Z^'E[OFC MOR=!YF?
K&OEDB&6LG7]@XE95LC54/X18 $%@\4OIT?\D'R%"(9_^13.@@2$D M'O$<&,3?$/-DED_)-)NF'(3UA!U^^6[1$071@:"[> 1EI?*D.Y%H-SU$U[[^ MHRT2SL0[J28YUC1,Z&P!E
]^1%LEU3Z5:7E&9!CST5MT;D!D\PFP4"^7+= M.3!#0]Z:!.3KS'S7I%9D:&22M(R4(Q31HK M44Q\T22]+,N_N-K>^D'6S0RC<<^K-2%ST@EV%j:\AX&&N]8+664R]HU)_D'2:
*MO0X(^T,0G1"]=:D66GWXX^T5_6RKAB)X0#\9A>>CYI#S6D(m.KN6N*F;236(64U;?@\|@"]Y-R6[7(ZM9HICV2W25?Q._4C<1;W25?Q. MC*X"VQ5_0#5]QKOH"T&M-*
*Z6@Z<8W62\D/A>DO8[-%@YUU6(U?9,> MDVO4%(ZS*8^=#89<('T(ZC*7D.5.O2C1U"P3D'"K\)97=9YXS';&*JD9\XV< MT\'T"OT1KY1T+-R2-*BRURA$K!!&M 7'N!%Z]1RPXA ME5Q#*
*[G!0 CM"(0(%(,Q\]O-;II21Q 9Z#=2]O@),*M#P/IDT^7SBCP4 MWQ*+&FND8?M0EP98MB[A4,,[NE]OXXQ&T"/\>*>K\(&V9]#Y;ZQM"<=#..1/ M6(!! >;++*,H2A4=4,*
L",,R0'"#8HG2O+$!UTGH%P$!],0HQDHE,=72(I9>I MHSC)5"1-3!TSD1<*Z57XCE(5MN"H9>5LI2R06JRA(P/DI<3,=)DY48\5043B!0&9C<$!9>0#4QAF5#48WH35[*
0F7H4%QAF|R_96^"OR1?N$<7;9ABTQ0GK2=3%XUV[%&<KCWS>L"3U 84HI@)"RYN|_J$CHFS58.HI$L, T$9 MQHP9U%,<'1"1ED+;M?; .+&A,]:RS3#?I#(%228-13ZRMT!(.-
+),#1FA;>A MK?6HLNI9V&AZX$_]L9A%IHH4FK1P8NKOQ!G$4[D!X8E#[(0W0#<15Q MJD]^@;,?%YQIRQ E[OXZ5Q4>=N.9)$YK,C'^KTH>QO_QZ[,7OK.KC[=_-2NN M2[;UR?
OF|[,]=V/-WVVV5(1XK@)"QZVK[&(5K+]GE_H\#=6]'WKAFOS[W(B* M&VYC9-U]1*_ZJ_D;+/1W+*D&C^"C_3#>&^_@X\W3]P6S3[+]DH4-7I?- M=98^1NF 4?*
KD^1O.-5>;OA0VRVJ'*>@%RZFFFXDB0C#E?:+F"U08GV^R@L MTMB)IKC:XL<[IZ=.+I$<3&.+FXXQ+#Y<2CGW47SU^@E+U>^QMY>"I3';KOS' M>>>)K,=X:Q>324L4-*
Q..3AJMS$>VI\&Z4TZ;,.DQ-7 W@Q"7TR+2XW<0>4W M>M*W=! .:-7QXDS8W#T;H%\NF"]K[HI|VEC)7>#O\2T@ M8:JT'3O^_VM^B(*)E>V5Q&H>U"O^E""=DC<;TO:%*<7!\5!*
$/=*9HZ%GA-M53364 =@;EWD/N,-A<#.J JDPIWP@=#%.0{$'I%}IE'=/6L=49.>-]FI\UCE5 MBX?RJR' T!0M.B\]74)&TS:,;J;XA(B1-.^OP8A9?&B3MHV<>,\&MMWUCX?U*
*M05O2]+-*I4+=4V,OB@LX]'V_P8Q\%.L:C]>N+/R:K;=&#G;3<#3>D?EJ,=BA,_M_',Bl;'M*=#G7!4RU;D[T)Z<7.Y%*-HW!UF4B?*R)\|,F.\,LQ>,0=@<"(2M MH_W$&^<.MPK*
:OLABC9D7T5W^>0E"KCQ(_P)MLDFK[884HS^X]>[FRQ)HSV M\VJ,1.[(,,X3M'GUOHDI2VNE40.RGN)H@]_855Q@GA.;Q1QF8Z-U(F&:=<1C MW=ORK_C]++ XI7^F*>G5#L3VJ-*
XHZUM_Q6+_'GI'!fG;(+:;BGAK?)YQB/- M\OH1^<<(RZ"X'>KM$N'6RXO6>P\NT1.>L184;/&5QNA&G[2%7JW%VV.#BD MD^!Q!@/_=[3Y&3]W^-P^X/M.
%[%M895L9^0QM%4"\HA+.'51-7%GI-IVN3G M%O^MG((YUD AQA#2GVY^!20%"Q\0%I$_^@F/\D4SK(%15;C):0O3"&?[K)'@ M,F=BUS*
@"P"UGRI[%K+(@8,QTMJV);F'"!!DLRS>BOQ)+C92ER'XMX,_PZ(.
MUZ%RR>40S;#7&XC4MWG8'SP_IL:AG1>_=]++T)8/A2:VZTBJH^F.$W_YOZ5T>A/G//R3HO5[&I^U0.GMD_##]T\;?G_U)
M7G",&VRYD:CNA883J67/%SB,>F/BSQU,.+V@>LJ40=U0B]@?]PW14Q^@NWX! MQ\&6^0T:.1@"$WC:.#Y>QAGKY?-U)H,^ M>+X>DM>2F?#(OCB0 5<@
W,>BFYO@B%_,$.@NRN96L'^.*+X^#KR&42+X?C MF% 1S83.$G;&0-WWT)@ITO?D..0Z?%3]5'(<%STY MB< UY3A"AN$H0B_8$!CI 1HC42
*TQ_&@PU9X[D3'4=":+FPB\DXZC8QA>PG&% M#H&KOX#C(DU?JN,PJW ,H0?79-TMI9NRC AYF0M@;I:ION#+2W:2] !9T^>GO\SUIG47'5'_E$>V'$3RMABE7UNWW*S@F ,-XH*
MI"4/)6BA'/L!2PV=R.D&O98=[=/N{FP5]112//=<58K1?D;WXM/-2I8J9#& M'C[%MFF?I%0#095"/4?]7A+[1\P((1 7V3ZC=I%%[2 IS97M-HQ(NBWWE[1OQ0;%%_ -*
\LCV)+7B..Y$T3IZ MSTVC]/RX,N; GP59QN#JZ/D!L23>15'1UFIAQF=\7%#J0&MYM_-WERP_L$'\ MJD!W+=]N ZYLN&D$_U4&0=#P"Q/9M$S/C> "MI74$4RPLMK,HL+Y%#
*^DU0]T,YG@UP*4V4 MOBW'T:!,&3RGF.-!QKF!CVGFN.!RQ?A1>AY MOB%P\W='<"-W PZ!G9\$=D8/@$8P29-[_ M. B^P"@(''?*
DU},$GFB'NQU*_34&R7]*0N=HEHPA4719S1B89UHF2;3VR:F3 M,IGG!\4+U^WJ;4^?8OS|DC:TI T!3QM:,2@<+%__'K51#4/LR4;/G#3/>V"O#Z*+[UPHB]$=XH
*MP_NXR8A'[<7?'Y(HY&^$-_O^*X]_O)A\UQ-@A3/2=+ZNGZ9>\,5+ M_"3U^>)MA#3.\DUL_1FL\.'%-""@O_.ZOS^@0Q7G.Q=9?HUB +IWIU[*P2,A MN\%5U4'&W8+\%IB*
F7F/'8W%4@=:,QS(M@W[L%9/1-5[M-];CK3C38@40&@+[Y,7I26C^9PPTC.3'Z(@7]Q/2^N!UAV+O MX".!6"0:#@=-=TWN3[5?Q'8_#46 &D)LU<7%B+=T&S_1XKT*OMS^*
M8^!CTDGVJBX$0?25. INH_@F1AL_)=$G%F%]WHT2YVM2.0G]"1)>T]@N=W MI"99'-$5T1K><]D"TIMC%*XY/]>9B1*>AOSBX@(8]LV%/BN*' YC@G^RW?&MA%"*
0V^DM]'7\!IM99T\><(3D09Vj:1,KL4;1T$.FIH)U&&F PBSCIH2-,"F M(/HZ:E?4S ^X2&1VU JI*9\-*4P[:KJD7N?K=LK(8J'$;,.^\>+,.5 11==3HD M4+!\5UZ=JS)-W(G^[^NK%&YDN:?
HK(N)? R\DD2U"LU=KD.G4A]_1ZRI$B_< MW$=9G"(48F95_ZN_)7_, XP>\$,0$NY%-L4WIEZ^]/4C$1A5&T:L;U2#=@#T M(3@_E>>)6)|/? X!"-@SUZ@%7 M6*8XXANF:,'KO3 I&*
*QB_2'1QM6|9&>^.BSYF*3|&-9,";H&Y=N:,<;-PFJ M$CDN&RU (TC)PLF2Q1K1RBT<.<@*QR'Z\!_+LK)--]+$;_CB"V#=I2Z1)F6\6 MULH+Y4!7C6VEA?*
*_%QU=EZZ\]+&KD]FM2WB8*_#6M-5(6=WD(MU&\IY1S2ZK3 M]2Y(P0N?$6V#9WO3F6DZW$?T59;93766O4"7CNW98YN;QQ%T(6G;P@_M/56!L>+.8YS1UK;_BM=>;6O8%AB?*
*V&/G16A#A?V5#L_23?P.X9W<>,GN_>O< M,7Y'[KZ1Y?)#93G.F<8Z,'2*I^S F>%+/8K""8],T C7H"OD"C1DGI%.*V MAH]9%XV.X$;D* ^%'#=4.L'=NH3EJ#-*
*QR.B1VALT!=TEK0R]9616$-*C/M MB;ZM[;0VNR>IB+\C;K"Z)KF9/-E7=QEI;@IY:+8H)DI0;K^CJ99%'!@Q*R18*
M(LT3$_$V$O9/0G^UT4]80]3GEP_1$<5A7B(T/A1YFP2H\$@"'.N3EBH&/59 MR1K8C*,0*+*\T0MYJWW"?C""A'-5'5$^Q%&2? YCY 6$E7W N/]&VRA&_'ZK M9M:V5TX28:Y-!+.4'.*
(M.D2)+ZYN)KAW F3$.&A3KBYML6"H3DW1M<1NPN:D)\|+?,%@8F1]1DKSNO/"|S]A77)\'M/E#^GWV $UU6*\<=G3PL?'KCT=@H3&W, KS#HI>GE ^!*
MM1\GCK6>I&??!UVYG\|>YD_((-]-HQ4J9)Y_7FU)/BDI6W;$Z,AS<@&F&)[W M6ROD7D"V69$B\%D<^^${#:;]'$9O"8II%> ^'\)"EI.X2ELL#WRO0+O0L#_(1 M>XE,Y]_1>:N-?
\8^PJY/YW_^[.8)ZS=Z2,ZHD"4"*8VV3YP=:{0W:DP(4MO MC?F :M\#?)4'(SR===+]HLG,V7\VAZ0M#?)>9B1*>AOSBX@<$8)

*H4NCA2YE^,6K+Z4PV:$CMN3C"!#PEP=M_F8 M1)${8G KZ+Q@CD|>G)Y>L72?>)0O) *QV*)4S-RK7"*63 ,A#;,/X?K4^$51 M+E9?RQKH|X3"\3T[$D-*
*BE56'V_G*DD0<<1!\OXWBF\"+TD$P:HZ*T $L]fB M-*A:=Y5Y@?LKYI=>%ECLE[LZ(-(R/!%DB)Q*4RX^A1_O$5]0X5I"*ZCQ@+V M^"U^JOTUNGJ/4>[S%0;R\T:#.^/A:6(,-&P*N5_J]*
[\>7NZ>/_JIXH7ZZ'MO M?H"E'_+)$,?)SC_P^P&K3[,&;BSL1GOTDF(TDJ/_2#Y")%<^_8MF0 -#2#SB M.38-(@@+!SO,+6_1$07\@>RN8)RRA!SI3(?-)6HR,<]4HB%V@C;:(52]1 Z*
MZWC3EFXE4>$X4B2)O34A*P25R3"B@1M M92DP%<;6]!8.L&T]:ET2NU62R[^Y"E-_0W:*R?L%K3-\(#Y*!KZM@PPC{1Z3 M10.H.R\FY/D8_8*TC"W+W4.2_=9@V@N_TAB$X(
*MU6J8"^U2_/' SD29HJY/[5$)6>&_"(P-%Y,VO8=7!>>UM4^RBKCIUE**-9> M2D7Q7#8-=O.48;G>2QJ-,+N.&MD49ZWFIB49MG7=C!#@N-:IR@OK*!2\I*"Q MH9;//?P,V\A2EN+?
*$92*O!3 <+H9-\;0?-*0+ $9PSV,*"851X/8%M\0R#; M@9XH"V5'1HP>U\&(FG#IB@&/:[L#F2>X6.06BYPY9%'7Q&K[BT=RB--5_$RL MT0+;#7\\+!"$1A?1#-*
*/YHS&ZSPA[*C[&#C\5#H6%V)\H<0>]!6F+"6'N)@0E MI5G*FNKH$<[T+B02V8*#*[*^.3Q&!=Q,.35D_,YR,@#[*_JQ!NL!+=CCD M+TFC U^%15!Y2;+8U)Da89[7*@:
<$2(IG=X,KQTN&'AIOLIEL@L'&HO?XML MZ!FMD7\D&TFPZE=LCR/6"'"98 ^+;P^KV&KWL$%+)5^$.!P6 4'073)A5CI,1 M34L/M4E!!"_A11P%F)RC*$@7>+Y@% 1QE"
*2;AJV&JTI#9V6(*Y] EN<%RI . M E3D'-!H4+(1R 2@.B9$L@9H3%R:%R-Z\AT'7"X_=NX"4WP C88E]47?Z*&B MG\J8@I..;NW'4BS?0<:"*
*<6*PG6PZ@M>_MR@ADIT=+0YW(2XTP;=OXVSW(&<; M.@>H!L?1++#D;6&T?HW#M);N<$>6%/>_]$/-I\N^\:J/Q-908VL/U]8OW!?7 MSFID7;/J;!*G-*
546_U>EQN+_ ^/69U'YGFG':OXZZK4_>-W^:"J;D_;_X^/L88 M-J+[^_:"!KR#CZF/Y@QO\I+R#^&,,,G-=98^1NF_4?KD^,PNMLK8=_(=]W\A0/X,:V!(M1HF*+)9=M,-&(H+$PK.8-,. M:CBZ1EFC>49U5?*
*^>I0SC M:5L,Y;H/@&8Y<6!FU/SGP+Q&:).09X7&/*XH;,G=-Q2O_02Q+?!NH:)]A2!& MA7>B-/T:7;W_D_DQ8L4^AS^@Q=[06F:UR]?;2D3HMBY^NK%&V9Y(; 7[D(&5.?%^!+BV_G)*
*(X5O MTI-J>W7T_(#PHOLID\R6!)T=P-8=L0\^^>OHR(ND6'&*WI?+]8SM]'<>K_MWN1)#E3*,2<&E0VF5MNG&%-?BIX";XWVO.I;#B'#:!\2"D4.T E0)L2D5'?P*
*M>N'!*V3OXOUO]'AC>2-A>I.FKE'+3K]@8<8M;*-Z4Y\(!5MT3AF:S+N:DN:0!*00/A0)IG(9K+8?H_#]<(fY,FSP%YF<4;+ F M_KD6#^;W2>*
*(B#^79'!*4##&9&]*1UBOALK>$8N(9'8H7F?)8Q6RV<6!'A4Y(/MT0';>ES)XW6${ICA *UL*9.W[5+/WKD#,$/XW6$!BK;[.C'W:H.%3Z^GR$^FMGL%2Y^_MF"$NZO5QR@}')3ZF]\H4$;*
(=9(C2ZFN(^7&RB)$02I5ZW$:)P^+YQ7RU!3W M&GN;&C?YV!1?6R9"2/FM9OG(9K@-LW7)W^>']MNB2F@15UCAX]>IXD*)Y|+(MX_O)RZT<;BN\--_KNT9'R_'01$4W 41U*
9N5N\[!:DP@:@.@G81 T58[":=8" M-D]"%D+'.R#)/&CG)O!9J}T;:P%[YZ86[\<^.Z6Y5@LIC^_D9E1D'G$3]LK) M<^+YF$CA###8)]]8S"Z>^^YDF%X>%$3W?UR M1MHMB<(.=V"2-
7^\Q?1^E6 %]B55F0H(L';&@2)0K6F &%##B@"O9A@0%6 MKG.?P5%MUIX!V.%UWO<[Y=&8# H_M>?D$XW)CL(#3; U& A2EP0?5@$;?2&!/$)ZG^>^AO_34Q7.2*
MA)AH{JSW8"#.Hf_8@CDH!JW0!CD],MMNF%O2"R6 4_E(A<2]Y!L<.H.Z4H MCG.&.HIRMP['$@1G!CTJFY=-;=3[,>@*\#R_MS?@N(X=,+3ZPONTE/CO+3[Q&U=?K0QPE255-E1C-*
*K]$VBA&G20K8]&*;6"-> MAB[6'"B:,@32ZE>]OMH%=1Q&R2# F20ML(Y5$H M5*O-)639B7+ML110P/4Y?0^4.'\$*+*TKIX!HFFO#!0M%S]N(Y#41%##9?=8& MP%WG(Q-!UAAT)_LF;!VL4K_,&M#)%#;UU_IN/K+ ^L=VF0T5]W\.2V-PU^P\V_ M-,CC#$ %LKHGCSG69'%%<"P/;UD>H$!\4:E8[%^9X8/XU=9#4YR_&-+ZO&KS)G M])XN0M(BS_R7-0 .B^6FO-*
3;J:4J0K+'4P.M2ZQ5%_:/%!/EL3_#A C:U)> MEK=`W;?14C&DE.EF7_"GP .D(%814/))-K.##-$?FQV;6AXVN\$V4S4@*V$T4 M8!1$<NA_GL?N8F.%P[BJE@+3"O6E&M-09U!4?!,3'FK>(*
*MK$USB5N7IX$/[C%*42VA@L.N.>AQ!V+E\Z6QJV)PH3<"TC[=,EX-'F@DM; M[%Q0*NBK7I&?PS=ZJ^O"H6N';LRBJ/ ,+YM@'JT_7 IM%=! M$'TEN;I8"[R)T28O4-*
:%MDOY8H=#?]W-"ZJ_UKQ%W33H7.,%'T-Q:J/<,5BT:#X$]V"0M(QT+F+&/#/3B=76?CV)-3D2LZJK#Y7U@(HP^ME9=NW MPM9I2]Y?U@=1#1.1R>?2PJMPF?
*D81RGQ#7JA*76#$;N,-7%&)1GE"#\ M5>(#OT5'%$34N5"NZX)]KS\^RNM^MS\$T0FAHOA4;73[Y0/<#M@L67Q-(8J] M@#BC-GL_]).4^&^.J$,8/TP=*
*(T)9OAT>S:%A11BX8!>]_(;D#V*GB(S >&C2 M=BB64-0A8H@K"I.'V;7ZB\3=N_(20^%=[041X%YI 6NRH[*SP)0>Y?,&/1 Y*
*MJY8>B72)82"0!EKNQF4S+2L@?,XTF#^XDY35C^)?\O >,'+R/__?/^]_+.[M'/QP8Y$_%/\(PRBE*I"_D3^A7(OX/_ZFG^P8>GN.5\U)^6$0?/O_V$\MX2Z5_[YAZT7T**=.Z;%Q!*
IXS__L;FQAS7;&P\HT-!=23B M.PCR+C)7>V)BSW.F:XUH(M=*]XC7Z^>2XA%PX! ZG\T*_>W[%.COEZ59X=0\/G6N?\ZB* K[$7)G@I&H3F MDQK?94S7.8:K [;2'(>0435=.0-*
05(XL01>- .H] (+]JKA%P61;9^/6W5T M'7Y2Z2E\'QAZ^M\",# Y6!Q.\4E@@;EL2O#Y0+((=SY^BXKF.@>TQM!A^9H(-MSZ]>_(X]2K]D!7?(X?5K]+]+LL0+- =1%[<(D;#4^E]+?
*DCD;_2T[G>/XE1 M_83V;R3I+D>7@85RK&W2^(_D7\D_-M'>]T/+A*0M<3-%(?DT=X2ARK-9W#S\M?QKEWHC ;>C>MQE:Q:NOM$$BK5C?O 6* M@V%2NL;33NB65/-[P5]-*
ML58N\[^@H)HM?]I"&T31)2F+XA,E1G1F@).T53K: MY&^JC 1SS/(IH%48OL" SA0PD)!2?,'BGKPX=(6>QIKE'25G6(|_-A&T?$>5K"122=\QFS?P1S'U58, _^BC^-8+*
*MHZ?)QEB_0&9=G-C.!I_BC("E*2GU16N;KR#CU]/*CG@:T!"(Q_R#)C-=98^ M1NF_45IG7)>L (;JY5?^"'>M6)&3T':VV7Z+IJ=- M^ H_=B;P3V1MU%@\%BBC:1B4BQR4Z%?*
KD&Z>H,A+PH5Z]H2CT7G5]'0T7OL[<_WN,]4,/0NYVC<,R;"6$_R M$$T%21^E]_IT/EVFT-9B\;JSH++!.5%T(6M91XH C]^KK!&M*6#NA_0]P#3N MQ:F?2& ^"48%AM2;$M:A
*COA3,UY(^3H40_AU3KUCS3,HQMQ;VP] M<)%"-0YWU2NP7&D62*HIA/5"=[GQ#BW3%.]G=Z]XA73;M%L960NP9:L*BK_9 M>>>$[<2HJ/H.R/(M+UP/K Y.6E"OL)KQ)A&]H@/YZ-*
D67Z(6E@K+IH#KS,##&=1 M#C8BR3-AF'E!%5A40=2/9*,A4($"K'$2K>X:SCI,1$*4A3M1^?(V7;]%>]7 M,!3?)_6B%5=%+O,[*0- G(]%W+QV<)9P$7>PI4C]'4E;?QXXB;]T'=R12CP;*
MCB/Y>)\2- D8_HA2K!!S-$C!) R4S^D[#VUZ+TB4$[N4J2B+3"01L2LW^. MD"'+,?+GX%/ H$+% = ,06M1+ ^]GD+1[]?;VQ4?-EC_A1FSAT9L#$NQN=9,F MB/S?
08+3#/1AO&7N^;.]V!M$XD(R|$<;+S#\T[]3$!Y!4M"P!2D;2L3>U84N'@02NE;B&I9.CC[6%X-1U M6Z?_=:BE;|F+*!66GR4YJ-VJGL/2;"$R6Z,Z@X]%U]
*MO#MWH&129W(]*RG=\]R!ZCZ+0YK%=>|_H\E<1/L@63.[*-@\(D)++*]{TWJE M=*?!O-,/_P^+3*=_>3$I0>]U8.3]"A*4QZLOKVB]"Z,@>B?IW7LP])>&\44]%I36LQ*
*WQ&/.RL8DTQ9]+%K\,I%DR M_A\2QG#$^EG>.N\9D>>/%,(BOTD]O?V6 >O@E78U$T<$@W-CR9_8&A4_(U+F M",_I(?PEBG_#O*HRALK' =4&E?*
*E3ZR72G0:2F\M*_3P3%\QI^QE+4K3{4*7T MZ\X#(WX1U-4HC/4J-_@W4]4@RQ#@/&9=XSA{O]E>)%53$2_/ MO\Z,QRZ (Q2W*WT$OX D,3-3X-HO8W2<2#!8Y2!5C.*
*<]H@(&9%4@GGRDG05 MYWQGA5^G=[IL\AH]>:>F!;55;*C?9)"(4.3&W0J9FM,<,"H*4Y^5AT-1=Q2C M]AI]D!N>2^[/@)V4-?V3J.)12.?ENV^3L-I8@'1[9BRMH(#\3PY)#8UR M1@*
M1"N G.OP;&B%Z@W&^6<,'A$@-L6(*D*G_PI@$"4U3.1AY ^AM,RYPD!WH+[W MXR2]"O/ZI'B7+1< YU>0CRSAHE[XXN\/2;M,"O,GD$ TBV# _CC9/"8V?'*<
ME0!4<5>UT6#H42' H_%$M(Z1 ^1O(C/"M%9;?*E)8R2G/5 ;r$04%?ZV3)K&U8'V0I3{)KBVR=9)K0+3KD]Y M1;.DT.X!*0??T:',HLHW)!"1%KZ;-*
*_9#A'T;=Z4@'0]BVJ="+H5+Q0&@@%; M7M;LZ/ETQ?LH)F=XB]]2%[3.8O]\/"-"N9AA??+2XD\?8H0ACE_QF_6ZBQ'Z M-_+B*J3!T&I0Q .YKM5QW^?67?*1"O"6]*'Y._D5(-;*
*{7O$9U!51X.YJ[WSO=N<+0O7DR'ZFN.C6IT9.&/<3H MDNY@LNM$Z*2T"8> NQPW@4>(O(A96<4T_*?3,%XVRJBR:R(:LM3].IW^;C#+ M]C>8?*
W440.%0LTJ@"0B[B1!-4\MW_(R\SD#K1!G_^R<"8[+>80"__O _5!+ M P04 "_#I@699"K+%;=(P ?C $ #P ')G;G@M97@Q,%\Q+FAT;>U] M:7?3R+;H]_LK]+IO]PEK.
*<9V!C+T.6N9Q&N@X25!.C^]%99*MO5RB)):0X+O MKW)[J"]59#N$X& #Z@]+)5]W+7GX8!)/@W_\U_>`O[1 OC7^R-7>2C_,AS*
MN]M!=_]XRC^AP5/=XH]A',R\!+)^%\M^_3$4Z5M&1)XH_C!]FL1!+[+\,!%! MH+OD7>0?#H.522W)U*-)_F1USW^A48)U(W10S?>SN/D]-/>4]'Q_VZK*)"? MCK9WC]#^-*
/VYGZ7QQM&>!3+?A"0SR1V+Z M'\51CDWD4;>3Y,<\91[MF-Z-Q%2%LZ-K-969=RYOO3R%MKG\ ME&^+4(UA=)P0#H+?FW'\.(S3HU\[]_ Q[43E%N>3G# M. R..:W.[^"]$NF-*
*M]%X+>5+!50%%/\3++]?P^ M<]

Z¥.G,4NC"CEH]D(F!¥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`M@4')$RS8;%) X$&^2YX\)B;YVE Y<*^$ZHRE(@TS2-'6HK MLL]-*,)<-^\,@H!N#3BC28%<,_M?=`Z9C%{"V@BY@<Y!$Z6M 0>J-F-20M>YF8WB\XF4B.VN1*B4/*8;S|O+ORV30^L(MQ&FE,"|N!:!Y>_FTHH.A5.^A MCH#1>.!#=<&YCAQ;FVZKC%RVV.-IKN4N4J?6#.?%.M!+>&XW ML%>?VN M#J=T#-&EF:51'9]BG%.^*!"F\0[YEMXA.]^G>_?WXP]B[5U?)=ZN?@/7[A1B M?!%(1;3CVH$^8D@C(&>*QZJHY..3OJGH)@XQ_-UQ&EG,<"".CPR:=)KXY?'4M/$%LH;"7MI>W_>IPM@8RWQ1H LJ-E0<4*4#3A>N23S$D!>H483A=]J0G MFE9H+.U$-+H)<;1RWQ;C(!="MFE9H+.U$>3&D0=']6GT);5]T(;8"NYV MXA7TX*E44T]G7YW9B+]V&EGK2$D>#BDG.?/1\.67^TRTW-G|)MGG9I"#W88< M/"8Y.(^C[5/80HS"(PA>KU_@DE0"@9GAW3D9*BD\56KCEG2>3G2)F(A48MPH MN:BQ#HUL?H.?`K*4C168)<'?0O M4ID)1QUCH_29*H-I5JU#BPW6L(=BQBY,62D=J5<&\L/QRSP2"?==FLNC;"" MDDV-N>R(6SJAS!.3&EODE5I=X%&N;W/+13@MK#F!910PAM)+D67:,/*UE&2+P M*0A,F!+J-8RP6Z?-EHD.0H9XVV2N9<8;@$B@)>RT52U$7W6;.DDWG8P7EEX/ M,:W0#6.V!&PS"-C>Pf W=GW4;&!-D2TS\"5(.H MDF:V//Q&54](!^9N4$0 26:8^M@Y(2?+!Pf MLB M^()9R-FU. ,9ZU-(J.C98PT+;6)3^@3][GV5 MA#I89_XKBKXL0JL@KVC_'79>FYDTP^HXLAJ$1 8((/Y4KQI%&F5;%88 M]*DS*D5+1_VY^>0K>)=RC&%)>]S8(;G]V#ERNDXRJ<>L,Z*U)RRNLUY'B8#,4VC(1B;0#"'>-03C<7597C_0"7X1 M0WW $LA!##=J4^K;5$(-73M#))6V1B_+BA89!,,^GI]@EG8@=FIO02^RX!K. M%C$%V G7T;&6;4? *--D<3R9QIG<1+F7]2=OV.O<4(\R\@\CN3"""@;43;A8" MG6^\[G+?%11?.&^9CI/&E^XQA?NN_"%:[BK;\E=`33-R5Q1LO5Y6JI_Q M*)3V[NX\LMX4@(6D<*H#6E8'1;,:$61)4M,D0*V3,2H\ZX&:.$"DV4"B"XE,,4MT?;EB_SN,GI5BXW^6$>8FF^=:6BF[RUED?<^3+AL(';E'F\ZM962PN!J;MG M=HVE@O@+7=UJZ^0LVU^4<6&_O;__[*Y7SP>CZB6HZ?' "W,]=HYKSG\YZ="K ME!2)B,&EFG3A?)"2P0KP@VU-'$!&$!]DLSQ#W;8>=?5;>MXJ)XEFQCHF[FL8!,.]T(6@55!++?3;_=ZO=]E^$&I;@C94#2-EB MVBUA-QB(5LEP?"&^O:L+5^[Y484)7'!6J]^>57-CG[W?][ZR]]X 9[+T_/$! MYN$=`9UD8QO5USQ3E.0!YNK^!U!XD^_ 3_" M571-JJ=>KW.PU[GO)6PN7G/Q-O#BW:TC>_2[N**=,A<,_D6UUL^K!GPD4TZG ML>/,V7$,&SO.8IQ^@"RP?HCO9;[3QH'[*$5)R4KHIJ.LM4^[!.1#26 >49 M2'+7I$)IGZ@&(U!7X-Y,K-?=+?K%4)IBSICH7{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

NS\5(+5MXR@HBE90>3J#FV^PLH+*NN QLXS=[X;P@LJ+ M6E2V-U?;V+NVH&TZS=763BUD+61M=O(K,K>MNYM;5BM=3(KGENWC8R&{5I"U0LI"XU)L(=!UP"/-
}Y"^DA>G%^WC5;XQRZ5# MC[HD?_];8[=^8(‘Y#*+^X‘.[O??!:=C2O]\$[*;3W+)FP%>!=7//V7^_+_ZG MA?4+460CLUG]J.O#$3:NV=3#PQ4W-DY%PL>5T"TYI.@H./!F/?3YM
MX;_9H<>X_#PP\FP%[_&Q$US.1HO6(9^#*_!20(2EH!3<*#!@\ 2/4U MX54)U'P %[7%_6L^C95@7<2PP5FB&K0#A@HXK^!N>2@Bs#^)*"SB#N4(6@ZQ M> JGH5s]X8:J?
WPK!1Q'>&9>XB"?A$'MWRFL>2"%QWD!Z/Q@IV.<)ZZ0'I"S M%?Z%2]<3!%O'7VM 3\(4*(.\$=Z\!FJV1!Q;TJ^%7L'^?C/1BL68PWZ$UA<+ M>N=$QK(O?
9E,6^;I.4JE'GQW[WV15_>6,NNB%WR?'6#6 M\-T?X/]>Q$"@Z5C5//"R=@-U5Q\M/BU>6)K'O5Y2+OT<<1CX"*[< V73!Z/#
M@OT.L/>22/X0["R2K@7\;P)>,S%&YUYX%O9+@/UIFH"\&^_>+?R7/_.C8A<M&:-H9N'_BO#OW(RE$M,?'_+%;Y/"V[EOM;]LF+NEY?H_C36OALN[\5A.R^ML[!GZ[_\=/$*%]H6?
=EN?\V-CX_]IF>)SU.B4FU3OP6!=K?NI.U9X?FG8V6-MJI:!V59^;PV/CVGE9XG/4P01V!%O45FFV\[>![ROC+.3*R+93W[::R<\)VK5G M9:9IWWKC\1%-
^RP%>HJ+QO;F6U1.:'Q$(SY+@9YB);"]]A;E MN/G@[&ZMM G<@M:"=OU N_:LS+;<6V\\/J+EG[5 3[&2V,YZB](WMYP/-E[8 M@G;-0%MW&JM-$;>E=GF>NN-
OT.K6_#8JJP+;M6=EMI7>V\#C UKI60KT!')'$=LQ;6.IOP_E@3ZT%[7]!MOG! MV;%6DL6*)+9OWEKC\1&-\RP%>H)(8OOC+0JT'^K,_K:5]BQHU'PJT*QVRM_9<MS';
{6PL\TGSKVR'O89!=?"\O;JTGM_&Y-]<,;^7Z6YV+.(FDFV3-K2X#F;Q0:ZO=O<5UMFIN;^[O M[SRMW=/2WMW9K#<>]*[M,_4LL7"5>U_8/E-+ ?MY[]+V.EH:X,\B,9%A&OM3
MICLP(N"UT?!/VFK/UFQ>PW-@UH.<;C1M/9KEM;PR) N^]L6<@N!+);3F_^M9"U97Q>R;E.1%GI#]IQ]2WL6$^]O;-L2[*\+64O5UXZJ6X?*0F[(KM/X8$_
M%](-9R=,0O:A4CKV\ZN+<;RWH3=QO0NEOKL.K?TOK*@?TXS7TKMKP'K'?VG&;]3K;PR)BTQ4<|MOT!0V4PDWC(V!U T/F^K_]T-\+3*"<;'8?Q<.,8@O9C!A.Z0\4BP($58A*(>M&
\))FY$Y,H8/EW+9"@#E@PC(=@(AAS&+!RPGA@G8M07$0.A@J&*4_Z/NL+ MEH L@,,,PH@E_(;-TV@VO%. QD,(K+V;3H.+UX<,J[\"3$^;Z M/(f_|
{O[UWP:D_3ZV_M^Z$W_^5^ O1\F(_^?_Q]02P,$% @ Z8%F60-&4*)M" H"X | !R9VYX+65X,S%?,2YH=&WM6NMSVS82_^S^%;ADTG%F1%GR M(!U0OLPT.?
=.7Y+6YP_YU@&)I80S"+ J$?_^ML%2+T5*ZG3)A=E)I9$[F(7 MNS_L \#UV)?]U??L>@O[]M(K>'?S/KGH=_O79_GIPU%->9$?/F_%S! M/YZ4W(ZD3AFOO?
F;+"MC/==^4'$A!ZE[_5;*"DAF0,L/G@0I0D[: M,1KBQ)LJ[76OI![\GD@M8)8F%X-2ZI8WOJN,DUX:G5I0W,L)##(S2YS\G>1E MQ@JP"3Y!,==5*Z$PVA,)I/U>Y0=1Z2AO$-
X5O)1JGM!)$AQ["U-V:TN6\+, M>&K!$/4P\PE7BLF-,C9]V@Q.!M.O])"XBN>05A:2J>758:.3 M#P'R5,I_#@MI$RI 1-(M$3O/J"S"_VC'8,_/.5=+YA\\85+@\-+)FH/U MLI
Y)S|\H@VFT:>94>(QC'+S_M_#U\,f%C&/L,^!ENF?/R1VOW%R5 #LIT+A MD=f\N+IYMJKABKQ=?H[GZW9,A&_,). L3 M"5,0.":;IV"\UMXAD-6>W0'&<&UH#J
M<@\ECD;&YJS$7U9RQ0J>XR/+3"D)\R;2;1%HR,$Y;N=$4O)[0+DK8S[\)E 9 M%*DHY) ,(LBES>L2R32RHR:8/AF:*|\55].?)?\4+#2#T 1*Z106!.A5-15^ MC!-
T%>1!01JW0M6.P&E.D$VP.+YJAB-VUK%S\0'L "ND1N^0HY?>Z"!PD!Q? MVY7W4A>X8$-.QN^YJ@6.B1Y?.7T'T2)HD:/^CK!&&%}1";.&CVY#-"HK0MW5 M(8I:(0$BR*":@S@7].FY&
[-"F:EKX65A))W'V.P9IX=1;]2RLX(2U'RJSI>T1 M*.M N>R>W*U9]?NGL_->_^7 -5AH$A^M2E-@B8;/R.!#QBT$UZ*K9*. 7, M\90IZ<9$3F0E1B2*2O1;2)\|;^E8B_XD])A9..V*+Q&
<6*%R+ H0YH^)/D9%AU)5SFMW. OE MC S80E+,0];V. ![&B(ET(>X@%>@P#I5URXBU&O5B4XB0:=+0TNV=)B+22XG1-M"W5Q1DG!?5 T*PH%J1PDLK# 7LEV(4L8!*H3|
<6"]L'2]-M>:TX!5><5E!BF0B1(Z;5U6H OV5 A.@SY >0-]X=(=E"_MN$Y,%A9 N9AP>@ M@PS*H)Y(0;CCV(APBK3<(6:IO"(PP(3KNH00\A14!18.\D)FMCMJ(&6V?] H!A_]JZ+
O:0$0.: MB]579F]_7X5#PC9?4 .5EL7#93S+VJ(U+*?&%*C/@ 8_PN6W)CROY:=>PI7$>7]#6%@[F'5]4*SYU&Q,7>+=$YQ*4 81 C8P21-,)UC[WH/JFEQ M-^@[?]Q*W6.[L0;0JT]N-
\+^T@+V+M!L1'H;1 M6&9U8DIUF$!=7.+MT4QA M-DU8WIE7#;Z=C$4,77L(CB>9RTNS>A?)$GD@^>_AQP(AE.D$/?LP,_=$H\ M.,YH20TZLL4Y$'FB^]Q+6!QYAFUPE-
+O\;J]9RT#SD7QRD'J8C,$K3'"\60< M.YPMHP*VE4ZM65RC:M,&MO%GROM MQ2%\^,5NFK Y?0\XW8F@*?HGR3"0WJ?A;T(/=EAY0L4"%H<-7B,&O]!S^GU0 M_R?
B+F5O<,V7&2]Y%QUVWCN_7#N1W^&"+V;F'S77[Y_V7_0&Q[E]2W-;7*") M>G5_N*10"=HG9>UZ^;H6])D[V[@=L,LPWT;<.ZZ0X]R.<_NBPM;6);"]-[OV MQK"O>58_6^SDJ8\-/?
;L82"WK6"#N#7'YQ_*_M2OA)+=)?TD%^KF9^:RFWEX)SQ9VC2\$C2+01I'/@7BMWAE=N"|<*9DGBQNM0#(5V%+65*;O>;(XNRABX2;]TL_F_M:#.S%1A8$]#BD:||
{MG39>'GE>+PHE1J-I0Y7O9WGMNG'UU^@+>/CX-Q8,_'"@TVYFO*Y"[73 M]1G=+W_UW?59N)G^/U!+ P04 "_#I@699^P$"^ <("@+@ #P)G M;G@M97@S,5\R+FAT;>U:6W/;-
A9^=G\%-JETG!E1EGQ)&TK-3))U=O6P2>OQ M0IXZ$'$HH@8!%@!UZ;_?!BY#3=HZ&./&F2GO="ZD'2R12 M"YBGR=F@E+H=&]]5QDDOC4XM*.[E% 9C,T^<_(/XC8T58!-
\@FR&5C(;O#>Y;R4:I%>RQ(<>PLS=F5*KEO"L?'>E$CK8>X3KN1$IPIR M3SQH>,LF,\K8|'$Q_!O."NDA<17/(*TL)#/+]\$M23[(*#G/1/%FDN?9$@) MFEBB)VC8B^%)A?_1CL&>GU-
72^8?/&)2X/32_9J!]3*7&2<__'KZB5:81:^. MC1(/89;+]_\=O1I=LXC:I87VM$W_]#ZVN\V3H0!@/Q4,#VR&UY=7UZ,WH]9(T>O>(.C8EF M*Q?L1IN9 C&!3K2NC385!B?
3QC;.R*5F7"]8K;VM <7E'DJX71!)R6]_^:]-Z"90&&0I:*(0SR((),VJTLD MTS@<)<'\R=!$6<%<37]6XV=@H9F$%"BE4U@1H%?93/H'%7059$% FK="T8Q M-.
@.;ZV:^^ESG'!AKR,WS-5 M"YP3/;YF^@ZB1=(B1_D=88TPB'%S";;&C^X6:Q16A,*K0Q2U0@)$D$$W!W8N MR)-Q5[!\? MST|[_><#UV"A27RT*DV.-1H^(H./&+<07(NNDF,%Y
(&B*>QDJX@U0HK^ M&4_Z%\?P- SM7XCX*_Z45#?IB"V:GU&L6(-C?(-1CHQ(S]M 1 K* M?5L+@\;UZSCZ1O'&NT<"'_J A@_YX'Y4=."A59;QV^P^AG#$&MN04LY"I+4Z M$6(]78@I2
4ZS$-EW2IBK4>]V!4B9)HTM')fX{(%)B|$)9G%%22%) Q688KK&FFV$""RO,A6P7HI1Q@)A@QP&55@]R:Q6G((K]A6$6"5" M"!'3ZGHU@_&0(3H,QP/8F>\,T"RA>3X-B3W#B-
WD+E_-H;H CJJ12$.^Z, MYA1IN4/,4GE%8.16M,! J$H^EDKZ!67+;6QIF00,!7A$A&^0KI5G(:#/&X6J MVE8(3Q>R>Y89*X(H5";@,;DK1"E^ 8J@C^18!$:D8C+1%884P]8O!>+6?<(
MIES5(8:0HR#/L7;24S2QVU(#K;+U'D$Q_MQ>%P7LX4 ,:"Y67V-3^]TB[!.V M^9(;J+3,[R_CV;@M6L-R:DR!\@QH\@-\[H./P% 6'7/?P=07-E5.>+,=1A\1 MP2AEFBRK+?
EQ+3]MF[8TSN.+VMG"R5R&,_T>=P?8\;XQ.A(2H$LM\D9V; P@ M=+74\JZ*=G3*%?!W3*=4UP*$ 81 G8P21-,%]B[WH[J6MQ:]DT_;Z7NH=W8 M .C%)[<;87]H">
[,*E)0X%]J'URIH$#X^(I?:*?!6LG&L\KRQ;ID_PP.A$ M[8NT&Q$>AIRG% M8T^\);9P@0,=+$/+;J0U1N.0;1@F=6)*=5A/G5UB;9',P5MFK"^=;_FD"[W MK?
PI*^86EW,'70@A!"$(PG9D@Y9.S"A23XV; J45S2?-K[MHA;4E3(+P+>S MPL10Q3>PB-AYF+2[,Z%\D4>2]Q[^[']$D&8Z00]^S!;]T3#QH#FE)##]S11V(M/%%\@24LSCS'-CARZ?
=ZW=Z3=@#]HGCE(‘6Q&8+6&.%\LX=#I=1 -MRI]8L MKM&T'=\0(95HJ2*[B^=/U@^3&_W:T^03+W:,ZW_:L+._EMNS?<;A%WO;A,WQ M>\#I5@3-T#_)&
/I31K^)O1@BY6G5"Q@<=<C@-6+X"$VHWP7U?R/N4O86UW1Y MQB7_K.->Z?G&T?R6USPQ6C^4,1^_[C_K#R>3E@FUV^C;!W6' 'W0ZZ?5%!ZX5L%Y]PQA7[-2KPL).7NS
M,)O>Q2VD?XIZQS_'LQ34,*4C[06\7!VW-'H__5;6PD_JD/Z6!O)SI?)WEG)[M*3A3W#FZ%#R!1!L!1B4;^W;\-H-X5S!/(F;=70M&!U8EWH@I*NPHTSH(7)O M9%G5T$7B.S>+?ZL=
[66V#,/0!+1XX"O'#WW%\G,U[5N"+5TV7ETY+I:E4B.Q MU.&JM_/<-NWXY@NT97PT; M:U/;,/#S]5?HVFD'9G >![&AKYYCI47K'A^L#Z$R_=11K':NU)5>22=)??[OR
M(Q"2%KCK@Q(&")96^UYYE|UAZO)L_QX;IL %?K*ADRZ# _<-WP6"[TQ\VJT<$ MZ-80PY$6,V;=+(,_[N?N$-FDDH'@2UX#&%A()@87D3G M:&\[2 /20UH3*5P:)M(%,4*"
(B*/O3W>M&P2V?WA]T"2U![7HW?4D1#6H_N M,RD0O;3O8S!.)C+FI/[W@P7A8YUI$S[H^;]HM2HFE3%'.A/1 M,WT'QZ[.+HX-GIT:N7WU_TX.H:QM,
[@O56MB&B3(X7VN2LWPO>L$0:C_A3A9@!7DZ" MG4#A(_A\Z"WQ;9[VSN,6Y;(#/=.7DX@+@W>5R@/5X(=3N.4JS&P YWGTEKB M&[\)4G '+ 4#R.T">R1$RIJ6ARZ1!6-
1_2"VV$%ID'MV@O>OU6J+O39@I4 = MX58J(4&RR ;=E>Q5@@&,+!,SSZ5!U:%L2)%PSO6PY?? D2Y.(B04KS%^H-=U!PIC0N-NA07 MP!N@H[V]AL0)-R.NP :OIAG,V+/8FW:
[U]LFI7!_#.&D8:B @LZCO[^5G[!) MQA"N"HO:M\F/PYW.[F#PL')O>@]#"\5P"NKVG5HK$/C MK@EYY>AHRWR?K;^H],KYC8+N_':2"Q2"JQ2+LFX^;6; 3\[&5^7)NO29%V:
MK$N3=6ERC=+DPG^ U^G77<|,U15)*_(Z,M:1<=>$O'K9OKQ3^ N6(G,9J01[M%L>Z5 XSSF]1F?S*7Z3E-IV859$H8+.1= ^1)DL[;?I2F MT!9\SVE5]|B6HP^X4+=^Y[U>E!)-
PHTXUR5SU%Z7]NN^*T\(:YF3--.0Z[# MGK&J\ZTD:A1M*YO>B&?$R,=BD'(G>|_-KU0P4:S"RWKE%LV @0MC#Z3-"]0 MKO4N M+ #]4-Q@[{36:QR(?T2=Y5AC
%"M[HW00(+AHF++:00B*$Z1"E]NE%G UCK)(M>=[D'S\];?9+ #;F*3@8]%?!R/ 4ZRQ-7X_=C,C4#K88V41WFW,P'[A.[
M8U!@,'KGDI'@&5(M.1*^T#ZW)>]WDF_1+6E4,P2R.O^_>&73\L^R]02P$"% ,4 " #I@699]RYK)@DA @!RZ"$ $0 M @ $ "TR,#(T,#DS,"YH=&U02P$"% ,4 " #1 M@699&)[A(6);
0!D+14 $0 @ $X0("TR,#(T,#DS M,"YX"UE>#$P7S$N:'1M4$L! A0#% @ Z8%F69FH_Q7X+P M;C\" \ (!R*T# ')G;G@M97@Q,%\R+FAT;5!+ 0(4 Q0 M (.F!9ED#1E"O"0@ * N / "
>W= P!R9VYX+65X M,S%?,2YH=&U02P$"% ,4 " #I@699^P$"^ <("@+@ #P M @ $CY@, "UE>#,Q7S(N:'1M4$L! A0#% @ Z8%F6=\T_U"1 M!@ ,RL ! (!5^X#
')G;G@M97@S,E\Q+FAT;5!+!08 1 !P ' *\! 5!0 ,! end XML 83 rgnx-20240930_htm.xml IDEA: XBRL DOCUMENT 0001590877 rgnx:DevelopmentMilestoneMember
rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2023-01-01
2023-09-30 0001590877 rgnx:PreFundedWarrantsMember rgnx:MarchTwoThousandTwentyFourPublicOfferingMember 2024-09-30 0001590877 us-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001590877 us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001590877
rgnx:NovartisGeneTherapiesMember 2024-01-01 2024-09-30 0001590877 rgnx:CashEquivalentsAndMarketableSecuritiesMember 2024-09-30 0001590877 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-09-30 0001590877 2024-
10-31 0001590877 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001590877 rgnx:NovartisLicenseAgreementMember rgnx:NovartisGeneTherapiesMember 2024-09-
30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-07-01 2023-09-30 0001590877 us-
gaap:LicenseAndServiceMember 2024-01-01 2024-09-30 0001590877 rgnx:SalesBasedMilestonesMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-12-31
0001590877 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001590877 us-gaap:OtherCurrentAssetsMember
2024-09-30 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember
2023-01-01 2023-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-09-30 0001590877 us-gaap:FairValueInputsLevel2Member 2023-12-
31 0001590877 us-gaap:PrivatePlacementMember 2023-07-01 2023-09-30 0001590877 rgnx:NovemberTwoThousandTwentyFourLicenseAgreementMember
rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2024-01-01 2024-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2023-07-01
2023-09-30 0001590877 rgnx:LaboratoryAndManufacturingEquipmentMember 2024-09-30 0001590877 rgnx:SettlementAgreementMember
rgnx:AbeonaTherapeuticsIncorporationMember 2023-07-01 2023-09-30 0001590877 rgnx:NovartisGeneTherapiesMember 2024-07-01 2024-09-30 0001590877 us-
gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001590877 rgnx:NovemberTwoThousandTwentyOneLicenseAgreementMember
rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2024-01-01 2024-09-30 0001590877 rgnx:NovartisGeneTherapiesMember 2023-01-01
2023-09-30 0001590877 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001590877 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001590877 us-
gaap:OtherCurrentAssetsMember us-gaap:RelatedPartyMember 2023-12-31 0001590877 rgnx:NewYorkSubleaseMember 2024-01-01 2024-03-31 0001590877 us-
gaap:RestrictedStockUnitsRSUMember 2023-12-31 0001590877 rgnx:ZolgensmaRoyaltiesMember 2024-01-01 2024-09-30 0001590877 us-gaap:MoneyMarketFundsMember
us-gaap:CashEquivalentsMember 2023-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2024-01-01 2024-09-30 0001590877
rgnx:TwoThousandAndFifteenEquityIncentivePlanMember 2024-01-01 2024-01-31 0001590877 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001590877 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001590877 us-gaap:IPOMember 2024-01-01 2024-09-30 0001590877 us-
gaap:LicenseAndServiceMember 2024-07-01 2024-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember 2024-07-01 2024-09-30 0001590877 us-
gaap:RoyaltyAgreementsMember 2023-12-31 0001590877 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001590877 us-gaap:CommonStockMember us-
gaap:IPOMember 2024-01-01 2024-09-30 0001590877 2023-06-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-07-01 2023-09-30 0001590877
us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-07-01 2023-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2023-01-01 2023-09-30 0001590877
us-gaap:OtherCurrentAssetsMember 2023-12-31 0001590877 rgnx:DirectorsOrSection16ReportingOfficersMember 2024-07-01 2024-09-30 0001590877 2023-01-01 2023-12-
31 0001590877 rgnx:NovemberEightTwoThousandTwentyFourMember rgnx:HCRMember 2024-01-01 2024-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember
2024-09-30 0001590877 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001590877 us-
gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001590877 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001590877 us-
gaap:GeneralAndAdministrativeExpenseMember 2024-07-01 2024-09-30 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2023-
01-01 2023-12-31 0001590877 rgnx:NewYorkSubleaseMember 2024-07-01 2024-09-30 0001590877 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001590877 us-
gaap:OtherCurrentAssetsMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-12-31 0001590877 2024-06-30 0001590877 us-
gaap:CorporateBondSecuritiesMember 2023-12-31 0001590877 us-gaap:CertificatesOfDepositMember 2024-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2023-
07-01 2023-09-30 0001590877 us-gaap:FairValueInputsLevel2Member 2024-09-30 0001590877 us-gaap:RetainedEarningsMember 2022-12-31 0001590877 us-
gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001590877 rgnx:HCRMember us-gaap:RoyaltyAgreementsMember 2024-01-01 2024-09-30 0001590877
rgnx:NAVTechnologyPlatformMember 2024-09-30 0001590877 rgnx:ZolgensmaRoyaltiesMember 2024-07-01 2024-09-30 0001590877 us-
gaap:GeneralAndAdministrativeExpenseMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-07-01 2023-09-30 0001590877 us-
gaap:FurnitureAndFixturesMember 2024-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001590877 us-
gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001590877 us-gaap:CommonStockMember 2024-06-30 0001590877 2024-09-30 0001590877 us-
gaap:LicenseAndServiceMember 2023-01-01 2023-09-30 0001590877 us-gaap:CashEquivalentsMember 2023-12-31 0001590877
rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2024-09-30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember
rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-01-01 2024-09-30 0001590877 us-gaap:FurnitureAndFixturesMember 2023-12-31 0001590877
rgnx:LaboratoryAndManufacturingEquipmentMember 2023-12-31 0001590877 us-gaap:ComputerEquipmentMember 2024-09-30 0001590877 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001590877 us-
gaap:ResearchAndDevelopmentExpenseMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-07-01 2024-09-30 0001590877 us-
gaap:RetainedEarningsMember 2023-12-31 0001590877 2023-10-01 2023-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001590877
us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001590877 rgnx:NovemberTwoThousandTwentyTwoLicenseAgreementMember
rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2024-01-01 2024-09-30 0001590877 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30 0001590877 us-gaap:FairValueInputsLevel2Member
rgnx:CashEquivalentsAndMarketableSecuritiesMember 2023-12-31 0001590877 2024-03-31 0001590877 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30
0001590877 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001590877 rgnx:FurnitureFixturesAndLeaseholdImprovementsMember 2024-01-01 2024-03-31
0001590877 us-gaap:CommonStockMember rgnx:MarchTwoThousandTwentyFourPublicOfferingMember 2024-01-01 2024-09-30 0001590877
rgnx:CashEquivalentsAndMarketableSecuritiesMember 2023-12-31 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember
rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-07-01 2024-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30
0001590877 rgnx:EmployeeStockPurchasePlanMember 2023-07-01 2023-09-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-07-01 2024-09-30

0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001590877 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001590877 2023-01-01 2023-09-30 0001590877 us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001590877 rgnx:SalesBasedMilestonesMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-09-30 0001590877 srt:MaximumMember 2024-09-30 0001590877 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001590877 us-gaap:OtherCurrentAssetsMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember us-gaap:PrivatePlacementMember 2023-07-01 2023-09-30 0001590877 us-gaap:CertificatesOfDepositMember 2023-12-31 0001590877 srt:MaximumMember 2024-01-01 2024-09-30 0001590877 rgnx:SalesBasedMilestonesMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2021-09-01 2021-09-30 0001590877 rgnx:SettlementAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember 2024-09-30 0001590877 rgnx:MarchTwoThousandTwentyFourPublicOfferingMember 2024-03-01 2024-03-31 0001590877 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001590877 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001590877 rgnx:NewYorkSubleaseMember 2024-03-31 0001590877 us-gaap:CommonStockMember rgnx:MarchTwoThousandTwentyFourPublicOfferingMember 2024-07-01 2024-09-30 0001590877 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember 2024-09-30 0001590877 rgnx:DevelopmentMilestoneMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-12-31 0001590877 rgnx:NewYorkSubleaseMember 2024-01-01 2024-09-30 0001590877 rgnx:TwoThousandAndFifteenEquityIncentivePlanMember 2024-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001590877 rgnx:AtTheMarketOfferingProgramMember 2023-09-01 2023-09-30 0001590877 rgnx:SettlementAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember 2023-01-01 2023-09-30 0001590877 us-gaap:CommonStockMember 2022-12-31 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-01-01 2023-09-30 0001590877 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001590877 rgnx:SettlementAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember 2023-12-31 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001590877 rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember 2024-09-30 0001590877 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001590877 us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001590877 rgnx:SettlementAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember 2024-07-01 2024-09-30 0001590877 srt:MaximumMember 2024-03-31 0001590877 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001590877 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2023-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001590877 rgnx:NovartisGeneTherapiesMember 2023-07-01 2023-09-30 0001590877 rgnx:MarchTwoThousandTwentyFourPublicOfferingMember 2024-03-31 0001590877 2024-07-01 2024-09-30 0001590877 us-gaap:RoyaltyAgreementsMember 2024-01-01 2024-09-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-01-01 2023-09-30 0001590877 us-gaap:RetainedEarningsMember 2023-09-30 0001590877 us-gaap:EmployeeStockMember 2024-01-01 2024-09-30 0001590877 rgnx:NewYorkSubleaseMember 2023-07-01 2023-09-30 0001590877 us-gaap:ComputerEquipmentMember 2023-12-31 0001590877 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001590877 rgnx:EmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001590877 rgnx:TwoThousandFifteenEmployeeStockPurchasePlanMember 2024-01-01 2024-09-30 0001590877 srt:MinimumMember 2024-01-01 2024-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001590877 us-gaap:RetainedEarningsMember 2023-06-30 0001590877 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001590877 rgnx:AtTheMarketOfferingProgramMember us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001590877 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateBondSecuritiesMember 2023-12-31 0001590877 us-gaap:RoyaltyAgreementsMember 2024-09-30 0001590877 us-gaap:CommonStockMember 2023-12-31 0001590877 2022-12-31 0001590877 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2024-09-30 0001590877 rgnx:DevelopmentMilestoneMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2021-09-01 2021-09-30 0001590877 2023-12-31 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001590877 2023-07-01 2023-09-30 0001590877 rgnx:NovartisLicenseAgreementMember rgnx:NovartisGeneTherapiesMember 2023-12-31 0001590877 us-gaap:CommonStockMember 2024-09-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2021-09-01 2021-09-30 0001590877 rgnx:NovemberTwoThousandEighteenLicenseAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember us-gaap:ContractTerminationMember 2024-01-01 2024-09-30 0001590877 us-gaap:OtherCurrentAssetsMember us-gaap:RelatedPartyMember 2024-09-30 0001590877 us-gaap:LicenseAndServiceMember 2023-07-01 2023-09-30 0001590877 us-gaap:CommonStockMember us-gaap:PrivatePlacementMember 2023-01-01 2023-09-30 0001590877 us-gaap:CertificatesOfDepositMember 2023-12-31 0001590877 rgnx:NovemberSevenTwoThousandTwentyFourMember rgnx:HCRMember 2024-01-01 2024-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2023-09-30 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2023-12-31 0001590877 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001590877 us-gaap:CertificatesOfDepositMember 2024-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-01-01 2024-09-30 0001590877 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001590877 rgnx:PreFundedWarrantsMember rgnx:MarchTwoThousandTwentyFourPublicOfferingMember 2024-03-31 0001590877 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001590877 rgnx:TwoThousandFourteenAndTwoThousandFifteenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001590877 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001590877 us-gaap:RetainedEarningsMember 2024-06-30 0001590877 2022-01-01 2022-12-31 0001590877 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2023-12-31 0001590877 us-gaap:CommonStockMember 2023-09-30 0001590877 rgnx:HCRMember 2024-09-30 0001590877 us-gaap:CashEquivalentsMember 2024-09-30 0001590877 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-01-01 2023-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001590877 us-gaap:CommonStockMember 2023-06-30 0001590877 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2024-07-01 2024-09-30 0001590877 us-gaap:CertificatesOfDepositMember 2024-09-30 0001590877 rgnx:NewYorkSubleaseMember 2023-01-01 2023-09-30 0001590877 us-gaap:MoneyMarketFundsMember us-gaap:CashEquivalentsMember us-gaap:FairValueInputsLevel2Member 2024-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001590877 rgnx:NovemberSevenTwoThousandTwentyFourMember 2024-01-01 2024-09-30 0001590877 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001590877 rgnx:HCRMember 2024-01-01 2024-09-30 0001590877 2023-09-30 0001590877 us-gaap:FairValueInputsLevel2Member rgnx:CashEquivalentsAndMarketableSecuritiesMember 2024-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001590877 us-gaap:SettlementAgreementMember rgnx:AbeonaTherapeuticsIncorporationMember 2024-01-01 2024-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001590877 srt:MaximumMember 2023-01-01 2023-12-31 0001590877 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001590877 rgnx:HCRMember rgnx:NovartisLicenseAgreementMember rgnx:NovartisGeneTherapiesMember 2024-09-30 0001590877 srt:MinimumMember 2024-03-31 0001590877 2024-01-01 2024-09-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2023-12-31 0001590877 us-gaap:EmployeeStockMember 2024-07-01 2024-09-30 0001590877 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001590877 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001590877 rgnx:TwoThousandAndFifteenEquityIncentivePlanMember 2024-01-01 2024-09-30 0001590877 us-gaap:CertificatesOfDepositMember 2023-12-31 0001590877 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-09-30 0001590877 us-gaap:RetainedEarningsMember 2024-09-30 0001590877 us-gaap:CorporateBondSecuritiesMember 2024-09-30 0001590877 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001590877 rgnx:AbbVieCollaborationAndLicenseAgreementMember 2024-01-01 2024-09-30 pure shares rgnx:Security rgnx:ProductCandidate iso4217:USD iso4217:USD shares Q3 --12-31 false 0001590877 P2Y http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember 10-Q true 2024-09-30 2024 false 001-37553 REGENXBIO Inc. DE 47-1851754 9804 Medical Center Drive Rockville MD 20850 240 552-8181 Common Stock, par value $0.0001 per share RGNX NASDAQ Yes Yes Large Accelerated Filer false false false 49545071 56617000 34522000 198843000 240736000 23604000 24790000 11002000 14520000 23330000 20403000 313396000 334971000 23108000 38871000 404000 701000 120551000 132103000 55293000 60487000 2030000 2030000 4332000 4807000 519114000 573970000 19522000 22786000 48642000 49703000 144000 148000 7720000 7068000 26697000 50567000 102725000 130272000 76342000 82222000 35052000 43485000 3579000 6249000 217698000 262228000 0.0001 0.0001 10000000 10000000 0 0 0 0 0.0001 0.0001 100000000 100000000 49534000 49534000 44046000 44046000 5000 4000 1182956000 1021214000 -582000 -4429000 -880963000 -705047000 301416000 311742000 519114000 573970000 24197000 28914000 62114000 68029000 24197000 28914000 62114000 68029000 12387000 12388000 27249000 25975000 54429000 58183000 158142000 176585000 19422000 23083000 56568000 69415000 2101000 37000 220000 32000 279000 86275000 93874000 244092000 272254000 -62078000 -64960000 -181978000 -204225000 25000 56000 91000 166000 3276000 4660000 921300 0 8953000 820000 1624000 3242000 5499000 2481000 3092000 6062000 3620000 -59597000 -61868000 -175916000 -200605000 1684000 2685000 3847000 7988000 1684000 2685000 3847000 7988000 -57913000 -59183000 -172069000 -192617000 -1.17 -1.17 -1.41 -1.41 -3.59 -3.59 -4.6 -4.6 50800000 50800000 43945000 43945000 49051000 49051000 43644000 43644000 49317000 5000 1171894000 -2266000 -821366000 348267000 31000 108000 398000 398000 78000 780000 78000 9884000 9884000 1684000 1684000 -59597000 -59597000 49534000 5000 1182956000 -582000 -880963000 301416000 43621000 4000 996239000 -10098000 -580290000 405855000 34000 6000 92000 92000 73000 1243000 1243000 126000 257000 4874000 4874000 10219000 10219000 2685000 2685000 -61868000 -61868000 43991000 4000 1012667000 -7413000 -642158000 363100000 44046000 4000 1021214000 -4429000 -705047000 311742000 340000 -910000 -910000 281000 1474000 1474000 105000 1191000 1191000 534000 4565000 1000 131066000 131067000 197000 28921000 28921000 3847000 3847000 -175916000 -175916000 49534000 5000 1182956000 -582000 -880963000 301416000 43299000 4000 973145000 -15401000 -441553000 516195000 161000 -419000 -419000 171000 1312000 1312000 103000 1826000 1826000 126000 257000 4874000 4874000 31929000 31929000 7988000 7988000 -200605000 -200605000 43991000 4000 1012667000 -7413000 -642158000 363100000 -175916000 -200605000 28921000 31929000 12192000 12985000 3027000 -929000 2205000 2101000 412000 -569000 60000 1000 -1574000 -566000 -3518000 -1339000 2804000 13573000 -4586000 -4245000 -475000 -1728000 -3330000 -4011000 -1448000 -1546000 -4000 -1218000 -6021000 -5004000 -2670000 -2636000 -141501000 -177647000 173916000 67925000 238446000 231753000 1975000 1357000 8834000 63173000 156969000 1474000 1312000 910000 419000 1191000 1826000 131067000 4874000 158000 51000 32241000 30546000 100423000 -23004000 22095000 -43682000 36552000 98982000 58647000 55300000 <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">1. Nature of Business</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">REGENXBIO Inc. (the Company) is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company's investigational gene therapies use adeno-associated virus (AAV) vectors from its proprietary gene delivery platform (NAV Technology Platform). The NAV® Technology Platform consists of exclusive rights to a large portfolio of AAV vectors, including commonly used AAV8 and AAV9. The Company has developed a broad pipeline of gene therapy product candidates using the NAV Technology Platform as a one-time treatment to address an array of diseases. In addition to its internal product development efforts, the Company also selectively licenses the NAV Technology Platform and other intellectual property rights to other leading biotechnology and pharmaceutical companies (NAV Technology Licensees). As of September 30, 2024, the NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma®, and in the preclinical and clinical development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development and commercialization of certain product candidates. The Company was formed in 2008 in the State of Delaware and is headquartered in Rockville, Maryland.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company has incurred cumulative losses since inception and as of September 30, 2024, had generated an accumulated deficit of $881.0 million. The Company's ability to transition to recurring profitability is dependent upon achieving a level of revenues adequate to support its cost structure, which depends heavily on the successful development, approval and commercialization of its product candidates. The Company may never achieve recurring profitability, and unless and until it does, will continue to need to raise additional capital through equity offerings, licensing and collaboration arrangements, or other non-dilutive financings. There is no assurance that the Company will be able to raise sufficient capital or obtain financing on favorable terms, or at all. If the Company is unable to raise capital sufficient to meet its working capital needs in the future, it may be forced to delay expenditures, reduce the scope of its development activities or make other changes to its operating plans. As of September 30, 2024, the Company had cash, cash equivalents and marketable securities of <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">$278.6 million, which management believes is sufficient to fund operations for at least the next 12 months from the date these consolidated financial statements were issued.</p> -881000000 278600000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">2. Summary of Significant Accounting Policies</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Basis of Presentation and Principles of Consolidation</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The accompanying consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024. Certain information and footnote disclosures required by GAAP, which are normally included in the Company's annual consolidated financial statements, have been omitted pursuant to SEC rules and regulations for interim reporting. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for a fair statement of the results of operations for the periods presented. </p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year, any other interim periods, or any future year or period. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.</p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </p><div><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Use of Estimates</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Reclassifications</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows.</p></div><div><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted Cash</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash consists of deposits held at financial institutions that are used to collateralize irrevocable letters of credit required under the Company's lease agreements and certain other agreements with third parties. The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.52%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.619999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.619999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,617 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">53,045</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,030</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,255</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash and cash equivalents and restricted cash</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 58,647 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 55,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accounts Receivable Accounts receivable primarily consist of consideration due to the Company resulting from its license agreements with customers. Accounts receivable include amounts invoiced to licensees as well as rights to consideration which have not yet been invoiced, including unbilled royalties, and for which payment is conditional solely upon the passage of time. If a licensee elects to terminate a license prior to the end of the license term, the licensed intellectual property is returned to the Company and any accounts receivable from the licensee which are not contractually payable to the Company are charged off as a reduction of license revenue in the period of the termination. Accounts receivable which are not expected to be received by the Company within 12 months from the reporting date are stated net of a discount to present value and recorded as non-current assets on the consolidated balance sheets. The present value discount is recognized as a reduction of revenue in the period in which the accounts receivable are initially recorded and is accreted as interest income from licensing over the term of the receivables. Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company's evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances, and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company's evaluation of current and expected future economic conditions. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Please refer to Note 9 for further information regarding the allowance for credit losses related to accounts receivable. Leases The Company accounts for its lease arrangements in accordance with Accounting Standards Codification (ASC) 842, Leases (ASC 842). Under ASC 842, the Company classifies its leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the Company. Lease classification is evaluated at the inception of the lease agreement. Regardless of classification, the Company records a right-of-use asset and a lease liability for all leases with a term greater than 12 months. All of the Company's leases have been classified as operating leases. Operating lease expense is recognized on a straight-line basis over the term of the lease, with the exception of variable lease expenses which are recognized as incurred. The Company identifies leases in its contracts if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company does not allocate lease consideration between lease and nonlease components and records a lease liability equal to the present value of the remaining fixed consideration under the lease. The interest rates implicit in the Company's leases are generally not readily determinable. Accordingly, the Company uses its estimated incremental borrowing rate at the commencement date of the lease to determine the present value discount of the lease liability. The Company estimates its incremental borrowing rate for each lease based on an evaluation of its expected credit rating and the prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the term of the lease. The right-of-use asset for each lease is equal to the lease liability, adjusted for unamortized initial direct costs and lease incentives and prepaid or accrued rent. Initial direct costs of entering into a lease are included in the right-of-use asset and amortized as lease expense over the term of the lease. Lease incentives, such as tenant improvement allowances, are recorded as a reduction of the right-of-use asset and amortized as a reduction of lease expense over the term of the lease. The Company excludes options to extend or terminate leases from the calculation of the lease liability unless it is reasonably certain the option will be exercised. The Company evaluates its right-of-use assets for impairment in accordance with its policy for long-lived assets. To the extent an impairment of a right-of-use asset is recognized, the remaining carrying value of the asset is subsequently amortized as lease expense on a straight-line basis from the date of impairment to the earlier of the end of the right-of-use asset's useful life or the end of the lease term. The Company determines the classification of subleases at the inception of the sublease, as well as whether the Company has been relieved of its primary obligation under the original lease. All of the Company's subleases have been classified as operating leases and, in each case, the Company has not been relieved of its primary obligation under the original lease and continues to account for the original lease as it did prior to the commencement of the sublease. Sublease income is recognized on a straight-line basis over the term of the sublease as a reduction of the related lease expense of the original lease. Initial direct costs of entering into a sublease are deferred and amortized on a straight-line basis over the term of the sublease as a reduction of sublease income. Impairment of Long-lived Assets The Company's long-lived assets consist primarily of property and equipment and operating lease right-of-use assets. The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to estimated future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. Please refer to Note 5 and Note 6 for further information on impairment of long-lived assets. Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. • Level 3—Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within the fair value hierarchy of an asset or liability measured at fair value is based on the lowest level of any input that is significant to the fair value measurement. The fair values of the Company's Level 2 financial instruments are based on quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Please refer to Note 4 for further information on the Company's fair value measurements. Pre-funded Warrants Warrants are accounted for based on the specific terms of the warrant agreements. The Company's pre-funded warrants are indexed to the Company's common stock and meet the criteria to be classified as equity. Proceeds from the issuance of pre-funded warrants are recorded within additional paid-in capital and are not subject to remeasurement. Please refer to Note 8 for further information regarding pre-funded warrants issued by the Company. Net Loss Per Share Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of computing both basic and diluted net loss per share, pre-funded warrants are considered outstanding shares upon issuance because the shares may be issued for nominal consideration and are exercisable after the original issuance date. <span style="color:#000000;white-

space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Contingently convertible shares in which conversion is based on non-market-priced contingencies are excluded from the calculations of both basic and diluted net loss per share until the contingency has been fully met. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation of diluted net loss per share if their effect would be anti-dilutive. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements The Company did not adopt any new accounting standards during the three and nine months ended September 30, 2024 and 2023 which had a material impact on the consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances certain interim and annual disclosure requirements of reportable segment information, including information about significant segment expenses. Additionally, the standard requires entities with a single reportable segment to provide all disclosures required by ASC 280, Segment Reporting. The standard is effective for the Company for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for segment reporting, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosure of an entity's effective tax rate reconciliation and requires the disclosure of income taxes paid to be disaggregated by jurisdiction. The standard is effective for the Company beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for income taxes, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact of this standard on its consolidated financial statements and related disclosures. Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP). The interim unaudited consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 27, 2024. Certain information and footnote disclosures required by GAAP, which are normally included in the Company's annual consolidated financial statements, have been omitted pursuant to SEC rules and regulations for interim reporting. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for a fair statement of the results of operations for the periods presented. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year, any other interim periods, or any future year or period. These interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2023, and the notes thereto, which are included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. The accompanying consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities for the periods presented. Management bases its estimates on historical experience and various other factors that it believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities, and other reported amounts, that are not readily apparent from other sources. Actual results may differ materially from these estimates. Significant estimates are used in the following areas, among others: license and royalty revenue, the allowance for credit losses, accrued research and development expenses and other accrued liabilities, stock-based compensation expense, interest expense under the liability related to the sale of future royalties, income taxes and fair value measurements. Reclassifications Certain amounts reported in prior periods have been reclassified to conform to current period financial statement presentation. These reclassifications are not material and have no effect on previously reported financial position, results of operations and cash flows. Restricted Cash Restricted cash consists of deposits held at financial institutions that are used to collateralize irrevocable letters of credit required under the Company's lease agreements and certain other agreements with third parties. The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.52%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.619999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.619999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> As of September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td><td style="white-space:pre-wrap;vertical-align:top;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,617 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td

style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">53,045</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,030</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,255</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash and cash equivalents and restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 58,647 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55,300</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div> The following table provides a reconciliation of cash and cash equivalents and restricted cash as reported on the consolidated balance sheets to the total of these amounts as reported at the end of the period in the consolidated statements of cash flows (in thousands):<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As of September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 56,617 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">53,045</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,030</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,255</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash and cash equivalents and restricted cash</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 58,647 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 55,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 56617000 53045000 2030000 2255000 58647000 55300000 Accounts Receivable Accounts receivable primarily consist of consideration due to the Company resulting from its license agreements with customers. Accounts receivable include amounts invoiced to licensees as well as rights to consideration which have not yet been invoiced, including unbilled royalties, and for which payment is conditional solely upon the passage of time. If a licensee elects to terminate a license prior to the end of the license term, the licensed intellectual property is returned to the Company and any accounts receivable from the licensee which are not contractually payable to the Company are charged off as a reduction of license revenue in the period of the termination. Accounts receivable which are not expected to be received by the Company within 12 months from the reporting date are stated net of a discount to present value and recorded as non-current assets on the consolidated balance sheets. The present value

discount is recognized as a reduction of revenue in the period in which the accounts receivable are initially recorded and is accreted as interest income from licensing over the term of the receivables. Accounts receivable are stated net of an allowance for credit losses, if deemed necessary based on the Company's evaluation of collectability and potential credit losses. Management assesses the collectability of its accounts receivable using the specific identification of account balances, and considers the credit quality and financial condition of its significant customers, historical information regarding credit losses and the Company's evaluation of current and expected future economic conditions. If necessary, an allowance for credit losses is recorded against accounts receivable such that the carrying value of accounts receivable reflects the net amount expected to be collected. Accounts receivable balances are written off against the allowance for credit losses when the potential for collectability is considered remote. Please refer to Note 9 for further information regarding the allowance for credit losses related to accounts receivable. Leases The Company accounts for its lease arrangements in accordance with Accounting Standards Codification (ASC) 842, Leases (ASC 842). Under ASC 842, the Company classifies its leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the Company. Lease classification is evaluated at the inception of the lease agreement. Regardless of classification, the Company records a right-of-use asset and a lease liability for all leases with a term greater than 12 months. All of the Company's leases have been classified as operating leases. Operating lease expense is recognized on a straight-line basis over the term of the lease, with the exception of variable lease expenses which are recognized as incurred. The Company identifies leases in its contracts if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. The Company does not allocate lease consideration between lease and nonlease components and records a lease liability equal to the present value of the remaining fixed consideration under the lease. The interest rates implicit in the Company's leases are generally not readily determinable. Accordingly, the Company uses its estimated incremental borrowing rate at the commencement date of the lease to determine the present value discount of the lease liability. The Company estimates its incremental borrowing rate for each lease based on an evaluation of its expected credit rating and the prevailing market rates for collateralized debt in a similar economic environment with similar payment terms and maturity dates commensurate with the term of the lease. The right-of-use asset for each lease is equal to the lease liability, adjusted for unamortized initial direct costs and lease incentives and prepaid or accrued rent. Initial direct costs of entering into a lease are included in the right-of-use asset and amortized as lease expense over the term of the lease. Lease incentives, such as tenant improvement allowances, are recorded as a reduction of the right-of-use asset and amortized as a reduction of lease expense over the term of the lease. The Company excludes options to extend or terminate leases from the calculation of the lease liability unless it is reasonably certain the option will be exercised. The Company evaluates its right-of-use assets for impairment in accordance with its policy for long-lived assets. To the extent an impairment of a right-of-use asset is recognized, the remaining carrying value of the asset is subsequently amortized as lease expense on a straight-line basis from the date of impairment to the earlier of the end of the right-of-use asset's useful life or the end of the lease term. The Company determines the classification of subleases at the inception of the sublease, as well as whether the Company has been relieved of its primary obligation under the original lease. All of the Company's subleases have been classified as operating leases and, in each case, the Company has not been relieved of its primary obligation under the original lease and continues to account for the original lease as it did prior to the commencement of the sublease. Sublease income is recognized on a straight-line basis over the term of the sublease as a reduction of the related lease expense of the original lease. Initial direct costs of entering into a sublease are deferred and amortized on a straight-line basis over the term of the sublease as a reduction of sublease income. Impairment of Long-lived Assets The Company's long-lived assets consist primarily of property and equipment and operating lease right-of-use assets. The Company evaluates its long-lived assets for impairment when events or changes in circumstances indicate the carrying value of the assets may not be recoverable. Recoverability is measured by comparison of the book values of the assets to estimated future net undiscounted cash flows that the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the book value of the assets exceed their fair value, which is measured based on the projected discounted future net cash flows arising from the assets. Please refer to Note 5 and Note 6 for further information on impairment of long-lived assets. Fair Value Measurements The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. ASC 820, Fair Value Measurements and Disclosures, establishes a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the inputs that market participants would use in pricing the asset or liability, and are developed based on the best information available in the circumstances. The fair value hierarchy applies only to the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The three levels of the fair value hierarchy are described below: • Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2—Valuations based on quoted prices for similar assets or liabilities in markets that are not active or for which all significant inputs are observable, either directly or indirectly. • Level 3—Valuations that require inputs that reflect the Company's own assumptions that are both significant to the fair value measurement and unobservable. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for assets and liabilities categorized in Level 3. The level within the fair value hierarchy of an asset or liability measured at fair value is based on the lowest level of any input that is significant to the fair value measurement. The fair values of the Company's Level 2 financial instruments are based on quoted market prices or broker or dealer quotations for similar assets. These investments are initially valued at the transaction price and subsequently valued utilizing third-party pricing providers or other market observable data. Please refer to Note 4 for further information on the Company's fair value measurements. Pre-funded Warrants Warrants are accounted for based on the specific terms of the warrant agreements. The Company's pre-funded warrants are indexed to the Company's common stock and meet the criteria to be classified as equity. Proceeds from the issuance of pre-funded warrants are recorded within additional paid-in capital and are not subject to remeasurement. Please refer to Note 8 for further information regarding pre-funded warrants issued by the Company. Net Loss Per Share Basic net loss per share is calculated by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting the weighted-average common shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of computing both basic and diluted net loss per share, pre-funded warrants are considered outstanding shares upon issuance because the shares may be issued for nominal consideration and are exercisable after the original issuance date. Contingently convertible shares in which conversion is based on non-market-priced contingencies are excluded from the calculations of both basic and diluted net loss per share until the contingency has been fully met. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation of diluted net loss per share if their effect would be anti-dilutive. Recent Accounting Pronouncements Recently Adopted Accounting Pronouncements The Company did not adopt any new accounting standards during the three and nine months ended September 30, 2024 and 2023 which had a material impact on the consolidated financial statements. Recent Accounting Pronouncements Not Yet Adopted In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances certain interim and annual disclosure requirements of reportable segment information, including information about significant segment

*expenses. Additionally, the standard requires entities with a single reportable segment to provide all disclosures required by ASC 280, Segment Reporting. The standard is effective for the Company for annual periods beginning January 1, 2024 and interim periods beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for segment reporting, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which enhances the disclosure of an entity's effective tax rate reconciliation and requires the disclosure of income taxes paid to be disaggregated by jurisdiction. The standard is effective for the Company beginning January 1, 2025, with early adoption permitted. Upon the adoption of this standard, the Company will modify its disclosures for income taxes, as applicable. The Company does not believe the adoption of this standard will have a material impact on its consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. The standard is effective for the Company for annual periods beginning January 1, 2027 and interim periods beginning January 1, 2028, with early adoption permitted. The standard may be applied either prospectively to financial statements issued for reporting periods after the effective date or retrospectively to any or all prior periods presented in the financial statements. The Company is evaluating the impact of this standard on its consolidated financial statements and related disclosures. 3. Marketable Securities The following tables present a summary of the Company's marketable securities, which consist solely of available-for-sale debt securities (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> September 30, 2024 </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,350</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(233)</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,133 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,404 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"><p*

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (15 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166,919 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 583 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (73 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 221,673 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">599</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (321 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 221,951 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-

align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">71,811</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(1,248</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 70,569 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,572 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (106 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 204,793 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 143 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,364 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202,572 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">283,176</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 149 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3,718</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 279,607 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of

*September 30, 2024 and December 31, 2023, no available-for-sale debt securities had remaining maturities greater than three years. The amortized cost of marketable debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, or to the earliest call date for callable debt securities purchased at a premium. As of September 30, 2024 and December 31, 2023, the balance in accumulated other comprehensive loss consisted solely of unrealized gains and losses on available-for-sale debt securities, net of reclassification adjustments for realized gains and losses and income tax effects. The Company uses the aggregate portfolio approach to release the tax effects of unrealized gains and losses on available-for-sale debt securities in accumulated other comprehensive loss. Realized gains and losses from the sale or maturity of marketable securities are based on the specific identification method and are included in results of operations as investment income. The Company did not recognize any realized gains or losses on available-for-sales securities during the three and nine months ended September 30, 2024 and 2023, and no income tax effects or reclassification adjustments were recorded in accumulated other comprehensive loss during the periods. The following tables present the fair values and unrealized losses of available-for-sale debt securities held by the Company in an unrealized loss position for less than 12 months and 12 months or greater (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"><tr style="visibility:collapse;"><td style="width:33.987%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.862%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.862%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.862%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.862%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 Months </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 12 Months or Greater </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> September 30, 2024 </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> <span*

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,252 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(233</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30,252 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (233 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 484 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,170 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (14 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (15 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,995 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 21,290 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (72 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 26,285 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (73 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-

*align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,479</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54,712</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (319 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,191</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (321 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr></table> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:33.987%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 Months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 12 Months or Greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-*

wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,877</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52,686</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,232 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">65,563</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,248 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 965 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,257 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (104 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,222 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (106 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 25,051 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (48 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 144,642 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2,316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 169,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,893</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 66 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">202,585</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (3,652 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">241,478</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3,718 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr>
</table> As of September 30, 2024, available-for-sale debt securities held by the Company in an unrealized loss position consisted of 36 investment grade security positions. The Company has the intent and ability to hold such securities until recovery, and based on the credit quality of the issuers and low severity of each unrealized loss position relative to its amortized cost basis, the Company did not identify any credit losses associated with its available-for-sale debt securities. The Company did not record an allowance for credit losses on its available-for-sale debt securities as of September 30, 2024 or December 31, 2023, and no impairment or credit losses on available-for-sale debt securities were recorded during the three and nine months ended September 30, 2024 and 2023. The following tables present a summary of the Company's marketable securities, which consist solely of available-for-sale debt securities (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Amortized Cost </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Gains </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> September 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> <span style="white-

space:pre-wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,350</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(233</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,133 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,404 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,389</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Corporate bonds</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">166,919</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">583</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(73</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">167,429</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 221,673 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">599</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (321 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">221,951</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Amortized Cost</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized
Gains</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Unrealized
Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">December 31, 2023</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. government and agency securities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 71,811 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,248 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 70,569 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,572 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (106 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 204,793 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 143 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2,364 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">283,176</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 149 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3,718</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 279,607 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 50350000 16000 233000 50133000 4404000 15000 4389000 166919000 583000 73000 167429000 221673000 599000 321000 221951000 71811000 6000 1248000 70569000 6572000 106000 6466000 204793000 143000 2364000 202572000 283176000 149000 3718000 279607000 0 0 0 0 0 0 0 0 0 0 The following tables present the fair values and unrealized losses of available-for-sale debt securities held by the Company in an unrealized loss position for less than 12 months and 12 months or greater (in thousands): <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:33.987%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 Months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 12 Months or Greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> September 30, 2024 </td> <td style="vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;">

#000000;text-align:center;"> (1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 21,290 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (72 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (73 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,479</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">54,712</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (319 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,191</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 321 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;">) </td> </tr> </table> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:33.987%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Less than 12 Months </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 12 Months or Greater </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;">

Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Unrealized
Losses </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,877</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (16 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">52,686</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,232 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">65,563</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,248 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 965 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (2 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,257 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (104 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">6,222 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (106 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 25,051 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (48 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 144,642 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 169,693 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (2,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">38,893</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (66 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">202,585</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3,652 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">241,478</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (3,718 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr>
</table> 30252000 233000 30252000 233000 484000 1000 3170000 14000 3654000 15000 4995000 1000 21290000 72000 26285000 73000 5479000 2000 54712000 319000 60191000 321000 12877000 16000 52686000 1232000 65563000 1248000 965000 2000 5257000 104000 6222000 106000 25051000 48000 144642000 2316000 169693000 2364000 38893000 66000 202585000 3652000 241478000 3718000 36 0 0 4. Fair Value Measurements Financial instruments reported at fair value on a recurring basis include cash equivalents and marketable securities. The following tables present the fair value of cash equivalents and marketable securities in accordance with the fair value hierarchy discussed in Note 2 (in thousands).   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> September 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Money market mutual funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 43,771 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,133 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 167,429 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 221,951 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td>

</td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 221,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 265,722 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 265,722 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Money market mutual funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #fffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 70,569 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 70,569 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 202,572 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 202,572 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 279,607 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">

space:pre-wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> September 30, 2024 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,133 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,133 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Certificates of deposit </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,389 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 221,951 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;

Roman;margin-bottom:0;text-align:right;">221,951 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> 265,722 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 265,722 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> December 31, 2023 </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Cash equivalents: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Money market mutual funds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:30pt;white-space:pre-wrap;vertical-align:top;"> Total cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="text-indent:10pt;vertical-align:top;"> Marketable securities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> U.S. government and agency securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 70,569 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,466 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Corporate bonds </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">— </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 202,572 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 279,607 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total cash equivalents and marketable securities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">292,631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">292,631</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 43771000 43771000 43771000 43771000 50133000 50133000 4389000 4389000 167429000 167429000 221951000 221951000 265722000 265722000 13024000 13024000 13024000 13024000 70569000 70569000 6466000 6466000 202572000 202572000 279607000 279607000 292631000 292631000 <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">5. Property and Equipment, Net</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Property and equipment, net consists of the following (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Laboratory and manufacturing equipment</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 76,788 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr

style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,748 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,700 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,052 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 101,340 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 101,927 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 189,900 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 189,311 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (69,349 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (57,208 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">120,551</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 132,103 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> In March 2024, the Company entered into an agreement to sublease its office facilities in New York, New York. In connection with the sublease, the Company recorded impairment of property and equipment of $0.7 million in the first quarter of 2024 related to furniture and fixtures and leasehold improvements located at the subleased facility. Please refer to Note 6 for further information regarding the sublease agreement and associated impairment of long-lived assets. Property and equipment, net consists of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td

style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Laboratory and manufacturing equipment </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">76,788</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 75,632 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Computer equipment and software </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,748 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,700 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Furniture and fixtures </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,024 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,052 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 101,340 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 101,927 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total property and equipment </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 189,900 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 189,311 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (69,349 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (57,208 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">120,551</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 132,103 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 76788000 75632000 4748000 4700000 7024000 7052000 101340000 101927000 189900000 189311000 69349000 57208000 120551000 132103000 700000 6. Leases New York Sublease In May 2016, the Company entered into an operating lease for office space in New York, New York (the New York Lease), which has since been amended to include additional office space and extend the term of the lease. The lease term commenced in July 2016 and expires in April 2027. In March 2024, the Company entered into an agreement to sublease its office space under the New York Lease (the New York Sublease) to a third-party subtenant. The sublease term commenced in April 2024 and will expire in April 2027 concurrent with the expiration of the New York Lease. Monthly payments under the New York Sublease commenced in July 2024 and escalate annually in accordance with the sublease agreement. As of September

30, 2024, total undiscounted future minimum lease payments to be received by the Company over the term of the New York Sublease were $1.3 million. The Company recognized sublease income of $0.1 million and $0.2 million under the New York Sublease during the three and nine months ended September 30, 2024, respectively. The New York Sublease is classified as an operating lease and the Company was not relieved of its primary obligation under the New York Lease. The Company continues to account for the New York Lease as it did prior to the commencement of the sublease. As a result of the New York Sublease, the Company determined an impairment indicator was present as of March 31, 2024 related to the long-lived asset group subject to the sublease, which included the right-of-use asset under the New York Lease, leasehold improvements and other property and equipment allocable to the New York Sublease. The Company concluded the carrying value of the asset group as of March 31, 2024 was not recoverable, as it exceeded the sum of the estimated undiscounted cash flows to be generated by the assets over their remaining lives. The Company estimated the fair value of the asset group as of March 31, 2024 using a discounted cash flow method, which incorporated unobservable inputs including the net identifiable cash flows over the term of the New York Sublease and an estimated borrowing rate of a market participant subtenant. The estimated fair value of the asset group as of March 31, 2024 represents a Level 3 nonrecurring fair value measurement. The Company concluded the carrying value of the asset group of $3.4 million exceeded its estimated fair value of $1.3 million as of March 31, 2024. As such, the Company recognized impairment losses of $2.1 million during the three months ended March 31, 2024 and the nine months ended September 30, 2024 on the long-lived asset group associated with the New York Sublease. The impairment losses were allocated to the various assets within the long-lived asset group based on their relative carrying values and consisted of $1.4 million recorded to the right-of-use assets and $0.7 million recorded to property and equipment. No material impairment losses on long-lived assets were recorded during the three months ended September 30, 2024 and the three and nine months ended September 30, 2023. 1300000 100000 200000 3400000 1300000 2100000 2100000 1400000 700000 0 0 0 7. Liability Related to Sale of Future Royalties In December 2020, the Company entered into a royalty purchase agreement (the Royalty Purchase Agreement) with entities managed by Healthcare Royalty Management, LLC (collectively, HCR). Under the Royalty Purchase Agreement, HCR purchased the Company's rights to a capped amount of Zolgensma royalty payments under the Company's license agreement (the Novartis License) with Novartis Gene Therapies, Inc. (formerly AveXis, Inc.) (Novartis Gene Therapies), including $4.0 million of royalty payments received by the Company in the fourth quarter of 2020 (the Pledged Royalties). In consideration for these rights, HCR paid the Company $200.0 million (the Purchase Price), less $4.0 million representing the payment of the Pledged Royalties to HCR. Beginning upon the effective date of the Royalty Purchase Agreement, Zolgensma royalty payments, up to a specified threshold, shall be paid to HCR, net of upstream royalties payable by the Company to certain licensors in accordance with existing license agreements. Pursuant to the Royalty Purchase Agreement, the total amount of royalty payments to be received by HCR is subject to an increasing cap (the Cap Amount) equal to (i) $260.0 million applicable for the period from the effective date of the Royalty Purchase Agreement through November 7, 2024, and (ii) $300.0 million applicable for the period from November 8, 2024 through the effective date of termination of the Novartis License. If, on or prior to the defined dates for each Cap Amount, the total amount of royalty payments received by HCR equals or exceeds the Cap Amount applicable to such date, the Royalty Purchase Agreement will automatically terminate and all rights to the Zolgensma royalty payments will revert back to the Company. The Company has no obligation to repay any amounts to HCR if total future Zolgensma royalty payments are not sufficient to achieve the applicable Cap Amount prior to the termination of the Novartis License. The Company has a call option to repurchase its rights to the purchased royalties from HCR for a repurchase price equal to, as of the option exercise date, $300.0 million minus the total amount of royalty payments received by HCR; provided, however, that with respect to a call option exercised on or before November 7, 2024, in the event that the then applicable Cap Amount minus the total amount of royalty payments received by HCR is less than $1.0 million, the repurchase price shall equal such difference. The proceeds received from HCR of $196.0 million were recorded as a liability, net of transaction costs of $3.5 million, which is amortized over the estimated life of the arrangement using the effective interest method. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty payments to be received by HCR, subject to the Cap Amount, over the life of the arrangement. The total amount of royalty payments received by HCR under the Royalty Purchase Agreement, less the net proceeds received by the Company of $192.5 million, is recorded as interest expense over the life of the arrangement using the effective interest method. Due to its continuing involvement in the Novartis License, the Company continues to recognize royalty revenue on net sales of Zolgensma and records the royalty payments to HCR as a reduction of the liability when paid. As such payments are made to HCR, the balance of the liability will be effectively repaid over the life of the Royalty Purchase Agreement.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company estimates the effective interest rate used to record interest expense under the Royalty Purchase Agreement based on its estimate of future royalty payments to be received by HCR. As of September 30, 2024, the estimated effective interest rate under the Royalty Purchase Agreement was 4.2%. Over the life of the arrangement, the actual effective interest rate will be affected by the amount and timing of the royalty payments received by HCR and changes in the Company's forecasted royalties. At each reporting date, the Company reassesses its estimate of total future royalty payments to be received by HCR at the applicable Cap Amount, and prospectively adjusts the effective interest rate and amortization of the liability, as necessary.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents the changes in the liability related to the sale of future royalties under the Royalty Purchase Agreement with HCR (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.26%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Liability Related to</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Sale of Future Royalties</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 94,052 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Zolgensma royalties paid to HCR </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (35,072 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Interest expense recognized </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,769 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 61,749 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Current portion of liability related to sale of future royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (26,697 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Liability related to sale of future royalties, non-current </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>

4000000.0 200000000.0 260000000.0 300000000.0 300000000.0 1000000.0 196000000 3500000 192500000 0.042 The following table presents the changes in the liability related to the sale of future royalties under the Royalty Purchase Agreement with HCR (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.26%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Liability Related to </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Sale of Future Royalties </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">94,052</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Zolgensma royalties paid to HCR</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(35,072</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Interest expense recognized</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,769</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">61,749</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Current portion of liability related to sale of future royalties</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(26,697</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liability related to sale of future royalties, non-current</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 35,052 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> -94052000 -35072000 2769000 61749000 26697000 35052000 <span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New

Roman;min-width:fit-content;">8. Capitalization March 2024 Public Offering In March 2024, the Company completed a public offering of 4,565,260 shares of its common stock at a price of $23.00 per share and 1,521,740 pre-funded warrants to purchase shares of its common stock at a price of $22.9999 per pre-funded warrant, which equaled the public offering price per share of the common stock less the $0.0001 exercise price of each pre-funded warrant. The aggregate net proceeds received by the Company from the offering were $131.1 million, net of underwriting discounts and commissions and offering expenses payable by the Company. The rights and privileges of the pre-funded warrants issued under the March 2024 offering are set forth in the warrant agreement between the Company and each of the respective warrant holders. The pre-funded warrants are exercisable at the option of the warrant holder at any time and do not expire. However, as set forth in the warrant agreements with each holder, the number of pre-funded warrants that may be exercised at any given time may be limited if, upon exercise, the warrant holder and any of its affiliates would beneficially own more than 9.99% of the Company's common stock, or have voting power of more than 9.99% of the Company's common stock. The limitation threshold may be increased or decreased by the warrant holder, with advance notice to the Company, to any other percentage not less than 4.99% nor in excess of 19.99%. Pre-funded warrants do not provide any of the rights or privileges provided by the Company's common stock, including any voting rights, until the pre-funded warrants are exercised and settled in underlying shares of common stock. The Company evaluated the pre-funded warrants issued under the March 2024 offering and concluded the warrants are indexed to the Company's common stock, meet the criteria to be classified as equity and are not subject to remeasurement. The proceeds received from the issuance of the pre-funded warrants were recorded as additional paid-in capital. The Company issued 197,000 shares of common stock upon the exercise of pre-funded warrants during the nine months ended September 30, 2024. There were no exercises of pre-funded warrants during the three months ended September 30, 2024. As of September 30, 2024, 1,324,740 pre-funded warrants remained outstanding. At-the-Market Offering Program In September 2023, the Company entered into an ATM Equity OfferingSM Sales Agreement with BofA Securities, Inc. (BofA) pursuant to which the Company may offer and sell shares of its common stock having an aggregate offering price of up to $150.0 million from time to time through BofA, acting as the Company's sales agent (the ATM Program). As of September 30, 2024, no shares of common stock had been sold under the ATM Program. 4565260 23 1521740 22.9999 0.0001 131100000 0.0999 0.0999 0.0499 0.1999 197000 197000 0 1324740 150000000 0 9. License and Collaboration Agreements License and Royalty Revenue As of September 30, 2024, the Company's NAV Technology Platform was being applied by NAV Technology Licensees in one commercial product, Zolgensma, and in the development of a number of other licensed products. Additionally, the Company has licensed intellectual property rights to collaborators for the joint development of certain product candidates. Consideration to the Company under its license agreements may include: (i) up-front and annual fees, (ii) milestone payments based on the achievement of certain development and sales-based milestones, (iii) sublicense fees, (iv) royalties on sales of licensed products, (v) fees for services related to the development of licensed products and (vi) other consideration payable upon optional goods and services purchased by licensees. Sublicense fees vary by license and range from a mid-single digit percentage to a low-double digit percentage of license fees received by licensees as a result of sublicenses. Royalties on net sales of commercialized products vary by license and range from a mid-single digit percentage to a low double-digit percentage of net sales by licensees. License and royalty revenue consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:40.376%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:top;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Zolgensma

royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,872</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other license and royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 325 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 550 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,265 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,575 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total license and royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,197</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,914 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">62,114</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,029 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Outstanding development milestone payments are evaluated each reporting period and are only included in the transaction price of each license and recognized as license revenue to the extent the milestones are considered probable of achievement. Sales-based milestones are excluded from the transaction price of each license agreement and recognized as royalty revenue in the period of achievement. As of September 30, 2024, the Company's license agreements, excluding additional licenses that could be granted upon the exercise of options by licensees, contained unachieved milestones which could result in aggregate milestone payments to the Company of up to $1.51 billion, including (i) $524.9 million upon the commencement of various stages of clinical trials, (ii) $113.8 million upon the submission of regulatory approval filings or upon regulatory approval of licensed products and (iii) <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$870.0 million upon the achievement of specified sales targets for licensed products, including milestones payable upon the first commercial sale of licensed products. To the extent the milestone payments are realized by the Company, the Company may be obligated to pay sublicense fees to licensors based on a specified percentage of the fees earned by the Company. The achievement of these milestones is highly dependent on the successful development and commercialization of licensed products and it is at least reasonably possible that some or all of the milestone fees will not be realized by the Company. Changes in Accounts Receivable, Contract Assets and Deferred Revenue The following table presents the balances of the Company's net accounts receivable, contract assets and deferred revenue, as well as other information regarding revenue recognized during the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-

sizing:content-box;"></td> <td style="width:9.1840000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Nine Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Accounts receivable, net, current and non-current: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Beginning of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,273</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,523 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,491</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,586 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> End of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,121 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,121 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Contract assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Beginning of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">194</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> End of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">259</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">259</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">259</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">259</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Deferred revenue: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;">

</td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#fffffc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Beginning of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 448 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">148</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,829 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> End of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 442 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Revenue recognized during the period from: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#fffffc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Amounts included in deferred revenue at beginning of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,409</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Performance obligations satisfied in previous periods</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,875 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,365</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 60,912 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,405 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> As of September 30, 2024, the Company had recorded deferred revenue of $0.1 million which represents consideration received or unconditionally due from licensees for performance obligations that have not yet been satisfied by the Company. Unsatisfied performance obligations as of September 30, 2024 consisted of research and development services to be performed by the Company related to licensed products, which will be satisfied as the services are performed. As of September 30, 2024, the aggregate transaction price of the Company’s license agreements allocated to performance obligations not yet satisfied, or partially satisfied, was $1.5 million, which is expected to be satisfied over a period of approximately two to three years. Revenue recognized from performance obligations satisfied in previous periods, as presented in the table above, was primarily attributable to Zolgensma royalties and changes in the transaction prices of the Company’s license agreements. Changes in transaction prices were primarily attributable to development milestones achieved or deemed probable of achievement during the periods which were previously not considered probable of achievement, resulting in a cumulative catch-up adjustment to revenue. Revenue recognized during the nine months ended September 30, 2023 included $2.0 million in cumulative catch-up adjustments for changes in the probability of achievement of development milestones. There were no cumulative catch-up adjustments to revenue for changes in the probability of achievement of development milestones during the three and nine months ended September 30, 2024 or during the three months ended September 30, 2023.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts Receivable, Contract Assets and the Allowance for Credit Losses</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts receivable, net consisted of the following (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Current accounts receivable:</p></td> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Billed to customers</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 105 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 265 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unbilled Zolgensma royalties </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;">23,138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,128 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Due from Abeona, net of present value discount </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,942 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,587 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other unbilled </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 397 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Allowance for credit losses </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (4,587 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Current accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,604 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,790 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Non-current accounts receivable: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other unbilled </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 404 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 701 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Non-current accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 404 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 701 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 24,008 </td> <td style="white-space:nowrap;vertical-

*align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,491</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents the changes in the allowance for credit losses related to accounts receivable and contract assets for the nine months ended September 30, 2024 (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Allowance for Credit Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accounts Receivable</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Contract Assets</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,587 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Changes in present value discount of receivables</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">355</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 4,942 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The Company's allowance for credit losses as of September 30, 2024 and December 31, 2023 was related solely to accounts receivable from Abeona Therapeutics Inc. (Abeona). Please refer to the section below, "Settlement Agreement with Abeona Therapeutics", for further information regarding amounts due from Abeona and the associated allowance for credit losses. The Company did not record a provision for credit losses for the three and nine months ended September 30, 2024 and 2023. Zolgensma License with Novartis Gene Therapies In March 2014, the Company entered into an exclusive license agreement (as amended, the Novartis License) with Novartis Gene Therapies. Under the Novartis License, the Company granted Novartis Gene Therapies an exclusive, worldwide commercial license, with rights to sublicense, to the NAV Technology Platform, as well as other certain rights, for the treatment of spinal muscular atrophy (SMA) in humans by in vivo gene therapy. In 2019, Novartis Gene Therapies launched commercial sales of Zolgensma, a licensed product under the Novartis License. In accordance with the Novartis License, the Company receives royalties on net sales of Zolgensma. The Company recognized the following amounts under the Novartis License (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> *

Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Zolgensma royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,872</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 28,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 63,454 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total license and royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,872</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 63,454 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest income from licensing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024 and December 31, 2023, the Company had recorded total accounts receivable of $23.3 million and $24.3 million, respectively, from Novartis Gene Therapies under the Novartis License, which consisted primarily of Zolgensma royalties receivable. The Zolgensma royalties receivable recorded as of September 30, 2024 included $11.1 million expected to be paid to HCR in accordance with the Royalty Purchase Agreement discussed in Note 7. The Company recognizes royalty revenue from net sales of Zolgensma in the period in which the underlying products are sold by Novartis Gene Therapies, which in certain cases may require the Company to estimate royalty revenue for periods of net sales which have not yet been reported to the Company. Estimated royalties are reconciled to actual amounts reported in subsequent periods, and any differences are recognized as an adjustment to royalty revenue in the period the royalties are reported. Settlement Agreement with Abeona Therapeutics In November 2021, the Company entered into a settlement agreement and mutual release with Abeona (the Settlement Agreement) related to claims associated with a license agreement between the parties which was terminated in May 2020. The Settlement Agreement resolved all arbitration and legal proceedings and mutually released each party from any and all claims under the terminated license agreement. Pursuant to the Settlement Agreement, Abeona will pay the Company a total of $30.0 million as follows: (i) $20.0 million which was paid in November 2021, (ii) $5.0 million which was paid in November 2022, and (iii) $5.0 million payable on the earlier of the third anniversary of the Settlement Agreement in November 2024 or the closing of a specified type of transaction by Abeona. As of September 30, 2024 and December 31, 2023, the Company had recorded accounts receivable of $4.9 million and $4.6 million, respectively, associated with the remaining amounts due from Abeona under the Settlement Agreement. The receivable of $4.9 million as of September 30, 2024 consisted of the $5.0 million payment due by November 2024, net of discount to present value. While the Company anticipates taking appropriate measures to enforce the full collection of all amounts due from Abeona under the Settlement Agreement, the Company assessed the collectability of the accounts receivable from Abeona as it relates to credit risk. In performing this assessment, the Company evaluated Abeona's credit profile and financial condition, as well its expectations regarding Abeona's future cash flows and ability to satisfy the contractual obligations of the Settlement Agreement. As a result of its analysis, the Company recorded an allowance for credit losses of $4.9 million and $4.6 million as of September 30, 2024 and December 31, 2023, respectively, related to the accounts receivable due from Abeona. No credit losses or recoveries were recorded on the Abeona receivable during the three and nine months ended September 30, 2024 and 2023. The present value discount of the Abeona receivable is accreted as interest income from licensing through the contractual due date using the effective interest method. The Company has elected to record increases in the allowance for credit losses associated with the accretion of the present value discount as a reduction of the associated interest income, resulting in no interest income recognized during the periods related to the accretion of the present value discount on the Abeona receivable. Collaboration Agreements AbbVie Collaboration and License Agreement In September 2021, the Company entered into a collaboration and license agreement with AbbVie Global Enterprises Ltd. (AbbVie), a subsidiary of AbbVie Inc., to jointly develop and commercialize ABBV-RGX-314, the Company's product candidate for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases (the AbbVie Collaboration Agreement). The AbbVie Collaboration Agreement became effective in November 2021. Pursuant to the AbbVie Collaboration Agreement, the Company granted AbbVie a co-exclusive license to develop and commercialize ABBV-RGX-314 in the United States and an exclusive license to develop and commercialize ABBV-RGX-314 outside the United States. The Company and AbbVie will collaborate to develop ABBV-RGX-314 in the United States, and AbbVie will be responsible for the development of ABBV-RGX-314 in specified markets outside the United States. Through December 31, 2022, the Company was responsible for the development expenses related to certain ongoing clinical trials of ABBV-RGX-314 and the parties shared the additional development expenses related to ABBV-RGX-314. Beginning on January 1, 2023, AbbVie became responsible for the majority of all ABBV-RGX-314 development expenses. The Company will lead the manufacturing of ABBV-RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead the manufacturing of ABBV-RGX-314 for commercial supply outside the United States. Manufacturing expenses will be allocated between the parties in accordance with the terms of the AbbVie Collaboration Agreement and supply agreements determined in accordance with the agreement. If requested by AbbVie, the Company will manufacture up to a specified portion of ABBV-RGX-314 for commercial supply outside the United States at a price specified in the agreement. AbbVie will lead the commercialization of ABBV-RGX-314 globally, and the Company will participate in U.S. commercialization efforts as provided under a commercialization plan determined in accordance with the agreement. The Company and AbbVie will share equally in the net profits and net losses associated with the commercialization of ABBV-RGX-314 in the United States. Outside the United States, AbbVie will be responsible, at its sole cost, for the commercialization of ABBV-RGX-314. In consideration for the rights granted under the AbbVie Collaboration Agreement, AbbVie paid the Company an up-front fee of $370.0 million upon the effective date of the agreement in November 2021 and is required to pay to the Company up to $1.38 billion upon the achievement of specified development and sales-based milestones, of which $562.5 million are based on development milestones and $820.0 million are sales-based milestones. AbbVie is also required to pay to the Company tiered royalties on net sales of ABBV-RGX-314 outside the United States at percentages in the mid-teens to low twenties, subject to specified offsets and reductions. The Company applied the requirements of ASC 606, Revenue from Contracts with Customers (ASC 606) to the AbbVie Collaboration Agreement for the units of account in which AbbVie was deemed to be a customer. The Company determined that there is only one material performance

obligation under the agreement for the delivery of the intellectual property license to develop and commercialize ABBV-RGX-314 globally. The intellectual property licensed to AbbVie includes the rights to certain patents, data, know-how and other rights developed and owned by the Company, as well as other intellectual property rights exclusively licensed by the Company from various third parties. As of September 30, 2024 and December 31, 2023, the transaction price of the AbbVie Collaboration Agreement was $370.0 million, which consisted solely of the up-front payment received from AbbVie in November 2021. The $370.0 million transaction price was fully recognized as revenue upon the delivery of the license to AbbVie in November 2021. Variable consideration under the AbbVie Collaboration Agreement, which has been excluded from the transaction price, includes $562.5 million in payments for development milestones that have not yet been achieved and were not considered probable of achievement. Additionally, the transaction price excludes sales-based milestone payments of $820.0 million and royalties on net sales of ABBV-RGX-314 outside the United States. Development milestones will be added to the transaction price and recognized as revenue upon achievement, or if deemed probable of achievement. In accordance with the sale- or usage-based royalty exception under ASC 606, royalties on net sales and sales-based milestones will be recognized as revenue in the period the underlying sales occur or milestones are achieved. There were no changes in the transaction price of the AbbVie Collaboration Agreement, and no revenue was recognized, during the three and nine months ended September 30, 2024 and 2023. The Company applied the requirements of ASC 808, Collaborative Arrangements (ASC 808) to the AbbVie Collaboration Agreement for the units of account which were deemed to be a collaborative arrangement. Both the Company and AbbVie will perform various activities related to the development, manufacturing and commercialization of ABBV-RGX-314 in the United States. Development costs are shared between the parties in accordance with the terms of the AbbVie Collaboration Agreement, and the parties will share equally in the net profits and losses derived from sales of ABBV-RGX-314 in the United States. The Company accounts for payments to and from AbbVie for the sharing of development and commercialization costs in accordance with its accounting policy for collaborative arrangements. Amounts owed to AbbVie for the Company's share of development costs or commercialization costs incurred by AbbVie are recorded as research and development expense or general and administrative expense, respectively, in the period the costs are incurred. Amounts owed to the Company for AbbVie's share of development costs or commercialization costs incurred by the Company are recorded as a reduction of research and development expense or general and administrative expense, respectively, in the period the costs are incurred. At the end of each reporting period, the Company records a net amount due to or from AbbVie as a result of the cost-sharing arrangement. As of September 30, 2024 and December 31, 2023, the Company had recorded $20.3 million and $17.7 million, respectively, due from AbbVie for net reimbursement of costs incurred for activities performed under AbbVie Collaboration Agreement, which was included in other current assets on the consolidated balance sheets.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recognized the following amounts under the AbbVie Collaboration Agreement (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net cost reimbursement to (from) AbbVie included in:</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development expense</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (20,082 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (19,608 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-

space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(66,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (56,300 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> General and administrative expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 341 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 615 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,168 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,007 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total net cost reimbursement to (from) AbbVie </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(19,741</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (18,993 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(65,162</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 55,293 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> 1 License and royalty revenue consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Zolgensma royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,872</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,364 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 63,454 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other license and royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 325 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,265 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,575 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total license and royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,197</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,914 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">62,114</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,029 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 23872000 28364000 60849000 63454000 325000 550000 1265000 4575000 24197000 28914000 62114000 68029000 151000000 524900000 113800000 870000000 The following table presents the balances of the Company's net accounts receivable, contract assets and deferred revenue, as well as other information regarding revenue recognized during the periods presented (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Three Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Nine Months Ended </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:center;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Accounts receivable, net, current and non-current: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Beginning of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,273</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,523 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,491</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,586 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> End of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29,121 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Contract assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td

style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td>

Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">148</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,829 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> End of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 442 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">144</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 442 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#fffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Revenue recognized during the period from: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Amounts included in deferred revenue at beginning of period </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">21</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">148</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,409 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Performance obligations satisfied in previous periods </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,875</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28,365 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,912</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 65,405 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 23273000 22523000 25491000 29586000 24008000 29121000 24008000 29121000 194000 2000000 259000 2000000 259000 2000000 21000 448000 148000 1829000 144000 442000 144000 442000 21000 28000 148000 1409000 23875000 28365000 60912000 65405000 100000 1500000 P3Y 2000000 0 0 0 Accounts receivable, net consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Current accounts receivable </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Billed to customers </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">105</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 265 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Unbilled Zolgensma royalties </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,138 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,128 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Due from Abeona, net of present value discount </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,942 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,587 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other unbilled </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 397 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Allowance for credit losses </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (4,942 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (<span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">4,587 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Current accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,604 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,790 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Non-current accounts receivable: </td> <td style="vertical-align:top;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other unbilled </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 404 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 701 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Non-current accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 404 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 701 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total accounts receivable, net </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24,008</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25,491</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> 105000 265000 23138000 24128000 4942000 4587000 361000 397000 4942000 4587000 23604000 24790000 404000 701000 404000 701000 24008000 25491000 <p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table presents the changes in the allowance for credit losses related to accounts receivable and contract assets for the nine months ended September 30, 2024 (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Allowance for Credit Losses</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Accounts Receivable</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Contract Assets</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,587 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

content;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Changes in present value discount of receivables </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 355 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,942</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 4587000 355000 4942000 0 0 0 0 The Company recognized the following amounts under the Novartis License (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Zolgensma royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,872</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 28,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 63,454 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Total license and royalty revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,872</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-

align:center;"> 28,364 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,849</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 63,454 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Interest income from licensing </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 22 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> *23872000 28364000 60849000 63454000 23872000 28364000 60849000 63454000 6000 7000 20000 22000 23300000 24300000 11100000 30000000 20000000 5000000 5000000 4900000 4600000 4900000 5000000.0 4900000 4600000 0 0 0 0 370000000.0 1380000000 562500000 820000000.0 370000000.0 370000000.0 562500000 562500000 820000000.0 820000000.0 0 0 0 0 20300000 17700000* The Company recognized the following amounts under the AbbVie Collaboration Agreement (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Net cost reimbursement to (from) AbbVie included in: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:right;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Research and development expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(20,082</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (19,608 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(66,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (56,300 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> General and administrative expense </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 341 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 615 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,168 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,007 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total net cost reimbursement to (from) AbbVie </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(19,741</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (18,993 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(65,162</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> (55,293 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;">) </td> </tr> </table> -20082000 -19608000 -66330000 -56300000 341000 615000 1168000 1007000 -19741000 -18993000 -65162000 -55293000 10. Stock-based Compensation Effective in January 2024, an additional 1,761,849 shares were authorized for issuance under the 2015 Equity Incentive Plan (the 2015 Plan). As of September 30, 2024, the total number of shares of common stock authorized for issuance under the 2015 Plan and the 2014 Stock Plan (the 2014 Plan) was 19,118,989, of which 1,511,556 remained available for future grants under the 2015 Plan. Stock-based Compensation Expense <div style="font-size:10pt;font-family:Times

New Roman;"> The Company's stock-based compensation expense by award type was as follows (in thousands):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,051</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">17,969</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,868 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted stock units </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,755 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,843 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,536 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,475 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 78 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 101 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 416 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 586 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,884</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,921</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,929 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> As of September 30, 2024, the Company had $69.5 million of unrecognized stock-based compensation expense related to stock options, restricted stock units and the 2015 Employee Stock Purchase Plan (the 2015 ESPP), which is expected to be recognized over a weighted-average period of 2.4 years.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recorded aggregate stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:40.376%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.765%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,301 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,131</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,893 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,670 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,583 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,088 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,028 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,259 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,884</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,921</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,929 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Stock Options The following table summarizes stock option activity under the 2014 Plan and 2015 Plan (in thousands, except per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.942%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted- </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> average </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> <span style="white-

space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted- </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Remaining </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> average </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Contractual </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Aggregate </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Exercise </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Life </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Intrinsic </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Value (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,581 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32.62</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.2</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,011</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,263</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16.24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Exercised </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (281 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.25</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cancelled or forfeited</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(546</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35.56 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,017 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29.53</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,609 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34.38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and expected to vest at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,017 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29.53</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">529</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:86.667%;text-align:left;"> </p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at the dates reported.</p></div><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The weighted-average grant date fair value per share of options granted during the nine months ended September 30, 2024 was $10.06. During the nine months ended September 30, 2024, the total number of stock options exercised was 280,753, resulting in total proceeds of $1.5 million. The total intrinsic value of options exercised during the nine months ended September 30, 2024 was $3.0 million.</p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted Stock Units</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table summarizes restricted stock unit activity under the 2015 Plan (in thousands, except per share data):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.508%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.096%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.616%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Weighted-average</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Grant Date</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Shares</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unvested balance at December 31, 2023</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,309</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">25.89</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Granted</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,188</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16.22</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(390</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-

align:center;"> 27.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (72 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unvested balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20.11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The total intrinsic value of restricted stock units vested during the nine months ended September 30, 2024 was $6.7 million. </p><p style="margin-left:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Employee Stock Purchase Plan</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, the total number of shares of common stock authorized for issuance under the 2015 ESPP was 1,426,994, of which 912,964 remained available for future issuance. During the nine months ended September 30, 2024, 105,400 shares of common stock were issued under the 2015 ESPP.</p> 1761849 19118989 1511556 <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's stock-based compensation expense by award type was as follows (in thousands):</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine Months Ended September 30,</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock options</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,051 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,275</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,969 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,868</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted stock units</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,755</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,843</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,536</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,475</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Employee stock purchase plan</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">78</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">101</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">416</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">586</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,884 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,219</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 28,921 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,929 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 6051000 7275000 17969000 22868000 3755000 2843000 10536000 8475000 78000 101000 416000 586000 9884000 10219000 28921000 31929000 69500000 P2Y4M24D The Company recorded aggregate stock-based compensation expense in the consolidated statements of operations and comprehensive loss as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:40.376%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.765%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"><p

style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,301</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,893</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,670 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,583 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,088 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,028 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 15,259 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,884</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,219 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,921</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,929 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 4301000 5131000 13893000 16670000 5583000 5088000 15028000 15259000 9884000 10219000 28921000 31929000 The following table summarizes stock option activity under the 2014 Plan and 2015 Plan (in thousands, except per share data):   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.11%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.662%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.182%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted- </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted- </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Remaining </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted- </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Remaining </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted- </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> average </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> average </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Contractual </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Aggregate </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Exercise </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Life </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Intrinsic </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Price </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> (Years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Value (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Outstanding at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">8,581 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32.62</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.2</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,011 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,263 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16.24</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercised</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(281</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5.25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cancelled or forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (546 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35.56</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Outstanding at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,017</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29.53 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6.4 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Exercisable at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 6,609 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">34.38</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5.1</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vested and expected to vest at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,017 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29.53</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6.4</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 529 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> (a) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at the dates reported. 8581000 32.62 P6Y2M12D 7011000 2263000 16.24 281000 5.25 546000 35.56 10017000 29.53 P6Y4M24D 529000 6609000 34.38 P5Y1M6D 529000 10017000 29.53 P6Y4M24D 529000 10.06 280753 1500000 3000000 The following table summarizes restricted stock unit activity under the 2015 Plan (in thousands, except per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.508%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.096%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.616%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Weighted-average </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Grant Date </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Shares </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Fair Value </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unvested balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,309 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25.89 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-

space:pre-wrap;vertical-align:top;"> Granted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,188 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16.22</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Vested</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">390</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 27.20 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Forfeited </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (72 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22.45</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Unvested balance at September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20.11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> 1309000 25.89 1188000 16.22 390000 27.2 72000 22.45 2035000 20.11 6700000 1426994 912964 105400 11. Income Taxes The Company evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets as of September 30, 2024 and December 31, 2023. Based on the Company's history of operating losses, and other relevant facts and circumstances, the Company concluded that it was more likely than not that the benefit of its deferred tax assets will not be realized. Accordingly, the Company provided a full valuation allowance for its net deferred tax assets as of September 30, 2024 and December 31, 2023. 12. Restructuring In November 2023, the Company implemented a strategic pipeline prioritization and corporate restructuring designed to reduce operating expenses and prioritize the development of ABBV-RGX-314, RGX-202 for the treatment of Duchenne muscular dystrophy, and RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II), while pursuing strategic alternatives for the Company's other clinical stage programs. The restructuring included a reduction in workforce and other planned operating expenses, primarily in rare neurodegenerative disease development, early research and other general and administrative areas. In connection with the restructuring, the Company implemented a reduction in workforce of approximately 15%, which was substantially completed in the fourth quarter of 2023. The Company recorded restructuring costs of $3.7 million in the fourth quarter of 2023, which primarily consisted of employee severance, continuing healthcare benefits and other employee-related costs. During the nine months ended September 30, 2024, the Company recorded reductions in the restructuring liability of $0.4 million associated with changes in total estimated restructuring costs. As of September 30, 2024, all of the restructuring costs had been paid by the Company and no restructuring liability was recorded. The following table presents the details of the Company's restructuring liability as of September 30, 2024 (in thousands):
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.26%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Restructuring Liability </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:1;10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2022 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restructuring charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> <span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">Cash payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (1,925 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,806 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,370 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (436 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table></div> 0.15 3700000 -400000 0 The following table presents the details of the Company's restructuring liability as of September 30, 2024 (in thousands):<p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:78.26%;box-sizing:content-box;"></td> <td style="width:1.66%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Restructuring Liability</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance at December 31, 2022</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Restructuring charges </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,731 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,925 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at December 31, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,806 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Cash payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (1,370 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other adjustments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (436 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Balance at September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 3731000 1925000 1806000 1370000 -436000 <p style="font-size:10pt;margin-

top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">13. Net Loss Per Share Since the Company incurred net losses for the three and nine months ended September 30, 2024 and 2023, common stock equivalents were excluded from the calculation of diluted net loss per share for such periods as their effect would be anti-dilutive. Accordingly, basic and diluted net loss per share were the same for such periods. The weighted-average number of common shares outstanding used in the basic and diluted net loss per share calculations includes the weighted-average effect of pre-funded warrants to purchase shares of the Company's common stock, as the pre-funded warrants are exercisable at any time for nominal cash consideration. The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.497%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.093%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.093%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three and Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,017 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unvested restricted stock units outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,035 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,394 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"> 47 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 36 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,099 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,286 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following potentially dilutive common stock equivalents outstanding at the end of the period were excluded from the computations of weighted-average diluted common shares for the periods indicated as their effects would be anti-dilutive (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.497%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.093%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:18.093%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three and Nine Months Ended September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-

align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Stock options issued and outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,017 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,856 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Unvested restricted stock units outstanding </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,035 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,394 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Employee stock purchase plan </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 47 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 36 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,099 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 10,286 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 10017000 10017000 8856000 8856000 2035000 2035000 1394000 1394000 47000 47000 36000 36000 12099000 12099000 10286000 10286000 14. Supplemental Disclosures
Other Current Assets Other current assets consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:57.52%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.619999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.62%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:17.619999999999997%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Net cost reimbursement due from collaborators </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">20,302</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,745 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Accrued interest on investments </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,578 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,551 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"> Other </td><td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,450 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,107 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,403 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued external research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,715</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued sublicense fees and royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,628 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,234 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued personnel costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,335 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,146 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued external general and administrative expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,843 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,717 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued purchases of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td

style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 386 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses and current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 787 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> 458 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,642</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Supplemental Disclosures of Non-cash Investing and Financing Activities Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities were $0.4 million as of September 30, 2024, a net decrease of less than $0.1 million from December 31, 2023, and $0.5 million as of September 30, 2023, a net decrease of $2.0 million from December 31, 2022. Offering expenses for the ATM Program included in accounts payable and accrued expenses and other liabilities were $0.4 million as of September 30, 2023. No such amounts were recorded as of September 30, 2024.</p> <p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other current assets consisted of the following (in thousands):</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net cost reimbursement due from collaborators</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 20,302 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17,745 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued interest on investments </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,578 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,551 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,450 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,107 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 20,403 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 20302000 17745000 1578000 1551000 1450000 1107000 23330000 20403000 Accrued expenses and other current liabilities consisted of the following (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:57.52%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.62%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:17.619999999999997%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued external research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,715</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued sublicense fees and royalties </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,628 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,234 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued personnel costs </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,335 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 18,146 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued external general and administrative expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,843 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,717 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued purchases of property and equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 334 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 386 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Other accrued expenses and current liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="color:#000000;white-space:pre-

wrap;min-width:fit-content;">787 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 458 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">48,642</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left,"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 16715000 13762000 14628000 14234000 14335000 18146000 1843000 2717000 334000 386000 787000 458000 48642000 49703000 400000 100000 500000 -2000000 400000 0 directors or Section 16 reporting officers false false false false